<SEC-DOCUMENT>0001347178-21-000005.txt : 20210211
<SEC-HEADER>0001347178-21-000005.hdr.sgml : 20210211
<ACCEPTANCE-DATETIME>20210211070413
ACCESSION NUMBER:		0001347178-21-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210211
DATE AS OF CHANGE:		20210211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vanda Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001347178
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				030491827
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34186
		FILM NUMBER:		21616644

	BUSINESS ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
		BUSINESS PHONE:		202-734-3400

	MAIL ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vnda-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:d614c307-4118-4611-a8d3-3c89a1b9f878,g:1f7774dc-f1ff-4a69-952a-c8825acf6b9a,d:78e7e943a648448d981304e612e68114--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:vnda="http://www.vandapharmaceuticals.com/20201231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vnda-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF80L2ZyYWc6YTc1MzljYzkzMWZjNDA2YWFmY2MwYTNlMzdjOTAxNjEvdGFibGU6MjRmYjY4MDJjNmZjNDZlOWEwNTZjNTUzYjQ5MDM4M2IvdGFibGVyYW5nZToyNGZiNjgwMmM2ZmM0NmU5YTA1NmM1NTNiNDkwMzgzYl80LTEtMS0xLTA_ee6f13e2-16f2-41d3-814f-66bcdd3a4bb5">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF80L2ZyYWc6YTc1MzljYzkzMWZjNDA2YWFmY2MwYTNlMzdjOTAxNjEvdGFibGU6MjRmYjY4MDJjNmZjNDZlOWEwNTZjNTUzYjQ5MDM4M2IvdGFibGVyYW5nZToyNGZiNjgwMmM2ZmM0NmU5YTA1NmM1NTNiNDkwMzgzYl82LTEtMS0xLTA_c30be886-3f79-4765-9da3-930a981dee8f">2020</ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF80L2ZyYWc6YTc1MzljYzkzMWZjNDA2YWFmY2MwYTNlMzdjOTAxNjEvdGFibGU6MjRmYjY4MDJjNmZjNDZlOWEwNTZjNTUzYjQ5MDM4M2IvdGFibGVyYW5nZToyNGZiNjgwMmM2ZmM0NmU5YTA1NmM1NTNiNDkwMzgzYl83LTEtMS0xLTA_e9088875-b84d-44ba-8877-26a732f6f59c">FY</ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF80L2ZyYWc6YTc1MzljYzkzMWZjNDA2YWFmY2MwYTNlMzdjOTAxNjEvdGFibGU6MjRmYjY4MDJjNmZjNDZlOWEwNTZjNTUzYjQ5MDM4M2IvdGFibGVyYW5nZToyNGZiNjgwMmM2ZmM0NmU5YTA1NmM1NTNiNDkwMzgzYl8xMC0xLTEtMS0w_9cf2f35e-c293-42bf-a057-c4020cf30b1c">0001347178</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vnda-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic58a5d7276774436bb7a5273a227e621_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0cdd21bdc0c645ba84491ec3d4e3be0e_I20210204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f26062015ff434da5708800b4290055_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i257e050f9fc943cca28700c4122282b1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5abb4b8a9434ae69f1ef6beffbc0493_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0074f63a213243feae2eb63ef3b3d8bc_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa64fe61cad4642af1fceb2198e6bcb_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926bf00cb18047ab87ba70c56d7331bb_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35541c52d30540b0bcc5d1c03313822b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2695d91d6f1c481d8edf3b68ee2898f3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic059f611bf8f4dfe887222e34e6e559c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b61d51b346e4a2da4ff3d0965c86883_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3b05afd51b244beb8e0ce8e0775250b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id26474ada35c4b5583a6d5ff5c85bdcf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96bafcfa87c1497a9ba610e7dafdc2a8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i085e6c9dd96d4b038e51f519dc41e37d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44c3f48cda746eb8848faa815ee7b25_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e49fdf29e54b778aae30d4a1501e76_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd9bd75bf594c4abbd1eedddf97813d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2876e1911793496ab09397265fb99368_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4633d2c610df4f1b8efd83504abf4563_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f91365a2a7f4aa084ca1a085338e9fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i765bec0d716f47f7ba015545f962331b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6908a347bbd14f9887021a5ce0273e9e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e47e23e944242d4a81577603ac3211a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc5301b024c4390bc0aabe019ad7ed3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992cb2bfa5d0475fa5bbaab433093f86_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia96fe03637474cd5998b5de2ac3a4f41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019a056c228946c5ac4dd9f6f794a1d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7446888cd5f945f79f3d4520f7511af9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia77cfbc0f34e4893bd812347680c5cf4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>vnda:segment</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>vnda:product</xbrli:measure></xbrli:unit><xbrli:context id="i424e0c1a909c43918460f4dd87afab4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b78e259ae349ce94d9e93829b687d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e03ba7540db4ef69e680c9d993fb6a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vnda:NoncurrentInventoryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d0645b788e347848286b67c1d3bd108_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vnda:NoncurrentInventoryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6797cc9249a14561aeec1ea22885a66a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f83003f7bb4ea681811d4c44d82646_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf54b4365b834d72b6c65f6179255cf7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia7d2c26d1a8c4ef7843d0e6970eeee5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23995355e19f4d9ca86f91468591e135_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa1c343c0de46f5a4a09cdf2ebcc104_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6f1b4c76e9497aaa45532e1227ad8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78c8ef22e15348c99b08db2c9df24f2c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644a9e8beacf4148bf19d98813c87d7d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea7d114004f648229f473f8282cbda31_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee0973839d144cf8989e256f4f67b49_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0d780548074d448d8fa037c0529ec7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79728196d61b4e99b2d02bfd59fa48b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e8e24272914f67bf876ad95f66ccdd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d06651aaae742ed909bbbb905f9bc60_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5fdfee666e741d38bae37b3799ca556_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd2ad127c2804ac9a3a22c5e5cd6fd79_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893a60e2f07e4beabea78d9092e5f827_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1cae17f9d144cfbac6ede34e4e28ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5fd1a532a29483fbd96f12b34922d1e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4fc5098f424b22bcd541acb7773579_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7520c5fde90b48c1b3be4f65d3e11085_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4aff6df1bae41c89733b2e7a1d327f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c607b03683846a192234cafe043197c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f400e70454f47359d4725431a87a437_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief538f6767dd4ce0b60f4fd839aebbf9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57b2e8bf447542a48106681a8f18fd2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfbcdcb15332468b82f91cdeca7c2d90_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieccc14d91ff74e1695188703bf8f103e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40340870e2a2486992b608dd3ae40740_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21fd1609a04e49b0bb22ec6b8e33dadc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib01d7291558c49ab8183941f323312e1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89fc42978e1140569719239aff32634c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7f4a59b89dd4fc5b2a51c78dbf422c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69b9f546af14feab861a844ee2190df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i526157fae9164658829ef8c67feeb4e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd2be23072740898c45df963bd01f36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f20c258cb11480789b0ddc9a38ebb80_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95233a42c2d2400c9e832af0546a849c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83bee279dbf04510bbc505415f41b886_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cee81eae3834f8a91784e60ea88cdd9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1931a9cde2641aead7a75d77a370fb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd654c3e3074ac5beb9219888a8397d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf5512406d242b3b334cdf95473932e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd2b9acca2e4a7e89256bcac7794b71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590279da68dd44789a39b09a2a7b4e5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aff0dba35f64b73909e86bb8cbb00e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4fa1365e34d44fc9764447fd2ec2e24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1521ac6ce4c4e3faa831a373c4b2943_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e789b5b4e8447591662fec5bda3261_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id26713507297483babfde81db7b9fa28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84837f39b7f470cb64a3244ed1fc84c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b552a7bd9b47038ad2a7e5c99411fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c688c60d8564383bf26445621f9ca74_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3faacc11ff44169093da58889d764b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4362e7304366445d990ded2bb3505b1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i792f4aa473234968ae82e33224c68d6c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0242a482bf8f427e89cb520b935b8dec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i572e6e7f0ee349d2b27aafb167ab28ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad2ca748413447168432f3afa16e0405_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7112e733b494f1a982cc5aac77faeae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27df4ba463ab4d5b86c334633ea1634e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba732339a56e4213b11aa8a21ae766e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnda:ComputerHardwareAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7b6f3b209b460b89808f786605b838_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnda:ComputerHardwareAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b8918e05b554009ab234e53619bc90e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnda:ComputerHardwareAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1c97ddaaee4131822793e4b11a1fc3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9c76d935aa454e9830545d747a662d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26247ebfe7eb4525a836402ffc21ca64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34b88e9659246eea1386afd588f2793_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9bd57d44144fa28e3d7c0a1cc6d107_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e6096930e004a5cb3b64a1d96cd3a18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a58cc236b3a4b2aa61a7e28fe9c07da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686659adf6bc48a2a6282c2af72dab52_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ice34ccdece6648b48a6896c3974844b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d5263305ac4d87882e5502fb408e09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:SubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib295f3c8735849ada24ac840f8aa6e79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia30bb33a28694ca0b45ea8f0d52a84cc_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6745c8d49094756a3fd1e677133183b_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a98ad86cb947b6b61d3738c4361015_D20150101-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b929e9cab449588933c3ffe31bc66f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9498b806f5e43439515d6d38d221880_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i712a2982fd6d4ab8ac21ead0059a6ab2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07f9ce99f5d440829beb69d57b267e2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia48b1e08808c4068b45beac65e2fc47e_D20040201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2004-02-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2321f5ecabd74d08919f170010c86d17_D20141231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vnda:StatementScenarioSecondaryAxis">vnda:ScenarioFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6fb1507ec54a02b3ed9ec15779f92e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce1828699d04ca897051ef167bc2cf9_D20120401-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-04-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a443bc8c89e453aab29432964b30663_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:PreNDAApprovalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c827b82caa44a79a4cef10d4761150_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b735133e1949cd9c6e0aeb4f8be530_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c1d7fb8dfe49699863ca274c5642ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib097b437c4ec4ac8a415c8716b033089_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37dcfaf9fa1c4d21a01c3abfb80350e7_D20170301-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c5916a7919c4f108df3dcee675165a5_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb19f1abf4e4d15b43df2933d3b57bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f739a8080b94ee0acf1864cc98cfab3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:FutureRegulatoryApprovalAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67d682d4b8343aabcab512b8d833546_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d164c813b754d099714d4875c7405de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1f829f974634d488f1643966850c384_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9544bb0d4445a097ccc5fa7f50cd38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:VQW765Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec535a14efca43c882d02e3f9ef3b063_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vnda:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81f399dfe554faa998124d94d076956_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i418ff91379b846d3988ba7db10522717_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vnda:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce88e2ed3eb4664882da8188a70d03a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd61525c1c634dbc97c9cb4caa360206_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>vnda:installment</xbrli:measure></xbrli:unit><xbrli:context id="i9396936ca284498ea1ea5d4f7a73b747_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:ServiceOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id82d67047689492daa3dc90ebad4142a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:ServiceOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dffeb908a7c4343be9d34ab1b2dd23a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea30e5f62224d9baf5e2ab37d1f16cb_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf7edbea6dae4c4584d42f4bfaada83b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5cafed82f414158a6563a9d462e2f6f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4accca8a781b42bc8a5a731e56f0eec6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie623210fe21f455fba6a25bfe1712547_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id14b5fd7c713420383f8b6f8cdaf4438_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cbcabe269184dbcb50a511cf3bdb9fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefdf2eff6cd54e0ea9ebdad5ee519b38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5dba30ea1414af0bf583a5a09975a52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a749d60ade74a138ef81f76767e56e9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd51d5e4edf48f2ad3197f761187562_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id823e499960c408ba259173b9f02984b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5dd64fe80b642d18d3588ccecb6c437_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i533bb21627594019891d85b5903ed825_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">vnda:IncomeBeforeIncomeTaxesCurrentYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3af2a96bce0440ec840b163636430f9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">vnda:IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1209ef3dad5a4c70b22c2b5ea6d9c116_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">vnda:EstimatedRealizabilityofDeferredTaxAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia35ff2ef50ed4a898205b8960a640489_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia324b88c017e451d84714c225aa51f90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">vnda:OrphanDrugMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i868e756c16d248bf88fef93ad48e1708_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0312bfa2fd454fdd90ab881abbadfeaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnda:UnitedStatesExcludingDistrictOfColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff6f745ed084863aae10666b4b2b891_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94da092e27b14db4aff38691563ff026_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i78e7e943a648448d981304e612e68114_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:15.643%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ2_ffdab0b6-b157-49a4-9cfe-51d0c9bd3f00">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:15.643%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ3_b1ad988a-b034-4ece-a56b-8cfe68ef72f6">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAxMTY5_e78d48e6-51b2-488c-8e3f-9499fac7663c"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAxMTY5_5c6de3c0-1264-4e59-ba38-57c408cffe40">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQz_f409b14b-9f13-440c-ad5e-05cc58036736">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4_5d783477-7a9f-4f9f-9124-6313a4eba6f6">001-34186</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:15.643%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODUx_aeb12bd7-1eed-4e11-bbf4-72064518ff26">VANDA PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:15.643%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjQ1Yzk0YTc3MTdlNGJmMWE1NDM4MGU5NTU3NGYzZDcvdGFibGVyYW5nZToyNDVjOTRhNzcxN2U0YmYxYTU0MzgwZTk1NTc0ZjNkN18wLTAtMS0xLTA_ffc620e9-1c7f-4d10-a653-6f4df29ebbfd">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjQ1Yzk0YTc3MTdlNGJmMWE1NDM4MGU5NTU3NGYzZDcvdGFibGVyYW5nZToyNDVjOTRhNzcxN2U0YmYxYTU0MzgwZTk1NTc0ZjNkN18wLTEtMS0xLTA_91a477d6-d976-4bd8-a95a-2df168a2d5f5">03-0491827</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU2_c9ba8822-a6cb-4421-b08e-0a078d463ef7">2200 Pennsylvania Avenue NW</ix:nonNumeric>, <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODUy_bf1488bb-7705-4c8f-ac69-1a1a805fd9cc">Suite 300 E</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ5_6ad97c98-dca5-4357-8589-8367bcdccd5c">Washington</ix:nonNumeric> <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODUz_0c9f8d86-77f8-4fbc-8cfa-ce58b22a3c27">DC</ix:nonNumeric> <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU3_5dc119e8-7f14-41df-b515-f0b6805b0abe">20037</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ0_a36c9522-9ec8-4ece-b1f3-21c431bf6b2b">202</ix:nonNumeric>) <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODUw_00ea8787-0594-4eeb-9997-ff7fbaef8cdd">734-3400</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MDIwNmUzMTE4NzFmNGM3YzkyMWQxMDgzYjc5OTRjODUvdGFibGVyYW5nZTowMjA2ZTMxMTg3MWY0YzdjOTIxZDEwODNiNzk5NGM4NV8xLTAtMS0xLTA_0051a7ff-9070-47cc-ba8e-a1fc342d9fab">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MDIwNmUzMTE4NzFmNGM3YzkyMWQxMDgzYjc5OTRjODUvdGFibGVyYW5nZTowMjA2ZTMxMTg3MWY0YzdjOTIxZDEwODNiNzk5NGM4NV8xLTEtMS0xLTA_e264c668-1898-460c-8fa8-cc796f141703">VNDA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MDIwNmUzMTE4NzFmNGM3YzkyMWQxMDgzYjc5OTRjODUvdGFibGVyYW5nZTowMjA2ZTMxMTg3MWY0YzdjOTIxZDEwODNiNzk5NGM4NV8xLTItMS0xLTA_0c9342c7-7f0d-4223-8524-6073e14fcc46">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Exchange Act: None</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:15.643%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzA0NTMy_8c3a35eb-4c19-412b-a69c-0c265cb2f65e">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU4_27995b06-2f02-4a0d-85f6-cd493d851d92">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU5_24f69eac-3f20-4b5d-8564-505623b6394c">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU0_08f5a8eb-65b0-428f-82c9-d4383b7f6bca">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.801%"><tr><td style="width:1.0%"></td><td style="width:43.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjI5NjY2MWJkMzdkNGI3YWE4N2Q4MTIzZmU0ODVlNzgvdGFibGVyYW5nZToyMjk2NjYxYmQzN2Q0YjdhYTg3ZDgxMjNmZTQ4NWU3OF8wLTAtMS0xLTA_29c4040f-d46f-475a-85d7-6551a771e158">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjI5NjY2MWJkMzdkNGI3YWE4N2Q4MTIzZmU0ODVlNzgvdGFibGVyYW5nZToyMjk2NjYxYmQzN2Q0YjdhYTg3ZDgxMjNmZTQ4NWU3OF8yLTYtMS0xLTA_1a179379-61dc-4182-bc23-cfa770d1f7b4">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjI5NjY2MWJkMzdkNGI3YWE4N2Q4MTIzZmU0ODVlNzgvdGFibGVyYW5nZToyMjk2NjYxYmQzN2Q0YjdhYTg3ZDgxMjNmZTQ4NWU3OF80LTYtMS0xLTA_b07c75c5-746d-4bf9-bf3c-5e1fc7af4907">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAyOTI3_46dc4fbc-e221-4c3d-b8c8-a478771e7666">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAyOTMw_52cb1950-f8f6-4a5b-b911-29039f8f8642">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2020, the last business day of the registrant&#8217;s last completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="ic58a5d7276774436bb7a5273a227e621_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAxMTE4_882d904a-4195-4b4b-ba4a-eecf0271a001">609.8</ix:nonFraction>&#160;million based on the closing price of the registrant&#8217;s Common Stock, as reported by The Nasdaq Global Market, on such date. Shares of Common Stock held by each executive officer and director and stockholders known by the registrant to own 10% or more of the outstanding stock based on public filings and other information known to the registrant have been excluded since such persons may be deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s Common Stock, par value $0.001 per share, outstanding as of February&#160;4, 2021 was <ix:nonFraction unitRef="shares" contextRef="i0cdd21bdc0c645ba84491ec3d4e3be0e_I20210204" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8xMDk5NTExNjM1MTAz_48c1e10e-7a98-41d5-b4fe-22360beee271">54,882,710</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibit index as required by Item&#160;601(a) of Regulation S-K is included in Item&#160;15 of Part IV of this report.</span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU1_5c94798d-6abf-4dc8-b2dc-cf642daa4a99" escape="true"><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified portions of the registrant&#8217;s proxy statement with respect to the registrant&#8217;s 2021 Annual Meeting of Stockholders, which is to be filed pursuant to Regulation 14A within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Form 10-K.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i78e7e943a648448d981304e612e68114_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vanda Pharmaceuticals Inc.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_10">Part I</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_13">Cautionary Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_1458">Summary of P</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_1458">rincipal Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_1458">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_19">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_22">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_25">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_28">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_31">55</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_34">Part II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_37">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_40">Selected Consolidated Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_40">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_43">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_46">Qualitative and Quantitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_46">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_49">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_49">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_52">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_52">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_55">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_55">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_58">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_58">67</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_61">Part III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_64">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_64">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_67">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_67">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_70">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_70">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_73">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_73">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_76">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_76">68</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_79">Part IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_82">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_82">68</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_85">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_85">69</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_172">Exhibit Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_172">98</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i78e7e943a648448d981304e612e68114_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i78e7e943a648448d981304e612e68114_13"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This annual report on Form 10-K (Annual Report) contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Words such as, but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and &#8220;could,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. If the risks, changes in circumstances or uncertainties materialize or the assumptions prove incorrect, the results of Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements in this Annual Report may include, among other things, statements about: </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to commercialize HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tasimelteon) capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in the United States (U.S.) and Europe and HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsules and oral suspension (HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in the U.S.;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to increase market awareness of Non-24 and SMS and market acceptance of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to generate U.S. sales of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iloperidone) oral tablets for the treatment of schizophrenia;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the novel coronavirus (COVID-19) on our business and operations, including our revenue, our supply chain, our commercial activities, our ongoing and planned clinical trial and our regulatory activities; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on third-party manufacturers to manufacture HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in sufficient quantities and quality;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our level of success in commercializing HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in new markets;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to reach agreement with the U.S. Food and Drug Administration (FDA) regarding our regulatory approval strategy, preclinical animal testing requirements or proposed path to approval for tradipitant; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to prepare, file, prosecute, defend and enforce any patent claims and other intellectual property rights;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain rights to develop and commercialize our products under our license agreements;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our products, and the labeling for any approved products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain approval from the FDA for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for the treatment of jet lag disorder;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the timing and success of preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of our products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S., Europe and other jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability to utilize some or all of our prior net operating losses and orphan drug and research and development credits;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of the potential markets for our products and our ability to serve those markets;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding trends with respect to our revenues, costs, expenses, liabilities and cash, cash equivalents and marketable securities;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify or obtain rights to new products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and effects of litigation;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain the capital necessary to fund our research and development or commercial activities;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential losses incurred from product liability claims made against us; and</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use of our existing cash, cash equivalents and marketable securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained throughout this report. We caution you not to rely too heavily </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the forward-looking statements we make or that are made on our behalf. Each forward-looking statement speaks only as of the date of this Annual Report, and we undertake no obligation, and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encourage you to read Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our consolidated financial statements contained in this Annual Report. We also encourage you to read </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Principal Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and Part&#160;I, Item 1A of this Annual Report, entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which contains a more complete discussion of the risks and uncertainties associated with our business. In addition to the risks described in this Annual Report, other unknown or unpredictable factors also could affect our results. Therefore, the information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission from time to time, including on Form 10-Q and Form 8-K, which may supplement, modify, supersede or update those risk factors. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_1458"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SUMMARY OF PRINCIPAL RISK FACTORS </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary briefly lists the principal risks and uncertainties facing our business, which are only a select portion of those risks. A more complete discussion of those risks and uncertainties is set forth in Part I, Item 1A of this Annual Report, entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additional risks not presently known to us or that we currently deem immaterial may also affect us. If any of these risks occur, our business, financial condition or results of operations could be materially and adversely affected. </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to the following principal risks and uncertainties:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Risks Related to our Business and Industry</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We are dependent on the commercial success of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Growth of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> may be slow or limited for a variety of reasons including competing products or unanticipated safety issues.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Global economic conditions may have an adverse effect on our business.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Global health crises and pandemics, such as the global outbreak of COVID-19, may adversely impact our business.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">The FDA may not accept for filing the New Drug Applications (NDAs) that we may submit for tradipitant for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia, or the FDA may determine that our clinical trial results for tradipitant for these indications do not demonstrate adequate safety and efficacy.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">The FDA may not approve our supplemental New Drug Application (sNDA) for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> for the treatment jet lag disorder.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may be unable to enter into third-party collaborations to develop and commercialize our products, or collaborations we enter into with any such third party may not be commercially successful.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Even after we obtain regulatory approvals of a product, acceptance of the product in the marketplace is uncertain.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We rely and will continue to rely on outsourcing arrangements for many of our activities, including preclinical and clinical development and supply of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">, HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">, Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> and our other products.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">We may experience disruptions to our HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">, HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> supply chains.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may fail to comply with government regulations regarding the sale and marketing of our products.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may fail to comply with regulations and obligations related to the ongoing oversight of our products regarding, among other things, development, manufacturing, labeling, recording keeping and reporting.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may not market or distribute our products in a manner compliant with federal or state healthcare fraud and abuse laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We rely on a limited number of specialty pharmacies for distribution of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> in the U.S., and the loss of one or more of these specialty pharmacies or their failure to distribute HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> effectively would materially harm our business.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our revenues from Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> are substantially dependent on sales through a limited number of wholesalers.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">FDA and foreign regulatory approval of our products is uncertain.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our products may cause undesirable side effects or have other properties that could delay, prevent or result in the revocation of their regulatory approval or limit their marketability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Clinical trials for our products are expensive and their outcomes are uncertain.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income is dependent on generating future taxable income and may be limited, including as a result of transactions involving our common stock.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our contract research organizations (CROs) may not successfully carry out their duties or we may lose our relationships with CROs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We rely on a limited number of third-party manufacturers to formulate and manufacture our products and these manufacturers may not able to satisfy our demand and alternative sources may not be available.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Materials necessary to manufacture our products may not be available on commercially reasonable terms, or at all.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may lose key scientists or management personnel or fail to recruit additional highly skilled personnel.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may be subject to product liability lawsuits.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">European Union (E.U.) Member States tend to impose strict price controls, which may delay or prevent the further commercial launch or impede the commercial success of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> in Europe and adversely affect our future results of operations.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may not be able to effectively market and sell our future products, if approved, in the U.S.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Healthcare legislative reform measures or developments arising from changes in political climate may have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Risks Related to Intellectual Property and Other Legal Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our rights to develop and commercialize our products are subject in part to the terms and conditions of licenses or sublicenses granted to us by other pharmaceutical companies.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our efforts to protect the proprietary nature of the intellectual property related to our products may not be adequate.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We are, have been, and may continue to be, involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful, and third parties may challenge the validity or enforceability of our patents and they may be successful.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may not be able to obtain protection under the Hatch-Waxman Act and similar foreign legislation to extend our patents and to obtain market exclusivity for our products.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">We may not be successful in the development of products for our own account.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:102%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:13.8pt">Litigation or third-party claims of intellectual property infringement could require us to divert resources and may prevent or delay our drug discovery and development efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BUSINESS</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to advance novel approaches to bring important, new medicines to market through responsible innovation. We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio is currently comprised of two products, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of schizophrenia. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first treatment for patients with Non-24 and SMS approved by the FDA. In addition, we have a number of drugs in development, including: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tasimelteon) for the treatment of jet lag disorder, pediatric Non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD); </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 2003 and are headquartered in Washington, D.C.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to further solidify our position as a leading global biopharmaceutical company focused on developing and commercializing innovative therapies addressing high unmet medical needs through the application of our drug development expertise and our pharmacogenetics and pharmacogenomics expertise. The key elements of our strategy to accomplish this goal are to:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Maximize the commercial success of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Enter into strategic partnerships to supplement our capabilities and to extend our commercial reach;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pursue the clinical development and regulatory approval of our products, including tradipitant;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Apply our pharmacogenetics and pharmacogenomics expertise to differentiate our products; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expand our product portfolio through the identification and acquisition of additional products; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Utilize novel and innovative approaches in pursuit of each of these strategies.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialized Products</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial product portfolio consists of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#00497f;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="background-color:#00497f;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#00497f;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#00497f;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#00497f;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Net Sales (in millions)</span></td><td colspan="3" style="background-color:#00497f;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#00497f;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Geography</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div><img src="vnda-20201231_g1.gif" alt="vnda-20201231_g1.gif" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"/><img src="vnda-20201231_g2.jpg" alt="vnda-20201231_g2.jpg" style="height:89px;margin-bottom:5pt;vertical-align:text-bottom;width:151px"/></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-24 (capsules)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nighttime sleep disturbances in SMS (capsules and HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> oral suspension)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$160.7</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States<br/><br/>Europe (Non-24 Only)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div><img src="vnda-20201231_g3.gif" alt="vnda-20201231_g3.gif" style="height:74px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"/></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schizophrenia (tablets)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$87.5</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States<br/><br/>Israel</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">for Non-24 (capsules)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules were approved in the U.S. for the treatment of adults with Non-24. Non-24 is a serious, rare and chronic circadian rhythm sleep-wake disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first FDA approved treatment for Non-24. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a melatonin agonist of the human MT1 and MT2 receptors, with greater specificity for MT2. These receptors are thought to be involved in the control of circadian rhythms. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is believed to reset the master body clock in the suprachiasmatic nucleus, located in the hypothalamus, resulting in the entrainment and alignment of the body&#8217;s melatonin and cortisol rhythms to the 24-hour day-night cycle. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most people have a master body clock that naturally runs longer than 24 hours and light is the primary environmental cue that resets it to 24 hours each day. Individuals with Non-24 have a master body clock that is not reset, and continually delays, resulting in prolonged periods of misalignment between their circadian rhythms and the 24-hour day-night cycle, including the timing of melatonin and cortisol secretion. As a result of this misalignment, Non-24 is associated with significant disruption of the sleep-wake cycle and impairments in social and occupational functioning, and marked subjective distress. Individuals with Non-24 cycle in and out of phase and suffer from disrupted nighttime sleep patterns and/or excessive daytime sleepiness.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched commercially in the U.S. in April 2014. In addition, in July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24 in totally blind adults and included post-marketing commitments related to a pediatric investigation plan. This authorization was renewed in July 2020 for an unlimited duration, and is valid in the 27 countries that are members of the European Union (E.U.), as well as European Economic Area members Iceland, Liechtenstein and Norway. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched commercially in Germany in August 2016.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2010, the FDA granted orphan drug designation status for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Non-24 in blind individuals. The FDA grants orphan drug designation to drugs that may provide significant therapeutic advantage over existing treatments and target conditions affecting 200,000 or fewer U.S. patients per year. Orphan drug designation provides potential financial and regulatory incentives, including study design assistance, tax credits, waiver of FDA user fees, and up to seven years of market exclusivity upon marketing approval. In February 2011, the European Medicines Agency (EMA) designated HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an orphan medicinal product for the same indication.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-24 affects a majority of totally blind individuals, or approximately 80,000 people in the U.S. Blind individuals who develop Non-24 lack the light sensitivity necessary to synchronize the master body clock in the brain with the 24-hour day-night cycle. Non-24 also can affect sighted individuals. As with the totally blind, Non-24 in sighted individuals appears to be a comorbidity with certain other conditions. For example, a comorbidity has been established between psychiatric mood disorders and Non-24.  Hospitalized individuals with neurological and psychiatric disorders can become insensitive to social cues, which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may predispose them to the development of Non-24. This recognition of comorbidity led Vanda to an initiative to engage with the psychiatric community. Patients diagnosed with traumatic brain injury, including concussions, frequently suffer from sleep disorders, some of which may be circadian rhythm sleep-wake disorders, including Non-24.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are no FDA or EC approved treatments for Non-24 other than HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there are a number of drugs approved and prescribed for patients with sleep disorders. The most commonly prescribed drugs are hypnotics. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of commonly prescribed drugs for patients with sleep disorders.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">for SMS (capsules and oral suspension)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> capsules and oral suspension (HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) were approved in the U.S. for the treatment of adults and children, respectively, with nighttime sleep disturbances in SMS. SMS is a developmental disorder that is caused by a small deletion of human chromosome 17p. In more rare cases, SMS is caused by a point mutation in the RAI1 gene, which resides in the deleted region. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is the first FDA-approved medication for patients with SMS. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2010, the FDA granted orphan drug designation status for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of sleep disorder in SMS. SMS is estimated to affect 1/15,000-25,000 births in the U.S. SMS is not usually inherited but rather is caused by a de-novo deletion. Patients with SMS present with a number of physical, mental and behavioral problems. The most common symptom of SMS is a severe sleep disorder associated with significant disruption in the lives of patients and their families.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are no FDA approved treatments for patients with SMS other than HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there are a number of drugs approved and prescribed for patients with sleep disorders that may be used to treat patients with SMS. The most commonly prescribed drugs are hypnotics. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of commonly prescribed drugs for patients with sleep disorders.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">for schizophrenia (tablets)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is a product for the treatment of schizophrenia. In May 2009, the FDA granted U.S. marketing approval of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the acute treatment of schizophrenia in adults. At that time, we had certain worldwide exclusive rights relating to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which we obtained pursuant to a sublicense agreement entered into with Novartis Pharma AG (Novartis) in June 2004. In October 2009, we amended and restated our sublicense agreement with Novartis pursuant to which Novartis retained exclusive commercialization rights to all formulations of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the U.S. and Canada. In January 2010, Novartis launched Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the U.S. On December&#160;31, 2014, Novartis transferred all the U.S. and Canadian commercial rights to the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> franchise to us as part of a settlement agreement. Additionally, our distribution partners launched Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in Israel in 2014. In May 2016, the FDA approved a supplemental New Drug Application (sNDA) for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the maintenance treatment of schizophrenia in adults.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion recommending against approval of Fanaptum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> did not outweigh its risks and recommended against marketing authorization. The negative opinion was upheld upon appeal in November 2017. (See Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Matters,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements in Part II, Item 8 of this Annual Report, which is incorporated herein by reference, for information relating to subsequent proceedings in this matter.)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schizophrenia is a chronic, debilitating mental disorder characterized by hallucinations, delusions, racing thoughts and other psychotic symptoms (collectively referred to as &#8220;positive symptoms&#8221;), as well as moodiness, anhedonia (inability to feel pleasure), loss of interest, eating disturbances and withdrawal (collectively referred to as &#8220;negative symptoms&#8221;), and attention and memory deficits (collectively referred to as &#8220;cognitive symptoms&#8221;). Schizophrenia develops in late adolescence or early adulthood in approximately 1% of the world&#8217;s population. Most schizophrenia patients today are treated with drugs known as &#8220;atypical&#8221; antipsychotics, which were first approved in the U.S. in the late 1980s. These antipsychotics have been named &#8220;atypical&#8221; for their ability to treat a broader range of negative symptoms than the first-generation &#8220;typical&#8221; antipsychotics, which were introduced in the 1950s and are now generic. Atypical antipsychotics are generally regarded as having improved side effect profiles and efficacy relative to typical antipsychotics. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of commonly prescribed atypical antipsychotics in addition to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a research and development organization that includes extensive expertise in the scientific disciplines of pharmacogenetics and pharmacogenomics. We operate cross-functionally and are led by an experienced research and development management team. We use rigorous project management techniques to assist us in making disciplined strategic research and development program decisions and to help limit the risk profile of our product pipeline. We also access relevant market information and key opinion leaders in creating target product profiles and, when appropriate, as we advance our programs towards commercialization. We engage third parties to conduct portions of our preclinical research. In addition, we utilize multiple clinical sites to conduct our clinical trials; however, we are not substantially dependent upon any one of these sites for our clinical trials nor do any of them conduct a major portion of our clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our product pipeline currently consists of the following products in clinical development or under regulatory review:</span></div><div style="margin-top:6pt"><img src="vnda-20201231_g4.jpg" alt="vnda-20201231_g4.jpg" style="height:478px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for jet lag disorder </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and May 2018, respectively, we announced the results of our JET8 and JET studies for the treatment of jet lag disorder. In the JET8 clinical study, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> demonstrated significant and clinically meaningful benefits in nighttime and daytime symptoms of jet lag disorder, including improvement in sleep time and benefits in measurements of next day alertness.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JET study showed effectiveness in treating travelers who traveled either five or eight time zones from Washington, DC to London and San Francisco or Los Angeles to London, respectively. The results support the previously reported pivotal JET5 and JET8 Phase III studies, which demonstrated improvements in patients who experienced circadian advances of five and eight hours, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in September 2018, we announced results from a driving study, which demonstrated that tasimelteon did not impair measures of driving performance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA accepted the filing of our sNDA for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of jet lag disorder in December 2018. The FDA determined the action target date under the Prescription Drug User Fee Act Amendments of 2017 (PDUFA-VI) to be August 16, 2019, and on that date, we received a complete response letter (CRL) from the FDA. The FDA asserted in the CRL that the measures demonstrating improved sleep were of unclear clinical significance. We met with the FDA to discuss the CRL in a Post Action meeting and we are determining our next steps.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jet lag disorder is a common circadian disorder frequently observed in millions of travelers who cross multiple time zones. Jet lag disorder is characterized by nighttime sleep disruption, a decrease in daytime alertness and impairment to social and occupational functioning. Jet lag disorder symptoms are more severe during eastward travel. U.S. Department of Commerce, International Trade Administration reports state that more than 20 million U.S. residents make trips abroad each year to overseas destinations in Europe, the Middle East and Asia.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for pediatric Non-24 </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of pediatric Non-24. A pharmacokinetic study of the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pediatric liquid formulation was completed in the first quarter of 2018. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for DSPD</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical program of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in DSPD is ongoing. DSPD is a circadian rhythm disorder in which a person's sleep is delayed beyond the socially acceptable or conventional bedtime. This delay in falling asleep causes difficulty in waking up at the desired time and affects social and occupational functioning.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for ASD</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical program of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of sleep disturbances in ASD is expected to be initiated in the first quarter of 2021. Sleep disturbances in ASD are a high unmet medical need in people with ASD and have been characterized in the literature to include difficulties falling and staying asleep.  </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for bipolar disorder </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase III study of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in bipolar disorder is ongoing. Bipolar disorders are brain disorders that cause changes in a person&#8217;s mood, energy and ability to function. Bipolar disorder is a category that includes three different conditions - bipolar I, bipolar II and cyclothymic disorder.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">People with bipolar disorders have extreme and intense emotional states that occur at distinct times, called mood episodes. These mood episodes are categorized as manic, hypomanic or depressive. People with bipolar disorders generally have periods of normal mood as well.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for schizophrenia (LAI)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we enrolled our first patient in a pharmacokinetic study of the LAI formulation of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; This pharmacokinetic study is ongoing and will serve to inform the dosing for a later clinical study of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LAI for the treatment of schizophrenia. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for PDP</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical program of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in PDP is expected to begin in 2021. Parkinson's disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain called substantia nigra. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">People with Parkinson's disease experience a combination of hallucinations and delusions and the disease is associated with significant caregiver burden. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tradipitant for gastroparesis</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced results in December 2018 from a Phase II randomized clinical study (2301) of tradipitant as a monotherapy in the treatment of gastroparesis. Several symptom severity scales were used to assess gastroparesis symptoms, including the Gastroparesis Symptom Index (GCSI), Patients Assessment of Upper Gastrointestinal Disorders-Symptoms </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(PAGI-SYM), and Patient Global Impression of Change (PGI-C) as well as a Clinician Global Impression of Severity (CGI-S). Tradipitant met the primary endpoint of the study of change in nausea score as measured by patient daily diaries and also met the related endpoint of improvement in the number of nausea free days. Tradipitant also showed significant improvement in most of the secondary endpoints studied, including several key scales reflecting overall gastroparesis symptoms, specifically GCSI, PAGI-SYM, CGI-S, and PGI-C. We are currently enrolling patients in a Phase III study of tradipitant in the treatment of both diabetic and idiopathic gastroparesis. This Phase III study is a 12-week study of similar design to the Phase II study in both target population and endpoints. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that tradipitant has a well-established safety profile, as demonstrated by the results of extensive testing in animals and humans. Despite these results, however, the FDA informed us in December 2018 that in order to treat patients beyond 12 weeks, we will have to conduct a 9-month non-rodent chronic toxicity study, which currently limits our ability to collect safety data in humans for more than 12 weeks. The non-rodent study required by the FDA necessitates the sacrifice of dozens of animals and we have disputed the necessity of a 9-month non-rodent chronic toxicity study. In February 2019, we filed a lawsuit in the U.S. District Court for the District of Columbia (DC District Court) challenging the FDA&#8217;s position, but ultimately did not prevail. Despite our disagreement with the FDA, the preclinical package has allowed us to continue to conduct all of the efficacy studies necessary for NDA filing. Moreover, in July 2020, the FDA approved the use of tradipitant for up to six months with an option of renewal for an individual patient who requested expanded access. Since then, other patients who experienced a unique benefit in tradipitant studies have requested expanded access. The expanded access program is ongoing and a number of patients have initiated treatment. Although this expanded access program is not intended for data collection, we will collect safety data from this cohort of expanded access patients and include this data in its NDA for tradipitant for the treatment of gastroparesis; however, the FDA may disregard such safety data when reviewing the NDA. The lack of long-term (&gt;12 weeks in humans) safety data would likely impact the FDA&#8217;s willingness to approve tradipitant for a chronic indication. However, because long-term safety data is not normally a requirement for short-term indications, and with a preclinical profile that has not precluded clinical development, we believe the package is complete for any NDA filing to treat patients for 12 weeks or less. In gastroparesis, for example, the FDA has communicated to us that it is considering an indication for the short-term relief of nausea in gastroparesis. While this short-term indication is not preferred, we would consider accepting this limited indication while continuing to pursue a chronic indication. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gastroparesis is a serious medical condition characterized by delayed gastric emptying associated with the symptoms of nausea, vomiting, bloating, fullness after meals and abdominal pain, along with significant impairment of social and occupational functioning. A paper by Rey et al published in the January 2012 Journal of Neurogastroenterology and Motility estimated the prevalence of gastroparesis in the U.S. to be over 5 million patients, many of whom remain undiagnosed. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tradipitant for motion sickness</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we reported tradipitant was effective in treating motion sickness in a Phase II clinical study conducted in the Pacific Ocean. In the study, 126 people with a prior history of motion sickness were subjected to sea travel in the Pacific Ocean. Study participants were randomized to receive either tradipitant or placebo in a blinded fashion. The study had two primary endpoints: percentage of participants vomiting, and Motion Sickness Severity Scale (MSSS) Worst score. In the overall population, a significantly higher percentage of participants experienced vomiting in the placebo arm as compared to the tradipitant arm. The MSSS Worst score endpoint also favored tradipitant, but the difference did not reach statistical significance. The protocol for a pivotal Phase III motion sickness study was discussed with the FDA at the end of Phase II meeting, and the FDA agreed with the adequacy of the program design to support an NDA. Preparations for this study have begun with the boat trip portion of the study expected to commence as soon as local restrictions related to the COVID-19 pandemic are lifted.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Motion sickness is a disorder that arises often as a response to real or perceived movement, as occurring during vehicular travel. Vomiting is the most disturbing symptom of motion sickness, although the disorder is often accompanied by a constellation of symptoms that includes nausea, sweating, pallor, headache and anorexia. Motion sickness is one of the most prevalent episodic disorders in the world, whose prevalence has dramatically increased with world population mobility over the last 100 years. It is reported that approximately 30% of the general population suffers from motion sickness under ordinary travel conditions that include sea, air and land travel. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tradipitant for atopic dermatitis</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced results in September 2017 from a randomized Phase II clinical study of tradipitant as a monotherapy in the treatment of patients with atopic dermatitis. Tradipitant was shown to improve the intensity of the worst itch patients experienced, as well as atopic dermatitis disease severity. On the pre-specified primary endpoint of Average Itch Visual Analog </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scale (VAS), tradipitant showed improvement over placebo, but this improvement was not significant due to high placebo effect and the lack of sensitivity of this measure. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we initiated EPIONE, a Phase III study of tradipitant for pruritus in atopic dermatitis. In October 2019, we began enrolling patients in EPIONE 2, a second Phase III clinical study of tradipitant in atopic dermatitis. We announced results of EPIONE in February 2020. The EPIONE study did not meet its primary endpoint in reduction of pruritus across the overall study population. However, the antipruritic effect of tradipitant was robust in the mild atopic dermatitis population. The EPIONE study continued to demonstrate that tradipitant is safe and well-tolerated. The ongoing EPIONE 2 study was placed on hold due to the COVID-19 pandemic.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by the symptom of intense and persistent pruritus or itch. Other clinical features include erythema, excoriation, edema, lichenification, oozing and xerosis. Atopic dermatitis is a common skin disorder affecting millions of people worldwide. Currently, there are very few safe systemic treatments available for atopic dermatitis, representing a significant unmet medical need in this population. A 2015 Decision Resources Group report estimated that 9.8 million individuals were diagnosed with atopic dermatitis in the U.S., of which approximately 6.4 million were drug-treated atopic dermatitis patients.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tradipitant for COVID-19 pneumonia </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. We received permission from the FDA to proceed with the study for the treatment and prevention of pneumonia associated with COVID-19. Enrollment in our Phase III clinical study of VLY-686-3501 is ongoing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 is associated with a lower respiratory tract inflammation that often progresses to acute respiratory distress syndrome requiring mechanical ventilation. Tradipitant targets the neurokinin-1 receptor, which is coded by the TACR1 gene and is the main receptor for substance P, an 11 amino acid neuropeptide with a diverse set of functions. It has been shown that the substance P NK-1R system is involved in the neuroinflammatory processes that leads to significant lung injury following a number of insults, including viral challenges.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VTR-297</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTR-297 is a small molecule HDAC inhibitor with potential use as a treatment for several oncology indications. The FDA accepted an Investigational New Drug (IND) application for VTR-297 in 2017 and provided authorization to proceed with the treatment of patients with relapsed and/or refractory hematologic malignancies. We initiated a clinical study in patients with hematologic malignancies in the fourth quarter of 2018. Enrollment in the Phase I clinical study (1101) of VTR-297 in hematologic malignancies is ongoing.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Portfolio of CFTR activators and inhibitors </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2020, the FDA accepted the IND application to evaluate CFTR activator VSJ-110 and provided authorization to proceed with clinical development. We are evaluating VSJ-110 for the treatment of allergic conjunctivitis. In November 2020, we initiated a study in human volunteers that will evaluate the acute anti-inflammatory effects of VSJ-110 in an ocular allergic challenge model, and will evaluate the prosecretory effects using standard tear production assessments. The results from the study will help guide further development of VSJ-110 to treat a variety of ocular inflammatory conditions, including dry eye, which has an estimated worldwide prevalence of 5-20%, with about 16 million affected individuals in the U.S. VSJ-110 (previously known as CFTRact-K267) is a small molecule nanomolar potency CFTR activator. VSJ-110 has shown efficacy in a dry eye model and exhibited anti-inflammatory properties in both in vitro and in vivo assays.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, an early stage CFTR inhibitor program is planned for BPO-27 for the treatment of secretory diarrhea disorders, including cholera. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other products</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VQW-765</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VQW-765 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist that we licensed from Novartis on December&#160;31, 2014 pursuant to a settlement agreement. The FDA accepted an IND application for VQW-765 in January 2020 and provided authorization to proceed with clinical development. We are evaluating VQW-765 for the treatment of psychiatric disorders. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For more detailed information regarding our clinical trial results and regulatory activities for our products please refer to our SEC filings and press releases, which can be found on the SEC Edgar system and on our website www.vandapharma.com.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rights to develop and commercialize our products are subject to the terms and conditions of licenses granted to us by other pharmaceutical companies.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2004, we entered into a license agreement with Bristol-Myers Squibb (BMS) under which we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have paid BMS $37.5 million in upfront fees and milestone obligations. We have no remaining milestone obligations to BMS. Additionally, we are obligated to make royalty payments on HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net sales to BMS in any territory where we commercialize HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for a period equal to the greater of 10 years following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, we are obligated to pay a&#160;10%&#160;royalty on net sales in that territory.&#160;The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. We are also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that we receive from a third party in connection with any sublicensing arrangement, at a rate which is in the&#160;mid-twenties.&#160;We have agreed with BMS in the license agreement for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to use commercially reasonable efforts to develop and commercialize HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may terminate the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> license agreement under certain circumstances, including a material breach of the agreement by the other. In the event we terminate our license, or if BMS terminates our license due to our breach, all rights licensed and developed by us under this agreement will revert or otherwise be licensed back to BMS on an exclusive basis.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of a settlement agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;franchise to us on December&#160;31, 2014. We paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December&#160;2019 related to manufacturing&#160;know-how.&#160;No further royalties on manufacturing&#160;know-how&#160;are payable by us. We are also obligated to pay Sanofi a fixed royalty on Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net sales equal up to 6% on Sanofi&#160;know-how&#160;not related to manufacturing under certain conditions for a period of up to 10 years in markets where the NCE patent has expired or was not issued. We are obligated to pay this 6% royalty on net sales in the U.S. through November 2026. No further royalties on know-how not related to manufacturing will be payable by us for net sales in the U.S. after November 2026. We may lose our rights to develop and commercialize Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;if we fail to comply with certain requirements in the Titan license agreement regarding our financial condition, or if we fail to comply with certain diligence obligations regarding our development or commercialization activities.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tradipitant (VLY-686)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2012, we entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which we acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an NK-1R antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. We have paid Lilly $3.0 million in upfront fees and development milestones, including a $2.0 million milestone payment as a result of enrolling the first subject into a Phase III study for tradipitant in July 2018. As of December 31, 2020, remaining milestones include a $2.0 million development milestone due upon the filing of the first marketing authorization for tradipitant in either the U.S. or the E.U,&#160;$10.0 million&#160;and&#160;$5.0 million&#160;for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to&#160;$80.0 million&#160;for sales milestones. We are obligated to use commercially reasonable efforts to develop and commercialize tradipitant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may terminate the agreement under certain circumstances, including a material breach of the agreement by the other. In the event that we terminate the agreement, or if Lilly terminates the agreement due to our breach or for certain other reasons set forth in the agreement, all rights licensed and developed by us under the agreement will revert or otherwise be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensed back to Lilly on an exclusive basis, subject to payment by Lilly to us of a royalty on net sales of products that contain tradipitant.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Portfolio of CFTR activators and inhibitors</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, we entered into a license agreement with the University of California San Francisco (UCSF), under which we acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, we will develop and commercialize the CFTR activators and inhibitors and are responsible for all development costs under the license agreement, including current&#160;pre-investigational&#160;new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as single-digit tiered-royalties on net sales. To date, we have paid UCSF $1.2 million in upfront fees and development milestones. As of December 31, 2020, remaining milestones include $12.2 million for development milestones and $33.0 million for future regulatory approval and sales milestones. Included in the $12.2 million in development milestones is a $350,000 milestone due upon the conclusion of a Phase I study for each licensed product, not to exceed $1.1 million in total for the CFTR portfolio. In the fourth quarter of 2020, we determined the $350,000 milestone to be probable and accrued it as a current liability as of December 31, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may terminate the agreement under certain circumstances. In the event that we terminate the agreement, or if UCSF terminates the agreement due to our breach or for certain other reasons set forth in the agreement, all rights licensed and developed by us under the agreement will revert or otherwise be licensed back to UCSF. Termination will not relieve us of our obligation to pay royalties or other payments owed, if any, to UCSF under the terms of the agreement.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VQW-765</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the settlement agreement with Novartis relating to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II&#160;alpha-7&#160;nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, we are obligated to use commercially reasonable efforts to develop and commercialize VQW-765 and are responsible for all development costs. We have no milestone obligations, but Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the&#160;mid-teens.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may terminate the agreement under certain circumstances, including a material breach of the agreement by the other. In the event that we terminate the agreement, or if Novartis terminates the agreement due to our breach or for certain other reasons set forth in the agreement, all rights licensed and developed by us under the agreement will revert or otherwise be licensed back to Novartis on an exclusive basis, subject to payment by Novartis to us of a royalty on net sales of products that contain VQW-765.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights; Hatch-Waxman Protection</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be able to protect our products from unauthorized use by others only to the extent that our products are covered through regulatory protections or by valid and enforceable patents, either licensed to us by others or generated through our activities internally, that give us sufficient proprietary rights. Accordingly, securing patents, regulatory data package protection, and other proprietary rights is an essential element of our business strategies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, tradipitant and VQW-765 are covered by NCE and other patents and patent applications related to their respective medicinal uses. In addition, NCE patent protection has been sought for VTR-297 and CFTR. Patent applications for these active ingredients remain pending. While the NCE patents protecting Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have expired, Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remains protected by medicinal patents. For more on the license and sublicense arrangements related to these active ingredients, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above. In addition, we have filed for patents based on our own discoveries that seek to provide additional protection for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comprehensive list of patents for our U.S. commercial products is available in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Orange Book) for our commercial products and is also provided in the table below. Members of these patent families are also issued or pending in a number of territories, such as Europe and Japan. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:17.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US&#160;5,856,529</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New&#160;chemical&#160;entity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,060,995</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,539,234</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,549,913</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,730,910</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,855,241</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US RE46604</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 10,071,977</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug substance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 10,149,829</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 10,179,119</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 10,376,487</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 10,449,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 10,610,510</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 10,610,511</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 10,829,465</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug substance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 8,586,610</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 8,652,776</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 8,999,638</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,072,742</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,074,254</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,074,255</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,074,256</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,138,432</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US 9,157,121</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method&#160;of&#160;treatment</span></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rights to the NCE patent covering HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related intellectual property have been acquired through a license with BMS. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its formulations, genetic markers and uses are the subject of numerous patent filings for which protection has been sought in selected countries worldwide. The NCE patent covering HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expires in December 2022 in the U.S., which is inclusive of a five-year extension granted under the Hatch-Waxman Act in October 2018. Corresponding NCE patent protection has expired in most other markets. The U.S. Patent and Trademark Office has issued 12 method of treatment patents for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that will expire between 2033 and 2035 and two drug substance patents that will expire in 2035. We also have other pending patent applications covering methods of treatment and compositions of tasimelteon (HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> active ingredient) oral suspensions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the law provides for 10 years of data exclusivity (with the potential for an additional year if a medicine is developed for a significant new indication). In addition, Europe provides for 10 years of market exclusivity for orphan indications. As such, in Europe, data or market exclusivity will provide protection for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for at least 10 years from approval. It is also possible that the protection through a basic patent (i.e., a patent that protects a product as such, a process to obtain a product, or an application of a product) in Europe could be extended for up to five years by the issuance of a supplementary protection certificate (SPC). A completed Pediatric Investigation Plan (PIP) could further extend SPC protection for an additional six months or the market exclusivity in an orphan indication for two additional years. Thus, a PIP could provide a total of 12 years of market exclusivity for an orphan indication. The European Patent Office has granted our patent application directed to the 20 mg/day dose. This patent will expire in 2027 and provides the basis for an SPC. Other pending patent applications in Europe, if granted, may offer additional protection for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. and Europe, data exclusivity will protect HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from generic competition for varying numbers of years depending on the country.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional patent applications directed to specific sleep disorders and to methods of treating patients with HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if issued, would provide exclusivity for such indications and methods of treatment, potentially extending the effective patent protection period in the U.S., Europe, and other markets.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NCE patent for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expired in 2016 in the U.S. and in 2010 in other countries, was owned by Sanofi. Other patents and patent applications relating to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are owned by Vanda. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> metabolites, formulations, genetic markers and uses are the subject of numerous patent filings in which protection has been sought in the U.S., Europe, and other markets. In November 2013, a U.S. patent (U.S. 8,586,610) directed to a method of treating patients with Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> based on genotype was issued to us by the U.S. Patent and Trademark Office. This patent, which was listed in the Orange Book in January 2015, is set to expire in 2027, potentially further extending the U.S. marketing exclusivity for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additional method of treatment patents have been issued in the U.S. and listed in the Orange Book, with the latest expiration date in December 2031. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also filed and plan on filing additional patent applications covering the use of iloperidone (Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> active ingredient) LAI formulations. Patents for the microsphere LAI formulation of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;expire in 2024 in the U.S. and 2022 in some markets in Europe. Patents for the aqueous microcrystals LAI formulation of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;expire in 2023 in the U.S. and in some markets in Europe. We have pending patent applications covering the use of iloperidone and plan on filing additional applications based on discoveries made throughout the development plan of this molecule.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the law provides for 10 years of regulatory exclusivity (with the potential for an additional year if the drug is developed for a significant new indication). No generic versions of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would be permitted to be marketed or sold during the applicable regulatory exclusivity period in most European countries. Outside the U.S. and Europe, similar regulatory package protection periods may be available and could protect Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from generic competition for varying numbers of years depending upon the country. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tradipitant</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly owns an NCE patent as well as patent applications directed to polymorphic forms of, and methods of making tradipitant. This patent protection was sought in the U.S. and in other countries worldwide. These patents and patent applications have been licensed to us. The NCE patent covering tradipitant expires in April 2023, except in the U.S., where it expires normally in June 2024, subject to any extension that may be received under the Hatch-Waxman Act. We have filed additional patent applications based on discoveries made during recent studies with tradipitant.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VTR-297</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTR-297 is a small molecule HDAC inhibitor with potential use as a treatment for several oncology indications. We have pending patent applications covering the use of VTR-297 and plan on filing additional applications based on discoveries made throughout the development plan of this molecule.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Portfolio of CFTR activators and inhibitors</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of CFTR activators and inhibitors may have broad applicability in addressing a number of high unmet medical needs, including chronic dry eye, constipation, polycystic kidney disease, cholestasis and secretory diarrheas.&#160;We plan on filing applications based on discoveries made throughout the development plan of these product candidates.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VQW-765</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis owns an NCE patent as well as patent applications directed to methods of using VQW-765, VQW-765 formulations, and combinations of VQW-765 with other active pharmaceutical ingredients. In connection with the settlement agreement with Novartis relating to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II&#160;alpha-7&#160;nicotinic acetylcholine receptor partial agonist. The NCE patent expires normally in 2023 in the U.S., Europe, and other markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other patents</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aside from the NCE patents and other in-licensed patents discussed above, we have obtained or filed numerous patents and patent applications, most of which have been filed in key markets including the U.S., relating to our products and product candidates. In addition, we have filed numerous other patent applications relating to drugs not presently in clinical studies. The claims in these various patents and patent applications are directed to compositions of matter, including claims covering other products, pharmaceutical compositions and methods of use.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary know-how</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For proprietary know-how that is not appropriate for patent protection, processes for which patents are difficult to enforce and any other elements of our discovery process that involve proprietary know-how and technology that are not covered by patent applications, we generally rely on trade secret protection and confidentiality agreements to protect our interests. We require all of our employees, relevant consultants and advisors to enter into confidentiality agreements. Where it is necessary to share our proprietary information or data with outside parties, our policy is to make available only that information and data required to accomplish the desired purpose and only pursuant to a duty of confidentiality on the part of those parties.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing and Sales</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules were approved in the U.S. for the treatment of Non-24 in January 2014 and HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules and oral suspension were approved for the treatment of nighttime sleep disturbances in SMS in December 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercially launched HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. in April 2014. Additionally, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules were approved in the E.U. for the treatment of Non-24 in totally blind adults in July 2015 and, in August 2016, we commercially launched HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Germany. Given the range of potential indications for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we may pursue one or more partnerships for the development and commercialization of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> worldwide.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oral tablets were approved in the U.S. for the treatment of schizophrenia in May 2009 and commercially launched in the U.S. in January 2010. We continue to explore the regulatory path and commercial opportunity for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oral formulation in other regions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are generated from product sales and are concentrated with specialty pharmacies, including Diplomat Pharmacy, Inc. (a subsidiary of UnitedHealth Group) and Accredo (a subsidiary of Express Scripts), and wholesalers, including Cardinal Health, Inc., AmerisourceBergen Drug Corporation, and McKesson Corporation. These 5 major customers each accounted for more than 10% of total revenues for 2020 and, as a group, represented 95% of total revenues for the year ended December&#160;31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry, in particular, is highly competitive and includes a number of established large and mid-sized companies with greater financial, technical and personnel resources than we have and significantly greater commercial infrastructures than we have. Our market segment also includes several smaller emerging companies whose activities are directly focused on our target markets and areas of expertise. Our products, once approved for commercial use, will compete with numerous therapeutic treatments offered by these competitors. While we believe that our products will have certain favorable features, existing and new treatments may also possess advantages. Additionally, the development of other drug technologies and methods of disease prevention are occurring at a rapid pace. These developments may render our products or technologies obsolete or noncompetitive.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the primary competitors for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of Non-24 and nighttime sleep disturbances in SMS, there are no FDA approved direct competitors. Sedative-Hypnotic treatments for certain sleep related disorders include, Ambien</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (zolpidem) by Sanofi (including Ambien CR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Lunesta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (eszopiclone) by Sunovion Pharmaceuticals Inc., Sonata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (zaleplon) by Pfizer Inc., Rozerem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ramelteon) by Takeda Pharmaceuticals Company Limited, Silenor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (doxepin) by Pernix Therapeutics, Belsomra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (suvorexant) by Merck&#160;&amp; Co., Inc., generic products such as zolpidem, trazodone and doxepin, and over-the-counter remedies such as Benadryl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Tylenol PM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class of melatonin agonists includes Rozerem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ramelteon) by Takeda Pharmaceuticals Company Limited, Valdoxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (agomelatine) by Servier, Circadin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (long-acting melatonin) by Neurim Pharmaceuticals Ltd. and the food supplement melatonin. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shift work and excessive sleepiness disorder treatments include Nuvigil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (armodafinil) and Provigil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (modafinil) both by Teva Pharmaceutical Industries Ltd. </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of schizophrenia, the atypical antipsychotics competitors are Risperdal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (risperidone), including the LAI formulation Risperdal Consta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Invega</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (paliperidone), including the LAI formulation Invega</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sustenna</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, each by Ortho-McNeil-Janssen Pharmaceuticals, Inc., Zyprexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (olanzapine), including the LAI formulation Zyprexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Relprevv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, each by Lilly, Seroquel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Seroquel XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (quetiapine) by AstraZeneca PLC, Abilify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (aripiprazole) by Otsuka America Pharmaceutical Inc., Abilify Maintena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the LAI formulation of Abilify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) by Lundbeck/Otsuka America Pharmaceutical Inc., Geodon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ziprasidone) by Pfizer Inc., Saphris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (asenapine) by Allergan plc, Latuda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lurasidone) by Sunovion Pharmaceuticals Inc., Rexulti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brexpiprazole) by Lundbeck/Otsuka America Pharmaceutical, Inc., Aristada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (aripiprazole lauroxil) extended-release injectable suspension by Alkermes, plc, Vraylar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (cariprazine) by Teva Pharmaceutical Industries Ltd., Perseris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (risperidone) extended-release injectable suspension by Indivior plc, Caplyta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(lumapteperone) by Intra-Cellular Therapies, and generic clozapine, as well as the typical antipsychotics haloperidol, chlorpromazine, thioridazine, and sulpiride (all of which are generic). </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete successfully will depend in part on our ability to utilize our pharmacogenetics and pharmacogenomics and drug development expertise to identify, develop, secure rights to and obtain regulatory approvals for promising pharmaceutical products before others are able to develop competitive products. Our ability to compete successfully will also depend on our ability to attract and retain skilled and experienced personnel. Additionally, our ability to compete may be affected because insurers and other third-party payors in some cases seek to encourage the use of cheaper, generic products, which could make our products less attractive.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently utilize a virtual supply manufacturing and distribution chain in which we do not have our own facilities to manufacture commercial or clinical trial supplies of drugs and we do not have our own distribution facilities. Additionally, we do not intend to develop such facilities for any product in the near future. Instead, we contract with third parties for the manufacture, warehousing, order management, billing and collection and distribution of our products and product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely solely on third-party manufacturers to manufacture drug substance and final drug products for both clinical development and commercial sale. However, there are numerous factors that could cause interruptions in the supply of our products, including regulatory reviews, changes in our sources for manufacturing, disputes with a manufacturer, or financial instability of manufacturers, all of which could negatively impact our operation and our financial results.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements in place with Patheon Pharmaceuticals Inc. and Patheon Inc. (collectively, Patheon), subsidiaries of Thermo Fisher Scientific, for the manufacture of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oral tablets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, we entered into a manufacturing agreement with Patheon for the manufacture of commercial supplies of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 20 mg capsules at Patheon&#8217;s Cincinnati, Ohio manufacturing site. Under the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing agreement, we are responsible for supplying the active pharmaceutical ingredient (tasimelteon) for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Patheon and have agreed to order from Patheon at least 80% of the total expected yearly production of new units of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules. Patheon is responsible for manufacturing the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 20 mg capsules, conducting quality control and stability testing, and packaging the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules. The HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing agreement had an initial term of five years and automatically renews after the initial term for successive terms of one year each, unless either party gives notice of its intention to terminate the agreement at least 12 months prior to the end of the then current term. Either party may terminate the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing agreement under certain circumstances upon specified written notice to the other party.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a settlement agreement in 2014, we assumed Novartis&#8217; manufacturing agreement with Patheon for the manufacture of commercial supplies of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In May 2016, we entered into a new manufacturing agreement with Patheon for the manufacture of commercial supplies of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 1, 2, 4, 6, 8, 10 and 12 mg tablets at Patheon&#8217;s Mississauga, Ontario, Canada manufacturing site. Under the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing agreement, we are responsible for sourcing the supply of the active pharmaceutical ingredient (iloperidone), and have agreed to order from Patheon at least 70% of the total expected yearly production of new units of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets for the U.S. and other specified countries each year for the term of the agreement. Patheon is responsible for manufacturing the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 1, 2, 4, 6, 8, 10 and 12 mg tablets, conducting quality control and stability testing, and packaging the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets. The Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing agreement has an initial term of five years and will automatically renew after the initial term for successive terms of one year each, unless either party gives notice of its intention </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to terminate the agreement at least 12 months prior to the end of the then current term. Either party may terminate the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing agreement under certain circumstances upon specified written notice to the other party.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a non-exclusive manufacturing agreement for the manufacture of commercial supplies of HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing agreement has an initial term of five years and automatically renews after the initial term for successive terms of one year each, unless either party gives notice of its intention to terminate the agreement at least 12 months prior to the end of the then current term. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the U.S., at the federal, state and local levels, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of pharmaceutical products. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the U.S. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Moreover, failure to comply with applicable regulatory requirements may result in, among other things, warning letters, clinical holds, civil or criminal penalties, recall or seizure of products, injunction, disbarment, partial or total suspension of production or withdrawal of the product from the market. Any agency or judicial enforcement action could have a material adverse effect on our business.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. government regulation</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. drug development and regulation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (FDCA) and related regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a drug candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND application sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. The sponsor must also include a protocol detailing, among other things, the objectives of the first phase of clinical trials, the parameters to be used in monitoring the safety of the trial, and the effectiveness criteria to be evaluated should the first phase lend itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by FDA, unless FDA, within the 30-day time period, places the clinical trial on a clinical hold. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with FDA good clinical practice (GCP) requirements, which include a requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and/or effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An Institutional Review Board (IRB) at each institution participating in the clinical trial must review and approve each protocol before a clinical trial may commence at the institution and must also approve the information regarding the trial as well as the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with all applicable IRB regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined in certain cases:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase I: The compound is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In most cases, initial Phase I clinical trials are conducted with healthy volunteers. However, where the compound being evaluated is for the treatment of severe or life-threatening diseases, such as cancer, and especially when the product may be too toxic to ethically administer to healthy volunteers, the initial human testing may be conducted on patients with the target disease or condition. Sponsors sometimes subdivide their Phase I clinical trials into Phase Ia and Phase Ib clinical trials. Phase Ib clinical trials are typically aimed at confirming dosage, pharmacokinetics and safety in a larger number of patients. Some Phase Ib studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases or conditions.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase II: This phase involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to confirm dosage tolerance and appropriate dosage.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase III: Phase III clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials, often referred to as &#8220;pivotal&#8221; clinical trials, are intended to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate basis for product labeling.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including any finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected, serious harm to study subjects. In addition, clinical trials may be overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this committee may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials may also be conducted after a drug receives initial marketing approval. These trials, often referred to as &#8220;Phase IV&#8221; trials, are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of such clinical trials as a condition of approval of an NDA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a new drug, sponsors are given several opportunities to meet with the FDA. These meetings can provide an opportunity for the sponsor to share information about the progress of the application or clinical trials, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. These meetings may occur prior to the submission of an IND, at the end of Phase II clinical trials, or before an NDA is ultimately submitted. Sponsors typically use the meetings at the end of the Phase II trials to discuss Phase II clinical results and present plans for the pivotal Phase III clinical trials that they believe will support approval of the new drug. Meetings at other times may be made upon request.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies typically complete additional, animal or other non-clinical studies, develop additional information about the chemistry and physical characteristics of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with the FDA&#8217;s current Good Manufacturing Practices (cGMP) requirements. The manufacturing process must consistently produce quality batches of the drug and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate the effectiveness of the packaging and that the compound does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the IND is active, progress reports summarizing the results of ongoing clinical trials and nonclinical studies performed since the last progress report must be submitted on at least an annual basis to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important, increased incidence of a serious adverse reaction compared to that listed in the protocol or investigator brochure.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also requirements governing the submission of certain clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial registration and results information, which is made publicly available at www.clinicaltrials.gov. Failure to properly report clinical trial results can result in civil monetary penalties. Disclosure of clinical trial results can often be delayed until the new product or new indication being studied has been approved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. review and approval process</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of which may be obtained under certain limited circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews NDAs to determine, among other things, whether the product is safe and effective for its intended use and whether it is manufactured in a cGMP-compliant manner, which will assure and preserve the product&#8217;s identity, strength, quality and purity. Under PDUFA-VI, the FDA has a goal of 10 months from the date of &#8220;filing&#8221; of a standard, completed NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to the FDA because FDA has 60 days to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a new drug to an advisory committee within the FDA. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether and under what conditions the application should be approved. The FDA is not bound by the recommendations of such an advisory committee, but it considers advisory committee recommendations carefully when making decisions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA will also inspect the facility where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Before approving an NDA, the FDA may also inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates an NDA, it will issue an approval letter or a CRL. A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase III trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pediatric Research Equity Act (PREA) requires IND sponsors to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under the PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug receives FDA approval, the approval may be limited to specific diseases and dosages, which could restrict the commercial value of the product. In addition, the FDA may require testing and surveillance programs to monitor the safety of approved products that have been commercialized, and may require a sponsor to conduct post-marketing clinical trials, which are designed to further assess a drug&#8217;s safety and effectiveness after NDA approval. The FDA may also place other conditions on approval, including a requirement for a risk evaluation and mitigation strategy (REMS) to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescribing or dispensing of products. Marketing approval may be withdrawn for non-compliance with REMS or other regulatory requirements, or if problems occur following initial marketing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-approval requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the drug reaches the market. Later discovery of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of the drug from the market. After approval, some types of changes to the approved drug, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approved products are, and any additional product manufactured or distributed by us following FDA approval will be, subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information regarding approved drugs that are placed on the market, and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product for a certain indication or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable governmental requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing clinical trials, enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties, any of which could have a material adverse effect on our business.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan drug designation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, generally a disease or condition that affects fewer than 200,000 individuals in the U.S or, if affects more than 200,000 individuals in the U.S., there is no reasonable expectation that sales of the drug will be sufficient to offset the cost of developing and making the drug available in the U.S.. Orphan drug designation must be requested before submitting an NDA. After the FDA grants Orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and development expenses and a waiver of the NDA application user fee.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited development and review programs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product is eligible for priority review if it is intended to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to currently marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date, as compared to 10 months for review of NDAs under its current PDUFA-VI review goals.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a product may be eligible for accelerated approval. Drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. Drugs receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing trials or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a compound as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fast track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. However, even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA provides periods of regulatory exclusivity, which provide the holder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&#8217;s approval of the NDA. Five years of exclusivity are available to NCEs. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (i.e., formed by the chemical interaction of two compounds), chelate (i.e., a chemical compound), or clathrate (i.e., a polymer framework that traps molecules), of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an abbreviated new drug application (ANDA) or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if it includes a certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid. If a product is not eligible for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year exclusivity is available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability or bioequivalence trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug&#8217;s approval. As a general matter, three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of marketing exclusivity available in the U.S. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">undertake the described clinical trials. In addition, orphan drug designation, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book listing, the Hatch-Waxman Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Orange Book. Drugs listed in the Orange Book can, in turn be cited by potential competitors in support of approval of an ANDA. An ANDA provides for marketing of a drug that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved drug in the Orange Book. Specifically, the applicant must certify that: (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new drug. A certification that the new drug will not infringe the already approved drug&#8217;s listed patents or that such patents are invalid is called a Paragraph IV certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced drug have expired.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA application also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a NCE, listed in the Orange Book for the referenced drug has expired. The U.S. Drug Price Competition and Patent Term Restoration Act of 1984, more commonly known as the &#8220;Hatch-Waxman Act,&#8221; provides a period of five years following approval of a drug containing no previously approved active ingredients, during which ANDAs for generic versions of those drugs cannot be submitted unless the submission contains a Paragraph IV challenge to a listed patent, in which case the submission may be made four years following the original drug approval. Federal law provides for a period of three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use, the approval of which was required to be supported by new clinical trials conducted by or for the sponsor, during which FDA cannot grant effective approval of an ANDA based on that listed drug.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraud and abuse laws and other U.S. regulatory matters</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies are subject to broadly applicable fraud and abuse and other healthcare laws and regulations, in addition to the FDCA, that may constrain the business or financial arrangements and relationships through which these companies market, sell and distribute the products for which they obtain marketing approval. Some of the laws and regulations that may affect the ability of pharmaceutical companies to operate are described below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-kickback laws</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease, or order of any health care item or service reimbursable under federal healthcare programs such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, and the government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of the law or specific intent to violate it. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, patients, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, the exceptions and safe harbors are drawn narrowly. Failure to meet all of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements of a particular statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute, but the legality of the arrangement will be evaluated on a case-by-case basis based on the totality of the facts and circumstances. Violations of the Anti-Kickback Statute are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from the participation in federal healthcare programs, such as Medicare and Medicaid. A number of states also have anti-kickback laws that establish similar prohibitions that may apply to items or services reimbursed by government programs, as well as any third-party payors, including commercial payors, known as "all-payor" laws. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prescription Drug Marketing Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sales and marketing process, pharmaceutical companies frequently provide healthcare providers with samples of approved drugs. The Prescription Drug Marketing Act (PDMA) imposes requirements and limitations upon the distribution of drugs and drug samples, and prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage and handling, as well as record keeping and other requirements. Violations of the PDMA may result in criminal and civil penalties. In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively known as the Affordable Care Act or ACA), discussed in more detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceutical Coverage, Pricing and Reimbursement and Healthcare Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below, imposes annual reporting requirements related to sample distribution.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">False Claims Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act prohibits, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds and knowingly making, or causing to be made or used, a false record or statement to get a false claim paid. Certain marketing practices may implicate the False Claims Act, including promotion of pharmaceutical products for unapproved uses, providing free product to customers with the expectation that customers would bill federal programs for the product, or inflating prices reported to private price publication services used to set drug reimbursement rates under federal healthcare programs. In addition, the ACA amended the Social Security Act to provide that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false claim for purposes of the False Claims Act. Actions under the False Claims Act may be brought by the government or as a qui tam action by private individuals who may receive financial awards if their claims are successful. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and monetary penalties of $5,500 to $11,000 per false claim or statement, which increased to a range of $11,665 to $23,331 in June 2020, with respect to violations occurring after November 2, 2015. Violations of the False Claims Act are also punishable by exclusion from participation in federal healthcare programs, such as Medicare and Medicaid. Pharmaceutical and other life sciences companies often resolve allegations without admissions of liability for significant and sometimes material amounts to avoid the uncertainty of treble damages and per claim penalties that may be awarded in litigation. These companies may be required, however, to enter into corporate integrity agreements with the government, which may impose substantial costs on companies to ensure compliance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 (HIPAA), includes federal criminal statutory provisions that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations, impose certain requirements and restrictions on certain types of individuals and entities relating to the privacy and security of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable not only to covered entities (e.g. health care providers and health plans), but also to business associates, i.e., independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Payment Sunshine Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Physician Payment Sunshine Act requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually (with certain exceptions) to Centers for Medicare &amp; Medicaid Services (CMS) information related to payments or other &#8220;transfers of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value&#8221; made to physicians and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members and payments or other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transfers of value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to such physician owners. Failure to report relevant data may result in civil fines and/or penalties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign Corrupt Practices Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act (FCPA), prohibits U.S. corporations and their representatives and intermediaries from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Violation of the FCPA could result in substantial civil and criminal penalties and remedies, including fines, disgorgement, and/or imprisonment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analogous state laws</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analogous state fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to the business practices of pharmaceutical companies, including but not limited to research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors and are generally broad and are enforced by many different federal and state agencies as well as through private actions. In addition to requiring reporting transfers of value, some states have imposed price reporting requirements. These state laws apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. In addition, a number of states require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products and to report gifts and payments to individual physicians in the states. Other states restrict when pharmaceutical companies may provide meals to prescribers or engage in other marketing related activities or require pharmaceutical companies to implement compliance programs or marketing codes of conduct, and file periodic reports or disclosures with states. Compliance with these laws requires significant resources and companies that do not comply may face civil penalties or other consequences.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many state laws govern the privacy and security of personal information in specified circumstances. For example, the California Consumer Privacy Act (CCPA), which became effective on January 1, 2020, established a new legal framework governing covered businesses' collection and use of personal information of California residents by, among other things, creating an expanded definition of covered personal information, establishing new privacy rights for California residents, imposing an opt-in standard for certain disclosures of personal information about minors, and creating a new and potentially severe statutory damages framework for businesses subject to certain data breaches resulting from the failure to implement and maintain reasonable security procedures and practices. While properly collected clinical trial data and all protected health information governed by HIPAA are exempt from the current version of the CCPA, other personal information may be applicable and possible changes to the CCPA may broaden its scope.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign regulation</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign drug development, review and approval processes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of whether we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement also vary greatly from country to country. Although governed by the applicable country, clinical trials conducted outside of the U.S. typically are administered with the three-Phase sequential process that is discussed above under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. drug development and regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, the foreign equivalent of an IND is not a prerequisite to performing pilot studies or Phase I clinical trials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under E.U. regulatory systems, we may submit Marketing Authorization Applications (MAAs) either under a centralized or decentralized procedure. The centralized procedure, which is available for drugs produced by biotechnology or which are highly innovative, provides for the grant of a single marketing authorization that is valid for all E.U. member states. This authorization is a marketing authorization approval. The decentralized procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize approval. This procedure is referred to as the mutual recognition procedure. In addition, regulatory approval of prices is required in most countries other than the U.S. We face the risk that the resulting prices would be insufficient to generate an acceptable return to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign fraud and abuse laws and other regulatory matters</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., we are subject to similar regulations in those countries where we market and sell products, including with respect to transparency, bribery and other laws mentioned above. In some foreign countries, including major markets in the E.U. and Japan, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take nine to 12 months or longer after the receipt of regulatory marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies, which can be costly and time-consuming.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and processing of personal data in the E.U. is governed by the General Data Protection Regulation (GDPR), which became applicable in May 2018. The GDPR implements stringent operational requirements for processors and controllers of personal data, including, for example, expanded disclosure requirements about how personal information is to be used, strengthened individual data subject rights, limitations on retention of personal data, increased requirements pertaining to health data and pseudonymised (i.e., key-coded) data, shortened mandatory data breach notification timelines and higher standards for controllers to demonstrate they have obtained valid consent for certain data processing activities. The GDPR provides that E.U. member states may make their own additional laws and regulations in relation to the processing of genetic, biometric or health data, which could result in differences between member states, limit our ability to use and share personal data or cause our costs to increase, and harm our business and financial condition. Further, the U.K.&#8217;s exit from the E.U. in January 2020, with a transition period that ended on December 31, 2020, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the U.K. While the transition period has now concluded, decisions are still to be made on how data transfers to and from the U.K. will be regulated. We are also subject to evolving and strict rules on the transfer of personal data out of the E.U. Failure to comply with E.U. data protection laws may result in significant fines, including GDPR fines of up to the higher of &#8364;20,000,000 or 4% of our total worldwide annual revenue of the preceding financial year, and other administrative penalties, which may be onerous and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Coverage, Pricing and Reimbursement and Healthcare Reform</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs in the U.S. such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs.&#160;Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last several years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the U.S. By way of example, in March 2010, the ACA was passed, ushering in significant changes to the coverage and payment for products under government health care programs. Among the provisions of the ACA of importance to pharmaceutical companies are: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, although this fee does not apply to sales of certain products approved exclusively for orphan indications; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; (AMP), for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicaid managed care plans; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the types of entities eligible for the 340B drug discount program; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established the Medicare Part&#160;D coverage gap discount program by requiring manufacturers to provide a 50% point&#8209;of&#8209;sale&#8209;discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part&#160;D. The Bipartisan Budget Act of 2018 increased the manufacturer discount from 50% to 70% effective in 2019; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a new Patient&#8209;Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">added a requirement to annually report product samples that manufacturers and distributors provide to physicians;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded healthcare fraud and abuse laws, including the False Claims Act and the federal Anti-Kickback Statute, and enhanced penalties for noncompliance; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the provisions of the ACA have yet to be fully implemented, however, while others have been subject to judicial and Congressional challenges, as well as efforts by the former Trump administration to repeal or replace certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing or delaying penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. Additionally, in December 2018, a Texas District Court judge ruled that the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. Further, in December 2019, the U.S. Court of Appeals for the 5th Circuit upheld the Texas District Court ruling that the individual mandate was unconstitutional and remanded the case back to the Texas District Court to determine whether the remaining provisions of the ACA are invalid as well. In March 2020, the U.S. Supreme Court granted the petitions for writs of certiorari and held oral arguments in November 2020. Accordingly, we continue to evaluate the effect that the ACA has on our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the federal level, the former Trump administration supported legislative proposals and issued certain Executive Orders seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. The Department of Health and Human Services (HHS), has solicited feedback on some of these measures and implemented others under its existing authority. The FDA also released a final rule in September 2020 providing guidance for states to build and submit importation plans for drugs from Canada. Further, in November 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Additionally, in December 2020, CMS issued a final rule that materially modifies current Medicaid Drug Rebate Program regulations by, among other things, broadening the definitions for &#8220;line extension&#8221; and &#8220;new formulation&#8221;, the key term within the line extension definition. A &#8220;line extension&#8221; drug is subject to a higher Medicaid rebate, thereby reducing the amount the manufacturer is paid with respect to such product. These new definitions will become effective as of January 1, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that started in 2013 and will stay in effect through 2024 unless additional congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. The ACA, as well as other federal, state and foreign healthcare reform measures that have been and may be adopted in the future, could have a material adverse effect on our business. Further, it is also possible that additional governmental action is taken in response to the COVID-19 pandemic as it continues into 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price for any approved product and/or the level of reimbursement physicians receive for administering any approved product. Reductions in reimbursement levels may negatively impact the prices we can charge or the frequency with which products are prescribed or administered.&#160;Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.&#160;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, pricing and reimbursement and the containment of healthcare costs has become a priority in a number of foreign jurisdictions. In the E.U., pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies, or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the E.U. provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. E.U. member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not provide favorable reimbursement and pricing arrangements.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had 292 full-time employees as of December&#160;31, 2020, compared with 284 employees as of December&#160;31, 2019. None of our employees are represented by a labor union. We have not experienced any work stoppages and consider our employee relations to be good. Our human capital objectives include attracting, training and retaining employees in a manner that supports innovation across our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in 2002. Our principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington D.C. 20037, and our telephone number is (202)&#160;734-3400. Our website address is www.vandapharma.com and the information contained in, or that can be accessed through, our website is not part of this Annual Report and should not be considered part of this Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934 (Exchange Act). The SEC maintains a website at </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make available free of charge on our Internet website at www.vandapharma.com our annual reports on Form&#160;10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our code of ethics, other corporate policies and procedures, and the charters of our Audit Committee, Compensation Committee and Nominating/Corporate Governance Committee are available through our Internet website at www.vandapharma.com.</span></div><div id="i78e7e943a648448d981304e612e68114_19"></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding any statement in this Annual Report or elsewhere. The following information should be read in conjunction with the consolidated financial statements and related notes in Part II, Item&#160;8, Financial Statements and Supplementary Data and Part II, Item&#160;7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because of the following factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business and Industry</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the commercial success of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is currently substantially dependent upon the commercial success of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules and oral suspension (HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oral tablets for the treatment of schizophrenia.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the U.S. Food and Drug Administration (FDA) approved our New Drug Application (NDA) for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24 and in April 2014, we commenced the U.S. commercial launch of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24 in totally blind adults, and in August 2016 we commenced the commercial launch of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Germany. This authorization is valid in the 27 countries that are members of the European Union (E.U.), as well as European Economic Area members Iceland, Liechtenstein and Norway. We have applied for renewal of this marketing authorization, which expires in the ordinary course in July 2020. In December 2020, the FDA approved our NDA and supplemental New Drug Application (sNDA) for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of nighttime sleep disturbances in SMS in adults and children, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2014, we acquired the U.S. commercial rights to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and began selling, marketing and distributing Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate significant product revenue from sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, both in the U.S. and abroad, in the near term will depend on, among other things, our ability to:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">minimize the impact of disruptions caused by the COVID-19 pandemic;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend our patents and intellectual property from generic competition;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain commercial manufacturing arrangements with third-party manufacturers;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">produce, through a validated process, sufficiently large quantities of inventory of our products to meet demand;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to maintain and grow a wide variety of internal sales, distribution and marketing capabilities sufficient to sustain growth in sales of our products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gain broad acceptance of our products from physicians, health care payors, patients, pharmacists and the medical community;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">properly price and obtain adequate coverage and reimbursement of these products by governmental authorities, private health insurers, managed care organizations and other third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain compliance with ongoing labeling, packaging, storage, advertising, promotion, recordkeeping, safety and other post-market requirements;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain regulatory approval to expand the labeling of our approved products for additional indications;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain regulatory approval for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in additional countries;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">renew and maintain our existing regulatory approval for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequately protect against and effectively respond to any claims by holders of patents and other intellectual property rights that our products infringe their rights; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequately protect against and effectively respond to any unanticipated adverse effects or unfavorable publicity that develops in respect to our products, as well as the emergence of new or existing competitive products, which may be proven to be more clinically effective and cost-effective.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and to utilize a substantial portion of our cash resources as we continue the commercialization of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, evaluate foreign market opportunities for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and continue to grow our operational capabilities, both domestically and abroad. This activity represents a significant investment in the commercial success of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is uncertain.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our continued commercial efforts are not successful with respect to HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., Europe or other jurisdictions in which these products may be approved for sale, our ability to generate increased product sales revenue may be jeopardized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of growing and maintaining a sales, marketing and distribution organization may exceed its cost effectiveness. If we fail to continue to develop sales, marketing and distribution capabilities, if sales efforts are not effective or if costs of developing sales, marketing and distribution capabilities exceed their cost effectiveness, our business, results of operations and financial condition could be materially adversely affected.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Growth of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> may be slow or limited for a variety of reasons including competing products or unanticipated safety issues. If either HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> is not successful in gaining broad commercial acceptance, our business would be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any increase in sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will be dependent on several factors, including our ability to educate physicians and to increase physician awareness of the benefits of our products relative to competing products. The degree of further market acceptance of any of our products, including with respect to new indications, or market acceptance of approved product candidates among physicians, patients, health care payors and the medical community will depend on a number of factors, including but not limited to:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptable evidence of safety and efficacy;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse side effects;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market awareness of the condition to be treated; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are subject to continual review by the FDA, and we cannot assure that newly discovered or reported safety issues will not arise. With the use of any newly marketed drug by a wider patient population, serious adverse events may occur from time to time that initially do not appear to relate to the drug itself. Any safety issues could cause us to suspend or cease marketing of our approved products, cause us to modify how we market our approved products, subject us to substantial liabilities and adversely affect our revenues and financial condition. In the event of a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">withdrawal of either HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the market, our revenues would decline significantly and our business would be seriously harmed.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic conditions may have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instability or a general decline in economic conditions in the U.S. and other countries where we sell our product could adversely affect our operations. Economic conditions, and uncertainty as to the general direction of the macroeconomic environment, are beyond our control and may make any necessary debt or equity financing more difficult, more costly, and more dilutive. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, an economic downturn or significant increase in our expenses could require additional financing on less than attractive rates or on terms that are excessively dilutive to existing stockholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our stock price and could require us to delay or abandon clinical development plans.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products will be dependent, in large part, on reimbursement from government health administration authorities, private health insurers, distribution partners and other organizations. In the event of economic decline, these organizations may be unable to satisfy their reimbursement obligations or may delay payment. In addition, federal and state health authorities may reduce Medicare and Medicaid reimbursements, and private insurers may increase their scrutiny of claims. A reduction in the availability or extent of reimbursement could negatively affect our product sales and revenue.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on third parties for several important aspects of our business. For example, we use third parties for sales, distribution, medical affairs and clinical research, and we rely upon several single source providers of raw materials and contract manufacturers for the manufacture of our products. During challenging and uncertain economic times and in tight credit markets, there may be a disruption or delay in the performance of our third-party contractors, suppliers or partners. If such third parties are unable to satisfy their commitments to us, our business and results of operations would be adversely affected.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global health crises and pandemics, such as the global outbreak of COVID-19, may adversely impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current global pandemic caused by the spread of the novel coronavirus (COVID-19) has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which the effects of shelter-in-place orders and our work-from-home policies may negatively impact productivity and disrupt our business will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales force has had physical access to healthcare providers curtailed, which may have a negative impact on our revenues. While we are implementing marketing and sales strategies aimed at overcoming the disruptions caused by the pandemic, we cannot ensure that these methods will be effective. Additionally, patients who might be currently using our products, or might otherwise be eligible to use our products, may be unable to meet with their healthcare providers, which may reduce the number of prescription refills or new patient starts, thereby adversely affecting our revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has impacted clinical research globally, including our previously reported clinical trials. While certain of our programs have resumed patient enrollment, other programs remain on hold. We may experience further disruptions that could adversely impact our supply chain, our ongoing and planned clinical trials, and other regulatory activities, including:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in receiving, supplies of the active pharmaceutical ingredients that our contract manufacturing organizations use to manufacture our products and any related interruption of, or delays in receiving, supplies of our products from these organizations, due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as procedures that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our employee resources or those of third-party clinical research organizations towards the development of our products, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of regulatory agencies, which may impact review and approval timelines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak may continue to impact our business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions and social distancing practices, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA does not accept for filing the NDAs that we may submit for tradipitant for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia, or the FDA determines that our clinical trial results for tradipitant for the treatment of gastroparesis, motion sickness, atopic dermatitis or COVID-19 pneumonia do not demonstrate adequate safety and efficacy, or the FDA does not approve an applicable PDUFA-VI date, continued development of tradipitant will be significantly delayed or terminated, our business will be significantly harmed, and the market price of our stock could decline. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we completed enrollment in EPIONE, a Phase III clinical study of tradipitant for the treatment of pruritus in atopic dermatitis and commenced enrollment in EPIONE 2, a second Phase III clinical study of tradipitant for the treatment of atopic dermatitis. We have also initiated Phase III clinical studies of tradipitant for the treatment of gastroparesis, motion sickness and COVID-19 pneumonia. If the results of our ongoing Phase III studies of tradipitant for the treatment of gastroparesis, motion sickness, atopic dermatitis and/or COVID-19 pneumonia are positive, we will likely submit an NDA with the FDA for these indications. Any adverse developments or results or perceived adverse developments or results with respect to our pre-NDA meeting with the FDA, our regulatory submission or the tradipitant clinical programs in any or all indications will significantly harm our business and could cause the market price of our stock to decline. Examples of such adverse developments include, but are not limited to: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA determining that additional clinical studies are required with respect to tradipitant for the treatment of atopic dermatitis and/or the treatment of gastroparesis and/or the treatment of motion sickness; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety, efficacy or other concerns arising from clinical or non-clinical studies in these programs;&#160;or </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA determining that the tradipitant clinical trial programs raise safety concerns or do not demonstrate adequate efficacy. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that tradipitant has a well-established safety profile, as demonstrated by the results of extensive testing in animals and humans. Despite these results, however, the FDA informed us in December 2018 that in order to treat patients beyond 12 weeks, we will have to conduct a 9-month non-rodent chronic toxicity study, which currently limits our ability to collect safety data in humans for more than 12 weeks. The non-rodent study required by the FDA necessitates the sacrifice of dozens of animals and we have disputed the necessity of a 9-month non-rodent chronic toxicity study. In February 2019, we filed a lawsuit in the U.S. District Court for the District of Columbia (DC District Court) challenging the FDA&#8217;s position, but ultimately did not prevail. Despite our disagreement with the FDA, the preclinical package has allowed us to continue to conduct all of the efficacy studies necessary for NDA filing. Moreover, in July 2020, the FDA approved the use of tradipitant for up to six months with an option of renewal for an individual patient who requested expanded access. Since then, other patients who experienced a unique benefit in tradipitant studies have requested expanded access. The expanded access program is ongoing and a number of patients have initiated treatment. Although this expanded access program is not intended for data collection, we will collect safety data from this cohort of expanded access patients and include this data in its NDA for tradipitant for the treatment of gastroparesis; however, the FDA may disregard such safety data when reviewing the NDA. The lack of long-term (&gt;12 weeks in humans) safety data would likely impact the FDA&#8217;s willingness to approve tradipitant for a chronic indication. However, because long-term safety data is not normally a requirement for short-term indications, and with a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical profile that has not precluded clinical development, we believe the package is complete for any NDA filing to treat patients for 12 weeks or less. In gastroparesis, for example, the FDA has communicated to us that it is considering an indication for the short-term relief of nausea in gastroparesis. While this short-term indication is not preferred, we would consider accepting this limited indication while continuing to pursue a chronic indication.  The chronic treatment of itch in atopic dermatitis would be expected to have a similar issue in review as gastroparesis. Our business will be materially adversely impacted if we are not able to agree with the FDA on a regulatory path to approval for tradipitant, we experience any delay in filing, or the FDA delays or denies approval of NDA filings for the treatment of gastroparesis, motion sickness, atopic dermatitis, or COVID-19 pneumonia.  </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA does not approve our sNDA for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for the treatment of jet lag disorder or continued development of tasimelteon for the treatment of jet lag disorder is significantly delayed or terminated, our business will be significantly harmed, and the market price of our stock could decline. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we announced that the FDA had accepted the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sNDA for the treatment of jet lag disorder. We received a complete response letter in August 2019 in which the FDA asserted that the measures of the study were of unclear clinical significance and declined to approve our sNDA. We met with the FDA to discuss the complete response letter in a Post Action meeting and we are determining our next steps.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional adverse developments or results or perceived adverse developments or results with respect to our regulatory submission for jet lag disorder will significantly harm our business and could cause the market price of our stock to decline. Examples of such adverse developments include, but are not limited to: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA determining that additional clinical studies are required with respect to the jet lag disorder program; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety, efficacy or other concerns arising from clinical or non-clinical studies in the jet lag disorder program, or the manufacturing processes or facilities used for the jet lag disorder program; or</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA determining that the jet lag disorder program raises safety concerns or does not demonstrate substantial evidence of efficacy. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may enter into third-party collaborations from time to time in order to develop and commercialize our products. If we are unable to identify or enter into an agreement with any material third-party collaborator, if our collaborations with any such third party are not commercially successful or if our agreement with any such third party is terminated or allowed to expire, we could be adversely affected financially or our business reputation could be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes entering into collaborations with corporate collaborators for the commercialization of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our other products. While we are not currently party to any material commercial collaborative arrangements, areas in which we may potentially enter into third-party collaboration arrangements include joint sales and marketing arrangements for sales and marketing in certain E.U. countries and elsewhere outside of the U.S., and future product development arrangements. If we are unable to identify or enter into an agreement with any material third-party collaborator, this could result in an adverse effect on our business, results of operations or financial condition. Any arrangements we do enter into may not be scientifically or commercially successful. The termination of any of these arrangements might adversely affect our ability to develop, commercialize and market our products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Our collaborators will have significant discretion in determining the efforts and resources that they will apply to these collaborations. We expect that the risks we face in connection with these future collaborations will include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaboration agreements are expected to be for fixed terms and subject to termination under various circumstances, including, in many cases, on short notice without cause;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborators may develop and commercialize, either alone or with others, products and services that are similar to or competitive with our products that are the subject of their collaboration with us; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborators may change the focus of their commercialization efforts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years there have been a significant number of mergers and consolidations in the pharmaceutical and biotechnology industries, some of which have resulted in the participant companies reevaluating and shifting the focus of their business following the completion of these transactions. The ability of our products to reach their potential could be limited if any of our future collaborators decreases or fails to increase spending relating to such products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations with pharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. With respect to our future collaborations, any such termination or expiration could adversely affect us financially as well as harm our business reputation.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even after we obtain regulatory approvals of a product, acceptance of the product in the marketplace is uncertain and failure to achieve commercial acceptance will prevent or delay our ability to generate significant revenue from such product.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after obtaining regulatory approvals for the sale of our products, the commercial success of these products will depend, among other things, on their acceptance by physicians, patients, third-party payors and other members of the medical community as therapeutic and cost-effective alternatives to competing products and treatments. The degree of market acceptance of any product will depend on a number of factors, including the demonstration of its safety and efficacy, its cost-effectiveness, its potential advantages over other therapies, the reimbursement policies of government and third-party payors with respect to such product, our ability to attract and maintain corporate partners, including pharmaceutical companies, to assist in commercializing our products, receipt of regulatory clearance of marketing claims for the uses that we are developing and the effectiveness of our marketing and distribution capabilities. If our approved products fail to gain market acceptance or do not become widely accepted by physicians, patients, third-party payors and other members of the medical community, it is unlikely that we will ever become profitable on a sustained basis or achieve significant revenues.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and will continue to rely on outsourcing arrangements for many of our activities, including preclinical and clinical development and supply of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> and our other products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had 292 full-time employees. We rely on outsourcing arrangements for a significant portion of our activities, including distribution, preclinical and clinical research and development, data collection and analysis and manufacturing, as well as for certain functions as a public company. We have limited control over these third parties and we cannot guarantee that they will perform their obligations in an effective and timely manner.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to our HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> supply chains could materially affect our level of success in commercializing HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, thereby reducing our future earnings and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A loss or disruption with any one of our manufacturers or suppliers could disrupt the supply of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, possibly for a significant time period, and we may not have sufficient inventories to maintain supply before the manufacturer or supplier could be replaced or the disruption is resolved. In addition, marketed drugs and their contract manufacturing organizations are subject to continual review, including review and approval by regulatory authorities of their manufacturing facilities and the manufacturing processes, which can result in delays in the regulatory approval process and/or commercialization. Introducing a replacement or backup manufacturer or supplier for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> requires a lengthy regulatory and commercial process and there can be no guarantee that we could obtain necessary regulatory approvals in a timely fashion or at all. In addition, it is difficult to identify and select qualified suppliers and manufacturers with the necessary technical capabilities, and establishing new supply and manufacturing sources involves a lengthy and technical engineering process.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with government regulations regarding the sale and marketing of our products could harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In U.S. markets, our ability to commercialize our products successfully, and to attract commercialization partners for our products, should we choose to do so, depends in significant part on the availability of adequate financial coverage and reimbursement from third-party payors, including, in the U.S., governmental payors such as the Medicare and Medicaid programs, managed care organizations, and private health insurers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the Medicaid Drug Rebate Program for both HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the Medicaid Drug Rebate Program, we are required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having our drugs eligible for coverage under Medicaid and Medicare Part B. Those rebates are based on pricing data that are reported by us on a monthly and quarterly basis to the Centers for Medicare&#160;&amp; Medicaid Services (CMS). Federal law requires that any company that participates in the Medicaid Drug Rebate Program also participate in the Public Health Service Act&#8217;s 340B drug pricing discount program (340B program), in order for the manufacturer&#8217;s drugs to be eligible for coverage under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. The ceiling price can represent a significant discount and is based on the pricing data reporting to the Medicaid Drug Rebate Program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA expanded the 340B program to include additional entity types: certain free-standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals, each as defined by ACA. The ACA exempts drugs designated under section 526 of the FDC Act as &#8220;orphan drugs&#8221; from the ceiling price requirements for these newly eligible entities. The ACA also obligates the Health Resources and Services Administration to create regulations and processes to improve the integrity of the 340B program and to update the agreement that manufacturers must sign to participate in the 340B program. A final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities became effective on January 1, 2019.  Implementation of this final regulation and the issuance of any other final regulations and guidance could affect our obligations under the 340B program in ways we cannot anticipate. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in the inpatient setting.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law also requires that for a drug manufacturer&#8217;s products to be eligible for coverage under the Medicaid and Medicare Part B programs and to be purchased by certain federal agencies and grantees, the manufacturer must participate in the Department of Veterans Affairs Federal Supply Schedule (FSS), pricing program, established by Section&#160;603 of the Veterans Health Care Act of 1992. Manufacturers that participate in the FSS pricing program must list their covered (innovator and authorized generic) drugs on an FSS contract and charge no more than Federal Ceiling Price (FCP), to the Department of Veterans Affairs, Department of Defense, Public Health Service, and Coast Guard when those agencies purchase from the FSS contract or a depot contract. FCP is calculated based on non-federal average manufacturer price data, which manufacturers must submit quarterly and annually. In addition, because our products are available in the retail and specialty pharmacy setting, we are required to provide rebates to the Department of Defense for prescriptions dispensed to Tricare beneficiaries from Tricare retail network pharmacies under the Tricare Retail Refund Program. To the extent we choose to participate in these government healthcare programs for our current and future products, these and other requirements may affect our ability to profitably sell any product for which we obtain marketing approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs. The calculations are complex and will often be subject to interpretation by us, governmental or regulatory agencies and the courts. If we become aware that our reporting of pricing data for a prior quarter was incorrect, we will be obligated to resubmit the corrected data. For the Medicaid Drug Rebate Program, corrected data must be submitted for a period not to exceed 12 quarters from the quarter in which the data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and other governmental pricing programs. We may be liable for errors associated with our submission of pricing data. If we are found to have knowingly submitted false pricing data to the Medicaid program or the FSS pricing program, we may be liable for civil monetary penalties in the amount of up to $100,000 per item of false information, adjusted for inflation as applicable. Our failure to submit pricing data to the Medicaid program or the FSS pricing program on a timely basis could result in a civil monetary penalty of $10,000 per day for each day the information is late, adjusted for inflation as applicable. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, which is the agreement under which we would participate in the Medicaid Drug Rebate Program. In the event that CMS terminates our rebate agreement, our products may no longer be eligible for coverage under Medicaid or Medicare Part B. There can be no assurance that our submissions will not be found to be incomplete or incorrect.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors decide which drugs they will cover and establish reimbursement and co-pay levels. Third-party payors are increasingly challenging the prices charged for medical products and services and examining their cost effectiveness, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost effectiveness of our products. Even with such studies, any of our products that are commercialized may be considered less cost-effective than other products, and third-party payors may not provide coverage and reimbursement, in whole or in part, for our products. Third-party payors also are increasingly considering new metrics as the basis for reimbursement rates. It is difficult to project the impact of these evolving reimbursement mechanics on the willingness of payors to cover any of our commercialized products. In addition, we anticipate that a significant portion of our revenue from sales of commercialized products will be obtained through government payors, including Medicare and Medicaid. Any failure to obtain eligibility for coverage under those programs for products we are able to commercialize would have a material adverse effect on revenues and royalties from sales of such products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing regulatory obligations and oversight of our products, and any failure by us to maintain compliance with applicable regulations may result in adverse consequences including the suspension of the manufacturing, marketing and sale of our respective products, the incurrence of significant additional expense and other limitations on our ability to commercialize our respective products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to ongoing regulatory requirements and review, including periodic audits pertaining to the development, manufacture, labeling, packaging, adverse event reporting, distribution, storage, marketing, promotion, record keeping and export of our respective products. Failure to comply with such regulatory requirements or the later discovery of previously unknown problems with the manufacture, distributions and storage of our products, or our third-party contract manufacturing facilities or processes by which we manufacture our products may result in restrictions on our ability to develop, manufacture, market, distribute or sell our products, including potential withdrawal of our products from the market. Any such restrictions could slow or stop production development or result in decreased sales, damage to our reputation or the initiation of lawsuits against us and/or our third-party contract manufacturers. We may also be subject to additional sanctions, including, but not limited, to the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Warning letters, public warnings and untitled letters;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Court-ordered seizures or injunctions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Civil or criminal penalties, or criminal prosecutions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Variation, suspension or withdrawal of regulatory approvals for our products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to the package insert of our products, such as additional warnings regarding potential side effects or potential limitations on the current dosage or administration;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requirements to communicate with physicians and other customers about concerns related to actual or potential safety, efficacy, or other issues involving our products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implementation of risk mitigation programs and post-approval obligations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on our continued manufacturing, marketing, distribution or sale of our products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Temporary or permanent closing of the facilities of our third-party contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruption or suspension of clinical trials; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusal by regulators to consider or approve applications for additional indications.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above sanctions could have a material adverse impact on our revenues or our reputation, and cause us to incur significant additional expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our products face any safety or efficacy issues, including drug interaction problems, under  the federal Food, Drug &amp; Cosmetic Act, the FDA has broad authority to force us to take any number of actions, including, but not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Requiring us to conduct post-approval clinical studies to assess product efficacy or known risks or new signals of serious risks, or to evaluate unexpected serious risks;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandating changes to a product&#8217;s label;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requiring us to implement a risk evaluation and mitigation strategy where necessary to assure safe use of the drug; or</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Removing an already approved product from the market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our partners, including our licensors, are subject to similar requirements and obligations as well as the attendant risks and uncertainties. If our partners, including our licensors, suffer material and adverse effects from such risks and uncertainties, our rights and benefits for our licensed products could be negatively impacted, which could have a material adverse effect on our business.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our products are marketed or distributed in a manner that violates federal or state healthcare fraud and abuse laws, marketing disclosure laws or other federal or state laws and regulations, we may be subject to civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA and related regulatory requirements, our general operations, and the research, development, manufacture, sale and marketing of our products, are subject to extensive additional federal and state healthcare regulation, including the federal Anti-Kickback Statute, the Prescription Drug Marketing Act, and the federal False Claims Act (FCA), the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal Health Insurance Portability and Accountability Act of 1996, the federal Physician Payment Sunshine Act and the Foreign Corrupt Practices Act (and their state analogues), as discussed above in Part I, Item 1 under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation - Fraud and abuse laws and other U.S. regulatory matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we or our partners, such as licensors, fail to comply with any federal and state laws or regulations governing our industry, we could be subject to administrative, criminal and civil penalties and a range of regulatory actions that could adversely affect our ability to commercialize our products, harm or prevent sales of our products, or substantially increase the costs and expenses of commercializing and marketing our products, all of which could have a material adverse effect on our business, financial condition and results of operations. In recent years, CMS has been actively proposing and implementing changes to the list of business practices that are protected by safe harbors. There is inherent risk and uncertainty in any changing regulatory environment as companies work to transition business practices to conform with new regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws, and private individuals have been active in bringing so-called &#8220;whistleblower&#8221; lawsuits on behalf of the government (as Relators) under the FCA and similar regulations in other countries. In addition, incentives exist under applicable U.S. law that encourage employees and physicians to report violations of rules governing promotional activities for pharmaceutical products. These incentives have led to, and could continue to lead to, FCA lawsuits, which attempt to recoup moneys paid by government agencies and extract penalties from manufacturers. For example, federal enforcement agencies have recently pursued enforcement actions against pharmaceutical companies&#8217; product and patient assistance programs, including relationships with specialty pharmacies, and support for charitable foundations providing patients with co-pay assistance. In addition, Relators have filed lawsuits involving manufacturer reimbursement support services as well as promotion of pharmaceutical products beyond labeled claims. Some FCA lawsuits have resulted in government enforcement authorities obtaining significant civil and criminal settlements. Such lawsuits, whether with or without merit, are typically time-consuming and costly to defend. Such suits may also result in related shareholder lawsuits, which are also costly to defend. (See Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in Part II, Item 8 of this Annual Report, which is incorporated herein by reference, for information regarding ongoing litigation related to similar matters.)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. A product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA also regulates the content of promotional material, including, among other things, the presentation of efficacy information, the types of comparative claims that can be made to distinguish products from those with similar indications, and the balance of risk information provided. For drug products that are approved by the FDA under the FDA&#8217;s accelerated approval regulations, unless otherwise informed by the FDA, the sponsor must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the promotional materials, which delays and may negatively impact a company&#8217;s ability to implement changes to its marketing materials, thereby negatively impacting revenues. For other products, the FDA does not review promotional materials prior to dissemination but does issue &#8220;Untitled Letters&#8221; or &#8220;Warning Letters&#8221; if it objects to content that has been used promotionally. The FDA may also withdraw approval of drug products under certain conditions. In particular, the FDA may withdraw approval of a drug if, among other things, the promotional materials are false or misleading, or other evidence demonstrates that the drug is not shown to be safe or effective under its conditions of use.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, in addition to federal legislation related to transparency reporting of transfers of value to healthcare providers and healthcare organizations, several states have enacted legislation requiring pharmaceutical companies to file periodic reports. Several states have adopted legislation to require pharmaceutical companies to establish marketing and promotional compliance programs or codes of conduct and/or to file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Several states have also adopted laws that prohibit certain marketing-related activities, including the provision of gifts, meals or other items to certain healthcare providers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a corporate compliance program based on what we believe are current best practices in the pharmaceutical industry; however, relevant compliance laws are broad in scope and there may not be regulations, guidance or court decisions that definitively interpret these laws in the context of particular industry practices. We cannot guarantee that we, our employees, our partners, our consultants or our contractors are or will be in compliance with all federal and state regulations. If we, our partners, or our representatives fail to comply with any of these laws or regulations, a range of fines, penalties and/or other sanctions and regulatory actions could be imposed on us, including, but not limited to, restrictions on how we market and sell our products, significant fines, exclusions from government healthcare programs, including Medicare and Medicaid, litigation, or other sanctions. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have a material adverse effect on our business, financial condition and results of operations. Such investigations or suits have resulted in, and may continue to result in, related shareholder lawsuits, which can also have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners, including our licensors, are subject to similar requirements and obligations as well as the attendant risks and uncertainties. If our partners, including our licensors, suffer material and adverse effects from such risks and uncertainties, our rights and benefits for our licensed products could be negatively impacted, which could have a material adverse effect on our business.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a limited number of specialty pharmacies for distribution of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in the U.S., and the loss of one or more of these specialty pharmacies or their failure to distribute HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> effectively would materially harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available for distribution through a limited number of specialty pharmacies in the U.S. A specialty pharmacy is a pharmacy that specializes in the dispensing of medications for complex or chronic conditions, which often require a high level of patient education and ongoing management. The use of specialty pharmacies involves certain risks, including, but not limited to, risks that these specialty pharmacies will:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not provide us accurate or timely information regarding their inventories, the number of patients who are using HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or complaints about HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not devote the resources necessary to sell HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the volumes and within the time frames that we expect;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be unable to satisfy financial obligations to us or others; or</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cease operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if one or more of our specialty pharmacies do not fulfill their contractual obligations to us, or refuse or fail to adequately serve patients, or their agreements are terminated without adequate notice, shipments of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and associated revenues, would be adversely affected. We expect that it would take a significant amount of time if we were required to replace one or more of our specialty pharmacies.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenues from Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> are substantially dependent on sales through a limited number of wholesalers, and such revenues may fluctuate from quarter to quarter.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily through a limited number of pharmaceutical wholesalers in the U.S. The use of pharmaceutical wholesalers involves certain risks, including, but not limited to, risks that these pharmaceutical wholesalers will:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not provide us accurate or timely information regarding their inventories, demand from wholesaler customers buying Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or complaints about Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not devote the resources necessary to sell Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the volumes and within the time frames that we expect;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be unable to satisfy financial obligations to us or others; or</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cease operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our reliance on a small number of wholesalers could cause revenues to fluctuate from quarter to quarter based on the buying patterns of these wholesalers. In addition, if any of these wholesalers fails to pay on a timely basis or at all, our business, financial condition and results of operations could be materially adversely affected.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend on our ability to demonstrate and maintain a competitive advantage with respect to our products and our ability to identify and develop additional products. Large, fully integrated pharmaceutical companies, either alone or together with collaborative partners, have substantially greater financial resources and have significantly greater experience than we do in:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">undertaking preclinical testing and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining FDA and other regulatory approvals of products; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing and selling products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies may invest heavily and quickly to discover and develop novel products that could make our products obsolete. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA or foreign regulatory approval or commercializing superior products or other competing products before we do. Technological developments or the FDA or foreign regulatory approval of new therapeutic indications for existing products may make our products obsolete or may make them more difficult to market successfully, any of which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, if successfully developed and approved for commercial sale, will compete with a number of drugs and therapies currently manufactured and marketed by major pharmaceutical and other biotechnology companies. Our products may also compete with new products currently under development by others or with products that may cost less than our products. Physicians, patients, third-party payors and the medical community may not accept or utilize any of our products that may be approved. If HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our other products, if and when approved, do not achieve significant market acceptance, our business, results of operations and financial condition would be materially adversely affected. (See Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business &#8211; Competition,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of the primary competitors for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.) </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may face competition from newly developed generic products. Under the Hatch-Waxman Act, newly approved drugs and indications may benefit from a statutory period of non-patent marketing exclusivity. The Hatch-Waxman Act seeks to stimulate competition by providing incentives to generic pharmaceutical manufacturers to introduce non-infringing forms of patented pharmaceutical products and to challenge patents on branded pharmaceutical products. If we are unsuccessful at challenging an ANDA, filed pursuant to the Hatch-Waxman Act, cheaper generic versions of our products, which may be favored by insurers and third-party payors, may be launched commercially, which would significantly harm our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain an ANDA approval for a generic drug, the generic company needs to show, among other things, that its version of the product is bioequivalent to the Reference Listed Drug (RLD). This usually requires the generic company to conduct bioequivalence studies comparing its product to the RLD, and to retain sufficient samples of the RLD used in testing after a study is complete. In recent years, the U.S. federal lawmakers and the FDA have been considering proposals to facilitate the generic drug company&#8217;s access to samples and foster the generic competition. For example, in February 2019, the U.S. House and Senate lawmakers reintroduced the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act), a bill intended to require brand drug manufacturers to provide sufficient drug samples to generic and biosimilar drug developers.  The proposed legislation, if enacted, would allow a biosimilar or generic product developer to bring a civil action against a brand drug manufacturer for failing to provide samples of the brand product for comparative testing &#8220;on commercially reasonable, market-based terms.&#8221; The developer could receive injunctive relief and a monetary award &#8220;sufficient to deter the license holder from failing to provide other eligible product developers with sufficient quantities of a covered product on commercially reasonable, market-based terms&#8221; in certain cases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have also taken similar actions. In 2018, Maine passed a new law that requires brand drug manufacturers to make samples of drugs distributed in the state available for sale in Maine at a price no greater than wholesale acquisition cost and without any restriction that would block or delay a biosimilar and generic drug application in a manner inconsistent with federal law. The state may seek injunctive relief and attorney&#8217;s fees from a drug manufacturer who fails to comply with this requirement.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA and foreign regulatory approval of our products is uncertain.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing and marketing of products such as those that we have developed or that we are developing are subject to extensive regulation by federal, state and local government authorities, including the FDA, as well as foreign regulatory authorities in jurisdictions in which we seek approval. To obtain regulatory approval of such products, we must demonstrate to the satisfaction of the applicable regulatory agency that, among other things, the product is safe and effective for its intended use. In addition, we must show that the manufacturing facilities used to produce such products are in compliance with cGMPs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining FDA and other required regulatory approvals and clearances can take many years and will require us to expend substantial time and capital. Despite the time and expense expended, regulatory approval is never guaranteed. The number of preclinical and clinical trials that will be required for FDA or foreign regulatory approval varies depending on the product, the disease or condition that the product is in development for, and the requirements applicable to that particular product. The FDA or applicable foreign regulatory agency can delay, limit or deny approval of a product for many reasons, including that:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product may not be shown to be safe or effective;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or foreign agency may interpret data from preclinical and clinical trials in different ways than we do;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or foreign agency may not approve our or our partners&#8217; manufacturing processes or facilities;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product may not be approved for all the indications we request;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or foreign agency may change its approval policies or adopt new regulations;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or foreign agency may not meet, or may extend, the PDUFA-VI date or its foreign equivalent with respect to a particular NDA or foreign application; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or foreign agency may not agree with our regulatory approval strategies or components of the regulatory filings, such as clinical trial designs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, if certain of our methods for analyzing trial data are not accepted by the FDA or the applicable foreign agency, we may fail to obtain regulatory approval for our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the approval procedure varies among countries and jurisdictions and can involve additional trials, and the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure to obtain regulatory approvals for our products will result in increased costs, could diminish competitive advantages that we may attain and would adversely affect the marketing and sale of our products. Other than HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and the countries in Europe covered by the centralized marketing authorization by the EC, and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., Mexico and Israel, we have not received, and may never receive, regulatory approval to market any of our products in any jurisdiction.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even following regulatory approval of our products, the FDA or the applicable foreign agency may impose limitations on the indicated uses for which such products may be marketed, subsequently withdraw approval or take other actions against us, or such products that are adverse to our business. The FDA and foreign agencies generally approve drugs for particular indications. An approval for a more limited indication reduces the size of the potential market for the product. Product approvals, once granted, may be withdrawn or modified if problems occur after initial marketing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners also are subject to numerous federal, state, local and foreign laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the environment and the use and disposal of hazardous substances used in connection with discovery, research and development work. In addition, we cannot predict the extent to which new governmental regulations might significantly impede the discovery, development, production and marketing of our products. We or our partners may be required to incur significant costs to comply with current or future laws or regulations, and we may be adversely affected by the cost of such compliance or the inability to comply with such laws or regulations.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may cause undesirable side effects or have other properties that could delay, prevent or result in the revocation of their regulatory approval or limit their marketability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our products could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing or continuing the commercialization of such products and generating revenues from their sale. We will continue to assess the side effect profile of our products in ongoing clinical development programs. However, we cannot predict whether the commercial use of our approved products (or our products in development, if and when they are approved for commercial use) will produce undesirable or unintended side effects that have not been evident in the use of, or in clinical trials conducted for, such products to date. For example, despite the positive results of our completed trials for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as the FDA&#8217;s approval of the NDA for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24 in January 2014, the NDA for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of schizophrenia in May 2009, the EC&#8217;s grant of the centralized marketing authorization for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24 in totally blind adults in July 2015, and the NDA and sNDA for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of nighttime sleep disturbances in SMS in December 2020, we are uncertain whether either of these products will ultimately prove to be effective and safe in humans long term and in all uses. Frequently, products that have shown promising results in clinical trials have suffered significant setbacks in later clinical trials or even long after they are approved for commercial sale. Additionally, incidents of product misuse may occur. These events, among others, could result in product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recalls, product liability actions or withdrawals or additional regulatory controls, any of which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if after receiving marketing approval of a product, we or others identify undesirable side effects caused by such product, we could face one or more of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our or the product&#8217;s reputation may suffer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating significant revenues from its sale.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials for our products are expensive and their outcomes are uncertain. Any failure or delay in completing clinical trials for our products could severely harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies and clinical trials required to demonstrate the safety and efficacy of our products are time-consuming and expensive and together take several years to complete. Before obtaining regulatory approvals for the commercial sale of any of our products, we must demonstrate through preclinical testing and clinical trials that such product is safe and effective for use in humans. We have incurred, and we will continue to incur, substantial expense for, and devote a significant amount of time to, preclinical testing and clinical trials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the results from preclinical testing and early clinical trials often have not predicted results of later clinical trials. A number of new drugs have shown promising results in clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals. Clinical trials conducted by us or by third parties on our behalf may not demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals for our products. Regulatory authorities may not permit us to undertake any additional clinical trials for our products, may force us to stop any ongoing clinical trials and it may be difficult to design efficacy studies for our products in new indications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development efforts performed by us may not be successfully completed or completed in a timely manner. Completion of clinical trials may take several years or more. The length of time can vary substantially with the type, complexity, novelty and intended use of the products and the size of the prospective patient population. Our ability to enroll patients in, and the commencement and rate of completion of, clinical trials for our products may be affected by many factors, including:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global health crises, like the COVID-19 pandemic;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and nature of the patient population;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the trial protocol for our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility and exclusion criteria for the trial in question;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of competing therapies and competing clinical trials, and physician and patient perception of our product candidates and our other product candidates being studied in relation to these other potential options;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of raw materials and the possibility of raw materials expiring prior to their use;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in maintaining contact with patients after treatment, resulting in incomplete data;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">poor effectiveness of our products during clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues or side effects;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and location of clinical sites in our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of time and resources at the institutions where clinical trials are and will be conducted;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate financing to fund ongoing clinical trial expenses;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the study endpoints that rely on subjective patient reported outcomes; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governmental or regulatory delays and changes in regulatory requirements and guidelines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to complete successfully, or have difficulty enrolling a sufficient number of patients for, our clinical trials, we or they may not receive the regulatory approvals needed to market that product. Any such failure or difficulty could have a material adverse effect on our business.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to achieve sustained profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been engaged in identifying and developing drug products since March 2003, which has required, and will continue to require, significant research and development expenditures. The continued commercialization of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will also require substantial additional expenditures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had an accumulated deficit of $197.3 million and we cannot estimate with precision the extent of our future income or loss. We may not succeed in gaining additional market acceptance of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and we may not succeed in commercializing HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the U.S. We may be unable to fully develop, obtain regulatory approval for, commercialize, manufacture, market, sell and derive revenue from our products in the timeframes we project, if at all, and our inability to do so would materially and adversely impact the market price of our common stock and our ability to raise capital and continue operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will achieve sustained profitability, which depends on many factors, including but not limited to, our ability to obtain regulatory approval for our products and achieve success in commercializing them in the U.S., Europe and our other target jurisdictions, as well as other factors described in this Annual Report. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the amount we spend on developing, obtaining and maintaining regulatory approval for and commercializing our products, among other expenditures described in this Annual Report, will impact our profitability. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income is dependent on generating future taxable income and may be limited, including as a result of transactions involving our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded deferred tax assets based on our assessment that we will be able to realize the benefits of our net operating losses and other favorable tax attributes. Realization of deferred tax assets involve significant judgments and estimates, which are subject to change and ultimately depends on generating sufficient taxable income of the appropriate character during the appropriate periods. Changes in circumstances may affect the likelihood of such realization, which in turn may trigger the need for additional valuation allowance against our deferred tax assets and adversely affect our net income and financial condition. In addition, we are potentially subject to ongoing and periodic tax examinations and audits in various jurisdictions, including with respect to the amount of our net operating losses and any limitation thereon. An adjustment to such net operating loss carryforwards, including an adjustment from a taxing authority, could result in higher tax costs, penalties and interest, thereby adversely impacting our financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Section&#160;382 of the Internal Revenue Code of 1986, as amended (IRC), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and certain other tax assets (tax attributes) to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than 50&#160;percentage points over such stockholders&#8217; lowest percentage ownership during the testing period (generally three&#160;years). Transactions involving our common stock, even those outside our control, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on our ability to utilize some or all of our NOLs or credits could have a material adverse effect on our results of operations and cash flows. Ownership changes occurred in the years ending December&#160;31, 2014 and 2008. We believe that the ownership changes in 2014 and 2008 will not impact our ability to utilize NOL and credit carryforwards; however, future ownership changes may cause our existing tax attributes to have additional limitations.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to adequately fund our research and development activities and commercialization efforts, we may be unable to continue operations or we may be forced to share our rights to commercialize our products with third parties on terms that may not be attractive to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities will necessitate significant uses of working capital throughout 2021 and beyond. It is uncertain whether cash provided by our operating activities, together with our existing funds, will be sufficient to meet our operating needs. As of December 31, 2020, our total cash and cash equivalents and marketable securities were $367.7 million. Our long-term capital requirements are expected to depend on many factors, including, among others:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our level of success in commercializing HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> globally;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">outcomes of ongoing and potential patent litigation;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of developing and maintaining sales, marketing and distribution channels and our ability to sell our products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs involved in establishing and maintaining manufacturing capabilities for commercial quantities of our products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of potential formulations and products in development;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">time and costs involved in obtaining regulatory (including FDA) approval;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs involved in preparing, filing, prosecuting, maintaining and enforcing patent, trademark and other intellectual property claims;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs for recruiting and retaining employees and consultants;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs for training physicians; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal, accounting, insurance and other professional and business-related costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may need to raise additional capital to fund our anticipated operating expenses and execute on our business plans. In our capital-raising efforts, we may seek to sell debt securities or additional equity securities, obtain a bank credit facility, or enter into partnerships or other collaboration agreements. The sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders and may also result in a lower price for our common stock. The incurrence of indebtedness would result in increased fixed obligations and could also result in covenants that could restrict our operations. However, we may not be able to raise additional funds on acceptable terms, or at all. If additional financing is not available when required or is not available on acceptable terms, we may be unable to fund our operations and planned growth, develop or enhance our technologies or products, take advantage of business opportunities or respond to competitive market pressures, any of which would materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our contract research organizations (CROs) do not successfully carry out their duties or if we lose our relationships with CROs, our drug development efforts could be delayed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our arrangements with CROs are critical to our success in bringing our products to the market. We are dependent on CROs, third-party vendors and investigators for preclinical testing and clinical trials related to our drug discovery and development efforts and we will likely continue to depend on them to assist in our future discovery and development efforts. These parties are not our employees and we cannot control the amount or timing of resources that they devote to our programs. As such, they may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The parties with which we contract for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. If they fail to devote sufficient time and resources to our drug development programs or if their performance is substandard, it will delay the development, approval and commercialization of our products. Moreover, these parties may also have relationships with other commercial entities, some of which may compete with us. If they assist our competitors, it could harm our competitive position.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs could merge with or be acquired by other companies or experience financial or other setbacks unrelated to our collaboration that could, nevertheless, materially adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to current Good Laboratory Practices as set forth in 21 Code of Federal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations (C.F.R.) Part 58 and Good Clinical Practices as set forth in 21 C.F.R. Part 50, 54, and 312, and similar international standards and we do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our products could be delayed.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a limited number of third-party manufacturers to formulate and manufacture our products and our business will be seriously harmed if these manufacturers are not able to satisfy our demand and alternative sources are not available.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have an in-house manufacturing capability and depend completely on a small number of third-party manufacturers and active pharmaceutical ingredient formulators for the manufacture of our products. Therefore, we are dependent on third parties for our formulation development and manufacturing of our products. This may expose us to the risk of not being able to directly oversee the production and quality of the manufacturing process and provide ample commercial supplies to successfully launch and maintain the marketing of our products. Furthermore, these third-party contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shut downs, employee strikes, or other unforeseeable events that may delay or limit production. Our inability to adequately establish, supervise and conduct (either ourselves or through third parties) all aspects of the formulation and manufacturing processes would have a material adverse effect on our ability to develop and commercialize our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements in place with Patheon Pharmaceuticals Inc. and Patheon Inc. (collectively, Patheon), subsidiaries of Thermo Fisher Scientific, for the manufacture of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In January 2014, we entered into a manufacturing agreement with Patheon for the manufacture of commercial supplies of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 20 mg capsules at Patheon&#8217;s Cincinnati, Ohio manufacturing site. In May 2016, we entered into a manufacturing agreement with Patheon for the manufacture of commercial supplies of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets at Patheon&#8217;s Mississauga, Ontario, Canada manufacturing site. Additionally, in December 2020, we entered into a non-exclusive third-party manufacturing agreement for the manufacture of commercial supplies of HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We do not have exclusive long-term agreements with any other third-party manufacturers of our products. If our current manufacturers, or any other third-party manufacturer, is unable or unwilling to perform its obligations under our manufacturing agreements for any reason, we may not be able to locate alternative acceptable manufacturers or formulators or enter into favorable agreements with them. Any inability to acquire sufficient quantities of our products in a timely manner from these third parties could adversely affect sales of our products, delay clinical trials and prevent us from developing our products in a cost-effective manner or on a timely basis. In addition, manufacturers of our products are subject to cGMP and similar foreign standards and we do not have control over compliance with these regulations by our manufacturers. If one of our contract manufacturers fails to maintain compliance, the production of our products could be interrupted, resulting in delays and additional costs. In addition, if the facilities of such manufacturers do not pass a pre-approval or post-approval plant inspection, the FDA will not grant approval and may institute restrictions on the marketing or sale of our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing strategy presents the following additional risks:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">because most of our third-party manufacturers and formulators are located outside of the U.S., there may be difficulties in importing our products or their components into the U.S. as a result of, among other things, FDA import inspections, incomplete or inaccurate import documentation or defective packaging; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">because of the complex nature of our products, our manufacturers may not be able to successfully manufacture our products in a cost-effective and/or timely manner.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Materials necessary to manufacture our products may not be available on commercially reasonable terms, or at all, which may delay the development, regulatory approval and commercialization of our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on manufacturers to purchase from third-party suppliers the materials necessary to produce our products for clinical trials and commercialization. Suppliers may not sell these materials to such manufacturers at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of these materials by these manufacturers. Moreover, we currently do not have any agreements for the commercial production of these materials. If the manufacturers are unable to obtain these materials for our clinical trials, product testing, potential regulatory approval of our products and commercial scale manufacturing could be delayed, significantly affecting our ability to further develop and commercialize our products. If we or our manufacturers are unable to purchase these materials for our products, there would be a shortage in supply or the commercial launch of such products would be delayed, which would materially and adversely affect our ability to generate revenues from the sale of such products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot identify, or enter into licensing arrangements for, new products, our ability to develop a diverse product portfolio will be limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A component of our business strategy is acquiring rights to develop and commercialize products discovered or developed by other pharmaceutical and biotechnology companies for which we may find effective uses and markets through our unique pharmacogenetics and pharmacogenomics expertise for the treatment of central nervous system disorders. Competition for the acquisition of these products is intense. If we are not able to identify opportunities to acquire rights to commercialize additional products, we may not be able to develop a diverse portfolio of products. Additionally, it may take substantial human and financial resources to secure commercial rights to promising products. Moreover, if other firms develop pharmacogenetics and pharmacogenomics capabilities, we may face increased competition in identifying and acquiring additional products.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose key scientists or management personnel, or if we fail to recruit additional highly skilled personnel, our ability to identify, develop, and commercialize new products will be impaired.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on principal members of our management team and scientific staff, including our Chief Executive Officer, Mihael H. Polymeropoulos, M.D. These executives each have significant pharmaceutical industry experience. The loss of any such executives, including Dr.&#160;Polymeropoulos, or any other principal member of our management team or scientific staff, would impair our ability to identify, develop and market new products. Our management and other employees may voluntarily terminate their employment with us at any time. The loss of the services of these or other key personnel, or the inability to attract and retain additional qualified personnel, could result in delays to development or approval, loss of sales and diversion of management resources. In addition, we depend on our ability to attract and retain other highly skilled personnel, including research scientists. Competition for qualified personnel is intense, and the process of hiring and integrating such qualified personnel is often lengthy. We may be unable to recruit such personnel on a timely basis, if at all, which would negatively impact our development and commercialization programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk that we may be sued on product liability claims is inherent in the development and sale of pharmaceutical products. For example, we face a risk of product liability exposure related to the testing of our products in clinical trials and will face even greater risks upon commercialization of our products. We believe that we may be at a greater risk of product liability claims relative to other pharmaceutical companies because certain of our products are intended to treat central nervous system disorders, among others, and it is possible that we may be held liable for the behavior and actions of patients who use our products. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and we may be forced to limit or forego further commercialization of one or more of our products. Although we maintain product liability insurance, our aggregate coverage limit under this insurance is $30.0 million, and while we believe this amount of insurance is sufficient to cover our product liability exposure, these limits may not be high enough to fully cover potential liabilities. As our development activities and commercialization efforts progress and we sell our products, this coverage may be inadequate, we may be unable to obtain adequate coverage at an acceptable cost or we may be unable to get adequate coverage at all or our insurer may disclaim coverage as to a future claim. This could prevent the commercialization or limit the commercial potential of our products. Even if we are able to maintain insurance that we believe is adequate, our results of operations and financial condition may be materially adversely affected by a product liability claim. Uncertainties resulting from the initiation and continuation of products liability litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Product liability litigation and other related proceedings may also require significant management time.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">E.U. Member States tend to impose strict price controls, which may delay or prevent the further commercial launch or impede the commercial success of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in Europe and adversely affect our future results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the E.U., prescription drug pricing and reimbursement are subject to governmental control and reimbursement mechanisms used by private and public health insurers in the E.U. vary by Member State. For the public systems, reimbursement is determined by guidelines established by the legislature or responsible national authority. As elsewhere, inclusion in reimbursement catalogues focuses on the medical usefulness, need, quality and economic benefits to patients and the health care system. Acceptance for reimbursement comes with cost, use and often volume restrictions, which can vary by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member State. Although we have received marketing authorization for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules from the EC, pricing negotiations with governmental authorities may take a considerable amount of time in those Member States that impose price controls. For example, we launched HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> commercially in Germany in August 2016, and concluded our pricing negotiations with German authorities in October 2017. In addition, to obtain reimbursement or pricing approval for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in some Member States, we may be required to conduct a clinical trial that compares the cost-effectiveness of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to other available therapies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some Member States require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some Member States, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may be subject to lengthy price regulations that delay or prevent the commercial launch of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a particular Member State and negatively impact the revenues that are generated from the sale of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in that country. If reimbursement of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is unavailable or limited in scope or amount, or if pricing for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is set at unsatisfactory levels or takes too long to establish, or if there is competition from lower priced cross-border sales, our results of operations will be negatively affected.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to effectively market and sell our future products, if approved, in the U.S.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to build our sales and marketing capabilities in the U.S. to commercialize future products, if approved. Our current sales and marketing capabilities in the U.S. may not be adequate to support the commercialization of future products and we would expect to build such capabilities by investing significant amounts of financial and management resources. Furthermore, the cost of establishing and maintaining marketing and sales capabilities may not be justifiable in light of the revenues generated by any future products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish and maintain adequate sales and marketing capabilities for future products or are unable to do so in a timely manner, we may not be able to generate product revenues from these products, which may prevent us from reaching or maintaining profitability.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures or developments arising from changes in the political climate may have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges, as well as efforts by the former Trump administration to repeal or replace certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing or delaying penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. Further, in December 2018, a Texas District Court judge ruled that the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. Further, in December 2019, the U.S. Court of Appeals for the 5th Circuit upheld the Texas District Court ruling that the individual mandate was unconstitutional and remanded the case back to the Texas District Court to determine whether the remaining provisions of the ACA are invalid as well. In March 2020, the U.S. Supreme Court granted the petitions for writs of certiorari and held oral arguments in November 2020. Accordingly, we continue to evaluate the effect that the ACA has on our business.  At the federal level, the former Trump administration supported legislative proposals and issued certain Executive Orders seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. The Department of Health and Human Services (HHS), has solicited feedback on some of these measures and implemented others under its existing authority. The FDA also released a final rule in September 2020 providing guidance for states to build and submit importation plans for drugs from Canada. Further, in November 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Additionally, in December 2020, CMS issued a final rule that materially modifies current Medicaid Drug Rebate Program regulations by, among other things, broadening the definitions for &#8220;line extension&#8221; and &#8220;new formulation&#8221;, the key term within the line extension definition. A &#8220;line extension&#8221; drug is subject to a higher Medicaid rebate, thereby reducing the amount the manufacturer is paid with respect to such product. These new definitions will become effective as of January 1, 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that started in 2013 and will stay in effect through 2024 unless additional congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could result in more rigorous coverage criteria and/or limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products and additional downward pricing pressures. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private third-party payors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price for any approved product and/or the level of reimbursement physicians receive for administering any approved product. Reductions in reimbursement levels may negatively impact the prices we can charge or the frequency with which products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment, and any negative sentiments towards the U.S. as a result of such changes, could also adversely affect our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.K.'s exit from the E.U. in January 2020, with a transition period that ended on December 31, 2020, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the U.K. While the transition period has now concluded, decisions are still to be made on how data transfers to and from the U.K. will be regulated. Since the regulatory framework for pharmaceutical products in the U.K. covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from E.U. directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of product candidates in the U.K. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the U.K. These possible negative impacts, and others resulting from the U.K.&#8217;s withdrawal from the E.U., may adversely affect our operating results and growth prospects as well as the manner in which we conduct our business operations in Europe.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to intellectual property and other legal matters</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our products are subject in part to the terms and conditions of licenses or sublicenses granted to us by other pharmaceutical companies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rights to our product portfolio are based in part on patents and other intellectual property licensed from third parties. These third parties may generally terminate the license agreements under certain circumstances, including a material breach of the agreement by the other. In the event we terminate our license, or if the third party terminates our license due to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our breach, rights to the intellectual property revert back to the licensor. Any termination or reversion of our rights to develop or commercialize our products would have a material adverse effect on our business.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of the intellectual property related to our products are not adequate, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Method of treatment patents protect the use of a product for the method specified in the patent claims. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for a use that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our patented methods, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method of treatment patents, such infringement may be difficult to prevent.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patents and patent applications may be challenged or fail to result in issued patents and our existing or future patents may be too narrow to prevent third parties from developing or designing around these patents. In addition, we generally rely on trade secret protection and confidentiality agreements to protect certain proprietary know-how that is not patentable, for processes for which patents are difficult to enforce and for any other elements of our drug development processes that involve proprietary know-how, information and technology that is not covered by patent applications. While we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to protect or defend the intellectual property related to our technologies, we will not be able to establish or maintain a competitive advantage in our market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are, have been, and may continue to be, involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful, and third parties may challenge the validity or enforceability of our patents and they may be successful.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even where laws provide protection or we are able to obtain patents, costly and time-consuming litigation may be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors could provoke them to bring counterclaims against us, and some of our competitors have substantially greater intellectual property portfolios than we have. To counter infringement or unauthorized use of any patents we may obtain, we may be required to file infringement claims, which can be expensive and time-consuming to litigate. In addition, if we or one of our future collaborators were to initiate legal proceedings against a third party to enforce a patent covering one of our products, current product candidates, or one of our future products, the defendant could counterclaim that the patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace and challenges to validity of patents in certain foreign jurisdictions are common as well. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the U.S. Patent and Trademark Office, or made a materially misleading statement, during prosecution. We may assert the patents in Hatch-Waxman litigation against the party filing the ANDA to keep the competing product off of the market until the patents expire but there is a risk that we will not succeed. The party filing the ANDA may also counterclaim in the litigation that our patents are not valid or unenforceable, and the court may find one or more claims of our patents invalid or unenforceable. If this occurs, a competing generic product could be marketed prior to expiration of our patents listed in the FDA&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, commonly known as the &#8220;Orange Book,&#8221; which would harm our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been and continue to be involved in number of lawsuits with a variety of generic drug manufacturers who have filed ANDAs relating to certain of our patents. We have been successful in asserting that these third parties have infringed certain of our patents, but we may not be successful in such lawsuits in the future. Please see Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Matters,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements in Part II, Item 8 of this Annual Report, which is incorporated herein by reference, for additional information. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation to extend our patents and to obtain market exclusivity for our products, our business will be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act provides for an extension of patent term for drugs for a period of up to five years to compensate for time spent in development. The HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. new chemical entity (NCE) patent (the primary patent covering the product as a new composition of matter) received the full five-year patent term extension under the Hatch-Waxman Act and so, assuming that we continue to have rights under our license agreement with respect to this product, this patent in the U.S. expires in December 2022. We also own HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. method of treatment patents (directed to the approved method of treatment as described in the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> label approved by the FDA), which expire normally between 2033 and 2035, and two drug substance patents that expire in 2035. The Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. NCE patent received the full five-year patent term extension under the Hatch-Waxman Act and so this patent in the U.S. expired in November 2016. In November 2013, a patent directed to a method of treating patients with Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> based on genotype was issued to us by the U.S.&#160;Patent and Trademark Office. This patent, which was listed in the Orange Book in January 2015, is set to expire in 2027. Please see the risk factor entitled &#8220;We are, have been, and may continue to be, involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful, and third parties may challenge the validity or enforceability of our patents and they may be successful,&#8221; and Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Matters,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements in Part II, Item 8 of this Annual Report, which is incorporated herein by reference, for additional information. Eight additional U.S. patents directed to methods of treating patients with Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which are set to expire between 2025 and 2031, were issued to us in 2015.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A directive in the E.U. provides that companies that receive regulatory approval for a new medicinal product will have a 10-year period of market exclusivity for that product (with the possibility of a further one-year extension), beginning on the date of such European regulatory approval, regardless of when the European NCE patent covering such product expires. A generic version of the approved drug may not be marketed or sold in Europe during such market exclusivity period. This directive is of material importance with respect to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, since the European NCE patent for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has expired.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we gain a five-year patent term restoration for tradipitant, and that we continue to have rights under our license agreement with respect to this product, we would have exclusive rights to tradipitant&#8217;s U.S. NCE patent until 2029. Assuming we gain a five-year patent term restoration for VQW-765, and that we continue to have rights under our license agreement with respect to this product, we would have exclusive rights to VQW-765&#8217;s U.S. NCE patent until 2028.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, there is no assurance that we will receive the extensions of our patents or other exclusive rights available under the Hatch-Waxman Act or similar foreign legislation. If we fail to receive such extensions or exclusive rights, our ability to prevent competitors from manufacturing, marketing and selling generic versions of our products will be materially impaired.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in the development of products for our own account.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our business strategy of acquiring rights to develop and commercialize products, we may develop products for our own account by applying our technologies to off-patent drugs as well as developing our own proprietary molecules. Because we will be funding the development of such programs, there is a risk that we may not be able to continue to fund all such programs to completion or to provide the support necessary to perform the clinical trials, obtain regulatory approvals or market any approved products. We expect the development of products for our own account to consume substantial resources. If we are able to develop commercial products on our own, the risks associated with these programs may be greater than those associated with our programs with collaborative partners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to divert resources and may prevent or delay our drug discovery and development efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our not infringing the patents and proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to develop and commercialize one or more of our products. Defense of these claims, regardless of their merit, would divert substantial financial and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, obtain one or more licenses from third parties or pay royalties. In addition, even in the absence of litigation, we may need to obtain additional licenses from third parties to advance our research or allow commercialization of our products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to develop and commercialize further one or more of our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the future we could be required to initiate litigation to enforce our proprietary rights against infringement by third parties. Prosecution of these claims to enforce our rights against others could divert substantial financial and employee resources from our business. If we fail to enforce our proprietary rights against others, our business will be harmed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described elsewhere in these risk factors and in Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in Part II, Item 8 of this Annual Report, incorporated herein by reference, we have initiated lawsuits to enforce our patent rights against certain generic pharmaceutical companies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been highly volatile and may be volatile in the future, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of any of the risks described in these risk factors or other unforeseen risks could have a dramatic and adverse effect on the market price of our common stock. Between January&#160;1, 2020 and December&#160;31, 2020, the high and low sale prices of our common stock as reported on The Nasdaq Global Market varied between $7.12 and $16.96. Additionally, market prices for securities of biotechnology and pharmaceutical companies, including ours, have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for reasons that were unrelated to the operating performance of any one company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following factors, in addition to the other risk factors described in this section, may also have a significant impact on the market price of our common stock:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our level of success in commercializing our products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our level of success in executing our commercialization strategies;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity regarding actual or potential testing or trial results relating to products under development by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of regulatory review relating to products under development by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any collaboration or other strategic transaction we may undertake;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity regarding actual or potential litigation involving us;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of patent issuances or denials, technological innovations or new commercial products by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety issues with our products or those of our competitors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products or methods by us or others;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in our quarterly operating results;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates of our financial results or recommendations by securities analysts or failure to meet such financial expectations;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in government regulations or policies;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in patent legislation or patent decisions or adverse changes to patent law;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel or members of our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the publication of negative research or articles about our company, our business or our products by industry analysts or others;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market rumors or press reports;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity regarding actual or potential transactions involving us; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other external factors beyond our control.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been and may in the future be subject to litigation, which could harm our stock price, business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been the subject of litigation in the past and may be subject to litigation in the future. In the past, following periods of volatility in the market price of their stock, many companies, including us, have been the subjects of securities class action litigation. Any such litigation can result in substantial costs and diversion of management&#8217;s attention and resources and could harm our stock price, business results of operations and financial condition. As a result of these factors, holders of our common stock might be unable to sell their shares at or above the price they paid for such shares.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If there are substantial sales of our common stock, our stock price could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A small number of institutional investors and private equity funds hold a significant number of shares of our common stock. Sales by these stockholders of a substantial number of shares, or the expectation of such sales, could cause a significant reduction in the market price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our outstanding common stock, as of December 31, 2020, there were a total of 5,246,381 shares of our common stock that we have registered and that we are obligated to issue upon the exercise of currently outstanding options and settlement of restricted stock unit awards granted under our 2006 and 2016 Equity Incentive Plans. Upon the exercise of these options or settlement of the shares underlying these restricted stock units, as the case may be, in accordance with their respective terms, these shares may be resold freely, subject to restrictions imposed on our affiliates under Rule 144. If significant sales of these shares occur in short periods of time, these sales could reduce the market price of our common stock. Any reduction in the trading price of our common stock could impede our ability to raise capital on attractive terms, if at all.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports or publish unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We currently have research coverage by securities and industry analysts. If one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases coverage of our company or fails to regularly publish reports on us, interest in the purchase of our stock could decrease, which could cause our stock price or trading volume to decline.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock may experience future dilution as a result of future equity offerings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in previous offerings. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in previous offerings, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively affected as a result of the actions of activist stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proxy contests have been waged against many companies in the biopharmaceutical industry, including us, over the last several years. If faced with a proxy contest or other type of shareholder activism, we may not be able to respond successfully to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the contest or dispute, which would be disruptive to our business. Even if we are successful, our business could be adversely affected by a proxy contest or shareholder dispute involving us because:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">responding to proxy contests and other actions by activist stockholders can be costly and time-consuming, disrupting operations and diverting the attention of management and employees;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived uncertainties as to future direction may result in the loss of potential acquisitions, collaborations or in-licensing opportunities, and may make it more difficult to attract and retain qualified personnel and business partners; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if individuals are elected to a board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement our strategic plan and create additional value for our stockholders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions could cause our stock price to experience periods of volatility.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter and bylaws and under Delaware law, and the adoption of a rights plan, could prevent or delay a change in control of our company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a Delaware corporation and the anti-takeover provisions of Section&#160;203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and bylaws may discourage, delay or prevent a change in our management or control over us that stockholders may consider favorable. Our amended and restated certificate of incorporation and bylaws:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that could be issued by our board of directors to thwart a takeover attempt;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">do not provide for cumulative voting in the election of directors, which would allow holders of less than a majority of the stock to elect some directors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors, as a result of which the successors to the directors whose terms have expired will be elected to serve from the time of election and qualification until the third annual meeting following their election;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that directors only be removed from office for cause;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on the board of directors, including newly created directorships, may be filled only by a majority vote of directors then in office;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call special meetings of stockholders;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent, requiring all actions to be taken at a meeting of the stockholders; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominating candidates for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors previously adopted a rights agreement, the provisions of which could have had the effect of discouraging, delaying or preventing a change in or management or control over us. While there is no plan to do so at this time, our board of directors may choose to adopt a new rights plan in the future. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to tax regulations to which we are subject could adversely affect us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to tax laws, treaties and regulations in the countries in which we operate, and these laws and treaties are subject to interpretation. New legislation or regulation that could affect our tax burden could be enacted by any governmental authority. We cannot predict the timing or extent of such tax-related developments which could have a negative impact on our financial results. We have taken, and will continue to take, tax positions based on our interpretation of such tax laws. However, a challenge by a taxing authority, our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions may cause our actual financial results to deviate from previous estimates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future transactions may harm our business or the market price of our stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review potential transactions related to technologies, products or product rights and businesses complementary to our business. These transactions could include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mergers;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic alliances;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensing agreements; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">co-promotion and similar agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to enter into one or more of these transactions at any time, which may cause substantial fluctuations in the market price of our stock. Moreover, depending upon the nature of any transaction, we may experience a charge to earnings, which could also materially adversely affect our results of operations and could harm the market price of our stock.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may undertake strategic acquisitions in the future, and difficulties integrating such acquisitions could damage our ability to achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have no experience in acquiring businesses, we may acquire businesses or assets that complement or augment our existing business. If we acquire businesses with promising products or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to move one or more products through preclinical and/or clinical development to regulatory approval and commercialization. Integrating any newly acquired businesses or technologies could be expensive and time-consuming, resulting in the diversion of resources from our current business. We may not be able to integrate any acquired business successfully. We cannot assure that, following an acquisition, we will achieve revenues, specific net income or loss levels that justify the acquisition or that the acquisition will result in increased earnings, or reduced losses, for the combined company in any future period. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses, which would result in dilution for stockholders or the incurrence of indebtedness and may not be available on terms which would otherwise be acceptable to us. We may not be able to operate acquired businesses profitably or otherwise implement our growth strategy successfully.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly due to a number of factors which make our future results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results will continue to be subject to fluctuations and are affected by numerous factors, including:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product sales;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost of product sales;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing and other expenses;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing or supply issues;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of royalties or milestone payments;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our addition or termination of development programs;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our products or future development programs;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our products or those of our competitors; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of collaborative, licensing or other arrangements, and the timing of payments we may make or receive under these arrangements;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement or other lawsuit in which we may become involved; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and recognition of stock-based compensation expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operating results fall below the expectations of investors or securities analysts or below any guidance we may provide, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are increasingly dependent on information technology systems, infrastructure and data. Cybersecurity breaches could expose us to liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure and data. Our computer systems may be vulnerable to service interruption or destruction, malicious intrusion and random attack. Security breaches pose a risk that sensitive data, including intellectual property, trade secrets or personal information may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, denial-of service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our key business partners face similar risks, and a security breach of their systems could adversely affect our security posture. While we continue to invest in data protection and information technology, there can be no assurance that our efforts will prevent service interruptions, or identify breaches in our systems, that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our collaborator, CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs for our product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our collaborators, CROs, and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state actors. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security breaches.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our independent drug development programs. For example, the loss of clinical trial data from ongoing or future clinical trials for any of our product candidates could result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. Our information security systems are also subject to laws and regulations requiring that we take measures to protect the privacy and security of certain information we gather and use in our business. For example, HIPAA and its implementing regulations impose, among other requirements, certain regulatory and contractual requirements regarding the privacy and security of personal health information. In addition to HIPAA, numerous other federal and state laws, including, without limitation, state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and storage of personal information. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of confidential or proprietary information or personal health information, we could incur substantial liability, our reputation would be damaged, and the further development of our product candidates could be delayed.</span></div><div><span><br/></span></div><div id="i78e7e943a648448d981304e612e68114_22"></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNRESOLVED STAFF COMMENTS</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i78e7e943a648448d981304e612e68114_25"></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTIES</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters office consists of a total of 43,462 square feet of office space located at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. under operating leases and subleases that expire between 2026 and 2028 and are subject to renewal options. In addition, we have 2,880 square feet of office space in London, England under an operating lease that has a lease term ending in 2023 and is subject to a renewal option, and other short-term leases. We believe that these facilities are suitable and adequate to meet our anticipated near-term needs. We anticipate that following the expiration of the leases, additional or alternative space will be available at commercially reasonable terms.</span></div><div id="i78e7e943a648448d981304e612e68114_28"></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LEGAL PROCEEDINGS</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect is item may be found in Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Matters,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements in Part II, Item 8 of this Annual Report, which is incorporated herein by reference. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MINE SAFETY DISCLOSURES</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i78e7e943a648448d981304e612e68114_34"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i78e7e943a648448d981304e612e68114_37"></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is quoted on The Nasdaq Global Market under the symbol &#8220;VNDA.&#8221; As of February&#160;4, 2021, there were seven holders of record of our common stock. The number of holders of record of our common stock does not reflect the number of beneficial holders whose shares are held by depositors, brokers or other nominees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Price of and Dividends on the Registrant&#8217;s Common Equity and Related Stockholder Matters</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows the cumulative five-year total return on our common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. An investment of $100 (with reinvestment of dividends) is assumed to have been made in our common stock and in each of the indexes on December&#160;31, 2015 and its relative performance is tracked through December&#160;31, 2020. The comparisons in the table are required by the Securities and Exchange Commission (SEC) and are not intended to forecast or be indicative of possible future performance of our common stock. We have never paid cash dividends to our stockholders and do not plan to pay dividends in the foreseeable future. The following graph and related information is being furnished solely to accompany this Annual Report pursuant to Item&#160;201(e) of Regulation S-K and shall not be deemed &#8220;soliciting materials&#8221; or to be &#8220;filed&#8221; with the SEC (other than as provided in Item&#160;201), nor shall such information be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, and irrespective of any general incorporation language in any such filing.</span></div><div style="margin-top:6pt;text-align:center"><img src="vnda-20201231_g5.jpg" alt="vnda-20201231_g5.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:666px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Incentive Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding securities authorized for issuance under equity incentive plans will be contained in our Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&#160;31, 2020 and is incorporated herein by reference pursuant to General Instruction G(3)&#160;to Form 10-K.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELECTED CONSOLIDATED FINANCIAL DATA</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Statements of Operations data for the years ended December&#160;31, 2020, 2019 and 2018 and the Consolidated Balance Sheet data as of December&#160;31, 2020 and 2019 are each derived from our audited consolidated financial statements included in this Annual Report. The Consolidated Statements of Operations data for the years ended December&#160;31, 2017 and 2016, and the Consolidated Balance Sheet data as of December&#160;31, 2018, 2017 and 2016 are each derived from our audited consolidated financial statements not included herein. Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following data should be read together with our consolidated financial statements and accompanying notes and Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this Annual Report.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for share and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018 (1)(2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017 (1)(2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016 (1)(2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations Data</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold excluding amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,588&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,903)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,431)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,906)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,010)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,427,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,137,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,859,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,735,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,449,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,190,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,847,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,045,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,735,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,449,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018 (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017 (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Data</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">We adopted Accounting Standards Codification (ASC) 842 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842), effective January 1, 2019, using a modified retrospective transition. Results for the years ended prior to December 31, 2019 are accounted for in accordance with ASC 840. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">We adopted ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606), effective January 1, 2018, using the modified retrospective method to those contracts that were not completed as of January&#160;1, 2018. Results for the years ended prior to December 31, 2018 are accounted for in accordance with ASC 605.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with Part II, Item 6, Selected Consolidated Financial Data, and our consolidated financial statements and related notes appearing in this annual report on Form&#160;10-K (Annual Report). This discussion and analysis generally addresses 2020 and 2019 items and year-to-year comparisons between 2020 and 2019. Discussions of 2018 items and year-to-year comparisons between 2019 and 2018 that are not included in this Annual Report can be found in Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report include historical information and other information with respect to our plans and strategy for our business and contain forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under Part I, Item 1A, Risk Factors, and elsewhere in this Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc. (we, our or Vanda) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to advance novel approaches to bring important, new medicines to market through responsible innovation. We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio is currently comprised of two products, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of schizophrenia. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first treatment for patients with Non-24 and SMS approved by the U.S. Food and Drug Administration (FDA). In addition, we have a number of drugs in development, including:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tasimelteon) for the treatment of jet lag disorder, pediatric Non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD); </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operational Highlights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda is encouraged by the strength of its commercial performance during the fourth quarter of 2020. Vanda continues to implement marketing and sales strategies aimed at supporting growth and minimizing the impact of disruptions caused by the COVID-19 pandemic, including the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for schizophrenia direct-to-consumer campaign, which was launched in 2020. Vanda is continuing its activities to support and facilitate the treatment of individuals in the U.S. living with SMS, and is committed to its awareness campaign and the support of patients suffering with Non-24.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradipitant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The gastroparesis Phase III clinical study (VP-VLY-686-3301) is ongoing. The study has a target enrollment of 200 randomized patients and is expected to complete enrollment in the first half of 2021, with a New Drug Application (NDA) filing projected in the second half of 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pneumonia Phase III clinical study (ODYSSEY VLY-686-3501) is ongoing.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tasimelteon)</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2020, the FDA approved HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsule and liquid formulations for the treatment of adults and children, respectively, with nighttime sleep disturbances in SMS. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules, for adults with SMS, were immediately available after approval and HETLIOZ LQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oral suspension, for children with SMS, is expected to be available in the first quarter of 2021. SMS is estimated to affect 1/15,000-25,000 births in the U.S. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first and only FDA approved medication for patients with SMS. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase III clinical study for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in DSPD is expected to be initiated in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A clinical development program for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in ASD is expected to be initiated in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iloperidone)</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Development of the LAI formulation of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is ongoing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A clinical program for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in PDP is expected to begin in the first quarter of 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we began operations, we have devoted substantially all of our resources to the in-licensing, clinical development and commercialization of our products. Our ability to generate meaningful product sales and achieve profitability largely depends on our level of success in commercializing HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and Europe, on our ability, alone or with others, to complete the development of our products, and to obtain the regulatory approvals for and to manufacture, market and sell our products. The results of our operations will vary significantly from year-to-year and quarter-to-quarter and depend on a number of factors, including risks related to our business, risks related to our industry, and other risks that are detailed in  Part I, Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our significant accounting policies appears in the notes to our audited consolidated financial statements for the year ended December&#160;31, 2020 included in this Annual Report. However, we believe that the following accounting policies are important to understanding and evaluating our reported financial results, and we have accordingly included them in this discussion.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from net product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our net product sales consist of sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and sales of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In accordance with ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606), we account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We recognize revenue when control of the product is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. We invoice and record revenue when customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., we sell HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Germany and have a distribution agreement with Megapharm Ltd. for the commercialization of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Israel. Receivables are carried at </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is determined based upon the consideration to which we will be entitled in exchange for transferring product to the customer. Our product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. We estimate the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and update our estimate at each reporting date. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which we have validated the insurance benefits.&#160;Reserves for variable consideration are classified as product revenue allowances on the Consolidated Balance Sheets, with the exception of prompt-pay discounts which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns that are resolved during the product expiry period specified in the customer contract. We currently record sales allowances for the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Prompt-pay:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Specialty pharmacies and wholesalers are offered discounts for prompt payment. We expect that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Part D coverage gap:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Medicare Part&#160;D prescription drug benefit requires manufacturers to fund approximately 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. We account for the Medicare Part D coverage gap using a point of sale model.&#160;Estimates for expected Medicare Part&#160;D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when we have validated the insurance benefits.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Service fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We receive sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. We accrue service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by our third-party administrator.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Product returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We generally offer direct customers a limited right to return as contractually defined with our customers. We consider several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. We do not expect returned goods to be resalable. There was no right of return asset as of December 31, 2020 or 2019.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes sales discounts and allowance activity as of and for the years ended December&#160;31, 2020, 2019 and 2018:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates &amp;<br/>Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts,<br/>Returns<br/>and&#160;Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,046)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for rebates and chargebacks of $70.6 million and $59.4 million for the years ended December&#160;31, 2020 and 2019, respectively, and their ending balances at December 31, 2020 and 2019, primarily represent Medicaid rebates applicable to sales of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, to a lesser extent, Medicaid rebates applicable to sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The provision for discounts, returns and other of $28.0 million and $26.9 million for the years ended December&#160;31, 2020 and 2019, primarily represents wholesaler distribution fees applicable to sales of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, to a lesser extent, estimated product returns of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and co-pay assistance costs and prompt pay discounts applicable to the sales of both HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ending balances of discounts, returns and other as of December 31, 2020 and 2019 primarily represent estimated product returns of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and wholesaler distribution fees applicable to sales of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. We use the Black-Scholes-Merton option pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the expected stock price volatility over the expected term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility rates are based on the historical volatility of our publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have never paid cash dividends to our stockholders and do not plan to pay dividends in the foreseeable future. As stock-based compensation expense recognized in the Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services for clinical trial use, milestone payments made under licensing agreements prior to regulatory approval, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. We expense research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments made under license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with our research and development efforts and has no alternative future use.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently complex, often involve multiple service providers, and can include payments made to investigator physicians at study sites. Because billing for services often lags delivery of service by a substantial amount of time, we often are required to estimate a significant portion of our accrued clinical expenses. Our assessments include, but are not limited to: (i)&#160;an evaluation by the project manager of the work that has been completed during the period, (ii)&#160;measurement of progress prepared internally and/or provided by the third-party service provider, (iii)&#160;analyses of data that justify the progress, and (iv)&#160;management&#8217;s judgment. In the event that we do not identify certain costs that have begun to be incurred or we under- or over-estimate the level of services performed or the costs of such services, our reported expenses for such period would be too low or too high.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our intangible assets consist of capitalized license costs for products approved by the FDA. We amortize our intangible assets on a straight-line basis over the estimated useful economic life of the related product patents. We assess the impairment of intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include significant underperformance relative to expected historical or projected future operating results, a significant adverse change in legal or regulatory factors that could affect the value or patent life including our ability to defend and enforce patent claims and other intellectual property rights and significant negative industry or economic trends. When we determine that the carrying value of our intangible assets may not be recoverable based upon the existence of one or more of the indicators of impairment, we measure any impairment based on the amount that carrying value exceeds fair value. No impairments have been recognized on our intangible assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We assess the need for a valuation allowance against our deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis is highly dependent upon historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, we concluded that it was more likely than not that substantially all of our deferred tax assets in the U.S. are realizable in future periods. A valuation allowance has been retained against certain District of Columbia state deferred tax assets as of December 31, 2020 and 2019. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements included in Part II, Item 8 of this Annual Report for information on recent accounting pronouncements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, including our and our partners&#8217; ability to continue to successfully commercialize our products, any possible payments made or received pursuant to license agreements, progress of our research and development efforts, the timing and outcome of clinical trials and related possible regulatory approvals, and the impact of the COVID-19 pandemic.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year ended December&#160;31, 2020 compared to year ended December&#160;31, 2019 </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Total revenues increased by $21.0 million, or 9%, to $248.2 million for the year ended December 31, 2020 compared to $227.2 million for the year ended December 31, 2019. Revenues were as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:45.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales increased by $17.7 million, or 12%, to $160.7 million for the year ended December 31, 2020 compared to $143.0 million for the year ended December 31, 2019. The increase to net product sales was attributable to an increase in volume and an increase in price net of deductions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales increased by $3.3 million, or 4%, to $87.5 million for the year ended December 31, 2020 compared to $84.2 million for the year ended December 31, 2019. The increase to net product sales was attributable to an increase in price net of deductions partially offset by a decrease in volume. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of goods sold.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of goods sold decreased by $1.1 million, or 5%, to $23.4 million for the year ended December 31, 2020 compared to $24.5 million for the year ended December 31, 2019. Cost of goods sold includes third-party manufacturing costs of product sold, third-party royalty costs and distribution and other costs. Third-party royalty costs were 10% and 5% of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net product sales in the U.S. and Germany, respectively. Third-party royalty costs on Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net product sales decreased from 9% to 6% beginning January 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to third-party royalty costs, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;cost of goods sold as a percentage of revenue depends upon our cost to manufacture inventory at normalized production levels with our third-party manufacturers. We expect that, in the future, total HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;manufacturing costs included in cost of goods sold will continue to be less than 2% of our HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales. We expect that, in the future, total Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;manufacturing costs included in cost of goods sold will continue to be less than 3% of our Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net product sales.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses increased by $6.9 million, or 14%, to $55.6 million for the year ended December 31, 2020 compared to $48.6 million for the year ended December 31, 2019. The increase was primarily due to an increase in clinical trial expenses associated with our Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and COVID-19 therapeutic development programs.&#160;The COVID-19 pandemic has impacted clinical research globally, including our previously reported clinical trials. While certain of our programs have resumed patient enrollment, other programs remain on hold.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the costs of our product development initiatives for the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct project costs (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradipitant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VTR-297</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CFTR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct project costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indirect project costs (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indirect overhead</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect project costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,383&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,649&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant research and development expenses as we continue to develop our products. In addition, we expect to incur licensing costs in the future that could be substantial, as we continue our efforts to expand our product pipeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative expenses increased by $10.8 million, or 8%, to $140.5 million for the year ended December 31, 2020 compared to $129.7 million for the year ended December 31, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019. The increase was primarily the result of increased spending on marketing activities for our commercial products, including the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for schizophrenia direct-to-consumer campaign, partially offset by decreased spending on legal activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible asset amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Intangible asset amortization was $1.5 million for each of the years ended December 31, 2020 and 2019.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other income was $4.4 million for the year ended December 31, 2020 compared to $6.2 million for the year ended December 31, 2019. Other income primarily consists of investment income, which decreased in 2020 as a result of lower yields on our marketable securities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A provision for income taxes of $8.3 million was recorded for the year ended December 31, 2020 and an income tax benefit of $86.5 million was recorded for the year ended December 31, 2019. The income tax benefit for the year ended December 31, 2019 was primarily due to the reduction of the tax valuation allowance against substantially all of its deferred tax assets in the U.S. Tax expense associated with U.S. income before income taxes for the year ended December 31, 2019 was offset by a corresponding tax benefit for the reduction of the valuation allowance recorded against tax attributes that were utilized in those periods. Income tax expense was recorded related to certain U.S. state and foreign jurisdictions for the year ended December 31, 2019. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements in Part II, Item 8 of this Annual Report for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, our total cash and cash equivalents and marketable securities were $367.7 million compared to $312.1 million at December 31, 2019. Our cash and cash equivalents are deposits in operating accounts and highly liquid investments with an original maturity of 90 days or less at date of purchase and consist of investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. Our marketable securities consist of investments in government sponsored and corporate enterprises and commercial paper.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity resources as of December 31, 2020 and 2019 are summarized as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we maintained all of our cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits, but we do not anticipate any losses with respect to such deposits.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plans, which include costs and expenses in connection with our continued clinical development of tradipitant and our other products, U.S. commercial activities for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pursuit of market approval of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in other regions, and payments due upon achievement of milestones under our license agreements, we believe that our cash, cash equivalents and marketable securities and cash received from product sales will be sufficient for at least the next 12 months. Our future capital requirements and the adequacy of our available funds will depend on many factors, primarily including our ability to generate revenue, the scope and costs of our commercial, manufacturing and process development activities, the magnitude of our discovery, preclinical and clinical development programs, and potential costs to acquire or license the rights to additional products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need or desire to obtain additional capital to finance our operations through debt, equity or alternative financing arrangements. We may also seek capital through collaborations or partnerships with other companies. The issuance of debt could require us to grant liens on certain of our assets that may limit our flexibility and debt securities may be convertible into common stock. If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings also may significantly dilute the ownership of our existing stockholders. If we are unable to obtain additional financing, we may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required to reduce the scope of our future activities which could harm our business, financial condition and operating results. There can be no assurance that any additional financing required in the future will be available on acceptable terms, if at all.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net cash flows from operating, investing and financing activities for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.459%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,731)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in operating assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,775&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,795)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases, sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,499)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,309)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,810&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,099)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by operating activities during the year ended December 31, 2020 were $51.8 million, an increase of $5.8 million compared to $45.9 million during the year ended December 31, 2019. The increase reflects an increase of $96.9 million in non-cash charges primarily due to the absence of the reduction of our tax valuation allowance against substantially all of our deferred tax assets in the U.S. and $1.2 million from the net change in operating assets and liabilities, partially offset by a decrease&#160;of $92.2 million in net income. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities during the year ended December 31, 2020 were $41.5 million, an increase of $26.8 million compared to cash used in investing activities of $68.3 million during the year ended December 31, 2019. Investing activities reflect continued net reinvestment of available cash and cash equivalents in our portfolio of marketable securities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by financing activities during the year ended December 31, 2020 were $5.6 million, a decrease of $0.6 million compared to $6.3 million during the year ended December 31, 2019. Financing activities include proceeds from exercises of common stock options.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements, as defined in Item&#160;303(a)(4)&#160;of the Securities and Exchange Commission&#8217;s Regulation&#160;S-K.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our non-cancellable long-term contractual cash obligations as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash payments due by year (4)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone obligation (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase commitments (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-cancellable long-term contractual cash obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,829&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Operating leases include the minimum lease payments for our operating lease liabilities. This table does not include obligations under short-term lease agreements, variable payments for building maintenance and other services and executory costs associated with our operating lease agreements.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">This table includes a probable future $350,000 milestone obligation under our license agreement with University of California San Francisco due upon the conclusion of a Phase I study. This table does not include potential future milestone obligations under our license agreements for which we have not deemed it probable that the milestone event will occur as of December 31, 2020. See Part I, Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business - License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Annual Report, for a description of our licensing arrangements and remaining milestone obligations. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Purchase commitments include non-cancellable purchase commitments for agreements longer than one year and primarily relate to commitments for data services. This table does not include various other long-term agreements entered into for services with other third-party vendors, such as inventory purchase commitments, due to the cancellable nature of the services or variable terms within the agreement. Additionally, this table does not include rebates, chargebacks or discounts recorded as liabilities at the time that product sales are recognized as revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">This table does not include liabilities related to uncertain tax positions taken as of December 31, 2020. Due to the uncertainties in the timing of potential tax audits, the timing associated with the resolution of these positions is also uncertain. </span></div><div><span><br/></span></div><div id="i78e7e943a648448d981304e612e68114_46"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk is currently confined to our cash and cash equivalents, marketable securities and restricted cash. We currently do not hedge interest rate exposure. We have not used derivative financial instruments for speculation or trading purposes. Because of the short-term maturities of our cash and cash equivalents and marketable securities, we do not believe that an increase in market rates would have any significant impact on the realized value of our investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deposit our cash with financial institutions that we consider to be of high credit quality and purchase marketable securities that are generally investment grade, liquid, short-term fixed income securities and money-market instruments denominated in U.S. dollars. Our marketable securities consist of commercial paper, corporate notes and U.S. government agency notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and accounts receivable are concentrated with specialty pharmacies and wholesalers. There were 5 major customers that each accounted for more than 10% of total revenues and, as a group, represented 95% of total revenues for the year ended December&#160;31, 2020. There were 5 major customers that each accounted for more than 10% of accounts receivable and, as a group, represented 90% of total accounts receivable at December&#160;31, 2020. We mitigate our credit risk relating to accounts receivable from customers by performing ongoing credit evaluations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks related to changes in foreign currency exchange rates relating to our foreign operations. The functional currency of our international subsidiaries is the local currency. We are exposed to foreign currency risk to the extent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we enter into transactions denominated in currencies other than our subsidiaries&#8217; respective functional currencies. We are also exposed to unfavorable fluctuations of the U.S. dollar, which is our reporting currency, against the currencies of our operating subsidiaries when their respective financial statements are translated into U.S. dollars for inclusion in our consolidated financial statements. We do not currently hedge our foreign currency exchange rate risk. Foreign currency has not had a material impact on our results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of inflation</span></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation has not had a material impact on our results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i78e7e943a648448d981304e612e68114_49"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements and related financial statement schedules required to be filed are listed in the Index to Consolidated Financial Statements and are incorporated in Part IV, Item&#160;15 of this Annual Report.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="i78e7e943a648448d981304e612e68114_52"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="i78e7e943a648448d981304e612e68114_55"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act)) as of December&#160;31, 2020. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of December&#160;31, 2020, the end of the period covered by this Annual Report, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as defined in the Exchange Act Rule 13a-15(f). Management conducted an assessment of our internal control over financial reporting based on the original framework established in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the assessment, management concluded that, as of December&#160;31, 2020, our internal control over financial reporting was effective. The effectiveness of our internal control over financial reporting as of December&#160;31, 2020 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report included in this Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fourth quarter of 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i78e7e943a648448d981304e612e68114_58"></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER INFORMATION</span></td></tr></table></div><div style="margin-bottom:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i78e7e943a648448d981304e612e68114_61"></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this item will be contained in our Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&#160;31, 2020 and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i78e7e943a648448d981304e612e68114_67"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXECUTIVE COMPENSATION</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this item will be contained in our Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&#160;31, 2020 and is incorporated herein by reference pursuant to General Instruction G(3) to Form&#160;10-K, except that information required by Item&#160;407(e)(5) of Regulation S-K will be deemed furnished in this Form 10-K and will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div id="i78e7e943a648448d981304e612e68114_70"></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this item will be contained in our Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&#160;31, 2020 and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.</span></div><div id="i78e7e943a648448d981304e612e68114_73"></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this item will be contained in our Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&#160;31, 2020 and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.</span></div><div id="i78e7e943a648448d981304e612e68114_76"></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></td></tr></table></div><div style="margin-bottom:24pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this item will be contained in our Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&#160;31, 2020 and is incorporated herein by reference pursuant to General Instruction&#160;G&#160;(3) to Form 10-K.</span></div><div id="i78e7e943a648448d981304e612e68114_79"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i78e7e943a648448d981304e612e68114_82"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements filed as part of this annual report on Form 10-K are listed in the Index to Consolidated Financial Statements. Certain schedules are omitted because they are not applicable, or not required, or because the required information is included in the consolidated financial statements or notes thereto. The Exhibits are listed in the Exhibit Index. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 and 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this annual report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanda&#160;Pharmaceuticals&#160;Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mihael H. Polymeropoulos, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mihael H. Polymeropoulos, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, this annual report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.552%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mihael H. Polymeropoulos, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mihael H. Polymeropoulos, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kevin Moran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin Moran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ H. Thomas Watkins</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and<br/>Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. Thomas Watkins</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Anne Sempowski Ward</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anne Sempowski Ward</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Phaedra Chrousos</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phaedra Chrousos</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard W. Dugan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard W. Dugan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Stephen Ray Mitchell</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen Ray Mitchell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vanda Pharmaceuticals Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_91">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_91">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_94">Consolidated Balance Sheets at December&#160;31, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_94">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_97">Consolidated Statements of Operations for the years ended December&#160; 31, 2020, 2019 and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_97">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_100">Consolidated Statements of Comprehensive Income for the years ended December&#160;31, 2020, 2019 and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_100">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_103">Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December&#160;31, 2020, 2019 and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_103">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_106">Consolidated Statements of Cash Flows for the years ended December&#160; 31, 2020, 2019 and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_106">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_109">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_109">78</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Vanda Pharmaceuticals Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Vanda Pharmaceuticals Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related consolidated statements of operations, of comprehensive income, of changes in stockholders&#8217; equity and of cash flows for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the COSO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Accounting Principle</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid Rebates for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, the allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization. The Company has recorded product revenue allowances of $34.4 million as of December 31, 2020, of which a significant amount relates to allowances for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Medicaid rebates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Medicaid rebates is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing the allowances, as these allowances are based on assumptions developed for estimated patient utilization, primarily payor mix and invoice lag; this in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence related to  the estimated patient utilization assumption. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the allowances for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Medicaid rebates, including controls over the assumptions used to estimate these rebates. These procedures also included, among others, (i) developing an independent estimate of the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Medicaid rebates by utilizing third-party information related to patient utilization, as well as the historical trends of the invoice lag; and (ii) comparing the independent estimate to management&#8217;s estimate. Developing the independent estimate involved (i) testing the completeness and accuracy of the patient utilization data from third-party reports, and (ii) testing rebate claims processed by the Company, including evaluating those claims for consistency with the contractual and mandated terms of the Medicaid Drug Rebate Program. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ PricewaterhouseCoopers LLP </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baltimore, Maryland</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;11, 2021 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2003.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for share and per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMy0xLTEtMS0w_838ef56a-fb39-42ea-80e1-7eae5e4892fb">61,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMy0zLTEtMS0w_ca1af1f4-f512-45bf-a44e-0761b59c8702">45,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNC0xLTEtMS0w_27f97e2a-d8eb-466b-856f-db7218806f53">306,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNC0zLTEtMS0w_0a6b699a-7a5b-4dcc-b743-407994ef40f3">267,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNS0xLTEtMS0w_09823b04-9f62-434e-a5ab-e19a1e8ad97e">30,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNS0zLTEtMS0w_905424e4-6310-49b4-b6a4-90a97019b1ad">26,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNi0xLTEtMS0w_5df8cc7d-0587-4c6a-8eda-6eca6e30b0bc">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNi0zLTEtMS0w_610b30c5-c1fb-49eb-8046-729abc3062a6">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNy0xLTEtMS0w_f44aa9a6-ef6b-463b-8e69-0904033e26a7">10,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNy0zLTEtMS0w_436c9659-792a-44f0-bca6-a898098c182c">14,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfOC0xLTEtMS0w_3766e902-2d2a-4cb1-8642-861d547bbdc6">409,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfOC0zLTEtMS0w_9831953d-c491-4662-9307-7a492df3fa95">354,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfOS0xLTEtMS0w_dbaae8fb-8361-4b88-a905-074e54a5e7f9">4,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfOS0zLTEtMS0w_16ff9804-0b06-455c-b627-72d049f87fb8">3,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTAtMS0xLTEtMA_b235a46d-4793-462f-9f35-1fd9440dccd5">10,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTAtMy0xLTEtMA_65d53a45-3cbb-4738-beea-8d8d9eb205ee">11,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTEtMS0xLTEtMA_35d83f57-d1eb-49b7-85fa-4734481729fd">21,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTEtMy0xLTEtMA_fbc7b382-1930-4a2b-96be-b92a4affea51">23,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTItMS0xLTEtMA_12363c8d-c938-4ce5-8a17-a9c38c595956">81,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTItMy0xLTEtMA_bc3dffab-ebf9-4a1f-a824-843f3b9abc0a">87,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventory and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:InventoryAndOtherNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTMtMS0xLTEtMA_4ed47986-fcf3-47b8-8e93-a8e6770cfc1e">6,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:InventoryAndOtherNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTMtMy0xLTEtMA_f5ee3360-c42a-4f2f-aa8c-2870fe164239">3,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTQtMS0xLTEtMA_a00da9ae-f49d-49c9-84e2-101d876736de">533,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTQtMy0xLTEtMA_e4ea8dfd-719c-4c8b-a216-00fda23d86bc">483,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTctMS0xLTEtMA_ea96fbbf-272a-4ac3-a2dd-b8eb6ae21f8d">31,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTctMy0xLTEtMA_25cffbd2-9f80-46a7-b8b4-5f4cb78b2f6e">27,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:ProductRevenueAllowancesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTgtMS0xLTEtMA_5fda8476-4d81-49d7-b77e-cf70f5959abd">34,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:ProductRevenueAllowancesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTgtMy0xLTEtMA_fd8a5d31-459f-4a63-8d81-de0c543ffb21">31,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjAtMS0xLTEtMA_b34b15b3-99c6-46cc-9416-c6f86717cae4">65,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjAtMy0xLTEtMA_0410546f-5aa6-4301-97d9-80a16346b04c">59,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjEtMS0xLTEtMA_8e39e393-e8f4-44da-a7e5-1ad5f94f76ba">11,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjEtMy0xLTEtMA_a7d2b4d8-2fac-4fa0-9d66-9bf47a9f1015">12,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjItMS0xLTEtMA_d8f66f6c-dcd8-4053-8099-45b5035394a9">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjItMy0xLTEtMA_dad05e03-4075-465b-81ab-aa0625c9dee7">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjMtMS0xLTEtMA_cc37e2a5-c297-4455-8fca-6da1ba1bab91">80,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjMtMy0xLTEtMA_31bd0e0e-67ab-46a3-a1cf-860fdd106f5c">72,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies (Notes 10 and 17)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjQtMS0xLTEtMA_ad25b386-412b-4f00-9d28-b4f494841d9b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjQtMy0xLTEtMA_0b143027-c709-4e90-8e38-c4c50e214e6f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzIx_73cfa972-487c-4aee-b39b-cc9485b4ff21"><ix:nonFraction unitRef="usdPerShare" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzIx_a2bf32a0-85cd-4c68-9c64-5b6f4008cef2">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzM1_1181fbac-b484-4dea-a701-63d76fc937aa"><ix:nonFraction unitRef="shares" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzM1_faa4686a-e757-42e0-8a9a-11ec73d12151">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized, and <ix:nonFraction unitRef="shares" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzYx_032dc89f-40e1-4b00-9e6c-2962600a2777"><ix:nonFraction unitRef="shares" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzYx_785c46a1-1873-4cd2-841f-a33fffbd194e"><ix:nonFraction unitRef="shares" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzYx_93fd6316-2518-41af-becf-bdf44aca5901"><ix:nonFraction unitRef="shares" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzYx_e9aa8071-79c5-41f0-acff-a8970a0bc3e0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December 31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMS0xLTEtMA_06c487c7-3d77-4694-be8d-992f311f2ce2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMy0xLTEtMA_1185ed23-aef6-41a3-bb7e-3819e656229d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzE4_a6b8c197-ad77-4eb8-a335-96818e2e30d6"><ix:nonFraction unitRef="usdPerShare" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzE4_f2f376a1-fa6b-4e25-8da2-7adc33a6187b">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzMy_3b10114a-3c9e-49eb-a7ab-0e46a2a2d994"><ix:nonFraction unitRef="shares" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzMy_b651f812-cca4-423b-b664-fe906c2998f5">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzU0_24ebfd16-718c-4775-ace5-d9526067fc0e"><ix:nonFraction unitRef="shares" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzU0_e079c981-1a08-4d78-946e-1786b6971efd">54,865,092</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzYx_ab8d36f2-7180-4652-b9c9-c68c30577f66"><ix:nonFraction unitRef="shares" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzYx_d8fcc0f2-d660-4e50-a2a1-e2ad8b7b9d72">53,549,612</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMS0xLTEtMA_99dc3f2e-0370-4464-a6ed-96ee137f25f8">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMy0xLTEtMA_85af2def-869f-4ca5-b452-8997173350a4">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjgtMS0xLTEtMA_cfa198e4-3f12-4317-88c1-de85aac1fdf3">650,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjgtMy0xLTEtMA_c2107dbd-84f5-41dd-9fa9-7c5ed27f737d">631,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjktMS0xLTEtMA_aa041062-c23c-4132-9468-8a1a3b4e79c3">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjktMy0xLTEtMA_b2f36002-2576-4280-8290-8865a55bc98b">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzAtMS0xLTEtMA_993e56f4-b8b1-4bf9-85f1-1be8279f79f3">197,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzAtMy0xLTEtMA_72ca4358-0d21-429b-952a-7319b489c9c0">220,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzEtMS0xLTEtMA_61977e1c-5ab1-4a15-ac05-4d25dc20a731">453,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzEtMy0xLTEtMA_98f90aca-a4c4-4189-9183-940cd316dfc8">410,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzItMS0xLTEtMA_23d66a6c-08a3-4050-a678-20ee592eb32b">533,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzItMy0xLTEtMA_170024bf-1cd0-401e-a933-b1665c191bf9">483,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for share and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMy0xLTEtMS0w_ddfba300-5144-4352-8d00-00ca17b732f1">248,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMy0zLTEtMS0w_1b961eea-e548-4ae3-8f9b-63a533caaee1">227,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMy01LTEtMS0w_034b5144-cda3-4f9a-abc1-156e1ce766c6">193,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNC0xLTEtMS0w_05be2b99-d93d-4a2a-88ad-2c59c209f07e">248,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNC0zLTEtMS0w_b1f0d663-8cd8-4499-b4ce-77e481f3e8fa">227,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNC01LTEtMS0w_7c535a77-5b98-46f6-9531-c508928184dc">193,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold excluding amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNi0xLTEtMS0w_114bbc1d-c036-47ab-b4ba-17ccbf1bddfc">23,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNi0zLTEtMS0w_ab14955b-c048-4fa6-9c19-d043c6722c44">24,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNi01LTEtMS0w_5aa89ce6-c9ae-41aa-a9c4-ff503aed1e97">20,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNy0xLTEtMS0w_9d497848-82bf-4a80-93d1-0903df10b8f4">55,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNy0zLTEtMS0w_03c3bcd7-6953-4d82-864f-071f2fda55f7">48,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNy01LTEtMS0w_d1a6a6d3-fe8b-4878-beb0-884e0d01c482">43,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOC0xLTEtMS0w_adb59108-6200-47bd-94ef-25361182815f">140,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOC0zLTEtMS0w_37b48860-fe29-48d8-ab1b-df044edd4fba">129,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOC01LTEtMS0w_a620ee56-8b0c-499a-a492-85455d88549f">105,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOS0xLTEtMS0w_69f61c4e-995d-420b-95c3-372300ca072f">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOS0zLTEtMS0w_2f7c0fa8-1009-4ae1-8280-d77c42a3e96c">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOS01LTEtMS0w_77852810-add6-4ce3-ad43-4e7b59171663">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTAtMS0xLTEtMA_bf1e3876-5a6f-4d2a-b6dc-7446431b2255">220,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTAtMy0xLTEtMA_8f2254d0-4290-4e45-bb40-a2ecd170ca6d">204,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTAtNS0xLTEtMA_0414a5fe-010b-4a23-b370-f8e5f54930c0">171,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTEtMS0xLTEtMA_add21153-e853-44e9-9b59-44d3c123ea7c">27,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTEtMy0xLTEtMA_c3631768-9a3d-4be0-a0d4-de193cb60278">22,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTEtNS0xLTEtMA_9200cd6f-c60d-4e1e-9629-e84ee08ef28d">21,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTItMS0xLTEtMA_ce1fa5fb-a7a9-4213-9fba-305a5afa33d9">4,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTItMy0xLTEtMA_2097fb28-79c6-46ff-98ed-8ba4e8e20b0a">6,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTItNS0xLTEtMA_cbd75ddc-4831-4ad9-8985-9a6ef0992daf">3,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTMtMS0xLTEtMA_4a3230b6-061e-4a57-9e5a-dd59c9b072bf">31,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTMtMy0xLTEtMA_8c041085-3126-421e-8293-3eb09c8e2154">29,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTMtNS0xLTEtMA_f047edf1-0f89-4399-945a-78a192ffa68e">25,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTQtMS0xLTEtMA_854eb8aa-5ebf-4791-a118-1674f51ec100">8,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTQtMy0xLTEtMA_b7ed4616-e28b-4a29-8702-92b2bbb92773">86,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTQtNS0xLTEtMA_62276639-3960-4c9e-b662-b11b980a08fd">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTUtMS0xLTEtMA_d077e7b9-66ca-4421-8a9a-f43016b3700f">23,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTUtMy0xLTEtMA_9c2ca608-2d60-405a-8e38-bc36e624e598">115,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTUtNS0xLTEtMA_03748a27-e4ab-4f26-b637-a0b802774418">25,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTctMS0xLTEtMA_96818a8f-58aa-4b5f-be05-c9989909e9d4">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTctMy0xLTEtMA_f29d9d8b-3fcc-4076-8d61-fd75bdfde413">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTctNS0xLTEtMA_6e01228e-fabb-48cd-ad92-a1a37324abf7">0.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTgtMS0xLTEtMA_7d4e7329-f8e5-423f-84a6-6abe43e9022b">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTgtMy0xLTEtMA_9dc8a7bb-bf42-4d87-b6d0-dcebd9198ac8">2.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTgtNS0xLTEtMA_4f38b2e0-f07b-40d8-869d-a0e92c5eead8">0.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjAtMS0xLTEtMA_00db5c04-c5f3-42de-b27b-4a32b71cf2c7">54,427,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjAtMy0xLTEtMA_22586b31-8691-4663-a31a-2d71ce214619">53,137,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjAtNS0xLTEtMA_b32027b4-9290-4d43-98e9-3637bd8a9073">50,859,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjEtMS0xLTEtMA_7af833bf-32e2-411c-8aa3-956eab0e599e">55,190,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjEtMy0xLTEtMA_c43f18f3-cdc5-48f7-bc10-78662795e084">54,847,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjEtNS0xLTEtMA_03c0b88c-95e9-40c2-9083-248022b33216">53,045,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzItMS0xLTEtMA_3025687f-5541-4fef-aef9-84b58ebefe60">23,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzItMy0xLTEtMA_4dd97932-15c8-43df-b94e-076d85659bb5">115,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzItNS0xLTEtMA_2c683bad-97ce-4943-af8d-03ce7227b5fb">25,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzQtMS0xLTEtMA_4b1d2219-2fdf-4319-ab10-59091e547170">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzQtMy0xLTEtMA_64c13c29-df03-4e29-aba5-495062f8c1d0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzQtNS0xLTEtMA_1cc01928-0949-427d-8419-5bb943b9cdff">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzUtMS0xLTEtMA_8a66ed27-25e0-46ba-8004-c6ab965a5db8">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzUtMy0xLTEtMA_5c957ca7-fb69-4318-9a69-8de602866534">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzUtNS0xLTEtMA_f3b29caa-eada-4272-b971-ba86b1230232">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (provision) on other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzYtMS0xLTEtMA_9a2beb2f-da50-4ee4-a77b-5aa7a7c68d09">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzYtMy0xLTEtMA_a910e31a-bead-4129-81f7-01d4bdd7f330">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzYtNS0xLTEtMA_dcd9c549-35b1-4fc4-bc89-8dc673f12562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzctMS0xLTEtMA_b8ff4cc4-5aec-4bfa-b73f-22c17e592008">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzctMy0xLTEtMA_423a567d-9bf6-4471-806f-431755b88ba3">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzctNS0xLTEtMA_e2ee6e9d-b0dd-4de3-92af-7b504623f111">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzgtMS0xLTEtMA_dfc740aa-3bc0-44aa-9235-103ca0b81e1e">23,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzgtMy0xLTEtMA_b737f126-aeda-41df-9f62-10d28f03e96f">115,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzgtNS0xLTEtMA_763321cf-790b-48ac-aa85-97d2a228c784">25,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:29.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/> Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/> Comprehensive<br/> Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/> Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i257e050f9fc943cca28700c4122282b1_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItMS0xLTEtMA_d3336ced-eeed-4036-8860-b0dbf1ed84ca">44,938,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257e050f9fc943cca28700c4122282b1_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItMy0xLTEtMA_ab936e4a-698c-41cf-a768-1c38ba150e12">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5abb4b8a9434ae69f1ef6beffbc0493_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItNS0xLTEtMA_f81b3cc8-dc7e-4926-9390-544124c270d7">492,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0074f63a213243feae2eb63ef3b3d8bc_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItNy0xLTEtMA_7c51400f-4456-4f71-a743-9f62a7105252">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa64fe61cad4642af1fceb2198e6bcb_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItOS0xLTEtMA_9eb40d8e-8145-4376-9727-196b685735da">361,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926bf00cb18047ab87ba70c56d7331bb_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItMTEtMS0xLTA_57d5caad-8f1f-4841-88dd-ab124381f073">131,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from public offering of common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMS0xLTEtOTc_8401820f-d5a6-44cb-905c-47746cca21af">6,325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMy0xLTEtOTc_2ce36f26-54a7-4efb-a5cc-228f62c52b50">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35541c52d30540b0bcc5d1c03313822b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtNS0xLTEtOTc_b26bad67-522c-455f-a18e-289922527ca6">100,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMTEtMS0xLTk3_52a26162-dee7-4bfa-81ab-11e9816274b3">100,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMS0xLTEtMA_264d2389-efa3-427e-8081-59a809906334">1,214,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMy0xLTEtMA_380bb5d4-5772-4691-918c-878d6f812e5d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35541c52d30540b0bcc5d1c03313822b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtNS0xLTEtMA_c816de43-bfca-4a68-84fc-3b4b4bca76df">6,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMTEtMS0xLTA_6489c5bb-9fc0-4d03-9c02-5143d15cd0dd">6,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35541c52d30540b0bcc5d1c03313822b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzQtNS0xLTEtMA_3c352a85-8f83-43d1-9c1a-5811f0c3b249">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzQtMTEtMS0xLTA_6cf3c6f4-1031-4cb9-85d8-a0e9f355c2eb">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2695d91d6f1c481d8edf3b68ee2898f3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzUtOS0xLTEtMA_ce96c610-c578-47e4-b46c-a831cbb29d82">25,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzUtMTEtMS0xLTA_08aa0917-4491-42e7-9a39-7652788aaee0">25,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic059f611bf8f4dfe887222e34e6e559c_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzYtNy0xLTEtMA_4fd12791-5e6a-4d2a-9d73-978480605e34">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzYtMTEtMS0xLTA_5cf93399-2924-4874-9d7b-166b843be289">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b61d51b346e4a2da4ff3d0965c86883_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctMS0xLTEtMA_ade17f84-f413-4abc-8c9f-782e31ae6622">52,477,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b61d51b346e4a2da4ff3d0965c86883_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctMy0xLTEtMA_910b7a96-54be-41d9-a52b-f211ff2e2317">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b05afd51b244beb8e0ce8e0775250b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctNS0xLTEtMA_000b453e-fe67-4fe5-a4cb-41dba53f48f9">611,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26474ada35c4b5583a6d5ff5c85bdcf_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctNy0xLTEtMA_68522caa-ff0c-4396-ad24-1ffe1b53ff75">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96bafcfa87c1497a9ba610e7dafdc2a8_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctOS0xLTEtMA_77e1c10e-70f9-425d-afaf-6fb5b7559f19">336,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctMTEtMS0xLTA_cb0727b4-eefc-463f-a710-50af385ee198">275,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i085e6c9dd96d4b038e51f519dc41e37d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzktMS0xLTEtMA_a762df80-345e-4c52-8877-a9a5e1427483">1,072,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085e6c9dd96d4b038e51f519dc41e37d_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzktMy0xLTEtMA_43bf0449-510c-42d1-ba2c-88254c9ae0ba">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44c3f48cda746eb8848faa815ee7b25_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzktNS0xLTEtMA_f8b337cf-0186-4a5f-89f0-cd68c5bc1b8f">6,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzktMTEtMS0xLTA_a3c6982b-f9b6-4a13-9192-b9a1f0f0e8c7">6,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44c3f48cda746eb8848faa815ee7b25_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEwLTUtMS0xLTA_e634e43a-e64c-4f38-9429-d16a9b9f7939">13,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEwLTExLTEtMS0w_25354198-ff64-4327-8c28-de97b25b9e59">13,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e49fdf29e54b778aae30d4a1501e76_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzExLTktMS0xLTA_4b7f1b1a-2525-4767-aafa-c5e5ad43ed02">115,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzExLTExLTEtMS0w_620fe29c-032d-4dcd-9b22-6191ac085151">115,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd9bd75bf594c4abbd1eedddf97813d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEyLTctMS0xLTA_2f63f1f8-b0fa-4562-a0fb-2b67a426d922">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEyLTExLTEtMS0w_2eed0598-f31d-4646-ab2d-72275f9602d9">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2876e1911793496ab09397265fb99368_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTEtMS0xLTA_625edc05-2b73-4265-a050-7ab57a7e7a99">53,549,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2876e1911793496ab09397265fb99368_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTMtMS0xLTA_24b73bfc-5b18-4850-bfc3-83a7e63193cb">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4633d2c610df4f1b8efd83504abf4563_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTUtMS0xLTA_0c1fa7be-09dd-4f86-be91-03888d821475">631,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f91365a2a7f4aa084ca1a085338e9fa_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTctMS0xLTA_d5ff06b8-3268-439b-91de-7f27f68be17f">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i765bec0d716f47f7ba015545f962331b_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTktMS0xLTA_d71cd8b3-86dd-4ead-892d-6f1767c71c4c">220,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTExLTEtMS0w_d03411bc-b730-4420-b8b4-ca13a4f7be96">410,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6908a347bbd14f9887021a5ce0273e9e_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE1LTEtMS0xLTA_a429372c-ee5b-436d-a585-00eda758b1e9">1,315,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6908a347bbd14f9887021a5ce0273e9e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE1LTMtMS0xLTA_cfa79c53-a930-4d76-92b7-ca0995612b3f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e47e23e944242d4a81577603ac3211a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE1LTUtMS0xLTA_6d2f71f0-68e8-4a60-8263-f1db79be86d2">5,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE1LTExLTEtMS0w_188acb37-803e-4802-8da5-68e4b1d2a1ce">5,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e47e23e944242d4a81577603ac3211a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE2LTUtMS0xLTA_e7486afd-e774-4988-b983-df3c0f1a4024">13,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE2LTExLTEtMS0w_f403e407-fc66-4116-a438-ac0637f0e026">13,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc5301b024c4390bc0aabe019ad7ed3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE3LTktMS0xLTA_e8ee9989-b486-4bad-bbb7-a07f2508627c">23,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE3LTExLTEtMS0w_847b43e6-f003-4a38-944e-f33114b4c1d7">23,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i992cb2bfa5d0475fa5bbaab433093f86_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE4LTctMS0xLTA_6cee5a3a-7861-4d1b-a7bd-0f120fa53d2c">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE4LTExLTEtMS0w_a1e4478e-a754-453e-916f-eba02fbc1283">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia96fe03637474cd5998b5de2ac3a4f41_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTEtMS0xLTA_92067aff-4e8f-4ae1-add4-977327c6db33">54,865,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96fe03637474cd5998b5de2ac3a4f41_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTMtMS0xLTA_21ce7ada-2a57-4dbb-a9f0-087f714eccc3">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i019a056c228946c5ac4dd9f6f794a1d0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTUtMS0xLTA_6848ab68-ac5d-4a6a-a0f0-d8da500cc029">650,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7446888cd5f945f79f3d4520f7511af9_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTctMS0xLTA_e1c08ccb-ae8c-427c-a095-5d1e2d2490a0">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77cfbc0f34e4893bd812347680c5cf4_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTktMS0xLTA_f0ed2a15-c2bd-4bc6-beac-9fd8519e144e">197,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTExLTEtMS0w_ff8a9e47-f920-4a63-ace8-b86ac3230cbb">453,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMtMS0xLTEtMA_bb74b4ad-52cf-4595-b9ea-b9a4cf77da70">23,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMtMy0xLTEtMA_1f024b97-2e09-4461-85c8-6e04edc331fa">115,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMtNS0xLTEtMA_020b26e9-822d-41c3-9e61-3ddf68ed8b9a">25,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzUtMS0xLTEtMA_00983092-b6fd-45dc-8e7c-2123e4a284d6">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzUtMy0xLTEtMA_9e60edb2-4fbc-4c7b-8cca-e09ba859e196">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzUtNS0xLTEtMA_7ac6d36d-6750-485e-98dd-29bdb958cdab">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzYtMS0xLTEtMA_fd88eada-feed-4b22-b95a-c6e59b3a863d">13,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzYtMy0xLTEtMA_e653321f-5916-42a1-8565-b84200a904d4">13,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzYtNS0xLTEtMA_c35afff9-2da3-4745-9e05-5f2413f6a1a7">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and accretion of discounts on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzctMS0xLTEtMA_fee5d027-4f0e-4da1-8772-470640b91d0f">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzctMy0xLTEtMA_6ec023ff-8f84-4cca-a9f6-bef9cde7c139">3,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzctNS0xLTEtMA_d8e85f7f-151e-442c-afed-54c983af72b6">2,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtMS0xLTEtMzgw_26d8c964-fbb9-46a1-8d95-afc8db3687e7">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtMy0xLTEtMzgz_83de0310-9059-4bdf-9b55-923e378e18a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtNS0xLTEtMzg1_2c810fd2-88f4-4641-9f2b-586c4374d450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtMS0xLTEtMA_c5bcd95a-ad52-4aa6-85df-43614e0562bc">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtMy0xLTEtMA_eb5585be-9307-45ae-b10b-271503bf7c38">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtNS0xLTEtMA_0525645e-13d1-4c22-8c72-3d686611e2c2">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzktMS0xLTEtMA_a752dec0-3c84-48e7-beb7-83ada68a823c">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzktMy0xLTEtMA_148dbe46-bc45-4f4d-bbe2-f8c4c9a6b96e">87,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzktNS0xLTEtMA_9c07b580-1a08-4614-b8af-94dd98b70037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash adjustments, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEwLTEtMS0xLTA_f2b372ef-bd31-4116-b1d9-7325eb22e16f">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEwLTMtMS0xLTA_26d84c4c-0079-4d9d-97a6-c71a7196e97b">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEwLTUtMS0xLTA_204a7cc7-ff6b-44bc-8965-1f8a6da018e7">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEyLTEtMS0xLTA_771a3cf4-b608-4863-8511-75a62cd061f0">3,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEyLTMtMS0xLTA_650d9887-d6b4-4850-989c-1f73bd4e2484">2,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEyLTUtMS0xLTA_d18ef5bd-7037-49e7-b30e-9cd90dc00d66">11,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEzLTEtMS0xLTA_27b5f19a-801e-49db-9501-d91d289282b3">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEzLTMtMS0xLTA_34be71c1-25ff-48d6-9f3b-bb586202571b">2,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEzLTUtMS0xLTA_33358e7b-fd9f-420d-9789-2e5326211ec9">4,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE0LTEtMS0xLTA_28bc4d1e-eff0-4324-85ff-dc60f760a546">2,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE0LTMtMS0xLTA_e9f38e05-0024-4675-bc4f-ae7952753c12">722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE0LTUtMS0xLTA_a7789fac-9e14-4f06-870a-8ea144192039">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE1LTEtMS0xLTA_3640b21a-cf2e-4086-9b77-74577c255cb7">3,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE1LTMtMS0xLTA_26b4a066-9f8d-4cd5-a34e-8e0f36371fcf">3,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE1LTUtMS0xLTA_a987c7ec-ca7e-46fa-9857-cdaaaf57d9e5">618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:IncreaseDecreaseProductRevenueAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE2LTEtMS0xLTA_b7ac9953-80e7-442a-8bd8-37adec7600a7">3,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="vnda:IncreaseDecreaseProductRevenueAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE2LTMtMS0xLTA_23c9e059-f677-4056-bd15-420a2ee275c6">761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="vnda:IncreaseDecreaseProductRevenueAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE2LTUtMS0xLTA_f2bbb580-1491-4f14-99df-4326899f46a5">8,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE3LTEtMS0xLTA_5fd683dd-dba3-48ef-88df-fdca3cccbe49">51,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE3LTMtMS0xLTA_9208a184-a8e2-428d-8612-46a53c4d44e2">45,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE3LTUtMS0xLTA_48189378-53a2-46d8-aebd-d27b0eeb3145">29,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE5LTEtMS0xLTA_bc62ca33-caca-47fe-97ef-8e2c34852290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE5LTMtMS0xLTA_789c589c-c7f4-4742-aab5-131146e16bff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE5LTUtMS0xLTA_90104aff-97ba-4f2e-b436-d5f87f8dc96e">25,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIwLTEtMS0xLTA_2bbe56a9-1192-4b64-90e1-81c98c308737">1,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIwLTMtMS0xLTA_1f523228-e867-4711-b1c6-a463cdad521f">1,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIwLTUtMS0xLTA_31650a4a-369e-44e3-94e1-37a86221fabe">368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIxLTEtMS0xLTA_439e25f7-2804-4980-bf29-9fc457058c74">346,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIxLTMtMS0xLTA_b035630c-89ab-4f79-b598-d7ad059d98b8">394,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIxLTUtMS0xLTA_92dc42a9-1ae8-4b1a-90ed-d3c0969b00ee">282,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIyLTEtMS0xLTA_00040dbd-56e3-402c-8a2a-cf299fd5c50e">306,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIyLTMtMS0xLTA_fc0f6780-ef5a-4c19-a9b0-49244f7d4ab8">327,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIyLTUtMS0xLTA_6f077cbe-f702-45e2-a797-2eec4591d093">198,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIzLTEtMS0xLTA_db90ad6b-b777-4c04-a345-d5f7137ece57">41,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIzLTMtMS0xLTA_2006bd02-bff0-42fa-9141-d9fd627b795d">68,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIzLTUtMS0xLTA_e46ef1b7-18ee-429e-9405-67366891f217">109,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from offering of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI1LTEtMS0xLTA_f15daeee-6227-44a2-84b4-8eef5500d42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI1LTMtMS0xLTA_26f50c6a-914b-4db9-8d3e-350f1c3b9222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI1LTUtMS0xLTA_996f9c09-c14f-4a53-a35d-a74dad077aca">100,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI2LTEtMS0xLTA_b933e915-be62-48b3-a866-b89cd425e1b4">5,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI2LTMtMS0xLTA_498c5ced-f0ff-4f0b-8010-f95cd547bce0">6,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI2LTUtMS0xLTA_d7ddc9aa-0703-4ab7-8b73-b02188468df0">6,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI3LTEtMS0xLTA_f589462d-1f4b-4489-a6aa-007431380b0d">5,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI3LTMtMS0xLTA_67d2ac52-52b2-4b12-bf45-0533d55a8e3e">6,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI3LTUtMS0xLTA_43269751-c267-4580-aec9-76f2986be33d">107,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI4LTEtMS0xLTA_0bb5fb1a-fc8b-4b04-8dc3-0dbd30914f1e">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI4LTMtMS0xLTA_51c6782c-38c9-46ed-8d38-11d564059fc8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI4LTUtMS0xLTA_696937ae-dbc0-43a8-a5bb-a8fe60982085">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI5LTEtMS0xLTA_d9d013df-5464-4e0a-93f2-a2108c6f48e6">15,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI5LTMtMS0xLTA_ea9e3266-561a-4408-9c36-a906b1d4bc5d">16,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI5LTUtMS0xLTA_43dd6a20-8b0b-4a5e-812a-895a2d015d1e">27,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMxLTEtMS0xLTA_b5ecca45-8a0c-47fe-b2f8-c2c103641915">45,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMxLTMtMS0xLTA_a67e0da4-91fa-45d2-a602-a5332b46e500">61,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926bf00cb18047ab87ba70c56d7331bb_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMxLTUtMS0xLTA_e79ad148-897e-4739-9442-b6ba0cd9f10f">34,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMyLTEtMS0xLTA_599beb7a-72f8-4434-8e8f-7bbd7a1f09fd">61,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMyLTMtMS0xLTA_0f1af580-1038-4a54-9f46-3028f474c38b">45,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMyLTUtMS0xLTA_c8f21f79-c9d6-44bf-96e9-ac66ee3bb8b7">61,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div id="i78e7e943a648448d981304e612e68114_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0Xzk2NA_50939536-59e6-4ee6-885c-c7313ffb5f45" continuedAt="i3a7f123846c044d7a509d9be945a6ec9" escape="true">Business Organization and Presentation</ix:nonNumeric></span></div><ix:continuation id="i3a7f123846c044d7a509d9be945a6ec9"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:DescriptionOfBusinessPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0Xzk2MQ_81f15a05-a7b2-4427-8519-91cd11189a4e" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Organization</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in <ix:nonFraction unitRef="segment" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0XzE3NA_d1c7c320-1794-4425-9a2f-7f16642cdb22">one</ix:nonFraction> reporting segment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commercial portfolio is currently comprised of <ix:nonFraction unitRef="product" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="vnda:NumberOfProductsInPortfolio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0XzI1OA_f00968f5-cc36-440b-87c0-d96c80a75660">two</ix:nonFraction> products, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of schizophrenia. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first treatment for patients with Non-24 and SMS approved by the United States Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tasimelteon) for the treatment of jet lag disorder, pediatric Non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD);</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia;</span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0Xzk2Mg_485f223e-e8b3-4651-a3fb-9fabf56fb613" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). All intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric></ix:continuation><div id="i78e7e943a648448d981304e612e68114_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTg3_b75e0583-373d-4d8d-bfc2-0b29f41fc971" continuedAt="i57e4d76b8e2f497284634b029d6704ec" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i57e4d76b8e2f497284634b029d6704ec" continuedAt="i37e5dc4aeaad4bf5ab978c87ffa4482c"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTg4_482c6929-815b-4745-92c5-3e63f55763b2" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#8217;s evaluation could change. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTY5_9077b070-ad4a-4322-9980-a8ab8f8caaaf" continuedAt="i90e3e75ecd67471f9e8a27505a18e87f" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90e3e75ecd67471f9e8a27505a18e87f">For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#8217;s Washington, D.C. headquarters.</ix:continuation>&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i37e5dc4aeaad4bf5ab978c87ffa4482c" continuedAt="i82a747e3d629473aa548811605e259d9"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDE0_f01077e0-21b5-4c35-9893-d5b66a8b7817" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzItMS0xLTEtMA_838ef56a-fb39-42ea-80e1-7eae5e4892fb">61,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzItMy0xLTEtMA_ca1af1f4-f512-45bf-a44e-0761b59c8702">45,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i424e0c1a909c43918460f4dd87afab4a_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzQtMS0xLTEtMA_5e4df526-6255-4617-9e9d-10c1fa2fb49c">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b78e259ae349ce94d9e93829b687d8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzQtMy0xLTEtMA_79a65fc6-6e62-4f8f-a0d8-c83f0d5b0815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventory and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e03ba7540db4ef69e680c9d993fb6a6_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzUtMS0xLTEtMA_e144f8d5-545f-4a7d-b05a-fcf8d543e8be">525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0645b788e347848286b67c1d3bd108_I20191231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzUtMy0xLTEtMA_6a359e17-9ce2-42b9-8442-e57fb7284064">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzYtMS0xLTEtMA_892d55dd-8c4f-45c4-9384-69adaf55dedf">61,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzYtMy0xLTEtMA_b181914f-b0ae-459a-8de1-8be6811e67d9">45,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDI2_288a5564-0a02-4045-82b1-2b375fe2fbce" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its marketable securities as available-for-sale securities. The Company&#8217;s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders&#8217; equity in accumulated other comprehensive income. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value. The Company also reviews its available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is the result of a change in creditworthiness or other factors. If declines in the value of available for-sale securities are determined to be credit-related, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the Consolidated Statements of Operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTc2_5f0c43d1-1cd6-42a8-bbc1-a80e0919ca46" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next 12 months. The Company classifies the estimate of such inventory as non-current.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDM2_9b6298d6-37cd-4d26-9e36-f2dce79f0953" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as research and development expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the estimated useful life is through July 2035, which is the estimated economic useful life of the related product patents. Intangible assets related Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been fully amortized on a straight-line basis to November 2016. The useful life estimate for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTg5_c0e3120e-5337-416e-88f3-6329998352bc" continuedAt="i599a3a2a1f004b2fb7ee3ab76a88a637" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i82a747e3d629473aa548811605e259d9" continuedAt="ie9cd50f46e6046f38bf447483ed27332"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i599a3a2a1f004b2fb7ee3ab76a88a637">straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.</ix:continuation></span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTk5_c8cc145b-c731-484a-af82-d3ffaaf1167b" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (ASC) 842,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing office leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For all office leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTgx_322fab2c-f124-4363-89cd-12f237f23351" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#8217;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management&#8217;s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i)&#160;an evaluation by the project manager of the work that has been completed during the period, (ii)&#160;measurement of progress prepared internally and/or provided by the third-party service provider, (iii)&#160;analyses of data that justify the progress, and (iv)&#160;management&#8217;s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company&#8217;s reported expenses for such period would be too low or too high.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTc3_b841889d-0bcc-48ce-9f1d-ace359deef97" continuedAt="i432fa75a50d24e39a5d97847b3939a09" escape="true">Revenue from Net Product Sales</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i432fa75a50d24e39a5d97847b3939a09" continuedAt="i0347cfab364b4e1199c9cd8a48737432"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0347cfab364b4e1199c9cd8a48737432"> (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTgy_b8019955-ef72-4eec-b953-1a4abe3030c2" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist of sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net sales by product for the years ended December 31, 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in&#160;thousands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzItMS0xLTEtMA_ab6e8757-e24b-40d7-9f21-66d0045d1a62">160,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6797cc9249a14561aeec1ea22885a66a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzItMy0xLTEtMA_30a41898-d09d-4e4e-bb6b-c839f19278ea">142,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzItNS0xLTEtMA_78766f79-4450-455a-a5dd-e72182e7997d">115,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzMtMS0xLTEtMA_fd87d0e9-cb7d-4fcd-9b7c-1e15f1fb0a50">87,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f83003f7bb4ea681811d4c44d82646_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzMtMy0xLTEtMA_8f1595ce-31fa-46e0-9277-d6a8ff7842d9">84,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf54b4365b834d72b6c65f6179255cf7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzMtNS0xLTEtMA_9ed37148-c803-4fa3-bbcc-88779b554497">77,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzQtMS0xLTEtMA_77019e9c-fff3-4015-a46b-52617543593c">248,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzQtMy0xLTEtMA_8b967806-2eb5-494a-b8f6-f7d76027abd8">227,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzQtNS0xLTEtMA_dfa822e6-5ed1-43d8-9605-4c4be4d4cb70">193,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:MajorCustomersPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDQ2_6776cd01-cd42-4fcf-aa40-f08d17e6d6b8" continuedAt="i7121aeb1fca84cda9f6d8b823aeae6a4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available in the United States (U.S.) for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="ie9cd50f46e6046f38bf447483ed27332" continuedAt="ide29466537a540fba90ed3ba9f39763b"><div style="margin-top:12pt"><ix:continuation id="i7121aeb1fca84cda9f6d8b823aeae6a4" continuedAt="id7203c830e5d41ba945ca2810ad62897"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., the Company sells HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Germany and has a distribution agreement for the commercialization of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id7203c830e5d41ba945ca2810ad62897">&#160;in Israel. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.</ix:continuation> &#160;</span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTky_d57543d0-89bb-49e8-a304-26bb16683b04" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents each major customer that represented more than 10% of total revenues for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Net Product Sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7d2c26d1a8c4ef7843d0e6970eeee5d_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzItMS0xLTEtMA_6b5195ab-eb4d-4f7b-8671-2602c3ed292a">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23995355e19f4d9ca86f91468591e135_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzItMy0xLTEtMA_610cebdd-cbd5-4234-94d7-6322113f8ed2">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2aa1c343c0de46f5a4a09cdf2ebcc104_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzItNS0xLTEtMA_89d6844b-9a77-4eff-ae04-0b2d45154c88">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a6f1b4c76e9497aaa45532e1227ad8a_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzMtMS0xLTEtMA_ea4390f1-6c8c-4ad1-a2a6-3feca18a7ad2">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78c8ef22e15348c99b08db2c9df24f2c_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzMtMy0xLTEtMA_2ac5de78-a334-4003-ae5a-6e42e040985f">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i644a9e8beacf4148bf19d98813c87d7d_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzMtNS0xLTEtMA_1463425b-a956-422f-870a-c3349c7d3508">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea7d114004f648229f473f8282cbda31_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzQtMS0xLTEtMA_1494add8-0d65-4b94-83ec-6afdb4854eb3">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ee0973839d144cf8989e256f4f67b49_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzQtMy0xLTEtMA_ab74549f-e923-46b3-9910-776d8fca5842">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa0d780548074d448d8fa037c0529ec7_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzQtNS0xLTEtMA_7cc61a62-cd6d-4155-920d-7e6fec1559e0">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79728196d61b4e99b2d02bfd59fa48b9_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzUtMS0xLTEtMA_c8c9a4ab-8c81-47b4-9bde-2dcd4bb2a1c3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64e8e24272914f67bf876ad95f66ccdd_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzUtMy0xLTEtMA_1494399b-21c2-4c99-9a59-67db0f3110d2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d06651aaae742ed909bbbb905f9bc60_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzUtNS0xLTEtMA_c32289de-9deb-4f83-a389-1f7a9bc8a0eb">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5fdfee666e741d38bae37b3799ca556_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzYtMS0xLTEtMA_2aeca7be-940d-4146-af57-2f4f3ada34f4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd2ad127c2804ac9a3a22c5e5cd6fd79_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzYtMy0xLTEtMA_e6b41ff9-b9e5-4e93-9571-ea404bd53dae">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i893a60e2f07e4beabea78d9092e5f827_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzYtNS0xLTEtMA_201237a4-aa72-4786-abfc-c3e820bd7ed2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTkw_eb0d028b-0424-4686-9627-be0c382bda86" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents each major customer that represented more than 10% of accounts receivable, net, as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Accounts Receivable, Net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb1cae17f9d144cfbac6ede34e4e28ea_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzItMS0xLTEtMA_c3164450-89e8-4a78-9365-f226ae366aef">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5fd1a532a29483fbd96f12b34922d1e_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzItMy0xLTEtMA_a96d3770-81ab-48ce-b022-dc7fd87dc72b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb4fc5098f424b22bcd541acb7773579_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMS0xLTEtNDcyNg_42f4f2ba-3e9f-42f7-830e-8edcc0eee3bb">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7520c5fde90b48c1b3be4f65d3e11085_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMy0xLTEtNDczMA_f53be92b-e252-41ab-9f96-a5a69ce35a0c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4aff6df1bae41c89733b2e7a1d327f4_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMS0xLTEtMjM5NQ_5e4bf898-123d-4ee8-84dc-c8d42de404b7">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c607b03683846a192234cafe043197c_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMy0xLTEtMjM5NQ_bc54aa06-ffeb-4899-985b-bea09498547a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f400e70454f47359d4725431a87a437_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMS0xLTEtMA_2ce2d9e8-a29e-4987-af7f-8592c4077b9e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief538f6767dd4ce0b60f4fd839aebbf9_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMy0xLTEtMA_c31e5115-b4a6-4bbf-afd3-88141d8f1ee8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57b2e8bf447542a48106681a8f18fd2d_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzUtMS0xLTEtMA_0e4e77c8-3407-40e2-b30e-419752c6f258">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfbcdcb15332468b82f91cdeca7c2d90_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzUtMy0xLTEtMA_c7e48c71-1bc7-4975-a815-304eaf22be13">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:ReservesForVariableConsiderationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDMy_95cf26fe-85df-471e-927a-b0165db5bf14" continuedAt="i1c5ee0fe3c9b49c2bb7c2bb8cd0b72d8" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company&#8217;s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.&#160;Reserves for variable consideration are classified as product revenue allowances on the Consolidated Balance Sheets, with the exception of prompt-pay discounts that are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns that are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Prompt-pay:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="ide29466537a540fba90ed3ba9f39763b" continuedAt="ibdf2b0728308481d83cd8103b3ecef2f"><ix:continuation id="i1c5ee0fe3c9b49c2bb7c2bb8cd0b72d8" continuedAt="i88244a6f7a094455a3aa1f95936b8bcf"><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Part D Coverage Gap:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Medicare Part&#160;D prescription drug benefit requires manufacturers to fund approximately <ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="2" name="vnda:PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzEwOTk1MTE2NzE1MTE_78b8099b-1d70-40cd-b96b-8d0841eb0968">70</ix:nonFraction>% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model.&#160;Estimates for expected Medicare Part&#160;D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when the Company has validated the insurance benefits.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Service Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-payment Assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company&#8217;s third-party administrator.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><ix:continuation id="i88244a6f7a094455a3aa1f95936b8bcf" continuedAt="i80c3bbcd65b44806aa695e7b63e3529c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Product Returns</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i80c3bbcd65b44806aa695e7b63e3529c">: The Company generally offers direct customers a limited right to return as contractually defined with its customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of December 31, 2020 or 2019.</ix:continuation> <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDIz_507da970-2044-4ae2-a50f-9ed77157a8b8" continuedAt="i9f90d227e34e41dda0e0a6589914a91b" escape="true">The following table summarizes activity for product returns as of and for the years ended December 31, 2020, 2019 and 2018, all of which relates to sales of Fanapt</ix:nonNumeric></span><ix:continuation id="i9f90d227e34e41dda0e0a6589914a91b" continuedAt="i0bb302d8f087492e82ecdc064dac38e7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></ix:continuation></div><ix:continuation id="i0bb302d8f087492e82ecdc064dac38e7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reserve for Product Returns</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieccc14d91ff74e1695188703bf8f103e_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzEtMS0xLTEtMA_80273d22-482c-4a5c-ae34-a2391fad9dd2">4,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40340870e2a2486992b608dd3ae40740_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzItMS0xLTEtMA_1d5d3a55-3770-416d-a99d-9defe017ff72">2,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40340870e2a2486992b608dd3ae40740_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzMtMS0xLTEtMA_ff83d382-5269-4ce1-b574-646762d8ddab">1,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21fd1609a04e49b0bb22ec6b8e33dadc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzQtMS0xLTEtMA_21b4f4bd-e21a-42a3-94a4-91fd66d768e8">5,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01d7291558c49ab8183941f323312e1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzUtMS0xLTEtMA_eff16f8d-1d0d-450c-b724-8ec3af6bb85c">3,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib01d7291558c49ab8183941f323312e1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzYtMS0xLTEtMA_a8315bce-af39-4bbe-bbeb-130f3c4da950">2,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fc42978e1140569719239aff32634c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzctMS0xLTEtMA_68c54c52-b39e-467c-ae05-08fd17e8890b">6,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f4a59b89dd4fc5b2a51c78dbf422c6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzgtMS0xLTEtMA_555d8a3e-9393-402e-b683-1a21e8b70790">3,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7f4a59b89dd4fc5b2a51c78dbf422c6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzktMS0xLTEtMA_44a53bbf-d548-427b-bd1c-c7ce4569c026">5,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69b9f546af14feab861a844ee2190df_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzEwLTEtMS0xLTA_d4ffb9b2-1e9e-4d53-83fb-f5e9edf9f8ef">4,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDQy_818e2112-d40d-42cc-91c8-3d025cffe487" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes royalties payable, the cost of inventory sold, costs to write down inventory to net realizable value, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Company&#8217;s distribution partners.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDAy_b0908275-9cd3-4a07-93f0-54a1f41f70f8" continuedAt="i50b7f3b5e8324d7bb6379164b4bc2a4b" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="ibdf2b0728308481d83cd8103b3ecef2f" continuedAt="i158939739f3a4f99b7bac990241f628a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i50b7f3b5e8324d7bb6379164b4bc2a4b">capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company&#8217;s research and development efforts and has no alternative future use.</ix:continuation></span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDI5_d524dbe4-092d-45f2-a31a-915e07a5fce1" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTY3_982e98ef-b8a1-41a3-bf66-dbd405ea339e" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award&#8217;s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTkz_a0794345-25fd-4881-980f-66c1adb962f8" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were&#160;$<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzE5ODQ0_bbfb5eb6-173e-4962-8667-4c9e773e63dd">12.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzE5ODQ4_254269bf-f9d3-4e60-afff-b6567a014b03">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzE5ODU1_0da47ddb-24e3-43c4-bde7-20e292275363">0.9</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTY4_7a2c9eb8-4289-4a40-bc14-5312ad88586a" continuedAt="ib54ed52c1bf04dc6a80ed83ff0f3467d" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reporting currency of the Company is the U.S. dollar. The functional currency of the Company&#8217;s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in accumulated other comprehensive income.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib54ed52c1bf04dc6a80ed83ff0f3467d">Transactions denominated in currencies other than subsidiaries&#8217; functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the Consolidated Balance Sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions.</ix:continuation> Foreign currency transaction gains and losses are included in other income and were not material for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDUw_ad6a0462-5c4a-418d-9bf0-50c3aafc57ce" continuedAt="i194bb96733d6477c9acfadf66bffe89f" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i194bb96733d6477c9acfadf66bffe89f">The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i158939739f3a4f99b7bac990241f628a" continuedAt="i62f12e2867964e0a89b9844856ea17ad"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the novel coronavirus known as COVID-19 has resulted in government-imposed quarantines, travel restrictions and other public health safety measures. As this pandemic endures, the extent to which COVID-19 may impact the Company's business, financial condition and results of operations is uncertain and will depend on many factors outside of the Company's control.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products under development require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the products will receive the necessary clearance. If the Company is denied clearance or clearance is delayed, it may have a material adverse impact on the Company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products are concentrated in rapidly changing, highly competitive markets, which are characterized by rapid technological advances, changes in customer requirements and evolving regulatory requirements and industry standards. Any failure by the Company to anticipate or to respond adequately to technological developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards or any significant delays in the development or introduction of products or services could have a material adverse effect on the Company&#8217;s business, operating results and future cash flows.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company depends on single source suppliers for critical raw materials for manufacturing, as well as other components required for the administration of its products. The loss of these suppliers could delay the clinical trials or prevent or delay commercialization of the products.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly rated financial institutions. At December 31, 2020, the Company maintained all of its cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographic Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="segment" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI0MTU5_0a74c4d3-5827-426d-90d9-dd350fbbb3df">one</ix:nonFraction> reporting segment and, accordingly, no segment disclosures are presented herein. Foreign sales were not material for each of the years ended December 31, 2020, 2019 and 2018.</span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDQx_d831c47c-c3ff-44a9-9e27-fbc3cca74305" continuedAt="idf95119b33cd4cad990f572ef624616f" escape="true"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which clarifies and simplifies certain aspects of the accounting for income taxes.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The standard is effective </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The adoption of this standard on January 1, 2021 is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="i62f12e2867964e0a89b9844856ea17ad" continuedAt="ib820ed1fc3b448ab8c7ec5d237a22fcc"><ix:continuation id="idf95119b33cd4cad990f572ef624616f" continuedAt="i0f06d3ba32434d76be766e4c8fb67115"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses, </span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib820ed1fc3b448ab8c7ec5d237a22fcc"><ix:continuation id="i0f06d3ba32434d76be766e4c8fb67115">which changed the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#8220;expected loss&#8221; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's consolidated financial results.</ix:continuation></ix:continuation> </span></div><div id="i78e7e943a648448d981304e612e68114_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90ZXh0cmVnaW9uOmZiOTRlM2I4ZTRkOTQzZGY5ZDZhMjcxOTU5MWJhYzJiXzMzOA_cd6224eb-cd14-4b4a-95b2-8a75fd2b1929" continuedAt="ib285a39b5e0f41f5951f65139b913ff4" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib285a39b5e0f41f5951f65139b913ff4" continuedAt="i6fc1e57243ff4ac88d660dabdf0cf3d4"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90ZXh0cmVnaW9uOmZiOTRlM2I4ZTRkOTQzZGY5ZDZhMjcxOTU5MWJhYzJiXzM0MA_8fc36d5f-7628-42ac-9872-608723c3cd6a" continuedAt="i58d39c63f34a48849632e5a4b1803aff" escape="true">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2020, which all have contractual maturities of less than two years:</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i6fc1e57243ff4ac88d660dabdf0cf3d4"><ix:continuation id="i58d39c63f34a48849632e5a4b1803aff"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzEtMS0xLTEtMA_80f28556-7044-492a-837b-0faf9f9d82ce">165,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzEtMy0xLTEtMA_b1e5a636-1538-462c-9bcb-c94fe1fed404">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzEtNS0xLTEtMA_ec7ef38a-9585-408c-9700-722844266adc">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzEtNy0xLTEtMA_975ec8e8-c331-4277-b7c5-dce64e884eed">166,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd2be23072740898c45df963bd01f36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzItMS0xLTEtMA_db36133d-a0e4-4d34-ae3c-da2c6ccfaca3">140,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd2be23072740898c45df963bd01f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzItMy0xLTEtMA_73d1a9d8-7505-45f0-9a7c-2eb52cd56c04">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd2be23072740898c45df963bd01f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzItNS0xLTEtMA_273eb9d4-4814-42e5-b951-351edd806747">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd2be23072740898c45df963bd01f36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzItNy0xLTEtMA_89fbf157-b08f-4b97-9934-d3f61b9a6866">140,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzQtMS0xLTEtMA_83cd50ab-0a63-4eaf-a892-817480928b10">306,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzQtMy0xLTEtMA_6167e8a7-11cb-4a30-887b-d558d67694ca">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzQtNS0xLTEtMA_0963adf1-0d4c-49a7-ac5e-ece76312a93a">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzQtNy0xLTEtMA_b628fb22-918c-4026-ad75-76fd8d956e67">306,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2019, which all have contractual maturities of less than two years:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzEtMS0xLTEtMA_ac616518-076b-492f-9745-ea2be551c1e1">88,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzEtMy0xLTEtMA_be7b7383-f28f-4482-8c05-a6277a3d1d63">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzEtNS0xLTEtMA_dfe72d89-d474-4d0c-aa1b-6729083206bf">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzEtNy0xLTEtMA_3ae2a900-d4e9-40d4-8feb-80a353ae3bbc">88,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzItMS0xLTEtMA_45af69ae-0fa2-4e5c-a0d4-d068cc364881">129,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzItMy0xLTEtMA_3881528f-fa23-4c44-97fe-436e19a5eeda">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzItNS0xLTEtMA_5fbc4aa3-a732-4f47-b14c-3aece7f8a7a2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzItNy0xLTEtMA_09fecce9-cc52-48a9-85f9-b5e78170783a">130,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzMtMS0xLTEtMA_6edc2931-c061-4b63-8314-b926af7a8966">48,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzMtMy0xLTEtMA_80c334a1-1d4d-4b8c-af62-8cfa6e671853">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzMtNS0xLTEtMA_b1445103-e1b6-443f-ad91-3b40105923d7">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzMtNy0xLTEtMA_11594154-26ce-4e7f-b279-d4d8f03137fd">48,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzQtMS0xLTEtMA_c1bf2fa3-4371-412d-8566-6fd80b265fc3">266,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzQtMy0xLTEtMA_1f0747e6-abd8-446d-8b46-4e4c07dbb551">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzQtNS0xLTEtMA_15b9340a-68ef-4820-a42d-69f1415ec468">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzQtNy0xLTEtMA_50397430-3768-449e-bdce-f57817208470">267,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="i78e7e943a648448d981304e612e68114_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90ZXh0cmVnaW9uOmY0OGQ1YTdhZTZiNzQ2ZTc4MTFjOGI3ZGE0ZTBmZDRmXzE5Nzk_76975e46-bb6d-4721-93df-2adf0e155b5b" continuedAt="ie5c295ece4c14aaa9c307a1e86132f54" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ie5c295ece4c14aaa9c307a1e86132f54" continuedAt="i8edaeac760f44dcfaf69456c8f734fa2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8212; defined as observable inputs such as quoted prices in active markets</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8212; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8212; defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's assets classified in Level&#160;1 and Level&#160;2 as of December 31, 2020 and 2019 consist of cash equivalents and available-for-sale marketable securities. The valuation of Level&#160;1 instruments is determined using a market approach and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of Level&#160;2 instruments is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level&#160;2 securities include certificates of deposit, commercial paper, corporate notes and asset-backed securities that use as their basis readily observable market parameters. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90ZXh0cmVnaW9uOmY0OGQ1YTdhZTZiNzQ2ZTc4MTFjOGI3ZGE0ZTBmZDRmXzE5ODI_16e5ea35-c086-4563-84c9-f46d09b23b4f" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2020, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:39.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement as of December 31, 2020 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets&#160;for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzItMS0xLTEtMA_378000ac-93c6-4da8-9867-c845716a332d">166,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83bee279dbf04510bbc505415f41b886_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzItMy0xLTEtMA_59ed92a6-0e1c-4e50-8d37-2b9c0d550565">166,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cee81eae3834f8a91784e60ea88cdd9_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzItNS0xLTEtMA_3324c392-78a6-469d-9a58-bd1fa4a8eae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1931a9cde2641aead7a75d77a370fb5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzItNy0xLTEtMA_02c8ab30-f2ce-46cf-b862-bc450c1057c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd2be23072740898c45df963bd01f36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzMtMS0xLTEtMA_cacfb031-0be2-44ec-ad9c-fab207f69da9">140,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd654c3e3074ac5beb9219888a8397d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzMtMy0xLTEtMA_47c519d0-3ee4-431c-a5a7-609dfa19e339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf5512406d242b3b334cdf95473932e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzMtNS0xLTEtMA_35d0537d-eb44-4592-b1c9-1226336bacfc">140,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd2b9acca2e4a7e89256bcac7794b71_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzMtNy0xLTEtMA_8d7c9d7b-6bb2-4c86-bd22-da45cf3e2322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzUtMS0xLTEtMA_2cf2b227-ac51-4c9d-87ed-798a6a81a44e">306,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590279da68dd44789a39b09a2a7b4e5c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzUtMy0xLTEtMA_08afd42f-ed5d-4e24-a391-b91d1c7763ba">166,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aff0dba35f64b73909e86bb8cbb00e0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzUtNS0xLTEtMA_314ffbd7-ffd4-48d7-a540-ea35f729a21d">140,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4fa1365e34d44fc9764447fd2ec2e24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzUtNy0xLTEtMA_955d0bae-c14c-4540-91c1-3963b34bc302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2019, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:39.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement as of December 31, 2019 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets&#160;for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzItMS0xLTEtMA_5a2a504b-8d31-401d-b3bb-84ea92a4b82e">88,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1521ac6ce4c4e3faa831a373c4b2943_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzItMy0xLTEtMA_fd928cb0-0118-48ed-abdd-1b58a5455e1a">88,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e789b5b4e8447591662fec5bda3261_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzItNS0xLTEtMA_3f0c5b40-def8-4484-a5f4-46311cbd83a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26713507297483babfde81db7b9fa28_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzItNy0xLTEtMA_2b2143b9-4e6c-41da-822c-bdc545280975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzMtMS0xLTEtMA_66816511-e398-4042-997f-d14e2dc9074d">137,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84837f39b7f470cb64a3244ed1fc84c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzMtMy0xLTEtMA_d1c94cc9-da21-4f28-86a5-0629076b27b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b552a7bd9b47038ad2a7e5c99411fa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzMtNS0xLTEtMA_8f17fa6e-c91b-4e4d-8705-a36afdb85a68">137,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c688c60d8564383bf26445621f9ca74_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzMtNy0xLTEtMA_9b21b0dc-8dd6-48ad-a074-90ba55bc52d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzQtMS0xLTEtMA_501ab422-69b5-41f8-8d82-1a57a30d93ee">48,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3faacc11ff44169093da58889d764b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzQtMy0xLTEtMA_c1b5b706-26a5-42b6-bd4b-4e90531090cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4362e7304366445d990ded2bb3505b1b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzQtNS0xLTEtMA_404ff35a-8294-4ff3-9351-fd57b9d676ed">48,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792f4aa473234968ae82e33224c68d6c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzQtNy0xLTEtMA_a716c86d-9d41-4c33-8f5d-d5ff78526122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzUtMS0xLTEtMA_3d5c3ab3-507c-4807-8eb0-68c0358694b6">274,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0242a482bf8f427e89cb520b935b8dec_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzUtMy0xLTEtMA_3913f415-fff7-49e5-b552-cfec90c285da">88,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i572e6e7f0ee349d2b27aafb167ab28ed_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzUtNS0xLTEtMA_d506a304-10a3-439a-b9f1-0130a416424b">185,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad2ca748413447168432f3afa16e0405_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzUtNy0xLTEtMA_8095db2f-132e-44b5-83ac-1e4f4eab4d91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i8edaeac760f44dcfaf69456c8f734fa2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value as of December 31, 2020 include <ix:nonFraction unitRef="usd" contextRef="ib7112e733b494f1a982cc5aac77faeae_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90ZXh0cmVnaW9uOmY0OGQ1YTdhZTZiNzQ2ZTc4MTFjOGI3ZGE0ZTBmZDRmXzY1OTcwNjk3NjkzODA_7b1a1be1-3d6d-462d-bbf5-6d1fcbd4a419">no</ix:nonFraction> cash equivalents. Total assets measured at fair value as of December 31, 2019 include $<ix:nonFraction unitRef="usd" contextRef="i27df4ba463ab4d5b86c334633ea1634e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90ZXh0cmVnaW9uOmY0OGQ1YTdhZTZiNzQ2ZTc4MTFjOGI3ZGE0ZTBmZDRmXzEwOTk1MTE2MzAxNDc_a9647cc5-c535-4a1f-9dbf-87a39bc51646">7.0</ix:nonFraction> million of cash equivalents.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances, and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.</span></div></ix:continuation><div id="i78e7e943a648448d981304e612e68114_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90ZXh0cmVnaW9uOjA1Yjk5NzQ5NGFjNzQxMTc5ZDA0ODI2ZGY1MDQwZjMzXzY0NQ_b0a0ee9c-d0f0-48e3-9f46-c29bd7c42951" continuedAt="i0f08e8364ff8448dbc6239218a1e4611" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i0f08e8364ff8448dbc6239218a1e4611"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:ScheduleOfInventoriesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90ZXh0cmVnaW9uOjA1Yjk5NzQ5NGFjNzQxMTc5ZDA0ODI2ZGY1MDQwZjMzXzY0Mg_8caaea7c-9ed3-42b9-9d43-1b55562544d4" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzItMS0xLTEtMA_1afed492-313c-435b-8ec7-79028401dca6">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzItMy0xLTEtMA_5f2ba9cf-12bc-4c7f-8295-857efbda46af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzMtMS0xLTEtMA_5edc9c26-b548-413f-b654-609d68e6d6cb">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzMtMy0xLTEtMA_3334da2a-a089-41df-91bf-077f463123db">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzQtMS0xLTEtMA_052f1ab8-1ab8-445c-b8f8-7d527376d07c">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzQtMy0xLTEtMA_aaecb227-7819-441b-a6b5-6473ca9bdadd">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="vnda:InventoryRawMaterialsNetOfReservesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzYtMS0xLTEtMA_59f35877-0565-4b30-becb-80cd2e8bdc8f">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="vnda:InventoryRawMaterialsNetOfReservesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzYtMy0xLTEtMA_b34e7e01-d272-4d1c-bf90-d4aea680c515">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:InventoryWorkInProcessNetOfReservesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzctMS0xLTEtMA_51d66da1-5944-46e2-b64d-d32ba7e975e6">4,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:InventoryWorkInProcessNetOfReservesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzctMy0xLTEtMA_d7a93963-4382-49bf-824e-a5c63f22bdb7">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="vnda:InventoryFinishedGoodsNetOfReservesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzgtMS0xLTEtMA_63ffdb95-0ed2-4ad7-a311-0e91445ebbe3">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:InventoryFinishedGoodsNetOfReservesNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzgtMy0xLTEtMA_298e776c-c666-4098-8737-7cf6a03e8091">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzktMS0xLTEtMA_885f69bb-2d3a-4040-9071-e46ea76fb808">5,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzktMy0xLTEtMA_fea94ccc-3c57-4b90-8397-c1bdb46d4c3f">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:Inventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzEwLTEtMS0xLTUwOQ_37b05e5f-56b7-4e02-bd56-4efafa1b0bcc">6,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:Inventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzEwLTMtMS0xLTUxMQ_5ee5347a-bcee-455c-a966-08b87a827b0e">3,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="i78e7e943a648448d981304e612e68114_127"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzIyMA_5a8d9ca4-329d-474f-9c5c-788a3d2e18c3" continuedAt="i32dcfe5ca64d4d4e9e5987490772207f" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i32dcfe5ca64d4d4e9e5987490772207f"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzIxNg_1507e6cf-437f-47ba-bcd2-24f09b51d026" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s property and equipment, at cost, as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful&#160;Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and other equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iba732339a56e4213b11aa8a21ae766e1_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzEtMS0xLTEtMA_1aecca5e-7478-44a2-8427-8408e013742d">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7b6f3b209b460b89808f786605b838_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzEtMy0xLTEtMA_554f059e-cf92-4878-8d3a-7f86c62e5ea9">5,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b8918e05b554009ab234e53619bc90e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzEtNS0xLTEtMA_72b5243d-e29d-4fc8-9677-f8cb3ea4383f">4,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b1c97ddaaee4131822793e4b11a1fc3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzItMS0xLTEtMC90ZXh0cmVnaW9uOmIzMDg2Mzc5NzdkMzQxOTBhNzljNTEyZWY0ODk4MTIwXzQ_7e23e5e7-6d82-49c1-b287-64b8a0c902e7">5</ix:nonNumeric> - <ix:nonNumeric contextRef="i3b9c76d935aa454e9830545d747a662d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzItMS0xLTEtMC90ZXh0cmVnaW9uOmIzMDg2Mzc5NzdkMzQxOTBhNzljNTEyZWY0ODk4MTIwXzk_0756e23f-7822-4c54-b5eb-ce1406d3ebcb">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26247ebfe7eb4525a836402ffc21ca64_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzItMy0xLTEtMA_564957b7-bf30-47b8-be67-2df04d31d5a0">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34b88e9659246eea1386afd588f2793_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzItNS0xLTEtMA_99e53394-100f-40a7-bec0-63b552e3895b">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0b9bd57d44144fa28e3d7c0a1cc6d107_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjZhMWUwMTlkM2NkNjRhZWE4N2VhZDMxMTUxOWYwZjEwXzQ_8385c956-7586-4930-9c0f-45c9480540d2">5</ix:nonNumeric> - <ix:nonNumeric contextRef="i1e6096930e004a5cb3b64a1d96cd3a18_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjZhMWUwMTlkM2NkNjRhZWE4N2VhZDMxMTUxOWYwZjEwXzk_63da4bea-cbf1-4ee8-984e-9b05cdd1a699">11</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a58cc236b3a4b2aa61a7e28fe9c07da_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzMtMy0xLTEtMA_456a8333-c2dd-41f9-b08d-e21f3eb12b03">5,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686659adf6bc48a2a6282c2af72dab52_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzMtNS0xLTEtMA_ba0f6ce5-b649-4d38-9af6-b1c6dc5f8cd8">4,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzQtMy0xLTEtMA_b480cc8a-de98-4df3-b8c3-bd33f6fc4eb0">12,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzQtNS0xLTEtMA_6628c9a0-8e45-437a-9dd6-ef553ae57694">10,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzUtMy0xLTEtMA_6ab8a104-5403-48a1-a5eb-4ff8af2301f3">8,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzUtNS0xLTEtMA_561964b5-6ca1-4af2-a189-19bf47a37cb6">6,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzYtMy0xLTEtMA_d357ac4b-a47a-47b0-b41d-35d75a9ed441">4,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzYtNS0xLTEtMA_3fcd8835-c413-475f-a46d-6b543bca9aed">3,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzE1Mg_697afb6a-dabc-469a-ad21-52c67e141961"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzE1Mg_9488321c-87e6-4694-802a-cd5aeb90e12c"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzE1Mg_fd4d3c98-561f-4a6c-b23b-5686d8f77a42">1.4</ix:nonFraction></ix:nonFraction></ix:nonFraction> million for each of the years ended December 31, 2020, 2019 and 2018.</span></div></ix:continuation><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="i78e7e943a648448d981304e612e68114_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzMyMzI_e523838a-6980-4ee1-87ba-38f83829d8f4" continuedAt="ib5bfe33edd2a489eb315898813772df7" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ib5bfe33edd2a489eb315898813772df7" continuedAt="i4bef449455bb472ea3238117c0b156af"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term leases primarily include operating leases and subleases for office space in Washington, D.C. and London, England. The Company recognized ROU assets and lease liabilities related to fixed payments for these long-term operating leases in its Consolidated Balance Sheet as of December 31, 2020 and 2019. The Company also has short-term leases, including office space in Berlin, Germany.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2011, the Company entered into an operating lease agreement under which it leases <ix:nonFraction unitRef="sqft" contextRef="ice34ccdece6648b48a6896c3974844b0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzQ4OQ_16491732-d181-4668-86d5-a95c8434d528">33,534</ix:nonFraction> square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. Subject to the prior rights of other tenants, the Company has the right to renew the lease for <ix:nonNumeric contextRef="ice34ccdece6648b48a6896c3974844b0_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzY5MA_45a2a569-b765-42f3-8e8d-b5712d6a1be0">five years</ix:nonNumeric> following its expiration in July 2028. As of December 31, 2020, the renewal period has not been included in the lease term. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions. The lease may be terminated early by the Company or the landlord under certain circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into a sublease agreement under which it subleases an additional <ix:nonFraction unitRef="sqft" contextRef="i98d5263305ac4d87882e5502fb408e09_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzExMDk_227e81f9-322d-41ae-913e-eb47e446b2f2">9,928</ix:nonFraction> square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. The sublease term began in </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i4bef449455bb472ea3238117c0b156af"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;2017 and ends in July&#160;2026 but may be terminated earlier by either party under certain circumstances. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into an operating lease agreement under which it leases <ix:nonFraction unitRef="sqft" contextRef="ib295f3c8735849ada24ac840f8aa6e79_I20201231" decimals="-1" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzE1NTY_aab8cca9-be3e-49ca-9086-a2531c89b3c4">2,880</ix:nonFraction> square feet of office space in London, England. In November 2020, the Company extended the non-cancellable portion of the lease term from 2021 to 2023 and has the option to renew the lease for an additional <ix:nonNumeric contextRef="ib295f3c8735849ada24ac840f8aa6e79_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzE2NTY_ef96d2c6-192f-423a-99d6-793766a8483e">three years</ix:nonNumeric> following its expiration.</span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzMyMzM_6bf2b453-5bbc-451e-850c-5b5b6a302e7d" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s ROU assets and operating lease liabilities as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzItNC0xLTEtMTg0_371a8b36-a0db-424d-ba8c-8935330ef3d4">10,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzItNC0xLTEtMA_7e8757ce-90af-413d-a3bd-99c01460ae89">11,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzUtNC0xLTEtMTg0_eec139cf-8ca2-4e08-ae9f-6c4096012cae">2,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzUtNC0xLTEtMA_eab89f54-d832-4e47-99e4-aa7c90dec123">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzYtNC0xLTEtMTg0_fa0528c9-7459-481e-adb2-32ccce4a22fe">11,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzYtNC0xLTEtMA_e702fa52-89c5-4ecc-89dc-b0bfd2f6eba9">12,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzctNC0xLTEtMTg0_ccdc4cd4-7f62-4386-a10a-bd565995cac2">13,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzctNC0xLTEtMA_7918dac6-7bb2-4d87-8177-a282ee3bc30d">14,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzktNC0xLTEtMTg0_6189cdbd-ae35-40ef-9610-9a6a22e37b96">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzktNC0xLTEtMA_5730478e-f4e8-4ab0-86e9-daece8c67698">8.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzEwLTQtMS0xLTE4NA_2fab0def-fde0-4b66-ac32-25f98956adca">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzEwLTQtMS0xLTA_062a6144-6b9f-4a28-ad4d-5b558d84030f">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the years ended December 31, 2020 and 2019, the Company recognized operating lease cost of $<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIwNTY_012a3b36-ec4a-417e-a9f8-2f8509195d3b"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIwNTY_a91ac197-80d2-4d12-8b83-a1f746cdbe30">2.3</ix:nonFraction></ix:nonFraction> million and short-term operating lease cost of $<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIwOTg_13d6836b-e8ff-43d0-8a94-4b77c84a3493"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIwOTg_735312ef-b3c6-4b87-93ec-8f5f52077046">0.4</ix:nonFraction></ix:nonFraction> million. The Company also recognized $<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:OperatingLeaseNonLeaseComponentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIxMzA_59cfc69d-385b-4425-84b2-6385f9b26c0f">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="vnda:OperatingLeaseNonLeaseComponentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzEwOTk1MTE2MzExNjM_10e900f1-1634-4098-aa83-1d8c671a3963">1.4</ix:nonFraction> million, respectively, of expense related to non-lease elements, such as building maintenance services and utilities, and executory costs associated with the operating leases. For existing leases as of January 1, 2019, executory costs are excluded from operating lease expense, which is consistent with the Company's accounting under ASC 840. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices. For the year ended December 31, 2018, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzI2NzE_de21d912-5bb5-47f5-8d0c-4c236ec39555">3.6</ix:nonFraction> million of rent expense, inclusive of lease expense, non-lease elements, and executory costs for short and long-term operating leases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities is included in operating cash flows and was $<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzI5NDg_6da415d6-1f27-4053-a85b-47828564c496">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzEwOTk1MTE2MzExOTk_e71910d2-27ba-4547-a90e-0a090006541b">2.5</ix:nonFraction> million for the years ended December 31, 2020 and 2019, respectively. </span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzMyMzA_45fdd03d-26ba-461e-acf2-e89e1b15b8cf" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of December 31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzItMi0xLTEtMA_cf145d20-88f6-4acb-a7e9-deab2abc149b">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzMtMi0xLTEtMA_7597e8c8-1989-43fd-a108-3c77c22a7a6e">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzQtMi0xLTEtMA_4ba6af70-eee7-4c73-99d9-f1588beeec47">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzUtMi0xLTEtMA_e8850b8b-63c2-4bf8-8b9e-9517083fdd51">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzYtMi0xLTEtMA_52b4bcfe-b904-477a-a4a8-d0e8f1d5249d">2,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzctMi0xLTEtMA_cb5e9bc9-1e1d-4939-87f5-4e8643e86ab3">5,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzgtMi0xLTEtMA_eccd9845-e77a-49ce-81f5-a95306a4ef7f">18,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzktMi0xLTEtMA_87875e11-ce44-4442-8811-8ea8f79937da">4,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzEwLTItMS0xLTA_f49769fb-9ee8-497f-8145-f739d1ae3314">13,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current obligations under leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzExLTItMS0xLTA_e44b8345-776e-4e3f-9394-c0f8c224da89">2,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzEyLTItMS0xLTA_1b145223-6845-40be-b9de-261177a8dd27">11,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzIwOTA_14921203-d109-43f3-a4a4-5002ece0d417" continuedAt="i6e3c52aa386646539eeae898d2064a5c" escape="true">Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i6e3c52aa386646539eeae898d2064a5c"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of $<ix:nonFraction unitRef="usd" contextRef="ia30bb33a28694ca0b45ea8f0d52a84cc_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzMxOQ_96515887-6230-48c3-acd8-4c73f8e6f431">8.0</ix:nonFraction> million to BMS. The $<ix:nonFraction unitRef="usd" contextRef="ia30bb33a28694ca0b45ea8f0d52a84cc_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzMzNA_96c82b45-b548-44aa-a99a-83437f1c348f">8.0</ix:nonFraction> million is being amortized on a straight-line basis over the estimated economic useful life of the related product patents. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company met its final milestone under its license agreement with BMS when cumulative worldwide sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;reached $<ix:nonFraction unitRef="usd" contextRef="if6745c8d49094756a3fd1e677133183b_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="vnda:CumulativeNetSalesToAchieveMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzYyMA_48c36b46-6a1d-48a4-83d5-d4adf7802850">250.0</ix:nonFraction> million. As a result of the achievement of this milestone, the Company made a payment to BMS of $<ix:nonFraction unitRef="usd" contextRef="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzcxMQ_b8d2b77d-9c44-47ac-9ea5-919ad874b03f">25.0</ix:nonFraction> million in 2018. The $<ix:nonFraction unitRef="usd" contextRef="ib4a98ad86cb947b6b61d3738c4361015_D20150101-20150331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzM4NDgyOTA2OTk2MDU_91604661-2b52-4a97-b498-f54418dd5983">25.0</ix:nonFraction>&#160;million, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated economic useful life of both the $<ix:nonFraction unitRef="usd" contextRef="ia30bb33a28694ca0b45ea8f0d52a84cc_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzExMDg_96515887-6230-48c3-acd8-4c73f8e6f431">8.0</ix:nonFraction> million and the $<ix:nonFraction unitRef="usd" contextRef="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzExMTk_5f4ed619-8942-48d6-8ad3-32eff6118d82">25.0</ix:nonFraction> million intangible assets were changed from February 2035 to July 2035 based on the July 2035 expiration date of U.S. patent number 10,376,487&#160;(&#8216;487 Patent) issued by the U.S. Patent and Trademark Office in August 2019.</span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzIwOTI_88dae927-51a2-4cf5-a681-5bfb1761dbde" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s intangible assets as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo5OWQwYmM5ZTU4MWQ0ZjJhYjg3MWVkZDNmZWZhMTNmMi90YWJsZXJhbmdlOjk5ZDBiYzllNTgxZDRmMmFiODcxZWRkM2ZlZmExM2YyXzItMy0xLTEtMA_282c58f7-3218-47f5-a190-017c890d043f">33,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo5OWQwYmM5ZTU4MWQ0ZjJhYjg3MWVkZDNmZWZhMTNmMi90YWJsZXJhbmdlOjk5ZDBiYzllNTgxZDRmMmFiODcxZWRkM2ZlZmExM2YyXzItNS0xLTEtMA_a2367aa7-e0a9-47b2-a1bd-b685bc93a745">11,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo5OWQwYmM5ZTU4MWQ0ZjJhYjg3MWVkZDNmZWZhMTNmMi90YWJsZXJhbmdlOjk5ZDBiYzllNTgxZDRmMmFiODcxZWRkM2ZlZmExM2YyXzItNy0xLTEtMA_7a81a528-ab22-4067-9dfa-bd674a40de79">21,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s intangible assets as of December 31, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9498b806f5e43439515d6d38d221880_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmZTBiMGI4NTZlNDQ0N2MwOTZmMDg3YThlMTZmMzY5ZS90YWJsZXJhbmdlOmZlMGIwYjg1NmU0NDQ3YzA5NmYwODdhOGUxNmYzNjllXzItMy0xLTEtMA_5b7b8d26-5a5b-41ca-a518-b2556386c551">33,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9498b806f5e43439515d6d38d221880_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmZTBiMGI4NTZlNDQ0N2MwOTZmMDg3YThlMTZmMzY5ZS90YWJsZXJhbmdlOmZlMGIwYjg1NmU0NDQ3YzA5NmYwODdhOGUxNmYzNjllXzItNS0xLTEtMA_fb6af6ff-4f16-4627-8ce3-c113ba5d4a8a">9,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9498b806f5e43439515d6d38d221880_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmZTBiMGI4NTZlNDQ0N2MwOTZmMDg3YThlMTZmMzY5ZS90YWJsZXJhbmdlOmZlMGIwYjg1NmU0NDQ3YzA5NmYwODdhOGUxNmYzNjllXzItNy0xLTEtMA_7aafc9fd-1af4-48b5-992d-f03848e8a375">23,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company also had $<ix:nonFraction unitRef="usd" contextRef="i712a2982fd6d4ab8ac21ead0059a6ab2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzE3NTk_00f81edd-0a27-4981-a99a-d3bb3a42f383"><ix:nonFraction unitRef="usd" contextRef="i07f9ce99f5d440829beb69d57b267e2c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzE3NTk_cd584af0-edd6-46bf-8611-622d6060b7e9">27.9</ix:nonFraction></ix:nonFraction> million of fully amortized intangible assets related to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful economic life using the straight-line method. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzIwOTQ_85c49e50-8dd6-4e62-9dc9-6d0ced2bee0b" continuedAt="i486d16440c2547a0bcdc2b867be6afeb" escape="true">Amortization expense for the years ended December 31, 2020, 2019 and 2018 was as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i486d16440c2547a0bcdc2b867be6afeb"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo4OTMwMjdkZjc4Mjg0NjVlYTVjZTgwZGIxMmExMDgxZS90YWJsZXJhbmdlOjg5MzAyN2RmNzgyODQ2NWVhNWNlODBkYjEyYTEwODFlXzItMS0xLTEtMA_d548e3bc-4b78-45d1-bf87-20476ddec036">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6797cc9249a14561aeec1ea22885a66a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo4OTMwMjdkZjc4Mjg0NjVlYTVjZTgwZGIxMmExMDgxZS90YWJsZXJhbmdlOjg5MzAyN2RmNzgyODQ2NWVhNWNlODBkYjEyYTEwODFlXzItMy0xLTEtMA_3db608cf-276d-4055-b06b-f3b5a0fbcb42">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo4OTMwMjdkZjc4Mjg0NjVlYTVjZTgwZGIxMmExMDgxZS90YWJsZXJhbmdlOjg5MzAyN2RmNzgyODQ2NWVhNWNlODBkYjEyYTEwODFlXzItNS0xLTEtMA_750b9d33-bff2-4c92-b559-14fb5c484ec4">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzIxMDE_2b673cb8-fb43-4702-8f2b-dd1fb7d51fd1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the future intangible asset amortization schedule as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtMS0xLTEtMA_767a7cb1-3b91-4c77-8cf3-1733705d673b">21,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtMy0xLTEtMA_9a399459-7ebd-4db7-a8ae-0a2c68e5dc65">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtNS0xLTEtMA_7ea13130-5bd7-4b55-b94b-898da4d8ed1a">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtNy0xLTEtMA_a2c9ec8e-a2b0-43d1-96da-2238147b9454">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtOS0xLTEtMA_268a98f4-75ec-4c50-86e9-4eaa2d2c3d8e">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtMTEtMS0xLTA_6501e0e6-f6a7-458f-a804-6ada3829ea22">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtMTMtMS0xLTA_6135fb36-e2fc-4852-a6c6-fdea02d278dd">14,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i78e7e943a648448d981304e612e68114_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90ZXh0cmVnaW9uOmZkOTQxNTY0MDQ3MTQzNTk5ODRkMDliY2U3NmQ2YTFiXzE1Mg_2004f8f4-9d38-46ba-89bb-b2cc9db93996" continuedAt="i00c19b7123774196bdd704110689b5d8" escape="true">Accounts Payable and Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="i00c19b7123774196bdd704110689b5d8"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90ZXh0cmVnaW9uOmZkOTQxNTY0MDQ3MTQzNTk5ODRkMDliY2U3NmQ2YTFiXzE1Mw_84710270-4e86-4c33-897c-0f2edcb68d94" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s accounts payable and accrued liabilities as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzEtMS0xLTEtMA_1c2cf754-ef42-453d-aa37-f3285ac4f4e3">10,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzEtMy0xLTEtMA_99175834-bea6-4b88-8b56-9ea77fb2c27e">6,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:AccruedResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzMtMS0xLTEtMA_64a822a0-9117-4768-bcba-e334263c09a9">6,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:AccruedResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzMtMy0xLTEtMA_63628f4a-0289-44ab-ab4e-18888a949afe">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzItMS0xLTEtMA_bcd064e3-1e62-462d-b916-f7491efa94d9">5,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzItMy0xLTEtMA_572ed289-ab61-4521-b524-ad2a6ccfba37">5,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and other professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzQtMS0xLTEtMA_7e4d40ef-b44a-438f-8f4e-ffff734ec823">5,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzQtMy0xLTEtMA_271e72a8-e084-4a75-a8a9-46ed51491d2e">5,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzUtMS0xLTEtMA_73df8e49-4195-4130-8d31-d74bd4543915">2,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzUtMy0xLTEtMA_f5743c0c-396d-4989-9e1c-5a954601ee7a">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone obligations under license agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="vnda:AccruedMilestoneObligationsUnderLicenseAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzYtMS0xLTEtNTY1OQ_d71d29a1-a7b9-4f29-a1d7-4a5f54b1f77b">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:zerodash" name="vnda:AccruedMilestoneObligationsUnderLicenseAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzYtMy0xLTEtNTY1OQ_b9e43e89-d73a-4446-8c65-f36e55138952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzYtMS0xLTEtMA_1e6f98c1-0966-43f8-b4dc-ab7c119e0276">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzYtMy0xLTEtMA_6e764860-714f-4a15-b7e0-872dda6e309a">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzctMS0xLTEtMA_e20b8a34-9110-4709-8e50-abd167215fc3">31,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzctMy0xLTEtMA_6d4cabc6-1a39-4c31-bf45-3ff3739e194c">27,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1Xzc2NzY_f9643456-2da7-443a-a644-cdf1453bc03e" continuedAt="i34d3ead617254147ab012c81c5b8bf9a" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i34d3ead617254147ab012c81c5b8bf9a" continuedAt="i272bf4510fa44df8a0a42cf3ef8a2c22"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#8217;s products. The term of these indemnification agreements is generally perpetual from the date of execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2020, the Company has paid BMS $<ix:nonFraction unitRef="usd" contextRef="ia48b1e08808c4068b45beac65e2fc47e_D20040201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzE2MDM_d2b330d1-6b05-464b-ba68-3af5e6b33028">37.5</ix:nonFraction> million in upfront fees and milestone obligations, including $<ix:nonFraction unitRef="usd" contextRef="ia48b1e08808c4068b45beac65e2fc47e_D20040201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzE2NTk_edab482a-da08-402d-802f-7582bddec127">33.0</ix:nonFraction> million of regulatory approval and commercial milestones capitalized as intangible assets (see Note 8). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net sales to BMS in any territory where the Company commercializes HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for a period equal to the greater of <ix:nonNumeric contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231" format="ixt-sec:duryear" name="vnda:RoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzIwMDY_30503168-d996-49c6-b519-f279a4ab9b8e">10</ix:nonNumeric> years following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a <ix:nonFraction unitRef="number" contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231" decimals="2" name="vnda:RoyaltyPayableOnNetSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzIyNDE_610c7927-bc2c-4386-9f89-2d09b77c5cfe">10</ix:nonFraction>% royalty on net sales in that territory.&#160;The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the <ix:nonNumeric contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231" format="ixt-sec:duryear" name="vnda:RoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzM4NDgyOTA3MDUyMDI_30503168-d996-49c6-b519-f279a4ab9b8e">10</ix:nonNumeric> years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the&#160;<ix:nonNumeric contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231" name="vnda:PercentageOfFutureSublicenseFeesPayable" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1Xzc2NzI_350dd093-9937-474f-b28a-8c69b264db2b">mid-twenties</ix:nonNumeric>.&#160;The Company is obligated&#160;to use its commercially reasonable efforts to develop and commercialize HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to the terms of a settlement agreement with Novartis Pharma AG (Novartis), Novartis transferred all U.S. and Canadian rights in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> franchise to the Company on December&#160;31, 2014. The Company paid directly to Sanofi S.A. (Sanofi) a fixed royalty of <ix:nonFraction unitRef="number" contextRef="i2321f5ecabd74d08919f170010c86d17_D20141231-20191231" decimals="2" name="vnda:RoyaltyPayableOnNetSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzMxNDg_c63f78c8-d7e5-4658-9174-74e8baa901cd">3</ix:nonFraction>% of net sales through December&#160;2019 related to manufacturing know-how. The Company is also obligated to pay Sanofi a fixed royalty on Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net sales equal to <ix:nonFraction unitRef="number" contextRef="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231" decimals="2" name="vnda:RoyaltyPayableOnNetSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzMzMzg_2696597c-dc5f-4c8e-b4ec-f6b7ba9c950a">6</ix:nonFraction>% on Sanofi&#160;know-how&#160;not related to manufacturing under certain conditions for a period of up to <ix:nonNumeric contextRef="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231" format="ixt-sec:duryear" name="vnda:RoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzM0MzY_cdf6cd88-bbc7-4254-afd0-af8a448c612d">10</ix:nonNumeric> years in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this <ix:nonFraction unitRef="number" contextRef="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231" decimals="2" name="vnda:RoyaltyPayableOnNetSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzM4NDgyOTA3MDUxOTE_2696597c-dc5f-4c8e-b4ec-f6b7ba9c950a">6</ix:nonFraction>% royalty on net sales in the U.S. through November 2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tradipitant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an&#160;NK-1R&#160;antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the <ix:nonNumeric contextRef="iae6fb1507ec54a02b3ed9ec15779f92e_D20200101-20201231" name="vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1Xzc2NzM_7070ed21-3c74-4caf-beed-cffb57fc074c">low double digits</ix:nonNumeric>. As of December 31, 2020, the Company has paid Lilly $<ix:nonFraction unitRef="usd" contextRef="icce1828699d04ca897051ef167bc2cf9_D20120401-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQyMzE_6441d925-e22d-4888-b08d-438281a00b54">3.0</ix:nonFraction> million in upfront fees and development milestones. As of December 31, 2020, remaining milestone obligations include a $<ix:nonFraction unitRef="usd" contextRef="i9a443bc8c89e453aab29432964b30663_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQ0NTk_cdb68c44-7956-48b2-bf81-5a81278b0327">2.0</ix:nonFraction> million development milestone due upon the filing of the first marketing authorization for tradipitant in either the U.S. or European Union (E.U.), $<ix:nonFraction unitRef="usd" contextRef="ic4c827b82caa44a79a4cef10d4761150_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQ2MDI_84981153-95fb-4212-8191-f5c1f6eef4e8">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i81b735133e1949cd9c6e0aeb4f8be530_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQ2MDk_56629265-f636-485c-9344-8bb43a3efbb1">5.0</ix:nonFraction> million for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to $<ix:nonFraction unitRef="usd" contextRef="i04c1d7fb8dfe49699863ca274c5642ca_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQ3MjY_4fbd5c70-f228-4cc2-8583-0e176ff97206">80.0</ix:nonFraction> million for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Portfolio of CFTR activators and inhibitors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as <ix:nonNumeric contextRef="ib097b437c4ec4ac8a415c8716b033089_D20200101-20201231" name="vnda:TieredRoyaltiesPayableOnFutureNetSales" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1Xzc2NzQ_0ab16059-b256-4798-b60b-c83ef837477b">single-digit</ix:nonNumeric> royalties on net sales. As of December 31, 2020, the Company has paid UCSF $<ix:nonFraction unitRef="usd" contextRef="i37dcfaf9fa1c4d21a01c3abfb80350e7_D20170301-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzYyOTk_c3d332fd-c58e-4cb8-a0ae-1f473a6c99a6">1.2</ix:nonFraction> million in upfront fees and development milestones, including a $<ix:nonFraction unitRef="usd" contextRef="i7c5916a7919c4f108df3dcee675165a5_D20190301-20190331" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY0MDc_8e2f5bc6-5737-4adc-9791-afc22d515ffb">0.2</ix:nonFraction> million development milestone payment in March 2019. As of December 31, 2020, remaining milestone obligations include </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i272bf4510fa44df8a0a42cf3ef8a2c22" continuedAt="i9dc17100cf584f99b7f1c7e84f971fa4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i3bb19f1abf4e4d15b43df2933d3b57bf_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY1MDk_b33ffe36-52cd-477b-8bb0-86b10793633b">12.2</ix:nonFraction> million for development milestones and $<ix:nonFraction unitRef="usd" contextRef="i4f739a8080b94ee0acf1864cc98cfab3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY1NDM_aa43c6f4-c7f5-41bd-9a8c-54e7632a6d24">33.0</ix:nonFraction> million for future regulatory approval and sales milestones. Included in the $<ix:nonFraction unitRef="usd" contextRef="i3bb19f1abf4e4d15b43df2933d3b57bf_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY2MTU_d8808419-b1ee-4e2b-867e-a33d17686657">12.2</ix:nonFraction> million of development milestones is a $<ix:nonFraction unitRef="usd" contextRef="if67d682d4b8343aabcab512b8d833546_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY2NDk_57701e95-e4b4-42e4-81f0-8fb9fa38d573">350,000</ix:nonFraction> milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed $<ix:nonFraction unitRef="usd" contextRef="i5d164c813b754d099714d4875c7405de_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY3NDk_be33caf9-db3f-4f7e-b629-878179b035e2">1.1</ix:nonFraction> million in total for the CFTR portfolio.  In the fourth quarter of 2020, the Company determined the $<ix:nonFraction unitRef="usd" contextRef="ia1f829f974634d488f1643966850c384_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:AccruedMilestoneObligationsUnderLicenseAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzM4NDgyOTA3MDY3NDI_0b30e1d2-c668-4e28-b009-2a2c506ea32c">350,000</ix:nonFraction> milestone to be probable and accrued it as a current liability as of December 31, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VQW-765.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with a settlement agreement with Novartis relating to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize VQW-765 and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the <ix:nonNumeric contextRef="i7d9544bb0d4445a097ccc5fa7f50cd38_D20200101-20201231" name="vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzYwNDczMTM5NjQyMjg_2a8f41f6-c2a3-45e7-a6f9-811f4ba4c01d">mid-teens</ix:nonNumeric>.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9dc17100cf584f99b7f1c7e84f971fa4">In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company&#8217;s current agreements for clinical, marketing and other services may be terminated on generally <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:durday" name="vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzcxMzM_b6ce530e-b406-4a91-8b38-ea850b3bcdb2">90</ix:nonNumeric> days&#8217; notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company&#8217;s contractors in closing out work in progress as of the effective date of termination.</ix:continuation> </span></div><div id="i78e7e943a648448d981304e612e68114_1439"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:PublicOfferingOfCommonStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8zODQ4MjkwNjk4ODcy_133ce68a-7e6d-4aa4-8d8c-d9d5d5f5ca6d" continuedAt="i2e394e89d49b4b5ea4daebd6c090744a" escape="true">Public Offering of Common Stock</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2e394e89d49b4b5ea4daebd6c090744a">In March 2018, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="iec535a14efca43c882d02e3f9ef3b063_D20180301-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8zODQ4MjkwNjk4ODg0_b358a4a7-3079-4265-8aea-d199574a6f8e">6,325,000</ix:nonFraction> shares of its common stock, including the exercise of the underwriters&#8217; option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ib81f399dfe554faa998124d94d076956_D20180301-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8xMDk5NTExNjI5Mzk3_ed591b41-b810-45e6-969a-62b141a285ca">825,000</ix:nonFraction> shares of common stock, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i418ff91379b846d3988ba7db10522717_I20180331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8xMDk5NTExNjI5NDA2_2f893677-ca54-4b38-bd6c-52c269b68200">17.00</ix:nonFraction> per share. Net cash proceeds from the public offering were $<ix:nonFraction unitRef="usd" contextRef="iec535a14efca43c882d02e3f9ef3b063_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8zODQ4MjkwNjk4OTEw_8f9abbb4-5238-4241-93e0-5a44800697c7">100.9</ix:nonFraction>&#160;million, after deducting the underwriting discounts and commissions and offering expenses.</ix:continuation></span></div><div id="i78e7e943a648448d981304e612e68114_148"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90ZXh0cmVnaW9uOjEyMzUyYjY3OTI0NjRkNzRhMDMyYzljMzRmNGQ2OWIzXzI3NQ_48b1258f-f2dc-41bb-95c8-5cb9fcd4d4f1" continuedAt="i2415bab4ddd04a62b653bdf222ef7a90" escape="true">Accumulated Other Comprehensive Income</ix:nonNumeric></span></div><ix:continuation id="i2415bab4ddd04a62b653bdf222ef7a90"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90ZXh0cmVnaW9uOjEyMzUyYjY3OTI0NjRkNzRhMDMyYzljMzRmNGQ2OWIzXzI3Ng_d943deb0-10ed-4a06-b26f-ece9862e46f9" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzEtMS0xLTEtMA_333470c1-6a3f-4324-8ddb-34dfa8a0c615">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzEtMy0xLTEtMA_f5acf39a-e090-47be-9fc3-58267eda233a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzItMS0xLTEtMA_0b2ad8d9-f6e5-4f45-a1aa-d72b53ff61cc">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzItMy0xLTEtMA_5628f4f0-0f79-4417-8972-1427bb6f6dd7">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzMtMS0xLTEtMA_35b2c1f7-c59a-4f6c-91ba-550d63774b7b">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzMtMy0xLTEtMA_4180d1da-77e4-4b15-bc50-402fc8dc1542">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i78e7e943a648448d981304e612e68114_151"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ2MDI_33446724-64cb-410c-97e1-3e9a1a07cea7" continuedAt="if98a4c8643e94b61b73a04e02a502408" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="if98a4c8643e94b61b73a04e02a502408" continuedAt="i605baf87f0df42a7bbcb76a2bfcb0336"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i0ce88e2ed3eb4664882da8188a70d03a_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzU1_c85efbd3-1399-4742-8349-f5abdd57863b">5,246,381</ix:nonFraction> shares subject to outstanding options and RSUs under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April&#160;2016, and the Company adopted the 2016 Plan. Outstanding options under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company&#8217;s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated three times to increase the number of shares reserved for issuance, among other administrative changes. Each of the amendments and restatements of the 2016 Plan was approved by the Company's stockholders. There is a total of <ix:nonFraction unitRef="shares" contextRef="idd61525c1c634dbc97c9cb4caa360206_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzg2Ng_b7119f14-b48e-4067-b981-9daa58fd6c4b">8,790,000</ix:nonFraction> shares of common stock authorized for issuance under the 2016 Plan, <ix:nonFraction unitRef="shares" contextRef="idd61525c1c634dbc97c9cb4caa360206_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzkzNQ_20aa4a7e-f1bf-491a-9097-2774fdec1a1b">3,991,612</ix:nonFraction> shares of which remained available for future grant as of December 31, 2020.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:duryear" name="vnda:ShareBasedCompensationOptionAwardsContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzEyNTM_1985ae73-2651-4045-a150-7c2a03233e33">10</ix:nonNumeric>-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:durwordsen" name="vnda:ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzEzOTQ_622c2c14-3f28-4b87-aa23-6d7ff10bc413">four years</ix:nonNumeric>, with the first <ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" name="vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzE0MTM_e3514478-382e-46a2-84e1-cf7dc2c97317">25</ix:nonFraction>% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining <ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" name="vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzE1MzI_2636bbbc-c498-4096-afbe-9c4b99a9f59e">75</ix:nonFraction>% of the shares subject to the service option awards in <ix:nonFraction unitRef="installment" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" name="vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzE1ODk_a8d18acd-5630-4fc8-9380-be196ae4817e">36</ix:nonFraction> equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards granted to employees and executive officers provide for partial </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i605baf87f0df42a7bbcb76a2bfcb0336" continuedAt="id084a54af7df4a8dba11fb4f74b31e63"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceleration of vesting if the employee or executive officer is subject to an involuntary termination, and full acceleration of vesting if the employee or executive officer is subject to an involuntary termination within <ix:nonNumeric contextRef="i9396936ca284498ea1ea5d4f7a73b747_D20200101-20201231" format="ixt-sec:durmonth" name="vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM4NDgyOTA3MDU5NTA_f86d052f-fd75-4158-aabd-d7b6c7040894">24</ix:nonNumeric> months after a change in control of the Company. Service option awards granted to directors provide for accelerated vesting if there is a change in control of the Company or if the director's service terminates as a result of the director's death or total and permanent disability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="id82d67047689492daa3dc90ebad4142a_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzIxNDk_dbefdfb0-4994-4ff8-a062-06a7344212a2">6.9</ix:nonFraction> million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i9396936ca284498ea1ea5d4f7a73b747_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzIzMDE_40ea8348-926e-40a7-b028-cd265c56eaa5">1.2</ix:nonNumeric> years. No option awards are classified as a liability as of December 31, 2020.</span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ2MDQ_831f5825-edd6-4fb5-a0b8-236aab61b134" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;for&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise&#160;Price&#160;at Grant Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Remaining&#160;Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dffeb908a7c4343be9d34ab1b2dd23a_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEtMS0xLTEtMA_c959dbbb-2293-4d67-83ad-790d5f3b0e9d">4,719,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5dffeb908a7c4343be9d34ab1b2dd23a_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEtMy0xLTEtMA_ca621e4f-f9d8-4294-ad35-f18e9ea92538">10.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ea30e5f62224d9baf5e2ab37d1f16cb_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEtNS0xLTEtMA_eeeab621-5bd8-40d3-9622-9165c8221da9">5.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dffeb908a7c4343be9d34ab1b2dd23a_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEtNy0xLTEtMA_d2c89c3b-95a9-43a1-9286-13e37f510528">24,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzItMS0xLTEtMA_c1979845-dd7c-48ef-b146-031840e368c1">567,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzItMy0xLTEtMA_0d047d38-325f-49ab-a697-1a528f96b1f1">19.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzMtMS0xLTEtMA_51b36024-6a83-436d-9c96-eac82f27e1f9">232,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzMtMy0xLTEtMA_7044a0ef-b441-4081-a646-c9b66d51ca5e">13.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzUtMS0xLTEtMA_e144a7eb-8272-450e-8a4d-aa5899019510">685,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzUtMy0xLTEtMA_08f5c4a9-58c7-4b12-b1ee-6706a08d19c4">9.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzUtNy0xLTEtMA_8a5eedeb-ac0f-49e2-85a5-e4da2747fa5a">5,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf7edbea6dae4c4584d42f4bfaada83b_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzYtMS0xLTEtMA_c766c9bb-8180-4778-9078-f7b89cc2f390">4,369,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf7edbea6dae4c4584d42f4bfaada83b_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzYtMy0xLTEtMA_e4c5df00-47c6-47b1-8cd0-f082d15680ec">11.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzYtNS0xLTEtMA_4fe9e8e2-748d-40c7-b87e-327d68fcd0d9">5.28</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7edbea6dae4c4584d42f4bfaada83b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzYtNy0xLTEtMA_f090f237-709a-4dfb-94e7-875c09fe12fd">65,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzctMS0xLTEtMA_af1ead16-7795-4755-9857-c1676ec756f3">687,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzctMy0xLTEtMA_6e68b90d-4818-4da3-9dee-63d3c0679e33">18.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzgtMS0xLTEtMA_4db5b119-9290-4955-94d2-2ce638cdcd38">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzgtMy0xLTEtMA_b0b5bfd7-576e-4fc9-ba0c-04117aaee0f6">7.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzktMS0xLTEtMA_12779eda-40da-4be0-952b-0a9123c7bd0a">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzktMy0xLTEtMA_04a651ce-1b3c-4991-a3c4-cb6f829ded49">14.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEwLTEtMS0xLTA_99d3607c-47c0-4c75-a284-95fbffae7524">546,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEwLTMtMS0xLTA_198e51ba-8d9b-4756-b196-503883348ca2">11.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEwLTctMS0xLTA_c28a1515-9ea5-4e70-aa4a-90998d158ea2">2,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5cafed82f414158a6563a9d462e2f6f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzExLTEtMS0xLTA_1d054b7a-615c-4eee-a6bb-06c808e0d36a">4,495,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5cafed82f414158a6563a9d462e2f6f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzExLTMtMS0xLTA_3e1bed2d-a662-47a4-a542-2ce363bf6c8b">12.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzExLTUtMS0xLTA_84e7a4e5-f3ff-4480-88b5-38047ed55f64">5.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5cafed82f414158a6563a9d462e2f6f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzExLTctMS0xLTA_4e6f0ab2-a84c-45ea-8a73-aff250d645ea">22,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEyLTEtMS0xLTA_383f6ae9-cac9-4585-b4fa-ead3b68f35b1">627,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEyLTMtMS0xLTA_e44a4cd5-1744-4913-89e2-1e04aac5dfe6">11.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEzLTEtMS0xLTA_00fe8311-f964-4d80-b907-60de217ba5cd">225,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEzLTMtMS0xLTA_15ca6432-37da-4999-a54b-2ec45632d8bf">18.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE0LTEtMS0xLTA_ebb75f44-bec4-4915-9523-e527e910b8bb">557,604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE0LTMtMS0xLTA_d68e8a5b-4e55-4d82-a657-1980ba1a7d43">14.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE1LTEtMS0xLTA_38fae373-22fa-479b-9dbc-37f6ab77f8e0">733,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE1LTMtMS0xLTA_ac4074a9-44a0-48d9-a2de-9d46cbf775e5">7.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE1LTctMS0xLTA_34e89fa0-3f5a-40c8-98af-08d7a8b885c8">2,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE2LTEtMS0xLTA_0e3d546f-d6a8-4562-99f4-1966be989257">3,606,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE2LTMtMS0xLTA_4af933ca-388c-49f8-9f34-741e5e565bd4">12.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE2LTUtMS0xLTA_7e0f41bf-4c07-4869-932c-0340a1da7907">5.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE2LTctMS0xLTA_9155dfe9-0594-4709-9bc2-f60051879145">8,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE3LTEtMS0xLTA_8e1b8a6e-3bd6-48b8-ac39-b8ac31ab9f0e">2,556,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE3LTMtMS0xLTA_0543dba3-2347-4c0e-82f2-86dc9de9de93">11.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE3LTUtMS0xLTA_a1b55d6f-cf96-46b0-ac95-811c6d406a78">4.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE3LTctMS0xLTA_179a58ba-256d-4680-8527-af74aaaa8797">7,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE4LTEtMS0xLTA_8c643304-07e4-4efa-8aa9-541c5a37db31">3,482,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE4LTMtMS0xLTA_ae670489-2d19-414e-acb5-48153ccbcca7">12.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE4LTUtMS0xLTA_0826057a-1d00-4f6b-a9c7-53e8e90b2ee8">5.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE4LTctMS0xLTA_7ead12b5-1f0c-4d1b-b75f-063ba988c693">8,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI1NTQ_097bced1-a02e-45aa-8e5b-09d99d698856">5.53</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI1NTg_e901ff75-b112-49e1-9fee-bbd8416fbe76">10.19</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI1NjU_74ea45ff-708c-4d9e-8409-7f46f9349023">10.66</ix:nonFraction> per share for the years ended December 31, 2020, 2019 and 2018, respectively. Proceeds from the exercise of stock options amounted to $<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI2ODM_918cd001-c3a4-4fbf-8820-6053505ba51b">5.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI2ODc_036c6769-2799-430c-b442-0740d65f8885">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI2OTQ_dd47e056-4165-4652-9ac0-3d39c6c6c9d6">6.3</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An RSU is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#8217;s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that are subject to terms and conditions established by the compensation committee of the board of directors. Service RSUs granted to employees vest in <ix:nonFraction unitRef="installment" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzMwODU_9204ebdc-2d08-4204-9285-32810838b8b2">four</ix:nonFraction> equal annual installments provided that the employee remains employed with the Company. Certain service RSUs granted to employees and executive officers provide for accelerated vesting if the employee or executive officer is subject to an involuntary termination within <ix:nonNumeric contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" format="ixt-sec:durmonth" name="vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM4NDgyOTA3MDU5NjQ_e51c4a64-0d64-406d-882b-f51909100e71">24</ix:nonNumeric> months after a change in control. Annual service RSUs granted to directors vest on the first anniversary of the grant date and provide for accelerated vesting if there is a change in control of the Company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i4accca8a781b42bc8a5a731e56f0eec6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzMyNzY_94898266-2ad9-4c16-99da-f298fe3b08d2">18.3</ix:nonFraction> million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM0MTE_c15f8099-8b42-43df-8011-53501141bfc5">1.6</ix:nonNumeric> years. No RSUs are classified as a liability as of December 31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="id084a54af7df4a8dba11fb4f74b31e63"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ2MDU_bc5f8437-f020-4e5c-87f3-bc6af9df07ea" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie623210fe21f455fba6a25bfe1712547_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEtMS0xLTEtMA_cfa0ceda-73d4-4b93-af56-e057087b9227">1,357,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie623210fe21f455fba6a25bfe1712547_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEtMy0xLTEtMA_a8023356-e708-494d-9124-932d6af9a58d">12.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzItMS0xLTEtMA_82a6fe15-cd13-4c8a-844a-34272712de9b">714,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzItMy0xLTEtMA_38a05259-2ded-4f83-b80a-b3ac4244febd">18.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzMtMS0xLTEtMA_531f1777-7205-4759-8825-7fefd93ff236">229,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzMtMy0xLTEtMA_82c86926-fe40-4451-9b21-f0ac0ac9be1c">15.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzQtMS0xLTEtMA_d89bcce5-5f0e-4af5-813d-eabe76e36fba">528,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzQtMy0xLTEtMA_5aebac0c-8d14-433e-8cdf-8c357a40860a">12.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id14b5fd7c713420383f8b6f8cdaf4438_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzUtMS0xLTEtMA_2f9282f1-2a83-4b96-a3ae-d90cf59cc16a">1,313,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id14b5fd7c713420383f8b6f8cdaf4438_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzUtMy0xLTEtMA_02942d78-4a73-4780-a4ce-4928dbd9db3f">15.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzYtMS0xLTEtMA_c6f6934b-3bc6-414d-8566-037bd3ed01eb">937,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzYtMy0xLTEtMA_5d8b766e-d60f-449b-8d7e-81ea7a25c8b2">19.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzctMS0xLTEtMA_4fb07eb3-18dc-4ef0-9206-bde5a34d645e">75,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzctMy0xLTEtMA_aed1f9bf-b2ee-409b-ab51-573682ecca04">18.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzgtMS0xLTEtMA_bf3a3a7b-3ba0-4c63-a1d9-d0df6b7e25a3">526,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzgtMy0xLTEtMA_c441696b-fd60-4b93-9f5c-b9434acd5e12">14.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cbcabe269184dbcb50a511cf3bdb9fd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzktMS0xLTEtMA_c976fb23-1258-482f-8b66-7103e37e0dd0">1,649,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cbcabe269184dbcb50a511cf3bdb9fd_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzktMy0xLTEtMA_1433199c-da24-4c99-9485-402ef5b656f3">18.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEwLTEtMS0xLTA_0284c4c4-4bd4-4da4-bbda-be3c4032de8b">832,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEwLTMtMS0xLTA_e5cceaab-be55-4f62-aad3-6c0212408cc3">11.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzExLTEtMS0xLTA_47ecff7f-abdd-494d-9f7b-033a1d9ac7e2">260,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzExLTMtMS0xLTA_7315368c-b914-410f-99dd-ec39c1089f0b">17.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEyLTEtMS0xLTA_57828b8e-1222-4d8c-924f-f1815084acb2">581,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEyLTMtMS0xLTA_a333d708-279f-4821-b616-89dab21d488c">16.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4accca8a781b42bc8a5a731e56f0eec6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEzLTEtMS0xLTA_d559895a-e843-4e83-abc7-35bdfaf71bef">1,639,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4accca8a781b42bc8a5a731e56f0eec6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEzLTMtMS0xLTA_d06f2107-5b9c-4abb-8dab-c15da0c2f5ef">15.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value for the <ix:nonFraction unitRef="shares" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM2MjA_ac145e3a-9cb6-4326-8457-4f2fa0f5e9ec">581,757</ix:nonFraction> shares underlying RSUs that vested during the year ended December 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM2ODc_a41a7f18-92ec-4445-bc6a-821228647856">9.6</ix:nonFraction> million.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ2MTA_bde01d94-1809-4f5f-96ab-063bb73bfe72" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the years ended December 31, 2020, 2019 and 2018 comprised of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefdf2eff6cd54e0ea9ebdad5ee519b38_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzItMS0xLTEtMA_16982bed-ae69-4e45-9dbc-5d604ee5e7fc">3,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dba30ea1414af0bf583a5a09975a52_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzItMy0xLTEtMA_ad39c14e-9dd1-418f-ac13-f14fcd03bef7">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a749d60ade74a138ef81f76767e56e9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzItNS0xLTEtMA_2bb0bb77-59da-4891-9a0d-eea30e0974eb">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd51d5e4edf48f2ad3197f761187562_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzMtMS0xLTEtMA_376cad25-1bdc-4ecd-be5a-e989da403a71">9,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id823e499960c408ba259173b9f02984b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzMtMy0xLTEtMA_ee516790-deed-4a6f-8600-53803d76dc65">10,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5dd64fe80b642d18d3588ccecb6c437_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzMtNS0xLTEtMA_9ff02fc1-18e1-4045-9f4e-7b1636fe8f1a">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzQtMS0xLTEtMA_20798eb2-46be-45aa-afeb-a460a21dcbd0">13,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzQtMy0xLTEtMA_ef743c1c-7c73-42a9-9c88-566fedea11a5">13,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzQtNS0xLTEtMA_22570d8e-db3e-43bb-bd9e-528c49ed037d">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company&#8217;s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ1OTg_dd710d64-07a4-4251-812c-a5462ead783d" continuedAt="i06b26dcfca214b8db73e7dce3da41d21" escape="true">Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December 31, 2020, 2019 and 2018 were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i06b26dcfca214b8db73e7dce3da41d21"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzItMS0xLTEtMA_2fa1426a-d505-4ab9-a36d-874862fc99b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzItMy0xLTEtMA_2430e352-b5ef-474b-b8aa-de27d6e665fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzItNS0xLTEtMA_cb1df2a4-ba0c-48ba-bcca-cfe8c91d3c59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzMtMS0xLTEtMA_f3f249f6-20c0-4b85-be06-9f979c01f261">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzMtMy0xLTEtMA_dc34ebe2-285c-4217-b7a0-8041d09b191a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzMtNS0xLTEtMA_6ec13857-4019-4c82-9070-fe1d24f1c63c">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzQtMS0xLTEtMA_934ed2bb-2c45-49b6-b58c-3609bfe0331b">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzQtMy0xLTEtMA_ba25ecf8-ed50-4000-99dd-2c43dc6e0853">5.95</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzQtNS0xLTEtMA_3384fef4-f1d7-4ef2-ba16-7ff09af124cb">5.90</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzUtMS0xLTEtMA_05d73b84-a3a6-46c2-af35-d75e58e639b5">1.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzUtMy0xLTEtMA_63659c5a-d00b-40ba-8a13-82d1bedb83c8">2.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzUtNS0xLTEtMA_1a6465ad-307f-4abc-869e-c22348a6b750">2.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div></ix:continuation><div id="i78e7e943a648448d981304e612e68114_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzU2Mg_466585c4-68e9-47a5-8f04-fda69f157ac4" continuedAt="i8b0b72a9f09d4d66bb105e930db0b59b" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b0b72a9f09d4d66bb105e930db0b59b">The Company has a defined contribution plan under IRC Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Currently, the Company matches <ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzMxNQ_dffbfac5-035c-4729-8b39-fd53b182204f">fifty</ix:nonFraction> percent up to the first <ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzM0Mg_15895c27-21af-42e9-8350-1caf06c77310">six</ix:nonFraction> percent of employee contributions. All matching contributions have been paid by the Company. The Company match vests over a <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" format="ixt-sec:duryear" name="vnda:DefinedContributionPlanVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzQ2OQ_93704d3c-8ee1-462e-a272-5d759722566f">4</ix:nonNumeric>-year period and amounted to $<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzUwMA_256d6037-6122-4c3d-a4fe-fe4e0af2a43c">0.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzUwNA_7692b188-f88b-4aa8-874e-ffd7fc60948e">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzUxMQ_7cd37b44-635c-4131-a6d1-01add7db18d3">0.9</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MTE_defb55b0-57d8-45dc-9df9-cdbf389f5c28" continuedAt="ica3339ec4d0646e99d7c79774783ee85" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ica3339ec4d0646e99d7c79774783ee85" continuedAt="i651dc9dfa1b14f18a2f047382f895cbd"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MDA_bcecbb45-571e-4a79-b915-d2d89fa0e79c" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the domestic and foreign components of income before income taxes for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzItMS0xLTEtMA_1705abdf-0238-4410-840d-1b2099c96832">31,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzItMy0xLTEtMA_9bb39440-4880-4a54-9112-88a055ce07ae">28,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzItNS0xLTEtMA_2b3b3e0c-06fa-4e90-9775-341b2601990d">25,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzMtMS0xLTEtMA_4e9d5b1e-615e-4179-bfb2-20c9459752e7">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzMtMy0xLTEtMA_efdac534-de6c-4858-81fb-75d264973598">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzMtNS0xLTEtMA_446ffbb8-91e2-4fe4-b407-05eb32ff2414">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzQtMS0xLTEtMA_97270964-d84f-4aeb-8487-c39c372f7fce">31,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzQtMy0xLTEtMA_39c249ce-2d52-4a65-aa2b-8c3238e3d627">29,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzQtNS0xLTEtMA_6f948f01-e0f5-42cf-81eb-f9143cf8cdf9">25,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MDk_d5bc989d-fa49-463e-ad71-9a225ee65ef2" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzMtMS0xLTEtMA_65604aee-16ed-4421-aebb-887c29b90f48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzMtMy0xLTEtMA_ef411c43-9f6f-4bf7-a746-196fd3ee3863">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzMtNS0xLTEtMA_33530d72-ae1e-463a-9d3a-168495f493e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzQtMS0xLTEtMA_0a2a22a1-73a4-4ce1-8901-32d1eaa1a2ef">2,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzQtMy0xLTEtMA_ddc17e63-3817-4900-b9fa-3b5b63a3891e">1,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzQtNS0xLTEtMA_8475e94d-19bb-4007-a8f1-d4e837d13524">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzUtMS0xLTEtMA_df6d5913-a607-4091-a6ac-bf713fcae3b9">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzUtMy0xLTEtMA_c224f72a-d651-44ab-9027-d26d0d067356">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzUtNS0xLTEtMA_0ffb86fe-3bf7-4ddf-a9bc-aeeb18aa8dfc">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzctMS0xLTEtMA_0be41c2e-c277-4acd-8834-2f0bf335373e">6,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzctMy0xLTEtMA_526509b2-bd26-4dae-91cd-c1f0df207af8">85,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzctNS0xLTEtMA_9c0e00ae-ce56-4c01-92a2-ca63e9cc4a51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzgtMS0xLTEtMA_1a4fc4bf-4032-48bb-9f80-2a566de25ea5">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzgtMy0xLTEtMA_9b2f172b-d816-466c-9428-2755e56164a9">2,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzgtNS0xLTEtMA_2a426915-df78-4e61-a395-75f05205b9ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzktMS0xLTEtMA_e213506c-437e-4470-8797-a433b50e44b5">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzktMy0xLTEtMA_fdc0710a-1c58-4fa9-99c3-f241b39fdea8">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzktNS0xLTEtMA_a7332ad5-b9e5-488d-af29-d44fae50e48b">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzEwLTEtMS0xLTA_4215e5ae-339c-4ce6-b7be-bdfba49a2bb0">8,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzEwLTMtMS0xLTA_568f1628-30a2-4f91-a736-9492d9d98505">86,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzEwLTUtMS0xLTA_73546325-9bce-4172-86b2-86f92cc74add">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance was retained against certain District of Columbia state deferred tax assets as of December 31, 2020, and 2019. </span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MTA_3d97e914-677c-4d09-bdf2-169572e53b7a" continuedAt="iaaeb712a0a8c401c87aac85e77ee8d71" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is reconciliation between the federal statutory tax rate and the Company&#8217;s effective tax rate for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzItMS0xLTEtMA_a8a47a6e-36ba-472b-bf71-0fa5980356e9">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzItMy0xLTEtMA_5083ce18-fe4c-48c9-9354-f2eb25ddd388">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzItNS0xLTEtMA_f627f61f-9ef9-47b0-930b-93c276a1d1d8">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzMtMS0xLTEtMA_b820c659-5874-4d70-bb6c-7662c57ee0f2">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzMtMy0xLTEtMA_d880fad6-28b8-43ec-a577-e0dbd6cb7e5c">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzMtNS0xLTEtMA_507f6577-305c-4a5d-90de-6547cb766228">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzYtMS0xLTEtMA_7ce85ddd-01b7-4e3e-9104-41a7e987c912">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzYtMy0xLTEtMA_ffc088cd-24aa-45d4-ae77-e88964a7a364">357.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzYtNS0xLTEtMA_78f5b808-79df-4a83-9aef-02c404a24363">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzctMS0xLTEtMA_1dc8f2ec-c913-438a-beb5-598d5100381b">5.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzctMy0xLTEtMA_57f8617d-b524-4109-acf2-2a5f64706526">10.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzctNS0xLTEtMA_d7cd59f1-83ac-46c6-a4d6-8834376f1849">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" sign="-" name="vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzgtMS0xLTEtMA_a56ef349-69ec-40b7-89be-0b5c21dd994a">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" name="vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzgtMy0xLTEtMA_1e271341-4195-4c26-adfd-b2f04fd72975">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" sign="-" name="vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzgtNS0xLTEtMA_3b982dd7-4dfb-4941-be98-9da7c225d1a2">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzktMS0xLTEtMA_acd051c1-b710-4568-a96d-eeb6aec98c8f">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzktMy0xLTEtMA_bde49724-f62c-4bc9-bf69-7573a8da7b4d">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzktNS0xLTEtMA_d89001c0-3169-4f77-bb65-97d9b714141b">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other tax rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEwLTEtMS0xLTA_e1ac5df6-5ea2-4397-b231-d6b82a9a7c6e">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEwLTMtMS0xLTA_39e7a53c-e0f0-4d89-b80e-36750981b70e">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEwLTUtMS0xLTA_300410ff-2fc8-4655-8259-8fb5805eb89a">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in state deferred taxes (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" format="ixt:zerodash" name="vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzExLTEtMS0xLTA_e665f627-2a58-45f7-8488-600f968a154c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" format="ixt:zerodash" name="vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzExLTMtMS0xLTA_9a3619c2-8c1d-4b54-85d9-8d32d4bb3180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" name="vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzExLTUtMS0xLTA_a84a7f96-1db7-4866-a88f-7d98d6ae675d">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" name="vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEyLTEtMS0xLTA_0bd60511-1530-410a-af45-d8d56980bfad">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" name="vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEyLTMtMS0xLTA_6d459b85-e8f2-48ec-b39d-72f5fc94cde5">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" format="ixt:zerodash" name="vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEyLTUtMS0xLTA_514e160c-1946-4aff-a530-049d2e70c434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEzLTEtMS0xLTA_9c07394c-2c33-48a8-8ead-f259f733be55">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEzLTMtMS0xLTA_ca4fe5cd-b39f-4a39-976f-6477eafa3602">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEzLTUtMS0xLTA_a406e420-9174-4e48-80fa-345caea53024">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE0LTEtMS0xLTA_5d36cbeb-f929-4af2-82af-0bd007f09610">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE0LTMtMS0xLTA_57e6a250-5ea4-4086-98ad-c4eeec6ee2a4">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE0LTUtMS0xLTA_ec715e03-bd0f-4ea1-9438-13a5aadceb42">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE1LTEtMS0xLTA_b56188d0-6c83-45f0-a4e4-6cbde031b911">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE1LTMtMS0xLTA_280bc356-b779-46d7-a6e6-5fc234887a7f">298.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE1LTUtMS0xLTA_2d7e8f72-4ae9-4add-82f2-188c2c075dd6">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.34pt">Reductions in 2020 valuation allowances are attributable to 2020 income before income taxes. Reductions in 2019 valuation allowances include $<ix:nonFraction unitRef="usd" contextRef="i533bb21627594019891d85b5903ed825_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzI2MTY_e6bf5a71-19e3-4bcf-953a-4ecd0f37ac69">7.5</ix:nonFraction> million related to 2019 U.S. income before income taxes, $<ix:nonFraction unitRef="usd" contextRef="i3af2a96bce0440ec840b163636430f9b_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzI2Njg_dda07a39-f8ca-4f5b-b167-a9c66d093ada">10.7</ix:nonFraction> related to adjustments for prior period credit carryforwards and uncertain tax positions and $<ix:nonFraction unitRef="usd" contextRef="i1209ef3dad5a4c70b22c2b5ea6d9c116_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzI3NjQ_99a46f65-b50b-4cdd-8c2b-17a44b09e109">85.6</ix:nonFraction> million related to a change in </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i651dc9dfa1b14f18a2f047382f895cbd" continuedAt="i8715d6d4ecac4a5f88b2f360cb585c24"><ix:continuation id="iaaeb712a0a8c401c87aac85e77ee8d71" continuedAt="i70cf68980bb843fab8f7fcb038ae9d73"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">2019 activity includes adjustments to prior year credit carryforwards and prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i70cf68980bb843fab8f7fcb038ae9d73" continuedAt="id7f1c14fd96946bb985427349d9a9ad0">(3)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"><ix:continuation id="id7f1c14fd96946bb985427349d9a9ad0">Includes adjustments to state deferred taxes based on changes to filing jurisdictions.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY4OTg_c72aeae0-0659-4f9b-ac18-7445e39e223f" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the components of the Company&#8217;s net deferred tax assets and the related tax valuation allowance as of December 31, 2020 and 2019. Certain prior period amounts in the table have been reclassified to conform to the current period presentation.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzItMS0xLTEtMA_f8150f85-1598-4714-a287-0cc3faa48c86">43,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzItMy0xLTEtMA_bfa47f1c-79ae-49d7-8308-c6b4332c3648">52,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzMtMS0xLTEtMA_d5360df4-e723-4af8-a1bb-f06ca1d4294d">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzMtMy0xLTEtMA_bb437d9a-1b4b-4c1e-9b1d-ffcec0bff8dd">5,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzQtMS0xLTEtMA_7dbf24d8-9ce0-4a99-b1e2-b8219159af7d">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzQtMy0xLTEtMA_75b14d53-25cf-48a5-bb10-61af165e180d">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for returns and credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzUtMS0xLTEtMA_edf8081f-7e88-4b1a-aeb4-ee91b293acc5">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzUtMy0xLTEtMA_9e18a3e2-b4c2-4b9b-81a3-3e9065a1eba2">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and orphan drug credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzYtMS0xLTEtMA_843d9e66-3453-4838-a2f7-0dcfaefcb4bb">37,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzYtMy0xLTEtMA_9ed084e5-6d64-4727-8f06-18dad9f03590">36,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzgtMS0xLTEtMA_3828bf1e-2cf3-47c8-92f6-4db976264450">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzgtMy0xLTEtMA_20561800-5b5e-44c1-b899-77d4cc665034">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzktMS0xLTEtMA_c95578b3-8e05-4501-8c39-f074bdd9034e">92,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzktMy0xLTEtMA_5e447249-141e-45b1-9600-00f743229ed3">100,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzExLTEtMS0xLTA_0ddd5146-c99e-4883-a56b-e86dd1ca1f71">1,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzExLTMtMS0xLTA_4c46f6b2-3518-4d4c-a829-b28dfd5644bc">1,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzEyLTEtMS0xLTA_3a9150f8-2cb6-414b-b1a1-220cb31b4c7a">2,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzEyLTMtMS0xLTA_562aad5e-fc24-4c9f-870f-08d8f8c3c059">2,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzEzLTEtMS0xLTA_f59827a7-cfc7-49d9-9fcd-a8b70401bb59">4,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzEzLTMtMS0xLTA_b8ce215e-59f1-45b8-92ba-826b3f9a8e7a">4,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE0LTEtMS0xLTA_03d076c6-19a9-4b1e-8d08-d2ad00c21d57">88,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE0LTMtMS0xLTA_b2a52267-d426-4082-b116-0d5264b82175">95,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE1LTEtMS0xLTA_f936684d-3f3f-4cc6-8bdc-4a0524509cab">7,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE1LTMtMS0xLTA_082f41c7-9491-4ed7-af88-efd8b032645d">8,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE2LTEtMS0xLTA_25d500da-37d6-4f65-8973-aafdab28fab9">81,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE2LTMtMS0xLTA_83740f82-c7da-42e0-93e5-c2e9a9295001">87,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY4OTU_24797887-a20d-48db-aff7-35c2b3103b83" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of changes in the Company&#8217;s tax valuation allowance for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:41.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzItMS0xLTEtMA_89e8c73c-158a-488b-9e4a-bdc81fea27f6">8,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="vnda:DeferredTaxAssetsValuationAllowanceIncrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzItMy0xLTEtMA_1e3a83c4-dbac-44b8-90a8-3fef9b5d28af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DeferredTaxAssetsValuationAllowanceDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzItNS0xLTEtMA_2e2edb8c-22a1-4fd2-bdfe-8fa53c2b187c">1,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzItNy0xLTEtMA_3cf8bcd7-789f-4400-a3e5-3397b3fc7799">7,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzMtMS0xLTEtMA_1e50bfcf-3ee7-4f30-8d78-1ec9da40053e">111,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="vnda:DeferredTaxAssetsValuationAllowanceIncrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzMtMy0xLTEtMA_0473df1c-1f10-4526-9b5d-ec5589b827d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DeferredTaxAssetsValuationAllowanceDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzMtNS0xLTEtMA_ea4f92d7-4b36-4f96-887b-7aa42e146239">103,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzMtNy0xLTEtMA_09420a9b-0af8-4c4d-98d4-f0a172a0042f">8,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926bf00cb18047ab87ba70c56d7331bb_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzQtMS0xLTEtMA_c755a7db-6f10-47c1-be94-9a600bc415d9">116,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DeferredTaxAssetsValuationAllowanceIncrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzQtMy0xLTEtMA_787a1438-15e3-4782-80f5-36188779d487">4,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="vnda:DeferredTaxAssetsValuationAllowanceDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzQtNS0xLTEtMA_dd0f9fbb-b7aa-4310-b5b8-5438dec29903">8,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzQtNy0xLTEtMA_092f403b-6c3c-4b3f-a4b0-c6ac8aab500b">111,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has NOL and other tax credit carryforwards in several jurisdictions. As of December 31, 2020, the Company has $<ix:nonFraction unitRef="usd" contextRef="ia35ff2ef50ed4a898205b8960a640489_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQxMjQ_4fb184fa-4e2d-424a-b2ac-ff3c2a3b56f7">35.2</ix:nonFraction> million of deferred tax assets relating to U.S. federal NOL carryforwards, along with deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQyMjg_bbfe0b2e-b905-458c-ba36-431be6a3082c">13.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia324b88c017e451d84714c225aa51f90_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQyMzU_10ca9449-39c0-481c-9311-6cdacfc5d96c">24.4</ix:nonFraction> million related to U.S. federal research and development credits and orphan drug credits, respectively. These tax attributes will begin to expire in <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:OperatingLossCarryforwardsBeginningExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQzNzk_a0e30678-bfa1-428b-8a66-7429747a44c9">2031</ix:nonNumeric>, <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:ResearchAndDevelopmentCreditBeginningExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQzODM_edbe2586-5975-46fc-8cf7-e0461aa68add">2024</ix:nonNumeric> and <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="vnda:OrphanDrugCreditBeginningExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQzOTA_731988dd-b8d3-4696-a6d6-379722a83009">2030</ix:nonNumeric>, respectively. In addition, the Company has $<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQ0Mzc_03bfe2d0-e5cd-4698-96c1-f3451a282642">8.4</ix:nonFraction> million of deferred tax assets relating to U.S. state NOL carryforwards, which primarily relate to the District of Columbia. State NOLs for the District of Columbia will begin to expire in <ix:nonNumeric contextRef="i868e756c16d248bf88fef93ad48e1708_D20200101-20201231" name="vnda:OperatingLossCarryforwardsBeginningExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQ2MjE_c0351d94-873e-4419-ace7-f250a5bd2971">2032</ix:nonNumeric> and other state NOLs will begin to expire in <ix:nonNumeric contextRef="i0312bfa2fd454fdd90ab881abbadfeaa_D20200101-20201231" name="vnda:OperatingLossCarryforwardsBeginningExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQ2Njk_f88acc1a-3171-402f-a817-13f48c4e23b4">2029</ix:nonNumeric>. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i8715d6d4ecac4a5f88b2f360cb585c24" continuedAt="id6ddc27f993d4a5090651f04cdb6d035"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MDY_a8341d87-f5aa-4058-b2e3-e904be990d5c" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzItMS0xLTEtMA_884a6e64-259b-47c3-806c-0f7066139d5f">9,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzItMy0xLTEtMA_8663f4fd-aea3-45d7-b466-7966f1dcf2d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926bf00cb18047ab87ba70c56d7331bb_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzItNS0xLTEtMA_f0cfb24d-706d-4a3b-ae03-eb146ed59f4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzMtMS0xLTEtMA_43ed39bb-1016-4d7b-ae10-0edf61bd84a7">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzMtMy0xLTEtMA_07e047b9-8fa7-4634-b9b7-e752f7dd0dcb">8,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzMtNS0xLTEtMA_155378af-bd14-4cef-afaa-9499a3748584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzQtMS0xLTEtMA_8530403c-c629-486f-863d-182e66ef118c">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzQtMy0xLTEtMA_c38dd537-b987-4ce5-8d76-0eea8d7cf759">1,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzQtNS0xLTEtMA_c6b26062-f86f-469c-9565-6ee6dfe21e59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzUtMS0xLTEtMA_6bf22a1b-e18d-4a40-bb4b-75f9261149a1">11,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzUtMy0xLTEtMA_92814ea1-3375-4e0c-a535-b4d945cfed5c">9,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzUtNS0xLTEtMA_0c53446b-1167-4c56-b9da-2639a43811f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of uncertain tax benefits that, if recognized, would impact the effective tax rate is $<ix:nonFraction unitRef="usd" contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzUyNzU_204a3ac0-de22-4a01-b086-46519659341a">11.2</ix:nonFraction> million. No material income tax interest or penalties have been recorded, and unrecognized tax benefits are not expected to change materially over the next 12 months. Income tax returns filed by the Company for all periods are open to examination by tax jurisdictions. As of December 31, 2020, the Company is not under examination by any federal or state tax jurisdiction.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id6ddc27f993d4a5090651f04cdb6d035">Certain tax attributes of the Company, including NOLs and credits, would be subject to a limitation should an ownership change as defined under the Internal Revenue Code of 1986, as amended (IRC), Section&#160;382, occur. The limitations resulting from a change in ownership could affect the Company&#8217;s ability to utilize its NOLs and credit carryforward (tax attributes). Ownership changes occurred in the years ending December&#160;31, 2014 and December&#160;31, 2008. The Company believes that the ownership changes in 2014 and 2008 will not impact its ability to utilize NOL and credit carryforwards; however, future ownership changes may cause the Company&#8217;s existing tax attributes to have additional limitations.</ix:continuation> </span></div><div id="i78e7e943a648448d981304e612e68114_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;<ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90ZXh0cmVnaW9uOjExMWZhNTc1N2IzMTQ3NjQ5ZGI0MTQzMmI4ODczNmE1XzkwOQ_10a2eee7-18f3-4d0d-bc26-33a8110316ab" continuedAt="id8bf633848c049cc859a564cb6934c56" escape="true"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90ZXh0cmVnaW9uOjExMWZhNTc1N2IzMTQ3NjQ5ZGI0MTQzMmI4ODczNmE1XzkxNQ_7eeac429-2c36-4be6-b4e0-fe9ee636c614" continuedAt="i05195e33ea1648c7aa0a36941c820e37" escape="true">Earnings per Share</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i05195e33ea1648c7aa0a36941c820e37"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id8bf633848c049cc859a564cb6934c56">Basic earnings per share (EPS) is calculated by dividing the net income by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.</ix:continuation></span></div><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90ZXh0cmVnaW9uOjExMWZhNTc1N2IzMTQ3NjQ5ZGI0MTQzMmI4ODczNmE1XzkxMw_668dc24f-27cc-4116-bee9-6499987cd582" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income per share of common stock for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for share and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzMtMS0xLTEtMA_94ee4542-9bef-4f8a-b729-df2aadac7e8c">23,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzMtMy0xLTEtMA_5a8c2a7e-0263-47c3-8929-bb9a0f07f598">115,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzMtNS0xLTEtMA_aebda3c2-42a5-4ac4-af2c-a0784b84c03e">25,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzUtMS0xLTEtMA_aa77e604-17e3-45b1-a429-5a80a6269d7f">54,427,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzUtMy0xLTEtMA_bbb64841-92fa-4847-8318-c2b20542b8de">53,137,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzUtNS0xLTEtMA_e8433e2c-2651-49ec-a8ca-f393d76ad7bc">50,859,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzYtMS0xLTEtMA_719ff5ed-f7a9-4fd6-b658-455f3effa259">763,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzYtMy0xLTEtMA_69526c25-88ab-4330-b60d-42c7069f034d">1,709,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzYtNS0xLTEtMA_4ba484bd-d35a-4ae2-8815-6e2c14f917ba">2,185,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzctMS0xLTEtMA_bc5f6f6d-805c-4283-8f98-39f810a2f7e5">55,190,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzctMy0xLTEtMA_fb816534-12fc-4493-aa2d-968b00a81e6b">54,847,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzctNS0xLTEtMA_44f95a9f-d60a-4d5f-a2a6-d49f4f5ac67f">53,045,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzktMS0xLTEtMA_30112877-03dd-4084-8ba7-68d16b698b46">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzktMy0xLTEtMA_b1db36aa-bf9f-4b89-ba59-9325d202bdb2">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzktNS0xLTEtMA_195ba7f7-5076-48a4-af69-64b41525ddc4">0.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzEwLTEtMS0xLTA_0d09719d-df4c-480b-97e8-56f7e94972ab">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzEwLTMtMS0xLTA_6875679d-88d5-429d-9cba-2bc5cf37169c">2.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzEwLTUtMS0xLTA_94e510b1-5f32-42b2-9a84-00c340c214f7">0.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive securities excluded from calculations of diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzExLTEtMS0xLTA_7d7dc96c-c4ce-4629-9d17-eac94d460ec4">3,407,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzExLTMtMS0xLTA_09613840-3e6f-46b4-afa9-ab93357c9d21">1,932,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzExLTUtMS0xLTA_835a1d8d-2a89-49fe-88a4-20f4fc854f1d">903,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i78e7e943a648448d981304e612e68114_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjYvZnJhZzpkNGJkYzJhYWQ4Mzg0MDcwYjNlNmM0NjRlNWU0NzBhOS90ZXh0cmVnaW9uOmQ0YmRjMmFhZDgzODQwNzBiM2U2YzQ2NGU1ZTQ3MGE5XzE0Nzcy_77689815-9999-4fe3-acfc-1253d7946032" continuedAt="if1607707923347508ae5c778d4e90772" escape="true">Legal Matters</ix:nonNumeric></span></div><ix:continuation id="if1607707923347508ae5c778d4e90772" continuedAt="ief93410284c04d80bcb7a7b3abf57061"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In 2014 and 2015, Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex) (collectively, the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Defendants) each submitted an Abbreviated New Drug Applications (ANDA) to the FDA seeking approval to market generic versions of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;prior to the expiration of certain of the Company&#8217;s patents covering Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, including U.S. Patent No. 8,586,610 (&#8216;610 Patent) and U.S. Patent No. 9,138,432 (&#8216;432 Patent). In response, the Company filed separate lawsuits in 2014 and 2015 against each of the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Defendants in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2016, the Delaware District Court ruled in the Company&#8217;s favor, permanently enjoining Roxane from manufacturing, using, selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane&#8217;s </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="ief93410284c04d80bcb7a7b3abf57061" continuedAt="i2a14909e49be4f2b8d054e0bb4e73b68"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ANDA until the expiration of the &#8216;610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. This ruling was affirmed on appeal by the Federal Circuit Court of Appeals in April 2018. West-Ward, having replaced Roxane as defendant following the acquisition of Roxane by West-Ward&#8217;s parent company, Hikma Pharmaceuticals PLC (Hikma), petitioned the U.S. Supreme Court for a writ of certiorari, which was denied in January 2020. The Company&#8217;s lawsuit against Hikma regarding the &#8216;432 Patent remains pending.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into separate license agreements with each of Taro, Apotex and Lupin resolving these lawsuits in October 2016, December 2016 and July 2020, respectively. The license agreements grant Taro, Apotex and Lupin non-exclusive licenses to manufacture and commercialize a version of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. effective as of the expiration of the &#8216;610 Patent or earlier under certain limited circumstances. The Company entered into a confidential stipulation with Inventia regarding any potential launch of its generic versions of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but the Company&#8217;s lawsuit against Inventia regarding the &#8216;610 and &#8216;432 Patents remains pending.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Between April and February 2021, the Company filed numerous patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Defendants) after having received multiple Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Defendants alleging that the Company&#8217;s patents covering HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, U.S. Patent Nos. RE46,604, 9,060,995, 9,539,234, 9,549,913, 9,730,910, 9,844,241, 10,071,977, 10,149,829, 10,376,487, 10,449,176, 10,610,510, 10,610,511, and 10,829,465, were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as described in the ANDAs submitted to the FDA by each of the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Defendants. These lawsuits have been consolidated and are schedule for trial in March 2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In February 2019, a qui tam action filed against the Company was unsealed by order of the U.S. District Court for the District of Columbia (DC District Court). The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint alleged that the Company violated these laws through the promotion and marketing of its products Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys&#8217; fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. In May 2020, the DC District Court dismissed the plaintiff&#8217;s complaint in its entirety, without prejudice. In June 2020, the plaintiff filed a second amended complaint with similar allegations and seeking the same relief. In July 2020, the Company filed another motion to dismiss and in October 2020 the plaintiff filed a reply. The DC District Court will hear the Company's motion to dismiss on February 24, 2021. The Company intends to continue to vigorously defend itself in the case.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, a securities class action, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gordon v. Vanda Pharmaceuticals Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company&#8217;s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Company&#8217;s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. In March 2020, the Company filed a motion to dismiss the complaint. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, a shareholder derivative complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samuel Williams v. Mihael Polymeropoulos, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael Bavaro v. Mihael Polymeropoulos, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><ix:continuation id="i2a14909e49be4f2b8d054e0bb4e73b68"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bavaro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">case to the Eastern District of New York, where the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gordon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Williams</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are pending. In March 2020, the Delaware District Court transferred the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bavaro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case to the Eastern District of New York, consolidating the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Williams</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bavaro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cases, and the plaintiffs filed a consolidated complaint in April 2020. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company&#8217;s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In July 2017, the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion recommending against approval of Fanaptum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA&#8217;s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the E.U. General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. In February 2020, the Company filed an appeal of this judgment with the Court of Justice of the E.U.</span></div></ix:continuation><div id="i78e7e943a648448d981304e612e68114_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90ZXh0cmVnaW9uOjI0M2IzZDlkNTdhODRmYjM5YTYwOTUwZWY0YzgwYjE3XzI2Mg_b1c95306-08c2-4ae0-ba9c-6e205c9b1452" continuedAt="i624957aeb22b4356a03bacdd3c133067" escape="true">Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="i624957aeb22b4356a03bacdd3c133067"><ix:nonNumeric contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90ZXh0cmVnaW9uOjI0M2IzZDlkNTdhODRmYjM5YTYwOTUwZWY0YzgwYjE3XzI1OA_341a30d5-4539-4831-b79b-a1431d6822e5" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of quarterly financial data for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzItMS0xLTEtMA_b9d827b7-ddbe-4b16-8415-c2ba87e6d793">58,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzItMy0xLTEtMA_2aa52874-89a8-4cc5-a59f-5684ae418258">62,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzItNS0xLTEtMA_3efac7ad-c8da-4ce9-89ef-93ec625fc779">60,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzItNy0xLTEtMA_d1d58758-f726-469c-b53c-2cfe2566f51e">67,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzMtMS0xLTEtMA_53f14944-0dcb-4c51-9c54-53f531039a47">52,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzMtMy0xLTEtMA_f63b7a42-6bf1-406f-8662-98ac198ff942">55,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzMtNS0xLTEtMA_f71a1f18-fcb9-432e-b1a2-c36db756be1f">54,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzMtNy0xLTEtMA_b94961eb-44fc-42a5-b754-c5c348775574">60,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzQtMS0xLTEtMA_192cd0d2-d800-47cc-af50-e52262aff355">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzQtMy0xLTEtMA_58cafc8b-a4c7-4321-9106-5a5d02bcc2f6">9,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzQtNS0xLTEtMA_b523cc24-a910-4efb-9a37-55a15d9869fc">7,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzQtNy0xLTEtMA_9cb9271d-1557-47dd-a860-9d015ce8de0c">10,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzUtMS0xLTEtMA_a32bb925-e668-47c2-8280-ca62115421aa">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzUtMy0xLTEtMA_9eca9503-222c-4664-b111-3415884db239">8,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzUtNS0xLTEtMA_d34ac4d5-3265-4fbe-8b5e-fd77666e0422">5,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzUtNy0xLTEtMA_7a0495aa-4605-4acd-a4a2-c75634d15d6f">8,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzYtMS0xLTEtMA_34ca6e56-43b5-4fc7-bb02-d13d53749389">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzYtMy0xLTEtMA_47be521c-3b59-431a-af87-a89e2d9ece65">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzYtNS0xLTEtMA_cdc51af2-75ac-4f90-9733-078c9e96f2d6">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzYtNy0xLTEtMA_52fd6738-be13-497f-aa29-3074ac964199">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzctMS0xLTEtMA_5b752e8e-5cd9-46c9-bdba-f5d705d41f15">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzctMy0xLTEtMA_1e687618-bbc1-42e5-908c-3a535685863b">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzctNS0xLTEtMA_3808848d-053e-4145-a666-83580f5dd221">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzctNy0xLTEtMA_5fcc695b-c155-4380-a4cf-9929cfb770e8">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzktMS0xLTEtMA_ab70f9a9-d6ad-4608-bcd0-e6fee3ceded7">47,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzktMy0xLTEtMA_077580e0-969c-4931-a28b-5ca38fb3c611">59,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzktNS0xLTEtMA_4cf44668-4d7d-42a5-ad86-fedc876aeb4f">59,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzktNy0xLTEtMA_80c9b7db-d489-4460-a797-47e8d8df0389">60,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEwLTEtMS0xLTA_cd966508-7495-450b-976f-52aba2a4eda7">42,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEwLTMtMS0xLTA_59c7bbf1-cd7a-40a2-9df7-571908d10151">52,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEwLTUtMS0xLTA_3f903f62-164a-44ba-b6a4-5259e022c7f5">52,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEwLTctMS0xLTA_e3ad0128-cd63-49a9-9a39-afd9efae2a2e">54,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzExLTEtMS0xLTA_d1cf26a2-af8f-40f2-966a-42bc49d722c3">2,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzExLTMtMS0xLTA_3fd73572-cac2-4471-9553-17843806d567">9,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzExLTUtMS0xLTA_33e7ce66-be5e-4fcd-96f5-b82ec84024fa">10,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzExLTctMS0xLTA_4212e848-4dc9-4382-bdca-6c8fd8c3f121">4,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEyLTEtMS0xLTA_3e55bd2e-2811-48eb-9584-bd67353c84dd">612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEyLTMtMS0xLTA_09d7e8ef-1d50-4902-a78a-6c0860141cb3">11,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEyLTUtMS0xLTA_85aa6df7-c48c-49d2-9cdf-9cf44b45ac13">100,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEyLTctMS0xLTA_23e31a77-6273-49f5-a992-8282c9d0803e">4,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEzLTEtMS0xLTA_2686f812-cf99-4fa2-bcd7-4978220cbc6b">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEzLTMtMS0xLTA_4c573962-a6ea-4586-8074-1c54cdb15979">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEzLTUtMS0xLTA_ef39a259-4a97-4dc2-9603-1dce39345c2c">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEzLTctMS0xLTA_db90c662-46c7-448a-98da-59603f04292c">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzE0LTEtMS0xLTA_5f6f9150-28f5-4ffd-88d7-455f8a9fb653">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzE0LTMtMS0xLTA_b68864bd-c526-4cd7-889f-f3acfd935abd">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzE0LTUtMS0xLTA_23fd98d4-0cb4-4796-9e2d-337c9a4d0a4b">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzE0LTctMS0xLTA_007ceda5-0b98-4dbf-9c45-f18b682b1f39">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Gross profit includes revenues less cost of goods sold excluding amortization, and less intangible asset amortization.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i78e7e943a648448d981304e612e68114_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000095013306001354/w15453a2exv3w8.htm">Form of Amended and Restated Certificate of Incorporation of the registrant (filed as Exhibit 3.8 to Amendment No.&#160; 2 to the registrant&#8217;s registration statement on Form S-1 (File No.&#160;333-130759) on March&#160;17, 2006 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515409169/d106778dex31.htm">Fourth Amended and Restated Bylaws of the registrant, as amended and restated on December&#160;17, 2015 (filed as Exhibit&#160; 3.1 to the registrant&#8217;s current report on Form&#160;8-K (File No.&#160;001-34186) on December&#160;21, 2015 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000095013306001354/w15453a2exv4w4.htm">Specimen certificate representing the common stock of the registrant (filed as Exhibit 4.4 to Amendment No.&#160; 2 to the registrant&#8217;s registration statement on Form S-1 (File No.&#160;333-130759) on March&#160;17, 2006, and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000095013506000892/w15453a1exv10w3.txt">Amended and Restated License, Development and Commercialization Agreement, dated July&#160;24, 2005, by and between Bristol-Myers Squibb Company and the registrant (relating to HETLIOZ&#174;) (filed as Exhibit 10.3 to Amendment No. 1 to the registrant&#8217;s registration Statement on Form S-1 (File No.&#160;333-130759) on February&#160;16, 2006 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000095012305015355/w15453exv10w11.txt">Form of Indemnification Agreement entered into by directors and executive officers (filed as Exhibit 10.11 to the registrant&#8217;s registration statement on Form S-1 (File No.&#160;333-130759) on December&#160;29, 2005 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000095013306001354/w15453a2exv10w17.htm">2006 Equity Incentive Plan, as amended (filed as Exhibit 10.17 to Amendment No. 2 to the registrant&#8217;s Registration Statement on Form S-1 (File No. 333-130759), as filed on March 17, 2006, and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000095012311024187/w81923exv10w39.htm">Amendment to Amended and Restated Employment Agreement, dated December&#160;16, 2010, by and between Mihael H. Polymeropoulos and the registrant (filed as Exhibit 10.39 to the registrant&#8217;s annual report on Form 10-K (File No.&#160;001-34186) on March&#160;10, 2011 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000095012311024187/w81923exv10w41.htm">Amended and Restated Tax Indemnity Agreement, dated December&#160;16, 2010, by and between Mihael H. Polymeropoulos and the registrant (filed as Exhibit 10.41 to the registrant&#8217;s annual report on Form 10-K (File No.&#160; 001-34186) on March&#160;10, 2011 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312511298600/d249617dex1042.htm">Lease, effective as of July&#160;25, 2011, by and between Square 54 Office Owner LLC and the registrant (filed as Exhibit 10.42 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on November&#160;7, 2011 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000095012310035902/w78139exv10w38.htm">Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of April&#160;15, 2010, by and between Bristol-Myers Squibb Company and the registrant (filed as Exhibit 10.38 to the registrant&#8217;s current report on Form 8-K (File No.&#160;001-34186) on April&#160;19, 2010 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312512253648/d360358dex1046.htm">Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of May&#160;24, 2012, by and between Bristol-Myers Squibb Company and the registrant (filed as Exhibit 10.46 to the registrant&#8217;s current report on Form 8-K (File No. 001-34186) on May&#160;30, 2012 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312512333283/d343835dex1048.htm">License, Development and Commercialization Agreement, dated as of April&#160;12, 2012, by and between Eli Lilly and Company and the registrant (filed as Exhibit 10.48 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on August&#160;3, 2012 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312513179730/d527706dex1050.htm">Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of April&#160;25, 2013, by and between Bristol-Myers Squibb Company and the registrant (filed as Exhibit 10.50 to the registrant&#8217;s current report on Form 8-K (File No. 001-34186) on April&#160;29, 2013 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312514188616/d695003dex1053.htm">Manufacturing Agreement, dated January&#160;24, 2014, by and between Patheon Pharmaceuticals Inc. and the registrant (relating to HETLIOZ</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312514188616/d695003dex1053.htm">&#174;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312514188616/d695003dex1053.htm">) (filed as Exhibit 10.53 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on May&#160;8, 2014 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312514188616/d695003dex1054.htm">Amendment to Lease Agreement, dated March&#160;18, 2014, by and between Square 54 Office Owner LLC and the registrant (filed as Exhibit 10.54 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on May&#160;8, 2014 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515091300/d824216dex1055.htm">Settlement Agreement and Mutual General Release, dated December&#160;22, 2014, by and among Novartis Pharma AG and the registrant (filed as Exhibit 10.55 to the registrant&#8217;s annual report on Form 10-K (File No. 001-34186) on March&#160;13, 2015 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515219327/d937895dex1056.htm">Asset Transfer Agreement, dated December&#160;22, 2014, by and among Novartis Pharma AG, Novartis AG and the registrant (relating to Fanapt&#174;) (filed as Exhibit 10.56 to the registrant&#8217;s annual report on Form 10-K/A (File No.&#160;001-34186) on June&#160;10, 2015 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/910267/0000891092-97-000483.txt">Sublicense Agreement, dated November&#160;20, 1997, by and between Titan Pharmaceuticals, Inc. and Novartis Pharma AG (filed as Exhibit 10.30 to Titan Pharmaceutical Inc.&#8217;s registration statement on Form S-3 (File No.&#160;333-42367) on December&#160;16, 1997 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515091300/d824216dex1058.htm">Amendment No.&#160;1 to Sublicense Agreement by and between Titan Pharmaceuticals, Inc. and Novartis Pharma AG, dated November 30, 1998 (filed as Exhibit 10.58 to the registrant&#8217;s annual report on Form 10-K (File No.&#160;001-34186) on March&#160;13, 2015 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515219327/d937895dex1059.htm">Amendment No.&#160;2 to Sublicense Agreement, dated April&#160;10, 2001, by and between Titan Pharmaceuticals, Inc. and Novartis Pharma AG (filed as Exhibit 10.59 to the registrant&#8217;s annual report on Form 10-K/A (File No.&#160; 001-34186) on June&#160;10, 2015 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515091300/d824216dex1060.htm">Amendment No.&#160;3 to Sublicense Agreement, dated June 4, 2004, by and between Titan Pharmaceuticals, Inc. and Novartis Pharma AG (filed as Exhibit 10.60 to the registrant&#8217;s annual report on Form 10-K (File No. 001-34186) on March&#160;13, 2015 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515091300/d824216dex1061.htm">Stock Purchase Agreement, dated December&#160;22, 2014, by and between Novartis AG and the registrant (filed as Exhibit 10.61 to the registrant&#8217;s annual report on Form 10-K (File No.&#160; 001-34186) on March&#160;13, 2015 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515091300/d824216dex1062.htm">License Agreement, dated December&#160;22, 2014, by and between Novartis Pharma AG and the registrant (relating to AQW051) (filed as Exhibit 10.62 to the registrant&#8217;s annual report on Form 10-K (File No.&#160;001-34186) on March&#160;13, 2015 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312516450055/d125062dex101.htm">Agreement, dated February&#160;2, 2016, by and among Titan Pharmaceuticals, Inc., Aventisub LLC, the successor-in-interest to Aventisub II Inc. Sanofi-Aventis and the registrant (filed as Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K (File No.&#160;001-34186) on February&#160;4, 2016 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1347178/000119312520166765/d945135dex101.htm">Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan, effective as of June&#160;11, 2020 (filed as Exhibit 10.1 to the registrant&#8217;s registration statement on Form S-8 (File No.&#160;333-239103) on June&#160;11, 2020 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312517204769/d397468dex102.htm">Form of Notice of Stock Option Grant and Stock Option Agreement under Amended and Restated 2016 Equity Incentive Plan (filed as Exhibit 10.2 to the registrant&#8217;s registration statement on Form S-8 (File No.&#160;333-218774) on June&#160;15, 2017 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312517204769/d397468dex103.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2016 Equity Incentive Plan (filed as Exhibit 10.3 to the registrant&#8217;s registration statement on Form S-8 (File No.&#160;333-218774) on June&#160;15, 2017 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312517204769/d397468dex104.htm">UK Sub Plan under the Amended and Restated 2016 Equity Incentive Plan (filed as Exhibit 10.4 to the registrant&#8217;s registration statement on Form S-8 (File No.&#160;333-218774) on June&#160;15, 2017 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312517204769/d397468dex105.htm">Form of Stock Option Grant and Stock Option Agreement under the UK Sub Plan under the Amended and Restated 2016 Equity Incentive Plan (filed as Exhibit 10.5 to the registrant&#8217;s registration statement on Form S-8 (File No.&#160;333-218774) on June&#160;15, 2017 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312517204769/d397468dex106.htm">Form of Restricted Stock Unit Award Agreement under the UK Sub Plan under the Amended and Restated 2016 Equity Incentive Plan (filed as Exhibit 10.6 to the registrant&#8217;s registration statement on Form S-8 (File No.&#160;333-218774) on June&#160;15, 2017 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312516661038/d196712dex1042.htm">Manufacturing Agreement, dated May&#160;6, 2016, by and between Patheon Pharmaceuticals Inc. and the registrant (relating to Fanapt&#174;) (filed as Exhibit 10.42 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160; 001-34186) on July&#160;28, 2016 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312516661038/d196712dex1043.htm">Second Amendment to Lease Agreement, dated June&#160;20, 2016, by and between Square 54 Office Owner LLC and the registrant (filed as Exhibit 10.43 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on July&#160;28, 2016 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312516661038/d196712dex1044.htm">Sublease Agreement, dated June&#160;22, 2016, by and between Hunton&#160; &amp; Williams LLP and the registrant (filed as Exhibit 10.44 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on July&#160;28, 2016 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312517047317/d474152dex1045.htm">License Agreement, dated October&#160;24, 2016, by and among Taro Pharmaceuticals USA, Inc., Taro Pharmaceuticals Industries Ltd. and the registrant (filed as Exhibit 10.45 to the registrant&#8217;s annual report on Form 10-K (File No.&#160;001-34186) on February&#160;17, 2017 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312517047317/d474152dex1046.htm">License Agreement, dated December&#160;7, 2016, by and between Apotex, Inc. and the registrant (filed as Exhibit 10.46 to the registrant&#8217;s annual report on Form 10-K (File No.&#160;001-34186) on February&#160;17, 2017 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312518148848/d561909dex1038.htm">Third Amendment to Lease Agreement, dated March 28, 2018, by and between Square 54 Office Owner LLC and the registrant (filed as Exhibit 10.38 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on May 2, 2018 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312518148848/d561909dex1039.htm">Fourth Amendment to Lease Agreement, dated March 29, 2018, by and between Square 54 Office Owner LLC and the registrant (filed as Exhibit 10.39 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on May 2, 2018 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312518148848/d561909dex1040.htm">Amended and Restated Employment Agreement, dated April 30, 2018, by and between Gunther Birznieks and the registrant (filed as Exhibit 10.40 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on May 2, 2018 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000134717818000010/vndaex104109302018.htm">Employment Agreement, dated August 13, 2018, by and between Timothy Williams and the registrant (filed as Exhibit 10.41 to the registrant&#8217;s quarterly report on Form 10-Q (File No.&#160;001-34186) on November 7, 2018 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000134717819000017/vndaex10400930201910q.htm">Employment Agreement, dated July 3, 2019, by and between Aranthan "AJ" Jones II and the registrant (filed as Exhibit 10.40 to the registrant&#8217;s quarterly report on Form 10-Q (File No. 001-34186) on November 7, 2019 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000134717819000017/vndaex10410930201910q.htm">Employment Agreement, dated August 5, 2019, by and between Joakim Wijkstrom and the registrant (filed as Exhibit 10.41 to the registrant&#8217;s quarterly report on Form 10-Q (File No. 001-34186) on November 7, 2019 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1347178/000134717820000013/vndaex1042331202010q.htm">Amended and Restated Employment Agreement, dated May 5, 2020, by and between Kevin Moran and the registrant (filed as Exhibit 10.42 to the registrant&#8217;s quarterly report on Form 10-Q (File No. 001-34186) on May 7, 2020 and incorporated herein by reference).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vndaex104012312020.htm">Fifth Amendment to Lease Agreement, dated April 11, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vndaex104012312020.htm">, by and between Square 54 Office Owner LLC and the registrant.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vndaex104112312020.htm">Sixth Amendment to Lease Agreement, dated May 7, 2020, by and between Square 54 Office Owner LLC and the registrant.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda12312020ex211.htm">List of Subsidiaries</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda12312020ex211.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda12312020ex231.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda12312020ex311.htm">Certification of the Chief Executive Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda12312020ex312.htm">Certification of the Chief Financial Officer as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda12312020ex321.htm">Certification of the Chief Executive Officer and Chief Financial Officer as required by Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from this annual report on Form 10-K for the fiscal year ended December&#160;31, 2020, formatted in Inline Extensible Business Reporting Language (iXBRL)&#160;and furnished electronically herewith: (i)&#160;Consolidated Balance Sheets as of December&#160;31, 2020 and 2019; (ii) Consolidated Statements of Operations for the years ended December&#160;31, 2020, 2019 and 2018; (iii) Consolidated Statements of Comprehensive Income (Loss) for the years ended December&#160;31, 2020, 2019 and 2018; (iv) Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December&#160;31, 2020, 2019 and 2018; (v) Consolidated Statements of Cash Flows for the years ended December&#160;31, 2020, 2019 and 2018; and (vi)&#160;Notes to the Consolidated Financial Statements.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78e7e943a648448d981304e612e68114_7">ontents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted with respect to certain provisions of this exhibit.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>2
<FILENAME>vndaex104012312020.htm
<DESCRIPTION>EX-10.40
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id35ce053f93f47b99a543672f484b769_57"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.40</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXECUTION COPY</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AMENDMENT NO. 5 TO LEASE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS AMENDMENT NO. 5 TO LEASE (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made as of the 11th day of April, 2019 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between SQUARE 54 OFFICE OWNER LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and VANDA PHARMACEUTICALS INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">WITNESSETH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, by Lease dated as of July 25, 2011 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as amended by that Amendment No. 1 to Lease dated as of March 18, 2014 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that Amendment No. 2 to Lease dated as of June 20, 2016 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that Amendment No. 3 to Lease dated as of March 28, 2018 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that Amendment No. 4 to Lease dated as of March 29, 2018 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (the Initial Lease, Amendment No. 1, Amendment No. 2, Amendment No. 3 and Amendment No. 4, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Landlord is leasing to Tenant thirty-three thousand five hundred thirty-four (33,534) square feet of rentable area (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) located in the East Tower of the building located at 2200 Pennsylvania Avenue, N.W., Washington, D.C. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which includes, without limitation, three thousand two hundred seventy-four (3,274) square feet of rentable area located on the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) floor more particularly defined as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 3 Expansion Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Landlord granted Tenant the Amendment No. 3 Allowance to be applied to Tenant alterations costs in the Amendment No. 3 Expansion Space&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Landlord and Tenant desire to amend the Lease to extend the period during which Tenant may requisition the Amendment No. 3 Allowance and to modify certain other terms of the Lease in accordance with and subject to the terms and conditions set forth below.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants and premises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree to amend the Lease as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All capitalized terms used herein and not otherwise defined herein shall have the same meanings as provided for such terms in the Lease.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Extension of Time for Amendment No. 3 Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Amendment No. 3 is hereby amended by deleting the phrase &#8220;within twelve (12) months after the Expansion Commencement Date&#8221; in the second-to-last line of Section 6(d)(iii) and inserting the phrase &#8220;on or before June 30, 2020&#8221; in its stead.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ratification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise expressly modified by the terms of this Amendment No. 5, the Lease shall remain unchanged and continue in full force and effect.  All </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">terms, covenants and conditions of the Lease not expressly modified herein are hereby confirmed and ratified and remain in full force and effect, and, as further amended hereby, constitute valid and binding obligations of Landlord and Tenant enforceable according to the terms thereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant each represent and warrant to the other that neither of them has employed or dealt with any broker, agent or finder in carrying on the negotiations relating to this Amendment No. 5.  Landlord and Tenant shall indemnify and hold the other harmless from and against any claim or claims for brokerage or other commissions asserted by any broker, agent or finder engaged by Landlord or Tenant or with whom Landlord or Tenant has dealt in connection with this Amendment No. 5.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;Tenant hereby represents and warrants to Landlord that Tenant is a duly organized and existing corporation and is in good standing under the laws of the State of Delaware and the District of Columbia, that all necessary corporate action has been taken to enter into this Amendment No. 5 and that the person signing this Amendment No. 5 on behalf of Tenant has been duly authorized to do so.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;Landlord hereby represents and warrants to Tenant that Landlord is a duly organized and existing limited liability company and is in good standing under the laws of the State of Delaware and the District of Columbia, that all necessary company action has been taken to enter into this Amendment No. 5 and that the person signing this Amendment No. 5 on behalf of Landlord has been duly authorized to do so.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord and Tenant Representations and Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;To the best of Tenant&#8217;s knowledge, Landlord has performed all of its obligations under the Lease.  To the best of Tenant&#8217;s knowledge, Landlord is not in default under the Lease as of the date hereof, and Tenant is unaware of any condition or circumstance which, but for the passage of time or delivery of notice, or both, would constitute an event of default by Landlord under the Lease.  Tenant has no current claims, defenses or set-offs of any kind to the payment or performance of Tenant&#8217;s obligations under the Lease.  Nothing contained herein shall be deemed to waive any sums due from Tenant to Landlord, or any default or event which, with the passage of time or delivery of notice, or both, would constitute a default by Tenant under the Lease as of the date hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;To the best of Landlord&#8217;s knowledge, Tenant has performed all of its obligations under the Lease.  To the best of Landlord&#8217;s knowledge, Tenant is not in default under the Lease as of the date hereof, and Landlord is unaware of any condition or circumstance which, but for the passage of time or delivery of notice, or both, would constitute an event of default by Tenant under the Lease.  Landlord has no current claims, defenses or set-offs of any kind to the payment or performance of Landlord&#8217;s obligations under the Lease.  Nothing contained herein shall be deemed to waive any sums due from Landlord to Tenant, or any default or event which, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with the passage of time or delivery of notice, or both, would constitute a default by Landlord under the Lease as of the date hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Mutual Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant each hereby covenants and agrees that each and every provision of this Amendment No. 5 has been jointly and mutually negotiated and authorized by both Landlord and Tenant, and in the event of any dispute arising out of any provision of this Amendment No. 5, Landlord and Tenant each does hereby waive any claim of authorship against the other party.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant agree that the terms and conditions of this Amendment No. 5 shall also be subject to the same provisions regarding confidentiality as are contained within Section 25.20 of the Initial Lease. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Amendment No. 5 shall not be effective and binding unless and until fully executed and delivered by each of the parties hereto.  All of the covenants contained in this Amendment No. 5, including, but not limited to, all covenants of the Lease as modified hereby, shall be binding upon and inure to the benefit of the parties hereto, their respective heirs, legal representatives, and permitted successors and assigns.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Remainder of page intentionally blank.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature page follows.&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment No. 5 to Lease as of the date and year first above written.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:171pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SQUARE 54 OFFICE OWNER LLC,</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div><div style="padding-left:171pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;BP&#47;DC PROPERTIES, INC.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Maryland corporation, its sole member and manager</font></div><div style="padding-left:171pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; John J. Stroman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">John J. Stroman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vice President, Leasing&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:202.5pt;text-align:justify;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:202.5pt;text-align:justify;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VANDA PHARMACEUTICALS INC.,</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Mihael H. Polymeropoulos&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Mihael H. Polymeropoulos&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">President and CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>3
<FILENAME>vndaex104112312020.htm
<DESCRIPTION>EX-10.41
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="idc3d50034ac946e2a3216ec53897dbee_57"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.41</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXECUTION COPY</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AMENDMENT NO. 6 TO LEASE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS AMENDMENT NO. 6 TO LEASE (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made as of the 7th day of May, 2020 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between SQUARE 54 OFFICE OWNER LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and VANDA PHARMACEUTICALS INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">WITNESSETH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, by Lease dated as of July 25, 2011 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as amended by that Amendment No. 1 to Lease dated as of March 18, 2014 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that Amendment No. 2 to Lease dated as of June 20, 2016 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that Amendment No. 3 to Lease dated as of March 28, 2018 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that Amendment No. 4 to Lease dated as of March 29, 2018 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that Amendment No. 5 to Lease dated as of April 11, 2019 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (the Initial Lease, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Landlord is leasing to Tenant thirty-three thousand five hundred thirty-four (33,534) square feet of rentable area (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) located in the East Tower of the building located at 2200 Pennsylvania Avenue, N.W., Washington, D.C. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which includes, without limitation, three thousand two hundred seventy-four (3,274) square feet of rentable area located on the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) floor more particularly defined as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 3 Expansion Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Landlord granted Tenant the Amendment No. 3 Allowance to be applied to Tenant alterations costs in the Amendment No. 3 Expansion Space&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, pursuant to section 6(d)(iii) of Amendment No. 3, as amended by Amendment No. 5, the period during which Tenant may requisition the Amendment No. 3 Allowance was extended to June 30, 2020&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Landlord and Tenant desire to amend the Lease to further extend the period during which Tenant may requisition the Amendment No. 3 Allowance to June 30, 2021, and to modify certain other terms of the Lease in accordance with and subject to the terms and conditions set forth below.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants and premises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree to amend the Lease as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All capitalized terms used herein and not otherwise defined herein shall have the same meanings as provided for such terms in the Lease.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Extension of Time for Amendment No. 3 Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The last sentence of Section 6(d)(iii) of Amendment No. 3, as amended, is hereby deleted in its entirety and replaced with the following&#58;  &#8220;Any portion of the Amendment No. 3 Allowance that has not been requisitioned in accordance with the foregoing on or before June 30, 2021 shall be deemed waived and forfeited.&#8221; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ratification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise expressly modified by the terms of this Amendment No. 6, the Lease shall remain unchanged and continue in full force and effect.  All terms, covenants and conditions of the Lease not expressly modified herein are hereby confirmed and ratified and remain in full force and effect, and, as further amended hereby, constitute valid and binding obligations of Landlord and Tenant enforceable according to the terms thereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant each represent and warrant to the other that neither of them has employed or dealt with any broker, agent or finder in carrying on the negotiations relating to this Amendment No. 6.  Landlord and Tenant shall indemnify and hold the other harmless from and against any claim or claims for brokerage or other commissions asserted by any broker, agent or finder engaged by Landlord or Tenant or with whom Landlord or Tenant has dealt in connection with this Amendment No. 6.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;Tenant hereby represents and warrants to Landlord that Tenant is a duly organized and existing corporation and is in good standing under the laws of the State of Delaware and the District of Columbia, that all necessary corporate action has been taken to enter into this Amendment No. 6 and that the person signing this Amendment No. 6 on behalf of Tenant has been duly authorized to do so.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;Landlord hereby represents and warrants to Tenant that Landlord is a duly organized and existing limited liability company and is in good standing under the laws of the State of Delaware and the District of Columbia, that all necessary company action has been taken to enter into this Amendment No. 6 and that the person signing this Amendment No. 6 on behalf of Landlord has been duly authorized to do so.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord and Tenant Representations and Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;To the best of Tenant&#8217;s knowledge, Landlord has performed all of its obligations under the Lease.  To the best of Tenant&#8217;s knowledge, Landlord is not in default under the Lease as of the date hereof, and Tenant is unaware of any condition or circumstance which, but for the passage of time or delivery of notice, or both, would constitute an event of default by Landlord under the Lease.  Tenant has no current claims, defenses or set-offs of any kind to the payment or performance of Tenant&#8217;s obligations under the Lease.  Nothing contained herein shall be deemed to waive any sums due from Tenant to Landlord, or any default or event which, with the passage of time or delivery of notice, or both, would constitute a default by Tenant under the Lease as of the date hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;To the best of Landlord&#8217;s knowledge, Tenant has performed all of its obligations under the Lease.  To the best of Landlord&#8217;s knowledge, Tenant is not in default under the Lease as of the date hereof, and Landlord is unaware of any condition or circumstance which, but for the passage of time or delivery of notice, or both, would constitute an event of default by Tenant under the Lease.  Landlord has no current claims, defenses or set-offs of any kind to the payment or performance of Landlord&#8217;s obligations under the Lease.  Nothing contained herein shall be deemed to waive any sums due from Landlord to Tenant, or any default or event which, with the passage of time or delivery of notice, or both, would constitute a default by Landlord under the Lease as of the date hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Mutual Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant each hereby covenants and agrees that each and every provision of this Amendment No. 6 has been jointly and mutually negotiated and authorized by both Landlord and Tenant, and in the event of any dispute arising out of any provision of this Amendment No. 6, Landlord and Tenant each does hereby waive any claim of authorship against the other party.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord and Tenant agree that the terms and conditions of this Amendment No. 6 shall also be subject to the same provisions regarding confidentiality as are contained within Section 25.20 of the Initial Lease. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Amendment No. 6 shall not be effective and binding unless and until fully executed and delivered by each of the parties hereto.  All of the covenants contained in this Amendment No. 6, including, but not limited to, all covenants of the Lease as modified hereby, shall be binding upon and inure to the benefit of the parties hereto, their respective heirs, legal representatives, and permitted successors and assigns.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Remainder of page intentionally blank.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature page follows.&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment No. 6 to Lease as of the date and year first above written.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:171pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SQUARE 54 OFFICE OWNER LLC,</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div><div style="padding-left:171pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;BP&#47;DC PROPERTIES, INC.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Maryland corporation, its sole member and manager</font></div><div style="padding-left:171pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; John J. Stroman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">John J. Stroman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SVP, Leasing&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:202.5pt;text-align:justify;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:202.5pt;text-align:justify;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VANDA PHARMACEUTICALS INC.,</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Mihael H. Polymeropoulos&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Mihael H. Polymeropoulos&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>vnda12312020ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i724b98af483b4501944504c8ebea0d80_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vanda Pharmaceuticals Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">List of Subsidiaries </font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.868%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of Wholly-Owned Subsidiary</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Jurisdiction of Organization</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name under which the subsidiary conducts business</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vanda Pharmaceuticals Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vanda Pharmaceuticals Limited</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vanda Pharmaceuticals GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vanda Pharmaceuticals GmbH</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vanda Pharmaceuticals Germany GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Germany</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vanda Pharmaceuticals Germany GmbH</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vanda Pharmaceuticals Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Netherlands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vanda Pharmaceuticals Netherlands B.V.</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>vnda12312020ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id981db0cb8ee4483801b88bf45fcf1d5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-133368, No.&#160;333-138070, No.&#160;333-141571, No.&#160;333-148924, No.&#160;333-156995, No.&#160;333-164567, No.&#160;333-171962, No.&#160;333-179265, No.&#160;333-186509, No.&#160;333-193614, No.&#160;333-201754, No.&#160;333-209144, No. 333-212255, No. 333-218774, No. 333-225599 and No. 333-239103) of Vanda Pharmaceuticals Inc. of our report dated February&#160;11, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baltimore, Maryland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;11, 2021 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>vnda12312020ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7bf6ebe5635c4108af382e8aba300a4d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mihael H. Polymeropoulos, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Vanda Pharmaceuticals Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mihael H. Polymeropoulos, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mihael H. Polymeropoulos, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>vnda12312020ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic69ec525a41348628c3fd93b82541917_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin Moran, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Vanda Pharmaceuticals Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Kevin Moran</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevin Moran</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice&#160;President, Chief&#160;Financial&#160;Officer&#160;and&#160;Treasurer<br>(Principal&#160;Financial&#160;Officer&#160;and&#160;Principal&#160;Accounting&#160;Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>vnda12312020ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib70ecf834d054abe869ff56c0b607d91_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Subsections (a)&#160;and (b)&#160;of Section&#160;1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Vanda Pharmaceuticals Inc., (the &#8220;Company&#8221;), does hereby certify, to the best of such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report on Form 10-K for the year ended December 31, 2020 (the Form 10-K) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Mihael H. Polymeropoulos, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mihael H. Polymeropoulos, M.D.<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 11, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Kevin Moran</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevin Moran<br>Senior Vice&#160;President, Chief&#160;Financial&#160;Officer&#160;and&#160;Treasurer<br>(Principal&#160;Financial&#160;Officer&#160;and&#160;Principal&#160;Accounting&#160;Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification &#8220;accompanies&#8221; the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>vnda-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d614c307-4118-4611-a8d3-3c89a1b9f878,g:1f7774dc-f1ff-4a69-952a-c8825acf6b9a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vnda="http://www.vandapharmaceuticals.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vandapharmaceuticals.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.vandapharmaceuticals.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOrganizationandPresentation" roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation">
        <link:definition>2101101 - Disclosure - Business Organization and Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOrganizationandPresentationDetail" roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail">
        <link:definition>2402401 - Disclosure - Business Organization and Presentation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities">
        <link:definition>2112103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables">
        <link:definition>2313302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail">
        <link:definition>2414408 - Disclosure - Marketable Securities - Available-For-Sale Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements">
        <link:definition>2115104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables">
        <link:definition>2316303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>2417409 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.vandapharmaceuticals.com/role/Inventory">
        <link:definition>2118105 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables">
        <link:definition>2319304 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetail" roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail">
        <link:definition>2420410 - Disclosure - Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipment">
        <link:definition>2121106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables">
        <link:definition>2322305 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentPropertyandEquipmentatCostDetail" roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail">
        <link:definition>2423411 - Disclosure - Property and Equipment - Property and Equipment-at Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail">
        <link:definition>2424412 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.vandapharmaceuticals.com/role/Leases">
        <link:definition>2125107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.vandapharmaceuticals.com/role/LeasesTables">
        <link:definition>2326306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2427413 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseAssetsandLiabilitiesDetails" roleURI="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails">
        <link:definition>2428414 - Disclosure - Leases - Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesDetails" roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails">
        <link:definition>2429415 - Disclosure - Leases - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesDetails_1" roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1">
        <link:definition>2429415 - Disclosure - Leases - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets">
        <link:definition>2130108 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables">
        <link:definition>2331307 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsHETLIOZAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail">
        <link:definition>2432416 - Disclosure - Intangible Assets - HETLIOZ - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsFanaptAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail">
        <link:definition>2433417 - Disclosure - Intangible Assets - Fanapt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsSummaryofIntangibleAssetsDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail">
        <link:definition>2434418 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsSummaryofAmortizationExpenseDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail">
        <link:definition>2435419 - Disclosure - Intangible Assets - Summary of Amortization Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail">
        <link:definition>2436420 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>2137109 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>2338308 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetail" roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail">
        <link:definition>2439421 - Disclosure - Accounts Payable and Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies">
        <link:definition>2140110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail">
        <link:definition>2441422 - Disclosure - Commitments and Contingencies - HETLIOZ - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFanaptAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail">
        <link:definition>2442423 - Disclosure - Commitments and Contingencies - Fanapt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTradipitantAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail">
        <link:definition>2443424 - Disclosure - Commitments and Contingencies - Tradipitant - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail">
        <link:definition>2444425 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesVQW765AdditionalInformationDetails" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails">
        <link:definition>2445426 - Disclosure - Commitments and Contingencies - VQW-765 - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesPurchaseCommitmentsDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail">
        <link:definition>2446427 - Disclosure - Commitments and Contingencies - Purchase Commitments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PublicOfferingofCommonStock" roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock">
        <link:definition>2147111 - Disclosure - Public Offering of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PublicOfferingofCommonStockDetails" roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails">
        <link:definition>2448428 - Disclosure - Public Offering of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>2149112 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>2350309 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail">
        <link:definition>2451429 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation">
        <link:definition>2152113 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables">
        <link:definition>2353310 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2454430 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail">
        <link:definition>2455431 - Disclosure - Stock-Based Compensation - Stock Option - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRSUAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail">
        <link:definition>2456432 - Disclosure - Stock-Based Compensation - RSU - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofOptionActivityDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail">
        <link:definition>2457433 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUActivityPlanDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail">
        <link:definition>2458434 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTotalStockBasedCompensationExpenseDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail">
        <link:definition>2459435 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail">
        <link:definition>2460436 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan">
        <link:definition>2161114 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetail" roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail">
        <link:definition>2462437 - Disclosure - Employee Benefit Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes">
        <link:definition>2163115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables">
        <link:definition>2364311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails">
        <link:definition>2465438 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Income Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail">
        <link:definition>2466439 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail">
        <link:definition>2467440 - Disclosure - Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail">
        <link:definition>2468441 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets and Related Valuation Allowance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail">
        <link:definition>2469442 - Disclosure - Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2470443 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails">
        <link:definition>2471444 - Disclosure - Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShare">
        <link:definition>2172116 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareTables">
        <link:definition>2373312 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetail" roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail">
        <link:definition>2474445 - Disclosure - Earnings per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMatters" roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters">
        <link:definition>2175117 - Disclosure - Legal Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2176118 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2377313 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetail" roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail">
        <link:definition>2478446 - Disclosure - Quarterly Financial Data (Unaudited) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vnda_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember" abstract="true" name="IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_ComputerHardwareAndOtherEquipmentMember" abstract="true" name="ComputerHardwareAndOtherEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_DefinedContributionPlanVestingPeriod" abstract="false" name="DefinedContributionPlanVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vnda_InventoryWorkInProcessNetOfReservesNonCurrent" abstract="false" name="InventoryWorkInProcessNetOfReservesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_TwoThousandSixteenPlanMember" abstract="true" name="TwoThousandSixteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_SalesMilestoneMember" abstract="true" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_HetliozMember" abstract="true" name="HetliozMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_TieredRoyaltiesPayableOnFutureNetSales" abstract="false" name="TieredRoyaltiesPayableOnFutureNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_RegulatoryApprovalMilestoneMember" abstract="true" name="RegulatoryApprovalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_Inventory" abstract="false" name="Inventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_UnitedStatesExcludingDistrictOfColumbiaMember" abstract="true" name="UnitedStatesExcludingDistrictOfColumbiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_NoncurrentInventoryAndOtherMember" abstract="true" name="NoncurrentInventoryAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_AccruedMilestoneObligationsUnderLicenseAgreements" abstract="false" name="AccruedMilestoneObligationsUnderLicenseAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vnda_StatementScenarioSecondaryDomain" abstract="true" name="StatementScenarioSecondaryDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_NumberOfProductsInPortfolio" abstract="false" name="NumberOfProductsInPortfolio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vnda_DeferredTaxAssetsValuationAllowanceRollForward" abstract="true" name="DeferredTaxAssetsValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_DeferredTaxAssetsValuationAllowanceIncrease" abstract="false" name="DeferredTaxAssetsValuationAllowanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_OperatingLeaseNonLeaseComponentExpense" abstract="false" name="OperatingLeaseNonLeaseComponentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_CftrActivatorsAndInhibitorsAbstract" abstract="true" name="CftrActivatorsAndInhibitorsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_CustomerFiveMember" abstract="true" name="CustomerFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_DeferredTaxAssetsValuationAllowanceDecrease" abstract="false" name="DeferredTaxAssetsValuationAllowanceDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_PreNDAApprovalMilestonesMember" abstract="true" name="PreNDAApprovalMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" abstract="true" name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vnda_SubleaseMember" abstract="true" name="SubleaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_CftrActivatorsAndInhibitorsMember" abstract="true" name="CftrActivatorsAndInhibitorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vnda_ServiceOptionAwardsMember" abstract="true" name="ServiceOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_ProductRevenueAllowancesCurrent" abstract="false" name="ProductRevenueAllowancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vnda_IncreaseDecreaseProductRevenueAllowances" abstract="false" name="IncreaseDecreaseProductRevenueAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_CumulativeNetSalesToAchieveMilestone" abstract="false" name="CumulativeNetSalesToAchieveMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" abstract="true" name="TwoThousandSixPlanAndTwoThousandSixteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vnda_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_OrphanDrugMember" abstract="true" name="OrphanDrugMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" abstract="false" name="ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" abstract="true" name="DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_AccruedResearchAndDevelopmentExpense" abstract="false" name="AccruedResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_FanaptAbstract" abstract="true" name="FanaptAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" abstract="false" name="AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vnda_OperatingLossCarryforwardsBeginningExpirationYear" abstract="false" name="OperatingLossCarryforwardsBeginningExpirationYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="vnda_HetliozAbstract" abstract="true" name="HetliozAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_IncomeBeforeIncomeTaxesCurrentYearMember" abstract="true" name="IncomeBeforeIncomeTaxesCurrentYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" abstract="false" name="SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" abstract="false" name="AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" abstract="true" name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_ScenarioFourMember" abstract="true" name="ScenarioFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vnda_RoyaltyPeriod" abstract="false" name="RoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" abstract="false" name="ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vnda_VQW765Member" abstract="true" name="VQW765Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_SECSchedule1209AllowanceProductReturnsMember" abstract="true" name="SECSchedule1209AllowanceProductReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" abstract="false" name="DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_CustomerFourMember" abstract="true" name="CustomerFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_PercentageOfFutureSublicenseFeesPayable" abstract="false" name="PercentageOfFutureSublicenseFeesPayable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_OrphanDrugCreditBeginningExpirationYear" abstract="false" name="OrphanDrugCreditBeginningExpirationYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="vnda_StatementScenarioSecondaryAxis" abstract="true" name="StatementScenarioSecondaryAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" abstract="false" name="PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" abstract="false" name="InventoryFinishedGoodsNetOfReservesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vnda_DescriptionOfBusinessPolicyTextBlock" abstract="false" name="DescriptionOfBusinessPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vnda_FanaptMember" abstract="true" name="FanaptMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_InventoryRawMaterialsNetOfReservesNonCurrent" abstract="false" name="InventoryRawMaterialsNetOfReservesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_EstimatedRealizabilityofDeferredTaxAssetMember" abstract="true" name="EstimatedRealizabilityofDeferredTaxAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" abstract="true" name="FutureRegulatoryApprovalAndSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" abstract="false" name="DevelopmentAndMilestoneObligationsPaidToThirdParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_RoyaltyPayableOnNetSalesPercentage" abstract="false" name="RoyaltyPayableOnNetSalesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vnda_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" abstract="false" name="EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" abstract="false" name="DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_ShareBasedCompensationOptionAwardsContractualTerm" abstract="false" name="ShareBasedCompensationOptionAwardsContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_ResearchAndDevelopmentCreditBeginningExpirationYear" abstract="false" name="ResearchAndDevelopmentCreditBeginningExpirationYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="vnda_TradipitantMember" abstract="true" name="TradipitantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="vnda_ReservesForVariableConsiderationPolicyTextBlock" abstract="false" name="ReservesForVariableConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vnda_InventoryAndOtherNonCurrent" abstract="false" name="InventoryAndOtherNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vnda_PublicOfferingOfCommonStockTextBlock" abstract="false" name="PublicOfferingOfCommonStockTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" abstract="false" name="FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vnda_ScheduleOfInventoriesTableTextBlock" abstract="false" name="ScheduleOfInventoriesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>vnda-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d614c307-4118-4611-a8d3-3c89a1b9f878,g:1f7774dc-f1ff-4a69-952a-c8825acf6b9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_05326254-63cb-4ce2-b170-7a42d1559f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4a589940-1f90-4452-997d-178606da939d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05326254-63cb-4ce2-b170-7a42d1559f4e" xlink:to="loc_us-gaap_LiabilitiesCurrent_4a589940-1f90-4452-997d-178606da939d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d2b6daa6-84ae-4673-a4ce-2fedbb42c04c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05326254-63cb-4ce2-b170-7a42d1559f4e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d2b6daa6-84ae-4673-a4ce-2fedbb42c04c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c31437fb-1e08-4fb6-bf02-dc0f325057b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05326254-63cb-4ce2-b170-7a42d1559f4e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c31437fb-1e08-4fb6-bf02-dc0f325057b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54012679-7dc3-48f1-b2a9-47c2ed1a9c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54012679-7dc3-48f1-b2a9-47c2ed1a9c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4ded1184-ea1e-4b91-a96f-cb74eb81c2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4ded1184-ea1e-4b91-a96f-cb74eb81c2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a667eee4-7c49-4f05-a9c1-85859115a384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a667eee4-7c49-4f05-a9c1-85859115a384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4cf77884-0e7f-4a3a-b187-6aa95776773e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_InventoryNet_4cf77884-0e7f-4a3a-b187-6aa95776773e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffc47c8c-f003-49fc-b79e-3a5f85b2d5de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c8c995b2-815b-4dd0-9965-e2383b95b4f3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffc47c8c-f003-49fc-b79e-3a5f85b2d5de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3f8ea3b7-7193-451c-8366-af6c1e375b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eb09d83a-01e6-4e11-a500-ddfe476ec033" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3f8ea3b7-7193-451c-8366-af6c1e375b9a" xlink:to="loc_us-gaap_Liabilities_eb09d83a-01e6-4e11-a500-ddfe476ec033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_15ff443c-0a7b-49b6-9008-775b877ffc97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3f8ea3b7-7193-451c-8366-af6c1e375b9a" xlink:to="loc_us-gaap_StockholdersEquity_15ff443c-0a7b-49b6-9008-775b877ffc97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_454d8926-c7c1-475c-a55a-2579105ce829" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3f8ea3b7-7193-451c-8366-af6c1e375b9a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_454d8926-c7c1-475c-a55a-2579105ce829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d90e347-b5af-4910-bd43-6d46986387b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f3807eb6-89a1-4463-a76d-552919f52c18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d90e347-b5af-4910-bd43-6d46986387b9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f3807eb6-89a1-4463-a76d-552919f52c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent_533a84a9-0be3-4ee2-b236-34c8c6294495" xlink:href="vnda-20201231.xsd#vnda_ProductRevenueAllowancesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d90e347-b5af-4910-bd43-6d46986387b9" xlink:to="loc_vnda_ProductRevenueAllowancesCurrent_533a84a9-0be3-4ee2-b236-34c8c6294495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e2a0e044-9a3f-4344-b2fd-0ca796405fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_PreferredStockValue_e2a0e044-9a3f-4344-b2fd-0ca796405fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_269b1120-3100-42bc-9ba6-73fcc687dc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_CommonStockValue_269b1120-3100-42bc-9ba6-73fcc687dc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89673a84-dcda-44ac-bc0a-a6160eb7c16e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89673a84-dcda-44ac-bc0a-a6160eb7c16e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_279c5721-f6cf-4086-a2d4-2349526742e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_279c5721-f6cf-4086-a2d4-2349526742e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9310e743-41b4-4da8-9d80-1cad5cf85771" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b26d095-c699-4b4f-b83c-40eaf34713f9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9310e743-41b4-4da8-9d80-1cad5cf85771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_72187e0b-c247-4898-881b-cd6e81b0509b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_AssetsCurrent_72187e0b-c247-4898-881b-cd6e81b0509b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0125507-805b-4a5b-a5cf-c2672b486095" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0125507-805b-4a5b-a5cf-c2672b486095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2febd7c-6646-4c07-afeb-f3dacde71f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2febd7c-6646-4c07-afeb-f3dacde71f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryAndOtherNonCurrent_03fe08d7-aef6-4282-a378-fefa651b504f" xlink:href="vnda-20201231.xsd#vnda_InventoryAndOtherNonCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_vnda_InventoryAndOtherNonCurrent_03fe08d7-aef6-4282-a378-fefa651b504f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f99435ed-2b35-4565-94d3-2ade2a0b1310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f99435ed-2b35-4565-94d3-2ade2a0b1310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b1c354bd-eb83-49ab-b2c7-bd84d5303d44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd0ce91c-c695-488f-8247-4354228c7060" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b1c354bd-eb83-49ab-b2c7-bd84d5303d44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1640d5a8-f544-4d88-bcbc-5ba81910a309" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_af93e3cf-46c2-4890-afa4-ce5d6b205841" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1640d5a8-f544-4d88-bcbc-5ba81910a309" xlink:to="loc_us-gaap_OperatingIncomeLoss_af93e3cf-46c2-4890-afa4-ce5d6b205841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_8dfb20c4-27dc-43f7-a21d-d77b26989b77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1640d5a8-f544-4d88-bcbc-5ba81910a309" xlink:to="loc_us-gaap_OtherIncome_8dfb20c4-27dc-43f7-a21d-d77b26989b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8c86b734-3a34-4ebd-9102-5f21931cf191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0cae88d1-711a-4073-92e0-1a689278af5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_8c86b734-3a34-4ebd-9102-5f21931cf191" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0cae88d1-711a-4073-92e0-1a689278af5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1d93f9fe-3e1d-4b9b-8100-02d3025aa05a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1d93f9fe-3e1d-4b9b-8100-02d3025aa05a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b243259f-63cc-48da-a0bb-5787fbde468e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b243259f-63cc-48da-a0bb-5787fbde468e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ef1bb7af-16cd-4d19-8848-8755c5cd94da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ef1bb7af-16cd-4d19-8848-8755c5cd94da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ebf9e8c1-cdd2-474b-9eab-30dbbbfc6a24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4ffda812-402a-4eab-92e1-2d647c4c9745" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ebf9e8c1-cdd2-474b-9eab-30dbbbfc6a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a98d86a1-d937-472f-90ea-c9544c4c02bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_449e1f37-9523-4e01-b918-40134a92f225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a98d86a1-d937-472f-90ea-c9544c4c02bf" xlink:to="loc_us-gaap_Revenues_449e1f37-9523-4e01-b918-40134a92f225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_afb8334b-1078-4961-afec-4579dda96467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a98d86a1-d937-472f-90ea-c9544c4c02bf" xlink:to="loc_us-gaap_CostsAndExpenses_afb8334b-1078-4961-afec-4579dda96467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7d53d68-6000-4476-8ac3-a7a654531244" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d999c57a-faad-495e-9bbe-669cbdedf91f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c7d53d68-6000-4476-8ac3-a7a654531244" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d999c57a-faad-495e-9bbe-669cbdedf91f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_04d8084a-d352-464d-9262-5b188a8e0cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c7d53d68-6000-4476-8ac3-a7a654531244" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_04d8084a-d352-464d-9262-5b188a8e0cf4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_17fae01f-59fe-4127-84f9-6297ae0c32b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_b9b72068-52d9-414a-9cf0-f46f2722fb3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_17fae01f-59fe-4127-84f9-6297ae0c32b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_b9b72068-52d9-414a-9cf0-f46f2722fb3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_92d0f98b-53b9-4d80-8789-a58b8b1e1810" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_17fae01f-59fe-4127-84f9-6297ae0c32b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_92d0f98b-53b9-4d80-8789-a58b8b1e1810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3f892dbd-c891-441a-bcaa-534b9203c82b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_17fae01f-59fe-4127-84f9-6297ae0c32b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_3f892dbd-c891-441a-bcaa-534b9203c82b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ad5dcf7-bc12-4936-9586-46a2a6e91ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d417c7b-83a2-4a70-899c-33b3ce5bb388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ad5dcf7-bc12-4936-9586-46a2a6e91ee1" xlink:to="loc_us-gaap_NetIncomeLoss_3d417c7b-83a2-4a70-899c-33b3ce5bb388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_973a7097-6901-481d-93bf-f11e1a2bc2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ad5dcf7-bc12-4936-9586-46a2a6e91ee1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_973a7097-6901-481d-93bf-f11e1a2bc2f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff31ea33-7d6f-4792-94e4-9a96897ff439" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2289278e-0d78-4556-95a4-df07d8d8439d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff31ea33-7d6f-4792-94e4-9a96897ff439" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2289278e-0d78-4556-95a4-df07d8d8439d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3f22405f-2cab-4f33-8674-2995acc9cd00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff31ea33-7d6f-4792-94e4-9a96897ff439" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3f22405f-2cab-4f33-8674-2995acc9cd00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_227bf70d-545e-457c-83c0-bd0d08cea012" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_227bf70d-545e-457c-83c0-bd0d08cea012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d83f6831-efe9-4199-9688-a8780631b0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d83f6831-efe9-4199-9688-a8780631b0fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b89f1215-ad0c-4f7b-a60f-1e005fe87397" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b89f1215-ad0c-4f7b-a60f-1e005fe87397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8a35ac99-caa6-41f2-a7bb-dbf79128f8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7b1a7f5-cf31-4914-9f29-82238b6429aa" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8a35ac99-caa6-41f2-a7bb-dbf79128f8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa00c59b-c7a1-4512-9872-7a9356e00b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa00c59b-c7a1-4512-9872-7a9356e00b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60ba9ef4-b14d-4abb-a9df-6c78b7a3d17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60ba9ef4-b14d-4abb-a9df-6c78b7a3d17b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c99043c-9d83-4015-91e3-eaa53d3d606d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c99043c-9d83-4015-91e3-eaa53d3d606d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8c2e30c-7fef-48fb-bf81-1a6aea4236ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1ebfb70-b436-4e08-9187-550002e4d21c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8c2e30c-7fef-48fb-bf81-1a6aea4236ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7dc0d51-d896-42eb-8294-c2c3af9dfe9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_NetIncomeLoss_c7dc0d51-d896-42eb-8294-c2c3af9dfe9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0b6e6f19-18de-42e8-9917-092484d5c95b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_Depreciation_0b6e6f19-18de-42e8-9917-092484d5c95b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9ed8a2d6-9c8b-4fee-9ba7-2bf4b88010fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_ShareBasedCompensation_9ed8a2d6-9c8b-4fee-9ba7-2bf4b88010fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_854e01ec-e237-416b-a854-323c246bf8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_854e01ec-e237-416b-a854-323c246bf8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e05fd818-b532-4693-8c7a-0d564b9aca62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e05fd818-b532-4693-8c7a-0d564b9aca62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_50fce6cf-5c21-4ccb-844e-5692013757d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_50fce6cf-5c21-4ccb-844e-5692013757d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_05573bc7-206f-4e55-b617-c38c6d9a6939" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_05573bc7-206f-4e55-b617-c38c6d9a6939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6fc72b2d-dc8d-4669-a08f-072221066e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6fc72b2d-dc8d-4669-a08f-072221066e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_52166816-28df-499e-b3bf-c02a2078e8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_52166816-28df-499e-b3bf-c02a2078e8a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9ac110ad-714d-43f1-8a4f-50d4e5820e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9ac110ad-714d-43f1-8a4f-50d4e5820e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bbb42608-d05b-43d3-b4cb-fcbee415077e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bbb42608-d05b-43d3-b4cb-fcbee415077e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances_9917b398-e6f0-492f-8e19-ec10b5120db6" xlink:href="vnda-20201231.xsd#vnda_IncreaseDecreaseProductRevenueAllowances"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_vnda_IncreaseDecreaseProductRevenueAllowances_9917b398-e6f0-492f-8e19-ec10b5120db6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_eacec850-2a7c-4e0a-a94b-7f184f5e1aca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_408d3ca7-6b8a-442f-a7de-1b8c881c3973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_eacec850-2a7c-4e0a-a94b-7f184f5e1aca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation" xlink:type="simple" xlink:href="vnda-20201231.xsd#BusinessOrganizationandPresentation"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#BusinessOrganizationandPresentationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce757eff-ea87-4930-915c-37ae50de7178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b1901a8-7838-488b-b0ba-1d3cbe0fef3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce757eff-ea87-4930-915c-37ae50de7178" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b1901a8-7838-488b-b0ba-1d3cbe0fef3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_2673ed33-dc60-4ede-9fae-cf62f56b33d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce757eff-ea87-4930-915c-37ae50de7178" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_2673ed33-dc60-4ede-9fae-cf62f56b33d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_236e9e9e-d906-45ca-b254-bfa98b428f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c09493d8-d933-4671-bdea-47a75ade17ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_236e9e9e-d906-45ca-b254-bfa98b428f8f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c09493d8-d933-4671-bdea-47a75ade17ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c8bad984-eb55-4282-a1b2-d3c4f78eeea3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_236e9e9e-d906-45ca-b254-bfa98b428f8f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c8bad984-eb55-4282-a1b2-d3c4f78eeea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9b339dad-950b-407b-b0d1-6ff3a3f2bd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_236e9e9e-d906-45ca-b254-bfa98b428f8f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9b339dad-950b-407b-b0d1-6ff3a3f2bd8b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="simple" xlink:href="vnda-20201231.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#InventoryDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_b8e8f5b6-9af0-461e-92fd-008457f26292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_74380255-cc1c-4f5d-a970-8fef398e7c9c" xlink:href="vnda-20201231.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_b8e8f5b6-9af0-461e-92fd-008457f26292" xlink:to="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_74380255-cc1c-4f5d-a970-8fef398e7c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_2dc7bbb4-f957-4217-ab69-10b9d677ea40" xlink:href="vnda-20201231.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_b8e8f5b6-9af0-461e-92fd-008457f26292" xlink:to="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_2dc7bbb4-f957-4217-ab69-10b9d677ea40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_c4bd037c-e1ba-4a6b-98f8-772ce3ad370d" xlink:href="vnda-20201231.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_b8e8f5b6-9af0-461e-92fd-008457f26292" xlink:to="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_c4bd037c-e1ba-4a6b-98f8-772ce3ad370d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_Inventory_f4c717dc-ac2b-4e36-a54b-54ca2071aa31" xlink:href="vnda-20201231.xsd#vnda_Inventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f7d5397e-0967-4a51-9eed-52d60d15a2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_Inventory_f4c717dc-ac2b-4e36-a54b-54ca2071aa31" xlink:to="loc_us-gaap_InventoryNoncurrent_f7d5397e-0967-4a51-9eed-52d60d15a2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bd15fd7a-bc34-47c5-a604-962dd07af292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_Inventory_f4c717dc-ac2b-4e36-a54b-54ca2071aa31" xlink:to="loc_us-gaap_InventoryNet_bd15fd7a-bc34-47c5-a604-962dd07af292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e0f1205f-519b-4d50-9400-68a5258a5b07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b0b1e663-fd86-4766-8237-fa81ba3753a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e0f1205f-519b-4d50-9400-68a5258a5b07" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b0b1e663-fd86-4766-8237-fa81ba3753a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_12bc63db-2019-422c-abe1-e932e1df6f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e0f1205f-519b-4d50-9400-68a5258a5b07" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_12bc63db-2019-422c-abe1-e932e1df6f9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentPropertyandEquipmentatCostDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1c220cfc-3c59-4a2b-8fc0-337650b77a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_658aed92-b1fb-43bb-8d9c-6f061a2a696f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1c220cfc-3c59-4a2b-8fc0-337650b77a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_658aed92-b1fb-43bb-8d9c-6f061a2a696f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1e0c0964-b7c5-4afc-a715-ebf637975e11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1c220cfc-3c59-4a2b-8fc0-337650b77a09" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1e0c0964-b7c5-4afc-a715-ebf637975e11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="simple" xlink:href="vnda-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0d7cc72d-1f75-4a87-86df-bdf88b16d55c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d68ddbe-7e60-477d-8d05-209bfb62a30e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0d7cc72d-1f75-4a87-86df-bdf88b16d55c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d68ddbe-7e60-477d-8d05-209bfb62a30e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adca047f-00e3-4dfc-b228-ba8f01dac334" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0d7cc72d-1f75-4a87-86df-bdf88b16d55c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adca047f-00e3-4dfc-b228-ba8f01dac334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e668ea7-5d0d-4f05-a949-34881721911d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_68286df1-5de2-4484-b640-52980ebd6116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e668ea7-5d0d-4f05-a949-34881721911d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_68286df1-5de2-4484-b640-52980ebd6116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1df85ce2-3d7c-4be1-a26e-13437f7f29d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e668ea7-5d0d-4f05-a949-34881721911d" xlink:to="loc_us-gaap_OperatingLeaseLiability_1df85ce2-3d7c-4be1-a26e-13437f7f29d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_649aa8e4-285a-4758-8a3c-c2c9182f3b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_649aa8e4-285a-4758-8a3c-c2c9182f3b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5e182a04-1541-434f-b14d-b75ce3073372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5e182a04-1541-434f-b14d-b75ce3073372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9027849d-50d4-4bd3-898e-78159d85b7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9027849d-50d4-4bd3-898e-78159d85b7ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7a906a46-e7cb-46c7-879c-5beace8e8f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7a906a46-e7cb-46c7-879c-5beace8e8f6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_06bf68f7-e19c-4d38-bbc7-d6290af37ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_06bf68f7-e19c-4d38-bbc7-d6290af37ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a7be60af-9863-4dbf-af8a-dd8b79225dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3576e7da-0fd0-4c7b-be3e-271a6bec8ab5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a7be60af-9863-4dbf-af8a-dd8b79225dcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsHETLIOZAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsFanaptAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofIntangibleAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b04f6602-107c-412c-a566-dbcce3764b42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_71e96c1d-bc21-4f59-9c56-c8c22a55e006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b04f6602-107c-412c-a566-dbcce3764b42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_71e96c1d-bc21-4f59-9c56-c8c22a55e006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_47cf6dee-6f4c-4934-acbd-19b75b0e1238" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b04f6602-107c-412c-a566-dbcce3764b42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_47cf6dee-6f4c-4934-acbd-19b75b0e1238" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofAmortizationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41ee0114-430c-4bf3-a9df-ab92a41e928b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41ee0114-430c-4bf3-a9df-ab92a41e928b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5b775648-82ee-4860-bbcc-b0fff434e640" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5b775648-82ee-4860-bbcc-b0fff434e640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5b9c41a8-ad01-4c5d-9fa0-db9d0b02a04b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5b9c41a8-ad01-4c5d-9fa0-db9d0b02a04b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e41d2669-da31-4f9a-a614-c83b38442838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e41d2669-da31-4f9a-a614-c83b38442838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ee910dee-0fe7-458a-b2ab-cd95b32fafd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ee910dee-0fe7-458a-b2ab-cd95b32fafd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9cd73295-e095-4384-96f2-6530436c4129" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6adb6924-c38d-408f-a38d-09912566fb45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9cd73295-e095-4384-96f2-6530436c4129" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_799405a9-f47f-45f9-9446-fcdc29ae539a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_799405a9-f47f-45f9-9446-fcdc29ae539a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e96c6ed2-eb65-44a7-9821-f05e8dbf7328" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e96c6ed2-eb65-44a7-9821-f05e8dbf7328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3590e84c-5952-452b-81bb-a3d90df1f964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3590e84c-5952-452b-81bb-a3d90df1f964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense_78b90a7e-b56c-45e1-9a68-e20f7e3a6df6" xlink:href="vnda-20201231.xsd#vnda_AccruedResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_vnda_AccruedResearchAndDevelopmentExpense_78b90a7e-b56c-45e1-9a68-e20f7e3a6df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_6268f6e0-ecb8-48a3-ad02-97231601dd57" xlink:href="vnda-20201231.xsd#vnda_AccruedMilestoneObligationsUnderLicenseAgreements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_6268f6e0-ecb8-48a3-ad02-97231601dd57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3608e49e-ab59-41af-819d-36856b57f2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3608e49e-ab59-41af-819d-36856b57f2bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_df928db9-a94f-42ba-9d3e-ebf0903c57e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_713bfc90-245d-4af2-ba2f-4e84e6d0ba3a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_df928db9-a94f-42ba-9d3e-ebf0903c57e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesHETLIOZAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesFanaptAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesTradipitantAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesVQW765AdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesPurchaseCommitmentsDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock" xlink:type="simple" xlink:href="vnda-20201231.xsd#PublicOfferingofCommonStock"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#PublicOfferingofCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99ae7b6d-8e4a-4b19-9d7b-f0276c607128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_42056bec-2150-4cce-b065-ffd09103d6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99ae7b6d-8e4a-4b19-9d7b-f0276c607128" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_42056bec-2150-4cce-b065-ffd09103d6d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2feafebf-2886-446e-9d6e-ed8b28383f99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99ae7b6d-8e4a-4b19-9d7b-f0276c607128" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2feafebf-2886-446e-9d6e-ed8b28383f99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationRSUAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationSummaryofOptionActivityDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationSummaryofRSUActivityPlanDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="vnda-20201231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#EmployeeBenefitPlanDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_56cc973d-31b7-498e-a0c2-3083f8eb03ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e4d10afd-f6f6-4c8f-a914-d31ed01ff00e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_56cc973d-31b7-498e-a0c2-3083f8eb03ae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e4d10afd-f6f6-4c8f-a914-d31ed01ff00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_43cecfcc-8e3d-4c81-a057-9d8ff74cda0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_56cc973d-31b7-498e-a0c2-3083f8eb03ae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_43cecfcc-8e3d-4c81-a057-9d8ff74cda0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a65b3f27-8c1d-4912-acad-1e5ba3577fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a65b3f27-8c1d-4912-acad-1e5ba3577fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_268e75d8-f6c7-4d07-9393-01db8255d993" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_268e75d8-f6c7-4d07-9393-01db8255d993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_44cc695f-ae7f-4c1b-9f37-28ece14866b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_44cc695f-ae7f-4c1b-9f37-28ece14866b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9a87a778-b8b2-4b8b-88ba-03beb7e8fbe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9a87a778-b8b2-4b8b-88ba-03beb7e8fbe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc72acce-cd11-490e-93a5-caea2642010d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc72acce-cd11-490e-93a5-caea2642010d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_26a46b29-24a5-4c40-b7e9-5b973ee3e12f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4a7cbc81-802a-4a4a-b5b9-010848739613" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_26a46b29-24a5-4c40-b7e9-5b973ee3e12f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a9a0048f-0f05-45e1-9db9-0d32436d7d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a9a0048f-0f05-45e1-9db9-0d32436d7d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9aadf1b3-dde1-4bfb-93ae-e0ab5f8d9c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9aadf1b3-dde1-4bfb-93ae-e0ab5f8d9c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bdd25422-4687-4d98-8e49-c116cd7dd923" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bdd25422-4687-4d98-8e49-c116cd7dd923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_97dbc9d3-0148-423b-b9b4-d4b2e7e8f443" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_97dbc9d3-0148-423b-b9b4-d4b2e7e8f443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_85633926-9601-494f-bbed-278ef7e4e1f4" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_85633926-9601-494f-bbed-278ef7e4e1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3a5f3bc7-ac25-47c6-9f8a-00887f2320cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3a5f3bc7-ac25-47c6-9f8a-00887f2320cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6b9b9f76-1154-4821-8180-401556bb105a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6b9b9f76-1154-4821-8180-401556bb105a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_32a31f3a-6b6f-45c9-ac4a-0b1bdab82258" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_32a31f3a-6b6f-45c9-ac4a-0b1bdab82258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_b079c08c-8c0b-42d3-a753-69a60ba96037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_b079c08c-8c0b-42d3-a753-69a60ba96037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_6bdae8c2-e562-410f-85c9-51aa8a5d2507" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_6bdae8c2-e562-410f-85c9-51aa8a5d2507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_c0465bb5-075e-4c5e-8a89-7cbc528448c8" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_acf9e086-600e-4373-9ef4-72fd89233e0f" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_c0465bb5-075e-4c5e-8a89-7cbc528448c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_48602615-0f72-4847-b546-b897c9e5d6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_30e8666a-3b37-4286-bd88-defd785b1d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_48602615-0f72-4847-b546-b897c9e5d6b5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_30e8666a-3b37-4286-bd88-defd785b1d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d6eab009-3bb1-4d5d-b681-79857c4c9f09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_48602615-0f72-4847-b546-b897c9e5d6b5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d6eab009-3bb1-4d5d-b681-79857c4c9f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_81d26a74-52dd-494e-8463-dafa3e2a4a7f" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_619cfd39-f812-44ec-a1d9-d391b2d7617c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_81d26a74-52dd-494e-8463-dafa3e2a4a7f" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_619cfd39-f812-44ec-a1d9-d391b2d7617c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_27900e8e-07e1-49da-9d94-5c20755a6386" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_81d26a74-52dd-494e-8463-dafa3e2a4a7f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_27900e8e-07e1-49da-9d94-5c20755a6386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ff7bc5de-a01b-44ba-888c-05cf7b56d2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_e2398a3d-145e-4d0d-9c9e-cfe459f7e867" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ff7bc5de-a01b-44ba-888c-05cf7b56d2fe" xlink:to="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_e2398a3d-145e-4d0d-9c9e-cfe459f7e867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d4ae02de-b365-4bc1-9876-5d42dd3c13ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ff7bc5de-a01b-44ba-888c-05cf7b56d2fe" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d4ae02de-b365-4bc1-9876-5d42dd3c13ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_66c54dbe-2569-4140-a3e4-7df6bba4b834" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_66c54dbe-2569-4140-a3e4-7df6bba4b834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_07b7db27-53e4-4f10-9fb9-cc663cf7776b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_07b7db27-53e4-4f10-9fb9-cc663cf7776b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8338a875-352d-49cd-a743-5a54f3625850" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8338a875-352d-49cd-a743-5a54f3625850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_4bb0e15e-c8a9-4505-95f0-6e4aa049374b" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_4bb0e15e-c8a9-4505-95f0-6e4aa049374b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_b4dba7ea-7afc-4056-a8cd-de3110d66519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_b4dba7ea-7afc-4056-a8cd-de3110d66519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_78d198ed-d603-4e88-9d3f-1c372d135e98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d244053-a19c-4cc8-83b2-f391cc252712" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_78d198ed-d603-4e88-9d3f-1c372d135e98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShare" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShare"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShareTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShareDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73badef0-3b9f-4e9c-af78-16c974c7f8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c4a40d76-89bd-43c6-a0e3-a1a1eb4bf575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73badef0-3b9f-4e9c-af78-16c974c7f8c2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c4a40d76-89bd-43c6-a0e3-a1a1eb4bf575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9a2b193c-5fb0-4757-b230-7eddca262149" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73badef0-3b9f-4e9c-af78-16c974c7f8c2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9a2b193c-5fb0-4757-b230-7eddca262149" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="simple" xlink:href="vnda-20201231.xsd#LegalMatters"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnauditedDetail"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>vnda-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d614c307-4118-4611-a8d3-3c89a1b9f878,g:1f7774dc-f1ff-4a69-952a-c8825acf6b9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended" id="ib4ede528d60d4bb89970d030ed8f392e_CoverPage"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i4f87769424bd434aab66b5aa8e6c9428_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="iddc91895b810465ba8b5c1fb39bfe6f0_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ib63a69de64064340bd0dad02f23cc60a_CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended" id="i6109440ab2164ccda2cdb1c75694e465_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="id2383ebf9ed847f99ff7f0cd8c28c78f_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f071f6b2-5a0b-4a3c-9449-f29ce26cab62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f071f6b2-5a0b-4a3c-9449-f29ce26cab62" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_70a634e5-a7f6-4e90-bcb4-db5b45cbe6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_70a634e5-a7f6-4e90-bcb4-db5b45cbe6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13884249-5e55-489c-8c16-d72bfbfeb95f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockholdersEquity_13884249-5e55-489c-8c16-d72bfbfeb95f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0317627-7142-4a88-b93c-8ee42752acb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0317627-7142-4a88-b93c-8ee42752acb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11091a17-2b32-4576-ae51-e3662fd00431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11091a17-2b32-4576-ae51-e3662fd00431" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c1ba5769-d09b-42e6-a455-c3669ca3c7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c1ba5769-d09b-42e6-a455-c3669ca3c7a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d9fc66a5-5715-468f-8ca8-d92ab6d2ae78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d9fc66a5-5715-468f-8ca8-d92ab6d2ae78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5aa3df7-66cb-4d09-b50a-958c63255860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5aa3df7-66cb-4d09-b50a-958c63255860" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a88238ea-555f-4516-8c54-c34d728d5f45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_NetIncomeLoss_a88238ea-555f-4516-8c54-c34d728d5f45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1eeba536-ce32-42c4-81a7-ea83b3a40b92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1eeba536-ce32-42c4-81a7-ea83b3a40b92" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d2a075b9-32c0-45c8-a3ed-d5e81485fd71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fdf48c63-9d27-4419-937e-c892b24f8e83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b25a8972-1419-4640-ac6c-50ac8f13d354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f071f6b2-5a0b-4a3c-9449-f29ce26cab62" xlink:to="loc_us-gaap_StatementTable_b25a8972-1419-4640-ac6c-50ac8f13d354" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ecf6f8e9-d6ba-4317-9fab-77249816126a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b25a8972-1419-4640-ac6c-50ac8f13d354" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ecf6f8e9-d6ba-4317-9fab-77249816126a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ecf6f8e9-d6ba-4317-9fab-77249816126a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ecf6f8e9-d6ba-4317-9fab-77249816126a" xlink:to="loc_us-gaap_EquityComponentDomain_ecf6f8e9-d6ba-4317-9fab-77249816126a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ecf6f8e9-d6ba-4317-9fab-77249816126a" xlink:to="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f1c14b57-d9cc-4033-9fe4-5143148eb256" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:to="loc_us-gaap_CommonStockMember_f1c14b57-d9cc-4033-9fe4-5143148eb256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_de9ccefd-f217-46c8-ad46-2af2139a2996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_de9ccefd-f217-46c8-ad46-2af2139a2996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30c5433c-eca5-406f-ab4f-e45ce5cbdb93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30c5433c-eca5-406f-ab4f-e45ce5cbdb93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7a85fedf-dd83-4903-97be-ac5183297e98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:to="loc_us-gaap_RetainedEarningsMember_7a85fedf-dd83-4903-97be-ac5183297e98" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i3fb99ee87179420aa43438ce28fc6951_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation" xlink:type="simple" xlink:href="vnda-20201231.xsd#BusinessOrganizationandPresentation"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation" xlink:type="extended" id="i7a980b6bd4b243c48fb7bb2fc8e2341a_BusinessOrganizationandPresentation"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#BusinessOrganizationandPresentationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail" xlink:type="extended" id="i33448c859b714b419cce0faa29b1a677_BusinessOrganizationandPresentationDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ie199e4be17724b0483b682b96f957bfc_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="if45c567cf4734106831ff1ae9333b569_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i4604370c2027495aae41989d881a5f6f_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i24e64368f43340bf88cbbe61e66c2347_SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2758726b-328e-418e-a141-0efa4cd31f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2758726b-328e-418e-a141-0efa4cd31f7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c9c53631-ed9a-473d-8af6-7f3e14970b44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c9c53631-ed9a-473d-8af6-7f3e14970b44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_8cc17f34-8fa4-4467-a4c4-fc06f9d3855d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c9c53631-ed9a-473d-8af6-7f3e14970b44" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_8cc17f34-8fa4-4467-a4c4-fc06f9d3855d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d4aba0c-7c64-4922-933b-03bde03550b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d4aba0c-7c64-4922-933b-03bde03550b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e836091-1e7f-4b5b-8b95-976fd4df74da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e836091-1e7f-4b5b-8b95-976fd4df74da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c506ac4-39f2-453a-905f-5e133f2691c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e836091-1e7f-4b5b-8b95-976fd4df74da" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c506ac4-39f2-453a-905f-5e133f2691c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6c506ac4-39f2-453a-905f-5e133f2691c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c506ac4-39f2-453a-905f-5e133f2691c1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6c506ac4-39f2-453a-905f-5e133f2691c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b8986265-5f1f-40a7-97b1-c4350f8bf4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c506ac4-39f2-453a-905f-5e133f2691c1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b8986265-5f1f-40a7-97b1-c4350f8bf4ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2bbecc0a-7512-453d-bf0c-0fd4a23c041f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8986265-5f1f-40a7-97b1-c4350f8bf4ac" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2bbecc0a-7512-453d-bf0c-0fd4a23c041f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_NoncurrentInventoryAndOtherMember_70bf4b01-f527-4e56-9c39-a329f2234885" xlink:href="vnda-20201231.xsd#vnda_NoncurrentInventoryAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8986265-5f1f-40a7-97b1-c4350f8bf4ac" xlink:to="loc_vnda_NoncurrentInventoryAndOtherMember_70bf4b01-f527-4e56-9c39-a329f2234885" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" xlink:type="extended" id="ic5af223d2b704532bb328500db99cbcb_SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c390d1a8-217f-43e4-9793-94b5abd51d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_374b5e92-eea9-456c-970c-232acacba650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c390d1a8-217f-43e4-9793-94b5abd51d4f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_374b5e92-eea9-456c-970c-232acacba650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1721921a-1e80-49e8-8af7-9b6039d24c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c390d1a8-217f-43e4-9793-94b5abd51d4f" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1721921a-1e80-49e8-8af7-9b6039d24c6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a154a8f7-204e-4612-bc87-8ddd593981f8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1721921a-1e80-49e8-8af7-9b6039d24c6e" xlink:to="loc_srt_ProductOrServiceAxis_a154a8f7-204e-4612-bc87-8ddd593981f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a154a8f7-204e-4612-bc87-8ddd593981f8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a154a8f7-204e-4612-bc87-8ddd593981f8" xlink:to="loc_srt_ProductsAndServicesDomain_a154a8f7-204e-4612-bc87-8ddd593981f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c207d623-9fb0-44bb-a465-69d51a3feaa5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a154a8f7-204e-4612-bc87-8ddd593981f8" xlink:to="loc_srt_ProductsAndServicesDomain_c207d623-9fb0-44bb-a465-69d51a3feaa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_08c710c4-44c1-4d1f-8f40-7b551065d202" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c207d623-9fb0-44bb-a465-69d51a3feaa5" xlink:to="loc_vnda_HetliozMember_08c710c4-44c1-4d1f-8f40-7b551065d202" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptMember_879ce115-8644-4828-a149-ed86264a60ea" xlink:href="vnda-20201231.xsd#vnda_FanaptMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c207d623-9fb0-44bb-a465-69d51a3feaa5" xlink:to="loc_vnda_FanaptMember_879ce115-8644-4828-a149-ed86264a60ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" xlink:type="extended" id="ic55eb1f4dc00427d8ed4dab3b1874d8e_SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a522b715-c5bc-4b02-9ae9-a62dc1ebbccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_79696a80-23ca-4401-88f6-308353c54c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a522b715-c5bc-4b02-9ae9-a62dc1ebbccf" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_79696a80-23ca-4401-88f6-308353c54c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a522b715-c5bc-4b02-9ae9-a62dc1ebbccf" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f7fe25b6-21ab-4904-a5ef-c97936b3a29c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f7fe25b6-21ab-4904-a5ef-c97936b3a29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f7fe25b6-21ab-4904-a5ef-c97936b3a29c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f7fe25b6-21ab-4904-a5ef-c97936b3a29c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f7fe25b6-21ab-4904-a5ef-c97936b3a29c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_015100e4-7b20-4e0d-86ea-e06e3237794d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f7fe25b6-21ab-4904-a5ef-c97936b3a29c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_015100e4-7b20-4e0d-86ea-e06e3237794d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8998c314-1164-4ef0-97ed-24908907347d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_015100e4-7b20-4e0d-86ea-e06e3237794d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8998c314-1164-4ef0-97ed-24908907347d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_997f76e7-8b74-40b2-87a6-bb5d3fccf53c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_997f76e7-8b74-40b2-87a6-bb5d3fccf53c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_997f76e7-8b74-40b2-87a6-bb5d3fccf53c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_997f76e7-8b74-40b2-87a6-bb5d3fccf53c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_997f76e7-8b74-40b2-87a6-bb5d3fccf53c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e3275f4-63e7-41b5-be43-f0da3bd718aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_997f76e7-8b74-40b2-87a6-bb5d3fccf53c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e3275f4-63e7-41b5-be43-f0da3bd718aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_bc385ce9-1683-439a-b04a-52ffe5e941a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e3275f4-63e7-41b5-be43-f0da3bd718aa" xlink:to="loc_us-gaap_SalesRevenueNetMember_bc385ce9-1683-439a-b04a-52ffe5e941a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9136337f-3d11-4820-aa70-dab04547aaa5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:to="loc_srt_MajorCustomersAxis_9136337f-3d11-4820-aa70-dab04547aaa5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9136337f-3d11-4820-aa70-dab04547aaa5_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9136337f-3d11-4820-aa70-dab04547aaa5" xlink:to="loc_srt_NameOfMajorCustomerDomain_9136337f-3d11-4820-aa70-dab04547aaa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9136337f-3d11-4820-aa70-dab04547aaa5" xlink:to="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerOneMember_40f986c8-8964-4c07-8761-ef2d010c559d" xlink:href="vnda-20201231.xsd#vnda_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerOneMember_40f986c8-8964-4c07-8761-ef2d010c559d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerTwoMember_83381fca-2a31-46a6-9df1-4620b14dde30" xlink:href="vnda-20201231.xsd#vnda_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerTwoMember_83381fca-2a31-46a6-9df1-4620b14dde30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerThreeMember_73e3528b-6542-472d-8fee-470ab6ae894e" xlink:href="vnda-20201231.xsd#vnda_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerThreeMember_73e3528b-6542-472d-8fee-470ab6ae894e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFiveMember_16bc6bfa-3620-465d-81fe-3ec74c3653b5" xlink:href="vnda-20201231.xsd#vnda_CustomerFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerFiveMember_16bc6bfa-3620-465d-81fe-3ec74c3653b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFourMember_2d931154-1fb6-4da2-a5bd-1f305c781f9b" xlink:href="vnda-20201231.xsd#vnda_CustomerFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerFourMember_2d931154-1fb6-4da2-a5bd-1f305c781f9b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" xlink:type="extended" id="i47eebd1840e94f6fb59dcb0cfa5f06a6_SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_814fe02b-3ca4-42e8-b6d3-0e47a022ee46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e0d10e86-0763-427c-8e16-cb27c6bd57d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_814fe02b-3ca4-42e8-b6d3-0e47a022ee46" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e0d10e86-0763-427c-8e16-cb27c6bd57d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_814fe02b-3ca4-42e8-b6d3-0e47a022ee46" xlink:to="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f2c2b4eb-66c1-4118-af67-263c2f72217d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f2c2b4eb-66c1-4118-af67-263c2f72217d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f2c2b4eb-66c1-4118-af67-263c2f72217d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f2c2b4eb-66c1-4118-af67-263c2f72217d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f2c2b4eb-66c1-4118-af67-263c2f72217d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a6032a1-c6eb-4c16-9bbe-4b7a563cdbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f2c2b4eb-66c1-4118-af67-263c2f72217d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a6032a1-c6eb-4c16-9bbe-4b7a563cdbb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_5baafc26-dcd2-42aa-8691-7d8f4d2ea4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5a6032a1-c6eb-4c16-9bbe-4b7a563cdbb0" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_5baafc26-dcd2-42aa-8691-7d8f4d2ea4c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f4ea2d40-31f4-41ed-939d-7584bffa7910" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f4ea2d40-31f4-41ed-939d-7584bffa7910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_79c8964e-ae0b-4cc2-a85f-83aed0bb5929" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f4ea2d40-31f4-41ed-939d-7584bffa7910" xlink:to="loc_us-gaap_AccountsReceivableMember_79c8964e-ae0b-4cc2-a85f-83aed0bb5929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dc70a4ad-248f-45e5-989c-e871f4780aad" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:to="loc_srt_MajorCustomersAxis_dc70a4ad-248f-45e5-989c-e871f4780aad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dc70a4ad-248f-45e5-989c-e871f4780aad_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_dc70a4ad-248f-45e5-989c-e871f4780aad" xlink:to="loc_srt_NameOfMajorCustomerDomain_dc70a4ad-248f-45e5-989c-e871f4780aad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_dc70a4ad-248f-45e5-989c-e871f4780aad" xlink:to="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerOneMember_b33089d8-e426-4b98-a8ef-06d365efd561" xlink:href="vnda-20201231.xsd#vnda_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerOneMember_b33089d8-e426-4b98-a8ef-06d365efd561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerTwoMember_4871faa1-cdfe-4fe6-bbde-419d7f42b08d" xlink:href="vnda-20201231.xsd#vnda_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerTwoMember_4871faa1-cdfe-4fe6-bbde-419d7f42b08d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerThreeMember_edb2059d-5adf-4975-a87f-96a3ac75cb72" xlink:href="vnda-20201231.xsd#vnda_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerThreeMember_edb2059d-5adf-4975-a87f-96a3ac75cb72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFourMember_5d024f27-3867-440c-b519-34d84ac0189e" xlink:href="vnda-20201231.xsd#vnda_CustomerFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerFourMember_5d024f27-3867-440c-b519-34d84ac0189e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFiveMember_166eefba-a1fb-4676-8a67-d8782f4af830" xlink:href="vnda-20201231.xsd#vnda_CustomerFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerFiveMember_166eefba-a1fb-4676-8a67-d8782f4af830" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i4c6ef16157df497d8c6a77844319bb8c_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" xlink:type="extended" id="i73bbb3280ab74a5eb0097ac2051755eb_SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65fb18b-ba70-423c-8d61-b2fc3b0cb3a7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65fb18b-ba70-423c-8d61-b2fc3b0cb3a7" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8bba59c7-4084-4e5c-8cce-4585ec7e6548" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8bba59c7-4084-4e5c-8cce-4585ec7e6548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_2f21a641-b269-43ee-9a66-6b5864dc5446" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_2f21a641-b269-43ee-9a66-6b5864dc5446" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_adb171c1-face-430a-85da-9961f155fd47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_adb171c1-face-430a-85da-9961f155fd47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0ad69b5d-e702-44fc-906c-80c265fff695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_804a7b6b-8e8b-476c-ba0b-c461bdf81749" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65fb18b-ba70-423c-8d61-b2fc3b0cb3a7" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_804a7b6b-8e8b-476c-ba0b-c461bdf81749" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_941725b7-6303-4074-9dda-d950cb106333" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_804a7b6b-8e8b-476c-ba0b-c461bdf81749" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_941725b7-6303-4074-9dda-d950cb106333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_941725b7-6303-4074-9dda-d950cb106333_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_941725b7-6303-4074-9dda-d950cb106333" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_941725b7-6303-4074-9dda-d950cb106333_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_904498a6-d508-430d-9f7b-a30e920cd602" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_941725b7-6303-4074-9dda-d950cb106333" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_904498a6-d508-430d-9f7b-a30e920cd602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SECSchedule1209AllowanceProductReturnsMember_07af03ec-5cb2-4432-a007-27d4235fbb8c" xlink:href="vnda-20201231.xsd#vnda_SECSchedule1209AllowanceProductReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_904498a6-d508-430d-9f7b-a30e920cd602" xlink:to="loc_vnda_SECSchedule1209AllowanceProductReturnsMember_07af03ec-5cb2-4432-a007-27d4235fbb8c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended" id="i2cc7aa8a1c5b4f0bb9c871f98d3209ff_MarketableSecurities"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended" id="i7bcbdd538b9c4092980fd42666cb39fc_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended" id="iee7b780004bd4faca606ce6d994f976c_MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f381a9f3-f26e-4d74-9015-b309640a745e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f381a9f3-f26e-4d74-9015-b309640a745e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_158d8ea1-2c70-4fad-b1e8-e44fa2e8a9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_158d8ea1-2c70-4fad-b1e8-e44fa2e8a9e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38113a5a-2277-4332-aa27-68f7d436ff40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38113a5a-2277-4332-aa27-68f7d436ff40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3bfa18f9-8144-4a5f-84c9-d124109a533c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3bfa18f9-8144-4a5f-84c9-d124109a533c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70855e4b-951b-482f-8c84-db48333c54fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70855e4b-951b-482f-8c84-db48333c54fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_845bb818-9dc9-44a9-b4d6-d97fba629177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70855e4b-951b-482f-8c84-db48333c54fc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_845bb818-9dc9-44a9-b4d6-d97fba629177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_845bb818-9dc9-44a9-b4d6-d97fba629177_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_845bb818-9dc9-44a9-b4d6-d97fba629177" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_845bb818-9dc9-44a9-b4d6-d97fba629177_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_845bb818-9dc9-44a9-b4d6-d97fba629177" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_d12c5ea1-241f-4cfd-85b4-ef72979fa08b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_d12c5ea1-241f-4cfd-85b4-ef72979fa08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_aac3f82d-f1ed-492d-89cc-89b838ee8c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_aac3f82d-f1ed-492d-89cc-89b838ee8c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9e51fea5-651b-43f9-bbc1-2aab32f228f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9e51fea5-651b-43f9-bbc1-2aab32f228f4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended" id="ieec0f1fb71234bc1a7252541da4e70f0_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i1ebd017a4393411e919ca38182adf7b4_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="i01c9b43be2104950951f772908c901a3_FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87d03a20-5148-4af4-9f82-af9aaaa3fccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_86f8cd00-e784-4bcd-b903-dbc284310604" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87d03a20-5148-4af4-9f82-af9aaaa3fccf" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_86f8cd00-e784-4bcd-b903-dbc284310604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87d03a20-5148-4af4-9f82-af9aaaa3fccf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_68d3975f-f181-4576-9233-076768631790" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_68d3975f-f181-4576-9233-076768631790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_68d3975f-f181-4576-9233-076768631790_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_68d3975f-f181-4576-9233-076768631790" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_68d3975f-f181-4576-9233-076768631790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ebd827c9-d106-411f-a478-e8a83ae65f94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_68d3975f-f181-4576-9233-076768631790" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ebd827c9-d106-411f-a478-e8a83ae65f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f8bf4b0e-93b6-488b-a61a-0c39598374c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ebd827c9-d106-411f-a478-e8a83ae65f94" xlink:to="loc_us-gaap_CashEquivalentsMember_f8bf4b0e-93b6-488b-a61a-0c39598374c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4e0cd787-442b-4192-b728-dbf5e6603c20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4e0cd787-442b-4192-b728-dbf5e6603c20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_59aace9c-1583-44a3-8467-122117281c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_59aace9c-1583-44a3-8467-122117281c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6f26ac70-de9b-4aea-8d36-5b3ce41981fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6f26ac70-de9b-4aea-8d36-5b3ce41981fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:to="loc_us-gaap_FinancialInstrumentAxis_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_942ae51d-13be-4dd8-a98f-738078dcf199" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_942ae51d-13be-4dd8-a98f-738078dcf199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a4755f18-13db-4f2e-af91-cd67f05afe4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a4755f18-13db-4f2e-af91-cd67f05afe4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_45527486-2440-4c7b-8b03-04337d78c7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_45527486-2440-4c7b-8b03-04337d78c7fb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="simple" xlink:href="vnda-20201231.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended" id="i69791a075f16433792c3922a01bb2d97_Inventory"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended" id="i6d8e8753cc6f440fa83f26421b4c7630_InventoryTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#InventoryDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended" id="i1e0d0dca84774b44af159a8381f89fd9_InventoryDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipment" xlink:type="extended" id="ibc98401a85ab4825a7558fc36866f863_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables" xlink:type="extended" id="i9ee7ba5774aa4d49b2ec494ce37a4361_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentPropertyandEquipmentatCostDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail" xlink:type="extended" id="i8ce122c19d394a559a3cb6fc1f6c9771_PropertyandEquipmentPropertyandEquipmentatCostDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bbeec3b9-a0c3-47d8-83c4-af3b7dd8fe99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bbeec3b9-a0c3-47d8-83c4-af3b7dd8fe99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6c51adab-bcb8-4e0c-9847-37a91a2d883c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6c51adab-bcb8-4e0c-9847-37a91a2d883c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_580cc214-753c-49e5-a469-b9306d5b7c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_580cc214-753c-49e5-a469-b9306d5b7c6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7d9bb2dc-8e1e-4c9b-9a97-413c3fa332d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7d9bb2dc-8e1e-4c9b-9a97-413c3fa332d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5873558a-41ec-4305-a4a4-8efa10983e74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5873558a-41ec-4305-a4a4-8efa10983e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5873558a-41ec-4305-a4a4-8efa10983e74_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5873558a-41ec-4305-a4a4-8efa10983e74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5873558a-41ec-4305-a4a4-8efa10983e74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5873558a-41ec-4305-a4a4-8efa10983e74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ComputerHardwareAndOtherEquipmentMember_dd2cf622-c446-46e6-9d55-f489e5f536a9" xlink:href="vnda-20201231.xsd#vnda_ComputerHardwareAndOtherEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:to="loc_vnda_ComputerHardwareAndOtherEquipmentMember_dd2cf622-c446-46e6-9d55-f489e5f536a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_066168cb-6c3f-4a31-9d3f-0e4d4406723c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_066168cb-6c3f-4a31-9d3f-0e4d4406723c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a2bba3f9-0292-4434-8760-c03f9690c93b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a2bba3f9-0292-4434-8760-c03f9690c93b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:to="loc_srt_RangeAxis_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd" xlink:to="loc_srt_RangeMember_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32423274-d8b4-4a85-9d77-3e7efaa5f41b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd" xlink:to="loc_srt_RangeMember_32423274-d8b4-4a85-9d77-3e7efaa5f41b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_73bda709-7dec-4fca-a5a4-8053949ac29e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32423274-d8b4-4a85-9d77-3e7efaa5f41b" xlink:to="loc_srt_MinimumMember_73bda709-7dec-4fca-a5a4-8053949ac29e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_93453578-18d5-408f-aa5d-8e4b5e31270f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32423274-d8b4-4a85-9d77-3e7efaa5f41b" xlink:to="loc_srt_MaximumMember_93453578-18d5-408f-aa5d-8e4b5e31270f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="extended" id="i2b92c9f7af81415893d4ed009efd0beb_PropertyandEquipmentAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="simple" xlink:href="vnda-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="extended" id="i0956ede79a9241b2a755fc478b9c81fd_Leases"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="extended" id="iea639ad70dbd4f1e929518dd8eeaf5c2_LeasesTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="i22af0b32577e4601ada5ec4b4fd229d7_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1242e263-3c91-40b6-8211-928dd7b4adea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1242e263-3c91-40b6-8211-928dd7b4adea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_df4e6f55-b878-4b94-a015-17e8f2e2a25d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_df4e6f55-b878-4b94-a015-17e8f2e2a25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_169ecb38-e6df-48d3-a837-6fa6e4dd7998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_OperatingLeaseCost_169ecb38-e6df-48d3-a837-6fa6e4dd7998" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_db37cca5-d246-41ba-abac-b50ef984c894" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_ShortTermLeaseCost_db37cca5-d246-41ba-abac-b50ef984c894" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OperatingLeaseNonLeaseComponentExpense_486b420f-27e9-4013-9aa1-19bf63bccc7f" xlink:href="vnda-20201231.xsd#vnda_OperatingLeaseNonLeaseComponentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_vnda_OperatingLeaseNonLeaseComponentExpense_486b420f-27e9-4013-9aa1-19bf63bccc7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_c85e14b7-65f5-44b5-94fd-53536a27b175" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_LeaseAndRentalExpense_c85e14b7-65f5-44b5-94fd-53536a27b175" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_b2dc519c-c31a-4ed0-89c3-5eef94460081" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_OperatingLeasePayments_b2dc519c-c31a-4ed0-89c3-5eef94460081" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bcb659bb-1e95-4aad-ac66-058c0900186c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bcb659bb-1e95-4aad-ac66-058c0900186c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcb659bb-1e95-4aad-ac66-058c0900186c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcb659bb-1e95-4aad-ac66-058c0900186c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcb659bb-1e95-4aad-ac66-058c0900186c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad779e47-9a6f-447c-b6fb-a3cfdb18cc5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcb659bb-1e95-4aad-ac66-058c0900186c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad779e47-9a6f-447c-b6fb-a3cfdb18cc5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SubleaseMember_f852fc24-111e-4d69-87aa-12ac7a8def73" xlink:href="vnda-20201231.xsd#vnda_SubleaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad779e47-9a6f-447c-b6fb-a3cfdb18cc5e" xlink:to="loc_vnda_SubleaseMember_f852fc24-111e-4d69-87aa-12ac7a8def73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:to="loc_srt_StatementGeographicalAxis_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af" xlink:to="loc_srt_SegmentGeographicalDomain_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e57db53-b62b-43b8-8598-da22fbd161cf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af" xlink:to="loc_srt_SegmentGeographicalDomain_8e57db53-b62b-43b8-8598-da22fbd161cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DC_a4c2b38e-c1dd-4520-9da4-949d65a989f0" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_DC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e57db53-b62b-43b8-8598-da22fbd161cf" xlink:to="loc_stpr_DC_a4c2b38e-c1dd-4520-9da4-949d65a989f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_3c13c97f-8081-4183-bb35-5af9fd138a5a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e57db53-b62b-43b8-8598-da22fbd161cf" xlink:to="loc_country_GB_3c13c97f-8081-4183-bb35-5af9fd138a5a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="extended" id="i83e10fe1ad7444caa7f4f25dcfb5a517_LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="extended" id="i75ea3257dd0e4f3f835de16c1624d1c1_LeasesMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended" id="ied95c666adaa46a4a3a613a50f5a536e_IntangibleAssets"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended" id="i12f82dfa86bf4a88ba02b57bda38a2cb_IntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsHETLIOZAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail" xlink:type="extended" id="ib552704f96a14508a1f574ba21e2ae51_IntangibleAssetsHETLIOZAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e2028ec6-628f-49b9-b7ba-2cf1931714e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e2028ec6-628f-49b9-b7ba-2cf1931714e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CumulativeNetSalesToAchieveMilestone_f198c2f9-914f-408c-b5de-786302f20fed" xlink:href="vnda-20201231.xsd#vnda_CumulativeNetSalesToAchieveMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:to="loc_vnda_CumulativeNetSalesToAchieveMilestone_f198c2f9-914f-408c-b5de-786302f20fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_3129a0d1-b044-4df3-80c5-30ad152bc046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_3129a0d1-b044-4df3-80c5-30ad152bc046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1e71ef03-dd14-4881-b925-278a9a7817fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1e71ef03-dd14-4881-b925-278a9a7817fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_869e122e-37a5-448e-96b1-bc7d677a243f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1e71ef03-dd14-4881-b925-278a9a7817fd" xlink:to="loc_srt_ProductOrServiceAxis_869e122e-37a5-448e-96b1-bc7d677a243f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_869e122e-37a5-448e-96b1-bc7d677a243f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_869e122e-37a5-448e-96b1-bc7d677a243f" xlink:to="loc_srt_ProductsAndServicesDomain_869e122e-37a5-448e-96b1-bc7d677a243f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0779af35-2524-42b1-a161-dfc6ef5d6737" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_869e122e-37a5-448e-96b1-bc7d677a243f" xlink:to="loc_srt_ProductsAndServicesDomain_0779af35-2524-42b1-a161-dfc6ef5d6737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_5af0b4af-d5af-4f29-999e-165251311d9d" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0779af35-2524-42b1-a161-dfc6ef5d6737" xlink:to="loc_vnda_HetliozMember_5af0b4af-d5af-4f29-999e-165251311d9d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsFanaptAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended" id="if3cfcb18557c475684c41b604882c550_IntangibleAssetsFanaptAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd203736-df62-442e-904c-63ca1160ce24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b66860b3-7b80-4faa-8005-ebafbee8408c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd203736-df62-442e-904c-63ca1160ce24" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b66860b3-7b80-4faa-8005-ebafbee8408c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0ab7ba7f-5ff1-4494-977c-c2723ce2bf65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd203736-df62-442e-904c-63ca1160ce24" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0ab7ba7f-5ff1-4494-977c-c2723ce2bf65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_47ff1226-dcfb-44e8-8889-23cbd7310a19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0ab7ba7f-5ff1-4494-977c-c2723ce2bf65" xlink:to="loc_srt_ProductOrServiceAxis_47ff1226-dcfb-44e8-8889-23cbd7310a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_47ff1226-dcfb-44e8-8889-23cbd7310a19_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_47ff1226-dcfb-44e8-8889-23cbd7310a19" xlink:to="loc_srt_ProductsAndServicesDomain_47ff1226-dcfb-44e8-8889-23cbd7310a19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bba9b7a0-3b20-4b86-a36e-3e72f9598089" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_47ff1226-dcfb-44e8-8889-23cbd7310a19" xlink:to="loc_srt_ProductsAndServicesDomain_bba9b7a0-3b20-4b86-a36e-3e72f9598089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptMember_784ec0b9-5e45-4ec0-a105-24d0c5ef68db" xlink:href="vnda-20201231.xsd#vnda_FanaptMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bba9b7a0-3b20-4b86-a36e-3e72f9598089" xlink:to="loc_vnda_FanaptMember_784ec0b9-5e45-4ec0-a105-24d0c5ef68db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofIntangibleAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail" xlink:type="extended" id="i6dc8ffa6d1fa43a48e8a9a344806f852_IntangibleAssetsSummaryofIntangibleAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3337ab51-6122-4975-af5c-35f83a1c140f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3337ab51-6122-4975-af5c-35f83a1c140f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b1963cd0-a7d0-47e6-9f71-254a989f5053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b1963cd0-a7d0-47e6-9f71-254a989f5053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_90269683-e01d-46dd-a989-be2c48915e87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_90269683-e01d-46dd-a989-be2c48915e87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_20c50fdf-91fd-4225-ad4f-9426e551303c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_20c50fdf-91fd-4225-ad4f-9426e551303c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bfc72620-4903-4ac4-b7b9-52313c58243f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_20c50fdf-91fd-4225-ad4f-9426e551303c" xlink:to="loc_srt_ProductOrServiceAxis_bfc72620-4903-4ac4-b7b9-52313c58243f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bfc72620-4903-4ac4-b7b9-52313c58243f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bfc72620-4903-4ac4-b7b9-52313c58243f" xlink:to="loc_srt_ProductsAndServicesDomain_bfc72620-4903-4ac4-b7b9-52313c58243f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af7cee0e-dadd-43ce-a735-a9179b4b01a0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bfc72620-4903-4ac4-b7b9-52313c58243f" xlink:to="loc_srt_ProductsAndServicesDomain_af7cee0e-dadd-43ce-a735-a9179b4b01a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_4cacb41e-f173-482b-a0b3-273ef0dbc58b" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af7cee0e-dadd-43ce-a735-a9179b4b01a0" xlink:to="loc_vnda_HetliozMember_4cacb41e-f173-482b-a0b3-273ef0dbc58b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofAmortizationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail" xlink:type="extended" id="i44c48a1471654afe8ef2e8643a3b1d8e_IntangibleAssetsSummaryofAmortizationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b3ad6bd-1180-4453-9d24-325d1d8190a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e6a240e8-563a-4ca1-a112-252e2d379c00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b3ad6bd-1180-4453-9d24-325d1d8190a7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e6a240e8-563a-4ca1-a112-252e2d379c00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69a2adaa-e315-4573-9c07-b5c5caf82090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b3ad6bd-1180-4453-9d24-325d1d8190a7" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69a2adaa-e315-4573-9c07-b5c5caf82090" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_185fbb3c-1f4c-40d6-b826-120ca53eeef5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69a2adaa-e315-4573-9c07-b5c5caf82090" xlink:to="loc_srt_ProductOrServiceAxis_185fbb3c-1f4c-40d6-b826-120ca53eeef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_185fbb3c-1f4c-40d6-b826-120ca53eeef5_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_185fbb3c-1f4c-40d6-b826-120ca53eeef5" xlink:to="loc_srt_ProductsAndServicesDomain_185fbb3c-1f4c-40d6-b826-120ca53eeef5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b24d49e0-81d8-4e11-ae1f-eee7734a7bc1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_185fbb3c-1f4c-40d6-b826-120ca53eeef5" xlink:to="loc_srt_ProductsAndServicesDomain_b24d49e0-81d8-4e11-ae1f-eee7734a7bc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_bb1b7569-b659-462c-9b60-209f2d844bb9" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b24d49e0-81d8-4e11-ae1f-eee7734a7bc1" xlink:to="loc_vnda_HetliozMember_bb1b7569-b659-462c-9b60-209f2d844bb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" xlink:type="extended" id="ice0d42886987439896f038e4fb4279e8_IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16de6078-d07a-4bab-af89-dc9718b99d36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16de6078-d07a-4bab-af89-dc9718b99d36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c716dedf-86fa-4102-b048-583eecbe4480" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c716dedf-86fa-4102-b048-583eecbe4480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2b25a9af-f872-4f43-9830-15ff0e2e2b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2b25a9af-f872-4f43-9830-15ff0e2e2b1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_da8e7140-6774-4fa7-9cbb-7c3f972f8a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_da8e7140-6774-4fa7-9cbb-7c3f972f8a2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e29f2010-d6ed-4b65-9cfb-5ff3c304ca6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e29f2010-d6ed-4b65-9cfb-5ff3c304ca6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ba10316e-514d-46fd-93f3-4a2ee172aea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ba10316e-514d-46fd-93f3-4a2ee172aea7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29ba06d7-e219-4e15-85d3-9a1ab8f5fb70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29ba06d7-e219-4e15-85d3-9a1ab8f5fb70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9ff6f339-6519-459d-ace2-b78404b597e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9ff6f339-6519-459d-ace2-b78404b597e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_32f54d2e-8b9f-4c57-a872-d3d0593e7c74" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9ff6f339-6519-459d-ace2-b78404b597e1" xlink:to="loc_srt_ProductOrServiceAxis_32f54d2e-8b9f-4c57-a872-d3d0593e7c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32f54d2e-8b9f-4c57-a872-d3d0593e7c74_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_32f54d2e-8b9f-4c57-a872-d3d0593e7c74" xlink:to="loc_srt_ProductsAndServicesDomain_32f54d2e-8b9f-4c57-a872-d3d0593e7c74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87354475-b283-4787-ab83-92fd6e55c572" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_32f54d2e-8b9f-4c57-a872-d3d0593e7c74" xlink:to="loc_srt_ProductsAndServicesDomain_87354475-b283-4787-ab83-92fd6e55c572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_1125ee9a-47f2-46a7-bbcc-b291e35a51be" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_87354475-b283-4787-ab83-92fd6e55c572" xlink:to="loc_vnda_HetliozMember_1125ee9a-47f2-46a7-bbcc-b291e35a51be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended" id="icc2e2d3d0eb84f109800967d3a92e097_AccountsPayableandAccruedLiabilities"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended" id="i3a3221d8e3f54899b5b776c464406a24_AccountsPayableandAccruedLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended" id="i0ac8f8896bf744f790faf9eb507d7697_AccountsPayableandAccruedLiabilitiesDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies" xlink:type="extended" id="i25ea592a904b48ae8314390bb4f0dcfe_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesHETLIOZAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" xlink:type="extended" id="id38599b447ae4c60ba672e2daac9697b_CommitmentsandContingenciesHETLIOZAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_02a1b58a-d25f-4b38-8e8e-2d79cdd9504b" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:href="vnda-20201231.xsd#vnda_HetliozAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_02a1b58a-d25f-4b38-8e8e-2d79cdd9504b" xlink:to="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_88764a27-d5f7-457f-9d56-94d6bccf2dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_88764a27-d5f7-457f-9d56-94d6bccf2dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_d808e4fa-4f02-40a0-b532-1595c6111872" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_d808e4fa-4f02-40a0-b532-1595c6111872" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPeriod_9965a706-6ee3-467f-9850-537669eb05ae" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_vnda_RoyaltyPeriod_9965a706-6ee3-467f-9850-537669eb05ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_17c1ad8e-be44-4e9c-8992-ee87bd77a8bf" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPayableOnNetSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_17c1ad8e-be44-4e9c-8992-ee87bd77a8bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PercentageOfFutureSublicenseFeesPayable_e7909b7f-b999-40d4-b244-75713717b3d8" xlink:href="vnda-20201231.xsd#vnda_PercentageOfFutureSublicenseFeesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_vnda_PercentageOfFutureSublicenseFeesPayable_e7909b7f-b999-40d4-b244-75713717b3d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_f7b74f70-8a7d-44b3-9275-1c778976c150" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_02a1b58a-d25f-4b38-8e8e-2d79cdd9504b" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_f7b74f70-8a7d-44b3-9275-1c778976c150" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28e72953-5b59-4df8-aff5-7299298e241b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_f7b74f70-8a7d-44b3-9275-1c778976c150" xlink:to="loc_srt_ProductOrServiceAxis_28e72953-5b59-4df8-aff5-7299298e241b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_28e72953-5b59-4df8-aff5-7299298e241b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_28e72953-5b59-4df8-aff5-7299298e241b" xlink:to="loc_srt_ProductsAndServicesDomain_28e72953-5b59-4df8-aff5-7299298e241b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a3cdf21c-9851-45fb-a1c7-9468da4b4c3e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_28e72953-5b59-4df8-aff5-7299298e241b" xlink:to="loc_srt_ProductsAndServicesDomain_a3cdf21c-9851-45fb-a1c7-9468da4b4c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_2d1641c9-2fe3-416c-96d6-893c933dbd94" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a3cdf21c-9851-45fb-a1c7-9468da4b4c3e" xlink:to="loc_vnda_HetliozMember_2d1641c9-2fe3-416c-96d6-893c933dbd94" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesFanaptAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail" xlink:type="extended" id="i1615e2d6cf2c4ccda444bfb865d0019b_CommitmentsandContingenciesFanaptAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_253f25c8-3437-486a-84ae-e889ebee6e9e" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptAbstract_ab589aa4-8e34-499b-b1cf-70c097c6190e" xlink:href="vnda-20201231.xsd#vnda_FanaptAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_253f25c8-3437-486a-84ae-e889ebee6e9e" xlink:to="loc_vnda_FanaptAbstract_ab589aa4-8e34-499b-b1cf-70c097c6190e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_7c794e87-ea19-4096-9c2e-67075e1fa7ee" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPayableOnNetSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_FanaptAbstract_ab589aa4-8e34-499b-b1cf-70c097c6190e" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_7c794e87-ea19-4096-9c2e-67075e1fa7ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPeriod_698aa616-3943-4b10-ad8f-45902f2f1096" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_FanaptAbstract_ab589aa4-8e34-499b-b1cf-70c097c6190e" xlink:to="loc_vnda_RoyaltyPeriod_698aa616-3943-4b10-ad8f-45902f2f1096" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_253f25c8-3437-486a-84ae-e889ebee6e9e" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_20babd1b-85ce-4fd1-865d-ae1a13ef0361" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:to="loc_srt_ProductOrServiceAxis_20babd1b-85ce-4fd1-865d-ae1a13ef0361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_20babd1b-85ce-4fd1-865d-ae1a13ef0361_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_20babd1b-85ce-4fd1-865d-ae1a13ef0361" xlink:to="loc_srt_ProductsAndServicesDomain_20babd1b-85ce-4fd1-865d-ae1a13ef0361_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_281ffbe3-1bc9-463b-8aeb-344e9b829fc2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_20babd1b-85ce-4fd1-865d-ae1a13ef0361" xlink:to="loc_srt_ProductsAndServicesDomain_281ffbe3-1bc9-463b-8aeb-344e9b829fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptMember_b2418315-1ba6-45bc-bfae-36cb119fac13" xlink:href="vnda-20201231.xsd#vnda_FanaptMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_281ffbe3-1bc9-463b-8aeb-344e9b829fc2" xlink:to="loc_vnda_FanaptMember_b2418315-1ba6-45bc-bfae-36cb119fac13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StatementScenarioSecondaryAxis_e87d578e-a803-4203-8901-05862174afdb" xlink:href="vnda-20201231.xsd#vnda_StatementScenarioSecondaryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:to="loc_vnda_StatementScenarioSecondaryAxis_e87d578e-a803-4203-8901-05862174afdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StatementScenarioSecondaryDomain_e87d578e-a803-4203-8901-05862174afdb_default" xlink:href="vnda-20201231.xsd#vnda_StatementScenarioSecondaryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vnda_StatementScenarioSecondaryAxis_e87d578e-a803-4203-8901-05862174afdb" xlink:to="loc_vnda_StatementScenarioSecondaryDomain_e87d578e-a803-4203-8901-05862174afdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StatementScenarioSecondaryDomain_922bfc56-ab52-4e55-b184-439c7d15e519" xlink:href="vnda-20201231.xsd#vnda_StatementScenarioSecondaryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vnda_StatementScenarioSecondaryAxis_e87d578e-a803-4203-8901-05862174afdb" xlink:to="loc_vnda_StatementScenarioSecondaryDomain_922bfc56-ab52-4e55-b184-439c7d15e519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScenarioFourMember_7d63e654-a750-4e98-abe8-62c6284092d9" xlink:href="vnda-20201231.xsd#vnda_ScenarioFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_StatementScenarioSecondaryDomain_922bfc56-ab52-4e55-b184-439c7d15e519" xlink:to="loc_vnda_ScenarioFourMember_7d63e654-a750-4e98-abe8-62c6284092d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesTradipitantAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended" id="i4b368689f7c8438488332cf0b82b6417_CommitmentsandContingenciesTradipitantAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_dd1f5dd9-f261-4069-ab1c-cca4713456cf" xlink:href="vnda-20201231.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_dd1f5dd9-f261-4069-ab1c-cca4713456cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6ca52ad4-b374-4844-9013-7b0963753530" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:to="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6ca52ad4-b374-4844-9013-7b0963753530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_ad98d9a2-a221-40a6-afd1-e2db72823176" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_ad98d9a2-a221-40a6-afd1-e2db72823176" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_54ab18a4-519b-4247-901e-37f475d7c3cb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:to="loc_srt_StatementGeographicalAxis_54ab18a4-519b-4247-901e-37f475d7c3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_54ab18a4-519b-4247-901e-37f475d7c3cb_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_54ab18a4-519b-4247-901e-37f475d7c3cb" xlink:to="loc_srt_SegmentGeographicalDomain_54ab18a4-519b-4247-901e-37f475d7c3cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9f4bf751-4dee-42d6-a94f-68d8865197ea" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_54ab18a4-519b-4247-901e-37f475d7c3cb" xlink:to="loc_srt_SegmentGeographicalDomain_9f4bf751-4dee-42d6-a94f-68d8865197ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_98049f1f-7fe9-4c8d-822c-d4d5317cdcff" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f4bf751-4dee-42d6-a94f-68d8865197ea" xlink:to="loc_country_US_98049f1f-7fe9-4c8d-822c-d4d5317cdcff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0c14becc-0558-4e8e-9924-ba4d8813c1ca" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f4bf751-4dee-42d6-a94f-68d8865197ea" xlink:to="loc_srt_EuropeMember_0c14becc-0558-4e8e-9924-ba4d8813c1ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fbd4890c-dae8-4506-b43a-3e5223c3df22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fbd4890c-dae8-4506-b43a-3e5223c3df22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbd4890c-dae8-4506-b43a-3e5223c3df22_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fbd4890c-dae8-4506-b43a-3e5223c3df22" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbd4890c-dae8-4506-b43a-3e5223c3df22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c21fd717-0d67-4175-b43d-3eb1dd496621" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fbd4890c-dae8-4506-b43a-3e5223c3df22" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c21fd717-0d67-4175-b43d-3eb1dd496621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TradipitantMember_bba62cc1-be83-48de-aa9d-61e6a5c14404" xlink:href="vnda-20201231.xsd#vnda_TradipitantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c21fd717-0d67-4175-b43d-3eb1dd496621" xlink:to="loc_vnda_TradipitantMember_bba62cc1-be83-48de-aa9d-61e6a5c14404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1c776518-330a-493c-800b-ec68f1d1acc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1c776518-330a-493c-800b-ec68f1d1acc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1c776518-330a-493c-800b-ec68f1d1acc6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1c776518-330a-493c-800b-ec68f1d1acc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1c776518-330a-493c-800b-ec68f1d1acc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1c776518-330a-493c-800b-ec68f1d1acc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PreNDAApprovalMilestonesMember_cdbbbb6e-773d-4f2b-ad26-3272612e1294" xlink:href="vnda-20201231.xsd#vnda_PreNDAApprovalMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:to="loc_vnda_PreNDAApprovalMilestonesMember_cdbbbb6e-773d-4f2b-ad26-3272612e1294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_f05fe834-e032-46ee-9759-2a31b380ab1a" xlink:href="vnda-20201231.xsd#vnda_RegulatoryApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_f05fe834-e032-46ee-9759-2a31b380ab1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SalesMilestoneMember_13014f15-48fd-4286-b468-f779aa5010d7" xlink:href="vnda-20201231.xsd#vnda_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:to="loc_vnda_SalesMilestoneMember_13014f15-48fd-4286-b468-f779aa5010d7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" xlink:type="extended" id="ife474724a3ab4b17a5c7ceacf964f7ce_CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_6287f364-2d92-4eab-9fc1-e611e63dcc11" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:href="vnda-20201231.xsd#vnda_CftrActivatorsAndInhibitorsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_6287f364-2d92-4eab-9fc1-e611e63dcc11" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TieredRoyaltiesPayableOnFutureNetSales_3c6b54b9-5092-41df-836d-baf75d79d39c" xlink:href="vnda-20201231.xsd#vnda_TieredRoyaltiesPayableOnFutureNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:to="loc_vnda_TieredRoyaltiesPayableOnFutureNetSales_3c6b54b9-5092-41df-836d-baf75d79d39c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_df194745-9b20-486b-8048-66df463c5fe5" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:to="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_df194745-9b20-486b-8048-66df463c5fe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_befa77d6-dd78-444c-ac96-ecc06410025b" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_befa77d6-dd78-444c-ac96-ecc06410025b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_d907954e-4f9b-43af-b31f-dc02ac0a9481" xlink:href="vnda-20201231.xsd#vnda_AccruedMilestoneObligationsUnderLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:to="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_d907954e-4f9b-43af-b31f-dc02ac0a9481" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_6287f364-2d92-4eab-9fc1-e611e63dcc11" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d089bdfc-7eec-4bc6-893b-a6947d66a78e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:to="loc_srt_RangeAxis_d089bdfc-7eec-4bc6-893b-a6947d66a78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d089bdfc-7eec-4bc6-893b-a6947d66a78e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d089bdfc-7eec-4bc6-893b-a6947d66a78e" xlink:to="loc_srt_RangeMember_d089bdfc-7eec-4bc6-893b-a6947d66a78e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c675df62-b782-428c-9d50-950bbabacf0b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d089bdfc-7eec-4bc6-893b-a6947d66a78e" xlink:to="loc_srt_RangeMember_c675df62-b782-428c-9d50-950bbabacf0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_109078db-8a0d-4d01-8ee2-b77c1bbb6bef" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c675df62-b782-428c-9d50-950bbabacf0b" xlink:to="loc_srt_MaximumMember_109078db-8a0d-4d01-8ee2-b77c1bbb6bef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fac17209-f724-40b2-80a3-2a6d57e3e87b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fac17209-f724-40b2-80a3-2a6d57e3e87b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fac17209-f724-40b2-80a3-2a6d57e3e87b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fac17209-f724-40b2-80a3-2a6d57e3e87b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_fac17209-f724-40b2-80a3-2a6d57e3e87b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fac17209-f724-40b2-80a3-2a6d57e3e87b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_8d637745-b1bd-409e-a3cf-ff1685773c25" xlink:href="vnda-20201231.xsd#vnda_RegulatoryApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_8d637745-b1bd-409e-a3cf-ff1685773c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_22af3e9f-0849-466c-abc3-e8d226b1774d" xlink:href="vnda-20201231.xsd#vnda_FutureRegulatoryApprovalAndSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:to="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_22af3e9f-0849-466c-abc3-e8d226b1774d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_8306d129-6593-4533-ade5-b0332f1a2552" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_8306d129-6593-4533-ade5-b0332f1a2552" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6bc07c47-fa4d-435a-836e-0938cf015576" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:to="loc_srt_ProductOrServiceAxis_6bc07c47-fa4d-435a-836e-0938cf015576" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6bc07c47-fa4d-435a-836e-0938cf015576_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6bc07c47-fa4d-435a-836e-0938cf015576" xlink:to="loc_srt_ProductsAndServicesDomain_6bc07c47-fa4d-435a-836e-0938cf015576_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5086646-2661-4292-8d26-39d9313a9e11" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6bc07c47-fa4d-435a-836e-0938cf015576" xlink:to="loc_srt_ProductsAndServicesDomain_d5086646-2661-4292-8d26-39d9313a9e11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsMember_f8169f77-5454-49f0-bbbe-e6d1e016c2e4" xlink:href="vnda-20201231.xsd#vnda_CftrActivatorsAndInhibitorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d5086646-2661-4292-8d26-39d9313a9e11" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsMember_f8169f77-5454-49f0-bbbe-e6d1e016c2e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesVQW765AdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails" xlink:type="extended" id="ibbcd0d905ba047e89026c37594f1de1c_CommitmentsandContingenciesVQW765AdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_19f38906-815e-46f0-9918-e4dea763b706" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_13c6544a-14f0-4700-94ba-5080b66e7880" xlink:href="vnda-20201231.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_19f38906-815e-46f0-9918-e4dea763b706" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_13c6544a-14f0-4700-94ba-5080b66e7880" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_ecbd1ef0-5a89-4f24-bd0d-0d6b25f51a4a" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_19f38906-815e-46f0-9918-e4dea763b706" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_ecbd1ef0-5a89-4f24-bd0d-0d6b25f51a4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_525071d8-d806-4300-be13-7ee44b6089d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_ecbd1ef0-5a89-4f24-bd0d-0d6b25f51a4a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_525071d8-d806-4300-be13-7ee44b6089d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_525071d8-d806-4300-be13-7ee44b6089d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_525071d8-d806-4300-be13-7ee44b6089d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_525071d8-d806-4300-be13-7ee44b6089d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50ed7d3d-210b-40da-9062-ebafb5b817e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_525071d8-d806-4300-be13-7ee44b6089d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50ed7d3d-210b-40da-9062-ebafb5b817e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_VQW765Member_5d0a6a0d-5247-4a14-903a-b43c0538da1f" xlink:href="vnda-20201231.xsd#vnda_VQW765Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50ed7d3d-210b-40da-9062-ebafb5b817e6" xlink:to="loc_vnda_VQW765Member_5d0a6a0d-5247-4a14-903a-b43c0538da1f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesPurchaseCommitmentsDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail" xlink:type="extended" id="i389e7893f1d248c0986a7e9883ef83b0_CommitmentsandContingenciesPurchaseCommitmentsDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock" xlink:type="simple" xlink:href="vnda-20201231.xsd#PublicOfferingofCommonStock"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock" xlink:type="extended" id="i5c6cad9d96e7497fb03bce37a01c09e0_PublicOfferingofCommonStock"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#PublicOfferingofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails" xlink:type="extended" id="i10cc2c15169945ec9ee53076e5fb8102_PublicOfferingofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_397dff60-c794-4d4a-a22e-3d9349864fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_397dff60-c794-4d4a-a22e-3d9349864fa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_07a2b442-f915-4032-b755-4fd6b02d23f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_07a2b442-f915-4032-b755-4fd6b02d23f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d9d960f-f44d-4c1c-a2a2-0fc98ad1cc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d9d960f-f44d-4c1c-a2a2-0fc98ad1cc4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a9518d45-d38c-464f-8c9c-19f3ebf91be2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a9518d45-d38c-464f-8c9c-19f3ebf91be2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a9518d45-d38c-464f-8c9c-19f3ebf91be2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfa199b-ed89-47e4-9ca6-79b7c20bfc4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfa199b-ed89-47e4-9ca6-79b7c20bfc4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PublicOfferingMember_6bcf673b-8d86-41d4-b6da-840e8cff245b" xlink:href="vnda-20201231.xsd#vnda_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfa199b-ed89-47e4-9ca6-79b7c20bfc4b" xlink:to="loc_vnda_PublicOfferingMember_6bcf673b-8d86-41d4-b6da-840e8cff245b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_0526a821-9a85-46d2-b4c3-42c29c4fab48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfa199b-ed89-47e4-9ca6-79b7c20bfc4b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_0526a821-9a85-46d2-b4c3-42c29c4fab48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended" id="i1f4e012ede6f4b23b1dda03d25a157dc_AccumulatedOtherComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended" id="ib12fb904d79b4c218652e95948c81fe3_AccumulatedOtherComprehensiveIncomeTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" xlink:type="extended" id="i531a526fcfff4009a1e3b03806a7e768_AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended" id="i5773f931ac9d41309e56d0a9bac5f58d_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended" id="i4d982ae3d5ab47f28c7bbe68bc793fd6_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="ia8b24302759242c08d7fb311c96da7fc_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_c9c5891d-822d-4bbe-9a8a-43b208371f5c" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_c9c5891d-822d-4bbe-9a8a-43b208371f5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1ca7fa54-f90e-41b4-8534-f11d8e2026a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1ca7fa54-f90e-41b4-8534-f11d8e2026a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_96f90d72-c736-4068-8d65-986bdb7da919" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_96f90d72-c736-4068-8d65-986bdb7da919" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d88d5ba9-e584-4dfb-b633-0c3f382210a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:to="loc_us-gaap_PlanNameAxis_d88d5ba9-e584-4dfb-b633-0c3f382210a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d88d5ba9-e584-4dfb-b633-0c3f382210a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d88d5ba9-e584-4dfb-b633-0c3f382210a0" xlink:to="loc_us-gaap_PlanNameDomain_d88d5ba9-e584-4dfb-b633-0c3f382210a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_947f384c-be3e-4caa-8dae-c2f3f141c972" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d88d5ba9-e584-4dfb-b633-0c3f382210a0" xlink:to="loc_us-gaap_PlanNameDomain_947f384c-be3e-4caa-8dae-c2f3f141c972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_7104ad51-a4c5-4e66-ab55-3a55277af0b9" xlink:href="vnda-20201231.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_947f384c-be3e-4caa-8dae-c2f3f141c972" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_7104ad51-a4c5-4e66-ab55-3a55277af0b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TwoThousandSixteenPlanMember_95f895ec-0145-4c04-bc92-9a19e94825fc" xlink:href="vnda-20201231.xsd#vnda_TwoThousandSixteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_7104ad51-a4c5-4e66-ab55-3a55277af0b9" xlink:to="loc_vnda_TwoThousandSixteenPlanMember_95f895ec-0145-4c04-bc92-9a19e94825fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_57f1fc46-7949-4561-9142-020a434c7608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:to="loc_us-gaap_AwardTypeAxis_57f1fc46-7949-4561-9142-020a434c7608" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57f1fc46-7949-4561-9142-020a434c7608_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_57f1fc46-7949-4561-9142-020a434c7608" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57f1fc46-7949-4561-9142-020a434c7608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d857a15a-92a3-47c8-8c72-5eecae7e2f11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_57f1fc46-7949-4561-9142-020a434c7608" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d857a15a-92a3-47c8-8c72-5eecae7e2f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_d2f83690-b704-4d53-a3d7-3a9a6502a4dc" xlink:href="vnda-20201231.xsd#vnda_StockOptionsAndRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d857a15a-92a3-47c8-8c72-5eecae7e2f11" xlink:to="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_d2f83690-b704-4d53-a3d7-3a9a6502a4dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended" id="i342ec25fcb274defb764ab355a12bce5_StockBasedCompensationStockOptionAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_3eee5256-f8e3-43fc-b4a1-9c66d0a3f56c" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationOptionAwardsContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_3eee5256-f8e3-43fc-b4a1-9c66d0a3f56c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_667a170f-462e-4188-ba15-af1bdadebb45" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_667a170f-462e-4188-ba15-af1bdadebb45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_d442b998-2e6a-4ae3-b91d-c8741cdab6f4" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_d442b998-2e6a-4ae3-b91d-c8741cdab6f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_75343dfc-150a-4369-aff2-eb8ab6760cb7" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_75343dfc-150a-4369-aff2-eb8ab6760cb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_ca21b738-04ce-4043-88a8-1aa036edcf99" xlink:href="vnda-20201231.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_ca21b738-04ce-4043-88a8-1aa036edcf99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_3bec778f-a2f7-46e4-879d-548fb39802f5" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_3bec778f-a2f7-46e4-879d-548fb39802f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_269474ce-bb56-4c53-bfcf-39901cc15c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_269474ce-bb56-4c53-bfcf-39901cc15c9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0512fc01-61e4-4f5f-9ca3-bcc4c724876b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0512fc01-61e4-4f5f-9ca3-bcc4c724876b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e8a9e14-39cd-4485-a2f9-9837f36f4f74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e8a9e14-39cd-4485-a2f9-9837f36f4f74" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_368076cf-26de-41f5-8376-0a4175893786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_368076cf-26de-41f5-8376-0a4175893786" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72b4c628-9287-4c63-868a-94cf087a22c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72b4c628-9287-4c63-868a-94cf087a22c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6b80d527-f562-4e77-b300-676b71717ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72b4c628-9287-4c63-868a-94cf087a22c4" xlink:to="loc_us-gaap_AwardTypeAxis_6b80d527-f562-4e77-b300-676b71717ab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b80d527-f562-4e77-b300-676b71717ab7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6b80d527-f562-4e77-b300-676b71717ab7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b80d527-f562-4e77-b300-676b71717ab7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8452d39-8fe6-433d-8ee5-cab18a7f8ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6b80d527-f562-4e77-b300-676b71717ab7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8452d39-8fe6-433d-8ee5-cab18a7f8ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ServiceOptionAwardsMember_d87028fe-5615-4a7b-a623-a95d3bb2f0aa" xlink:href="vnda-20201231.xsd#vnda_ServiceOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8452d39-8fe6-433d-8ee5-cab18a7f8ce4" xlink:to="loc_vnda_ServiceOptionAwardsMember_d87028fe-5615-4a7b-a623-a95d3bb2f0aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationRSUAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail" xlink:type="extended" id="ifdd8bc94a91d493d95f4180479ce415d_StockBasedCompensationRSUAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_09b0eff0-e718-4f24-a40a-5849575d28b9" xlink:href="vnda-20201231.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_09b0eff0-e718-4f24-a40a-5849575d28b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_aab2c6f2-7a65-4cc5-9c07-5c2c7e340f4c" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_aab2c6f2-7a65-4cc5-9c07-5c2c7e340f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2210a6fe-97ce-4edd-9471-21bbb659cfcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2210a6fe-97ce-4edd-9471-21bbb659cfcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_33b66308-2d63-4c86-afc7-878896576b06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_33b66308-2d63-4c86-afc7-878896576b06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c47aabb-73fd-4b04-a606-7d47b88e452e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c47aabb-73fd-4b04-a606-7d47b88e452e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_25c57fbc-9096-4d1f-8a2b-f0231ca6bed2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_25c57fbc-9096-4d1f-8a2b-f0231ca6bed2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbb9420e-e577-4d3b-a1cf-fa5f1fe03fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbb9420e-e577-4d3b-a1cf-fa5f1fe03fc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4936b296-7682-463e-8576-f1a01029958c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbb9420e-e577-4d3b-a1cf-fa5f1fe03fc8" xlink:to="loc_us-gaap_AwardTypeAxis_4936b296-7682-463e-8576-f1a01029958c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4936b296-7682-463e-8576-f1a01029958c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4936b296-7682-463e-8576-f1a01029958c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4936b296-7682-463e-8576-f1a01029958c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dca895a1-f1a8-4679-9ab9-bdb36614d427" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4936b296-7682-463e-8576-f1a01029958c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dca895a1-f1a8-4679-9ab9-bdb36614d427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ab0dd738-1610-4845-b5e4-abfd81401174" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dca895a1-f1a8-4679-9ab9-bdb36614d427" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ab0dd738-1610-4845-b5e4-abfd81401174" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationSummaryofOptionActivityDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="extended" id="i7c7ce17e29a041749da65cb1f78b68d8_StockBasedCompensationSummaryofOptionActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5c2b558-c4fa-4d65-a5a0-26ca8d1d39c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5c2b558-c4fa-4d65-a5a0-26ca8d1d39c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7262f447-0efc-4742-810c-a2bccbbe9964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7262f447-0efc-4742-810c-a2bccbbe9964" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7501fab3-631a-42cf-946a-98b9ae31dc57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7501fab3-631a-42cf-946a-98b9ae31dc57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_678c590a-95f5-4066-80fb-6c359b14a684" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_678c590a-95f5-4066-80fb-6c359b14a684" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aac0e4ca-7a9f-4075-85cd-648177c9b1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aac0e4ca-7a9f-4075-85cd-648177c9b1f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d232b9f-92a2-46c9-916e-6e604e8f3957" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2c3cbe43-72df-45fe-8a10-e1f1c7162d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2c3cbe43-72df-45fe-8a10-e1f1c7162d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_739ce2d7-8280-4b4e-8206-de546c5b2342" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_739ce2d7-8280-4b4e-8206-de546c5b2342" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ab0499b7-58f5-43ff-9445-d4cf1e53b676" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ab0499b7-58f5-43ff-9445-d4cf1e53b676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c863c829-3a33-406a-bbdb-158a1f4ff50f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c863c829-3a33-406a-bbdb-158a1f4ff50f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_92fa8ef7-f317-4d98-ac01-a34be6b7a9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_92fa8ef7-f317-4d98-ac01-a34be6b7a9cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0b1c6d72-35c3-4cec-9e5a-8092c8d35170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0b1c6d72-35c3-4cec-9e5a-8092c8d35170" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_69d57a5e-3248-4fef-9322-bf69534a8d05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_69d57a5e-3248-4fef-9322-bf69534a8d05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5decf572-13fd-4261-8209-93048fcf935a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9a0a46f5-558b-4868-aaf0-21d41de1d37c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9a0a46f5-558b-4868-aaf0-21d41de1d37c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0fe6fd1f-5479-49cd-a62a-51d9e2528d80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0fe6fd1f-5479-49cd-a62a-51d9e2528d80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_904a9f85-37f6-48fb-a953-f96af474c713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_904a9f85-37f6-48fb-a953-f96af474c713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_afaab0f6-8dde-45f9-9446-71e0cce757d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_afaab0f6-8dde-45f9-9446-71e0cce757d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b246e2eb-8083-4b65-952e-de04ad31aef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b246e2eb-8083-4b65-952e-de04ad31aef9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_081b6169-5d75-486f-a20b-93f468baceaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_081b6169-5d75-486f-a20b-93f468baceaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_364cf032-15c5-4a6a-89f2-4bc52219fdcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_364cf032-15c5-4a6a-89f2-4bc52219fdcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_027b277a-396e-456c-8e87-9a3ddec23b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_46cf5960-4e63-4084-96cf-0e4dba85c144" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_46cf5960-4e63-4084-96cf-0e4dba85c144" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8d9a0a61-36e8-4b83-9710-31710efd75aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8d9a0a61-36e8-4b83-9710-31710efd75aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8beb7d7-e090-43cb-97ea-1f0b840be6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8beb7d7-e090-43cb-97ea-1f0b840be6bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_adeaea9e-c23e-41c2-97b5-2dfcc72e3486" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8beb7d7-e090-43cb-97ea-1f0b840be6bf" xlink:to="loc_us-gaap_PlanNameAxis_adeaea9e-c23e-41c2-97b5-2dfcc72e3486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_adeaea9e-c23e-41c2-97b5-2dfcc72e3486_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_adeaea9e-c23e-41c2-97b5-2dfcc72e3486" xlink:to="loc_us-gaap_PlanNameDomain_adeaea9e-c23e-41c2-97b5-2dfcc72e3486_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_df6282dc-772d-4760-ab2d-1084ce793bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_adeaea9e-c23e-41c2-97b5-2dfcc72e3486" xlink:to="loc_us-gaap_PlanNameDomain_df6282dc-772d-4760-ab2d-1084ce793bd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_c9a7713a-b4aa-4caf-a27e-2917e63225c0" xlink:href="vnda-20201231.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_df6282dc-772d-4760-ab2d-1084ce793bd5" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_c9a7713a-b4aa-4caf-a27e-2917e63225c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationSummaryofRSUActivityPlanDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail" xlink:type="extended" id="i12ee487d75f14790a830a7e8948bba7a_StockBasedCompensationSummaryofRSUActivityPlanDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_9bc44b2d-b70e-43f5-b0bb-b1005610fbcc" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_9bc44b2d-b70e-43f5-b0bb-b1005610fbcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6458173-60eb-4a86-979b-b924f99f8938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6458173-60eb-4a86-979b-b924f99f8938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17570e7c-90c9-4da9-b155-d4ea3bc184b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17570e7c-90c9-4da9-b155-d4ea3bc184b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bb221cdb-45d6-4c65-8b1a-071ff8509e16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bb221cdb-45d6-4c65-8b1a-071ff8509e16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86b13826-9121-484d-8099-51b97b28970c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86b13826-9121-484d-8099-51b97b28970c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7af9dfee-03f2-4cf9-a840-f5ad32f35cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_9bc44b2d-b70e-43f5-b0bb-b1005610fbcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e45ca8cd-70a8-4d3b-b0bd-8fc2da426fac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e45ca8cd-70a8-4d3b-b0bd-8fc2da426fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6b08b2b-3b04-48f8-b9e5-c97058eebbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6b08b2b-3b04-48f8-b9e5-c97058eebbd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b49d3d9e-4130-43b0-8d33-45649aa49d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b49d3d9e-4130-43b0-8d33-45649aa49d81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7cadc8f1-6ac4-4021-9b2a-d409daa7d6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7cadc8f1-6ac4-4021-9b2a-d409daa7d6cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_082effae-d495-46a0-a578-4c1f3b794c73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_22f99eea-08a1-48f4-a209-04a1b6cd595d" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_9bc44b2d-b70e-43f5-b0bb-b1005610fbcc" xlink:to="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_22f99eea-08a1-48f4-a209-04a1b6cd595d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4f0283b8-d846-4735-a267-08d106da0362" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_22f99eea-08a1-48f4-a209-04a1b6cd595d" xlink:to="loc_us-gaap_AwardTypeAxis_4f0283b8-d846-4735-a267-08d106da0362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f0283b8-d846-4735-a267-08d106da0362_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4f0283b8-d846-4735-a267-08d106da0362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f0283b8-d846-4735-a267-08d106da0362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc830ccb-2641-4f9d-8104-849c56dde73f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4f0283b8-d846-4735-a267-08d106da0362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc830ccb-2641-4f9d-8104-849c56dde73f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_189d25d3-342d-4638-a76a-ed2348d653c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc830ccb-2641-4f9d-8104-849c56dde73f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_189d25d3-342d-4638-a76a-ed2348d653c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended" id="i0d14e30980b442a781522d351216c826_StockBasedCompensationTotalStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f3b0062e-479f-4a67-8906-e09d476ba406" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b82a0876-5074-4f76-a549-a5ec4385327c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f3b0062e-479f-4a67-8906-e09d476ba406" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b82a0876-5074-4f76-a549-a5ec4385327c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c530f42-e988-41bb-911f-7236548d63d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f3b0062e-479f-4a67-8906-e09d476ba406" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c530f42-e988-41bb-911f-7236548d63d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8671adb0-98de-46e4-b14a-def264466920" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c530f42-e988-41bb-911f-7236548d63d9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8671adb0-98de-46e4-b14a-def264466920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8671adb0-98de-46e4-b14a-def264466920_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8671adb0-98de-46e4-b14a-def264466920" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8671adb0-98de-46e4-b14a-def264466920_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d57ef1bc-0c4e-4333-93c4-8efbdd31c881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8671adb0-98de-46e4-b14a-def264466920" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d57ef1bc-0c4e-4333-93c4-8efbdd31c881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65116a54-d47b-46fb-884c-121ab5800a19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d57ef1bc-0c4e-4333-93c4-8efbdd31c881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65116a54-d47b-46fb-884c-121ab5800a19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_822a544b-5a7a-487b-b9df-ac37749bc73c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d57ef1bc-0c4e-4333-93c4-8efbdd31c881" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_822a544b-5a7a-487b-b9df-ac37749bc73c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" xlink:type="extended" id="id9954827e0c94470b4eca1d1aa7edcdf_StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="vnda-20201231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" xlink:type="extended" id="id27f8f66098e439cb92ab19c391f5fb8_EmployeeBenefitPlan"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#EmployeeBenefitPlanDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" xlink:type="extended" id="if83ed209eac646448dd30f503400851e_EmployeeBenefitPlanDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended" id="i9949925d13284597a6402b2d049ab4f5_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" xlink:type="extended" id="i560570b12c304f0eb7e2da70b3c95255_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" xlink:type="extended" id="i02439c9daffb415b8e38ea6bbafd9324_IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" xlink:type="extended" id="id4f69964624e4139960e7cf41ea8fbd8_IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" xlink:type="extended" id="ie2bcedee9c2e4e7096a377e400bf1455_IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_5189b049-af02-4348-801e-a5ae82193e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_24d91548-d443-4623-a904-5aad4797e4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_5189b049-af02-4348-801e-a5ae82193e46" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_24d91548-d443-4623-a904-5aad4797e4a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_d898e303-9ac6-47d4-836b-4d7f26b4ce83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_5189b049-af02-4348-801e-a5ae82193e46" xlink:to="loc_us-gaap_ValuationAllowanceTable_d898e303-9ac6-47d4-836b-4d7f26b4ce83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ce53bf4-e947-4d08-9923-b9ad17a40844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_d898e303-9ac6-47d4-836b-4d7f26b4ce83" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ce53bf4-e947-4d08-9923-b9ad17a40844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_6ce53bf4-e947-4d08-9923-b9ad17a40844_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ce53bf4-e947-4d08-9923-b9ad17a40844" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_6ce53bf4-e947-4d08-9923-b9ad17a40844_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ce53bf4-e947-4d08-9923-b9ad17a40844" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeBeforeIncomeTaxesCurrentYearMember_9e17371c-42c4-4f64-9f37-4987d863f8d0" xlink:href="vnda-20201231.xsd#vnda_IncomeBeforeIncomeTaxesCurrentYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:to="loc_vnda_IncomeBeforeIncomeTaxesCurrentYearMember_9e17371c-42c4-4f64-9f37-4987d863f8d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember_6c69d829-0724-4991-9cb5-1f3d1cd71d38" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:to="loc_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember_6c69d829-0724-4991-9cb5-1f3d1cd71d38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EstimatedRealizabilityofDeferredTaxAssetMember_1498c03b-046d-46a5-ba0b-e9286fa4aca6" xlink:href="vnda-20201231.xsd#vnda_EstimatedRealizabilityofDeferredTaxAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:to="loc_vnda_EstimatedRealizabilityofDeferredTaxAssetMember_1498c03b-046d-46a5-ba0b-e9286fa4aca6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" xlink:type="extended" id="i80db305c3c924858baea528c35ce2356_IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" xlink:type="extended" id="ica55e4991d0d4afcbca2434746c0b819_IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="ifa3a3d591c5a425c9748e16916afbe03_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_afbcb2e4-6fe9-4343-9530-1a788fe30c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_afbcb2e4-6fe9-4343-9530-1a788fe30c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7e11d180-9d3d-4a95-af89-276741049622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7e11d180-9d3d-4a95-af89-276741049622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ba27b65f-a94f-4508-9199-86deeb46ad50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ba27b65f-a94f-4508-9199-86deeb46ad50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OperatingLossCarryforwardsBeginningExpirationYear_db09f730-ea2e-41b5-b3b5-a72e1a5e7e1e" xlink:href="vnda-20201231.xsd#vnda_OperatingLossCarryforwardsBeginningExpirationYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_vnda_OperatingLossCarryforwardsBeginningExpirationYear_db09f730-ea2e-41b5-b3b5-a72e1a5e7e1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear_276d9b48-7ad7-4c1a-8bc2-2e9a6ddca498" xlink:href="vnda-20201231.xsd#vnda_ResearchAndDevelopmentCreditBeginningExpirationYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear_276d9b48-7ad7-4c1a-8bc2-2e9a6ddca498" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OrphanDrugCreditBeginningExpirationYear_da8b6ea4-8003-4a52-bb6e-8acecad98c61" xlink:href="vnda-20201231.xsd#vnda_OrphanDrugCreditBeginningExpirationYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_vnda_OrphanDrugCreditBeginningExpirationYear_da8b6ea4-8003-4a52-bb6e-8acecad98c61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_92e288ff-5dd2-4add-8621-e176cde914fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_92e288ff-5dd2-4add-8621-e176cde914fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c6481294-fabd-49d4-b06d-b85053f4aeac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c6481294-fabd-49d4-b06d-b85053f4aeac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_95111cc2-6aad-4914-a784-97c1883af0f1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:to="loc_srt_StatementGeographicalAxis_95111cc2-6aad-4914-a784-97c1883af0f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_95111cc2-6aad-4914-a784-97c1883af0f1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_95111cc2-6aad-4914-a784-97c1883af0f1" xlink:to="loc_srt_SegmentGeographicalDomain_95111cc2-6aad-4914-a784-97c1883af0f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_24dc236f-e3d7-40bd-baec-8daa82b92706" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_95111cc2-6aad-4914-a784-97c1883af0f1" xlink:to="loc_srt_SegmentGeographicalDomain_24dc236f-e3d7-40bd-baec-8daa82b92706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DC_ddaa7ba0-7560-4759-badf-3faacad5c56e" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_DC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_24dc236f-e3d7-40bd-baec-8daa82b92706" xlink:to="loc_stpr_DC_ddaa7ba0-7560-4759-badf-3faacad5c56e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_UnitedStatesExcludingDistrictOfColumbiaMember_19d38bc6-85ad-4815-ac7b-ebe81d2c91ee" xlink:href="vnda-20201231.xsd#vnda_UnitedStatesExcludingDistrictOfColumbiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_24dc236f-e3d7-40bd-baec-8daa82b92706" xlink:to="loc_vnda_UnitedStatesExcludingDistrictOfColumbiaMember_19d38bc6-85ad-4815-ac7b-ebe81d2c91ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_eb67adc0-dc35-48c9-85e3-c0bc636be460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_eb67adc0-dc35-48c9-85e3-c0bc636be460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_eb67adc0-dc35-48c9-85e3-c0bc636be460_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_eb67adc0-dc35-48c9-85e3-c0bc636be460" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_eb67adc0-dc35-48c9-85e3-c0bc636be460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0a72841c-4130-4c3d-941a-6b4aeb8d2d33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_eb67adc0-dc35-48c9-85e3-c0bc636be460" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0a72841c-4130-4c3d-941a-6b4aeb8d2d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f0c9a40e-304d-4dd4-9497-3cf2bf7d398e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0a72841c-4130-4c3d-941a-6b4aeb8d2d33" xlink:to="loc_us-gaap_DomesticCountryMember_f0c9a40e-304d-4dd4-9497-3cf2bf7d398e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OrphanDrugMember_240bad92-51d9-4ce2-a1b5-12c5b956bae8" xlink:href="vnda-20201231.xsd#vnda_OrphanDrugMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0a72841c-4130-4c3d-941a-6b4aeb8d2d33" xlink:to="loc_vnda_OrphanDrugMember_240bad92-51d9-4ce2-a1b5-12c5b956bae8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="extended" id="ie98632024bd44b66af1eeaf17118609d_IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShare" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShare"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShare" xlink:type="extended" id="icf3365c3228b442fb6e71812b5c46852_EarningsperShare"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShareTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShareTables" xlink:type="extended" id="i30e6243ec7dc481a8d009ded80be8e71_EarningsperShareTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShareDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail" xlink:type="extended" id="ic6c263a978c54a768889664041a10e83_EarningsperShareDetail"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="simple" xlink:href="vnda-20201231.xsd#LegalMatters"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended" id="id58c4576fe864d328041b3ce92e22bb3_LegalMatters"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" id="i1b66d6de90a246a78ae861088ca26482_QuarterlyFinancialDataUnaudited"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" id="i8a52601eccc148dfa3d9894bebaa57f3_QuarterlyFinancialDataUnauditedTables"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnauditedDetail"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" xlink:type="extended" id="ib6abbd51d5874f02b5e0eb76c0576ada_QuarterlyFinancialDataUnauditedDetail"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>vnda-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d614c307-4118-4611-a8d3-3c89a1b9f878,g:1f7774dc-f1ff-4a69-952a-c8825acf6b9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_vnda_SubleaseMember_0ad6da42-cb82-4508-bb9f-bdfb3fb23b26_terseLabel_en-US" xlink:label="lab_vnda_SubleaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease</link:label>
    <link:label id="lab_vnda_SubleaseMember_label_en-US" xlink:label="lab_vnda_SubleaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease [Member]</link:label>
    <link:label id="lab_vnda_SubleaseMember_documentation_en-US" xlink:label="lab_vnda_SubleaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SubleaseMember" xlink:href="vnda-20201231.xsd#vnda_SubleaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SubleaseMember" xlink:to="lab_vnda_SubleaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6d4ed042-da85-45c1-b6e6-7bad67a1edc8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_67bca6c1-1566-4e58-a141-7599c6a9c556_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0a4016e4-38e4-432f-b6fa-f31bd0d5fe2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3f9dfee4-02a3-447f-b941-37ae00194f9f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_b35b1d8d-a8b2-479c-a514-4d089e4209e0_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_b454dcd4-b17b-472a-bf36-04437c96d4d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_9fab64ec-a7f4-4449-aa75-feba448c5c6d_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period for subsequent stock options granted to directors</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Annual Award Vesting Period Employees and New Directors</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:to="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsMember_c6f7b444-0ada-4744-ada0-1357d3f82c7a_terseLabel_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CFTR Activators and Inhibitors</link:label>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsMember_label_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CFTR activators and inhibitors [Member]</link:label>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsMember_documentation_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CFTR activators and inhibitors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsMember" xlink:href="vnda-20201231.xsd#vnda_CftrActivatorsAndInhibitorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsMember" xlink:to="lab_vnda_CftrActivatorsAndInhibitorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_073fde21-ded9-418f-b7a0-247706fab667_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e78e9f6f-a214-4c4b-8e85-d4853ab5316d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_90a24d1e-ff77-4267-a19c-029a18726e86_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_a4f50ac1-4b12-40bc-a03d-ce4f7f2df34d_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits/payments</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_21b2c040-1b04-443a-b0be-c0f8605caf50_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4c50a313-c1fe-487d-96a0-3a1f3a88b9cf_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_df51ab18-de55-4806-a648-a53a35ed0568_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation option awards contractual term</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Option Awards Contractual Term</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of stock option awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationOptionAwardsContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:to="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_32290ab7-e43c-4c27-97b8-5e646ef432ef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_919c9286-2690-4781-a5f5-27a04284d376_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CustomerThreeMember_f31a37fc-ab9d-44b2-a6d4-353c22d7e957_terseLabel_en-US" xlink:label="lab_vnda_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor C</link:label>
    <link:label id="lab_vnda_CustomerThreeMember_label_en-US" xlink:label="lab_vnda_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3 [Member]</link:label>
    <link:label id="lab_vnda_CustomerThreeMember_documentation_en-US" xlink:label="lab_vnda_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerThreeMember" xlink:href="vnda-20201231.xsd#vnda_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CustomerThreeMember" xlink:to="lab_vnda_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_IncomeTaxesTable_ea9ea140-f137-42de-9069-7d9abf6816d1_terseLabel_en-US" xlink:label="lab_vnda_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vnda_IncomeTaxesTable_label_en-US" xlink:label="lab_vnda_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vnda_IncomeTaxesTable_documentation_en-US" xlink:label="lab_vnda_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxesTable" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_IncomeTaxesTable" xlink:to="lab_vnda_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD_73ae3699-ed82-4696-8993-5b92107e9117_terseLabel_en-US" xlink:label="lab_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of insurance coverage gap allocated for prescription drugs under Medicare Part D</link:label>
    <link:label id="lab_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD_label_en-US" xlink:label="lab_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Responsibility for Patients Cost of Branded Prescription under Medicare Part D</link:label>
    <link:label id="lab_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD_documentation_en-US" xlink:label="lab_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of responsibility for patient's cost of branded prescription taken by the manufacturers under Medicare Part D.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" xlink:href="vnda-20201231.xsd#vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" xlink:to="lab_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_31a35fcb-7ca7-4f26-8754-23483d7140b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_dd49ea65-c5a0-49e5-af78-701c2be690bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at the end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_FanaptAbstract_ccd474a2-fc93-49bd-8ba5-17e5f826099e_terseLabel_en-US" xlink:label="lab_vnda_FanaptAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fanapt</link:label>
    <link:label id="lab_vnda_FanaptAbstract_label_en-US" xlink:label="lab_vnda_FanaptAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fanapt [Abstract]</link:label>
    <link:label id="lab_vnda_FanaptAbstract_documentation_en-US" xlink:label="lab_vnda_FanaptAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fanapt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptAbstract" xlink:href="vnda-20201231.xsd#vnda_FanaptAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FanaptAbstract" xlink:to="lab_vnda_FanaptAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8866bae1-8ec8-4de8-b77c-092ba8dcf556_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_RoyaltyPayableOnNetSalesPercentage_edbe95a1-c53e-4431-8ce0-140ec76b53f7_terseLabel_en-US" xlink:label="lab_vnda_RoyaltyPayableOnNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payable percentage on net sales</link:label>
    <link:label id="lab_vnda_RoyaltyPayableOnNetSalesPercentage_label_en-US" xlink:label="lab_vnda_RoyaltyPayableOnNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payable On Net Sales Percentage</link:label>
    <link:label id="lab_vnda_RoyaltyPayableOnNetSalesPercentage_documentation_en-US" xlink:label="lab_vnda_RoyaltyPayableOnNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPayableOnNetSalesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_RoyaltyPayableOnNetSalesPercentage" xlink:to="lab_vnda_RoyaltyPayableOnNetSalesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6492acb3-8355-437d-ae07-39cc5b4a3fb8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_fd49325a-680c-4a6c-b096-f8942b8b78a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f5fd86c2-e034-4dd5-917c-c38c522f6774_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6481de22-38c6-4c1b-befe-a3537a7d492f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f082347b-2178-413a-8472-1287b213be22_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9d673950-bb2b-4015-88ac-a6b93df00c95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of common stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40caeafd-86bb-45af-ae9a-c5a284cbbce0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1bc77577-fc95-484a-8cd6-8645695ebf70_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9a41dcdf-9e06-4fac-9c90-89e9014284dd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from offering of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b5a69182-a4b3-4b68-8d20-7992cc612c06_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_6a97dd9c-e856-4bd8-90f2-17a7d4e78519_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_8877bd14-6a7b-4ccd-b131-4aafa0ca4503_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_715f6b2d-720b-4043-9e68-e7ff74aab1b9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b2d9f45a-e395-45e7-8559-fc677ad88042_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceRollForward_bfb6c884-5e9b-44f5-94a8-71ac8a3252f1_terseLabel_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceRollForward_label_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsValuationAllowanceRollForward" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DeferredTaxAssetsValuationAllowanceRollForward" xlink:to="lab_vnda_DeferredTaxAssetsValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_99275c04-1c40-4681-b07e-d5d2551e4411_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2be1bfd9-2e1e-4a3c-8508-73e6be13418c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76a14a9c-f050-4788-9dbc-0c27c0c39f88_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_74f62ac3-5973-4e8b-9618-c03a57b33904_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3fe40c40-6722-40e1-9a31-a43e0cf4d599_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ef34dccb-444e-445e-befc-f9c381323959_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from public offering of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_087d2562-2231-4919-b42d-147889d29930_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_44f71e3c-1431-4d59-8431-629e874edaf6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b229ac91-4eb4-42c6-9a8d-c0f9bab2c9b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_fd427913-c369-48bc-ab9f-b5b891c7ac0d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6b18708a-11c7-4a43-bac7-13dfbd3a01a8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aca904a2-a19d-4803-8a1d-4fc9128322ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_590ce4b2-9776-403d-bda3-9354795ca02a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_65b59791-19d5-4dd9-ae95-ec9592f4114b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_70b5fd1d-aa20-419d-91cd-83870a6465c8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_622a8ca4-8a63-4b56-9be3-1f88ea8a0658_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_94887a09-5e26-476e-ba65-c0fab2f194e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ac067d15-9924-4166-8e51-f6006c32fde4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dc0d4ecb-f362-4a4c-a93d-729bab125fb1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_13878d0a-5d69-4dd9-9de9-e5733f074275_terseLabel_en-US" xlink:label="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_label_en-US" xlink:label="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves, Non Current</link:label>
    <link:label id="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_documentation_en-US" xlink:label="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:href="vnda-20201231.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:to="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ScheduleOfInventoriesTableTextBlock_1ada44c7-7949-41ca-846b-58597c8ae8a9_terseLabel_en-US" xlink:label="lab_vnda_ScheduleOfInventoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_vnda_ScheduleOfInventoriesTableTextBlock_label_en-US" xlink:label="lab_vnda_ScheduleOfInventoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Inventories [Table Text Block]</link:label>
    <link:label id="lab_vnda_ScheduleOfInventoriesTableTextBlock_documentation_en-US" xlink:label="lab_vnda_ScheduleOfInventoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfInventoriesTableTextBlock" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfInventoriesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScheduleOfInventoriesTableTextBlock" xlink:to="lab_vnda_ScheduleOfInventoriesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60756925-4b90-4d5b-b0cb-c91200ace83d_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_f839c298-793f-442b-b79e-86027922f6da_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ServiceOptionAwardsMember_3efa5b1a-1947-4614-ae32-e400c4ed9ecc_terseLabel_en-US" xlink:label="lab_vnda_ServiceOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service option awards</link:label>
    <link:label id="lab_vnda_ServiceOptionAwardsMember_label_en-US" xlink:label="lab_vnda_ServiceOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Option Awards [Member]</link:label>
    <link:label id="lab_vnda_ServiceOptionAwardsMember_documentation_en-US" xlink:label="lab_vnda_ServiceOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Option Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ServiceOptionAwardsMember" xlink:href="vnda-20201231.xsd#vnda_ServiceOptionAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ServiceOptionAwardsMember" xlink:to="lab_vnda_ServiceOptionAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_PublicOfferingMember_a8d1693b-7d2a-4ba5-8738-67dd76534cd3_terseLabel_en-US" xlink:label="lab_vnda_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_vnda_PublicOfferingMember_label_en-US" xlink:label="lab_vnda_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_vnda_PublicOfferingMember_documentation_en-US" xlink:label="lab_vnda_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PublicOfferingMember" xlink:href="vnda-20201231.xsd#vnda_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_PublicOfferingMember" xlink:to="lab_vnda_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_a1167704-5d5d-4135-b3b6-a89b1c562f04_terseLabel_en-US" xlink:label="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_label_en-US" xlink:label="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves, Non Current</link:label>
    <link:label id="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_documentation_en-US" xlink:label="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:href="vnda-20201231.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:to="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5dc520c-baa9-4547-8f5b-f9b9a1f55281_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_781ae0fe-6523-4d6b-a57c-d5b0ba56a47a_terseLabel_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in state deferred taxes</link:label>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_label_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment</link:label>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_documentation_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" xlink:to="lab_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3b69cf93-bdb2-403f-83b5-a08df8f5bbb2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2940fbc1-83a6-46df-997c-144dca2efcdd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_07c170cb-a42d-4a6c-8846-2f4ca9988576_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f592875-c35b-4f52-8f37-3af0120fb4bb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8c9c933f-9b69-4098-bb3b-604d32759ec5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_69eccffd-1326-4244-893b-fdcba19fee6e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_361be129-9211-4a13-8084-ace8be6f9a8a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a62c0560-1b9d-40b7-bf46-6a3f8de979b2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_d92c21ac-ab47-4d55-b97f-ccc562cc7a30_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1ad3f633-8739-4e2a-bfeb-34ecaad69f8b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_973078c4-524b-4a75-88ed-c5750151e278_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_d32d418f-ef5f-4c9e-890d-23b2fd066c8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d08b7ade-d11c-42fe-a693-b483b6a7daf7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Notes 10 and 17)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52306227-6971-4f9f-9374-0379855a94a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3cbc671-0a53-41ea-971c-94d6b43803f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fa9e2d0-3b80-44a0-b3bf-3c5e373d74c9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_29ea94c6-9761-4952-b0a1-6a31d995ee96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_f0c38177-fadf-48dc-b8a1-c07675051808_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_87a78a66-8d8c-426f-8f74-548965187663_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan matching amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e33b7b5e-54ed-4a5d-aa8a-c07bedfc041e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ReservesForVariableConsiderationPolicyTextBlock_b0166599-07d5-4071-88fa-1176209e7817_terseLabel_en-US" xlink:label="lab_vnda_ReservesForVariableConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Variable Consideration</link:label>
    <link:label id="lab_vnda_ReservesForVariableConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_vnda_ReservesForVariableConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Variable Consideration [Policy Text Block]</link:label>
    <link:label id="lab_vnda_ReservesForVariableConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_vnda_ReservesForVariableConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for variable consideration policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ReservesForVariableConsiderationPolicyTextBlock" xlink:href="vnda-20201231.xsd#vnda_ReservesForVariableConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ReservesForVariableConsiderationPolicyTextBlock" xlink:to="lab_vnda_ReservesForVariableConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_f2f67028-ab46-492c-bae8-a449c96c677b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering of common stock (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_78504e62-a1a3-4b56-8d33-517e79947f51_terseLabel_en-US" xlink:label="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future percentage of royalty payments based net sales</link:label>
    <link:label id="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_label_en-US" xlink:label="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Percentage Of Royalty Payments Based On Net Sales</link:label>
    <link:label id="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_documentation_en-US" xlink:label="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Percentage Of Royalty Payments Based On Net Sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:href="vnda-20201231.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:to="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_590bde0c-3734-487b-8570-63b18dd3e362_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share, basic and diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bae1c8e5-fc56-47e7-9680-d048dcab8bcc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expenses related to unvested RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1d98b5b9-1399-49b4-af4c-7f771d80ec2c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce2ad438-f46f-4849-b755-02ff1351c187_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e5fb0964-9fda-4d40-a85b-84cab2a1cbc3_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7c275529-9e0b-41aa-884e-f55831b71ff0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b79113f2-b9c1-4559-bdc4-8873d7236018_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Deferred Tax Assets and Related Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_9f8d115a-4916-4ecf-9f90-61350108349a_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Lease</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_dc9a5e38-6488-4c15-8ce2-d7dc7b8c4cd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_b205871f-6537-4230-9842-e9f2c1c4600d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_8ec83264-eeea-48e6-806d-a5fd0f333026_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2afce134-5d78-4a01-ae6f-c25d00c15db9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_74a4bcfe-6ded-4f89-b7e5-05eea2ad9c0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ac181e0f-0d79-4bdd-bc71-18550a8238e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_016d1415-ea89-48c0-94f0-1deabc39922d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_967022a4-ca8e-494f-8468-3173af63a488_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_EstimatedRealizabilityofDeferredTaxAssetMember_7a2d51f2-cd93-4962-ae5a-16a60bab5e6f_terseLabel_en-US" xlink:label="lab_vnda_EstimatedRealizabilityofDeferredTaxAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Realizability of Deferred Tax Asset</link:label>
    <link:label id="lab_vnda_EstimatedRealizabilityofDeferredTaxAssetMember_label_en-US" xlink:label="lab_vnda_EstimatedRealizabilityofDeferredTaxAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Realizability of Deferred Tax Asset [Member]</link:label>
    <link:label id="lab_vnda_EstimatedRealizabilityofDeferredTaxAssetMember_documentation_en-US" xlink:label="lab_vnda_EstimatedRealizabilityofDeferredTaxAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Realizability of Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EstimatedRealizabilityofDeferredTaxAssetMember" xlink:href="vnda-20201231.xsd#vnda_EstimatedRealizabilityofDeferredTaxAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_EstimatedRealizabilityofDeferredTaxAssetMember" xlink:to="lab_vnda_EstimatedRealizabilityofDeferredTaxAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_PercentageOfFutureSublicenseFeesPayable_3564d3d3-3466-4ee1-8dc9-72cd0d51e50f_terseLabel_en-US" xlink:label="lab_vnda_PercentageOfFutureSublicenseFeesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future sublicense fees payable to third-party</link:label>
    <link:label id="lab_vnda_PercentageOfFutureSublicenseFeesPayable_label_en-US" xlink:label="lab_vnda_PercentageOfFutureSublicenseFeesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Future Sublicense Fees Payable</link:label>
    <link:label id="lab_vnda_PercentageOfFutureSublicenseFeesPayable_documentation_en-US" xlink:label="lab_vnda_PercentageOfFutureSublicenseFeesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PercentageOfFutureSublicenseFeesPayable" xlink:href="vnda-20201231.xsd#vnda_PercentageOfFutureSublicenseFeesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_PercentageOfFutureSublicenseFeesPayable" xlink:to="lab_vnda_PercentageOfFutureSublicenseFeesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_eb8d7b74-eb8a-4abe-9497-ae7e577ccb00_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_33d78d56-8bc1-4e90-b223-ab049fb41244_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_HetliozMember_74ec6bb8-ce75-4752-8416-32c5a1abf720_verboseLabel_en-US" xlink:label="lab_vnda_HetliozMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HETLIOZ&#174;</link:label>
    <link:label id="lab_vnda_HetliozMember_label_en-US" xlink:label="lab_vnda_HetliozMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hetlioz [Member]</link:label>
    <link:label id="lab_vnda_HetliozMember_documentation_en-US" xlink:label="lab_vnda_HetliozMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hetlioz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_HetliozMember" xlink:to="lab_vnda_HetliozMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_eeb27819-23a1-4b38-9f02-d7b1d92fc413_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fcabf19c-fefa-4411-b889-f572766a21f7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_720f5724-9afa-4c17-a8d0-039b46678895_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_300a3551-ac32-42be-bf01-c09b13cb0c97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_476e1ab0-8691-4542-bd37-2493775a0f61_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dcb60c02-e85b-488b-af7e-61f120cdc8bf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_a8c74896-875e-4dc0-9977-315820269034_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7074f1e4-bbe7-4a1b-bc80-ad0c64ba8761_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f255cb52-5df6-4046-818b-039aaccdb7c8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_531af12b-dd4b-4035-85bd-4bc90d1cc617_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_4f202d41-5c48-40b2-ba41-b39df3250417_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_86860c3f-3a28-4bcf-b03e-348f3fe3bf45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_8c10130f-4a4a-4327-a57b-ab6c00358b07_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8935bc95-db29-480b-883f-8ee9951314ce_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ae725401-f5bd-4f8e-bf3b-361798169765_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd25a725-470d-45be-a5fe-04837ceaebd2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f80f7eaf-75cd-43d8-b89e-5d71c88b975b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a62270d6-78ff-4363-a5d0-ed4a4b3117e5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_19b268d3-f70e-425d-aa70-bea7dc2364cf_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2a67c1fe-71b1-4b68-b609-5b7049cedb18_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_ce911991-d605-45b4-888b-225fb3f8cba6_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of new hire stock option award that vests monthly after one year of service.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7c215fce-2e42-4d55-be19-6b8701b1ee6a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c6cb213c-81cb-46ce-a57a-d3c66f981653_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_60240890-7336-44a0-b251-86e3ef0b67da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e5ec186c-dde6-447b-8b4c-517e2ca2b686_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d05eb8b0-41ce-4118-9abb-ca471b6e9d0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160;Price&#160;at Grant Date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d3376de9-227a-427a-be91-b4ce44955b62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14881c0f-dc7b-405f-899a-1ec6c4b84c9e_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3cbb0d2c-ba9e-4915-a56d-45d90509eaa8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_717c2f27-6af4-4209-b2e2-9b3b430cc6b1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5f51c19d-2947-424b-a19f-83337113e579_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_eb240ba9-1324-4f3a-9a6f-e701cecd2533_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2771231e-6e0f-4c43-afa2-e21bb58d94c0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_d1fe81e2-d57b-495d-9e26-145da7c72fb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Product Sales</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3e8eaa90-8862-4f41-b772-aef928206c98_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_219e9096-475f-4219-9282-b9cbe2501976_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices&#160;in Active&#160;Markets&#160;for Identical&#160;Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_189f0b0b-967b-4d6b-9ab2-54077849d6c5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1f368d73-f445-427e-bb4a-fc3e5e6a5deb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_359dcd1a-f7a5-429e-94f0-8b04fa17f502_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_85bf649e-73ef-4e79-b75c-f811f044c75b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock_2c86f42e-ae1d-4f05-8fd8-3fead8feb65c_terseLabel_en-US" xlink:label="lab_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Product Return Allowance</link:label>
    <link:label id="lab_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule Of Valuation And Qualifying Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="vnda-20201231.xsd#vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_29b9cf25-4dcd-4057-b845-6671faea3552_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_PreNDAApprovalMilestonesMember_760e85fc-08bd-405b-bf64-cb0058b2afee_terseLabel_en-US" xlink:label="lab_vnda_PreNDAApprovalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-NDA Approval Milestones</link:label>
    <link:label id="lab_vnda_PreNDAApprovalMilestonesMember_label_en-US" xlink:label="lab_vnda_PreNDAApprovalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-NDA Approval Milestones [Member]</link:label>
    <link:label id="lab_vnda_PreNDAApprovalMilestonesMember_documentation_en-US" xlink:label="lab_vnda_PreNDAApprovalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-NDA Approval Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PreNDAApprovalMilestonesMember" xlink:href="vnda-20201231.xsd#vnda_PreNDAApprovalMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_PreNDAApprovalMilestonesMember" xlink:to="lab_vnda_PreNDAApprovalMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_FanaptMember_2af1a71a-2af4-480e-be92-6d276285d5cf_verboseLabel_en-US" xlink:label="lab_vnda_FanaptMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fanapt&#174;</link:label>
    <link:label id="lab_vnda_FanaptMember_label_en-US" xlink:label="lab_vnda_FanaptMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fanapt [Member]</link:label>
    <link:label id="lab_vnda_FanaptMember_documentation_en-US" xlink:label="lab_vnda_FanaptMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fanapt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptMember" xlink:href="vnda-20201231.xsd#vnda_FanaptMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FanaptMember" xlink:to="lab_vnda_FanaptMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_79a79091-fc90-4954-94d2-67934ea841ea_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0904446d-f426-4def-ad97-e66b9dce25a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cf40dbc7-e844-4da4-ad40-175246217ffe_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 162(m) limitation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_61efba96-25e1-47a8-b494-dddc50cf3751_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_6e8995be-b701-47af-ad33-0bc41edc1ed4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_bd493f3d-8fed-4d82-98ab-0179b85e5793_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37358131-2574-4246-98fa-ecacae325820_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f5ce7e94-a972-44cb-9dd7-53522c5a2701_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment-at Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_d011727b-d4ce-4f3d-b5bd-4727ae1e9c91_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers</link:label>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:to="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e425623b-c628-42f7-9e52-a69e4d66d455_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_AccruedResearchAndDevelopmentExpense_c081c3af-567e-4c37-97db-4b3dc347853c_terseLabel_en-US" xlink:label="lab_vnda_AccruedResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_vnda_AccruedResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_vnda_AccruedResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense</link:label>
    <link:label id="lab_vnda_AccruedResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_vnda_AccruedResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense" xlink:href="vnda-20201231.xsd#vnda_AccruedResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_AccruedResearchAndDevelopmentExpense" xlink:to="lab_vnda_AccruedResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1a69e93b-d246-47f7-91ab-eef30fdf061d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_9945f16d-60e3-40cc-9a72-15432350c7c9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_91d5c412-2b00-432f-b87d-a5b6bfcb33cc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_e700e86a-239e-4ddc-8084-7b4af8d8e75d_terseLabel_en-US" xlink:label="lab_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and orphan drug credit carryforwards</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_label_en-US" xlink:label="lab_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research and Other</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_documentation_en-US" xlink:label="lab_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit and other tax credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:to="lab_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_6b0112c3-1481-43a6-a195-e5ff3f378317_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d89c4780-349e-426b-851e-2cf0500e01dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5856d156-a0ea-441f-b3c3-bcfe3ac381f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_SECSchedule1209AllowanceProductReturnsMember_fd319344-a8d2-4759-969f-e145944f3fab_terseLabel_en-US" xlink:label="lab_vnda_SECSchedule1209AllowanceProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Product Returns</link:label>
    <link:label id="lab_vnda_SECSchedule1209AllowanceProductReturnsMember_label_en-US" xlink:label="lab_vnda_SECSchedule1209AllowanceProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Product Returns [Member]</link:label>
    <link:label id="lab_vnda_SECSchedule1209AllowanceProductReturnsMember_documentation_en-US" xlink:label="lab_vnda_SECSchedule1209AllowanceProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Product Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SECSchedule1209AllowanceProductReturnsMember" xlink:href="vnda-20201231.xsd#vnda_SECSchedule1209AllowanceProductReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SECSchedule1209AllowanceProductReturnsMember" xlink:to="lab_vnda_SECSchedule1209AllowanceProductReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0135b5d3-b5fa-4f53-a668-cad63843652e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_2b6c6162-4e4a-4c8b-a951-6c0e83aeaa8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_95c9d96a-66ed-40d0-8618-00ae0e97fbff_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_809cdd5e-e255-4655-8525-6ec19ddf74a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13f4f327-0988-4f0d-990b-71f6225c51a1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_50c3294d-138d-4234-a10b-59e8979bc746_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold excluding amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_73eb2b19-32c9-4d8d-b909-40495b2a0bf8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_eb2f2ca7-a1c0-4c2f-b8d0-93e1a58e482f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term of lease agreement</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_223b77cf-368c-429a-87a6-9ae4fc4f4767_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_TradipitantMember_e260fc3b-c3d1-4ea3-9aa5-c358b7bb2dbf_terseLabel_en-US" xlink:label="lab_vnda_TradipitantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tradipitant</link:label>
    <link:label id="lab_vnda_TradipitantMember_label_en-US" xlink:label="lab_vnda_TradipitantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tradipitant [Member]</link:label>
    <link:label id="lab_vnda_TradipitantMember_documentation_en-US" xlink:label="lab_vnda_TradipitantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tradipitant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TradipitantMember" xlink:href="vnda-20201231.xsd#vnda_TradipitantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_TradipitantMember" xlink:to="lab_vnda_TradipitantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_30ca1746-bbd7-4a71-be9c-a7670aba1586_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d547d8e-0594-44ce-8e1e-dda1fed2edbb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_163a8621-0c0a-4046-bacb-3bd323441960_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_cfedcf45-181b-48f6-ab60-c1334c39535b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e1e6f8df-caf6-4b49-a1ef-6ee4a5a9f099_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_65333cdc-1c83-4902-af98-5a9b8cae87e7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_338a57b1-d552-4349-b5a5-4ffa9f590bc6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b96496e8-8be1-43a6-8f03-ca6eded1c266_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_69971b8d-7df8-401b-a22c-a4f875716b1b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_60b90942-3895-4609-8976-a74becac878a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_c738affc-36a6-4d04-a0d5-1cf8b99a61ca_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a01b9aa9-188b-4909-99f7-5b4b574742f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_e2a07c80-81f2-463e-a8f1-566d0f9c16a1_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ab4babc-9af1-4410-a650-b4a1307448bd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_03bf9b7b-81e3-4efb-8676-a7f4d9708b50_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e7bec72d-8e6c-480f-86af-604cf091136d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_04bbe7b9-e4b3-4e22-b639-9ce5715334d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7074c44a-f0d2-4d22-841a-0ebbcbc2822f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CommitmentsAndContingenciesLineItems_fb4cef92-9c8c-4e15-a333-076f85ded58b_terseLabel_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_vnda_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_vnda_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems" xlink:to="lab_vnda_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_12b39638-8f61-4867-ac8b-fd79052b841d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_8ee7c651-aa5c-45d3-9442-5968cfd142da_terseLabel_en-US" xlink:label="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding options and RSUs granted (RSUs)</link:label>
    <link:label id="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:href="vnda-20201231.xsd#vnda_StockOptionsAndRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:to="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_d0b032ee-f891-430d-91dc-cb5b702a6780_terseLabel_en-US" xlink:label="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2006 Plan and 2016 Plan</link:label>
    <link:label id="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_label_en-US" xlink:label="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]</link:label>
    <link:label id="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_documentation_en-US" xlink:label="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:href="vnda-20201231.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:to="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d6e16fe4-6170-431f-a330-4c41688dd540_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8ac7f960-6c61-4ac0-9db0-68f6b45f71d3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CustomerFiveMember_68e5ecd0-96ed-4f0d-a015-36043b8aa9e5_terseLabel_en-US" xlink:label="lab_vnda_CustomerFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor E</link:label>
    <link:label id="lab_vnda_CustomerFiveMember_label_en-US" xlink:label="lab_vnda_CustomerFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 5 [Member]</link:label>
    <link:label id="lab_vnda_CustomerFiveMember_documentation_en-US" xlink:label="lab_vnda_CustomerFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 5 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFiveMember" xlink:href="vnda-20201231.xsd#vnda_CustomerFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CustomerFiveMember" xlink:to="lab_vnda_CustomerFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3cd64761-32de-4aaa-a63d-45f1e56ac061_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_180d9e9c-59e9-4f41-91b9-47609c083a9e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_RoyaltyPeriod_bc81537f-9c66-4a98-bf88-baa47caf75f3_terseLabel_en-US" xlink:label="lab_vnda_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment period</link:label>
    <link:label id="lab_vnda_RoyaltyPeriod_label_en-US" xlink:label="lab_vnda_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Period</link:label>
    <link:label id="lab_vnda_RoyaltyPeriod_documentation_en-US" xlink:label="lab_vnda_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPeriod" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_RoyaltyPeriod" xlink:to="lab_vnda_RoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3f92a47e-3333-4903-a99d-31ce6bc99334_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2f382138-cd87-4413-80b1-71849d44bcec_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_017898a0-0a80-499e-a104-7a628a90ae77_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for returns and credit losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_abd08fd4-6718-4aae-904c-3f7d76835627_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_a3b3f152-9ae1-4518-a7c0-f4d0d362f3a4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets capitalized</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_8fdce1f9-954a-40df-9555-008beab283ce_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Tax Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_RegulatoryApprovalMilestoneMember_cc34f1ca-7da4-42c6-b3b9-0254d54d625b_terseLabel_en-US" xlink:label="lab_vnda_RegulatoryApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval Milestone</link:label>
    <link:label id="lab_vnda_RegulatoryApprovalMilestoneMember_label_en-US" xlink:label="lab_vnda_RegulatoryApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_vnda_RegulatoryApprovalMilestoneMember_documentation_en-US" xlink:label="lab_vnda_RegulatoryApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember" xlink:href="vnda-20201231.xsd#vnda_RegulatoryApprovalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_RegulatoryApprovalMilestoneMember" xlink:to="lab_vnda_RegulatoryApprovalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7b41df1c-24eb-4c8e-92d4-371fe10a0583_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a87eb1c4-57f6-42f4-a680-c77650abe752_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e17cf195-bcdf-4988-bdfc-04746dc63fe4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_7eb8a2f6-2683-4a4d-bae0-f1931af339c2_terseLabel_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible future milestone payment</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_a4763b6a-c75d-47f9-9690-6ce054541bf6_verboseLabel_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible future milestone payments</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_label_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Milestone Payments Potentially Due To Third Party</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_documentation_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:to="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_055de748-1aa4-425a-ac1b-56f734a73fff_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_64487fd4-9633-44da-98cb-fbc5b004e3c3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceIncrease_922200fa-72bd-46a9-bc1b-06b6915e8335_terseLabel_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceIncrease_label_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Valuation Allowance, Increase</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceIncrease_documentation_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in the period related to valuation allowance for deferred tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsValuationAllowanceIncrease" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsValuationAllowanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DeferredTaxAssetsValuationAllowanceIncrease" xlink:to="lab_vnda_DeferredTaxAssetsValuationAllowanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b664bcc9-a16b-49cb-985f-fcd0796fccd6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6942d178-d721-481c-ac4f-953b30c9f056_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_fbf80a37-9620-4764-a3ba-be0cabbf1107_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60338186-c5a2-45b0-973f-d8e3fb5a78a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, weighted average fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_88d4a6de-4174-4430-b7f5-91b7a3eacc03_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d982cd7e-8db9-4dfe-b337-81286ecc6fb6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_a8af3619-254b-4b50-ac35-ecad7d71223b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9cf0df02-c6c3-4087-97fe-3ca8038d4ac4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f26d2902-0bb5-47f0-8b4c-07cd8c0ec80f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_bee4f433-c0d6-4244-8a40-a948436c2545_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_NoncurrentInventoryAndOtherMember_4c4f0d2f-12d4-4874-ac9b-f44b3e4ea347_terseLabel_en-US" xlink:label="lab_vnda_NoncurrentInventoryAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventory and other</link:label>
    <link:label id="lab_vnda_NoncurrentInventoryAndOtherMember_label_en-US" xlink:label="lab_vnda_NoncurrentInventoryAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Inventory and Other [Member]</link:label>
    <link:label id="lab_vnda_NoncurrentInventoryAndOtherMember_documentation_en-US" xlink:label="lab_vnda_NoncurrentInventoryAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Inventory and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_NoncurrentInventoryAndOtherMember" xlink:href="vnda-20201231.xsd#vnda_NoncurrentInventoryAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_NoncurrentInventoryAndOtherMember" xlink:to="lab_vnda_NoncurrentInventoryAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ProductRevenueAllowancesCurrent_df308056-3c17-4e1d-b1f3-8c6776e44177_terseLabel_en-US" xlink:label="lab_vnda_ProductRevenueAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue allowances</link:label>
    <link:label id="lab_vnda_ProductRevenueAllowancesCurrent_label_en-US" xlink:label="lab_vnda_ProductRevenueAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue Allowances, Current</link:label>
    <link:label id="lab_vnda_ProductRevenueAllowancesCurrent_documentation_en-US" xlink:label="lab_vnda_ProductRevenueAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue Allowances, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent" xlink:href="vnda-20201231.xsd#vnda_ProductRevenueAllowancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ProductRevenueAllowancesCurrent" xlink:to="lab_vnda_ProductRevenueAllowancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1269783e-32c8-40cb-9da7-b9ac44896025_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_9fd65981-37ce-4e9e-9787-e779ecd89819_terseLabel_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Milestone Payment, Conclusion Of Phase I Study</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_label_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Milestone Payment, Conclusion Of Phase I Study [Member]</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_documentation_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Milestone Payment, Conclusion Of Phase I Study [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:to="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceDecrease_9653241a-158f-4827-91a2-5485ddc4c660_negatedLabel_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceDecrease_label_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Valuation Allowance, Decrease</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsValuationAllowanceDecrease_documentation_en-US" xlink:label="lab_vnda_DeferredTaxAssetsValuationAllowanceDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of decrease in the period related to valuation allowance for deferred tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsValuationAllowanceDecrease" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsValuationAllowanceDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DeferredTaxAssetsValuationAllowanceDecrease" xlink:to="lab_vnda_DeferredTaxAssetsValuationAllowanceDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_3b447908-22eb-4d2c-948f-eca06483fbd8_terseLabel_en-US" xlink:label="lab_vnda_AccruedMilestoneObligationsUnderLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone obligations under license agreements</link:label>
    <link:label id="lab_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_label_en-US" xlink:label="lab_vnda_AccruedMilestoneObligationsUnderLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Obligations Under License Agreements</link:label>
    <link:label id="lab_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_documentation_en-US" xlink:label="lab_vnda_AccruedMilestoneObligationsUnderLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Obligations Under License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements" xlink:href="vnda-20201231.xsd#vnda_AccruedMilestoneObligationsUnderLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements" xlink:to="lab_vnda_AccruedMilestoneObligationsUnderLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CustomerOneMember_17deb84b-1842-43f5-8a54-147a50633dcf_terseLabel_en-US" xlink:label="lab_vnda_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor A</link:label>
    <link:label id="lab_vnda_CustomerOneMember_label_en-US" xlink:label="lab_vnda_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1 [Member]</link:label>
    <link:label id="lab_vnda_CustomerOneMember_documentation_en-US" xlink:label="lab_vnda_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerOneMember" xlink:href="vnda-20201231.xsd#vnda_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CustomerOneMember" xlink:to="lab_vnda_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1d63218a-77e9-4e80-a0f7-34ed009cdbfe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_d2133987-c4aa-43e5-923b-0e016253b0de_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_OrphanDrugCreditBeginningExpirationYear_de1da829-8b33-48fa-8d3b-bd01801e458a_terseLabel_en-US" xlink:label="lab_vnda_OrphanDrugCreditBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit beginning expiration year</link:label>
    <link:label id="lab_vnda_OrphanDrugCreditBeginningExpirationYear_label_en-US" xlink:label="lab_vnda_OrphanDrugCreditBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Credit , Beginning Expiration Year</link:label>
    <link:label id="lab_vnda_OrphanDrugCreditBeginningExpirationYear_documentation_en-US" xlink:label="lab_vnda_OrphanDrugCreditBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Credit , Beginning Expiration Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OrphanDrugCreditBeginningExpirationYear" xlink:href="vnda-20201231.xsd#vnda_OrphanDrugCreditBeginningExpirationYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_OrphanDrugCreditBeginningExpirationYear" xlink:to="lab_vnda_OrphanDrugCreditBeginningExpirationYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5b89eb67-5a1b-45b2-a724-6a83de1efdb4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0040d312-6190-4579-a674-29d34a62dfd7_totalLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_14072c57-f822-4116-a2c6-d7decfe4fe03_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_aa4d42cc-e526-4b54-b253-fc59e07364c4_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f01013b2-4ce9-4503-8f77-1a6cc9987fd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock_35f17829-70cf-466d-8b60-b5e369cf9dec_terseLabel_en-US" xlink:label="lab_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net</link:label>
    <link:label id="lab_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block]</link:label>
    <link:label id="lab_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock_documentation_en-US" xlink:label="lab_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f66de3cd-9ff4-46ee-b56b-62be6d21de04_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1dea6169-12bc-4174-b158-91043676e5d6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_66a56aa9-5869-444b-a871-784ff9ab9bc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_ab2578d4-dec8-4dc2-8619-403ca2f0453f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_dce7a290-8d37-432c-ab22-a6953dcc50bd_terseLabel_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]</link:label>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_label_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]</link:label>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_documentation_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:to="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a1f74f80-8cbd-4e40-97f1-1a25dde059cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_e866f43f-155c-4107-996d-a28cf2a7cc74_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_471f50fa-5770-42c4-b3f8-90ebbc32e811_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_215698de-004d-47d3-a9b4-b6d6216e97d2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_PublicOfferingOfCommonStockTextBlock_aa6ed249-7eec-4d51-81d8-26912e7684c5_terseLabel_en-US" xlink:label="lab_vnda_PublicOfferingOfCommonStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering of Common Stock</link:label>
    <link:label id="lab_vnda_PublicOfferingOfCommonStockTextBlock_label_en-US" xlink:label="lab_vnda_PublicOfferingOfCommonStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering Of Common Stock [Text Block]</link:label>
    <link:label id="lab_vnda_PublicOfferingOfCommonStockTextBlock_documentation_en-US" xlink:label="lab_vnda_PublicOfferingOfCommonStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering Of Common Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PublicOfferingOfCommonStockTextBlock" xlink:href="vnda-20201231.xsd#vnda_PublicOfferingOfCommonStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_PublicOfferingOfCommonStockTextBlock" xlink:to="lab_vnda_PublicOfferingOfCommonStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_80a4a151-bfd5-49e7-a001-678a7c2e893e_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8f525be8-1b9f-4ca4-972c-931deb2ee414_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful&#160;Life (Years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CustomerTwoMember_b3eff5bd-77a4-4dba-9ad3-f9290c7036e4_terseLabel_en-US" xlink:label="lab_vnda_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor B</link:label>
    <link:label id="lab_vnda_CustomerTwoMember_label_en-US" xlink:label="lab_vnda_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2 [Member]</link:label>
    <link:label id="lab_vnda_CustomerTwoMember_documentation_en-US" xlink:label="lab_vnda_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerTwoMember" xlink:href="vnda-20201231.xsd#vnda_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CustomerTwoMember" xlink:to="lab_vnda_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_684b21cb-97a4-479f-a3d9-a8cd8f7e6877_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of common stock vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0783c1ab-5b8a-42a5-9102-abaa14cddc02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5c842a87-1e81-43e6-9b49-389c34c27dcc_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c9a40ad8-25af-4253-9adc-3a35a3997b77_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_eaf5fe3d-644c-4896-a840-8f1122dae223_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3d2c26bd-45f4-48d2-babd-e449a6aba9b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_349f83bb-4442-44fb-bc15-e03d038f5fd9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f2d5efff-1b53-4469-a28e-818dddea0f41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8d6d1206-bf75-4d65-8eed-110b88e07743_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_b57eeaba-bbce-457e-9b9d-2857cf9ada12_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5b7aff2d-f8f7-4aed-be5f-00b416cb9d76_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2eb2d8c7-dcbf-4521-ad4e-c43381ffcb79_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b5a72849-30e4-4671-a82b-30a42266c3fd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_dbcc35dc-174c-40bc-ad85-e4ce80236e54_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4fd5b83f-1b54-4675-bd42-8b15dd75babd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1833bcd1-4d94-4521-939c-784440a1b603_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_ce89b4a6-5172-4ed6-a54f-34d34dfcf7d1_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_13d97d5c-d4ed-4a57-9982-3689883c242d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_24085f97-2540-4716-a2df-71adc2719e7a_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;Average Remaining&#160;Term (Years)</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a4a9a9a2-22dd-4eb5-89b0-6bb363af62e2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_5325491a-5270-4a5e-9d8e-1b19859e5df1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Net Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_514ee5d9-ec89-408e-9a05-250a0c2b6aee_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e493e415-e8f3-4fb3-81c4-7a461d9f24c7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_54b4408f-8a90-495f-a002-48bb424fb740_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_4762964d-e7fe-4347-acfd-1314ad70d7ae_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e71970c9-10e1-4f9b-8480-01d58db659ca_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_2ec07530-a2f3-42d7-bcd3-ab2d9ef7e138_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CumulativeNetSalesToAchieveMilestone_a2b34595-054f-4d6c-885a-760b02ebfd2b_terseLabel_en-US" xlink:label="lab_vnda_CumulativeNetSalesToAchieveMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative worldwide sales milestone</link:label>
    <link:label id="lab_vnda_CumulativeNetSalesToAchieveMilestone_label_en-US" xlink:label="lab_vnda_CumulativeNetSalesToAchieveMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Net Sales To Achieve Milestone</link:label>
    <link:label id="lab_vnda_CumulativeNetSalesToAchieveMilestone_documentation_en-US" xlink:label="lab_vnda_CumulativeNetSalesToAchieveMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CumulativeNetSalesToAchieveMilestone" xlink:href="vnda-20201231.xsd#vnda_CumulativeNetSalesToAchieveMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CumulativeNetSalesToAchieveMilestone" xlink:to="lab_vnda_CumulativeNetSalesToAchieveMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d554368f-2bfc-42c6-9bde-989091d2a6a7_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrentAbstract_a1bf2dde-18b4-4c16-8756-bc0dc0f860fb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract" xlink:to="lab_us-gaap_InventoryNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_aa2c8e93-2a09-40ba-8b9a-46a6bfeba1d0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_08322363-1aeb-4eb8-bc22-ed8cb44431b7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_IncomeBeforeIncomeTaxesCurrentYearMember_de48050a-00d2-46e4-8c96-6ecd679a0fa3_terseLabel_en-US" xlink:label="lab_vnda_IncomeBeforeIncomeTaxesCurrentYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Income Taxes, Current Year</link:label>
    <link:label id="lab_vnda_IncomeBeforeIncomeTaxesCurrentYearMember_label_en-US" xlink:label="lab_vnda_IncomeBeforeIncomeTaxesCurrentYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Income Taxes, Current Year [Member]</link:label>
    <link:label id="lab_vnda_IncomeBeforeIncomeTaxesCurrentYearMember_documentation_en-US" xlink:label="lab_vnda_IncomeBeforeIncomeTaxesCurrentYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Income Taxes, Current Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeBeforeIncomeTaxesCurrentYearMember" xlink:href="vnda-20201231.xsd#vnda_IncomeBeforeIncomeTaxesCurrentYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_IncomeBeforeIncomeTaxesCurrentYearMember" xlink:to="lab_vnda_IncomeBeforeIncomeTaxesCurrentYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7d1aad38-4a14-4738-a83f-d9c19965ecc6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_81bf30fb-9260-473a-98ae-c124318ce0c4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_a87dcad6-5759-4f00-9c8e-bb149c0005f7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4e0c77bb-1dc7-4522-b32e-3f3ccec639f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bd6e43f0-4a1a-4e4c-8cef-0d1b462e26f5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f8d9bfb1-e56c-4691-83ef-74ecde14fffa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ab40ff83-6cce-4a53-85f4-c88f30b0a492_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1e6e69f3-2b54-4049-9005-ab5a718c1c55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_StatementScenarioSecondaryDomain_ea887386-20ee-4432-8e9b-c7a4be234431_terseLabel_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario Secondary [Domain]</link:label>
    <link:label id="lab_vnda_StatementScenarioSecondaryDomain_label_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario Secondary [Domain]</link:label>
    <link:label id="lab_vnda_StatementScenarioSecondaryDomain_documentation_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario Secondary [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StatementScenarioSecondaryDomain" xlink:href="vnda-20201231.xsd#vnda_StatementScenarioSecondaryDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_StatementScenarioSecondaryDomain" xlink:to="lab_vnda_StatementScenarioSecondaryDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_79362dbe-1154-4731-b0ea-b94e94f2c73c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_InventoryAndOtherNonCurrent_4ecfc158-0fb9-49bf-91f0-c09d03a72981_terseLabel_en-US" xlink:label="lab_vnda_InventoryAndOtherNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventory and other</link:label>
    <link:label id="lab_vnda_InventoryAndOtherNonCurrent_label_en-US" xlink:label="lab_vnda_InventoryAndOtherNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Other Non Current</link:label>
    <link:label id="lab_vnda_InventoryAndOtherNonCurrent_documentation_en-US" xlink:label="lab_vnda_InventoryAndOtherNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryAndOtherNonCurrent" xlink:href="vnda-20201231.xsd#vnda_InventoryAndOtherNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_InventoryAndOtherNonCurrent" xlink:to="lab_vnda_InventoryAndOtherNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c14799d5-6a63-4cba-afbd-f3e0999a72ca_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_12a9b796-5a5f-4bfa-a975-f94493ee85cc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1d970496-3f3f-4818-af96-295cf854d64a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_2cbf945e-2886-4464-b1d2-237f7aea6305_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_92ed0d2e-e5a9-4ea8-9c14-491439729cb0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_79898bec-823e-4a36-81f5-0c660d4d8a8d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ac2c35f0-953f-43d7-a838-341a25a1216d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e6af5ab-cfca-4c29-bdd1-b08a105eaf6e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7e871fc3-d710-464d-91ac-878b86792de4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_54095ea7-bc48-461e-9859-29b8bba5d3bb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_7bdfb500-65cc-409a-bba4-6573c29923fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting and other professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e1f224e2-3840-4edf-bbda-24e87250c616_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_e8b0ef04-01fd-42b6-9f3b-388bd6e5a82e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_47d2bebd-4039-4722-89ed-d31bad91a080_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4ffbb79c-273c-4875-8250-3691d9d61baf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6985da2c-21ca-43b2-b410-7dbb2b08c638_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_6e3d5951-242f-4cc4-82a2-926d0cad89e6_terseLabel_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit</link:label>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_label_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug</link:label>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_documentation_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" xlink:to="lab_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f6b154d2-018d-4231-834b-080435901a1a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2b92e27f-a69b-4673-b34d-7923b96231d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_408b6e5d-fa2c-4ee2-b2ca-61aea0efd803_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6a4e790f-fb4b-402e-b94e-c2e6e3b4d3bc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ab6d55e8-09f8-4aa5-9a12-4c60efb9d331_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_830a51ed-39c4-47ff-a439-d8adf417e910_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_TwoThousandSixteenPlanMember_14d3488e-07ee-4c2c-88e6-e960566c587a_terseLabel_en-US" xlink:label="lab_vnda_TwoThousandSixteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_vnda_TwoThousandSixteenPlanMember_label_en-US" xlink:label="lab_vnda_TwoThousandSixteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Plan [Member]</link:label>
    <link:label id="lab_vnda_TwoThousandSixteenPlanMember_documentation_en-US" xlink:label="lab_vnda_TwoThousandSixteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TwoThousandSixteenPlanMember" xlink:href="vnda-20201231.xsd#vnda_TwoThousandSixteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_TwoThousandSixteenPlanMember" xlink:to="lab_vnda_TwoThousandSixteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_637e024a-116b-495c-b879-625f186887c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_b0078c8c-bcd6-4524-b432-14f8b23cfc2a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_94f57fd3-3df9-41e1-a83a-82503c41eca4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_c1d93eee-cfa0-42a7-a6b7-97e6c4956889_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_3835d0b2-05d7-4e29-bae5-00e297c5b6d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_082f0895-1ccf-49c6-8d57-c1d8990f6b55_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_a9652d77-497a-4052-a7d4-77836435d155_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit (provision) on other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_8ba04963-baf9-485d-8443-5d877f195d49_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7605e72b-0d1a-429a-8f6f-c3b6d64e0db8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Future Cash Obligations to Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feb10cf2-adc2-4820-9490-9385ec69978c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_40d5e4ca-1681-4d90-82e7-21ef8318b87e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_196d045c-7aed-4083-ae0f-6071394c1464_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_002f6160-5169-4032-8e6b-abf26b61853c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_3aa28eb4-b685-4ae8-ba3d-af3f16eb21f8_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e6e82f16-d44c-45d7-953b-dcdb3ca2753c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_56bf0e31-3518-4cbf-835f-12c2f1a8670e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aaabb401-b22f-475d-a1c1-fcdd8cc4919b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7455e07f-ac7b-4a20-b0de-e5341536c5a0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2f12380e-4bc2-4b3d-ac6d-b927adb7d027_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_a992ca15-0229-4d28-a50f-42965a4a4a30_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2e9cbbee-f5a2-465c-b4a7-887355972b9d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_e295cc3e-5a0b-4435-8853-3c2a055a43a7_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6e654f84-f5d2-492b-9f53-0996c1bba382_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5e0a3665-5052-4d63-933a-36bbe379f9de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dd8a7700-49af-4386-b18b-293880ac75d0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_161bc6dd-6c67-456e-856a-212deba4f10e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Intangible Asset Amortization</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_87f70cbe-7141-4da9-9a4d-132ef8502b58_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3ad4797b-a666-4be9-81ed-a3b950cb9757_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_a14ff40f-3c39-4c39-a3ff-f1116aed6068_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E.U.</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bbac4c4f-6eb9-4fd3-a697-c22cc7dc15f9_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount of lease payments representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_db0fde80-2e20-4333-9c0b-eb39b2d8fed4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7e6a36a2-3832-4ebf-9a21-1ff34b2250e5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9fe8db29-04d2-4a77-b587-a064675bcfa0_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_533b7b66-e90b-4e0c-bfe3-903d58accb90_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e363942a-b809-49fa-a507-9699bebdf7be_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1f9188b6-afe6-4291-8db9-93ac7e5dcae2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_HetliozAbstract_5c2d445f-0ab5-4bc5-ad2e-3f9765b3b131_terseLabel_en-US" xlink:label="lab_vnda_HetliozAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HETLIOZ</link:label>
    <link:label id="lab_vnda_HetliozAbstract_label_en-US" xlink:label="lab_vnda_HetliozAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hetlioz [Abstract]</link:label>
    <link:label id="lab_vnda_HetliozAbstract_documentation_en-US" xlink:label="lab_vnda_HetliozAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hetlioz [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozAbstract" xlink:href="vnda-20201231.xsd#vnda_HetliozAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_HetliozAbstract" xlink:to="lab_vnda_HetliozAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_acbe28ae-1b6f-4e1f-a332-889e108405b5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_IncreaseDecreaseProductRevenueAllowances_891ada3e-0db6-4d3d-8240-b8b72dfa6339_terseLabel_en-US" xlink:label="lab_vnda_IncreaseDecreaseProductRevenueAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue allowances</link:label>
    <link:label id="lab_vnda_IncreaseDecreaseProductRevenueAllowances_label_en-US" xlink:label="lab_vnda_IncreaseDecreaseProductRevenueAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Product Revenue Allowances</link:label>
    <link:label id="lab_vnda_IncreaseDecreaseProductRevenueAllowances_documentation_en-US" xlink:label="lab_vnda_IncreaseDecreaseProductRevenueAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances" xlink:href="vnda-20201231.xsd#vnda_IncreaseDecreaseProductRevenueAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_IncreaseDecreaseProductRevenueAllowances" xlink:to="lab_vnda_IncreaseDecreaseProductRevenueAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5e733be9-4e66-4d00-b990-de89c5a1612d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6b0c7fd3-8e81-4fa8-8ad8-5cb832df92e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_8a93c91f-9bb6-476c-8ede-5f3fd2e400c5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0529e965-a9d6-45fc-b7f5-2ef71aa17ad5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_150a550e-8944-4968-9a2d-686df715282c_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0badf9ce-33cd-4c26-95a7-1fb746c6dd0f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f8dd137a-fc97-4f07-b8ea-dfa434ff37ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_1eb8468f-9e9d-44fe-a130-fb4665aedeb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember_39bfd8ca-31be-4288-9819-c4ca15619e5e_terseLabel_en-US" xlink:label="lab_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Credit Carryforwards and Uncertain Tax Positions</link:label>
    <link:label id="lab_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember_label_en-US" xlink:label="lab_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Credit Carryforwards and Uncertain Tax Positions [Member]</link:label>
    <link:label id="lab_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember_documentation_en-US" xlink:label="lab_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Credit Carryforwards and Uncertain Tax Positions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember" xlink:to="lab_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1874d47f-b2fb-43ab-8198-34f0e4ca7c30_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f564143f-21ec-45ab-ab95-40cf2fb4a7a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1007b354-0ec4-4741-a295-a1eb773a9f3e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_IncomeTaxesLineItems_1e43a377-8544-4051-98af-e17da31962a9_terseLabel_en-US" xlink:label="lab_vnda_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vnda_IncomeTaxesLineItems_label_en-US" xlink:label="lab_vnda_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vnda_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_vnda_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxesLineItems" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_IncomeTaxesLineItems" xlink:to="lab_vnda_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_71f520bb-7fab-4ad0-8a4c-d9bc453040d6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_786ad91f-88a5-455b-a25b-fe95665fa8ea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_a51b9414-8fd2-4284-b349-c45e91c0c766_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory, non-current</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dac9d8d-1ac0-4f90-adae-b20fed46b363_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6fb77db6-f28f-4c84-82d4-0b66844fb86e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Organization and Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock_3554299e-b621-4e5a-ab8c-38a1b1063f1d_terseLabel_en-US" xlink:label="lab_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities</link:label>
    <link:label id="lab_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Lease Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Lease Assets And Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1049b139-6677-4b96-9f58-8f8e567d5cbe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bae83035-c8fd-41b2-b733-e27b538841a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4d9fee29-e84b-448a-bf30-d77a19c15c49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_5f3dd606-e951-4022-b162-3597c41230af_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares subject to outstanding options and RSUs (in shares)</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options and Restricted Stock Units (RSUs) Outstanding Number</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_SalesMilestoneMember_3b20868f-8511-409a-83d8-228263d8b428_terseLabel_en-US" xlink:label="lab_vnda_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:label id="lab_vnda_SalesMilestoneMember_label_en-US" xlink:label="lab_vnda_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_vnda_SalesMilestoneMember_documentation_en-US" xlink:label="lab_vnda_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SalesMilestoneMember" xlink:href="vnda-20201231.xsd#vnda_SalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SalesMilestoneMember" xlink:to="lab_vnda_SalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_869cdc41-7535-444f-99a9-098e19484902_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0f5d9d71-330c-48f5-91c4-73f5b7d53de9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock_03b80bf1-5ae2-4f83-aff8-110c8694290d_terseLabel_en-US" xlink:label="lab_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" xlink:href="vnda-20201231.xsd#vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" xlink:to="lab_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0306fe18-1f7c-4069-9824-14bd69a19d37_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_cb06e1ad-6c21-41f8-9a29-3da55078ee62_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1712fc43-ded7-4ab9-8781-e68752183ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_804b13dc-a54f-4e05-a459-2ae7b550fa77_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6114a975-f7cd-480e-83d2-d6d3bc9657ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4229bbf6-2fcf-45ed-895b-071e104471a3_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current obligations under leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c649009b-2c7f-48cb-8888-5729be07f8eb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f72294d9-50b5-4a5b-8100-0308e9f6555f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_884081be-0584-446e-95f9-caa253f6deb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Income Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cd78d2f4-4407-4ff3-abe1-0d9025c837f8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_2a024be5-4b6b-4b06-93a7-880973514966_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8943c99e-c18c-4e9e-b955-d7a38518531e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_bfe2b862-e469-4005-b5b4-808d1db28fa7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_33ac38ab-5380-4580-835b-58642c3aca94_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_33117c2c-7304-48cd-b66a-f4dbda704f7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;Other Observable&#160;Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_44d807f5-e31a-4f29-a265-1bd1bc2d42b0_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_18658136-89dc-4bfd-a9fb-0cd1fb54224b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_8a37c4da-5f70-4ba5-a010-fb091550726a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangible asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_5457040e-65bc-48ca-95e1-ba259c8e1eb2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_0c33ce47-2643-49c5-8be2-23e159b66849_terseLabel_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]</link:label>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_label_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]</link:label>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_documentation_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:to="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ScenarioFourMember_e7d4590f-5073-4f98-a731-e58f494eba6c_terseLabel_en-US" xlink:label="lab_vnda_ScenarioFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 16,2016 through December 31,2019</link:label>
    <link:label id="lab_vnda_ScenarioFourMember_label_en-US" xlink:label="lab_vnda_ScenarioFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario 4 [Member]</link:label>
    <link:label id="lab_vnda_ScenarioFourMember_documentation_en-US" xlink:label="lab_vnda_ScenarioFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario 4 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScenarioFourMember" xlink:href="vnda-20201231.xsd#vnda_ScenarioFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScenarioFourMember" xlink:to="lab_vnda_ScenarioFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_Inventory_eddfc13a-c42b-497a-9d4d-0a04c4b15d1b_totalLabel_en-US" xlink:label="lab_vnda_Inventory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_vnda_Inventory_label_en-US" xlink:label="lab_vnda_Inventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_vnda_Inventory_documentation_en-US" xlink:label="lab_vnda_Inventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_Inventory" xlink:href="vnda-20201231.xsd#vnda_Inventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_Inventory" xlink:to="lab_vnda_Inventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_52f0efd3-098e-4ca4-8bcf-4a2a5cf1495e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e4d0c74a-fe59-40cb-a34b-07c22c343879_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_TieredRoyaltiesPayableOnFutureNetSales_7e406dd9-2dc4-412a-ac81-d46c1d193d5e_terseLabel_en-US" xlink:label="lab_vnda_TieredRoyaltiesPayableOnFutureNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalties payable on future net sales</link:label>
    <link:label id="lab_vnda_TieredRoyaltiesPayableOnFutureNetSales_label_en-US" xlink:label="lab_vnda_TieredRoyaltiesPayableOnFutureNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalties Payable on Future Net Sales</link:label>
    <link:label id="lab_vnda_TieredRoyaltiesPayableOnFutureNetSales_documentation_en-US" xlink:label="lab_vnda_TieredRoyaltiesPayableOnFutureNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalties potentially due to third party under license agreement based on future net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TieredRoyaltiesPayableOnFutureNetSales" xlink:href="vnda-20201231.xsd#vnda_TieredRoyaltiesPayableOnFutureNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_TieredRoyaltiesPayableOnFutureNetSales" xlink:to="lab_vnda_TieredRoyaltiesPayableOnFutureNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3bf1c161-6466-47d3-9972-b5c5aa9a8b9c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_5431842f-f523-468e-967b-368acb44db73_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_6bac0abd-7cef-4c37-be58-763b16902ca4_terseLabel_en-US" xlink:label="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vesting equal installments</link:label>
    <link:label id="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_label_en-US" xlink:label="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments</link:label>
    <link:label id="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_documentation_en-US" xlink:label="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:href="vnda-20201231.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:to="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_dbe99503-058a-4880-b797-fa3f1f2f7200_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5f283e2b-b7aa-441c-8c73-7fda64d85b20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0b8e6ae7-dbb1-4ff8-aad9-a588c9137cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aafa13de-dd37-4c12-aa1a-5105953cd5b1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a31af191-8a22-4d8a-a9a6-da4f805a257c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_VQW765Member_853c9abe-2b61-4df3-80a7-6a17818a5b2d_terseLabel_en-US" xlink:label="lab_vnda_VQW765Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VQW-765</link:label>
    <link:label id="lab_vnda_VQW765Member_label_en-US" xlink:label="lab_vnda_VQW765Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VQW-765 [Member]</link:label>
    <link:label id="lab_vnda_VQW765Member_documentation_en-US" xlink:label="lab_vnda_VQW765Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VQW-765</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_VQW765Member" xlink:href="vnda-20201231.xsd#vnda_VQW765Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_VQW765Member" xlink:to="lab_vnda_VQW765Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3c0d283e-ffdc-4f33-967b-7040c11a81f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_UnitedStatesExcludingDistrictOfColumbiaMember_fc115e68-4f2a-449b-90f6-9f2890a72eda_terseLabel_en-US" xlink:label="lab_vnda_UnitedStatesExcludingDistrictOfColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other States</link:label>
    <link:label id="lab_vnda_UnitedStatesExcludingDistrictOfColumbiaMember_label_en-US" xlink:label="lab_vnda_UnitedStatesExcludingDistrictOfColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States, Excluding District Of Columbia [Member]</link:label>
    <link:label id="lab_vnda_UnitedStatesExcludingDistrictOfColumbiaMember_documentation_en-US" xlink:label="lab_vnda_UnitedStatesExcludingDistrictOfColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States, Excluding District Of Columbia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_UnitedStatesExcludingDistrictOfColumbiaMember" xlink:href="vnda-20201231.xsd#vnda_UnitedStatesExcludingDistrictOfColumbiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_UnitedStatesExcludingDistrictOfColumbiaMember" xlink:to="lab_vnda_UnitedStatesExcludingDistrictOfColumbiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_03b191d4-c1de-477f-9cf0-ab9ecb1b877a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_8e9b4494-1e92-40a7-ad54-5321d6db93c2_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and accretion of discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f6676abe-319f-496c-a742-2faa043840bb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ea5e9218-6847-43c3-884b-14e50d3e6655_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc395897-2855-43e7-87c3-003a942a8a6d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_115b0dde-c38e-4e3e-bd46-e135dd39619f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_15a8cec4-88ac-4b5b-856f-9b6865cf73f4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_d2a3aa1a-561e-47b1-a91e-0d5a3289abfc_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_97dd1d4c-ba94-4aea-92e4-a183ccae2526_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_eca8ddd8-7c61-483a-a69a-cc619cfc0284_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Full acceleration of vesting, employee or executive officer subject to involuntary termination, period post change of control of the Company</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Service Option Awards, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Service Option Awards, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ComputerHardwareAndOtherEquipmentMember_feb775e1-1967-483e-b916-e550304e334f_terseLabel_en-US" xlink:label="lab_vnda_ComputerHardwareAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and other equipment</link:label>
    <link:label id="lab_vnda_ComputerHardwareAndOtherEquipmentMember_label_en-US" xlink:label="lab_vnda_ComputerHardwareAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware and Other Equipment [Member]</link:label>
    <link:label id="lab_vnda_ComputerHardwareAndOtherEquipmentMember_documentation_en-US" xlink:label="lab_vnda_ComputerHardwareAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware and Other Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ComputerHardwareAndOtherEquipmentMember" xlink:href="vnda-20201231.xsd#vnda_ComputerHardwareAndOtherEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ComputerHardwareAndOtherEquipmentMember" xlink:to="lab_vnda_ComputerHardwareAndOtherEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0ae28555-2bb8-44d0-ab8e-2511adfd9432_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75b4d348-d223-4cf3-a934-c233ab1b20d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d711cbec-0906-4ddb-8e80-d160a5fe899f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0012ad46-05c6-44fe-b58d-f0cfae6a63da_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_OperatingLeaseNonLeaseComponentExpense_20292b0d-9624-4f53-a8f9-d133de658a4f_terseLabel_en-US" xlink:label="lab_vnda_OperatingLeaseNonLeaseComponentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-lease component expense</link:label>
    <link:label id="lab_vnda_OperatingLeaseNonLeaseComponentExpense_label_en-US" xlink:label="lab_vnda_OperatingLeaseNonLeaseComponentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-Lease Component Expense</link:label>
    <link:label id="lab_vnda_OperatingLeaseNonLeaseComponentExpense_documentation_en-US" xlink:label="lab_vnda_OperatingLeaseNonLeaseComponentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-Lease Component Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OperatingLeaseNonLeaseComponentExpense" xlink:href="vnda-20201231.xsd#vnda_OperatingLeaseNonLeaseComponentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_OperatingLeaseNonLeaseComponentExpense" xlink:to="lab_vnda_OperatingLeaseNonLeaseComponentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_05b8d232-dfeb-49b5-af11-cc39fce07db4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_NumberOfProductsInPortfolio_49b73eda-47b0-477a-896e-7f85aa8e7c80_terseLabel_en-US" xlink:label="lab_vnda_NumberOfProductsInPortfolio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products in portfolio</link:label>
    <link:label id="lab_vnda_NumberOfProductsInPortfolio_label_en-US" xlink:label="lab_vnda_NumberOfProductsInPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products In Portfolio</link:label>
    <link:label id="lab_vnda_NumberOfProductsInPortfolio_documentation_en-US" xlink:label="lab_vnda_NumberOfProductsInPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products In Portfolio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_NumberOfProductsInPortfolio" xlink:href="vnda-20201231.xsd#vnda_NumberOfProductsInPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_NumberOfProductsInPortfolio" xlink:to="lab_vnda_NumberOfProductsInPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_26f3c28f-4e67-4782-a677-d856468133d2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expenses, weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_DC_3adaaeaa-251c-439b-baa9-b2a8b32f3052_verboseLabel_en-US" xlink:label="lab_stpr_DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Washington, D.C. Lease</link:label>
    <link:label id="lab_stpr_DC_68536946-0080-41ac-ab80-a3807087aa11_terseLabel_en-US" xlink:label="lab_stpr_DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">District of Columbia</link:label>
    <link:label id="lab_stpr_DC_label_en-US" xlink:label="lab_stpr_DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISTRICT OF COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_DC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_DC" xlink:to="lab_stpr_DC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9a1c20db-61b3-4328-a1ae-45affb6abda0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c3d9843e-93d8-4aaf-a0d1-6732362744a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3a4cbed5-e7ee-4506-9b8e-3bf3669f28dd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_2a0d2769-16ef-4305-a0df-8c6013fde28c_terseLabel_en-US" xlink:label="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and milestone payments to third party</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_label_en-US" xlink:label="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Milestone Obligations Paid To Third Party</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_documentation_en-US" xlink:label="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Milestone Obligations Paid To Third Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:to="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_3d6bf551-8421-4943-bb8e-e0eec17f9208_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CommitmentsAndContingenciesTable_4b23448d-76e7-4bf0-b2e1-658eacde4b58_terseLabel_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_vnda_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_vnda_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CommitmentsAndContingenciesTable" xlink:to="lab_vnda_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b65f0cb0-524a-490c-821e-96856a05fbc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_72cceb6d-2321-4e04-bc62-bfcbcbf2e84e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_3120dc1d-1a4b-4d5a-9fe3-fa8c9c245bd1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_870c136d-6a9e-4f47-91b4-1f232e729e96_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_fc91ee83-7b17-4a3e-8c91-7df6da0f6c5c_terseLabel_en-US" xlink:label="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Regulatory Approval And Sales Milestones</link:label>
    <link:label id="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_label_en-US" xlink:label="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Regulatory Approval And Sales Milestones [Member]</link:label>
    <link:label id="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_documentation_en-US" xlink:label="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Regulatory Approval And Sales Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:href="vnda-20201231.xsd#vnda_FutureRegulatoryApprovalAndSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:to="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_afbcd4a2-b091-4aed-8b09-f3f334d7c089_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_63878169-bbb9-4ef3-bac1-a41e07d570f4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_25aaedff-c829-416c-8885-0de06256c4e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5a6945e1-4219-4fb8-9c7e-d50e7494b5f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_86e6c336-8476-4699-8e48-5d841be9dfa9_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b48c93d6-3295-4ce6-8a79-2de580881ed4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_911f8d27-44ac-4809-88a4-3f19e709d566_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b1ab9e7e-5a25-4cc8-ace7-38f915f681d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Domestic and Foreign Components of Income Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6ef3798c-20b0-4710-9f39-de7e6876a729_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_01b0b338-cca4-4bc9-a69f-6816f3a8030f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_45e33a42-7ce8-45ba-8fbc-eac68b3582d5_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_8aa2b0ac-53d1-40aa-ab13-d1c6673d7657_totalLabel_en-US" xlink:label="lab_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_label_en-US" xlink:label="lab_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Liabilities Before Valuation Allowance Net</link:label>
    <link:label id="lab_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_documentation_en-US" xlink:label="lab_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" xlink:to="lab_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ff09d597-0fe7-43d2-8a99-3420075032a0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_946d9a0b-0a4c-485d-808a-34eaa7135bb3_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3b049bc-5775-4e6b-b382-e2c0f4e79c15_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_ea484d92-90a5-4fc9-bd18-8f84eac43e9c_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased square footage</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82664e0f-603c-47ca-8bec-d98aa7a469f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DefinedContributionPlanVestingPeriod_d183fd55-8fb1-489b-9bd1-fc39f58d162b_terseLabel_en-US" xlink:label="lab_vnda_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan vesting period</link:label>
    <link:label id="lab_vnda_DefinedContributionPlanVestingPeriod_label_en-US" xlink:label="lab_vnda_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Vesting Period</link:label>
    <link:label id="lab_vnda_DefinedContributionPlanVestingPeriod_documentation_en-US" xlink:label="lab_vnda_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period which an employee's right to employer matching contribution to defined contribution plan is no longer contingent on satisfaction of a service condition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DefinedContributionPlanVestingPeriod" xlink:href="vnda-20201231.xsd#vnda_DefinedContributionPlanVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DefinedContributionPlanVestingPeriod" xlink:to="lab_vnda_DefinedContributionPlanVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_ccd4ea7b-0f0c-4a25-b4b9-0a58ed70e5ce_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d6aaabd0-3c9c-415c-bc9d-eca32f1401a5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ce3b9b84-857c-4a65-97ff-ee1f56a37711_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_581e2e74-3e90-45ab-9c46-fa93c5256ffb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_OperatingLossCarryforwardsBeginningExpirationYear_ba92e2a0-5fa5-4d9f-8928-d5b0bdb1988a_terseLabel_en-US" xlink:label="lab_vnda_OperatingLossCarryforwardsBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards beginning expiration year</link:label>
    <link:label id="lab_vnda_OperatingLossCarryforwardsBeginningExpirationYear_label_en-US" xlink:label="lab_vnda_OperatingLossCarryforwardsBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Beginning Expiration Year</link:label>
    <link:label id="lab_vnda_OperatingLossCarryforwardsBeginningExpirationYear_documentation_en-US" xlink:label="lab_vnda_OperatingLossCarryforwardsBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The year in which operating loss carryforwards begin to expire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OperatingLossCarryforwardsBeginningExpirationYear" xlink:href="vnda-20201231.xsd#vnda_OperatingLossCarryforwardsBeginningExpirationYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_OperatingLossCarryforwardsBeginningExpirationYear" xlink:to="lab_vnda_OperatingLossCarryforwardsBeginningExpirationYear" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_ec440150-360e-4953-9618-e9039714a55c_terseLabel_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_label_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent</link:label>
    <link:label id="lab_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_documentation_en-US" xlink:label="lab_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:to="lab_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_a59a678f-7544-4778-923c-5e6221200679_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_e14e3103-92c8-4e28-93aa-caea837d9e8d_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e325450e-9587-48d1-9656-857f931ef547_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets related to U.S. federal research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_8c319b73-cb5a-4f15-915d-ec164ed3a172_terseLabel_en-US" xlink:label="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_label_en-US" xlink:label="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves, Non Current</link:label>
    <link:label id="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_documentation_en-US" xlink:label="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:href="vnda-20201231.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:to="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b6d3dadb-12cc-45f5-88c5-0a0611fdd513_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_d7056e3b-126f-43a9-973f-f020baf3356d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan employer matching percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_93aa8e32-b913-47ed-913b-0771106141be_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_8a2b28a2-4653-4392-8afa-c55c7a849458_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5a89e997-ffe4-4a60-a320-eef60fc3b9b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_646a569c-3962-448b-a0e2-7eaee4c04682_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad15877d-27e9-4314-a03d-821d7a645ba0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_3c094f94-45a0-4879-a007-f09749826b3d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_dc243b0a-297c-451c-b165-ff2d39b10960_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_OrphanDrugMember_965169b5-f4dd-4b98-8be6-53ed4d957cba_terseLabel_en-US" xlink:label="lab_vnda_OrphanDrugMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug</link:label>
    <link:label id="lab_vnda_OrphanDrugMember_label_en-US" xlink:label="lab_vnda_OrphanDrugMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug [Member]</link:label>
    <link:label id="lab_vnda_OrphanDrugMember_documentation_en-US" xlink:label="lab_vnda_OrphanDrugMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OrphanDrugMember" xlink:href="vnda-20201231.xsd#vnda_OrphanDrugMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_OrphanDrugMember" xlink:to="lab_vnda_OrphanDrugMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CustomerFourMember_a0823ee4-2b53-4418-9a06-cd6651be1902_terseLabel_en-US" xlink:label="lab_vnda_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor D</link:label>
    <link:label id="lab_vnda_CustomerFourMember_label_en-US" xlink:label="lab_vnda_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 4 [Member]</link:label>
    <link:label id="lab_vnda_CustomerFourMember_documentation_en-US" xlink:label="lab_vnda_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 4 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFourMember" xlink:href="vnda-20201231.xsd#vnda_CustomerFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CustomerFourMember" xlink:to="lab_vnda_CustomerFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_69718452-28bb-485c-8267-38cb9d23bfc8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1ce219b8-e6e4-471a-bc75-3f73a520a6a9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f401d3b5-1f14-41fd-bdf8-6ca43f980f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_StatementScenarioSecondaryAxis_f004f381-31af-471a-a67c-909de89ab1bf_terseLabel_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario Secondary [Axis]</link:label>
    <link:label id="lab_vnda_StatementScenarioSecondaryAxis_label_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario Secondary [Axis]</link:label>
    <link:label id="lab_vnda_StatementScenarioSecondaryAxis_documentation_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario Secondary [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StatementScenarioSecondaryAxis" xlink:href="vnda-20201231.xsd#vnda_StatementScenarioSecondaryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_StatementScenarioSecondaryAxis" xlink:to="lab_vnda_StatementScenarioSecondaryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2322e3df-4588-46c9-bd73-d8a32c97329c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5672633-cbbf-4706-84c1-b6fa9073e07a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d89cbf7d-7806-4f90-9d40-6867f5201a2e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6d8fc8da-91be-4e57-a760-a059e3400e81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_cfd4d054-4389-4631-af79-9bf2924651bb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c0d52c04-f524-4855-9b23-4140bfb624d2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from public offering of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5ce13ec5-2fb0-4f71-9797-28f7b44e2b9a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_dc1611a5-b488-409d-b182-e0149fcc1d70_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_94ec3d13-0e97-4079-aea8-d765a318c2b4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_DescriptionOfBusinessPolicyTextBlock_61246af4-f265-4f7b-bc19-acdc9088551f_terseLabel_en-US" xlink:label="lab_vnda_DescriptionOfBusinessPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Organization</link:label>
    <link:label id="lab_vnda_DescriptionOfBusinessPolicyTextBlock_label_en-US" xlink:label="lab_vnda_DescriptionOfBusinessPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business [Policy Text Block]</link:label>
    <link:label id="lab_vnda_DescriptionOfBusinessPolicyTextBlock_documentation_en-US" xlink:label="lab_vnda_DescriptionOfBusinessPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DescriptionOfBusinessPolicyTextBlock" xlink:href="vnda-20201231.xsd#vnda_DescriptionOfBusinessPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DescriptionOfBusinessPolicyTextBlock" xlink:to="lab_vnda_DescriptionOfBusinessPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f9f65796-62d1-489c-801b-1dda93413e79_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6e7d0a8a-b704-4dc0-b1c8-8372b0b8fa5f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_fd9a2048-2fc6-432b-9e92-96663c44d859_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in valuation allowances</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bc3b8ce8-342e-44ed-a4fb-e552eeb6470e_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_76cf2418-a50f-43a2-ae77-845e47b46234_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a6b5b484-90e5-42e2-b3ef-ec8934afbb87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Provision (Benefit) for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4554299a-6d09-4aea-824a-6a2c5bdf6c1a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b45cde68-f61b-4249-b5f9-e132d1e06171_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6d0375d5-4d2d-454c-aa03-edec532ea61f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Between Statutory Tax Rate and Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2940af05-a607-49c3-b5c9-6a6563a9b02d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 150,000,000 shares authorized; 54,865,092 and 53,549,612 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_c02e3a27-1975-4fdd-b2f6-078a5aaf37db_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1a313850-0a6e-42b1-b04e-948c2997d830_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_3633b450-0e7f-487a-8dbe-3484cd714f38_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f6d5c286-5789-4e27-b4d0-b30b1fd09984_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8264046b-b600-4970-99f7-011a6817e820_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d142a9ef-c34e-44ad-be2c-37f4906595a5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3ca663a7-ccf5-4235-b7f1-83a8e4a8dba9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_caa43e01-5eee-4596-8b4f-795d0d8e0c79_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_53d69bb9-6868-4b34-8ad1-e49736a8a25a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d5bb3bd-cc09-4858-bdec-294329bbfdbd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d1c5941a-ea35-4d03-b588-3c3bef9234cc_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f0865cd-bcba-491c-b0d1-7d74302eff8d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6edc8049-789a-4ab3-ab5e-a4197521468c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_dafb324a-12c1-4f0b-93ed-75d3d10b0849_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in:</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9da1a7f4-9302-40b1-8a02-d40b95abdaba_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f4890666-ad27-4038-869e-6a9188077389_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear_488ffbc0-7765-4f20-99c2-3fd92880f874_terseLabel_en-US" xlink:label="lab_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. research and development credit beginning expiration year</link:label>
    <link:label id="lab_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear_label_en-US" xlink:label="lab_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development, Credit Beginning, Expiration Year</link:label>
    <link:label id="lab_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear_documentation_en-US" xlink:label="lab_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development, Credit Beginning, Expiration Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear" xlink:href="vnda-20201231.xsd#vnda_ResearchAndDevelopmentCreditBeginningExpirationYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear" xlink:to="lab_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cd176987-696f-493f-aded-aa6d1333bfc3_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d37ee82f-93b3-4dae-b36e-9e2ff723db71_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_868d081d-bcd1-4eb5-8e3e-ed7c2bd22aff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1a91d429-ac8e-4084-8130-d41b3fa121e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant&#160;Date Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a022c775-08b5-4708-94dc-1585758ce5c9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_c523eb2c-ff72-41b5-8208-634edffb5251_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_36227063-f2aa-40be-bddb-85dcb326c330_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3ef100ab-9ff2-4e19-ae77-6f1f4d627732_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2ff23210-4bfb-4620-9267-86546d8f01ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_32a67c92-3cde-416d-979b-cf25d6f3605d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_19e2c829-c0cb-4ddc-aa26-dc90e6b67e9b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fc6bb487-ff13-4e5a-866d-461d6200e6a9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50787379-11c5-4023-b591-2cbf36c2064e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_e1c8405b-7a1c-4045-b41e-fe883577045b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_18b07912-2fd2-47d7-a146-f5f8fb5b33da_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ba94dc3b-b21e-4e87-a337-eda2def7cfa8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_45fda77f-e01a-45fe-b185-d5259a3e2806_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_aa15e68e-e2da-4a61-a0eb-7a335f791aab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_38d17d32-381c-424b-b1a8-e0631dfc17f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_093e815a-5eac-4372-b2c7-5d340d10dafd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d43cf47e-93c5-4b66-ac31-8a51734f1dd9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_1b0bd358-8dc3-4ca6-a40e-836dd94d36ce_terseLabel_en-US" xlink:label="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements for clinical and marketing services, termination notice period</link:label>
    <link:label id="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_label_en-US" xlink:label="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements For Clinical And Marketing Services, Termination Notice Period</link:label>
    <link:label id="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_documentation_en-US" xlink:label="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements For Clinical And Marketing Services, Termination Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:href="vnda-20201231.xsd#vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:to="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_278f491f-118b-4c57-86e5-8a257de68170_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_9bf35aca-d012-4821-8a5f-24e5006e3fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsAbstract_794dd4a3-f20f-42b7-92a5-5ab38785bd40_terseLabel_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CFTR activators and inhibitors</link:label>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsAbstract_label_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CFTR activators and inhibitors [Abstract]</link:label>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsAbstract_documentation_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CFTR activators and inhibitors [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsAbstract" xlink:href="vnda-20201231.xsd#vnda_CftrActivatorsAndInhibitorsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract" xlink:to="lab_vnda_CftrActivatorsAndInhibitorsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8baeb475-11c9-4eb9-b4d3-e145e9d223f4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_39022cc4-a92f-4612-b379-2ffd22f1da6b_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of initial stock options granted to employees that vests on employee's first anniversary</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of new hire stock option award that vests after one year of service.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_bfa42ecd-3737-4958-8093-494ebc74c6f0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fully amortized intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8fcd6b7a-9663-4c3c-a3a0-8f9cfd8797fd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_0fa761f4-4bd0-4e83-90a7-525d76813c03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Major Customers that Represented More Than 10% of Total Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0c52c33f-278d-4203-ab8b-9f6ace5d1e26_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3916ad20-0b19-4138-9a49-d137c4f6eaae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets relating to U.S. state NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_734d6f78-9ee5-429e-b54f-f56e4e036452_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from calculations of diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4a228ede-9a86-44f0-8778-cc09c69f7a1e_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_49f65334-ea57-4766-bd89-d16f5999f40b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0bac2e8b-8054-4aec-a48b-f98c3f9fbede_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_dc32bcc0-1919-4d35-85b7-445fa5866101_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_760b7e12-738c-4eaa-910d-16071f03e9f8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_947defac-a6a5-4bd5-b299-0f0b5d7b8ed8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5f4c88b8-fe99-42bf-a7d6-ef800098fd3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_30fdfa73-d8bd-4fdb-996c-4b89f2ef301d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6ca33edd-00ea-41ba-a0bf-b4c9cdf28760_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1e6b0235-12c5-48c7-a510-ea21464b8aa3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b7e54b94-f60e-4eee-a2c4-57221cd2a438_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_546082a2-ab2f-4f85-bf06-b6c09a46a111_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan maximum employee contribution percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_67271c37-568e-4649-9e72-21050d58af1f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_2d78c993-c7c1-464a-b99f-fc98ce2b0838_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government agencies</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_4ca1ed81-a8f8-4570-bd04-28cc92e03e89_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax rate changes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_49c2209a-a445-49bc-b9a6-b5df9bf64707_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8e99e80e-3d94-4ce6-9bcc-19a4f08aef09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_69ad00f6-453f-421b-b07a-46fbc68ed8aa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_1ad11d67-28cd-4318-9633-65f9ac17aa09_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_048d7236-bde2-48bc-94bc-21d38c34baa6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>vnda-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d614c307-4118-4611-a8d3-3c89a1b9f878,g:1f7774dc-f1ff-4a69-952a-c8825acf6b9a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_849e3739-8f76-40e3-a10c-26618793f48f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_DocumentType_849e3739-8f76-40e3-a10c-26618793f48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ff9fdf50-a9bc-4530-b644-4ba1d52249b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_DocumentAnnualReport_ff9fdf50-a9bc-4530-b644-4ba1d52249b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_33410d28-7c40-4903-b670-5d13e6a9bdce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_DocumentPeriodEndDate_33410d28-7c40-4903-b670-5d13e6a9bdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6f000469-2ec6-469d-ac82-a60cd4ae4c2d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_CurrentFiscalYearEndDate_6f000469-2ec6-469d-ac82-a60cd4ae4c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_14f6332e-76b2-4a2c-a1ec-668759a920a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_DocumentTransitionReport_14f6332e-76b2-4a2c-a1ec-668759a920a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_10dc2dcb-f385-4964-b4e0-fd123a90acc6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityFileNumber_10dc2dcb-f385-4964-b4e0-fd123a90acc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_14cdb931-6e37-420c-a6e8-9b5e5d0b2a97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityRegistrantName_14cdb931-6e37-420c-a6e8-9b5e5d0b2a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9094e4ca-f74c-4b2b-b3c5-5762aca7f2f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9094e4ca-f74c-4b2b-b3c5-5762aca7f2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_76c297a3-ac7b-4691-aca8-4fb3febb7079" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityTaxIdentificationNumber_76c297a3-ac7b-4691-aca8-4fb3febb7079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_73177610-251e-40b3-be02-31299592a10b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityAddressAddressLine1_73177610-251e-40b3-be02-31299592a10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_5360856a-a305-470f-a19b-f4f81c443f69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityAddressAddressLine2_5360856a-a305-470f-a19b-f4f81c443f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e3d7ac1f-dd56-4ce4-83d8-7edef467f664" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityAddressCityOrTown_e3d7ac1f-dd56-4ce4-83d8-7edef467f664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2a8330bf-66f3-4f82-b8e6-e7f4a423824f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityAddressStateOrProvince_2a8330bf-66f3-4f82-b8e6-e7f4a423824f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2ed749c1-c198-4d94-ab3b-2ce07a923bb9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityAddressPostalZipCode_2ed749c1-c198-4d94-ab3b-2ce07a923bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9358d032-9fa6-4dc3-9972-019fc06e7544" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_CityAreaCode_9358d032-9fa6-4dc3-9972-019fc06e7544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fb2531e3-1b24-4d96-bb59-cb7f701d5bae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_LocalPhoneNumber_fb2531e3-1b24-4d96-bb59-cb7f701d5bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2ee1cd17-4748-4047-9199-8361f6959302" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_Security12bTitle_2ee1cd17-4748-4047-9199-8361f6959302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2b23c549-25a0-48f5-a83c-4a5748c61217" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_TradingSymbol_2b23c549-25a0-48f5-a83c-4a5748c61217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_10738c98-afea-40a6-be48-50dd60ace1d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_SecurityExchangeName_10738c98-afea-40a6-be48-50dd60ace1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_d93624bd-edd5-4171-a96d-0725e39c5caf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_d93624bd-edd5-4171-a96d-0725e39c5caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_17e5947e-c1ec-4ec8-956d-5a2cc0eb6818" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityVoluntaryFilers_17e5947e-c1ec-4ec8-956d-5a2cc0eb6818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_41437f1d-8db2-496a-b424-7694f5fca491" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityCurrentReportingStatus_41437f1d-8db2-496a-b424-7694f5fca491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1004f3dc-8b8f-4694-87f9-496e5b6cfb80" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityInteractiveDataCurrent_1004f3dc-8b8f-4694-87f9-496e5b6cfb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_878f0abe-6bc5-443b-812e-615358fe1c1c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityFilerCategory_878f0abe-6bc5-443b-812e-615358fe1c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_aad8947d-573f-4372-b124-55b99b385dbf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntitySmallBusiness_aad8947d-573f-4372-b124-55b99b385dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b46da89f-87e8-455a-8e38-2d90400db4c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityEmergingGrowthCompany_b46da89f-87e8-455a-8e38-2d90400db4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_11ee0de9-7e4e-4c52-ba37-595b78f45297" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_IcfrAuditorAttestationFlag_11ee0de9-7e4e-4c52-ba37-595b78f45297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_be4928cb-447b-408b-82d3-287590f592f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityShellCompany_be4928cb-447b-408b-82d3-287590f592f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_6970f6c1-2c97-44ef-9d4e-b69d635ff963" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityPublicFloat_6970f6c1-2c97-44ef-9d4e-b69d635ff963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6dbb748b-8e51-4cef-90bd-64cf937d8491" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6dbb748b-8e51-4cef-90bd-64cf937d8491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_46fc3bbd-6b0d-4781-8125-5f53f595b56e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_46fc3bbd-6b0d-4781-8125-5f53f595b56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_015c0101-8b03-4ac9-a762-4dce2f8015d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_AmendmentFlag_015c0101-8b03-4ac9-a762-4dce2f8015d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_96d0346c-92f5-459e-8db8-600f7c5fd837" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_DocumentFiscalYearFocus_96d0346c-92f5-459e-8db8-600f7c5fd837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1fe859f3-46fd-4676-b5a2-bb48b827218b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1fe859f3-46fd-4676-b5a2-bb48b827218b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1c255f6c-bf14-4067-b9f8-4b6c15379ecc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44ad2bd5-8434-487f-9721-8fe0e6097915" xlink:to="loc_dei_EntityCentralIndexKey_1c255f6c-bf14-4067-b9f8-4b6c15379ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_550923ee-4ed4-41a6-8d9c-685da9baf34e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_550923ee-4ed4-41a6-8d9c-685da9baf34e" xlink:to="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_88c62d0e-da59-4431-8aa6-0c49f8d867b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_88c62d0e-da59-4431-8aa6-0c49f8d867b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef131a03-339d-4c7e-ab33-df852f5f9ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_88c62d0e-da59-4431-8aa6-0c49f8d867b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef131a03-339d-4c7e-ab33-df852f5f9ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b117c99c-4910-46d4-b62c-d3833da1bf14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_88c62d0e-da59-4431-8aa6-0c49f8d867b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b117c99c-4910-46d4-b62c-d3833da1bf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9056ef34-e9d1-4df6-80e8-e23d1e4f549a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_88c62d0e-da59-4431-8aa6-0c49f8d867b0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9056ef34-e9d1-4df6-80e8-e23d1e4f549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e0e09f75-b37b-4c1a-b66e-7159bfd0c00c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_88c62d0e-da59-4431-8aa6-0c49f8d867b0" xlink:to="loc_us-gaap_InventoryNet_e0e09f75-b37b-4c1a-b66e-7159bfd0c00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d37b68e0-64b9-4a94-840e-0bf2dae7ac05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_88c62d0e-da59-4431-8aa6-0c49f8d867b0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d37b68e0-64b9-4a94-840e-0bf2dae7ac05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_04dc571f-1c7c-4237-a3b4-a2569fb2ac8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_88c62d0e-da59-4431-8aa6-0c49f8d867b0" xlink:to="loc_us-gaap_AssetsCurrent_04dc571f-1c7c-4237-a3b4-a2569fb2ac8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bfb88678-a582-4b85-ad40-29bdf49dd6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bfb88678-a582-4b85-ad40-29bdf49dd6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_37219cf2-a79a-442a-8c34-6ec0d4f69a04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_37219cf2-a79a-442a-8c34-6ec0d4f69a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa69182e-6ae7-4cc6-8b8d-3a219aba498a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa69182e-6ae7-4cc6-8b8d-3a219aba498a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_84169acf-dce0-431e-8eaf-88135a1650d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_84169acf-dce0-431e-8eaf-88135a1650d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryAndOtherNonCurrent_37bdbe96-5b5d-4938-9858-e61c123b941e" xlink:href="vnda-20201231.xsd#vnda_InventoryAndOtherNonCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:to="loc_vnda_InventoryAndOtherNonCurrent_37bdbe96-5b5d-4938-9858-e61c123b941e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cbb1623b-18aa-415c-ad72-3b09cab44574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b110264-3161-46c5-a2c5-514dc45bf54d" xlink:to="loc_us-gaap_Assets_cbb1623b-18aa-415c-ad72-3b09cab44574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_550923ee-4ed4-41a6-8d9c-685da9baf34e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_24fb3004-e3f2-4f03-bc3e-543e17bd6402" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_24fb3004-e3f2-4f03-bc3e-543e17bd6402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_90e9ed8a-561d-4974-8852-9560262f55da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24fb3004-e3f2-4f03-bc3e-543e17bd6402" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_90e9ed8a-561d-4974-8852-9560262f55da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent_514187cf-c36e-4cb7-9ead-9169a3c33632" xlink:href="vnda-20201231.xsd#vnda_ProductRevenueAllowancesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24fb3004-e3f2-4f03-bc3e-543e17bd6402" xlink:to="loc_vnda_ProductRevenueAllowancesCurrent_514187cf-c36e-4cb7-9ead-9169a3c33632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e0946bae-9430-4079-9bb4-6f3d8ad47992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24fb3004-e3f2-4f03-bc3e-543e17bd6402" xlink:to="loc_us-gaap_LiabilitiesCurrent_e0946bae-9430-4079-9bb4-6f3d8ad47992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2a33062a-2215-4691-8d90-193a3d0077d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2a33062a-2215-4691-8d90-193a3d0077d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_70c83301-2c21-4807-83a5-2ede386f6579" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_70c83301-2c21-4807-83a5-2ede386f6579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_51886d46-69ab-4143-8ff6-cadafd875cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:to="loc_us-gaap_Liabilities_51886d46-69ab-4143-8ff6-cadafd875cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2de0b7f1-6099-4805-a6fd-fdf8015abf82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2de0b7f1-6099-4805-a6fd-fdf8015abf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5dc7b8f3-b716-43dd-ac94-e6e4e940e9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5dc7b8f3-b716-43dd-ac94-e6e4e940e9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4dc479b3-ba13-4275-8e46-25898543b744" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dc7b8f3-b716-43dd-ac94-e6e4e940e9b7" xlink:to="loc_us-gaap_PreferredStockValue_4dc479b3-ba13-4275-8e46-25898543b744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_59fc06bf-6ba0-45da-8203-54e16061ff07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dc7b8f3-b716-43dd-ac94-e6e4e940e9b7" xlink:to="loc_us-gaap_CommonStockValue_59fc06bf-6ba0-45da-8203-54e16061ff07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a3d50804-9d0c-4705-9ea3-f0969fef5809" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dc7b8f3-b716-43dd-ac94-e6e4e940e9b7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a3d50804-9d0c-4705-9ea3-f0969fef5809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_47ef00bd-4b7d-4fa4-9631-d164a1c1789d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dc7b8f3-b716-43dd-ac94-e6e4e940e9b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_47ef00bd-4b7d-4fa4-9631-d164a1c1789d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5559931-0f7f-437d-aa2f-cee3e170d292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dc7b8f3-b716-43dd-ac94-e6e4e940e9b7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5559931-0f7f-437d-aa2f-cee3e170d292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_44c9c930-762e-4398-80bb-c9e5a446eeee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dc7b8f3-b716-43dd-ac94-e6e4e940e9b7" xlink:to="loc_us-gaap_StockholdersEquity_44c9c930-762e-4398-80bb-c9e5a446eeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d29c39b-11a3-470e-be58-420d78a103ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e2196c6a-1387-47b3-84fe-1f01f10cf533" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d29c39b-11a3-470e-be58-420d78a103ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cfe7efe0-d002-42de-a494-33be5c3f7b98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cfe7efe0-d002-42de-a494-33be5c3f7b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e4433a89-90a1-4c3b-bf6c-111b59ebee46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e4433a89-90a1-4c3b-bf6c-111b59ebee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f4638042-2553-4bf5-bbf5-ef199947e734" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f4638042-2553-4bf5-bbf5-ef199947e734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d85e00b3-89c4-4646-903d-9c163cf5d1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d85e00b3-89c4-4646-903d-9c163cf5d1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_98d6d722-8f30-455c-8c55-31f01cdf6078" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_98d6d722-8f30-455c-8c55-31f01cdf6078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b5e11599-b72e-4444-8da7-15a418961232" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b5e11599-b72e-4444-8da7-15a418961232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a43d061e-6990-4b1d-aa67-a04ced8812c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:to="loc_us-gaap_CommonStockSharesIssued_a43d061e-6990-4b1d-aa67-a04ced8812c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a255d012-3251-4f36-a35b-4696a9c83209" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_af8793f9-7201-4889-a4e5-eaee16b1e31c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a255d012-3251-4f36-a35b-4696a9c83209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b1cfec4e-cd5d-4fe3-97f9-4544de99177e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_RevenuesAbstract_b1cfec4e-cd5d-4fe3-97f9-4544de99177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6f18c0c-7979-49e3-bfca-1460ae408e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b1cfec4e-cd5d-4fe3-97f9-4544de99177e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6f18c0c-7979-49e3-bfca-1460ae408e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_26cebf21-c46e-465f-b7d5-1bb360e6ffde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b1cfec4e-cd5d-4fe3-97f9-4544de99177e" xlink:to="loc_us-gaap_Revenues_26cebf21-c46e-465f-b7d5-1bb360e6ffde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2cfcf9cc-624b-4a6d-a62b-ec9f8fc546bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2cfcf9cc-624b-4a6d-a62b-ec9f8fc546bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_aca9ab34-0e5b-4f84-91e5-9794ad870d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2cfcf9cc-624b-4a6d-a62b-ec9f8fc546bc" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_aca9ab34-0e5b-4f84-91e5-9794ad870d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_baba5936-13f0-4f18-bbf9-c10b4864b941" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2cfcf9cc-624b-4a6d-a62b-ec9f8fc546bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_baba5936-13f0-4f18-bbf9-c10b4864b941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00a37441-599e-451b-bef0-a022253d2f47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2cfcf9cc-624b-4a6d-a62b-ec9f8fc546bc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00a37441-599e-451b-bef0-a022253d2f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4b058152-5a02-4c8c-b7ce-594999dc4c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2cfcf9cc-624b-4a6d-a62b-ec9f8fc546bc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4b058152-5a02-4c8c-b7ce-594999dc4c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1af07407-6ccc-437b-9cc3-f0b182a97b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2cfcf9cc-624b-4a6d-a62b-ec9f8fc546bc" xlink:to="loc_us-gaap_CostsAndExpenses_1af07407-6ccc-437b-9cc3-f0b182a97b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_93596151-a305-4d9b-953c-cfcc8537f0ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_OperatingIncomeLoss_93596151-a305-4d9b-953c-cfcc8537f0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_5922b8b5-dac1-4ba1-9bb1-ff928d7b730f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_OtherIncome_5922b8b5-dac1-4ba1-9bb1-ff928d7b730f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bd0fd2dd-3e27-49c2-be6c-daa5e1ed16c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bd0fd2dd-3e27-49c2-be6c-daa5e1ed16c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a228a74b-1a3f-4543-973b-a54a9354ae47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a228a74b-1a3f-4543-973b-a54a9354ae47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b4c50f98-21dd-41fd-bd27-655cf4f7152a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_NetIncomeLoss_b4c50f98-21dd-41fd-bd27-655cf4f7152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f9ba08e9-13b5-42b4-a0c5-e932a294dadb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f9ba08e9-13b5-42b4-a0c5-e932a294dadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a66aa3f7-fb39-496f-96c8-4e3727c70f03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f9ba08e9-13b5-42b4-a0c5-e932a294dadb" xlink:to="loc_us-gaap_EarningsPerShareBasic_a66aa3f7-fb39-496f-96c8-4e3727c70f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_da08d62e-4c25-43b0-ba03-23e5926cec82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f9ba08e9-13b5-42b4-a0c5-e932a294dadb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_da08d62e-4c25-43b0-ba03-23e5926cec82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d901ae17-5876-4198-a53f-c60940529779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6c0c936-7cd9-4952-8971-4f7c543e1f10" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d901ae17-5876-4198-a53f-c60940529779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04d7a337-f9ad-46c8-ab41-9d521a7ca454" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d901ae17-5876-4198-a53f-c60940529779" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04d7a337-f9ad-46c8-ab41-9d521a7ca454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5d8ea1e-de3d-45be-8ef2-c414dba8bae0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d901ae17-5876-4198-a53f-c60940529779" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5d8ea1e-de3d-45be-8ef2-c414dba8bae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_96499c5c-9c07-48c3-9918-150f74b33d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1814e04-197d-4874-81f4-e74bda935e96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_96499c5c-9c07-48c3-9918-150f74b33d99" xlink:to="loc_us-gaap_NetIncomeLoss_a1814e04-197d-4874-81f4-e74bda935e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_224d2dba-ba6a-4eea-8da2-76c4546e29c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_96499c5c-9c07-48c3-9918-150f74b33d99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_224d2dba-ba6a-4eea-8da2-76c4546e29c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_ce46e65b-709d-4867-ad15-c2347409ddd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_224d2dba-ba6a-4eea-8da2-76c4546e29c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_ce46e65b-709d-4867-ad15-c2347409ddd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_8a36537b-3210-48e7-b4ad-25682258556f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_224d2dba-ba6a-4eea-8da2-76c4546e29c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_8a36537b-3210-48e7-b4ad-25682258556f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_048bc61a-b73a-4266-8a57-974a6ad84033" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_224d2dba-ba6a-4eea-8da2-76c4546e29c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_048bc61a-b73a-4266-8a57-974a6ad84033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_be733a6b-74e5-48f6-9fd7-0007bb04fab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_224d2dba-ba6a-4eea-8da2-76c4546e29c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_be733a6b-74e5-48f6-9fd7-0007bb04fab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f28ec62e-bcbf-464e-904e-573425f8ff02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_96499c5c-9c07-48c3-9918-150f74b33d99" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f28ec62e-bcbf-464e-904e-573425f8ff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_624578e7-4230-40fc-b29f-f1b52b2952bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b25a8972-1419-4640-ac6c-50ac8f13d354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_624578e7-4230-40fc-b29f-f1b52b2952bd" xlink:to="loc_us-gaap_StatementTable_b25a8972-1419-4640-ac6c-50ac8f13d354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ecf6f8e9-d6ba-4317-9fab-77249816126a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b25a8972-1419-4640-ac6c-50ac8f13d354" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ecf6f8e9-d6ba-4317-9fab-77249816126a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ecf6f8e9-d6ba-4317-9fab-77249816126a" xlink:to="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f1c14b57-d9cc-4033-9fe4-5143148eb256" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:to="loc_us-gaap_CommonStockMember_f1c14b57-d9cc-4033-9fe4-5143148eb256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_de9ccefd-f217-46c8-ad46-2af2139a2996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_de9ccefd-f217-46c8-ad46-2af2139a2996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30c5433c-eca5-406f-ab4f-e45ce5cbdb93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30c5433c-eca5-406f-ab4f-e45ce5cbdb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7a85fedf-dd83-4903-97be-ac5183297e98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ef990b2-fbf8-4fd7-8dde-2453400dda1c" xlink:to="loc_us-gaap_RetainedEarningsMember_7a85fedf-dd83-4903-97be-ac5183297e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f071f6b2-5a0b-4a3c-9449-f29ce26cab62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b25a8972-1419-4640-ac6c-50ac8f13d354" xlink:to="loc_us-gaap_StatementLineItems_f071f6b2-5a0b-4a3c-9449-f29ce26cab62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f071f6b2-5a0b-4a3c-9449-f29ce26cab62" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_70a634e5-a7f6-4e90-bcb4-db5b45cbe6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_70a634e5-a7f6-4e90-bcb4-db5b45cbe6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13884249-5e55-489c-8c16-d72bfbfeb95f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockholdersEquity_13884249-5e55-489c-8c16-d72bfbfeb95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0317627-7142-4a88-b93c-8ee42752acb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0317627-7142-4a88-b93c-8ee42752acb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11091a17-2b32-4576-ae51-e3662fd00431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11091a17-2b32-4576-ae51-e3662fd00431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c1ba5769-d09b-42e6-a455-c3669ca3c7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c1ba5769-d09b-42e6-a455-c3669ca3c7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d9fc66a5-5715-468f-8ca8-d92ab6d2ae78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d9fc66a5-5715-468f-8ca8-d92ab6d2ae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5aa3df7-66cb-4d09-b50a-958c63255860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5aa3df7-66cb-4d09-b50a-958c63255860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a88238ea-555f-4516-8c54-c34d728d5f45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_NetIncomeLoss_a88238ea-555f-4516-8c54-c34d728d5f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1eeba536-ce32-42c4-81a7-ea83b3a40b92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1eeba536-ce32-42c4-81a7-ea83b3a40b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d2a075b9-32c0-45c8-a3ed-d5e81485fd71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d2a075b9-32c0-45c8-a3ed-d5e81485fd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fdf48c63-9d27-4419-937e-c892b24f8e83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c86df7a-eab2-40a9-ae8b-0fbd4cefa17a" xlink:to="loc_us-gaap_StockholdersEquity_fdf48c63-9d27-4419-937e-c892b24f8e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vnda-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1b22da74-e10e-48d8-ab07-78f41e0602fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_dfde98c3-e451-4962-80e8-bb9a79fc667f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b22da74-e10e-48d8-ab07-78f41e0602fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_dfde98c3-e451-4962-80e8-bb9a79fc667f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a3a2129-aad4-4bdb-a1da-2b1205e977c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_dfde98c3-e451-4962-80e8-bb9a79fc667f" xlink:to="loc_us-gaap_NetIncomeLoss_1a3a2129-aad4-4bdb-a1da-2b1205e977c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_dfde98c3-e451-4962-80e8-bb9a79fc667f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e4e6dcd2-c5e9-4626-8057-30e87eafab79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:to="loc_us-gaap_Depreciation_e4e6dcd2-c5e9-4626-8057-30e87eafab79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bfda4bc6-7f8a-4532-91d0-ded341b6e354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:to="loc_us-gaap_ShareBasedCompensation_bfda4bc6-7f8a-4532-91d0-ded341b6e354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_30a360eb-effa-4c69-b113-89bc576b1225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_30a360eb-effa-4c69-b113-89bc576b1225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_fe0876fb-ddcb-4389-b051-bc549537df47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_fe0876fb-ddcb-4389-b051-bc549537df47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f1d50825-0598-4a48-8843-aa0d26a96c31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f1d50825-0598-4a48-8843-aa0d26a96c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_291a8313-f1ff-4f9e-a4a7-a8451dc7accf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_291a8313-f1ff-4f9e-a4a7-a8451dc7accf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b0adf6a3-2b25-483e-8c13-977a89c6ec2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b0adf6a3-2b25-483e-8c13-977a89c6ec2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_e1e4a0cb-8a59-4117-9e06-eb6a69002039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_058f1943-3465-48e7-a35e-ecb9fa6f4c42" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_e1e4a0cb-8a59-4117-9e06-eb6a69002039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c4513848-f96e-4201-b040-a60c335057f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_e1e4a0cb-8a59-4117-9e06-eb6a69002039" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c4513848-f96e-4201-b040-a60c335057f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d9aa25b7-414c-4098-a568-fe2195c5db94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_e1e4a0cb-8a59-4117-9e06-eb6a69002039" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d9aa25b7-414c-4098-a568-fe2195c5db94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6a4c3a20-babb-42cc-b30f-d842c5fd7ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_e1e4a0cb-8a59-4117-9e06-eb6a69002039" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6a4c3a20-babb-42cc-b30f-d842c5fd7ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3423bbed-f840-4bbf-82a0-71b8b9ff64b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_e1e4a0cb-8a59-4117-9e06-eb6a69002039" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3423bbed-f840-4bbf-82a0-71b8b9ff64b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances_6af9b307-12af-4001-b303-030c580c0521" xlink:href="vnda-20201231.xsd#vnda_IncreaseDecreaseProductRevenueAllowances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_e1e4a0cb-8a59-4117-9e06-eb6a69002039" xlink:to="loc_vnda_IncreaseDecreaseProductRevenueAllowances_6af9b307-12af-4001-b303-030c580c0521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04abdb-03d3-4e36-963d-521d77264d13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_dfde98c3-e451-4962-80e8-bb9a79fc667f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04abdb-03d3-4e36-963d-521d77264d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c71078dc-e491-46e5-a9b7-fa83cf5d8574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b22da74-e10e-48d8-ab07-78f41e0602fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c71078dc-e491-46e5-a9b7-fa83cf5d8574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_df8d799f-b1af-4662-b42c-8c846b9405e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c71078dc-e491-46e5-a9b7-fa83cf5d8574" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_df8d799f-b1af-4662-b42c-8c846b9405e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8a7a5ad5-1a9e-4f7b-b6a5-f50f0db29730" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c71078dc-e491-46e5-a9b7-fa83cf5d8574" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8a7a5ad5-1a9e-4f7b-b6a5-f50f0db29730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6358a20b-8d5a-4f19-95a8-3660bdecc28f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c71078dc-e491-46e5-a9b7-fa83cf5d8574" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6358a20b-8d5a-4f19-95a8-3660bdecc28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f7d96a91-1108-4405-b1c4-110e65dca5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c71078dc-e491-46e5-a9b7-fa83cf5d8574" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f7d96a91-1108-4405-b1c4-110e65dca5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a107765-ef3b-49c7-8390-40d195552196" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c71078dc-e491-46e5-a9b7-fa83cf5d8574" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a107765-ef3b-49c7-8390-40d195552196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a150360c-1e5f-4272-8452-db960328b0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b22da74-e10e-48d8-ab07-78f41e0602fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a150360c-1e5f-4272-8452-db960328b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_98bd070f-9b2b-4c08-939c-6fd608e0a26c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a150360c-1e5f-4272-8452-db960328b0ef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_98bd070f-9b2b-4c08-939c-6fd608e0a26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_44f5dee8-85fc-427c-90b3-4ba07c2602fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a150360c-1e5f-4272-8452-db960328b0ef" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_44f5dee8-85fc-427c-90b3-4ba07c2602fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6bbfd6ed-5f22-406d-9a1d-0d9c2a1243b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a150360c-1e5f-4272-8452-db960328b0ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6bbfd6ed-5f22-406d-9a1d-0d9c2a1243b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3aef3eb-f90f-494a-93f5-85672d6561c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b22da74-e10e-48d8-ab07-78f41e0602fc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3aef3eb-f90f-494a-93f5-85672d6561c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de4d3f5d-37a2-4425-b81f-f0c75ce524aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b22da74-e10e-48d8-ab07-78f41e0602fc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de4d3f5d-37a2-4425-b81f-f0c75ce524aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_fa87b8ab-a9dd-4c77-b3a5-6f3215984499" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b22da74-e10e-48d8-ab07-78f41e0602fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_fa87b8ab-a9dd-4c77-b3a5-6f3215984499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3c38231-94ac-438a-b579-67758413d79f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_fa87b8ab-a9dd-4c77-b3a5-6f3215984499" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3c38231-94ac-438a-b579-67758413d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21d94651-4c05-438c-b0ec-ae5b1be509e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_fa87b8ab-a9dd-4c77-b3a5-6f3215984499" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21d94651-4c05-438c-b0ec-ae5b1be509e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation" xlink:type="simple" xlink:href="vnda-20201231.xsd#BusinessOrganizationandPresentation"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7617615b-1167-402d-bad4-54c5a05f8737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_bf3fc37f-4986-4545-98dd-d77b948c8948" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7617615b-1167-402d-bad4-54c5a05f8737" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_bf3fc37f-4986-4545-98dd-d77b948c8948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#BusinessOrganizationandPresentationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df5140f1-5f8e-435d-bbd1-b63daa17de11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_02dd4b28-6811-4e95-a4dc-2e492b966f52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df5140f1-5f8e-435d-bbd1-b63daa17de11" xlink:to="loc_us-gaap_NumberOfOperatingSegments_02dd4b28-6811-4e95-a4dc-2e492b966f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_NumberOfProductsInPortfolio_3a32bd60-98de-4e8a-bc51-626df1806385" xlink:href="vnda-20201231.xsd#vnda_NumberOfProductsInPortfolio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df5140f1-5f8e-435d-bbd1-b63daa17de11" xlink:to="loc_vnda_NumberOfProductsInPortfolio_3a32bd60-98de-4e8a-bc51-626df1806385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_451da444-cbb1-4389-b7b1-4fe9e8ead635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_507681e5-01a0-411c-876f-15558331d4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_451da444-cbb1-4389-b7b1-4fe9e8ead635" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_507681e5-01a0-411c-876f-15558331d4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DescriptionOfBusinessPolicyTextBlock_1062af0d-4f29-4f63-abbf-c700fca82654" xlink:href="vnda-20201231.xsd#vnda_DescriptionOfBusinessPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_vnda_DescriptionOfBusinessPolicyTextBlock_1062af0d-4f29-4f63-abbf-c700fca82654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a967e8be-e9af-4531-98b1-db3000bff786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a967e8be-e9af-4531-98b1-db3000bff786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f6b4ce29-be65-403a-b5f2-66861c689d29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_UseOfEstimates_f6b4ce29-be65-403a-b5f2-66861c689d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_84feaa2d-af45-4848-a33a-112f3f71682a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_84feaa2d-af45-4848-a33a-112f3f71682a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_2c3cd4f5-f84d-4f29-b4ee-f8b6e4268195" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_2c3cd4f5-f84d-4f29-b4ee-f8b6e4268195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_2ef94f62-a750-425d-a27b-f427a414c035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_2ef94f62-a750-425d-a27b-f427a414c035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_0ed96d09-7877-418a-afee-e9b9e7e25dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_0ed96d09-7877-418a-afee-e9b9e7e25dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_af9c19ed-7f47-40ef-aa67-7acf8fd56ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_af9c19ed-7f47-40ef-aa67-7acf8fd56ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_7e150009-c44b-41d7-b958-6d2149d7c004" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_7e150009-c44b-41d7-b958-6d2149d7c004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock_b78c869e-a19f-4883-80d1-d35be144bd2c" xlink:href="vnda-20201231.xsd#vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock_b78c869e-a19f-4883-80d1-d35be144bd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_a95f1ca8-256f-4486-9c19-5507bf920818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_a95f1ca8-256f-4486-9c19-5507bf920818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_b9451869-f8d5-4d55-96ac-81ee609c2b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_b9451869-f8d5-4d55-96ac-81ee609c2b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ReservesForVariableConsiderationPolicyTextBlock_2bab943b-fe1f-49a0-bfe9-dce37f890bd0" xlink:href="vnda-20201231.xsd#vnda_ReservesForVariableConsiderationPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_vnda_ReservesForVariableConsiderationPolicyTextBlock_2bab943b-fe1f-49a0-bfe9-dce37f890bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_aefcd316-eb1e-4f67-82f2-f7d03aa36276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_aefcd316-eb1e-4f67-82f2-f7d03aa36276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0fa67a58-9aee-43dc-93c6-94fd9a526835" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0fa67a58-9aee-43dc-93c6-94fd9a526835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_1acad2e4-e48b-4e62-bc0f-64e3dbc30248" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_1acad2e4-e48b-4e62-bc0f-64e3dbc30248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7ee31482-6105-4d7e-b4e4-3ec7159c76a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7ee31482-6105-4d7e-b4e4-3ec7159c76a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_59d41b5e-4d11-4638-bb4d-be9f726d57eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_59d41b5e-4d11-4638-bb4d-be9f726d57eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d7aae0f9-6b6d-47a6-953e-c727f1f43fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d7aae0f9-6b6d-47a6-953e-c727f1f43fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2981c7bc-914c-408b-9395-a95639eb2482" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2981c7bc-914c-408b-9395-a95639eb2482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f635e3a8-3418-4414-99b9-3dc4f71dcd24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f635e3a8-3418-4414-99b9-3dc4f71dcd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_d005e9bb-0690-4c5c-b538-7a35d855c591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3207ffe-e105-45e7-898a-020c2101636a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_d005e9bb-0690-4c5c-b538-7a35d855c591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_89a3d649-3930-4743-ab1c-e996530e8dec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c6f21be5-849c-40d1-9acf-161a5b5ebd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89a3d649-3930-4743-ab1c-e996530e8dec" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c6f21be5-849c-40d1-9acf-161a5b5ebd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8ce1e237-47fc-49d9-a70f-e7fd50dde1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89a3d649-3930-4743-ab1c-e996530e8dec" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8ce1e237-47fc-49d9-a70f-e7fd50dde1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_50407ea9-6d74-4019-8d05-2d6c896b735d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89a3d649-3930-4743-ab1c-e996530e8dec" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_50407ea9-6d74-4019-8d05-2d6c896b735d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock_a612601a-22a5-4743-b2bc-b4ba6bbde73e" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89a3d649-3930-4743-ab1c-e996530e8dec" xlink:to="loc_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock_a612601a-22a5-4743-b2bc-b4ba6bbde73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock_b5139a6b-722c-4127-a87a-900857e98dbe" xlink:href="vnda-20201231.xsd#vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89a3d649-3930-4743-ab1c-e996530e8dec" xlink:to="loc_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock_b5139a6b-722c-4127-a87a-900857e98dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_19e5ecd3-84fb-4c33-8f56-60307f7782a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e836091-1e7f-4b5b-8b95-976fd4df74da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19e5ecd3-84fb-4c33-8f56-60307f7782a3" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e836091-1e7f-4b5b-8b95-976fd4df74da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c506ac4-39f2-453a-905f-5e133f2691c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e836091-1e7f-4b5b-8b95-976fd4df74da" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c506ac4-39f2-453a-905f-5e133f2691c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b8986265-5f1f-40a7-97b1-c4350f8bf4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c506ac4-39f2-453a-905f-5e133f2691c1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b8986265-5f1f-40a7-97b1-c4350f8bf4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2bbecc0a-7512-453d-bf0c-0fd4a23c041f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8986265-5f1f-40a7-97b1-c4350f8bf4ac" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2bbecc0a-7512-453d-bf0c-0fd4a23c041f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_NoncurrentInventoryAndOtherMember_70bf4b01-f527-4e56-9c39-a329f2234885" xlink:href="vnda-20201231.xsd#vnda_NoncurrentInventoryAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8986265-5f1f-40a7-97b1-c4350f8bf4ac" xlink:to="loc_vnda_NoncurrentInventoryAndOtherMember_70bf4b01-f527-4e56-9c39-a329f2234885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e836091-1e7f-4b5b-8b95-976fd4df74da" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2758726b-328e-418e-a141-0efa4cd31f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2758726b-328e-418e-a141-0efa4cd31f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c9c53631-ed9a-473d-8af6-7f3e14970b44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c9c53631-ed9a-473d-8af6-7f3e14970b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_8cc17f34-8fa4-4467-a4c4-fc06f9d3855d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c9c53631-ed9a-473d-8af6-7f3e14970b44" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_8cc17f34-8fa4-4467-a4c4-fc06f9d3855d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d4aba0c-7c64-4922-933b-03bde03550b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6126a924-a3f5-4af3-8ca3-291e92782ff4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d4aba0c-7c64-4922-933b-03bde03550b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7ca17182-fae1-4259-b388-3b1dcea3b90d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1721921a-1e80-49e8-8af7-9b6039d24c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ca17182-fae1-4259-b388-3b1dcea3b90d" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1721921a-1e80-49e8-8af7-9b6039d24c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a154a8f7-204e-4612-bc87-8ddd593981f8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1721921a-1e80-49e8-8af7-9b6039d24c6e" xlink:to="loc_srt_ProductOrServiceAxis_a154a8f7-204e-4612-bc87-8ddd593981f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c207d623-9fb0-44bb-a465-69d51a3feaa5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a154a8f7-204e-4612-bc87-8ddd593981f8" xlink:to="loc_srt_ProductsAndServicesDomain_c207d623-9fb0-44bb-a465-69d51a3feaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_08c710c4-44c1-4d1f-8f40-7b551065d202" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c207d623-9fb0-44bb-a465-69d51a3feaa5" xlink:to="loc_vnda_HetliozMember_08c710c4-44c1-4d1f-8f40-7b551065d202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptMember_879ce115-8644-4828-a149-ed86264a60ea" xlink:href="vnda-20201231.xsd#vnda_FanaptMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c207d623-9fb0-44bb-a465-69d51a3feaa5" xlink:to="loc_vnda_FanaptMember_879ce115-8644-4828-a149-ed86264a60ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c390d1a8-217f-43e4-9793-94b5abd51d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1721921a-1e80-49e8-8af7-9b6039d24c6e" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c390d1a8-217f-43e4-9793-94b5abd51d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_374b5e92-eea9-456c-970c-232acacba650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c390d1a8-217f-43e4-9793-94b5abd51d4f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_374b5e92-eea9-456c-970c-232acacba650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1f6b73cb-4330-4b4e-b2ae-7816f35cd8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1f6b73cb-4330-4b4e-b2ae-7816f35cd8d4" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f7fe25b6-21ab-4904-a5ef-c97936b3a29c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f7fe25b6-21ab-4904-a5ef-c97936b3a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_015100e4-7b20-4e0d-86ea-e06e3237794d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f7fe25b6-21ab-4904-a5ef-c97936b3a29c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_015100e4-7b20-4e0d-86ea-e06e3237794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8998c314-1164-4ef0-97ed-24908907347d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_015100e4-7b20-4e0d-86ea-e06e3237794d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8998c314-1164-4ef0-97ed-24908907347d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_997f76e7-8b74-40b2-87a6-bb5d3fccf53c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_997f76e7-8b74-40b2-87a6-bb5d3fccf53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e3275f4-63e7-41b5-be43-f0da3bd718aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_997f76e7-8b74-40b2-87a6-bb5d3fccf53c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e3275f4-63e7-41b5-be43-f0da3bd718aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_bc385ce9-1683-439a-b04a-52ffe5e941a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e3275f4-63e7-41b5-be43-f0da3bd718aa" xlink:to="loc_us-gaap_SalesRevenueNetMember_bc385ce9-1683-439a-b04a-52ffe5e941a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9136337f-3d11-4820-aa70-dab04547aaa5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:to="loc_srt_MajorCustomersAxis_9136337f-3d11-4820-aa70-dab04547aaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9136337f-3d11-4820-aa70-dab04547aaa5" xlink:to="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerOneMember_40f986c8-8964-4c07-8761-ef2d010c559d" xlink:href="vnda-20201231.xsd#vnda_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerOneMember_40f986c8-8964-4c07-8761-ef2d010c559d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerTwoMember_83381fca-2a31-46a6-9df1-4620b14dde30" xlink:href="vnda-20201231.xsd#vnda_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerTwoMember_83381fca-2a31-46a6-9df1-4620b14dde30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerThreeMember_73e3528b-6542-472d-8fee-470ab6ae894e" xlink:href="vnda-20201231.xsd#vnda_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerThreeMember_73e3528b-6542-472d-8fee-470ab6ae894e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFiveMember_16bc6bfa-3620-465d-81fe-3ec74c3653b5" xlink:href="vnda-20201231.xsd#vnda_CustomerFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerFiveMember_16bc6bfa-3620-465d-81fe-3ec74c3653b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFourMember_2d931154-1fb6-4da2-a5bd-1f305c781f9b" xlink:href="vnda-20201231.xsd#vnda_CustomerFourMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc65bd34-ac6f-4c01-8090-8a59bfc487bb" xlink:to="loc_vnda_CustomerFourMember_2d931154-1fb6-4da2-a5bd-1f305c781f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a522b715-c5bc-4b02-9ae9-a62dc1ebbccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f02c203c-7931-40f8-90fb-66ca54faf312" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a522b715-c5bc-4b02-9ae9-a62dc1ebbccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_79696a80-23ca-4401-88f6-308353c54c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a522b715-c5bc-4b02-9ae9-a62dc1ebbccf" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_79696a80-23ca-4401-88f6-308353c54c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_afb28260-5b83-44b0-85c0-802b49bec4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afb28260-5b83-44b0-85c0-802b49bec4e3" xlink:to="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f2c2b4eb-66c1-4118-af67-263c2f72217d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f2c2b4eb-66c1-4118-af67-263c2f72217d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a6032a1-c6eb-4c16-9bbe-4b7a563cdbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f2c2b4eb-66c1-4118-af67-263c2f72217d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a6032a1-c6eb-4c16-9bbe-4b7a563cdbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_5baafc26-dcd2-42aa-8691-7d8f4d2ea4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5a6032a1-c6eb-4c16-9bbe-4b7a563cdbb0" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_5baafc26-dcd2-42aa-8691-7d8f4d2ea4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f4ea2d40-31f4-41ed-939d-7584bffa7910" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494ac2c9-8aeb-4cb0-b88c-5030ec5a71f1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f4ea2d40-31f4-41ed-939d-7584bffa7910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_79c8964e-ae0b-4cc2-a85f-83aed0bb5929" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f4ea2d40-31f4-41ed-939d-7584bffa7910" xlink:to="loc_us-gaap_AccountsReceivableMember_79c8964e-ae0b-4cc2-a85f-83aed0bb5929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dc70a4ad-248f-45e5-989c-e871f4780aad" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:to="loc_srt_MajorCustomersAxis_dc70a4ad-248f-45e5-989c-e871f4780aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_dc70a4ad-248f-45e5-989c-e871f4780aad" xlink:to="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerOneMember_b33089d8-e426-4b98-a8ef-06d365efd561" xlink:href="vnda-20201231.xsd#vnda_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerOneMember_b33089d8-e426-4b98-a8ef-06d365efd561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerTwoMember_4871faa1-cdfe-4fe6-bbde-419d7f42b08d" xlink:href="vnda-20201231.xsd#vnda_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerTwoMember_4871faa1-cdfe-4fe6-bbde-419d7f42b08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerThreeMember_edb2059d-5adf-4975-a87f-96a3ac75cb72" xlink:href="vnda-20201231.xsd#vnda_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerThreeMember_edb2059d-5adf-4975-a87f-96a3ac75cb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFourMember_5d024f27-3867-440c-b519-34d84ac0189e" xlink:href="vnda-20201231.xsd#vnda_CustomerFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerFourMember_5d024f27-3867-440c-b519-34d84ac0189e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CustomerFiveMember_166eefba-a1fb-4676-8a67-d8782f4af830" xlink:href="vnda-20201231.xsd#vnda_CustomerFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_44292069-3ae9-44fc-a2f9-1b92e260162e" xlink:to="loc_vnda_CustomerFiveMember_166eefba-a1fb-4676-8a67-d8782f4af830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_814fe02b-3ca4-42e8-b6d3-0e47a022ee46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_28fe8f76-76c0-4962-aaec-30020c050a82" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_814fe02b-3ca4-42e8-b6d3-0e47a022ee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e0d10e86-0763-427c-8e16-cb27c6bd57d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_814fe02b-3ca4-42e8-b6d3-0e47a022ee46" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e0d10e86-0763-427c-8e16-cb27c6bd57d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_76f318fe-fbea-4584-8a69-bc40d410a539" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD_41998dd6-0d1e-4491-ae04-77a92b7c5af0" xlink:href="vnda-20201231.xsd#vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76f318fe-fbea-4584-8a69-bc40d410a539" xlink:to="loc_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD_41998dd6-0d1e-4491-ae04-77a92b7c5af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_9e0f90f9-ed40-466c-baf6-90d0a6c76c49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76f318fe-fbea-4584-8a69-bc40d410a539" xlink:to="loc_us-gaap_AdvertisingExpense_9e0f90f9-ed40-466c-baf6-90d0a6c76c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_8bd85b75-2c6b-448b-9c68-6a235041d5cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76f318fe-fbea-4584-8a69-bc40d410a539" xlink:to="loc_us-gaap_NumberOfReportableSegments_8bd85b75-2c6b-448b-9c68-6a235041d5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7d4e41b1-68bf-487a-b5f8-4a30b4153ece" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_804a7b6b-8e8b-476c-ba0b-c461bdf81749" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d4e41b1-68bf-487a-b5f8-4a30b4153ece" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_804a7b6b-8e8b-476c-ba0b-c461bdf81749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_941725b7-6303-4074-9dda-d950cb106333" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_804a7b6b-8e8b-476c-ba0b-c461bdf81749" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_941725b7-6303-4074-9dda-d950cb106333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_904498a6-d508-430d-9f7b-a30e920cd602" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_941725b7-6303-4074-9dda-d950cb106333" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_904498a6-d508-430d-9f7b-a30e920cd602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SECSchedule1209AllowanceProductReturnsMember_07af03ec-5cb2-4432-a007-27d4235fbb8c" xlink:href="vnda-20201231.xsd#vnda_SECSchedule1209AllowanceProductReturnsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_904498a6-d508-430d-9f7b-a30e920cd602" xlink:to="loc_vnda_SECSchedule1209AllowanceProductReturnsMember_07af03ec-5cb2-4432-a007-27d4235fbb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65fb18b-ba70-423c-8d61-b2fc3b0cb3a7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_804a7b6b-8e8b-476c-ba0b-c461bdf81749" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65fb18b-ba70-423c-8d61-b2fc3b0cb3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b65fb18b-ba70-423c-8d61-b2fc3b0cb3a7" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8bba59c7-4084-4e5c-8cce-4585ec7e6548" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8bba59c7-4084-4e5c-8cce-4585ec7e6548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_2f21a641-b269-43ee-9a66-6b5864dc5446" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_2f21a641-b269-43ee-9a66-6b5864dc5446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_adb171c1-face-430a-85da-9961f155fd47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_adb171c1-face-430a-85da-9961f155fd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0ad69b5d-e702-44fc-906c-80c265fff695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f41e112e-6384-4c57-bf83-57260263f1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0ad69b5d-e702-44fc-906c-80c265fff695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc00d41-93f7-41bb-918f-5031bdf5f25e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_456a5c6d-dacf-410a-b53f-bfc72ec026d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc00d41-93f7-41bb-918f-5031bdf5f25e" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_456a5c6d-dacf-410a-b53f-bfc72ec026d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa764ee4-6f3f-4468-92e8-5572578ac201" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9a7ccc88-0159-4955-a407-ad75712a4ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa764ee4-6f3f-4468-92e8-5572578ac201" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9a7ccc88-0159-4955-a407-ad75712a4ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1f357b4-6d0c-4f01-8ea8-90e9fb807d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70855e4b-951b-482f-8c84-db48333c54fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1f357b4-6d0c-4f01-8ea8-90e9fb807d2e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70855e4b-951b-482f-8c84-db48333c54fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_845bb818-9dc9-44a9-b4d6-d97fba629177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70855e4b-951b-482f-8c84-db48333c54fc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_845bb818-9dc9-44a9-b4d6-d97fba629177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_845bb818-9dc9-44a9-b4d6-d97fba629177" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_d12c5ea1-241f-4cfd-85b4-ef72979fa08b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_d12c5ea1-241f-4cfd-85b4-ef72979fa08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_aac3f82d-f1ed-492d-89cc-89b838ee8c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_aac3f82d-f1ed-492d-89cc-89b838ee8c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9e51fea5-651b-43f9-bbc1-2aab32f228f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37efbbfb-41a1-4a92-89ee-79421793eeff" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9e51fea5-651b-43f9-bbc1-2aab32f228f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70855e4b-951b-482f-8c84-db48333c54fc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f381a9f3-f26e-4d74-9015-b309640a745e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f381a9f3-f26e-4d74-9015-b309640a745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_158d8ea1-2c70-4fad-b1e8-e44fa2e8a9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_158d8ea1-2c70-4fad-b1e8-e44fa2e8a9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38113a5a-2277-4332-aa27-68f7d436ff40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38113a5a-2277-4332-aa27-68f7d436ff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3bfa18f9-8144-4a5f-84c9-d124109a533c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a107f6a-06a8-4f0a-8053-1fae24851b76" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3bfa18f9-8144-4a5f-84c9-d124109a533c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89cbf58c-79b9-4468-9294-a086e1485105" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_18c64e33-43ed-4e5a-8b03-940ba1ecd6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89cbf58c-79b9-4468-9294-a086e1485105" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_18c64e33-43ed-4e5a-8b03-940ba1ecd6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f27cf3d1-8579-4141-b470-3a084f2a2f85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_258dc2b9-0a29-427b-8455-194c1653f10a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f27cf3d1-8579-4141-b470-3a084f2a2f85" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_258dc2b9-0a29-427b-8455-194c1653f10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_600fb4d6-1c0b-44ea-89e9-b2bcd69cd4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_600fb4d6-1c0b-44ea-89e9-b2bcd69cd4ce" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_68d3975f-f181-4576-9233-076768631790" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_68d3975f-f181-4576-9233-076768631790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ebd827c9-d106-411f-a478-e8a83ae65f94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_68d3975f-f181-4576-9233-076768631790" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ebd827c9-d106-411f-a478-e8a83ae65f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f8bf4b0e-93b6-488b-a61a-0c39598374c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ebd827c9-d106-411f-a478-e8a83ae65f94" xlink:to="loc_us-gaap_CashEquivalentsMember_f8bf4b0e-93b6-488b-a61a-0c39598374c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8dcc32c1-ad96-4d22-a17b-7ed7162acbc9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4e0cd787-442b-4192-b728-dbf5e6603c20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4e0cd787-442b-4192-b728-dbf5e6603c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_59aace9c-1583-44a3-8467-122117281c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_59aace9c-1583-44a3-8467-122117281c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6f26ac70-de9b-4aea-8d36-5b3ce41981fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0854d785-fe6b-4d5e-91b3-8b8555dc54da" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6f26ac70-de9b-4aea-8d36-5b3ce41981fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:to="loc_us-gaap_FinancialInstrumentAxis_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_faad4aa5-9879-4510-a3f8-bcc7a4dcd3c0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_942ae51d-13be-4dd8-a98f-738078dcf199" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_942ae51d-13be-4dd8-a98f-738078dcf199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a4755f18-13db-4f2e-af91-cd67f05afe4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a4755f18-13db-4f2e-af91-cd67f05afe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_45527486-2440-4c7b-8b03-04337d78c7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fa489de-34c2-4904-82ca-fb9764e1e33e" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_45527486-2440-4c7b-8b03-04337d78c7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87d03a20-5148-4af4-9f82-af9aaaa3fccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_43b5a91a-3ec2-47fd-b514-af9541ace044" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87d03a20-5148-4af4-9f82-af9aaaa3fccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_86f8cd00-e784-4bcd-b903-dbc284310604" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87d03a20-5148-4af4-9f82-af9aaaa3fccf" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_86f8cd00-e784-4bcd-b903-dbc284310604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="simple" xlink:href="vnda-20201231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_07ae1581-978e-4aac-abf6-02016187cf43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_52048fc3-4660-487b-b8b8-e5a4dcbbf6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_07ae1581-978e-4aac-abf6-02016187cf43" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_52048fc3-4660-487b-b8b8-e5a4dcbbf6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_83488168-fb5a-4e24-8207-d01a7fe5275b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfInventoriesTableTextBlock_dd766e39-8b94-4404-8173-437db94421ff" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfInventoriesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_83488168-fb5a-4e24-8207-d01a7fe5275b" xlink:to="loc_vnda_ScheduleOfInventoriesTableTextBlock_dd766e39-8b94-4404-8173-437db94421ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#InventoryDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4ae7aeb9-11ea-4293-91ee-4a3c115d35f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_19e27197-d3f4-47cb-95ca-1a3d2cd07eff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4ae7aeb9-11ea-4293-91ee-4a3c115d35f0" xlink:to="loc_us-gaap_InventoryNetAbstract_19e27197-d3f4-47cb-95ca-1a3d2cd07eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e6a56463-b257-4338-9e87-4281f75a2656" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_19e27197-d3f4-47cb-95ca-1a3d2cd07eff" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e6a56463-b257-4338-9e87-4281f75a2656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4616b325-07a8-45f3-a327-43e2ca0e000d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_19e27197-d3f4-47cb-95ca-1a3d2cd07eff" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4616b325-07a8-45f3-a327-43e2ca0e000d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e978f031-c0b2-4b34-85e2-c0315a7e3084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_19e27197-d3f4-47cb-95ca-1a3d2cd07eff" xlink:to="loc_us-gaap_InventoryNet_e978f031-c0b2-4b34-85e2-c0315a7e3084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrentAbstract_7ae82ef7-2eca-4629-8e3d-c54c8a53569e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4ae7aeb9-11ea-4293-91ee-4a3c115d35f0" xlink:to="loc_us-gaap_InventoryNoncurrentAbstract_7ae82ef7-2eca-4629-8e3d-c54c8a53569e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_fc71169e-9bef-454f-8ad7-3b3eaadc3b26" xlink:href="vnda-20201231.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_7ae82ef7-2eca-4629-8e3d-c54c8a53569e" xlink:to="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_fc71169e-9bef-454f-8ad7-3b3eaadc3b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_e41624ef-310d-46ab-9370-a9d56e43c7a0" xlink:href="vnda-20201231.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_7ae82ef7-2eca-4629-8e3d-c54c8a53569e" xlink:to="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_e41624ef-310d-46ab-9370-a9d56e43c7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_a30a331f-8feb-4c12-8aae-3dd112afa1f8" xlink:href="vnda-20201231.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_7ae82ef7-2eca-4629-8e3d-c54c8a53569e" xlink:to="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_a30a331f-8feb-4c12-8aae-3dd112afa1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c481844a-752e-4b36-bd65-ee71f9e046a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_7ae82ef7-2eca-4629-8e3d-c54c8a53569e" xlink:to="loc_us-gaap_InventoryNoncurrent_c481844a-752e-4b36-bd65-ee71f9e046a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_Inventory_4a654679-93e9-4845-b325-b88731311b7d" xlink:href="vnda-20201231.xsd#vnda_Inventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4ae7aeb9-11ea-4293-91ee-4a3c115d35f0" xlink:to="loc_vnda_Inventory_4a654679-93e9-4845-b325-b88731311b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_54ae0876-06a6-4e73-9996-cadfa83d577a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fcfa037e-75fa-4e21-8271-68d1098a365e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_54ae0876-06a6-4e73-9996-cadfa83d577a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fcfa037e-75fa-4e21-8271-68d1098a365e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_584f8181-03ba-4b38-9290-5d11c1b0d6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_aa7dfe34-6301-48f7-bb0e-82b74ca4d5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_584f8181-03ba-4b38-9290-5d11c1b0d6cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_aa7dfe34-6301-48f7-bb0e-82b74ca4d5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentPropertyandEquipmentatCostDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fe179fff-255d-4407-b183-304f4c0a311d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fe179fff-255d-4407-b183-304f4c0a311d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5873558a-41ec-4305-a4a4-8efa10983e74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5873558a-41ec-4305-a4a4-8efa10983e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5873558a-41ec-4305-a4a4-8efa10983e74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ComputerHardwareAndOtherEquipmentMember_dd2cf622-c446-46e6-9d55-f489e5f536a9" xlink:href="vnda-20201231.xsd#vnda_ComputerHardwareAndOtherEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:to="loc_vnda_ComputerHardwareAndOtherEquipmentMember_dd2cf622-c446-46e6-9d55-f489e5f536a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_066168cb-6c3f-4a31-9d3f-0e4d4406723c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_066168cb-6c3f-4a31-9d3f-0e4d4406723c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a2bba3f9-0292-4434-8760-c03f9690c93b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a3172f0c-c3c9-4483-8059-57131cb6fe53" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a2bba3f9-0292-4434-8760-c03f9690c93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:to="loc_srt_RangeAxis_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32423274-d8b4-4a85-9d77-3e7efaa5f41b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f3e1f8fa-ba3e-4a23-bb27-3a61cdc7eedd" xlink:to="loc_srt_RangeMember_32423274-d8b4-4a85-9d77-3e7efaa5f41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_73bda709-7dec-4fca-a5a4-8053949ac29e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32423274-d8b4-4a85-9d77-3e7efaa5f41b" xlink:to="loc_srt_MinimumMember_73bda709-7dec-4fca-a5a4-8053949ac29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_93453578-18d5-408f-aa5d-8e4b5e31270f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32423274-d8b4-4a85-9d77-3e7efaa5f41b" xlink:to="loc_srt_MaximumMember_93453578-18d5-408f-aa5d-8e4b5e31270f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3cb088a2-6f1f-4460-b4de-411cc99fafea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bbeec3b9-a0c3-47d8-83c4-af3b7dd8fe99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bbeec3b9-a0c3-47d8-83c4-af3b7dd8fe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6c51adab-bcb8-4e0c-9847-37a91a2d883c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6c51adab-bcb8-4e0c-9847-37a91a2d883c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_580cc214-753c-49e5-a469-b9306d5b7c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_580cc214-753c-49e5-a469-b9306d5b7c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7d9bb2dc-8e1e-4c9b-9a97-413c3fa332d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc229aaf-f5e9-41d7-8929-734c7ddb1ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7d9bb2dc-8e1e-4c9b-9a97-413c3fa332d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#PropertyandEquipmentAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6048ed12-09bf-4802-b07a-adca9c228df0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5e753b8a-0c4c-4622-80cc-55277cd84240" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6048ed12-09bf-4802-b07a-adca9c228df0" xlink:to="loc_us-gaap_Depreciation_5e753b8a-0c4c-4622-80cc-55277cd84240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="simple" xlink:href="vnda-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2cf8ddaa-3568-4eab-bca2-d3923e55f2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9db93c87-1db8-4e76-b145-df972b0adcb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2cf8ddaa-3568-4eab-bca2-d3923e55f2cc" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_9db93c87-1db8-4e76-b145-df972b0adcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9a3e1a00-dc7e-440d-a0bc-2d87858971d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock_fdab55fb-d317-46f2-80fb-bcdc8a0b2181" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9a3e1a00-dc7e-440d-a0bc-2d87858971d2" xlink:to="loc_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock_fdab55fb-d317-46f2-80fb-bcdc8a0b2181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_caeb492b-ec78-42d8-877a-e407662b82c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9a3e1a00-dc7e-440d-a0bc-2d87858971d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_caeb492b-ec78-42d8-877a-e407662b82c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fc1f2fa3-9bea-42c5-9758-c3b2a8033c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc1f2fa3-9bea-42c5-9758-c3b2a8033c3b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bcb659bb-1e95-4aad-ac66-058c0900186c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bcb659bb-1e95-4aad-ac66-058c0900186c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad779e47-9a6f-447c-b6fb-a3cfdb18cc5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcb659bb-1e95-4aad-ac66-058c0900186c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad779e47-9a6f-447c-b6fb-a3cfdb18cc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SubleaseMember_f852fc24-111e-4d69-87aa-12ac7a8def73" xlink:href="vnda-20201231.xsd#vnda_SubleaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad779e47-9a6f-447c-b6fb-a3cfdb18cc5e" xlink:to="loc_vnda_SubleaseMember_f852fc24-111e-4d69-87aa-12ac7a8def73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:to="loc_srt_StatementGeographicalAxis_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e57db53-b62b-43b8-8598-da22fbd161cf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8c2d36e8-f87a-40d7-8b7c-d7385cc5b8af" xlink:to="loc_srt_SegmentGeographicalDomain_8e57db53-b62b-43b8-8598-da22fbd161cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DC_a4c2b38e-c1dd-4520-9da4-949d65a989f0" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_DC"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e57db53-b62b-43b8-8598-da22fbd161cf" xlink:to="loc_stpr_DC_a4c2b38e-c1dd-4520-9da4-949d65a989f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_3c13c97f-8081-4183-bb35-5af9fd138a5a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e57db53-b62b-43b8-8598-da22fbd161cf" xlink:to="loc_country_GB_3c13c97f-8081-4183-bb35-5af9fd138a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63621d94-f673-43a9-8282-6c597bde5db6" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1242e263-3c91-40b6-8211-928dd7b4adea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1242e263-3c91-40b6-8211-928dd7b4adea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_df4e6f55-b878-4b94-a015-17e8f2e2a25d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_df4e6f55-b878-4b94-a015-17e8f2e2a25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_169ecb38-e6df-48d3-a837-6fa6e4dd7998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_OperatingLeaseCost_169ecb38-e6df-48d3-a837-6fa6e4dd7998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_db37cca5-d246-41ba-abac-b50ef984c894" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_ShortTermLeaseCost_db37cca5-d246-41ba-abac-b50ef984c894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OperatingLeaseNonLeaseComponentExpense_486b420f-27e9-4013-9aa1-19bf63bccc7f" xlink:href="vnda-20201231.xsd#vnda_OperatingLeaseNonLeaseComponentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_vnda_OperatingLeaseNonLeaseComponentExpense_486b420f-27e9-4013-9aa1-19bf63bccc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_c85e14b7-65f5-44b5-94fd-53536a27b175" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_LeaseAndRentalExpense_c85e14b7-65f5-44b5-94fd-53536a27b175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_b2dc519c-c31a-4ed0-89c3-5eef94460081" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ca673d72-4c20-47f5-a87d-b6651b2a450f" xlink:to="loc_us-gaap_OperatingLeasePayments_b2dc519c-c31a-4ed0-89c3-5eef94460081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0b4c063d-7472-4726-a7f8-8e0da29044f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2a09d294-44d0-47f9-b695-e410702cb9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b4c063d-7472-4726-a7f8-8e0da29044f6" xlink:to="loc_us-gaap_AssetsAbstract_2a09d294-44d0-47f9-b695-e410702cb9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f6c0f2fb-e109-4e83-85bd-4dc8bad78343" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2a09d294-44d0-47f9-b695-e410702cb9aa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f6c0f2fb-e109-4e83-85bd-4dc8bad78343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a1bc6366-24b8-4d94-9945-5b276eb9ac9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b4c063d-7472-4726-a7f8-8e0da29044f6" xlink:to="loc_us-gaap_LiabilitiesAbstract_a1bc6366-24b8-4d94-9945-5b276eb9ac9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4cf93140-2559-4a3a-802f-e56c560d1b41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a1bc6366-24b8-4d94-9945-5b276eb9ac9a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4cf93140-2559-4a3a-802f-e56c560d1b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c8816381-a980-4248-96ed-7301019ddb51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a1bc6366-24b8-4d94-9945-5b276eb9ac9a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c8816381-a980-4248-96ed-7301019ddb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4e6c7717-3aaf-4cab-9345-cb9bdc93926b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a1bc6366-24b8-4d94-9945-5b276eb9ac9a" xlink:to="loc_us-gaap_OperatingLeaseLiability_4e6c7717-3aaf-4cab-9345-cb9bdc93926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b329f489-b850-439a-b679-83bb5ac57d65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b4c063d-7472-4726-a7f8-8e0da29044f6" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b329f489-b850-439a-b679-83bb5ac57d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c0ae0200-57e1-4129-beda-07b0f24ecfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b4c063d-7472-4726-a7f8-8e0da29044f6" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c0ae0200-57e1-4129-beda-07b0f24ecfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6c88ea24-4734-400d-9c58-308b018bf0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c88ea24-4734-400d-9c58-308b018bf0a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_18c9ba69-bd15-41da-aeb9-3f1aae7e41e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_18c9ba69-bd15-41da-aeb9-3f1aae7e41e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8889895a-d97d-4ee3-8026-08450b9640ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8889895a-d97d-4ee3-8026-08450b9640ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f0b42efc-286f-4436-b222-c5372cdcc2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f0b42efc-286f-4436-b222-c5372cdcc2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ba0c5585-4c4b-44a6-86f6-22f521b06569" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ba0c5585-4c4b-44a6-86f6-22f521b06569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_309993ce-629e-47a3-842e-b177029d4afc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_309993ce-629e-47a3-842e-b177029d4afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5c107b29-b7da-4b9c-b4cd-08efc4b02eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5c107b29-b7da-4b9c-b4cd-08efc4b02eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b6d1a59-2344-43a8-8b14-6e0a21eedb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b6d1a59-2344-43a8-8b14-6e0a21eedb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_942fe8ea-7543-45cf-b151-760361c1d4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_942fe8ea-7543-45cf-b151-760361c1d4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7ac55843-2549-4768-ad65-b0aa0e4a0718" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_OperatingLeaseLiability_7ac55843-2549-4768-ad65-b0aa0e4a0718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9677a2ae-c5ac-4081-a3dd-1ee991e1ce7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9677a2ae-c5ac-4081-a3dd-1ee991e1ce7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c3adfdd-ebcb-4f3a-b3d6-2f42f6938220" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0460f94-058d-49cc-821f-3ebdb6cc205e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c3adfdd-ebcb-4f3a-b3d6-2f42f6938220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1" xlink:type="simple" xlink:href="vnda-20201231.xsd#LeasesMaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1b334219-97fb-4d96-a55b-ef9293d5f25c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_58065d38-f87a-452e-8b67-149d00810109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1b334219-97fb-4d96-a55b-ef9293d5f25c" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_58065d38-f87a-452e-8b67-149d00810109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a9bb39c0-839f-4fdc-9503-dd0fbb739b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7409bc09-1166-48b5-859b-8a92c2c49b43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a9bb39c0-839f-4fdc-9503-dd0fbb739b4f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7409bc09-1166-48b5-859b-8a92c2c49b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_cc97047f-d789-487f-a06a-e26e8352a5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a9bb39c0-839f-4fdc-9503-dd0fbb739b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_cc97047f-d789-487f-a06a-e26e8352a5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f3953b11-7897-4eae-ae4a-f0df9dbc4483" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a9bb39c0-839f-4fdc-9503-dd0fbb739b4f" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f3953b11-7897-4eae-ae4a-f0df9dbc4483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsHETLIOZAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c53900b5-2c49-4a19-b36d-5e5215c618b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1e71ef03-dd14-4881-b925-278a9a7817fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c53900b5-2c49-4a19-b36d-5e5215c618b4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1e71ef03-dd14-4881-b925-278a9a7817fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_869e122e-37a5-448e-96b1-bc7d677a243f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1e71ef03-dd14-4881-b925-278a9a7817fd" xlink:to="loc_srt_ProductOrServiceAxis_869e122e-37a5-448e-96b1-bc7d677a243f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0779af35-2524-42b1-a161-dfc6ef5d6737" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_869e122e-37a5-448e-96b1-bc7d677a243f" xlink:to="loc_srt_ProductsAndServicesDomain_0779af35-2524-42b1-a161-dfc6ef5d6737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_5af0b4af-d5af-4f29-999e-165251311d9d" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0779af35-2524-42b1-a161-dfc6ef5d6737" xlink:to="loc_vnda_HetliozMember_5af0b4af-d5af-4f29-999e-165251311d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1e71ef03-dd14-4881-b925-278a9a7817fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e2028ec6-628f-49b9-b7ba-2cf1931714e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e2028ec6-628f-49b9-b7ba-2cf1931714e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CumulativeNetSalesToAchieveMilestone_f198c2f9-914f-408c-b5de-786302f20fed" xlink:href="vnda-20201231.xsd#vnda_CumulativeNetSalesToAchieveMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:to="loc_vnda_CumulativeNetSalesToAchieveMilestone_f198c2f9-914f-408c-b5de-786302f20fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_3129a0d1-b044-4df3-80c5-30ad152bc046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b18cb4e7-4b08-41e8-a2bf-c8d5ca58af5e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_3129a0d1-b044-4df3-80c5-30ad152bc046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsFanaptAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3e7d7046-3ea5-44e0-8277-47de5e490a18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0ab7ba7f-5ff1-4494-977c-c2723ce2bf65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3e7d7046-3ea5-44e0-8277-47de5e490a18" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0ab7ba7f-5ff1-4494-977c-c2723ce2bf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_47ff1226-dcfb-44e8-8889-23cbd7310a19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0ab7ba7f-5ff1-4494-977c-c2723ce2bf65" xlink:to="loc_srt_ProductOrServiceAxis_47ff1226-dcfb-44e8-8889-23cbd7310a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bba9b7a0-3b20-4b86-a36e-3e72f9598089" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_47ff1226-dcfb-44e8-8889-23cbd7310a19" xlink:to="loc_srt_ProductsAndServicesDomain_bba9b7a0-3b20-4b86-a36e-3e72f9598089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptMember_784ec0b9-5e45-4ec0-a105-24d0c5ef68db" xlink:href="vnda-20201231.xsd#vnda_FanaptMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bba9b7a0-3b20-4b86-a36e-3e72f9598089" xlink:to="loc_vnda_FanaptMember_784ec0b9-5e45-4ec0-a105-24d0c5ef68db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd203736-df62-442e-904c-63ca1160ce24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0ab7ba7f-5ff1-4494-977c-c2723ce2bf65" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd203736-df62-442e-904c-63ca1160ce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b66860b3-7b80-4faa-8005-ebafbee8408c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd203736-df62-442e-904c-63ca1160ce24" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b66860b3-7b80-4faa-8005-ebafbee8408c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofIntangibleAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_382388d6-3978-4ecc-9d8f-a25b53dd3f31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_20c50fdf-91fd-4225-ad4f-9426e551303c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_382388d6-3978-4ecc-9d8f-a25b53dd3f31" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_20c50fdf-91fd-4225-ad4f-9426e551303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bfc72620-4903-4ac4-b7b9-52313c58243f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_20c50fdf-91fd-4225-ad4f-9426e551303c" xlink:to="loc_srt_ProductOrServiceAxis_bfc72620-4903-4ac4-b7b9-52313c58243f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af7cee0e-dadd-43ce-a735-a9179b4b01a0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bfc72620-4903-4ac4-b7b9-52313c58243f" xlink:to="loc_srt_ProductsAndServicesDomain_af7cee0e-dadd-43ce-a735-a9179b4b01a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_4cacb41e-f173-482b-a0b3-273ef0dbc58b" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af7cee0e-dadd-43ce-a735-a9179b4b01a0" xlink:to="loc_vnda_HetliozMember_4cacb41e-f173-482b-a0b3-273ef0dbc58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_20c50fdf-91fd-4225-ad4f-9426e551303c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3337ab51-6122-4975-af5c-35f83a1c140f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3337ab51-6122-4975-af5c-35f83a1c140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b1963cd0-a7d0-47e6-9f71-254a989f5053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b1963cd0-a7d0-47e6-9f71-254a989f5053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_90269683-e01d-46dd-a989-be2c48915e87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8dee5837-f0e0-41e4-8a27-7555e1eb1b3d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_90269683-e01d-46dd-a989-be2c48915e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofAmortizationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f291e600-6520-4752-8f86-755f3a683687" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69a2adaa-e315-4573-9c07-b5c5caf82090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f291e600-6520-4752-8f86-755f3a683687" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69a2adaa-e315-4573-9c07-b5c5caf82090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_185fbb3c-1f4c-40d6-b826-120ca53eeef5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69a2adaa-e315-4573-9c07-b5c5caf82090" xlink:to="loc_srt_ProductOrServiceAxis_185fbb3c-1f4c-40d6-b826-120ca53eeef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b24d49e0-81d8-4e11-ae1f-eee7734a7bc1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_185fbb3c-1f4c-40d6-b826-120ca53eeef5" xlink:to="loc_srt_ProductsAndServicesDomain_b24d49e0-81d8-4e11-ae1f-eee7734a7bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_bb1b7569-b659-462c-9b60-209f2d844bb9" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b24d49e0-81d8-4e11-ae1f-eee7734a7bc1" xlink:to="loc_vnda_HetliozMember_bb1b7569-b659-462c-9b60-209f2d844bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b3ad6bd-1180-4453-9d24-325d1d8190a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69a2adaa-e315-4573-9c07-b5c5caf82090" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b3ad6bd-1180-4453-9d24-325d1d8190a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e6a240e8-563a-4ca1-a112-252e2d379c00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b3ad6bd-1180-4453-9d24-325d1d8190a7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e6a240e8-563a-4ca1-a112-252e2d379c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b288a19b-2ad6-4328-9b80-426136a3e32c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9ff6f339-6519-459d-ace2-b78404b597e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b288a19b-2ad6-4328-9b80-426136a3e32c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9ff6f339-6519-459d-ace2-b78404b597e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_32f54d2e-8b9f-4c57-a872-d3d0593e7c74" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9ff6f339-6519-459d-ace2-b78404b597e1" xlink:to="loc_srt_ProductOrServiceAxis_32f54d2e-8b9f-4c57-a872-d3d0593e7c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87354475-b283-4787-ab83-92fd6e55c572" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_32f54d2e-8b9f-4c57-a872-d3d0593e7c74" xlink:to="loc_srt_ProductsAndServicesDomain_87354475-b283-4787-ab83-92fd6e55c572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_1125ee9a-47f2-46a7-bbcc-b291e35a51be" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_87354475-b283-4787-ab83-92fd6e55c572" xlink:to="loc_vnda_HetliozMember_1125ee9a-47f2-46a7-bbcc-b291e35a51be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9ff6f339-6519-459d-ace2-b78404b597e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16de6078-d07a-4bab-af89-dc9718b99d36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16de6078-d07a-4bab-af89-dc9718b99d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c716dedf-86fa-4102-b048-583eecbe4480" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c716dedf-86fa-4102-b048-583eecbe4480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2b25a9af-f872-4f43-9830-15ff0e2e2b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2b25a9af-f872-4f43-9830-15ff0e2e2b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_da8e7140-6774-4fa7-9cbb-7c3f972f8a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_da8e7140-6774-4fa7-9cbb-7c3f972f8a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e29f2010-d6ed-4b65-9cfb-5ff3c304ca6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e29f2010-d6ed-4b65-9cfb-5ff3c304ca6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ba10316e-514d-46fd-93f3-4a2ee172aea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ba10316e-514d-46fd-93f3-4a2ee172aea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29ba06d7-e219-4e15-85d3-9a1ab8f5fb70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02586b75-5f68-48a8-9270-19c76f79ff81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29ba06d7-e219-4e15-85d3-9a1ab8f5fb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5fb6c7f4-b8e7-4782-bcca-5e0d867ffaa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_27ed6ff4-8c5f-45ff-8e3c-6ac122ee369a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5fb6c7f4-b8e7-4782-bcca-5e0d867ffaa6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_27ed6ff4-8c5f-45ff-8e3c-6ac122ee369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3e038b7c-f5f9-4185-b81d-15ce738fd9da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_eee251e6-b4be-4fb3-9acc-abe515a48b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3e038b7c-f5f9-4185-b81d-15ce738fd9da" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_eee251e6-b4be-4fb3-9acc-abe515a48b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccountsPayableandAccruedLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_793c5093-b2b9-438e-ba5f-af784f562565" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_793c5093-b2b9-438e-ba5f-af784f562565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense_c30e807d-035b-4cac-a756-d1cc41f93c63" xlink:href="vnda-20201231.xsd#vnda_AccruedResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:to="loc_vnda_AccruedResearchAndDevelopmentExpense_c30e807d-035b-4cac-a756-d1cc41f93c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_932dc9da-a263-4efb-b305-47c26053f59a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_932dc9da-a263-4efb-b305-47c26053f59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3949b93e-4c0b-4b84-b058-4466ecad5bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3949b93e-4c0b-4b84-b058-4466ecad5bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_128c92bc-816f-46c2-ad82-6eac9bbdd797" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_128c92bc-816f-46c2-ad82-6eac9bbdd797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_98a257e3-5614-48b1-b64d-224019185d95" xlink:href="vnda-20201231.xsd#vnda_AccruedMilestoneObligationsUnderLicenseAgreements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:to="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_98a257e3-5614-48b1-b64d-224019185d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8dc36300-b8ca-46f7-83f2-bbacbc432f09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8dc36300-b8ca-46f7-83f2-bbacbc432f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_003db50b-24c6-48e2-91c9-cebe11b77173" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7bcc0370-fcc3-4f87-a6a9-1d68779f3905" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_003db50b-24c6-48e2-91c9-cebe11b77173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d18137e-295e-4d24-9a70-7ec42e7d8a05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8f32602e-0c5a-441f-b331-e516b4c82af6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d18137e-295e-4d24-9a70-7ec42e7d8a05" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8f32602e-0c5a-441f-b331-e516b4c82af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesHETLIOZAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9da70761-5f51-4b09-8b25-8efd7fd9a4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_f7b74f70-8a7d-44b3-9275-1c778976c150" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9da70761-5f51-4b09-8b25-8efd7fd9a4fb" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_f7b74f70-8a7d-44b3-9275-1c778976c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28e72953-5b59-4df8-aff5-7299298e241b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_f7b74f70-8a7d-44b3-9275-1c778976c150" xlink:to="loc_srt_ProductOrServiceAxis_28e72953-5b59-4df8-aff5-7299298e241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a3cdf21c-9851-45fb-a1c7-9468da4b4c3e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_28e72953-5b59-4df8-aff5-7299298e241b" xlink:to="loc_srt_ProductsAndServicesDomain_a3cdf21c-9851-45fb-a1c7-9468da4b4c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozMember_2d1641c9-2fe3-416c-96d6-893c933dbd94" xlink:href="vnda-20201231.xsd#vnda_HetliozMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a3cdf21c-9851-45fb-a1c7-9468da4b4c3e" xlink:to="loc_vnda_HetliozMember_2d1641c9-2fe3-416c-96d6-893c933dbd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_02a1b58a-d25f-4b38-8e8e-2d79cdd9504b" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_f7b74f70-8a7d-44b3-9275-1c778976c150" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_02a1b58a-d25f-4b38-8e8e-2d79cdd9504b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:href="vnda-20201231.xsd#vnda_HetliozAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_02a1b58a-d25f-4b38-8e8e-2d79cdd9504b" xlink:to="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_88764a27-d5f7-457f-9d56-94d6bccf2dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_88764a27-d5f7-457f-9d56-94d6bccf2dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_d808e4fa-4f02-40a0-b532-1595c6111872" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_d808e4fa-4f02-40a0-b532-1595c6111872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPeriod_9965a706-6ee3-467f-9850-537669eb05ae" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_vnda_RoyaltyPeriod_9965a706-6ee3-467f-9850-537669eb05ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_17c1ad8e-be44-4e9c-8992-ee87bd77a8bf" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPayableOnNetSalesPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_17c1ad8e-be44-4e9c-8992-ee87bd77a8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PercentageOfFutureSublicenseFeesPayable_e7909b7f-b999-40d4-b244-75713717b3d8" xlink:href="vnda-20201231.xsd#vnda_PercentageOfFutureSublicenseFeesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_462e06f0-6263-4fba-824f-2982cb67026b" xlink:to="loc_vnda_PercentageOfFutureSublicenseFeesPayable_e7909b7f-b999-40d4-b244-75713717b3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesFanaptAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9fd80cdf-f058-4253-9e2e-134fb438d492" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9fd80cdf-f058-4253-9e2e-134fb438d492" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_20babd1b-85ce-4fd1-865d-ae1a13ef0361" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:to="loc_srt_ProductOrServiceAxis_20babd1b-85ce-4fd1-865d-ae1a13ef0361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_281ffbe3-1bc9-463b-8aeb-344e9b829fc2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_20babd1b-85ce-4fd1-865d-ae1a13ef0361" xlink:to="loc_srt_ProductsAndServicesDomain_281ffbe3-1bc9-463b-8aeb-344e9b829fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptMember_b2418315-1ba6-45bc-bfae-36cb119fac13" xlink:href="vnda-20201231.xsd#vnda_FanaptMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_281ffbe3-1bc9-463b-8aeb-344e9b829fc2" xlink:to="loc_vnda_FanaptMember_b2418315-1ba6-45bc-bfae-36cb119fac13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StatementScenarioSecondaryAxis_e87d578e-a803-4203-8901-05862174afdb" xlink:href="vnda-20201231.xsd#vnda_StatementScenarioSecondaryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:to="loc_vnda_StatementScenarioSecondaryAxis_e87d578e-a803-4203-8901-05862174afdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StatementScenarioSecondaryDomain_922bfc56-ab52-4e55-b184-439c7d15e519" xlink:href="vnda-20201231.xsd#vnda_StatementScenarioSecondaryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_StatementScenarioSecondaryAxis_e87d578e-a803-4203-8901-05862174afdb" xlink:to="loc_vnda_StatementScenarioSecondaryDomain_922bfc56-ab52-4e55-b184-439c7d15e519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScenarioFourMember_7d63e654-a750-4e98-abe8-62c6284092d9" xlink:href="vnda-20201231.xsd#vnda_ScenarioFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_StatementScenarioSecondaryDomain_922bfc56-ab52-4e55-b184-439c7d15e519" xlink:to="loc_vnda_ScenarioFourMember_7d63e654-a750-4e98-abe8-62c6284092d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_253f25c8-3437-486a-84ae-e889ebee6e9e" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_27f81b03-1bdc-49e5-b00c-36b59ef41db6" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_253f25c8-3437-486a-84ae-e889ebee6e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FanaptAbstract_ab589aa4-8e34-499b-b1cf-70c097c6190e" xlink:href="vnda-20201231.xsd#vnda_FanaptAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_253f25c8-3437-486a-84ae-e889ebee6e9e" xlink:to="loc_vnda_FanaptAbstract_ab589aa4-8e34-499b-b1cf-70c097c6190e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_7c794e87-ea19-4096-9c2e-67075e1fa7ee" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPayableOnNetSalesPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_FanaptAbstract_ab589aa4-8e34-499b-b1cf-70c097c6190e" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_7c794e87-ea19-4096-9c2e-67075e1fa7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RoyaltyPeriod_698aa616-3943-4b10-ad8f-45902f2f1096" xlink:href="vnda-20201231.xsd#vnda_RoyaltyPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_FanaptAbstract_ab589aa4-8e34-499b-b1cf-70c097c6190e" xlink:to="loc_vnda_RoyaltyPeriod_698aa616-3943-4b10-ad8f-45902f2f1096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesTradipitantAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_06ae5338-6e77-49e8-bce6-67456bd98306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_06ae5338-6e77-49e8-bce6-67456bd98306" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_54ab18a4-519b-4247-901e-37f475d7c3cb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:to="loc_srt_StatementGeographicalAxis_54ab18a4-519b-4247-901e-37f475d7c3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9f4bf751-4dee-42d6-a94f-68d8865197ea" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_54ab18a4-519b-4247-901e-37f475d7c3cb" xlink:to="loc_srt_SegmentGeographicalDomain_9f4bf751-4dee-42d6-a94f-68d8865197ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_98049f1f-7fe9-4c8d-822c-d4d5317cdcff" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f4bf751-4dee-42d6-a94f-68d8865197ea" xlink:to="loc_country_US_98049f1f-7fe9-4c8d-822c-d4d5317cdcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0c14becc-0558-4e8e-9924-ba4d8813c1ca" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f4bf751-4dee-42d6-a94f-68d8865197ea" xlink:to="loc_srt_EuropeMember_0c14becc-0558-4e8e-9924-ba4d8813c1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fbd4890c-dae8-4506-b43a-3e5223c3df22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fbd4890c-dae8-4506-b43a-3e5223c3df22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c21fd717-0d67-4175-b43d-3eb1dd496621" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fbd4890c-dae8-4506-b43a-3e5223c3df22" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c21fd717-0d67-4175-b43d-3eb1dd496621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TradipitantMember_bba62cc1-be83-48de-aa9d-61e6a5c14404" xlink:href="vnda-20201231.xsd#vnda_TradipitantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c21fd717-0d67-4175-b43d-3eb1dd496621" xlink:to="loc_vnda_TradipitantMember_bba62cc1-be83-48de-aa9d-61e6a5c14404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1c776518-330a-493c-800b-ec68f1d1acc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1c776518-330a-493c-800b-ec68f1d1acc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1c776518-330a-493c-800b-ec68f1d1acc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PreNDAApprovalMilestonesMember_cdbbbb6e-773d-4f2b-ad26-3272612e1294" xlink:href="vnda-20201231.xsd#vnda_PreNDAApprovalMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:to="loc_vnda_PreNDAApprovalMilestonesMember_cdbbbb6e-773d-4f2b-ad26-3272612e1294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_f05fe834-e032-46ee-9759-2a31b380ab1a" xlink:href="vnda-20201231.xsd#vnda_RegulatoryApprovalMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_f05fe834-e032-46ee-9759-2a31b380ab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SalesMilestoneMember_13014f15-48fd-4286-b468-f779aa5010d7" xlink:href="vnda-20201231.xsd#vnda_SalesMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4aeb7a4a-48d5-42be-a361-e4abef44c3a0" xlink:to="loc_vnda_SalesMilestoneMember_13014f15-48fd-4286-b468-f779aa5010d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_76e9bccc-3fbd-44a9-9675-7402ad4ac069" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_dd1f5dd9-f261-4069-ab1c-cca4713456cf" xlink:href="vnda-20201231.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_dd1f5dd9-f261-4069-ab1c-cca4713456cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6ca52ad4-b374-4844-9013-7b0963753530" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:to="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6ca52ad4-b374-4844-9013-7b0963753530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_ad98d9a2-a221-40a6-afd1-e2db72823176" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_c10c67de-7338-480f-b2c8-f96d6546fa9f" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_ad98d9a2-a221-40a6-afd1-e2db72823176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_292a86c2-c795-4212-a0e1-d06f3186b434" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_292a86c2-c795-4212-a0e1-d06f3186b434" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d089bdfc-7eec-4bc6-893b-a6947d66a78e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:to="loc_srt_RangeAxis_d089bdfc-7eec-4bc6-893b-a6947d66a78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c675df62-b782-428c-9d50-950bbabacf0b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d089bdfc-7eec-4bc6-893b-a6947d66a78e" xlink:to="loc_srt_RangeMember_c675df62-b782-428c-9d50-950bbabacf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_109078db-8a0d-4d01-8ee2-b77c1bbb6bef" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c675df62-b782-428c-9d50-950bbabacf0b" xlink:to="loc_srt_MaximumMember_109078db-8a0d-4d01-8ee2-b77c1bbb6bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fac17209-f724-40b2-80a3-2a6d57e3e87b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fac17209-f724-40b2-80a3-2a6d57e3e87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fac17209-f724-40b2-80a3-2a6d57e3e87b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_8d637745-b1bd-409e-a3cf-ff1685773c25" xlink:href="vnda-20201231.xsd#vnda_RegulatoryApprovalMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_8d637745-b1bd-409e-a3cf-ff1685773c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_22af3e9f-0849-466c-abc3-e8d226b1774d" xlink:href="vnda-20201231.xsd#vnda_FutureRegulatoryApprovalAndSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:to="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_22af3e9f-0849-466c-abc3-e8d226b1774d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_8306d129-6593-4533-ade5-b0332f1a2552" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1203fccb-d680-4276-a594-cc6e7f853468" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_8306d129-6593-4533-ade5-b0332f1a2552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6bc07c47-fa4d-435a-836e-0938cf015576" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:to="loc_srt_ProductOrServiceAxis_6bc07c47-fa4d-435a-836e-0938cf015576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5086646-2661-4292-8d26-39d9313a9e11" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6bc07c47-fa4d-435a-836e-0938cf015576" xlink:to="loc_srt_ProductsAndServicesDomain_d5086646-2661-4292-8d26-39d9313a9e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsMember_f8169f77-5454-49f0-bbbe-e6d1e016c2e4" xlink:href="vnda-20201231.xsd#vnda_CftrActivatorsAndInhibitorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d5086646-2661-4292-8d26-39d9313a9e11" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsMember_f8169f77-5454-49f0-bbbe-e6d1e016c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_6287f364-2d92-4eab-9fc1-e611e63dcc11" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_8b2c9565-1ca8-47ef-9355-ad58885c0a20" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_6287f364-2d92-4eab-9fc1-e611e63dcc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:href="vnda-20201231.xsd#vnda_CftrActivatorsAndInhibitorsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_6287f364-2d92-4eab-9fc1-e611e63dcc11" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TieredRoyaltiesPayableOnFutureNetSales_3c6b54b9-5092-41df-836d-baf75d79d39c" xlink:href="vnda-20201231.xsd#vnda_TieredRoyaltiesPayableOnFutureNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:to="loc_vnda_TieredRoyaltiesPayableOnFutureNetSales_3c6b54b9-5092-41df-836d-baf75d79d39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_df194745-9b20-486b-8048-66df463c5fe5" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:to="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_df194745-9b20-486b-8048-66df463c5fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_befa77d6-dd78-444c-ac96-ecc06410025b" xlink:href="vnda-20201231.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_befa77d6-dd78-444c-ac96-ecc06410025b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_d907954e-4f9b-43af-b31f-dc02ac0a9481" xlink:href="vnda-20201231.xsd#vnda_AccruedMilestoneObligationsUnderLicenseAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_347ba72c-7ede-466e-887b-17012e97369a" xlink:to="loc_vnda_AccruedMilestoneObligationsUnderLicenseAgreements_d907954e-4f9b-43af-b31f-dc02ac0a9481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesVQW765AdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9109a95-bcb9-4371-bd8e-a8b9e9759a96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_ecbd1ef0-5a89-4f24-bd0d-0d6b25f51a4a" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9109a95-bcb9-4371-bd8e-a8b9e9759a96" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_ecbd1ef0-5a89-4f24-bd0d-0d6b25f51a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_525071d8-d806-4300-be13-7ee44b6089d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_ecbd1ef0-5a89-4f24-bd0d-0d6b25f51a4a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_525071d8-d806-4300-be13-7ee44b6089d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50ed7d3d-210b-40da-9062-ebafb5b817e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_525071d8-d806-4300-be13-7ee44b6089d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50ed7d3d-210b-40da-9062-ebafb5b817e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_VQW765Member_5d0a6a0d-5247-4a14-903a-b43c0538da1f" xlink:href="vnda-20201231.xsd#vnda_VQW765Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50ed7d3d-210b-40da-9062-ebafb5b817e6" xlink:to="loc_vnda_VQW765Member_5d0a6a0d-5247-4a14-903a-b43c0538da1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_19f38906-815e-46f0-9918-e4dea763b706" xlink:href="vnda-20201231.xsd#vnda_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_ecbd1ef0-5a89-4f24-bd0d-0d6b25f51a4a" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_19f38906-815e-46f0-9918-e4dea763b706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_13c6544a-14f0-4700-94ba-5080b66e7880" xlink:href="vnda-20201231.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_19f38906-815e-46f0-9918-e4dea763b706" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_13c6544a-14f0-4700-94ba-5080b66e7880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#CommitmentsandContingenciesPurchaseCommitmentsDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_32c096dd-669d-4eca-9faa-7448a94d963f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_506f2561-a82e-4741-ab52-b4569b628c80" xlink:href="vnda-20201231.xsd#vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_32c096dd-669d-4eca-9faa-7448a94d963f" xlink:to="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_506f2561-a82e-4741-ab52-b4569b628c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock" xlink:type="simple" xlink:href="vnda-20201231.xsd#PublicOfferingofCommonStock"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ec27fe55-b6eb-4af6-8846-eb336391df62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PublicOfferingOfCommonStockTextBlock_91b3a782-8fa4-4071-9d9e-a6e07806e881" xlink:href="vnda-20201231.xsd#vnda_PublicOfferingOfCommonStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec27fe55-b6eb-4af6-8846-eb336391df62" xlink:to="loc_vnda_PublicOfferingOfCommonStockTextBlock_91b3a782-8fa4-4071-9d9e-a6e07806e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#PublicOfferingofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5cdf83af-5d3d-4b04-8885-dded61baa1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a9518d45-d38c-464f-8c9c-19f3ebf91be2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5cdf83af-5d3d-4b04-8885-dded61baa1a5" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a9518d45-d38c-464f-8c9c-19f3ebf91be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a9518d45-d38c-464f-8c9c-19f3ebf91be2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfa199b-ed89-47e4-9ca6-79b7c20bfc4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5dd3c48f-09d1-42ae-8a6c-61b4a19559ca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfa199b-ed89-47e4-9ca6-79b7c20bfc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_PublicOfferingMember_6bcf673b-8d86-41d4-b6da-840e8cff245b" xlink:href="vnda-20201231.xsd#vnda_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfa199b-ed89-47e4-9ca6-79b7c20bfc4b" xlink:to="loc_vnda_PublicOfferingMember_6bcf673b-8d86-41d4-b6da-840e8cff245b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_0526a821-9a85-46d2-b4c3-42c29c4fab48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfa199b-ed89-47e4-9ca6-79b7c20bfc4b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_0526a821-9a85-46d2-b4c3-42c29c4fab48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a9518d45-d38c-464f-8c9c-19f3ebf91be2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_397dff60-c794-4d4a-a22e-3d9349864fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_397dff60-c794-4d4a-a22e-3d9349864fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_07a2b442-f915-4032-b755-4fd6b02d23f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_07a2b442-f915-4032-b755-4fd6b02d23f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d9d960f-f44d-4c1c-a2a2-0fc98ad1cc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_17a7c657-d1fd-4af2-8815-9117c0f30e6e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d9d960f-f44d-4c1c-a2a2-0fc98ad1cc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2b4e59af-ca8d-4e29-bff8-e38bb9987865" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_990dbcf4-7f32-45ab-8ec4-32bd79217fef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2b4e59af-ca8d-4e29-bff8-e38bb9987865" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_990dbcf4-7f32-45ab-8ec4-32bd79217fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_41701815-9651-48a4-b820-3b798e70c658" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_846e6069-c062-469f-9cb0-1e10e19ccc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_41701815-9651-48a4-b820-3b798e70c658" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_846e6069-c062-469f-9cb0-1e10e19ccc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f04c02d7-7a99-4671-b483-8c5b76faff6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_afc01704-8b54-4747-84af-1b6ac677b757" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f04c02d7-7a99-4671-b483-8c5b76faff6b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_afc01704-8b54-4747-84af-1b6ac677b757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_38e1c075-5e0e-461b-bd5d-4a93cb6b6f96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f04c02d7-7a99-4671-b483-8c5b76faff6b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_38e1c075-5e0e-461b-bd5d-4a93cb6b6f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_50fa4e23-c8e8-4160-bae3-f25e34d31348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f04c02d7-7a99-4671-b483-8c5b76faff6b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_50fa4e23-c8e8-4160-bae3-f25e34d31348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5903e42-1d9a-4c16-9248-688ddae4e59e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c40fdd0d-a300-48bc-a9a9-a9a0c9ef7afd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5903e42-1d9a-4c16-9248-688ddae4e59e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c40fdd0d-a300-48bc-a9a9-a9a0c9ef7afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2263b5f-cf92-4ff4-a0d5-1d165b5be3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ce2ef692-d072-4a08-aaa2-587e9e8d6e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2263b5f-cf92-4ff4-a0d5-1d165b5be3f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ce2ef692-d072-4a08-aaa2-587e9e8d6e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bf5139de-558b-46c7-af4b-054bcdc748a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2263b5f-cf92-4ff4-a0d5-1d165b5be3f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bf5139de-558b-46c7-af4b-054bcdc748a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7814161d-1c7e-450b-b641-47ff29fd1f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2263b5f-cf92-4ff4-a0d5-1d165b5be3f5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7814161d-1c7e-450b-b641-47ff29fd1f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_880c71d0-20da-4a67-90b5-9e824ed075bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2263b5f-cf92-4ff4-a0d5-1d165b5be3f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_880c71d0-20da-4a67-90b5-9e824ed075bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3694c72a-c703-4685-ba99-c835b6cbe7f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3694c72a-c703-4685-ba99-c835b6cbe7f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d88d5ba9-e584-4dfb-b633-0c3f382210a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:to="loc_us-gaap_PlanNameAxis_d88d5ba9-e584-4dfb-b633-0c3f382210a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_947f384c-be3e-4caa-8dae-c2f3f141c972" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d88d5ba9-e584-4dfb-b633-0c3f382210a0" xlink:to="loc_us-gaap_PlanNameDomain_947f384c-be3e-4caa-8dae-c2f3f141c972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_7104ad51-a4c5-4e66-ab55-3a55277af0b9" xlink:href="vnda-20201231.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_947f384c-be3e-4caa-8dae-c2f3f141c972" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_7104ad51-a4c5-4e66-ab55-3a55277af0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TwoThousandSixteenPlanMember_95f895ec-0145-4c04-bc92-9a19e94825fc" xlink:href="vnda-20201231.xsd#vnda_TwoThousandSixteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_7104ad51-a4c5-4e66-ab55-3a55277af0b9" xlink:to="loc_vnda_TwoThousandSixteenPlanMember_95f895ec-0145-4c04-bc92-9a19e94825fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_57f1fc46-7949-4561-9142-020a434c7608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:to="loc_us-gaap_AwardTypeAxis_57f1fc46-7949-4561-9142-020a434c7608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d857a15a-92a3-47c8-8c72-5eecae7e2f11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_57f1fc46-7949-4561-9142-020a434c7608" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d857a15a-92a3-47c8-8c72-5eecae7e2f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_d2f83690-b704-4d53-a3d7-3a9a6502a4dc" xlink:href="vnda-20201231.xsd#vnda_StockOptionsAndRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d857a15a-92a3-47c8-8c72-5eecae7e2f11" xlink:to="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_d2f83690-b704-4d53-a3d7-3a9a6502a4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_904d2627-442f-4b46-8b21-3b3e8667d713" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_c9c5891d-822d-4bbe-9a8a-43b208371f5c" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_c9c5891d-822d-4bbe-9a8a-43b208371f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1ca7fa54-f90e-41b4-8534-f11d8e2026a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1ca7fa54-f90e-41b4-8534-f11d8e2026a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_96f90d72-c736-4068-8d65-986bdb7da919" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e511656-8b19-481a-8723-bf3ea6a4ae3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_96f90d72-c736-4068-8d65-986bdb7da919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8bf7004-e4f4-42da-8f7b-257a14013d72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72b4c628-9287-4c63-868a-94cf087a22c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8bf7004-e4f4-42da-8f7b-257a14013d72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72b4c628-9287-4c63-868a-94cf087a22c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6b80d527-f562-4e77-b300-676b71717ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72b4c628-9287-4c63-868a-94cf087a22c4" xlink:to="loc_us-gaap_AwardTypeAxis_6b80d527-f562-4e77-b300-676b71717ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8452d39-8fe6-433d-8ee5-cab18a7f8ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6b80d527-f562-4e77-b300-676b71717ab7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8452d39-8fe6-433d-8ee5-cab18a7f8ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ServiceOptionAwardsMember_d87028fe-5615-4a7b-a623-a95d3bb2f0aa" xlink:href="vnda-20201231.xsd#vnda_ServiceOptionAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8452d39-8fe6-433d-8ee5-cab18a7f8ce4" xlink:to="loc_vnda_ServiceOptionAwardsMember_d87028fe-5615-4a7b-a623-a95d3bb2f0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72b4c628-9287-4c63-868a-94cf087a22c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_3eee5256-f8e3-43fc-b4a1-9c66d0a3f56c" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationOptionAwardsContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_3eee5256-f8e3-43fc-b4a1-9c66d0a3f56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_667a170f-462e-4188-ba15-af1bdadebb45" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_667a170f-462e-4188-ba15-af1bdadebb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_d442b998-2e6a-4ae3-b91d-c8741cdab6f4" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_d442b998-2e6a-4ae3-b91d-c8741cdab6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_75343dfc-150a-4369-aff2-eb8ab6760cb7" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_75343dfc-150a-4369-aff2-eb8ab6760cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_ca21b738-04ce-4043-88a8-1aa036edcf99" xlink:href="vnda-20201231.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_ca21b738-04ce-4043-88a8-1aa036edcf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_3bec778f-a2f7-46e4-879d-548fb39802f5" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_3bec778f-a2f7-46e4-879d-548fb39802f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_269474ce-bb56-4c53-bfcf-39901cc15c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_269474ce-bb56-4c53-bfcf-39901cc15c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0512fc01-61e4-4f5f-9ca3-bcc4c724876b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0512fc01-61e4-4f5f-9ca3-bcc4c724876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e8a9e14-39cd-4485-a2f9-9837f36f4f74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e8a9e14-39cd-4485-a2f9-9837f36f4f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_368076cf-26de-41f5-8376-0a4175893786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60eb7c6-09d9-4200-9e0c-968ddbf65daa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_368076cf-26de-41f5-8376-0a4175893786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationRSUAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf5edcb3-3bdc-448d-9ded-7865d8eda121" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbb9420e-e577-4d3b-a1cf-fa5f1fe03fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf5edcb3-3bdc-448d-9ded-7865d8eda121" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbb9420e-e577-4d3b-a1cf-fa5f1fe03fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4936b296-7682-463e-8576-f1a01029958c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbb9420e-e577-4d3b-a1cf-fa5f1fe03fc8" xlink:to="loc_us-gaap_AwardTypeAxis_4936b296-7682-463e-8576-f1a01029958c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dca895a1-f1a8-4679-9ab9-bdb36614d427" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4936b296-7682-463e-8576-f1a01029958c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dca895a1-f1a8-4679-9ab9-bdb36614d427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ab0dd738-1610-4845-b5e4-abfd81401174" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dca895a1-f1a8-4679-9ab9-bdb36614d427" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ab0dd738-1610-4845-b5e4-abfd81401174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbb9420e-e577-4d3b-a1cf-fa5f1fe03fc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_09b0eff0-e718-4f24-a40a-5849575d28b9" xlink:href="vnda-20201231.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_09b0eff0-e718-4f24-a40a-5849575d28b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_aab2c6f2-7a65-4cc5-9c07-5c2c7e340f4c" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl_aab2c6f2-7a65-4cc5-9c07-5c2c7e340f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2210a6fe-97ce-4edd-9471-21bbb659cfcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2210a6fe-97ce-4edd-9471-21bbb659cfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_33b66308-2d63-4c86-afc7-878896576b06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_33b66308-2d63-4c86-afc7-878896576b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c47aabb-73fd-4b04-a606-7d47b88e452e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2c47aabb-73fd-4b04-a606-7d47b88e452e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_25c57fbc-9096-4d1f-8a2b-f0231ca6bed2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e32f408-c152-4102-aaac-3147e0f7dec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_25c57fbc-9096-4d1f-8a2b-f0231ca6bed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationSummaryofOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f07000cb-13f3-4318-b7af-5339f895556e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8beb7d7-e090-43cb-97ea-1f0b840be6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f07000cb-13f3-4318-b7af-5339f895556e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8beb7d7-e090-43cb-97ea-1f0b840be6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_adeaea9e-c23e-41c2-97b5-2dfcc72e3486" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8beb7d7-e090-43cb-97ea-1f0b840be6bf" xlink:to="loc_us-gaap_PlanNameAxis_adeaea9e-c23e-41c2-97b5-2dfcc72e3486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_df6282dc-772d-4760-ab2d-1084ce793bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_adeaea9e-c23e-41c2-97b5-2dfcc72e3486" xlink:to="loc_us-gaap_PlanNameDomain_df6282dc-772d-4760-ab2d-1084ce793bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_c9a7713a-b4aa-4caf-a27e-2917e63225c0" xlink:href="vnda-20201231.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_df6282dc-772d-4760-ab2d-1084ce793bd5" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_c9a7713a-b4aa-4caf-a27e-2917e63225c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8beb7d7-e090-43cb-97ea-1f0b840be6bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5c2b558-c4fa-4d65-a5a0-26ca8d1d39c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5c2b558-c4fa-4d65-a5a0-26ca8d1d39c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7262f447-0efc-4742-810c-a2bccbbe9964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7262f447-0efc-4742-810c-a2bccbbe9964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7501fab3-631a-42cf-946a-98b9ae31dc57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7501fab3-631a-42cf-946a-98b9ae31dc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_678c590a-95f5-4066-80fb-6c359b14a684" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_678c590a-95f5-4066-80fb-6c359b14a684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aac0e4ca-7a9f-4075-85cd-648177c9b1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aac0e4ca-7a9f-4075-85cd-648177c9b1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d232b9f-92a2-46c9-916e-6e604e8f3957" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be9a8815-8c56-4132-9500-5dc99a78d836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d232b9f-92a2-46c9-916e-6e604e8f3957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2c3cbe43-72df-45fe-8a10-e1f1c7162d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2c3cbe43-72df-45fe-8a10-e1f1c7162d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_739ce2d7-8280-4b4e-8206-de546c5b2342" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_739ce2d7-8280-4b4e-8206-de546c5b2342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ab0499b7-58f5-43ff-9445-d4cf1e53b676" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ab0499b7-58f5-43ff-9445-d4cf1e53b676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c863c829-3a33-406a-bbdb-158a1f4ff50f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c863c829-3a33-406a-bbdb-158a1f4ff50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_92fa8ef7-f317-4d98-ac01-a34be6b7a9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_92fa8ef7-f317-4d98-ac01-a34be6b7a9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0b1c6d72-35c3-4cec-9e5a-8092c8d35170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0b1c6d72-35c3-4cec-9e5a-8092c8d35170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_69d57a5e-3248-4fef-9322-bf69534a8d05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_69d57a5e-3248-4fef-9322-bf69534a8d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5decf572-13fd-4261-8209-93048fcf935a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0587d10a-07c7-446b-9f85-4d591b1a8de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5decf572-13fd-4261-8209-93048fcf935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9a0a46f5-558b-4868-aaf0-21d41de1d37c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9a0a46f5-558b-4868-aaf0-21d41de1d37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0fe6fd1f-5479-49cd-a62a-51d9e2528d80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0fe6fd1f-5479-49cd-a62a-51d9e2528d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_904a9f85-37f6-48fb-a953-f96af474c713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_904a9f85-37f6-48fb-a953-f96af474c713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_afaab0f6-8dde-45f9-9446-71e0cce757d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_afaab0f6-8dde-45f9-9446-71e0cce757d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b246e2eb-8083-4b65-952e-de04ad31aef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dc3d6b44-1248-4b48-b424-ead457a51d36" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b246e2eb-8083-4b65-952e-de04ad31aef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:href="vnda-20201231.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_414e8efa-886a-4e53-9d49-3ef9ccb11051" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_081b6169-5d75-486f-a20b-93f468baceaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_081b6169-5d75-486f-a20b-93f468baceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_364cf032-15c5-4a6a-89f2-4bc52219fdcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_364cf032-15c5-4a6a-89f2-4bc52219fdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_027b277a-396e-456c-8e87-9a3ddec23b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_027b277a-396e-456c-8e87-9a3ddec23b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_46cf5960-4e63-4084-96cf-0e4dba85c144" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_46cf5960-4e63-4084-96cf-0e4dba85c144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8d9a0a61-36e8-4b83-9710-31710efd75aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_826d38c5-011b-4736-a03c-718fb98123a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8d9a0a61-36e8-4b83-9710-31710efd75aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationSummaryofRSUActivityPlanDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_edc86f51-86fb-4ac4-b011-9cc19e22c06f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_22f99eea-08a1-48f4-a209-04a1b6cd595d" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_edc86f51-86fb-4ac4-b011-9cc19e22c06f" xlink:to="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_22f99eea-08a1-48f4-a209-04a1b6cd595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4f0283b8-d846-4735-a267-08d106da0362" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_22f99eea-08a1-48f4-a209-04a1b6cd595d" xlink:to="loc_us-gaap_AwardTypeAxis_4f0283b8-d846-4735-a267-08d106da0362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc830ccb-2641-4f9d-8104-849c56dde73f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4f0283b8-d846-4735-a267-08d106da0362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc830ccb-2641-4f9d-8104-849c56dde73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_189d25d3-342d-4638-a76a-ed2348d653c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc830ccb-2641-4f9d-8104-849c56dde73f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_189d25d3-342d-4638-a76a-ed2348d653c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_9bc44b2d-b70e-43f5-b0bb-b1005610fbcc" xlink:href="vnda-20201231.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_22f99eea-08a1-48f4-a209-04a1b6cd595d" xlink:to="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_9bc44b2d-b70e-43f5-b0bb-b1005610fbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_9bc44b2d-b70e-43f5-b0bb-b1005610fbcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6458173-60eb-4a86-979b-b924f99f8938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6458173-60eb-4a86-979b-b924f99f8938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17570e7c-90c9-4da9-b155-d4ea3bc184b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17570e7c-90c9-4da9-b155-d4ea3bc184b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bb221cdb-45d6-4c65-8b1a-071ff8509e16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bb221cdb-45d6-4c65-8b1a-071ff8509e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86b13826-9121-484d-8099-51b97b28970c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86b13826-9121-484d-8099-51b97b28970c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7af9dfee-03f2-4cf9-a840-f5ad32f35cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7a30f5d8-b6d4-493f-bdf9-7d42dcdb82b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7af9dfee-03f2-4cf9-a840-f5ad32f35cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_9bc44b2d-b70e-43f5-b0bb-b1005610fbcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e45ca8cd-70a8-4d3b-b0bd-8fc2da426fac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e45ca8cd-70a8-4d3b-b0bd-8fc2da426fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6b08b2b-3b04-48f8-b9e5-c97058eebbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6b08b2b-3b04-48f8-b9e5-c97058eebbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b49d3d9e-4130-43b0-8d33-45649aa49d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b49d3d9e-4130-43b0-8d33-45649aa49d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7cadc8f1-6ac4-4021-9b2a-d409daa7d6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7cadc8f1-6ac4-4021-9b2a-d409daa7d6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_082effae-d495-46a0-a578-4c1f3b794c73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aea488f3-349b-4abb-96bf-583e05d01143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_082effae-d495-46a0-a578-4c1f3b794c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8563ffc-6f43-4c3f-a74d-45366b0672d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c530f42-e988-41bb-911f-7236548d63d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8563ffc-6f43-4c3f-a74d-45366b0672d1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c530f42-e988-41bb-911f-7236548d63d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8671adb0-98de-46e4-b14a-def264466920" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c530f42-e988-41bb-911f-7236548d63d9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8671adb0-98de-46e4-b14a-def264466920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d57ef1bc-0c4e-4333-93c4-8efbdd31c881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8671adb0-98de-46e4-b14a-def264466920" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d57ef1bc-0c4e-4333-93c4-8efbdd31c881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65116a54-d47b-46fb-884c-121ab5800a19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d57ef1bc-0c4e-4333-93c4-8efbdd31c881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65116a54-d47b-46fb-884c-121ab5800a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_822a544b-5a7a-487b-b9df-ac37749bc73c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d57ef1bc-0c4e-4333-93c4-8efbdd31c881" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_822a544b-5a7a-487b-b9df-ac37749bc73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f3b0062e-479f-4a67-8906-e09d476ba406" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c530f42-e988-41bb-911f-7236548d63d9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f3b0062e-479f-4a67-8906-e09d476ba406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b82a0876-5074-4f76-a549-a5ec4385327c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f3b0062e-479f-4a67-8906-e09d476ba406" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b82a0876-5074-4f76-a549-a5ec4385327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6968a8fb-1317-4636-9567-3edb838fac7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e943b7f0-c56b-468e-8fac-f0c44ce58516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6968a8fb-1317-4636-9567-3edb838fac7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e943b7f0-c56b-468e-8fac-f0c44ce58516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_157722c4-0a06-402d-afd0-79e3fb1b2dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6968a8fb-1317-4636-9567-3edb838fac7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_157722c4-0a06-402d-afd0-79e3fb1b2dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0642dbb5-b6da-4793-8878-2890852cb48f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6968a8fb-1317-4636-9567-3edb838fac7a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0642dbb5-b6da-4793-8878-2890852cb48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1511b9ae-8475-45f7-8c19-43f257182ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6968a8fb-1317-4636-9567-3edb838fac7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1511b9ae-8475-45f7-8c19-43f257182ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="vnda-20201231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_55b690a0-e009-407b-9fb0-8ef03951e42a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_614c1455-f03d-44ef-9798-0f40e5fd1551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_55b690a0-e009-407b-9fb0-8ef03951e42a" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_614c1455-f03d-44ef-9798-0f40e5fd1551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#EmployeeBenefitPlanDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a45363c0-54a6-41b2-9a14-f39f3eda1ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_90c91f48-0d89-4ba0-8667-024746d8fc86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a45363c0-54a6-41b2-9a14-f39f3eda1ca7" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_90c91f48-0d89-4ba0-8667-024746d8fc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_c1db1d9c-2a24-4dc4-bb5c-745316391619" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a45363c0-54a6-41b2-9a14-f39f3eda1ca7" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_c1db1d9c-2a24-4dc4-bb5c-745316391619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DefinedContributionPlanVestingPeriod_b79812bd-6d2f-4dc3-a329-aeb7d76a265e" xlink:href="vnda-20201231.xsd#vnda_DefinedContributionPlanVestingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a45363c0-54a6-41b2-9a14-f39f3eda1ca7" xlink:to="loc_vnda_DefinedContributionPlanVestingPeriod_b79812bd-6d2f-4dc3-a329-aeb7d76a265e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_3bbfa222-a532-44f0-8988-6e6d3a1d3623" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a45363c0-54a6-41b2-9a14-f39f3eda1ca7" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_3bbfa222-a532-44f0-8988-6e6d3a1d3623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6881bbdc-373d-46c9-abd6-97e91cd68742" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_43a11951-6631-445a-9a42-42e71f86265b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6881bbdc-373d-46c9-abd6-97e91cd68742" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_43a11951-6631-445a-9a42-42e71f86265b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3e1ec808-3c80-4423-8837-cc94cdb41599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d6dee837-0606-4df8-bccb-48efe777edbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e1ec808-3c80-4423-8837-cc94cdb41599" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d6dee837-0606-4df8-bccb-48efe777edbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_59f04913-303b-4679-8d51-44ef2c2359f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e1ec808-3c80-4423-8837-cc94cdb41599" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_59f04913-303b-4679-8d51-44ef2c2359f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5b9c972e-4633-4d07-92b6-93aaaaf482f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e1ec808-3c80-4423-8837-cc94cdb41599" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5b9c972e-4633-4d07-92b6-93aaaaf482f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f204d5b1-6ce6-4a7b-a196-5e517aba99ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e1ec808-3c80-4423-8837-cc94cdb41599" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f204d5b1-6ce6-4a7b-a196-5e517aba99ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_c80f0939-63b0-4b1b-85bb-59984b8d7635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e1ec808-3c80-4423-8837-cc94cdb41599" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_c80f0939-63b0-4b1b-85bb-59984b8d7635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b590983f-3901-4ff5-8cce-a9dc5adbbb62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e1ec808-3c80-4423-8837-cc94cdb41599" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b590983f-3901-4ff5-8cce-a9dc5adbbb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_13ea7677-86a5-43a5-86bc-419ca4f25907" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0c3f7043-7a70-4f84-b883-950dc422bde1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13ea7677-86a5-43a5-86bc-419ca4f25907" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0c3f7043-7a70-4f84-b883-950dc422bde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ef4c7658-e35a-4f99-86a0-7233b550584b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13ea7677-86a5-43a5-86bc-419ca4f25907" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ef4c7658-e35a-4f99-86a0-7233b550584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bac2e2e7-5f88-4695-931c-42d772091858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13ea7677-86a5-43a5-86bc-419ca4f25907" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bac2e2e7-5f88-4695-931c-42d772091858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c9c8303d-1e4b-4918-9f71-cf9b3e26d8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_19a67e38-cca0-4714-b6ba-b18950b86fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9c8303d-1e4b-4918-9f71-cf9b3e26d8c6" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_19a67e38-cca0-4714-b6ba-b18950b86fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7b6e7590-69b3-427d-bf83-a3671387806b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_19a67e38-cca0-4714-b6ba-b18950b86fb9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7b6e7590-69b3-427d-bf83-a3671387806b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e30b78d0-7cbb-45b0-beab-0512eb497213" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_19a67e38-cca0-4714-b6ba-b18950b86fb9" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e30b78d0-7cbb-45b0-beab-0512eb497213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fbd8c63e-87d5-4113-a47e-edeb4797467c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_19a67e38-cca0-4714-b6ba-b18950b86fb9" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fbd8c63e-87d5-4113-a47e-edeb4797467c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_72490974-d408-4af3-a638-52baacd67444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9c8303d-1e4b-4918-9f71-cf9b3e26d8c6" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_72490974-d408-4af3-a638-52baacd67444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1c31a791-549b-44a7-9a1b-15da7bc9f433" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_72490974-d408-4af3-a638-52baacd67444" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1c31a791-549b-44a7-9a1b-15da7bc9f433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_70251750-a6f1-4bdd-b34d-3018a7248eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_72490974-d408-4af3-a638-52baacd67444" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_70251750-a6f1-4bdd-b34d-3018a7248eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7f791258-dbeb-4191-a631-665749dba163" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_72490974-d408-4af3-a638-52baacd67444" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7f791258-dbeb-4191-a631-665749dba163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1dd28c37-b2e7-4a41-a645-c2011cbc630e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9c8303d-1e4b-4918-9f71-cf9b3e26d8c6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1dd28c37-b2e7-4a41-a645-c2011cbc630e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2bdf05bc-da1a-4189-b6e4-842c84ae4c03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2bdf05bc-da1a-4189-b6e4-842c84ae4c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_08ce36d3-8d15-44d1-a33b-5448fd3262c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_08ce36d3-8d15-44d1-a33b-5448fd3262c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3b54c9f7-ed65-455a-9f48-fa55f078a7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3b54c9f7-ed65-455a-9f48-fa55f078a7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_0dc59902-85b3-4ad4-8f8f-849fc4166a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_0dc59902-85b3-4ad4-8f8f-849fc4166a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_c93c9700-49a8-4b57-b11d-368c7e3401c8" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug_c93c9700-49a8-4b57-b11d-368c7e3401c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_12c0ac4b-8778-42c5-8421-48ba5f485646" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_12c0ac4b-8778-42c5-8421-48ba5f485646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ef91c2e2-e28f-4b08-bc02-50d5a376f44b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ef91c2e2-e28f-4b08-bc02-50d5a376f44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_5ef33ec3-8bf9-450a-8d65-86f8f1f2c4c8" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment_5ef33ec3-8bf9-450a-8d65-86f8f1f2c4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_a76048b7-032c-4b4c-b433-74af1082e7b9" xlink:href="vnda-20201231.xsd#vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_a76048b7-032c-4b4c-b433-74af1082e7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_5b31d11e-0cbe-4b21-9fdb-881b76177575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_5b31d11e-0cbe-4b21-9fdb-881b76177575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_c63864ac-1aa0-46f6-84cf-7c2ee2f39b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_c63864ac-1aa0-46f6-84cf-7c2ee2f39b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e595672-12d8-4906-bf14-67817b5be837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e595672-12d8-4906-bf14-67817b5be837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_d898e303-9ac6-47d4-836b-4d7f26b4ce83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d898954e-e986-41a1-97db-78d63972a509" xlink:to="loc_us-gaap_ValuationAllowanceTable_d898e303-9ac6-47d4-836b-4d7f26b4ce83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ce53bf4-e947-4d08-9923-b9ad17a40844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_d898e303-9ac6-47d4-836b-4d7f26b4ce83" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ce53bf4-e947-4d08-9923-b9ad17a40844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_6ce53bf4-e947-4d08-9923-b9ad17a40844" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeBeforeIncomeTaxesCurrentYearMember_9e17371c-42c4-4f64-9f37-4987d863f8d0" xlink:href="vnda-20201231.xsd#vnda_IncomeBeforeIncomeTaxesCurrentYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:to="loc_vnda_IncomeBeforeIncomeTaxesCurrentYearMember_9e17371c-42c4-4f64-9f37-4987d863f8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember_6c69d829-0724-4991-9cb5-1f3d1cd71d38" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:to="loc_vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember_6c69d829-0724-4991-9cb5-1f3d1cd71d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_EstimatedRealizabilityofDeferredTaxAssetMember_1498c03b-046d-46a5-ba0b-e9286fa4aca6" xlink:href="vnda-20201231.xsd#vnda_EstimatedRealizabilityofDeferredTaxAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_7214f1cd-cfc6-4670-80d8-e65cf7b279f1" xlink:to="loc_vnda_EstimatedRealizabilityofDeferredTaxAssetMember_1498c03b-046d-46a5-ba0b-e9286fa4aca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_5189b049-af02-4348-801e-a5ae82193e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_d898e303-9ac6-47d4-836b-4d7f26b4ce83" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_5189b049-af02-4348-801e-a5ae82193e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_24d91548-d443-4623-a904-5aad4797e4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_5189b049-af02-4348-801e-a5ae82193e46" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_24d91548-d443-4623-a904-5aad4797e4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c0a8f46f-b030-4282-8a55-52a26ea3300c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c0a8f46f-b030-4282-8a55-52a26ea3300c" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1c929164-000c-4813-9a5a-6598d436834d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1c929164-000c-4813-9a5a-6598d436834d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_087343ba-78be-4b0c-a69d-9a783a7d6ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_087343ba-78be-4b0c-a69d-9a783a7d6ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9322690d-a230-4bc8-aff6-2ff7736d6ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9322690d-a230-4bc8-aff6-2ff7736d6ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_16d07166-e8f4-4965-ad26-80c03eebc043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_16d07166-e8f4-4965-ad26-80c03eebc043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_04a9b1bf-87d7-48a5-8dc2-9eb2e7f64c1e" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:to="loc_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_04a9b1bf-87d7-48a5-8dc2-9eb2e7f64c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_c994e2d5-39c1-4c7b-b7a9-05883abaad0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_c994e2d5-39c1-4c7b-b7a9-05883abaad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ac16143a-3dc6-4efe-91cf-d6f3ab93d979" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a7392d6c-41df-433b-a1a5-c2106862ef47" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ac16143a-3dc6-4efe-91cf-d6f3ab93d979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_51ce4693-a4cb-4436-a6d1-5ae541666da6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c0a8f46f-b030-4282-8a55-52a26ea3300c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_51ce4693-a4cb-4436-a6d1-5ae541666da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_89482fcc-dd3b-4ac1-846a-af87e471aea2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_51ce4693-a4cb-4436-a6d1-5ae541666da6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_89482fcc-dd3b-4ac1-846a-af87e471aea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_619d4006-98fd-44d7-b746-890524349481" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_51ce4693-a4cb-4436-a6d1-5ae541666da6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_619d4006-98fd-44d7-b746-890524349481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ebdaeec0-fabb-49e0-b62f-7dd68ffca562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_51ce4693-a4cb-4436-a6d1-5ae541666da6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ebdaeec0-fabb-49e0-b62f-7dd68ffca562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_72249b54-f3a4-4279-993c-23aef401e493" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c0a8f46f-b030-4282-8a55-52a26ea3300c" xlink:to="loc_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet_72249b54-f3a4-4279-993c-23aef401e493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cd879d09-ea3c-45de-9c14-1cffc942d0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c0a8f46f-b030-4282-8a55-52a26ea3300c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cd879d09-ea3c-45de-9c14-1cffc942d0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_18e879ac-e772-4d37-8039-969c6fdc8b93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c0a8f46f-b030-4282-8a55-52a26ea3300c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_18e879ac-e772-4d37-8039-969c6fdc8b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7af0d690-850a-4e71-b879-aab96774b8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsValuationAllowanceRollForward_321d3170-d1ea-498e-baaa-0ea37e8036b9" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7af0d690-850a-4e71-b879-aab96774b8c3" xlink:to="loc_vnda_DeferredTaxAssetsValuationAllowanceRollForward_321d3170-d1ea-498e-baaa-0ea37e8036b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aacef7e9-a879-4af5-819c-1d9664c4ccf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_DeferredTaxAssetsValuationAllowanceRollForward_321d3170-d1ea-498e-baaa-0ea37e8036b9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aacef7e9-a879-4af5-819c-1d9664c4ccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsValuationAllowanceIncrease_9c14bca0-bb4d-48cf-9a49-67405895ae09" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsValuationAllowanceIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_DeferredTaxAssetsValuationAllowanceRollForward_321d3170-d1ea-498e-baaa-0ea37e8036b9" xlink:to="loc_vnda_DeferredTaxAssetsValuationAllowanceIncrease_9c14bca0-bb4d-48cf-9a49-67405895ae09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_DeferredTaxAssetsValuationAllowanceDecrease_c54b0f5b-1281-460e-82bd-84e4b02fe2f8" xlink:href="vnda-20201231.xsd#vnda_DeferredTaxAssetsValuationAllowanceDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_DeferredTaxAssetsValuationAllowanceRollForward_321d3170-d1ea-498e-baaa-0ea37e8036b9" xlink:to="loc_vnda_DeferredTaxAssetsValuationAllowanceDecrease_c54b0f5b-1281-460e-82bd-84e4b02fe2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a12fdcb3-a277-45ef-8f99-10ce89abeb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_DeferredTaxAssetsValuationAllowanceRollForward_321d3170-d1ea-498e-baaa-0ea37e8036b9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a12fdcb3-a277-45ef-8f99-10ce89abeb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ddc1f5a1-0f61-4418-9dda-34ad6f301860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddc1f5a1-0f61-4418-9dda-34ad6f301860" xlink:to="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_95111cc2-6aad-4914-a784-97c1883af0f1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:to="loc_srt_StatementGeographicalAxis_95111cc2-6aad-4914-a784-97c1883af0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_24dc236f-e3d7-40bd-baec-8daa82b92706" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_95111cc2-6aad-4914-a784-97c1883af0f1" xlink:to="loc_srt_SegmentGeographicalDomain_24dc236f-e3d7-40bd-baec-8daa82b92706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_DC_ddaa7ba0-7560-4759-badf-3faacad5c56e" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_DC"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_24dc236f-e3d7-40bd-baec-8daa82b92706" xlink:to="loc_stpr_DC_ddaa7ba0-7560-4759-badf-3faacad5c56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_UnitedStatesExcludingDistrictOfColumbiaMember_19d38bc6-85ad-4815-ac7b-ebe81d2c91ee" xlink:href="vnda-20201231.xsd#vnda_UnitedStatesExcludingDistrictOfColumbiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_24dc236f-e3d7-40bd-baec-8daa82b92706" xlink:to="loc_vnda_UnitedStatesExcludingDistrictOfColumbiaMember_19d38bc6-85ad-4815-ac7b-ebe81d2c91ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_eb67adc0-dc35-48c9-85e3-c0bc636be460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_eb67adc0-dc35-48c9-85e3-c0bc636be460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0a72841c-4130-4c3d-941a-6b4aeb8d2d33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_eb67adc0-dc35-48c9-85e3-c0bc636be460" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0a72841c-4130-4c3d-941a-6b4aeb8d2d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f0c9a40e-304d-4dd4-9497-3cf2bf7d398e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0a72841c-4130-4c3d-941a-6b4aeb8d2d33" xlink:to="loc_us-gaap_DomesticCountryMember_f0c9a40e-304d-4dd4-9497-3cf2bf7d398e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OrphanDrugMember_240bad92-51d9-4ce2-a1b5-12c5b956bae8" xlink:href="vnda-20201231.xsd#vnda_OrphanDrugMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0a72841c-4130-4c3d-941a-6b4aeb8d2d33" xlink:to="loc_vnda_OrphanDrugMember_240bad92-51d9-4ce2-a1b5-12c5b956bae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:href="vnda-20201231.xsd#vnda_IncomeTaxesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesTable_cc36cbcb-c189-431f-a4f3-6df9d96eb131" xlink:to="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_afbcb2e4-6fe9-4343-9530-1a788fe30c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_afbcb2e4-6fe9-4343-9530-1a788fe30c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7e11d180-9d3d-4a95-af89-276741049622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7e11d180-9d3d-4a95-af89-276741049622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ba27b65f-a94f-4508-9199-86deeb46ad50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ba27b65f-a94f-4508-9199-86deeb46ad50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OperatingLossCarryforwardsBeginningExpirationYear_db09f730-ea2e-41b5-b3b5-a72e1a5e7e1e" xlink:href="vnda-20201231.xsd#vnda_OperatingLossCarryforwardsBeginningExpirationYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_vnda_OperatingLossCarryforwardsBeginningExpirationYear_db09f730-ea2e-41b5-b3b5-a72e1a5e7e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear_276d9b48-7ad7-4c1a-8bc2-2e9a6ddca498" xlink:href="vnda-20201231.xsd#vnda_ResearchAndDevelopmentCreditBeginningExpirationYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear_276d9b48-7ad7-4c1a-8bc2-2e9a6ddca498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_OrphanDrugCreditBeginningExpirationYear_da8b6ea4-8003-4a52-bb6e-8acecad98c61" xlink:href="vnda-20201231.xsd#vnda_OrphanDrugCreditBeginningExpirationYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_vnda_OrphanDrugCreditBeginningExpirationYear_da8b6ea4-8003-4a52-bb6e-8acecad98c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_92e288ff-5dd2-4add-8621-e176cde914fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_92e288ff-5dd2-4add-8621-e176cde914fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c6481294-fabd-49d4-b06d-b85053f4aeac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_IncomeTaxesLineItems_9cc94c3c-47dc-45c6-80fb-a4242a1c6ee9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c6481294-fabd-49d4-b06d-b85053f4aeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="simple" xlink:href="vnda-20201231.xsd#IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_45c9d37d-0e87-4c53-ad25-ecfe8a93050d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ffbf52b8-5a6b-4eb3-9111-14873b76b061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45c9d37d-0e87-4c53-ad25-ecfe8a93050d" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ffbf52b8-5a6b-4eb3-9111-14873b76b061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_da687719-fda0-477b-be93-d614566e57cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ffbf52b8-5a6b-4eb3-9111-14873b76b061" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_da687719-fda0-477b-be93-d614566e57cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_be357066-e7d0-4749-a8dd-254446d0b1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ffbf52b8-5a6b-4eb3-9111-14873b76b061" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_be357066-e7d0-4749-a8dd-254446d0b1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6e2d8615-d3a4-4775-9032-a3d209e24cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ffbf52b8-5a6b-4eb3-9111-14873b76b061" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6e2d8615-d3a4-4775-9032-a3d209e24cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4724e5e9-e67c-4604-ba38-3722446f82f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ffbf52b8-5a6b-4eb3-9111-14873b76b061" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4724e5e9-e67c-4604-ba38-3722446f82f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0528de2f-cc2a-42d6-aab6-24716df6798e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ffbf52b8-5a6b-4eb3-9111-14873b76b061" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_0528de2f-cc2a-42d6-aab6-24716df6798e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShare" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_91a4d9d3-1de1-401a-87eb-8b36b2b7f6fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2988fb80-e6bd-442a-b552-936c850b10d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_91a4d9d3-1de1-401a-87eb-8b36b2b7f6fd" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2988fb80-e6bd-442a-b552-936c850b10d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3da18d03-34a0-4328-9648-07d99f12ba18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6d6b2079-d764-4dd5-98cf-fba236b7473c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3da18d03-34a0-4328-9648-07d99f12ba18" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6d6b2079-d764-4dd5-98cf-fba236b7473c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#EarningsperShareDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_79e528ef-6d44-4a83-b32b-65b9e2863197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_ea7cb96b-9033-45d3-9964-3d5a285cc0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79e528ef-6d44-4a83-b32b-65b9e2863197" xlink:to="loc_us-gaap_NetIncomeLossAbstract_ea7cb96b-9033-45d3-9964-3d5a285cc0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_deb8574d-63b1-418a-a4f6-4184e8a3eb8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_ea7cb96b-9033-45d3-9964-3d5a285cc0ab" xlink:to="loc_us-gaap_NetIncomeLoss_deb8574d-63b1-418a-a4f6-4184e8a3eb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ba598029-6419-44a1-80a2-21ec962ea624" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79e528ef-6d44-4a83-b32b-65b9e2863197" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ba598029-6419-44a1-80a2-21ec962ea624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae4754df-c96c-4987-8a01-b44dd595aa27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ba598029-6419-44a1-80a2-21ec962ea624" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae4754df-c96c-4987-8a01-b44dd595aa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ebefaad4-2788-4c37-8641-950aa2e1a6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ba598029-6419-44a1-80a2-21ec962ea624" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ebefaad4-2788-4c37-8641-950aa2e1a6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51f7964b-dc89-4c97-b1ca-cf543e0e7dea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ba598029-6419-44a1-80a2-21ec962ea624" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51f7964b-dc89-4c97-b1ca-cf543e0e7dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_287171c3-ba19-4a13-ae1b-12089f94c5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79e528ef-6d44-4a83-b32b-65b9e2863197" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_287171c3-ba19-4a13-ae1b-12089f94c5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_39d78759-1661-42b1-be5a-6251cf5547cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_287171c3-ba19-4a13-ae1b-12089f94c5a9" xlink:to="loc_us-gaap_EarningsPerShareBasic_39d78759-1661-42b1-be5a-6251cf5547cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9eecca0f-70d4-422f-b9c2-3f3b80322628" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_287171c3-ba19-4a13-ae1b-12089f94c5a9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9eecca0f-70d4-422f-b9c2-3f3b80322628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fec6716e-8d1d-4110-b84c-98fded1024ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_79e528ef-6d44-4a83-b32b-65b9e2863197" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fec6716e-8d1d-4110-b84c-98fded1024ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="simple" xlink:href="vnda-20201231.xsd#LegalMatters"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0434ac00-a77f-45e5-b87d-09575c7eafec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_13265319-b113-4ae0-8704-a0643c58c727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0434ac00-a77f-45e5-b87d-09575c7eafec" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_13265319-b113-4ae0-8704-a0643c58c727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_db88c407-3359-4c12-a6e5-a395b7565022" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1afcbefe-5488-4064-8135-bdd59300923a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_db88c407-3359-4c12-a6e5-a395b7565022" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1afcbefe-5488-4064-8135-bdd59300923a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_e12a3c0b-9746-48c5-a0e8-207d49287a84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_3c97cf6a-cc49-4296-843c-93dcee101236" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_e12a3c0b-9746-48c5-a0e8-207d49287a84" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_3c97cf6a-cc49-4296-843c-93dcee101236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" xlink:type="simple" xlink:href="vnda-20201231.xsd#QuarterlyFinancialDataUnauditedDetail"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5458bcd8-87e6-4517-b6d0-106b925c4c90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f3b46dd8-a28b-425d-b531-3ab7b5a1b415" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5458bcd8-87e6-4517-b6d0-106b925c4c90" xlink:to="loc_us-gaap_Revenues_f3b46dd8-a28b-425d-b531-3ab7b5a1b415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_0f15dc87-b0ba-4597-85ba-cd67e1a6385f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5458bcd8-87e6-4517-b6d0-106b925c4c90" xlink:to="loc_us-gaap_GrossProfit_0f15dc87-b0ba-4597-85ba-cd67e1a6385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a42caec8-4d4c-4a36-bc6d-a1714ca08ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5458bcd8-87e6-4517-b6d0-106b925c4c90" xlink:to="loc_us-gaap_OperatingIncomeLoss_a42caec8-4d4c-4a36-bc6d-a1714ca08ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db9bc7cd-7bb8-46ca-aed9-b2c1cebaddf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5458bcd8-87e6-4517-b6d0-106b925c4c90" xlink:to="loc_us-gaap_NetIncomeLoss_db9bc7cd-7bb8-46ca-aed9-b2c1cebaddf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e2787fca-fa37-4ff2-9987-8a548eaf3219" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5458bcd8-87e6-4517-b6d0-106b925c4c90" xlink:to="loc_us-gaap_EarningsPerShareBasic_e2787fca-fa37-4ff2-9987-8a548eaf3219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dfd84ead-17d6-422d-8fda-3dc3518e23ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5458bcd8-87e6-4517-b6d0-106b925c4c90" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dfd84ead-17d6-422d-8fda-3dc3518e23ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>vnda-20201231_g1.gif
<TEXT>
begin 644 vnda-20201231_g1.gif
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M/FFU*V0]$M;-*N2F^H"K9R\"V;?6I; C62E;__K7DX#!"PU)@&QGFX"%2%4
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M%WX9X5Z@9GCSUG3_D&3TI6J1QV_])A#X!6M1%G46J'T#876SY7F;YW(:=U=
M!7.^91"[)6F]!WPPEER,-FD/1E@5EE@7AET;'>=5>->"'TA>OD5RNO9;BG:#
M/AA[)[9=%C=__QZQ:8G'? /!"*7&@$O'"$Q'$%(&!A:H>=BW?;6&<'*W95HH
M --655U8>EH'85>%8$@U;0L6;&]G=H:F8R16;;5'$-TF>O='@LE%:#4H?KAF
M81+7<?J@8Q&F:R:&@Q(!7XEG= /!@"Z@:JBV;Q%(?6#P!5*X!/LU=5.7@0G
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1JPJMW/N]X!N^XCN^$140 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>vnda-20201231_g2.jpg
<TEXT>
begin 644 vnda-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#V17AI9@  34T *@    @ !P,!  4
M   !   (;@,#  $    !     %$0  $    ! 0   %$1  0    !   .PU$2
M  0    !   .PX=I  0    !   (=NH<  <   @,    8@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                       !AJ   +&/  60 P "
M%   $,20!  "    %   $-B2D0 "     S P  "2D@ "     S P  #J'  '
M   (#   "+@     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M   R,#(Q.C Q.C$R(# X.C,W.C$R #(P,C$Z,#$Z,3(@,#@Z,S<Z,3(   #_
MX0F<:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z
M>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(^/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT
M87@M;G,C(CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U
M8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^/'AM<#I#<F5A=&5$871E
M/C(P,C$M,#$M,3)4,#@Z,S<Z,3(\+WAM<#I#<F5A=&5$871E/CPO<F1F.D1E
M<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $,  @$! @$! @("
M @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'
M"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( (\ _ ,!
M(@ "$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U
M$  " 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!
M%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:
M8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T
MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_
MQ  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$
M!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*
M%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ
M<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"
MP\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#
M$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX8_X.'/VL?B%^QA
M_P $[KCQK\,O$DWA7Q1'XCT^R6^BMH+AA#)YN]-LR.G.T<[<\5]SU^:?_!U[
M_P HF[O_ +&W2_\ VM54_B1,_A9[U_P0U_:*\9_M8_\ !+7X7_$#XA:Y)XC\
M7Z__ &K]OU&2"*!KCR=7O;>/*1*B#;%%&ORJ,[<G)))^LJ^%_P#@VL_Y0I?!
M?_N.?^G[4:^Z**GQ,(_"C\5_^"[/_!47X\_LE?\ !5KX>?#SX=_$&\\-^#=;
MT;1KJ]TV/3K.=9Y)]0N896WRPO(-T<:+PP QD8.37[45_.S_ ,',O_*<+X3_
M /8O>'__ $[7E?O%^U3^U5X&_8N^"&L?$+XB:U'H?AG157S)2IDEGD8X2&*,
M?-)(YX"CW)P 2-*D?=C8F+U=ST2BOQMA_P"#DWX^?M,:AJ>H?L\_LB^+/&/@
MW36DQJEU!>WTDX0 D,+6/RHY>?\ 5++*Q[9SQ[/_ ,$S_P#@XP\/?MA?'S_A
M3WQ3\ ZE\&OBA<3M:6%I>3O):ZA<  _9F\R..6WN#SMC=2&VX#[F5#+I22N5
MSH^U_P!LW]L?P3^P;\ M4^)/Q!N=0M?#>DRPP2&RM&NIY))7"1HJ#NS$#)(
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M9,%S$&8*V.05+(PY5F'-*5.45=A&2>Q[517XF_\ $5Q\6/\ HT'7O_!U>?\
MROJEXA_X.W?B-X2TJ2^U;]E'4=+L82 ]Q=^(;J&)"2 ,LU@ ,D@#GJ:KV,_Z
ML3[2)^W]%?%G_!%O_@K+J7_!6CX8>-?$UY\/4\!V_A35(=+A$>J-J$=\[Q>:
M^',,0#("F5&>'4G&16;^WU\6_%?@W_@H-\'=%T?Q-XATK1]4;3_MEA9ZC-!;
M7>Z_9&\R-6"OE?E.X'(XZ5X^;9G' *FZD6^><8:=')VO\CZ7A?A^IG6*EA:4
MU%J$YW=]H*[7S/N6BBLGQWXXTOX:^#=3\0:U=)8Z3H]N]U=3MT1%&3QU)[ #
MDD@"N^K4A3@ZE1VBE=M[)+=L\*E3G4FJ=--R;LDM6V]DO-FM17YN2?&7XX?\
M%1/'^I:?X!O+GP'\.=-F\N2Z69K?*]O.EC^>65EY\I#L (!_O'HY/^")&KZ1
M&=2TGXO:A%XDQN-R=->$2-Z>8LY=><?-\W3IZ?'T^*,;BE[;+L%*I2Z2<HPY
MEWC&6K7;:Y^F5?#_ "[+[4,^S.&'KM)^S4)U7&^RFXZ1?=:_-'Z 5\=_'O\
MX*/?$OX":]\5(KKX/^$-8T_X;MI"P-8^/KC[9K/]J7@M[,"%]*5(FV[FD!E<
M*P55,@)=?-O@[^V?\3OV'/C1:_#GXZRS:MH-YM6TUN20SR01D[5F68@--#G[
MP?\ >+^&T_9_B+]FWP)X_P!6U?5[_1X[ZX\33:3>7TRWLX6[?39OM%BP"N%
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M+TZRL]KE3T\QN3CF*.TK[6*J;H_HPO+R'3K26XN)8X+>!#)))(P5(U R6)/
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M +$7Q!T'X3ZE:ZQ\;_%6@7>WQ7J,"PQSZH+:062!#O\ *M8YV5MAW$Y9FW'
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M#O[;>M66J^/O"_VS6M/B^SQ:E9W4EG=-$"2(W:,CS%!)(#@[<G&,G/<?L_\
M[*OP_P#V7OA,/ _@CPS8:/X:8NUQ:D&<WKR +(\[R%FE9E 4ER?E 7A0 /H/
M[2P_U14>2\DUZ:/7[]OF>#B,RHU,+"A&&L;=K:;OYG\JVJ>.M:UOQG+XCO-6
MU*Y\03W?V^34I+EVNWN-V_SC+G=OW<[LYSS7[,?M?_M'>./BO_P:\ZEXT\07
MEQ;^+-<TBPTR^OY<B2XA.O067G/QDM<6X!) P3/GA<D>TZY_P;K?LVZW\6&\
M3?V9XJL[&27SG\/6VK>7I+,6+$ ;#.JG.-JS!0. !7O/[<O[(UC^TC^P'\0/
M@_H=AI^GPZQX9DTW0[2-!!:VEQ"@>R4 #"1I-%#T' 6NK/,XPV)IP5.#]UW=
MUT_E^9S8[%0KQC&GH^_8^,?^"[?[//@G0_\ @E7\*X/^$7T"[F\&ZOX8T'1K
MJYT^&:YT^R9X8I((I&7<D<B11AU4A7"+D' K#_X*4^&/@/\ LA_MP>%]8U#P
MGIGQ&UMOAI<>%/ ?P/\ #7A".ZELI'NY)_[5C0'R+6)0+I"RPAR#*RE_+(5G
MBO4/&G_!6;_@A)X3T?X?:2NK?%KX<ZQH^E^)?#UW<PVEY!J6D2QQW,;^<\2)
M(ZA9@KNG#[<AABM+Q?\ #O\ :X\(_MC:U\?O"_[-NB>(M>^+WP^M_#5[H.H>
M.].C?X=W44NQU:Y+*+J&18HIBL !8M@E&CP_SNK4HM_:EUZ.*_!ZK_@GD<MH
M+RBOO4G^6_G8^=?@[\)_$&I?\$H?V-/CA+\/?^%N>"_@CK/B]_%_@F2!+Z6X
MTVZUFYA%S%;N&CF-FMN=J8.T,"-J*S+Y[\2/A;X*^'GQW_8/U;X;^-M/\9^
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M %8?Q-^(^C_![X<Z]XL\17BZ?H/AG3Y]4U&Y*,_D6\,;22-M4%FPJDX )/0
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M2;H&\Y=K/L<X.47C/YW_ +.?[?W[3_A_XD?LW^/?B=XNT:^\'?M)>+KWP_\
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MWG)557,C,<*!G@5I&HE;396]=;W?Y$RIWOKOKZ:6T_KOW/S]_;1_;%T/P/\
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M<%8PH/>MJ\E/5;VM_P"E?YG/3IN,7#HVW]ZBOT/R:\(_\JZG[(O_ &6JW_\
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M+1>(=;FDG>6XU**UWY>%YGD>1P0 [L,5Z5<>#-(U3_@FY_P4XOKC2]/FOO\
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M[Q9X$_X*+?'_ ..?C>XT.X;Q[%IFA>$8;&YDFET[2;6/$BRAT4(TLB0R%$+
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>vnda-20201231_g3.gif
<TEXT>
begin 644 vnda-20201231_g3.gif
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M=8.AG%>(5P05<  FTEL!=![IN.N=P 34>P+V@L&^2'" ?J/RB5[Q +\H< "
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M=U"@?,0'>X0W9'CV;Q#8<-5F;S/V>O]&@19(7QSH=6H'?%!79$G7>[N&:.=
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L,CNS-%NS-GNS.)NS.AR[LSS;LS[[LT ;M$([M$1;M$9[M$B;M$H;M"$  #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>vnda-20201231_g4.jpg
<TEXT>
begin 644 vnda-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ QP#'  #_X3BH17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(Q.C Q.C$X(# Y.C S.C4S   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,W,@  DI(  @    ,W,@  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,3HP,3HQ." P.#HU.#HT,0 R,#(Q.C Q.C$X(# X.C4X.C0Q      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  )OP         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ M $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M,>]9D_QGU2VE,<_AD1N#@JTS C_QVNV&$C**=]SSYXV49-*.PS_A=FH .?\
MA'%P@RQ\]OE&<<_+ZU'_ ,+TNO\ H P_^!)_^)J_J2[D?VA)?9#_ (7I=?\
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M;2^IQ_F']>E_*1'XV:@!D^'% ]?.;_XFI=/^-5S>ZE:VAT2)!/,D187!.-Q
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MS2)"S0QB20?=0MM!_&J7VK5?^@9%_P"!7_V-95)5$_=C?YV_0EM]$'VK5?\
MH&1?^!7_ -C1]JU7_H&1?^!7_P!C4>TK?R?C_P  5Y=@^U:K_P! R+_P*_\
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M4R6:*&-I)9$1%ZLQP!2<XI7;"XY'26-7C8,C#(93D$4ZFFFKH HI@%% !10
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MT<M;^9!:7</)U3_G\MO_  &/_P 71Y.J?\_EM_X#'_XNCEK?S(+2[AY.J?\
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M/3S;W"-8)ND/[O:BC8/WG0]?XD_[Y]J4W^E+;1*ELSRQH,%XDP6QGYB/O $
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M^%;G0&9/[J?]]?\ UJ,R?W4_,_X4 &9/[J?F?\*,R?W4_,_X4 &9/[J?F?\
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MMK_\<K\/_.?U3\S_ (4><_JGYG_"C^P*?\[#_62I_(?N!_PT=\*O^BE^$?\
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MC^P*?\[#_62I_(?M^?VCOA3_ -%+\(G_ +CMK_\ '*L:9\>OAIK.I6VGZ?\
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M3_G8?ZR5/Y#]P/\ AH[X5?\ 12_"/_@]M?\ XY1_PT=\*O\ HI?A'_P>VO\
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M5_T4OPC_ .#VU_\ CE?A_P"<_JGYG_"CSG]4_,_X4?V!3_G8?ZR5/Y#]P/\
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M .#VU_\ CE?A_P"<_JGYG_"CSG]4_,_X4?V!3_G8?ZR5/Y#]P/\ AH[X5?\
M12_"/_@]M?\ XY1_PT=\*O\ HI?A'_P>VO\ \<K\0/-?U3\S_A1YKGNGYG_"
MC^P:?\[#_62I_(?M_P#\-'?"K_HI?A'_ ,'MK_\ '*/^&COA5_T4OPC_ .#V
MU_\ CE?B!YK^J?F?\*3SG]4_,_X4?V!3_G8_]8ZF_(?N!_PT=\*O^BE^$?\
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M7X?^<_JGYG_"CSG]4_,_X4?V!3_G8?ZR5/Y#]P/^&COA5_T4OPC_ .#VU_\
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M'MK_ /'*/^&COA5_T4OPC_X/;7_XY7X?^<_JGYG_  H\Y_5/S/\ A1_8%/\
MG8?ZR5/Y#]P/^&COA5_T4OPC_P"#VU_^.4?\-'?"K_HI?A'_ ,'MK_\ '*_#
M_P Y_5/S/^%'G/ZI^9_PH_L"G_.P_P!9*G\A^X'_  T=\*O^BE^$?_![:_\
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MKT+]GG_DOGPT_P"QGTW_ -*HZYZ_\&?]=#?#_P :'JOS/H#_ (*B?\E\\/\
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MSM'<XZX'^>H]1D9"J@GH1GW]L^F?UQ0*S&T4NTXSVI*!!1110 4444 %%%%
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M:JEE+*05[G</7%"KN7<.5Z;AT_.OIGX'?LR^%OBE^S7X[^(VL7>LQ:]X?_M
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MU[;:=JAN1)-I[HDR>7:RRJ061@.8P.G>O3J5/8T_:/9(\>A"=::I0W9YCCW
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M&5XXIG16<@ $D#L*Y2NV,E.*FNIQ5(.G-PENM HHHJC,**** "BBB@ HHHH
M**** '1_ZQ?\]J^__P!K[_DP3X)_]P7_ --<U? $?^L7_/:OO_\ :^_Y,$^"
M?_<%_P#37-7CX[^/A_\ $>YE_P# Q'^']3X /04*N[/;N23@4'H*4YVX7:3C
M(#@D''.#^5>LM+MGAK6R$VCIG!Z_7Z>M-8A>_P"5??WA7]AOX-CX0^#/&/C/
MQQK'AI=;TRRN&FN]6L[6W\^:W64QQF6'V8A<YPI/8UHZ+^PK\!/&TMU8^#/B
MM>:QK<=NTR16NLZ??B, A0\D,<09HPS+D97J!N4D$>-+-:,G\+/>63UW:S7I
MU/SS6)F!)5@!G@C!/T'?H>GH:1L#(R,]QGD?7TKW?X;?LUS77[4>G?"3QS+/
M:3>?.EU/I5TKO\EHUS&Z2%.5=?+(RBE1U522*Y;]I'X8:;\&_C1XC\%Z)=7-
MSI>G/;^7)J#(TY+VL4I+R*%4?,[\%?3GU]".)I\ZI0U;5_D<-3!5:<'4GI9V
M^:/+Z*E\IFCW!2!DCYN.G4<^E,CC\QPJLF3GJX X&>N?_P!?:NF_<X-1M%*R
ME5+$<!=Q]5'N.WXTY8F>0H"N0<%BP"CC/7IT_P *H+-C**4+G [X!.3C&>F?
M3\:<8G#*-C?,=JG'#$XZ'OU'3L0>XHV=F-1;V0RBG*C,H8*2"1C /.0"#]#D
M<T%2HSE2/8@^N#].#]:E24MB1%4MT%*<M\VY2O\ >R,?G73?"SPO;>-OB=X1
M\.WDLT-GJ^L6=A/);D"18Y9T1BI((# ,2"01D#BO4OVR/@3HO[._Q,L/#?AZ
M^O[NQN]%COY'U,QRR;VFG0JI1451^Z7&5;DFN:IBHTZBI-:L[:>&J5*;JQV3
MM]YX3Y;-\QX'JQQT'7Z>],SN;!__ %^X]:^GOVU/V8?#7[-S>#E\-W^J7QUE
M+PRKJ\T<JKY/DE0NR-, ^:1SGH*/CI^S#X9^&'[,OP[^(NFZAJ]QK'B#^S_M
M$%Y-$UO&)[*2=_+58PPPR#&6(P3^&"Q].7LY17Q.R-G@:D?:1EO!'S$R[>*;
M3FY;--KTM-T>8%%%% !1110 4444 %%%% !_@?Y&OT%_9%_Y,&^-?_<:_P#3
M5#7Y]?X'^1K]!?V1?^3!OC7_ -QK_P!-4->-FW\&/JOS/<R?_>'_ (9?D?GY
M)]\_4_R%*(RP) )QR<"DD^^?J?Y"G1NJLH9%<$]6)POOQST]*]J.J/$2=E88
MJ[ER",>N1_GM0HWL%# 9[DX ^I[5]>_LG?LE^!/C?\)=:\9^--:UK17TO49K
M6:XM+RWC@2%+>"0LQDA8@#>3RV*] D_9#_9:\ML_&?<1S\_B;2V (/7'D\]#
M^M>-+,Z4)N$TVT>W3RJI5@JBDDGW9\"-"RIN*D#..01SZ?6F5],?M@?L>7/[
M.\EEKNC7\NK^#+Z1;:)KHI]KMKC8TAB8*J[T*QLRLH. K*V"H:3YJ:)E0.1E
M"I8,.00.^?\ .:]'#UJ>*AST=4>;B,-5PM3V=5:C**7'RE@5*YQN##'3/7_/
MZ4Y(C(NY2I7GG<,#'7/TKHY7V.:S2NQE%."$^WIDXSR1_0_E2^4WEA\8'OP?
MIC_/4>HI+780RGB,L"0"<<G IJKN7<I#+_>4Y'YU+"I9E7RA*&(&[DA.AR2.
MG'\Z<6F.S(U4LI92"O<[AZXH5=R[ARO3<.GYU]-_ W]F+PQ\5/V:O'_Q'UBZ
MUF+7?#?]H"".UN(1 QAL8IE^_"S8R_9J^:'9FYD1=YRQD+G( )X)/M@^E<='
M$QJU)4V_A.RMAI48QE_-L1&A1N.,J/=B /S-*J,XR 3P2/?&>GKG!QZ]LUUW
MPM^$OB/XS>,;;PMX9LDN[ZX&^621ML-M",%II7'W$&1EAD_, H+,H/3.2@G*
M3LD<T8.<E&.K9Q_3:?[PR.>HHKHO'WA?_A#O'7B7PY'*;_\ LC4[JR%V(M@F
M\J5T:14'" [,D D85>P!//\ EMNV_P 70C/(.<8/H<\8ZTHR4E="E!Q;78;1
M2@94,.G0^WU]/QI?+8KD?,/5>>V>U7TYNA&VXVBA<-O^= %ZLS #WY[X[^E/
M$3%BO (;8=Q ^;T^O:AZ;CLQE%+M8QJX5BC+O5@,@KZCVSQ]1CK0R,C%6!5@
M2"",$$8S_/\ GZ&CR 2BBB@04444 %?0'[!O_)V'@;_M^_\ 2&XKY_KZ _8-
M_P"3L/ W_;]_Z0W%<6._W6?H=^!_WFGZG["Q_P 7U_H**(_XOK_045^8G[ M
MA\W^K;Z5^>__  5<_P!9\,/^XG_[:5^A$W^K;Z5^>_\ P5<_UGPP_P"XG_[:
M5ZF6?[U \3.?]SD? #=:2E;K25^D2W/RL****0'H7[/$AC^/GPW(;:/^$ETW
M=QGC[5$?7CI7U)_P47^)WC3P9\;M$L/#WC'7_#5E)H,$HM])U.>V1YC<SJ6V
MHP4G:JCD'MGBOEG]GEMOQ\^&I[_\)+IO_I5'7Z0?M/?ML?\ #.'C^P\,IX-7
MQ)]KTV/4C=-J?V?8#++&%V^2^<>43G(ZU\YCDUC(.%/GDXO1GU.7\CP-3VE1
MP2DM4CS'XA:EK7CS_@F;!K'C"*6]\0B.WNX+K4X3Y[*-1"0RH6&\LUL>),EF
M5\DL6)/"^"O^";=UXV\(^$/$5MX_MK>VURSM=1NK*32/GABDA,BXQ,1*X8JN
M6V<,QSD!3Y/^TE^U_P"(_P!HVSLM(N-,LO#_ (8LKA;R#38&::7[1LVAI9V"
M[U7=)M"J@&_Y@VU6'T)^U=?36?[ _P ((+>]DCL[J/1()XED*QW40TR20*X'
M5=ZQM@@_,BD#<!7)_M&'4:<7R.;;MN=<98?%.I5DG-4XK?2[N>2>#/V%=7\;
M?&;Q;X/T;Q';W'A7PS*MK>>,$LRRO=&!&:W2/S3NF1V*.JN-F"7*L$1ZOQF_
M8EOO OPOB\>^#?%EG\2?#D9D:\N=*MU3[/"IVM*@22598U97WE6'E[2Q!&]D
M]:T21-'_ ."6-YJ&D;].N[P.EU<VZJLUUOU<6S^84QNWQ*(VSU0A>@Q1_P $
MP'37/#OQ6T+4V6\T5Q8[])NR)(#YR722GRSD-YBQHK<881J.=M#Q.(BI57/X
M6E;N3]5PLY1IJEK).5[[?\,?,W[./[,OB?\ :.\17MEHUU9:5IVF"&74=0OB
MQ,4;R,H$2+\SR$1S$=%_=D%U)4U]K?LE?LP3?!/XXZMJVE^*],\9>&UT>[T>
MYN;#9')87R7-L_V:6,22?,4W,3G(((95RI;B/V-)#HG[$_QAUVQ\K3]=B.IE
MM5@ BG5HM-C>)FD ##:69@2> ^1R37$?\$O=6N4^-WB2V%U-':7'AV2XFM=V
MU)95N+<+(Z#^("23:3VD?'5J6*KU:ZK)2]U:6'A*%'#SP]XWE+6]SF-'_9]_
MX:._:\^*OAH:V-!-CJFL:D+HV?VK=LOQ'MV^8F,^;G.3TZ<Y'GG@G]G\>,/V
MC[OX2KKS6:1ZEJ&GG56LE<,;1)R',7F#@^2O\?\ %7U+^R&ZM^WQ\9\$'_D.
M#(/?^UH>/T/Y5YS\$]K?\%*+S+##>)?$) S]X&*\[=ZZOK-2//%/2,$U]QS_
M %6FU"35KSDOQ/,?$G[*_B.']HB\^$7A6XCU_4;6*#S-0N(#;0QPM%%++-+@
MNT40\XKD,22P5068"O8=3_X)W1:AI?B+_A#?BKH_C#Q)HF$N=%CLH8W64,08
MFD6=OLSG;( &4 LBABJAC7T]\(=-CN/VO/VB;SRXVNHE\/Q1S  2HIL@SH&P
M<*VQ3COC\:_+G1;SQ=JUWXBO-)GUB>]N-/NI=?N=-FE:6>S;FX>X=0=T;GEW
M?*DG'& :C#XG$XF7)&IRV2^96(HX?!I2G3YDVT?H1_P3C^'-OX/\%>)M8GUB
M$^(=2$-OJGAKR_)N-">WFND59@SLX:3+/M9%Q@@9%?#'QX^%^A_"7Q=:Z+X?
M\;6/C^S-FL\FJ6)C*Q.7>/R&\N60!E$6[D@X<# "\_6?_!+&<[OBE(N]1C3?
MF9?F./MG)SW.,G QEN":^ H$2.,Q*T<FT#:RX)9?4L -W&.?\:UP49_7*G-.
M^WS.;&SI_4:48QMN.(Q2445](VGL?-A1112 **** "BBB@ HHHH **** "BB
MB@ HHHH 5>M>A?L\_P#)?/AI_P!C/IO_ *51UYZO6O0OV>?^2^?#3_L9]-_]
M*HZYZ_\ !G_70WP_\:'JOS/H#_@J)_R7SP__ -BS;_\ I5=5\>5]A_\ !43_
M )+YX?\ ^Q9M_P#TJNJ^/*Y<N_W2GZ'?FW^_5?4] _9Z_P"2^_#7_L9M-_\
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M_M6>!5\X2IOU!@% *C-E<DX.!CDG ''Y5M"%6+Q,W*]C"K.G..$CRV,7XU?
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MVOO^3 _@G_W!?_37-7Y^UXV4_P !_P")GN9Q_O$?\,?R'P@F1=HR?_K5]_\
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M1F=&A3J1E0:M):V=]?4_0#_G%!_P/_W.U\!R=$_W?ZFOOP@_\.H?;=_[G:^
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MG*D JRF-4(PT3;P6(/S;^Q[XLU?X@?MJ>&->U[49-4UB_EU">XO;D#S'S8W
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M>^FJ+?BO_@GYX'\7?#F_UOX.>-IO%FL6#[5CFU*TN[6Z95#R0B2&-5CF*LC
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MM?\ !3K7]0O?B_X2T-KM1I=CH0O(4/RLDTUS+'(0P&6W"WC&WL$/'S$CV/\
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MJ.85XTU3BEHM^MNJ/>?V1?VF7_9O\6ZG=7.F2:CX=UI((KZRM)%CEB,<@VS
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M],W/[8$'AW]K;7OBWX9TJ\O=)U2W2TGTS4VCMYIX4M(XPA=?.$?[^)) 4'(
M!P"<^EK^VA\%_A]_PE_BCX=?#K6(?B#K8DD:[U;:L,LC3-*<M]HE:./>[.8X
MPH8A5.T89/AG[Q]*,XX!I/+</4LHMJVGJ5'-,13O9IWUU6Q]*_LN_M?2_!+X
MA>+=8\4V4WB"T\6.;G5+JQ1$G6Z5I726*(LB%6:5@RDK@,N"-FUO,/CCKWPY
MU[Q19R?##0-4\/>'X[-4FM]6E,LSW/FR%W+M-*Q!5HP/G'1LKGD^<JQ4Y%.,
MA-=$<)2IU?:P,*N+K5*7L79K<::2BBNW8\ZW8****!684444!9A1110%F%%%
M% 684444!9A1110%F%%%% 68J]:]"_9Y_P"2^?#3_L9]-_\ 2J.O/5KT+]GG
M_DOGPT_[&?3?_2J.N>O_  9^C_(VPZ?MX>J_,^@/^"HG_)?/#_\ V+-O_P"E
M5U7QY7V'_P %1/\ DOGA_P#[%FW_ /2JZKX\KERW_=*?H>AFR?UZKZG<? O4
M+71_C;\/K^^N(K.QM?$.GSSW%PX2.*-;F,L[,>%4 9)/ KW'_@HUXVT#QY\:
MM&U#PWK6GZ_81^'88'NM+NDN8DD%S<L5+(2 0"#@]B/6OE=>_. 1@]>1W'!I
MV[:/DED3N"0<Y]<AACH.<'H/>M*N&YZT:R?1K[S&CBITZ+H):-W^X^V_^"E?
MQ$\+>/V^''_"->(])\0?8SJ:7/\ 9=]%<^2S"U(#[&.TG!Z^AI?V8?B)X7T/
M]B?XNZ+J/B/2;'6;MM6^SZ==7\44TV_3HXT 1F!.7!'X9KXCA:./Y2K>6QVL
MJ]2G;GUZ\]>:2/RV7+*5< ;/G#8R</D[?3%<JP*5".&;T3N=7]H2^L2Q,EJU
M8^T_V*?VEO!&B_#_ %SX3_$.YDM='U:6;['?74L@M'AN0D4MJWE\VP.XOYFX
M*6DE=F5OF?U/X,Q_LY?LT_$>2+0/B#_;FMZY9FV&HWFJ0R6=C:JDDK^9/&L<
M* M;J,%FD!*!5568M^;6Y-NU%9 V=^X[MW..#P<$=J;P5/S,5^]M?NW8D X(
MR%R".@%16RQ3G*2G92Z&]+-)4XPC*"?+UZGU-\7O&6@ZI_P4%L/$MGK5E>Z
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M[K]EWXB>%O#?[;?Q;U[5_$>DZ7HEZVL);:E>WL4-M.SZE"Z!)&8*Q*@D $Y
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MY&4) 4[J_/\  B6'RU+*J@J%9BV5/49XSU/4=#3$D,<;!6DPW]XX;/KD''.
M#QTQ7/\ V7'WN>;?,K&SS:=E[."7*TSZS_;"\*_"GPK>1>.?AU\2)]7\;:UK
M\FHO:Z5K4-S!:+EYI)8C"FZ-A,8=A9\Y.1G!(]<L_C%\$?VT/ 6F6GQ5U&'P
M-XRTA)669M0-BB$O"))()9"82LNQ!Y4A9U&X#.WS*_/-E1=WS[F)QD#C R%
M/' &,<=Z8H'+9PR\KGIG_.:UEEKE!)SUCUZF*S+EK2FH>Z]T??7Q(^/GPO\
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M@#CZ50KU</25&C&FNB/%Q51UZTJO=A11172<MF%%%% 685] ?L&_\G8>!O\
MM^_](;BOG^OH#]@T?\98^!A_U_?^D-Q7%CO]TGZ'?@?]YIKS/V%C_B^O]!12
M+(%9Q[_T%%?F)^PI.P^;_5GC/:OA;_@I=X!\4>/I/AT?#'AS5_$?V7^TO/\
M[*L);GR<FU"[MBG&2K8SZ&ONF92T9 W?\!.#5=;<*23GGK\W7WQTKIP];ZO4
M51;HX\5A8XRC*E-V/Q";]GWXIMR?AIXN_P#!%=?_ !ND_P"&?/BE_P!$T\7?
M^"*Z_P#C=?N%M3T./K_]>C:GH?S'^->XL^K=D?-?ZMTNDF?A[_PSY\4O^B:>
M+O\ P177_P ;H_X9\^*7_1-/%W_@BNO_ (W7[A;4]#^8_P :-J>A_,?XT_[>
MK]D'^K=+^9GX>_\ #/GQ2_Z)IXN_\$5U_P#&Z/\ AGSXI?\ 1-/%W_@BNO\
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M_P""*Z_^-U^XGDC^XWYC_&CR1_<;\Q_C1_;U?^5!_JW2_F9^'?\ PSY\4O\
MHFGB[_P177_QNC_AGSXI?]$T\7?^"*Z_^-U^XGDC^XWYC_&CR1_<;\Q_C1_;
MU?\ E0?ZMTOYF?AW_P ,^?%+_HFGB[_P177_ ,;H_P"&?/BE_P!$T\7?^"*Z
M_P#C=?N)Y(_N-^8_QH\D?W&_,?XT?V]7_E0?ZMTOYF?AW_PSY\4O^B:>+O\
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MD?W&_,?XT>2/[C?F/\:/[>K_ ,J#_5NE_,S\._\ AGSXI?\ 1-/%W_@BNO\
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MB>2/[C?F/\:/)']QOS'^-']O5_Y4'^K=+^9GX=_\,^?%+_HFGB[_ ,$5U_\
M&Z/^&?/BE_T33Q=_X(KK_P"-U^XGDC^XWYC_ !H\D?W&_,?XT?V]7_E0?ZMT
MOYF?AW_PSY\4O^B:>+O_  177_QNC_AGSXI?]$T\7?\ @BNO_C=?N)Y(_N-^
M8_QH\D?W&_,?XT?V]7_E0?ZMTOYF?AW_ ,,^?%+_ *)IXN_\$5U_\;H_X9\^
M*7_1-/%W_@BNO_C=?N)Y(_N-^8_QH\D?W&_,?XT?V]7_ )4'^K=+^9GX=_\
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M_P :/)']QOS'^-']O5_Y4'^K=+^9GX>#]GWXI#_FFGB[_P $5U_\;I5_9_\
MBHK K\-_&"=B1H=V./?"<_2OW!\D?W#^?_UZ/+_V3^?_ ->D\^K/1Q0UPW2W
MYV?AVO[/7Q2VEC\,_%X92%C']A7(X)^8G]T>V?>E_P"&?OBCM"K\,?&"9Y?=
MH=TV2"0,'R\].U?N)Y?^RWY__7I/+_V3^?\ ]>E'/:L5;E1?^KM)_:9^'?\
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M[_P177_QNC_AGSXI?]$T\7?^"*Z_^-U^XGDC^XWYC_&CR1_<;\Q_C1_;U?\
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M )\M4_[]I_\ '*^;,>]&/>C_ %JQ_P#,ON#Z]4/I/_AI7PY_SY:I_P!^T_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#VKR']IK_
M )$;3_\ L(I_Z*EKUX]J\A_::_Y$;3_^PBG_ **EKQ,[_P"1;7_PG-B/X4CY
MHQ[T8]Z,>]&/>OP@^5#'O1CWHQ[T8]Z0!CWHQ[T8]Z,>] !CWHQ[T8]Z,>]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HI*,T +13=PI<T +12;A2T %%%% !1110 4444 %%%% !1110 4444 %%
M%% "'M7D/[37_(C:?_V$4_\ 14M>O'M7D/[37_(C:?\ ]A%/_14M>)G?_(MK
M_P"$YL1_"D?-&/>C'O1CWHQ[U^$'RH8]Z,>]&/>C'O2 ,>]&/>C'O1CWH ,>
M]&/>C'O1CWHZV ,>]&/>C'O1CWIV8@Q[T8]Z,>]&/>EOL 8]Z,>]&/>C'O0G
M=70PQ[T8]Z,>]&/>BX:ACWHQ[T8]Z,>].SO8+,,>]&/>C'O1CWI!J&/>C'O1
MCWHQ[T &/>C'O1CWHQ[T70688]Z,>]&/>C'O0 8]Z,>]&/>C'O0 8]Z,>]&/
M>C'O0 8]Z,>]&/>C'O0 8]Z,>]&/>C'O0 8]Z3N/\]J7'O2=Q_GM4/J-;,^U
MOA[_ ,B-X?\ ^O"#_P!%K70USWP]_P"1&\/_ /7A!_Z+6NAK^C<+_ AZ+\CZ
MZG\""D)V_P#ZJ6O%?VGOC1KGP9A^%O\ 8=MI]RWBOQYI7A:\_M&*1Q';77F^
M8\>QUQ(-@P3N'4;3D8Z30]I5@WK^(-(\BQXW'J<# R35>URF!ER,D8;+>F"#
MZ8_G[&N7^+_CQ?AK\*_&/BX6PU#^P-&O=6-GYGE_:1!!))Y8DVL%+% -VUL9
M'!Z$ [#S%)P#D]#QTH5@W3/3/((KA?@KXPU+XD?!OP)XKU6*VM-1U[0+'4[J
M.Q5EACDFMDD=8PQ)"AG.,EN .3UKC;3XS:ZO[8[?"1[6P'AT^ O^$K%P4D-Y
M]J.H?9BA??L\L+DXV9R1\V!@@'MU%-9U3&3C/ ]3WXIHN(R2-XX.#^)(_F"*
M )**C\Y-VW< V,[3P<9QFG*X;.#GM0 ,P1<L<"FK,C*2#D D9P>H."/SKB_C
MEXSO_AQ\&/'?B[2XX9M1\/Z#?ZM;PW09H9)(+:25%D"LK%"R#(#*2,\U\P^&
M_'G[9OC7X9Z/XXT2P^#%[:ZOH<.L6&GXU.*[D\Z!98X5#R",2,'5/GDV!LDL
M!0!]IK*K8P>O3BE5@W0Y[U\\^ /C]XE_:*^ >J^(_A;IMAH/Q%L+W^RKK0_'
M4%W';Z9J,4D9N[:<QJLC;8W.TCJQC#+&=R+] 1R;%+-NQCDD'DY/0<G\/<8H
M L45&;B,,!O!). !R<T[S%/0Y'J.E #J1F"X!(!8X'O3!,C9^;H<'CH<9Y_.
MHY)E=4:-1+\P/T![CCTS^M $GVB/@;N3G [G'7'K^%*LJ/MPP)89 [XKP[XJ
M_&77/!'[2'P0^'UE;6<FE>.1K8OYY8G::W^QV:3)Y+!@!EF(.1TYKVI;A1*2
M57;C 9.3DG., 9SC!- %JBH_M$?S?.!MZYXQU_P-*LBM(4# NHR5[B@!]%%%
M !1110 4444 %%%% !1110 4444 %%(3BF-.BMM+<^G^?K0*Y)14?GIZ_I1Y
MR>OZ4KH+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\
MY/7]*+H+HDHJ/SD]?TH\Y/7]*+H+HDHJ/SD]?TH\Y/7]*+H+H<[;5R:;N'TJ
M.XFC:,@R;/\ :Z8KYU^(GQXU235KS3- FCLH+1S$]PS*TLC>H!#8'X9Z<UY.
M89GA\MASU7=]D95*T:4>9GT8TBA6(/09-+'*'/'(P#G''/O7QE8_$GQ987'V
ME/$%VURNXJ9)#)'D@C&QOE[^E>Y?!_XPOXNN%TG5(4CU18=WVF(G9<$=3@_=
M(],D=<8Z5Y6 XDP6.J>R5U+SV.:CC:=7W>IZ\I&ZG4Q6#'BGU]8=X4444 %%
M%% !1110 4444 %%%% !1110 4444 (>U>0_M-?\B-I__813_P!%2UZ\>U>0
M_M-?\B-I_P#V$4_]%2UXF=_\BVO_ (3FQ'\*1\T8]Z,>]&/>C'O7X0?*ACWH
MQ[T8]Z,>]( Q[T8]Z,>]&/>CR ,>]&T]LG@GCV&:,>](4WJR!G#,-HVG'7_Z
MV:B6J:6Z$]$*RE,DAB%!)P"<8&>WM2M&5QGN-PY[9(_H:]L^'VEV=U\$O$MV
MUM%+/$MWY<A4;L"(%>?RKQ(KPISG.?RSQ^I->KBL!/#0I5'*ZFKG74HJ*374
M%4LP4<D]!ZT;>O.".H)Y_*NN^$MG%??$31X)HTEB9WRL@R#B-C_2K_QOT^*R
M^(MS%!%#!&+>$!8QMRQ!)]O2CZG+ZG+%+ORF:I^YSG!8]Z,>](65<Y8#!P>>
M]*B^9C:1D].0*\WW5:*Z:&.O4 I/_P"NEV_*6W# Z_,*ZCX;^!X_B!XA.F27
M1MD\AIR5Y8A648Q_P*L?Q9HUKHGB+4-,5?,6TD, DW 9P<9(SZBNBIAJM/#K
M$->Y)V-?92Y5-%2.RGDC=UBD,:XR^"%&6*CGIU!J!L*H8L,'D<CUQ_.O=+RU
MMXOV:FN/+5'*KOD"\Y%UC\>IKB]*T[P@?AM=O,\?]OL['R=Q+C#':!]1S7IU
M\H]BX14[7CS:FU3#N/7H>?\ 1BO.1UI<>].'F2)OW_NVZ*1@C'KFF[?F4;@2
MQP-K UX,7[JYMSC5^X8]Z,>](<!F4L,KUYX_.A<-T.:MZ;@*%R0.]-W#_:/T
M!/?%/"DA@O+;6VCWP:['X<V]K)#>S7$8=D*?*XQ\AC?<1GK\^P8'/.>@-;T*
M*Q%2,"E%M[G&9^8K\P8=0012X]ZZWXA6]K;WEM]F"@R*[G;Z>8VW/I\NWBN2
MQ[TJU%T)N#=RI1Y7:X8]Z,>]&/>C'O6) 8]Z,>]&/>C'O0 8]Z,>]&/>C'O0
M 8]Z,>]&/>C'O0 8]Z3N/\]J7'O2=Q_GM4/J-;,^UOA[_P B-X?_ .O"#_T6
MM=#7/?#W_D1O#_\ UX0?^BUKH:_HW"_P(>B_(^NI_ AK.$QG//H"?Y5\K_MZ
M3*T7[/3(W*_&/P\.1QD&X!!/8=1G!KU3]J?P7XL^('[/_C71? VN:EX>\726
M7VC3+W2)F@NFGA=9E@CD$D>PS&/R2V\ "4DY&0?FK5_B#XN_;"\;_!/0E^#_
M (Z^&]EX<\2VGC/7]8\4::8;.W>QC8I9VY+)]H\V:78'PC* )/*8;Q'TFAXS
MX\^*O[//QJ_:&^)-U^T?XHNUL_"NLW?ACPQX)\K47L[.&!HUFU#S;*-2TEQ,
MC'8S94 JQE'E>5K_  O\7>'/B=^R/^U!\+]/\1WGQ-^'W@/21J/AC7]3\ZWN
M#:FTDO+2W>,HDA^RW-F1O8XD VB..-52O8K;Q%XL_8W^,7Q$L&^&'BWXC?#;
MQYK%SXNTS5/!5F^IZC8:E,L2WMM=1 1A(BXW1D'(4 9E+/Y70>&M'^.?QH_9
MW^,FJ>.K6WTK5/&VA7D'A3X?K%%')H\;VDT4*3W+!&:>8M&7$A 3&<1[C%&
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M?A?X$^#8/"O@VPFTO0(9'FCL9-0N;M('?!<1&=W9$9MSE00-S,V,LQ/S7<>
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M //W\6']GR_G9\6_]^_SH_[]_G7VE_PK[PW_ - #3/\ P#C_ ,*/^%?>&_\
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M\*/]4:__ #]_%A_9\OYV?%O_ '[_ #H_[]_G7VE_PK[PW_T -,_\ X_\*/\
MA7WAO_H :9_X!Q_X4?ZHU_\ G[^+#^SY?SL^+?\ OW^='_?O\Z^TO^%?>&_^
M@!IG_@''_A1_PK[PW_T -,_\ X_\*/\ 5&O_ ,_?Q8?V?+^=GQ;_ -^_SH_[
M]_G7VE_PK[PW_P! #3/_  #C_P */^%?>&_^@!IG_@''_A1_JC7_ .?OXL/[
M/E_.SXM_[]_G1_W[_.OM+_A7WAO_ * &F?\ @''_ (4?\*^\-_\ 0 TS_P
MX_\ "C_5&O\ \_?Q8?V?+^=GQ;_W[_.C_OW^=?:7_"OO#?\ T -,_P# ./\
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M,_\  ./_  H_U1K_ //W\6']GR_G9\6_]^_SH_[]_G7VE_PK[PW_ - #3/\
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M1K_\_?Q8?V?+^=GQ;_W[_.C_ +]_G7VE_P *^\-_] #3/_ ./_"C_A7WAO\
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M]X;_ .@!IG_@''_A1_JC7_Y^_BP_L^7\[/BW_OW^='_?O\Z^TO\ A7WAO_H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]=3^!!11172:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 M%)NHW4 +12;J-U "T4FZC=0 M%)NHW4 +12;J-U "T4FZC=0 M%)NHW4
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M0?*ACWHQ[T8]Z,>]( Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@
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MP\^-OA#3OB-JTMK\2I])N/[1UVT2^OK*2SN#<R22RK)$+EI9';G"%>,ESEJ
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MQ9^(6L>')[";Q[J2Z>OBE;?46GN$$43+9^="9&$&8BVW"IO )YQFN?\ CY\
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MXA_:#_E/M#_A8WAC_H8M*_\  V/_ !H_X6-X8_Z&+2O_  -C_P :^+]_N/\
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MABTK_P #8_\ &OB_?[C_ +Z_^RHW^X_[Z_\ LJ/];J__ #Y_$/[0?\I]H?\
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M $,6E?\ @;'_ (U\7[_<?]]?_94;_<?]]?\ V5'^MU?_ )\_B']H/^4^T/\
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M4;_<?]]?_94?ZW5_^?/XA_:#_E/M#_A8WAC_ *&+2O\ P-C_ ,:/^%C>&/\
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M3,VX\;UPJC&/X3UKNOAY\=--\77,-E>0?V1J,SE([<N94<XR,2!0 3@\$#G
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M--=%8^ABDE9!1116PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:YO_ (3JQ_YY77_?"_XT?\)U8_\ /*Z_[X7_ !H Z3</6C</6N;_ .$ZL?\
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M+_C1_P )U8_\\KK_ +X7_&@#I-P]:-P]:YO_ (3JQ_YY77_?"_XT?\)U8_\
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M1_PG5C_SRNO^^%_QH Z3</6C</6N;_X3JQ_YY77_ 'PO^-'_  G5C_SRNO\
MOA?\: .DW#UHW#UKF_\ A.K'_GE=?]\+_C1_PG5C_P \KK_OA?\ &@#I-P]:
M-P]:YO\ X3JQ_P">5U_WPO\ C1_PG5C_ ,\KK_OA?\: .DW#UHW#UKF_^$ZL
M?^>5U_WPO^-'_"=6/_/*Z_[X7_&@#I-P]:-P]:YO_A.K'_GE=?\ ?"_XT?\
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M_P"$NTG_ )^C_P!^G_PH_P"$NTG_ )^C_P!^G_PH V**Q_\ A+M)_P"?H_\
M?I_\*/\ A+M)_P"?H_\ ?I_\* -BBL?_ (2[2?\ GZ/_ 'Z?_"C_ (2[2?\
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M%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z*
M&;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[
M[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_O
MM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A
M3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%
M&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &
M;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[
M?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM
M^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3
MZ* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&
MQO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;
M&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?
MI_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^
MG^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z
M* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* (9+=9EQ(%E7K
MMD (^O2H&TNW;_ETMV^J#_"KM% %#^R;;_GQM?\ OA?_ (FC^R;;_GQM?^^%
M_P#B:OT4 4/[)MO^?&U_[X7_ .)H_LFV_P"?&U_[X7_XFK]% %#^R;;_ )\;
M7_OA?_B:/[)MO^?&U_[X7_XFK]% %#^R;;_GQM?^^%_^)H_LFV_Y\;7_ +X7
M_P")J_10!0_LFV_Y\;7_ +X7_P")H_LFV_Y\;7_OA?\ XFK]% %#^R;;_GQM
M?^^%_P#B:/[)MO\ GQM?^^%_^)J_10!0_LFV_P"?&U_[X7_XFC^R;;_GQM?^
M^%_^)J_10!0_LFV_Y\;7_OA?_B:/[)MO^?&U_P"^%_\ B:OT4 4/[)MO^?&U
M_P"^%_\ B:/[)MO^?&U_[X7_ .)J_10!0_LFV_Y\;7_OA?\ XFC^R;;_ )\;
M7_OA?_B:OT4 4/[)MO\ GQM?^^%_^)H_LFV_Y\;7_OA?_B:OT4 4/[)MO^?&
MU_[X7_XFC^R;;_GQM?\ OA?_ (FK]% %#^R;;_GQM?\ OA?_ (FC^R;;_GQM
M?^^%_P#B:OT4 4/[)MO^?&U_[X7_ .)H_LFV_P"?&U_[X7_XFK]% %#^R;;_
M )\;7_OA?_B:/[)MO^?&U_[X7_XFK]% %#^R;;_GQM?^^%_^)H_LFV_Y\;7_
M +X7_P")J_10!0_LFV_Y\;7_ +X7_P")H_LFV_Y\;7_OA?\ XFK]% %#^R;;
M_GQM?^^%_P#B:/[)MO\ GQM?^^%_^)J_10!0_LFV_P"?&U_[X7_XFC^R;;_G
MQM?^^%_^)J_10!0_LFV_Y\;7_OA?_B:/[)MO^?&U_P"^%_\ B:OT4 4/[)MO
M^?&U_P"^%_\ B:/[)MO^?&U_[X7_ .)J_10!0_LFV_Y\;7_OA?\ XFC^R;;_
M )\;7_OA?_B:OT4 4/[)MO\ GQM?^^%_^)H_LFV_Y\;7_OA?_B:OT4 4/[)M
MO^?&U_[X7_XFC^R;;_GQM?\ OA?_ (FK]% %#^R;;_GQM?\ OA?_ (FC^R;;
M_GQM?^^%_P#B:OT4 4/[)MO^?&U_[X7_ .)H_LFV_P"?&U_[X7_XFK]% %#^
MR;;_ )\;7_OA?_B:/[)MO^?&U_[X7_XFK]% %#^R;;_GQM?^^%_^)H_LFV_Y
M\;7_ +X7_P")J_10!0_LFV_Y\;7_ +X7_P")H_LFV_Y\;7_OA?\ XFK]% %#
M^R;;_GQM?^^%_P#B:/[)MO\ GQM?^^%_^)J_10!0_LFV_P"?&U_[X7_XFC^R
M;;_GQM?^^%_^)J_10!0_LFV_Y\;7_OA?_B:/[)MO^?&U_P"^%_\ B:OT4 4/
M[)MO^?&U_P"^%_\ B:/[)MO^?&U_[X7_ .)J_10!0_LFV_Y\;7_OA?\ XFC^
MR;;_ )\;7_OA?_B:OT4 4/[)MO\ GQM?^^%_^)H_LFV_Y\;7_OA?_B:OT4 4
M/[)MO^?&U_[X7_XFC^R;;_GQM?\ OA?_ (FK]% %#^R;;_GQM?\ OA?_ (FC
M^R;;_GQM?^^%_P#B:OT4 4/[)MO^?&U_[X7_ .)H_LFV_P"?&U_[X7_XFK]%
M %#^R;;_ )\;7_OA?_B:/[)MO^?&U_[X7_XFK]% %#^R;;_GQM?^^%_^)H_L
MFV_Y\;7_ +X7_P")J_10!0_LFV_Y\;7_ +X7_P")H_LFV_Y\;7_OA?\ XFK]
M% %#^R;;_GQM?^^%_P#B:/[)MO\ GQM?^^%_^)J_10!0_LFV_P"?&U_[X7_X
MFC^R;;_GQM?^^%_^)J_10!0_LFV_Y\;7_OA?_B:/[)MO^?&U_P"^%_\ B:OT
M4 4/[)MO^?&U_P"^%_\ B:/[)MO^?&U_[X7_ .)J_10!0_LFV_Y\;7_OA?\
MXFC^R;;_ )\;7_OA?_B:OT4 4/[)MO\ GQM?^^%_^)H_LFV_Y\;7_OA?_B:O
MT4 4/[)MO^?&U_[X7_XFC^R;;_GQM?\ OA?_ (FK]% %#^R;;_GQM?\ OA?_
M (FC^R;;_GQM?^^%_P#B:OT4 4/[)MO^?&U_[X7_ .)H_LFV_P"?&U_[X7_X
MFK]% %#^R;;_ )\;7_OA?_B:/[)MO^?&U_[X7_XFK]% %#^R;;_GQM?^^%_^
M)H_LFV_Y\;7_ +X7_P")J_10!0_LFV_Y\;7_ +X7_P")H_LFV_Y\;7_OA?\
MXFK]% %#^R;;_GQM?^^%_P#B:/[)MO\ GQM?^^%_^)J_10!0_LFV_P"?&U_[
MX7_XFC^R;;_GQM?^^%_^)J_10!0_LFV_Y\;7_OA?_B:/[)MO^?&U_P"^%_\
MB:OT4 4/[)MO^?&U_P"^%_\ B:/[)MO^?&U_[X7_ .)J_10!0_LFV_Y\;7_O
MA?\ XFC^R;;_ )\;7_OA?_B:OT4 4/[)MO\ GQM?^^%_^)H_LFV_Y\;7_OA?
M_B:OT4 4/[)MO^?&U_[X7_XFC^R;;_GQM?\ OA?_ (FK]% %#^R;;_GQM?\
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M)_\ !1?_ /QBCZIB/^?;^YA]>PO_ #]C]Z/H2BOGO_AOSX#_ /0\G_P47_\
M\8H_X;\^ _\ T/)_\%%__P#&*/JF(_Y]O[F'U["_\_8_>CZ$HKY[_P"&_/@/
M_P!#R?\ P47_ /\ &*/^&_/@/_T/)_\ !1?_ /QBCZIB/^?;^YA]>PO_ #]C
M]Z/H2BOGO_AOSX#_ /0\G_P47_\ \8H_X;\^ _\ T/)_\%%__P#&*/JF(_Y]
MO[F'U["_\_8_>CZ$HKY[_P"&_/@/_P!#R?\ P47_ /\ &*/^&_/@/_T/)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)M))V@9SN&.G6@!]%,:15P"<'.*%F1GV _/C<5[@>M #Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\X_WM^B/TW(/]R7JSRK]J[/_  R]\7RIPP\(:N0>X(LI3QP>:^7O@Q_P3I^
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M9% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49%
M7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%H
MI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,B
MC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H
M"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM
M%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D
M49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49% 7%HI,BC(H"XM%)D49%
M 7%HI,BC(H"XM%)D49% 7%HI,BC(H"X&C--DD2-"S'"CD\$U@>+/'&B>#[6.
M;5[M8%E8K$FPNSD#/  )Q[]!D<\BLJM2%&//4=D#DDKMG0>8H4L3@#KGBE#
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M,0D<#;YQ7[QS@GOBO$X/V -;TG2M=\ Z%\:?$GA_X%ZO//++X&L[.*6[AAF
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M7IJ'0XK4/C1X.TO4+BSN=5,5S;R-%(OV:8[64X(R$QU]*@_X7OX(_P"@T?\
MP$G_ /B*^9_'F#XXU[YE_P"/^X_B']\G^HK"P/[Z_P#?0K\MK\4XZE5G34(V
M3MJG_F>+/&UHR:43ZU_X7OX(_P"@T?\ P$G_ /B*/^%[^"/^@T?_  $G_P#B
M*^2L#^^O_?0HP/[Z_P#?0K#_ %LQW\D?N?\ F9_7JW\J/K7_ (7OX(_Z#1_\
M!)__ (BC_A>_@C_H-'_P$G_^(KY*P/[Z_P#?0HP/[Z_]]"C_ %LQW\D?N?\
MF'UZM_*CZU_X7OX(_P"@T?\ P$G_ /B*/^%[^"/^@T?_  $G_P#B*^2L#^^O
M_?0HP/[Z_P#?0H_ULQW\D?N?^8?7JW\J/K7_ (7OX(_Z#1_\!)__ (BC_A>_
M@C_H-'_P$G_^(KY*P/[Z_P#?0HP/[Z_]]"C_ %LQW\D?N?\ F'UZM_*CZU_X
M7OX(_P"@T?\ P$G_ /B*/^%[^"/^@T?_  $G_P#B*^2L#^^O_?0HP/[Z_P#?
M0H_ULQW\D?N?^8?7JW\J/K7_ (7OX(_Z#1_\!)__ (BC_A>_@C_H-'_P$G_^
M(KY*P/[Z_P#?0HP/[Z_]]"C_ %LQW\D?N?\ F'UZM_*CZU_X7OX(_P"@T?\
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M!)__ (BC_A>_@C_H-'_P$G_^(KY*P/[Z_P#?0HP/[Z_]]"C_ %LQW\D?N?\
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M(KY*P/[Z_P#?0HP/[Z_]]"C_ %LQW\D?N?\ F'UZM_*CZU_X7OX(_P"@T?\
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M\+W\$?\ 0:/_ ("3_P#Q%'_"]_!'_0:/_@)/_P#$5\S_ /" ^)O^A?U7_P
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M .(KYG_X0'Q-_P!"_JO_ (!R?_$T?\(#XF_Z%_5?_ .3_P")H_UBS7_GRO\
MP&7^8?6L3_(?3'_"]_!'_0:/_@)/_P#$4?\ "]_!'_0:/_@)/_\ $5\S_P#"
M ^)O^A?U7_P#D_\ B:/^$!\3?]"_JO\ X!R?_$T?ZQ9K_P ^5_X#+_,/K6)_
MD/IC_A>_@C_H-'_P$G_^(H_X7OX(_P"@T?\ P$G_ /B*^9_^$!\3?]"_JO\
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M$?\ 0:/_ ("3_P#Q%?,__" ^)O\ H7]5_P# .3_XFC_A ?$W_0OZK_X!R?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6=?BF\87C:3YUUXHM;?5KMXM/=X=MQO8JK+)&6>-(W(&S=3/B1X@\+7GQ5^
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M#2-<;P%9ZQ9ZAJ6L^1+F:Y2\S'#&(HWVQ0,Z;MT[._RPJ?NNB@#X+^%O@O\
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MR2,\FUFWR%@&.-L<8&*]7H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^FY!_N2]6%%%%>(?1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M36&I5:JBN:)XK8_\%$O'R:H]QJ5KIUQIV\NUG]CCR$Y& 0.N*^\/!?AGP/\
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MVF7+ !]I /X$_A7G/[ +12?'GXMF( 1&]O-F.RBY4#\*XW_@J1Q\0/!H /\
MR#Y1TXSYI/\ (BN*C3A4QG(COKXBI3P,I62U.0^'_P 5#\<OC+K^NZM;V\>L
M36,$.G6PX5(T>$2[21A69-XSD'WK<_:ONM';P'J%\ECY-M>3QC2+6<EYTE#+
MYC%FRP4DS-@D#D<=*^0=/NY[:ZAGMKF2RF0[EEC8JP_+FK&K:[JFM20OJ.H7
M%XJ@@+/(6V>F/K7T[PCA4]W8^568*=+DG'4I.6$9#2"4;L!@,8P3Q^M14YR.
M #D8!_$]:;7HQCRJQXH44459+"BBB@04444 ?8?_  2Y_P"3@=>_[%FX_P#2
MJTK]2*_+?_@ES_R<#KW_ &+-Q_Z56E?J17Y_G'^]OT1^FY!_N2]6%%-9@HR3
MBA9%8X!SQGCTKQ#Z,=1110 4444 %%%(6 QF@!:*:9%')/TXZT*P8D \@X-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNP=W&. ><].HZU(L:%,YS_M+R/SK339&5I16J(Z*3^(XZ4M!FPHHHH$%%%%
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M.?Q9K7C;]CGP!K/B+5M0UO6;@:AY]]J=W)<SRA=0N$7=(Y+-A551D\!<#C%
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M'^&_]F?\2_\ M'[89LKYICV[2N#D*W9NF*X3_AJ!_P#H61_X'-_\:KQ<3G.
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M_<^F-WO1N]Z^9_\ AI/Q+_SYZ5_W[D_^+H_X:3\2_P#/GI7_ '[D_P#BZ/\
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ME(8#_O@?S[U[M7[GEN*>,PL*S5FT?34JGM(*04445Z9J%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M (4E:QX:RV*M[._S?^8?4Z78\#'[+[G_ )F%1_W#Q_\ '*7_ (9=;_H8E_\
M!>/_ (Y7O@%+MK5<.Y9_S[_&7^92PM%=#P+_ (9=;_H8E_\ !>/_ (Y1_P ,
MNM_T,2_^"\?_ !RO?=M&VC_5W+/^?;^^7^8_JM'^4\"_X9=;_H8E_P#!>/\
MXY1_PRZW_0Q+_P""\?\ QRO?=M&VC_5W+/\ GV_OE_F'U6C_ "G@7_#+K?\
M0Q+_ ."\?_'*/^&76_Z&)?\ P7C_ ..5[[MHVT?ZNY9_S[?WR_S#ZK1_E/ O
M^&76_P"AB7_P7C_XY1_PRZW_ $,2_P#@O'_QRO?=M&VC_5W+/^?;^^7^8?5:
M/\IX%_PRZW_0Q+_X+Q_\<H_X9=;_ *&)?_!>/_CE>^[:-M'^KN6?\^W]\O\
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M+NJ7XO\ 4/JU+^4\@_X9K\/?\_\ J?\ W\C_ /B*/^&:_#W_ #_ZG_W]C_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UJ3_&E:D_
MQI@?CM^WE_R=;X\_W['_ -(+:O *]_\ V\O^3K?'G^_8_P#I!;5X!7Z9@?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M2?XTK4G^-,#\=OV\
MO^3K?'G^_8_^D%M7@%>__MY?\G6^//\ ?L?_ $@MJ\ K],P/^[0]$?CN._WF
MIZL****[CA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#[#_X)<_\G Z]_P!BS<?^E5I7
MZD5^6_\ P2Y_Y.!U[_L6;C_TJM*_4BOS_./][?HC]-R#_<EZLCF5G4!0N<Y^
M89 ]\=Z;%$4<DX(QZ<Y[\Y_I4U%>(?1A1110 5',K,HV8#9ZG/IZ=ZDHH @A
MC*R D#.""<=>G(Y/^0*GHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH :U)_C2M2?XTP/QV_;R_Y.M\>?[]C_P"D%M7@
M%>__ +>7_)UOCS_?L?\ T@MJ\ K],P/^[0]$?CN._P!YJ>K"BBBNXX0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^P_^"7/_ "<#KW_8LW'_ *56E?J17Y;_ /!+G_DX
M'7O^Q9N/_2JTK]2*_/\ ./\ >WZ(_3<@_P!R7JPHHHKQ#Z,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HI*3<*5TMP'44F:6F 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #6I/\ &E:D_P :8'X[?MY?\G6^//\ ?L?_ $@MJ\ KW_\ ;R_Y
M.M\>?[]C_P"D%M7@%?IF!_W:'HC\=QW^\U/5A1117<<(4444 %%%% !1110
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M.'QK^(VK6FF>%_#NJ6>CQOJ5Q?[A>&QMIGGOYU?"VL:)<0P[2P)^Q,Y #@D
M]P\Y-H.>I ]^:3[1'NV[OFP"5P<@$X!-?).B_P#!2+X;ZUJ6D7,V@^-_#_@O
M5M0;3;'X@:UHGV;PY/(#(J,+EI,A':-AEE4H0=^P*Q'U;G=\F&5T ?9E2>,'
M:,CMD<]LT 6%N$=B%)..ORG'?_#^7J*7SD]>^WIU/MZU\#:7^S)\.?VCOVX?
MVET^(7AE/$)T<^&C:;K^ZM_*$VF_.#Y,J9RL$?7=R,\=#OVOPSC_ &$_V@?
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MFX/B71M=LS'J>C^2KLYN+9"S8VQL1MW9,;J,LC* #W#SDV@YZD#WYI!.ADV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 -:D_QIS4WIQ0!^.W[>7_ "=;
MX\_W['_T@MJ\ KW_ /;R_P"3K?'G^_8_^D%M7@%?IV!3^K4_1'X[CO\ >:GJ
MPHHHKNLSA"BBBBS ****+, HHHHLP"BBBBS ****+, HHHHLP"BBBBS ****
M+, HHHHLP"BBBBS ****+, HHHHLP"BBBBS ****+, HHHHLP"BBBBS ^P_^
M"7/_ "<#KW_8LW'_ *56E?J17Y;_ /!+G_DX'7O^Q9N/_2JTK]2*_/\ .?\
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ME5ES*5CXN_[]_G1_W[_.OM%?A[X;_P"@!IO_ ("1_P"%+_PK[PW_ - #3/\
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M@!IG_@''_A1_JC7_ .?OXL/[/E_.SXM_[]_G1_W[_.OM+_A7WAO_ * &F?\
M@''_ (4?\*^\-_\ 0 TS_P  X_\ "C_5&O\ \_?Q8?V?+^=GQ;_W[_.C_OW^
M=?:7_"OO#?\ T -,_P# ./\ PH_X5]X;_P"@!IG_ (!Q_P"%'^J-?_G[^+#^
MSY?SL^+?^_?YT?\ ?O\ .OM+_A7WAO\ Z &F?^ <?^%'_"OO#?\ T -,_P#
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M#C_PH_X5]X;_ .@!IG_@''_A1_JC7_Y^_BP_L^7\[/BW_OW^='_?O\Z^TO\
MA7WAO_H :9_X!Q_X4?\ "OO#?_0 TS_P#C_PH_U1K_\ /W\6']GR_G9\6_\
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MU_\ G[^+#^SY?SL^+?\ OW^='_?O\Z^TO^%?>&_^@!IG_@''_A1_PK[PW_T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2SSWG@W2YM0NHH;PJLTMSI&F1BPG=XPA+QDR'"X1BWS(0 *X[XA?!&W\:?\
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M!<?P'M#HS2"7Y;(ZHGV=?WW[P?NRF _S?WN16;>?LF?'[PKX'\4?!KX?^+/
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M%!&L2%V4 %BJ*20H!/;L #I**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M * MS_WV_P#\30%F=+FC-<U_PD=[_P! 6Y_[[?\ ^)H_X2.]_P"@+<_]]O\
M_$T!9G2YHS7-?\)'>_\ 0%N?^^W_ /B:/^$CO?\ H"W/_?;_ /Q- 69TN:,U
MS7_"1WO_ $!;G_OM_P#XFC_A([W_ * MS_WV_P#\30%F=+FC-<U_PD=[_P!
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M] 6Y_P"^W_\ B:/^$CO?^@+<_P#?;_\ Q-(#I<T9KFO^$CO?^@+<_P#?;_\
MQ-'_  D=[_T!;G_OM_\ XF@#I<U%<1B1 "N\ AMOKCGU%<__ ,)'>_\ 0%N?
M^^W_ /B:/^$CO?\ H"W/_?;_ /Q- '!?L_\ [,V@_L^WOBO4;#7?$_BS7O$L
MMM)JFO\ B[5?M]]<B"+RX8RX11MC4M@D;OG()VJ@'L6:YK_A([W_ * MS_WV
M_P#\31_PD=[_ - 6Y_[[?_XF@#I<T9KFO^$CO?\ H"W/_?;_ /Q-'_"1WO\
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MFC_\31_PG0_Y\_\ R:/_ ,30!V&:,UQ__"=#_GS_ /)H_P#Q-'_"=#_GS_\
M)H__ !- '89HS7'_ /"=#_GS_P#)H_\ Q-'_  G0_P"?/_R:/_Q- '89HS7'
M_P#"=#_GS_\ )H__ !-'_"=#_GS_ /)H_P#Q- '89HS7'_\ "=#_ )\__)H_
M_$T?\)T/^?/_ ,FC_P#$T =AFC-<?_PG0_Y\_P#R:/\ \31_PG0_Y\__ ":/
M_P 30!V&:,UQ_P#PG0_Y\_\ R:/_ ,31_P )T/\ GS_\FC_\30!V&:,UQ_\
MPG0_Y\__ ":/_P 31_PG0_Y\_P#R:/\ \30!V&:,UQ__  G0_P"?/_R:/_Q-
M'_"=#_GS_P#)H_\ Q- '89HS7'_\)T/^?/\ \FC_ /$T?\)T/^?/_P FC_\
M$T =AFC-<?\ \)T/^?/_ ,FC_P#$T?\ "=#_ )\__)H__$T =AFC-<?_ ,)T
M/^?/_P FC_\ $T?\)T/^?/\ \FC_ /$T =AFC-<?_P )T/\ GS_\FC_\31_P
MG0_Y\_\ R:/_ ,30!V&:,UQ__"=#_GS_ /)H_P#Q-'_"=#_GS_\ )H__ !-
M'89HS7'_ /"=#_GS_P#)H_\ Q-'_  G0_P"?/_R:/_Q- '89HS7'_P#"=#_G
MS_\ )H__ !-'_"=#_GS_ /)H_P#Q- '89HS7'_\ "=#_ )\__)H__$T?\)T/
M^?/_ ,FC_P#$T =AFC-<?_PG0_Y\_P#R:/\ \31_PG0_Y\__ ":/_P 30!V&
M:,UQ_P#PG0_Y\_\ R:/_ ,31_P )T/\ GS_\FC_\30!V&:,UQ_\ PG0_Y\__
M ":/_P 31_PG0_Y\_P#R:/\ \30!V&:,UQ__  G0_P"?/_R:/_Q-'_"=#_GS
M_P#)H_\ Q- '89HS7'_\)T/^?/\ \FC_ /$T?\)T/^?/_P FC_\ $T =AFC-
M<?\ \)T/^?/_ ,FC_P#$T?\ "=#_ )\__)H__$T =AFC-<?_ ,)T/^?/_P F
MC_\ $T?\)T/^?/\ \FC_ /$T =AFC-<?_P )T/\ GS_\FC_\31_PG0_Y\_\
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MW_PG5C_SRNO^^%_QH_X3JQ_YY77_ 'PO^- '2;AZT;AZUS?_  G5C_SRNO\
MOA?\:/\ A.K'_GE=?]\+_C0!TFX>M&X>M<W_ ,)U8_\ /*Z_[X7_ !H_X3JQ
M_P">5U_WPO\ C0!TFX>M&X>M<W_PG5C_ ,\KK_OA?\:/^$ZL?^>5U_WPO^-
M'2;AZT;AZUS?_"=6/_/*Z_[X7_&C_A.K'_GE=?\ ?"_XT =)N'K1N'K7-_\
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M3F?W'']<H]6?2N/\Y-&/\Y-?-7_#2GB7_GRTO_OU)_\ %T?\-*>)?^?+2_\
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M'^M&7?SO[@^N4.Y]*X_SDT8_SDU\U?\ #2GB7_GRTO\ []2?_%T?\-*>)?\
MGRTO_OU)_P#%T?ZT9=_._N#ZY0[GTKC_ #DT8_SDU\U?\-*>)?\ GRTO_OU)
M_P#%T?\ #2GB7_GRTO\ []2?_%T?ZT9=_._N#ZY0[GTKC_.31C_.37S5_P -
M*>)?^?+2_P#OU)_\71_PTIXE_P"?+2_^_4G_ ,71_K1EW\[^X/KE#N?2N/\
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MXS:?3_QXT;3Z?^/&GT4 ,VGT_P#'C1M/I_X\:?10 S:?3_QXT;3Z?^/&GT4
M,VGT_P#'C1M/I_X\:?10 S8>Q*_CG^=&QO[[?I_A3Z* &;&_OM^G^%&QO[[?
MI_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^
MG^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z
M* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&Q
MO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&
M_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I_A3Z* &;&_OM^G^%&QO[[?I
M_A3Z3- #=C?WV_3_  HV-_?;]/\ "G49% #=C?WV_3_"C8W]]OT_PIV11D4
M-V-_?;]/\*-C?WV_3_"G9%&10 W8W]]OT_PHV-_?;]/\*=D49% #=C?WV_3_
M  HV-_?;]/\ "G9%&10 W8W]]OT_PHV-_?;]/\*=D49% #=C?WV_3_"C8W]]
MOT_PIV11D4 -V-_?;]/\*-C?WV_3_"G9%&10 W8W]]OT_P *-C?WV_3_  IV
M11D4 -V-_?;]/\*-C?WV_3_"G9%&10 W8W]]OT_PHV-_?;]/\*=D49% #=C?
MWV_3_"C8W]]OT_PIV11D4 -V-_?;]/\ "C8W]]OT_P *=D49% #=C?WV_3_"
MC8W]]OT_PIV11D4 -V-_?;]/\*-C?WV_3_"G9%&10 W8W]]OT_PHV-_?;]/\
M*=D49% #=C?WV_3_  HV-_?;]/\ "G9%&10 W8W]]OT_PHV-_?;]/\*=D49%
M #=C?WV_3_"C8W]]OT_PIV11D4 -V-_?;]/\*-C?WV_3_"G9%&10 W8W]]OT
M_P *-C?WV_3_  IV11D4 -V-_?;]/\*-C?WV_3_"G9%&10 W8W]]OT_PHV-_
M?;]/\*=D49% #=C?WV_3_"C8W]]OT_PIV11D4 -V-_?;]/\ "C8W]]OT_P *
M=D49% #=C?WV_3_"C8W]]OT_PIV11D4 -V-_?;]/\*-C?WV_3_"G9%&10 W8
MW]]OT_PHV-_?;]/\*=D49% #=C?WV_3_  HV-_?;]/\ "G9%&10 W8W]]OT_
MPHV-_?;]/\*=D49% #=C?WV_3_"C8W]]OT_PIV11D4 -V-_?;]/\*-C?WV_3
M_"G9%&10 W8W]]OT_P *-C?WV_3_  IV11D4 -V-_?;]/\*-C?WV_3_"G9%&
M10 W8W]]OT_PHV-_?;]/\*=D49% #=C?WV_3_"C8W]]OT_PIV11D4 -V-_?;
M]/\ "C8W]]OT_P *=D49% #=C?WV_3_"C8W]]OT_PIV11D4 -V-_?;]/\*-C
M?WV_3_"G9%&10 W8W]]OT_PHV-_?;]/\*=D49% #=C?WV_3_  HV-_?;]/\
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M5^B@"A_9-M_SXVO_ 'PO_P 31_9-M_SXVO\ WPO_ ,35^B@"A_9-M_SXVO\
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M-D_QH_X6!XB_Z#NI?^!LG^-'^M]#_GR_O#^T8=C[7WK[4;U]J^*/^%@>(O\
MH.ZE_P"!LG^-'_"P/$7_ $'=2_\  V3_ !H_UOH?\^7]X?VC#L?:^]?:C>OM
M7Q1_PL#Q%_T'=2_\#9/\:/\ A8'B+_H.ZE_X&R?XT?ZWT/\ GR_O#^T8=C[7
MWK[4;U]J^*/^%@>(O^@[J7_@;)_C1_PL#Q%_T'=2_P# V3_&C_6^A_SY?WA_
M:,.Q]K[U]J-Z^U?%'_"P/$7_ $'=2_\  V3_ !H_X6!XB_Z#NI?^!LG^-'^M
M]#_GR_O#^T8=C[7WK[4;U]J^*/\ A8'B+_H.ZE_X&R?XT?\ "P/$7_0=U+_P
M-D_QH_UOH?\ /E_>']HP['VOO7VHWK[5\4?\+ \1?]!W4O\ P-D_QH_X6!XB
M_P"@[J7_ (&R?XT?ZWT/^?+^\/[1AV/M?>OM1O7VKXH_X6!XB_Z#NI?^!LG^
M-'_"P/$7_0=U+_P-D_QH_P!;Z'_/E_>']HP['VOO7VHWK[5\4?\ "P/$7_0=
MU+_P-D_QH_X6!XB_Z#NI?^!LG^-'^M]#_GR_O#^T8=C[7WK[4;U]J^*/^%@>
M(O\ H.ZE_P"!LG^-'_"P/$7_ $'=2_\  V3_ !H_UOH?\^7]X?VC#L?:^]?:
MC>OM7Q1_PL#Q%_T'=2_\#9/\:/\ A8'B+_H.ZE_X&R?XT?ZWT/\ GR_O#^T8
M=C[7WK[4;U]J^*?^$^\1_P#0=U+_ ,#9/\:7_A//$O7^V=6Q_>^U2X_/-+_7
M##[>R?WA_:,.Q]J[U]J-Z^U?%7_">>)/^@WJG_@9)_C1_P )YXD_Z#>J?^!D
MG^-5_K=1_P"?+^\?]H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\
M\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_
M  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X
M3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7
M>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/
ME_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3
M_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\
M\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_
M  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X
M3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7
M>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/
ME_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3
M_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\
M\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_
M  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X
M3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7
M>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/
ME_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3
M_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\
M\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_
M  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X
M3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7
M>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/
ME_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3
M_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\
M\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_
M  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7>OM1O7VKXJ_X
M3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/E_>']H1_E/M7
M>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3_&C_ %NH_P#/
ME_>']H1_E/M7>OM1O7VKXJ_X3SQ)_P!!O5/_  ,D_P :/^$\\2?]!O5/_ R3
M_&C_ %NH_P#/E_>']H1_E/L;7-8LM#TNXO[Z7R;6W7?(V"<#IT'7K7SCXN^/
M^O7^M2_V+,NFV$7RQCRU>24'G<VX$#IP!ZUY_?\ BW6M4M9+6]U:^FM9.'6:
M:25<?3FLK>2P#C:Q&1CG('%?/YKQ+5Q45##)P./$8UR7N*QZ#:_'KQC9W$4\
MVH1WD4;!FMYH$59.V"47(ZU]%> ?'.G^/-.:[LRR3Q82XA8$&-B,X)Z-TX(K
MXT;Y58]<#->N_LSW$P\97@\T^3<6#RM%GHPDC /Y$_G5\/YQB/KD*%2;E&7<
MTPF)J.I[.>I],BEIJTZOU\]T****8!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M #_ZG_W]C_\ B*]?VT8-<G]B9?\ \^49O#TOY3R#_AFOP]_S_P"I_P#?V/\
M^(H_X9K\/?\ /_J?_?V/_P"(KU_!HP:/[$R__GRA?5Z7\IY!_P ,U^'O^?\
MU/\ [^Q__$4?\,U^'O\ G_U/_O['_P#$5Z_@T8-']B9?_P ^4'U>E_*>0?\
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MS7X>_P"?_4_^_L?_ ,17K^#1@T?V)E__ #Y0?5Z7\IY!_P ,U^'O^?\ U/\
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M]B9?_P ^4'U>E_*>0?\ #-?A[_G_ -3_ ._L?_Q%'_#-?A[_ )_]3_[^Q_\
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M_H$?^3$O_P 51_PHGP5_T"/_ "8E_P#BJ[_;[4;?:C^RL#_SYC_X"@]C3['
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M ,51_P *)\%?] C_ ,F)?_BJ[_;[4;?:C^RL#_SYC_X"@]C3[' ?\*)\%?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ,>]&/>C'O0 8]Z,>]&/>C'O0 8]Z,>]&/>C'O0 8]Z,>]&/>C'O0 8]ZW?
M?_([:!_V$;7_ -')6%CWK=\!_P#([:!_V$;7_P!')75A?]XI_P")?FC2G\:/
MM2/[P_'^=2U%']X?C_.I:_HA;'U_1!1113 **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)_\ XBC^T<'_ ,_H_>A^VI_S+[SOZ*X#_A?'@?\ Z#1_\!)__B*/^%\>!_\
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M,G_P$F_^(H_X7QX'_P"@R?\ P$F_^(I?VI@?^?\ '_P)![:E_,OO._HK@/\
MA?'@?_H,G_P$F_\ B*/^%\>!_P#H,G_P$F_^(H_M3 _\_P"/_@2#VU+^9?>=
M_17 ?\+X\#_]!D_^ DW_ ,11_P +X\#_ /09/_@)-_\ $4?VI@?^?\?_  )!
M[:E_,OO._HK@/^%\>!_^@R?_  $F_P#B*/\ A?'@?_H,G_P$F_\ B*/[4P/_
M #_C_P"!(/;4OYE]YW]%<!_POCP/_P!!D_\ @)-_\11_POCP/_T&3_X"3?\
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M?\?_  )![:E_,OO._HK@/^%\>!_^@R?_  $F_P#B*/\ A?'@?_H,G_P$F_\
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M^(H_X7QX'_Z#)_\  2;_ .(H_M3 _P#/^/\ X$@]M2_F7WG?T5P'_"^/ _\
MT&3_ . DW_Q%'_"^/ __ $&3_P" DW_Q%']J8'_G_'_P)![:E_,OO._HK@/^
M%\>!_P#H,G_P$F_^(H_X7QX'_P"@R?\ P$F_^(H_M3 _\_X_^!(/;4OYE]YW
M]%<!_P +X\#_ /09/_@)-_\ $4?\+X\#_P#09/\ X"3?_$4?VI@?^?\ '_P)
M![:E_,OO._HK@/\ A?'@?_H,G_P$F_\ B*/^%\>!_P#H,G_P$F_^(H_M3 _\
M_P"/_@2#VU+^9?>=_17 ?\+X\#_]!D_^ DW_ ,11_P +X\#_ /09/_@)-_\
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M>\U 6VJ>&O#_ (\T:WOK0O\ :/M>GP?VG<PS)$N^,3M;PA2Q.8\#++(Q^O\
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M]"_JG_@')_\ $U]I^3[#]/\ "CR?8?I_A1_JC1_Y^O[@_L^/<^+/^$#\2_\
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M(LGQ-3%JM*+C&.NJL5A</-U$Y*R.VA4JQ!Z8P#GKQ4U-7/4TZOV,^@"BBB@
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M?F*VS<$3<%(!VK7944 <[_PANDCPK_PBYT>SD\-K9_V:=*,,8M&M/+$7D"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 (:8ZY%/;/:DP:35]P&1IM:I::!3J44HJR ***
M*H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH,O.P;P#@,5X P,G.!R;GQHU[^S/B-H'B*U9[BRBMHIHI;=\";9*Y**PXY#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWE3! =J;G?[Q%;W_  2XTZRL_P!B;P'<VUC#;SWTFH27;QQJ'N)%O[F-6D.
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MAL -I!S_ ,3/4@,< '/Y]37TY&P;_@J&""8A+\'L^6Y(8YUG/ .,'@D_0^M
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M^./^@&W_ (%0_P#Q=']K9[_SZ?\ X P]MB?Y7]QZQ_PTKX<_Y\M4_P"_:?\
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MHOQQ_P! 1O\ P*@_^+H^O<0_RO\ \ 7^0>TQ?9_<=W_PU"W_ $+:_P#@P/\
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M[&]_PU W_0L_^3[?_&J/^&H&_P"A9_\ )]O_ (U6#_PS5XH_Y^M*_P"_K_\
MQJC_ (9J\4?\_6E?]_7_ /C5'M^)?/\ \!B'M,=V-[_AJ!O^A9_\GV_^-4?\
M-0-_T+/_ )/M_P#&JP?^&:O%'_/UI7_?U_\ XU1_PS5XH_Y^M*_[^O\ _&J/
M;\2^?_@,0]ICNQO?\-0-_P!"S_Y/M_\ &J/^&H&_Z%G_ ,GV_P#C58/_  S5
MXH_Y^M*_[^O_ /&J/^&:O%'_ #]:5_W]?_XU1[?B7S_\!B'M,=V-[_AJ!O\
MH6?_ "?;_P"-4?\ #4#?]"S_ .3[?_&JP?\ AFKQ1_S]:5_W]?\ ^-4?\,U>
M*/\ GZTK_OZ__P :H]OQ+Y_^ Q#VF.[&]_PU W_0L_\ D^W_ ,:H_P"&H&_Z
M%G_R?;_XU6#_ ,,U>*/^?K2O^_K_ /QJC_AFKQ1_S]:5_P!_7_\ C5'M^)?/
M_P !B'M,=V-[_AJ!O^A9_P#)]O\ XU1_PU W_0L_^3[?_&JP?^&:O%'_ #]:
M5_W]?_XU1_PS5XH_Y^M*_P"_K_\ QJCV_$OG_P" Q#VF.[&]_P -0-_T+/\
MY/M_\:H_X:@;_H6?_)]O_C58/_#-7BC_ )^M*_[^O_\ &J/^&:O%'_/UI7_?
MU_\ XU1[?B7S_P# 8A[3'=C>_P"&H&_Z%G_R?;_XU1_PU W_ $+/_D^W_P :
MK!_X9J\4?\_6E?\ ?U__ (U1_P ,U>*/^?K2O^_K_P#QJCV_$OG_ . Q#VF.
M[&]_PU W_0L_^3[?_&J/^&H&_P"A9_\ )]O_ (U6#_PS5XH_Y^M*_P"_K_\
MQJC_ (9J\4?\_6E?]_7_ /C5'M^)?/\ \!B'M,=V-[_AJ!O^A9_\GV_^-4?\
M-0-_T+/_ )/M_P#&JP?^&:O%'_/UI7_?U_\ XU1_PS5XH_Y^M*_[^O\ _&J/
M;\2^?_@,0]ICNQO?\-0-_P!"S_Y/M_\ &J/^&H&_Z%G_ ,GV_P#C58/_  S5
MXH_Y^M*_[^O_ /&J/^&:O%'_ #]:5_W]?_XU1[?B7S_\!B'M,=V-[_AJ!O\
MH6?_ "?;_P"-4?\ #4#?]"S_ .3[?_&JP?\ AFKQ1_S]:5_W]?\ ^-4?\,U>
M*/\ GZTK_OZ__P :H]OQ+Y_^ Q#VF.[&]_PU W_0L_\ D^W_ ,:H_P"&H&_Z
M%G_R?;_XU6#_ ,,U>*/^?K2O^_K_ /QJC_AFKQ1_S]:5_P!_7_\ C5'M^)?/
M_P !B'M,=V-[_AJ!O^A9_P#)]O\ XU1_PU W_0L_^3[?_&JP?^&:O%'_ #]:
M5_W]?_XU1_PS5XH_Y^M*_P"_K_\ QJCV_$OG_P" Q#VF.[&]_P -0-_T+/\
MY/M_\:H_X:@;_H6?_)]O_C58/_#-7BC_ )^M*_[^O_\ &J/^&:O%'_/UI7_?
MU_\ XU1[?B7S_P# 8A[3'=C>_P"&H&_Z%G_R?;_XU1_PU W_ $+/_D^W_P :
MK!_X9J\4?\_6E?\ ?U__ (U1_P ,U>*/^?K2O^_K_P#QJCV_$OG_ . Q#VF.
M[&]_PU W_0L_^3[?_&J/^&H&_P"A9_\ )]O_ (U6#_PS5XH_Y^M*_P"_K_\
MQJC_ (9J\4?\_6E?]_7_ /C5'M^)?/\ \!B'M,=V-[_AJ!O^A9_\GV_^-4?\
M-0-_T+/_ )/M_P#&JP?^&:O%'_/UI7_?U_\ XU1_PS5XH_Y^M*_[^O\ _&J/
M;\2^?_@,0]ICNQO?\-0-_P!"S_Y/M_\ &J/^&H&_Z%G_ ,GV_P#C58/_  S5
MXH_Y^M*_[^O_ /&J/^&:O%'_ #]:5_W]?_XU1[?B7S_\!B'M,=V-[_AJ!O\
MH6?_ "?;_P"-4?\ #4#?]"S_ .3[?_&JP?\ AFKQ1_S]:5_W]?\ ^-4?\,U>
M*/\ GZTK_OZ__P :H]OQ+Y_^ Q#VF.[&]_PU W_0L_\ D^W_ ,:H_P"&H&_Z
M%G_R?;_XU6#_ ,,U>*/^?K2O^_K_ /QJC_AFKQ1_S]:5_P!_7_\ C5'M^)?/
M_P !B'M,=V-[_AJ!O^A9_P#)]O\ XU1_PU W_0L_^3[?_&JP?^&:O%'_ #]:
M5_W]?_XU1_PS5XH_Y^M*_P"_K_\ QJCV_$OG_P" Q#VF.[&]_P -0-_T+/\
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M72XE,,#[)971@FXA?E&&W;8RGTQ10!%&K;]Q78N,!>,_CQVY[U+110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH :W2O /VH/\ F6OI<?RBKW]NE> ?M0?\RU]+C^45
M?-<0_P#(MJ_(X\9_ D>%8]Z,>]&/>C'O7XB?+K9!CWHQ[T8]Z,>] PQ[T8]Z
M,>]&/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&
M/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@
MQ[T8]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[T8
M]Z,>]&/>@ Q[T8]Z,>]&/>@ Q[UN^ _^1VT#_L(VO_HY*PL>];O@/_D=M _[
M"-K_ .CDKJPO^\4_\2_-&E/XT?:D?WA^/\ZEJ*/[P_'^=2U_1"V/K^B"BBBF
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 UNE> ?M0?\ ,M?2X_E%7O[=*\ _:@_YEKZ7'\HJ^:XA
M_P"1;5^1QXS^!(\*Q[T8]Z,>]&/>OQ$^76R#'O1CWHQ[T8]Z!ACWHQ[T8]Z,
M>] !CWHQ[T8]Z,>] !CWHQ[T8]Z,>] !CWHQ[T8]Z,>] !CWHQ[T8]Z,>] !
MCWHQ[T8]Z,>] !CWHQ[T8]Z,>] !CWHQ[T8]Z,>] !CWHQ[T8]Z,>] !CWHQ
M[T8]Z,>] !CWHQ[T8]Z,>] !CWHQ[T8]Z,>] !CWHQ[T8]Z,>] !CWHQ[T8]
MZ,>] !CWHQ[T8]Z,>] !CWK=\!_\CMH'_81M?_1R5A8]ZW? ?_([:!_V$;7_
M -')75A?]XI_XE^:-*?QH^U(_O#\?YU+44?WA^/\ZEK^B%L?7]$%%(S!1EB
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M4 %%%% !1110 4444 %%%% !1110 4444 -;I7@'[4'_ #+7TN/Y15[^W2O
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M@^-OC*WC5%UN0J/^>D,3G\RN36L.+\+M*G)>EAK,8=CZ^Y]:*^1?^%Z>-/\
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MNTUK;0H S%1'&)7=3T#%U(W+CMP<]>*T/"O[0FO6=Y:PZPL&HV#/MGGV^7<
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M^PO9-6@T2.0&_GC5'N)))7GE8(IQ&IEED*IEMJA068Y8^IT4 0)$8V8 <-W
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MB5)8>()O'%EI-^FO:"(X+"VFMTEBDL!"[B8>6)%6.0HP>*(,[K(Q2OJNBB@
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M_P#%5W^WVHV^U']E8'_GS'_P%![&GV. _P"%$^"O^@1_Y,2__%4?\*)\%?\
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MHV^U']E8'_GS'_P%![&GV. _X43X*_Z!'_DQ+_\ %4?\*)\%?] C_P F)?\
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M5=_M]J-OM1_96!_Y\Q_\!0>QI]C@/^%$^"O^@1_Y,2__ !5'_"B?!7_0(_\
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M (BO7\&C!I?V)E__ #Y0?5Z7\IY!_P ,U^'O^?\ U/\ [^Q__$4?\,U^'O\
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M0?\ #-?A[_G_ -3_ ._L?_Q%'_#-?A[_ )_]3_[^Q_\ Q%>OX-&#1_8F7_\
M/E!]7I?RGD'_  S7X>_Y_P#4_P#O['_\11_PS7X>_P"?_4_^_L?_ ,17K^#1
M@T?V)E__ #Y0?5Z7\IY!_P ,U^'O^?\ U/\ [^Q__$4?\,U^'O\ G_U/_O['
M_P#$5Z_@T8-']B9?_P ^4'U>E_*>0?\ #-?A[_G_ -3_ ._L?_Q%'_#-?A[_
M )_]3_[^Q_\ Q%>OX-&#1_8F7_\ /E!]7I?RGD'_  S7X>_Y_P#4_P#O['_\
M11_PS7X>_P"?_4_^_L?_ ,17K^#1@T?V)E__ #Y0?5Z7\IY!_P ,U^'O^?\
MU/\ [^Q__$4?\,U^'O\ G_U/_O['_P#$5Z_@T8-']B9?_P ^4'U>E_*>0?\
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M\ Y/_B:^T_)]A^G^%'D^P_3_  H_U1H_\_7]P?V?'N?%G_"!^)?^A?U3_P
MY/\ XFC_ (0/Q+_T+^J?^ <G_P 37VGY/L/T_P */)YQCG\/\*/]4:/_ #]?
MW!_9\>Y\6?\ "!^)?^A?U3_P#D_^)H_X0/Q+_P!"_JG_ (!R?_$U]I^3[#]/
M\*/)]A^G^%'^J-'_ )^O[@_L^/<^+/\ A _$O_0OZI_X!R?_ !-'_"!^)?\
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M^%'D^P_3_"C_ %1H_P#/U_<']GQ[GQ9_P@?B7_H7]4_\ Y/_ (FC_A _$O\
MT+^J?^ <G_Q-?:?D^P_3_"CR?8?I_A1_JC1_Y^O[@_L^/<^+?^$"\2_]"_JO
M_@')_P#$UL>#?!?B"S\7:)+/H6IQ0QWT#N[6<@"JLBLQ)V\  &OKOR?;^7^%
M(T)ZXR1T^;'\J<.$L/3J1J\[;31<<#"+3[#HP58#V-2U%&A5AV&.1U&:EK[V
MYZ84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%)2>8._'U&* '44WS%_O#\Z/,7^
M\/SH =13?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\
M/SH =13?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/
MSH =13?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/S
MH =13?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH
M =13?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH
M=13?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =
M13?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =1
M3?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13
M?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?
M,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,
M7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7
M^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^
M\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^\
M/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^\/
MSH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^\/S
MH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^\/SH
M\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^\/SH\
MQ?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^\/SH\Q
M?[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^\/SH\Q?
M[P_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z/,7^\/SH =13?,7^\/SH\Q?[
MP_.@!U%-\Q?[P_.CS%_O#\Z '44WS%_O#\Z-ZGH0?I0 ZBDHH 6H+Q))(&$6
MWS.V_I_(U,6"]:;YJ\<XR,\C% '.+IOB,YS?6H7/">6./_'*7^S/$'_/[:_]
M^Q_\171>8OK2^8OK2O?8#G/[,\0?\_MK_P!^Q_\ $4?V9X@_Y_;7_OV/_B*Z
M/S%]:/,7UIBNCG/[,\0?\_MK_P!^Q_\ $4?V9X@_Y_;7_OV/_B*Z/S%]:/,7
MUH"Z.<_LSQ!_S^VO_?L?_$4?V9X@_P"?VU_[]C_XBNC\Q?6CS%]: NCG/[,\
M0?\ /[:_]^Q_\11_9GB#_G]M?^_8_P#B*Z/S%]:/,7UH"Z.;;3]?123=0N>P
MC1,Y_%:JX\4-P4/L<P_X5UWF+ZT>8OK0%T<CY?B?^Z?_ "#_ (4>7XG_ +I_
M\@_X5UWF+ZT>8OK0%T<CY?B?^Z?_ "#_ (4>7XG_ +I_\@_X5UWF+ZT>8OK0
M%T<CY?B?^Z?_ "#_ (4>7XG_ +I_\@_X5UWF+ZT>8OK0%T<CY?B?^Z?_ "#_
M (4>7XG_ +I_\@_X5UWF+ZT>8OK0%T<CY?B?^Z?_ "#_ (4>7XG_ +I_\@_X
M5UWF+ZT>8OK0%T<CY?B?^Z?_ "#_ (4>7XG_ +I_\@_X5UWF+ZT>8OK0%T<C
MY?B?^Z?_ "#_ (4>7XG_ +I_\@_X5UWF+ZT>8OK0%T<CY?B?^Z?_ "#_ (4>
M7XG_ +I_\@_X5UWF+ZT>8OK0%T<CY?B?^Z?_ "#_ (4>7XG_ +I_\@_X5UWF
M+ZT>8OK0%T<CY?B?^Z?_ "#_ (4>7XG_ +I_\@_X5UWF+ZT>8OK0%T<CY?B?
M^Z?_ "#_ (4>7XG_ +I_\@_X5UWF+ZT>8OK0%T<CY?B?^Z?_ "#_ (4>7XG_
M +I_\@_X5UWF+ZTGFKQSG/I2NMA^9R7E^)_[I_\ (/\ A1Y?B?\ NG_R#_A7
M7*X;I_*G4P./\OQ/_=/_ )!_PH\OQ/\ W3_Y!_PKL** ./\ +\3_ -T_^0?\
M*/+\3_W3_P"0?\*["B@#C_+\3_W3_P"0?\*/+\3_ -T_^0?\*["B@#C_ "_$
M_P#=/_D'_"CR_$_]T_\ D'_"NPHH X_R_$_]T_\ D'_"CR_$_P#=/_D'_"NP
MHH X_P OQ/\ W3_Y!_PH\OQ/_=/_ )!_PKL** ./\OQ/_=/_ )!_PH\OQ/\
MW3_Y!_PKL** ./\ +\3_ -T_^0?\*/+\3_W3_P"0?\*["B@#C_+\3_W3_P"0
M?\*/+\3_ -T_^0?\*["B@#C_ "_$_P#=/_D'_"CR_$_]T_\ D'_"NPHH X_R
M_$_]T_\ D'_"CR_$_P#=/_D'_"NPHH X_P OQ/\ W3_Y!_PH\OQ/_=/_ )!_
MPKL** ./\OQ/_=/_ )!_PH\OQ/\ W3_Y!_PKL** ./\ +\3_ -T_^0?\*/+\
M3_W3_P"0?\*["B@#C_+\3_W3_P"0?\*/+\3_ -T_^0?\*["B@#C_ "_$_P#=
M/_D'_"CR_$_]T_\ D'_"NPHH X_R_$_]T_\ D'_"CR_$_P#=/_D'_"NPHH X
M_P OQ/\ W3_Y!_PH\OQ/_=/_ )!_PKL** ./\OQ/_=/_ )!_PH\OQ/\ W3_Y
M!_PKL** ./\ +\3_ -T_^0?\*/+\3_W3_P"0?\*["B@#C_+\3_W3_P"0?\*/
M+\3_ -T_^0?\*["B@#C_ "_$_P#=/_D'_"CR_$_]T_\ D'_"NPHH X_R_$_]
MT_\ D'_"CR_$_P#=/_D'_"NPHH X_P OQ/\ W3_Y!_PH\OQ/_=/_ )!_PKL*
M* ./\OQ/_=/_ )!_PH\OQ/\ W3_Y!_PKL** ./\ +\3_ -T_^0?\*/+\3_W3
M_P"0?\*["B@#C_+\3_W3_P"0?\*/+\3_ -T_^0?\*["B@#C_ "_$_P#=/_D'
M_"CR_$_]T_\ D'_"NPHH X_R_%'4+GZF(?RQ5F.Z\2*N&L(Y?]Z1/\:Z>B@#
MF_MGB'_H%P?]_%_^*H^V>(?^@7!_W\7_ .*KI** .;^V>(?^@7!_W\7_ .*H
M^V>(?^@7!_W\7_XJNDHH YO[9XA_Z!<'_?Q?_BJ/MGB'_H%P?]_%_P#BJZ2B
M@#F_MGB'_H%P?]_%_P#BJ/MGB'_H%P?]_%_^*KI** .;^V>(?^@7!_W\7_XJ
MC[9XA_Z!<'_?Q?\ XJNDHH YO[9XA_Z!<'_?Q?\ XJC[9XA_Z!<'_?Q?_BJZ
M2B@#F_MGB'_H%P?]_%_^*H^V>(?^@7!_W\7_ .*KI** .;^V>(?^@7!_W\7_
M .*H^V>(?^@7!_W\7_XJNDHH YO[9XA_Z!<'_?Q?_BJ/MGB'_H%P?]_%_P#B
MJZ2B@#F_MGB'_H%P?]_%_P#BJ/MGB'_H%P?]_%_^*KI** .;^V>(?^@7!_W\
M7_XJC[9XA_Z!<'_?Q?\ XJNDHH YO[9XA_Z!<'_?Q?\ XJC[9XA_Z!<'_?Q?
M_BJZ2B@#F_MGB'_H%P?]_%_^*H^V>(?^@7!_W\7_ .*KI** .;^V>(?^@7!_
MW\7_ .*H^V>(?^@7!_W\7_XJNDHH YO[9XA_Z!<'_?Q?_BJ/MGB'_H%P?]_%
M_P#BJZ2B@#F_MGB'_H%P?]_%_P#BJ/MGB'_H%P?]_%_^*KI** .;^V>(?^@7
M!_W\7_XJC[9XA_Z!<'_?Q?\ XJNDHH YO[9XA_Z!<'_?Q?\ XJC[9XA_Z!<'
M_?Q?_BJZ2B@#F_MGB'_H%P?]_%_^*H^V>(?^@7!_W\7_ .*KI** .;^V>(?^
M@7!_W\7_ .*H^V>(?^@7!_W\7_XJNDHH YO[9XA_Z!<'_?Q?_BJ/MGB'_H%P
M?]_%_P#BJZ2B@#F_MGB'_H%P?]_%_P#BJBN-4UZV0,^E1D$X_=_.?R!-=32-
M_GG% '(?\)%K7_0)/_?IZ/\ A(M:_P"@2?\ OT]=;M/I_P"/&C:?3_QXT <E
M_P )%K7_ $"3_P!^GH_X2+6O^@2?^_3UUNT^G_CQHVGT_P#'C0!R7_"1:U_T
M"3_WZ>C_ (2+6O\ H$G_ +]/76[3Z?\ CQHVGT_\>- ')?\ "1:U_P! D_\
M?IZ/^$BUK_H$G_OT]=;M/I_X\:-I]/\ QXT <E_PD6M?] D_]^GH_P"$BUK_
M *!)_P"_3UUNT^G_ (\:-I]/_'C0!R7_  D6M?\ 0)/_ 'Z>C_A(M:_Z!)_[
M]/76[3Z?^/&C:?3_ ,>- ')?\)%K7_0)/_?IZ/\ A(M:_P"@2?\ OT]=;M/I
M_P"/&C:?3_QXT <E_P )%K7_ $"3_P!^GH_X2+6O^@2?^_3UUNT^G_CQHVGT
M_P#'C0!R7_"1:U_T"3_WZ>C_ (2+6O\ H$G_ +]/76[3Z?\ CQHVGT_\>- '
M)?\ "1:U_P! D_\ ?IZ/^$BUK_H$G_OT]=;M/I_X\:-I]/\ QXT <E_PD6M?
M] D_]^GH_P"$BUK_ *!)_P"_3UUNT^G_ (\:-I]/_'C0!R7_  D6M?\ 0)/_
M 'Z>C_A(M:_Z!)_[]/76[3Z?^/&C:?3_ ,>- ')?\)%K7_0)/_?IZ/\ A(M:
M_P"@2?\ OT]=;M/I_P"/&C:?3_QXT <E_P )%K7_ $"3_P!^GH_X2+6O^@2?
M^_3UUNT^G_CQHVGT_P#'C0!R7_"1:U_T"3_WZ>C_ (2+6O\ H$G_ +]/76[3
MZ?\ CQHVGT_\>- ')?\ "1:U_P! D_\ ?IZ/^$BUK_H$G_OT]=;M/I_X\:-I
M]/\ QXT <E_PD6M?] D_]^GH_P"$BUK_ *!)_P"_3UUNT^G_ (\:-I]/_'C0
M!R7_  D6M?\ 0)/_ 'Z>C_A(M:_Z!)_[]/76[3Z?^/&C:?3_ ,>- ')?\)%K
M7_0)/_?IZ/\ A(M:_P"@2?\ OT]=;M/I_P"/&C:?3_QXT <E_P )%K7_ $"3
M_P!^GH_X2+6O^@2?^_3UUNT^G_CQHVGT_P#'C0!R7_"1:U_T"3_WZ>C_ (2+
M6O\ H$G_ +]/76[3Z?\ CQHVGT_\>- ')?\ "1:U_P! D_\ ?IZ/^$BUK_H$
MG_OT]=;M/I_X\:-I]/\ QXT <E_PD6M?] D_]^GH_P"$BUK_ *!)_P"_3UUN
MT^G_ (\:-I]/_'C0!R7_  D6M?\ 0)/_ 'Z>C_A(M:_Z!)_[]/76[3Z?^/&C
M:?3_ ,>- ')?\)%K7_0)/_?IZ/\ A(M:_P"@2?\ OT]=;M/I_P"/&C:?3_QX
MT <E_P )%K7_ $"3_P!^GH_X2+6O^@2?^_3UUNT^G_CQHVGT_P#'C0!R7_"1
M:U_T"3_WZ>C_ (2+6O\ H$G_ +]/76[3Z?\ CQHVGT_\>- ')?\ "1:U_P!
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MD6M?] D_]^GH_P"$BUK_ *!)_P"_3UUNT^G_ (\:-I]/_'C0!R7_  D6M?\
M0)/_ 'Z>C_A(M:_Z!)_[]/76[3Z?^/&C:?3_ ,>- ')?\)%K7_0)/_?IZ/\
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M- &=97$NH6ZR7$,MM)_SS*-15YX6)^5F'_ C10 MP"R@*<$\;O3CKCO7RO\
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M?C1_9.$_Y]_B']N8_P#G_ _0+_AZXW_1+S_X4/\ ]RT?\/7&_P"B7G_PH?\
M[EK\_?QH_&C^R<)_S[_$/[<Q_P#/^!^@7_#UQO\ HEY_\*'_ .Y:/^'KC?\
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M8?0U9J&!=OY5-7P7<_3+WU"BBBF 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,]O/:SQLDD4B,5964C*D,"#GN#Z5E"I"I+E@[LUG1J4XJ4XM)E:BM_PM\/\
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MJO\ W[C_ /CE']N9=_S_ $'UBEW1Z]N'J*-P]17D/_#2GAK_ )\M5_[]Q_\
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MK(!G#JI'TP/YUJU^PTY<\%/N>^M@HHHJQA1110 4444 %%%% !1110 4444
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MF$']7I__  HSQO\ ] 1O_ J#_P"+KZXVXXP2/6EQ[5TQX1P26LY?>O\ (?\
M9]'NSY&_X49XW_Z C?\ @5!_\71_PHSQO_T!&_\  J#_ .+KZYQ[48]JK_5'
M _SR^]?Y!_9]'NSY&_X49XW_ .@(W_@5!_\ %T?\*,\;_P#0$;_P*@_^+KZY
MQ[48]J/]4<#_ #R^]?Y!_9]'NSY&_P"%&>-_^@(W_@5!_P#%T?\ "C/&_P#T
M!&_\"H/_ (NOKG'M1CVH_P!4<#_/+[U_D']GT>[/D;_A1GC?_H"-_P"!4'_Q
M='_"C/&__0$;_P "H/\ XNOKG'M1CVH_U1P/\\OO7^0?V?1[L^1O^%&>-_\
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MP+\&?"C6-2UVU\.>$Q9FQN;"X@CO96MK5[:+S9#"R\HY+;4&6"D8 ((!\G_
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M\UQ>0/+)F=G4AE>6=W<($Y&%VJ%  /GQ?A[\2?$/[=?[05KX(^*Z_"*>[M-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&R?=_&ORX_X*@?\ )?M!_P"Q9M__ $JNZ_4>3[OXU^7'_!3[GX_:%C_H6;?_
M -*KNO=R7_?(^C/G<^_W&7JCX]HHHK[V.Q^9/<****JS$%%%%%F 444468!1
M1119@%%%%%F 444468!11119@%%%%%F 444468!11119@%%%%%F 444468!1
M1119@%%%%%F 444468!11119@%>A?L]?\EZ^&G_8S:9_Z5Q5Y[7H7[/?_)>?
MAJ?^IFTS_P!*XJYZW\.?HSIPW\:'JC]Q(?Z5+44/]*EK\K/V<**** "BBB@
MJ*X5FC.T,3_L-@],<5+10!P6G_ _P#HOBT^++#P)X9M_%;3S7+:Y!H]M'>F6
M;?YK>>$#Y?S'W-DE@S YSSW$:%).06X^^<$_C^?^>E2T4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1S$!>>.:_+K_@I
M]@_'S0F!&/\ A&K<9S_T]7=?J),A?;A0V#GD]/>O /CM^QCX0_:'\7V?B3Q)
MJ.NV.H6MDM@BZ7<0)&8P[/T>%SG+GOWZ5Z67UX8:NJD^S/'S3#5<7AG2I]T?
MCQQCJ*./4?G7ZAG_ ()<_"_MX@\8_P#@9:?_ "-2?\.N?AA_T,'C'_P,M/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %(2!UI:S-4UJ+2%#S!RK
M': F,^O<^U &CN'K1N'K7.?\)S8_W+C\D_QH_P"$YL?[EQ^2?XT ='N'K1N'
MK7.?\)S8_P!RX_)/\:/^$YL?[EQ^2?XTK@='N'K1N'K7.?\ "<V/]RX_)/\
M&C_A.;'^Y<?DG^-%P.CW#UHW#UKG/^$YL?[EQ^2?XT?\)S8_W+C\D_QHN!T>
MX>M&X>M<Z/'%DW2.Y/T5#_6F_P#"=6/3R[@GT"H3_.F!TFX>M&X>M<W_ ,)U
M8_\ /*Z_[X7_ !H_X3JQ_P">5U_WPO\ C0!TFX>M&X>M<W_PG5C_ ,\KK_OA
M?\:/^$ZL?^>5U_WPO^- '2;AZT;AZUS?_"=6/_/*Z_[X7_&C_A.K'_GE=?\
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MRNO^^%_QH_X3JQ_YY77_ 'PO^- '2;AZT;AZUS?_  G5C_SRNO\ OA?\:/\
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M_&C_ (3JQ_YY77_?"_XT =)N'K1N'K7-_P#"=6/_ #RNO^^%_P :/^$ZL?\
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M_P"$NTG_ )^C_P!^G_PH V**Q_\ A+M)_P"?H_\ ?I_\*/\ A+M)_P"?H_\
M?I_\* -BBL?_ (2[2?\ GZ/_ 'Z?_"C_ (2[2?\ GZ/_ 'Z?_"@#8HK'_P"$
MNTG_ )^C_P!^G_PH_P"$NTG_ )^C_P!^G_PH V**Q_\ A+M)_P"?H_\ ?I_\
M*/\ A+M)_P"?H_\ ?I_\* -BBL?_ (2[2?\ GZ/_ 'Z?_"C_ (2[2?\ GZ/_
M 'Z?_"@#8HK'_P"$NTG_ )^C_P!^G_PH_P"$NTG_ )^C_P!^G_PH V**Q_\
MA+M)_P"?H_\ ?I_\*/\ A+M)_P"?H_\ ?I_\* -BBL?_ (2[2?\ GZ/_ 'Z?
M_"C_ (2[2?\ GZ/_ 'Z?_"@#8HK'_P"$NTG_ )^C_P!^G_PH_P"$NTG_ )^C
M_P!^G_PH V**Q_\ A+M)_P"?H_\ ?I_\*/\ A+M)_P"?H_\ ?I_\* -BBL?_
M (2[2?\ GZ/_ 'Z?_"C_ (2[2?\ GZ/_ 'Z?_"@#8HK'_P"$NTG_ )^C_P!^
MG_PH_P"$NTG_ )^C_P!^G_PH V**Q_\ A+M)_P"?H_\ ?I_\*/\ A+M)_P"?
MH_\ ?I_\* -BBL?_ (2[2?\ GZ/_ 'Z?_"C_ (2[2?\ GZ/_ 'Z?_"@#8HK'
M_P"$NTG_ )^C_P!^G_PH_P"$NTG_ )^C_P!^G_PH V**Q_\ A+M)_P"?H_\
M?I_\*/\ A+M)_P"?H_\ ?I_\* -BBL?_ (2[2?\ GZ/_ 'Z?_"C_ (2[2?\
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MC_A+=)_Y^_\ R&_^% &Q16/_ ,);I/\ S]_^0W_PH_X2W2?^?O\ \AO_ (4
M;%%8_P#PEND_\_?_ )#?_"C_ (2W2?\ G[_\AO\ X4 ;%%8__"6Z3_S]_P#D
M-_\ "C_A+=)_Y^__ "&_^% &Q16/_P );I/_ #]_^0W_ ,*/^$MTG_G[_P#(
M;_X4 ;%%8_\ PEND_P#/W_Y#?_"C_A+=)_Y^_P#R&_\ A0!L45C_ /"6Z3_S
M]_\ D-_\*/\ A+=)_P"?O_R&_P#A0!L45C_\);I/_/W_ .0W_P */^$MTG_G
M[_\ (;_X4 ;%%8__  END_\ /W_Y#?\ PH_X2W2?^?O_ ,AO_A0!L45C_P#"
M6Z3_ ,_?_D-_\*/^$MTG_G[_ /(;_P"% &Q16/\ \);I/_/W_P"0W_PH_P"$
MMTG_ )^__(;_ .% &Q16/_PEND_\_?\ Y#?_  H_X2W2?^?O_P AO_A0!L45
MC_\ "6Z3_P _?_D-_P#"C_A+=)_Y^_\ R&_^% &Q16/_ ,);I/\ S]_^0W_P
MH_X2W2?^?O\ \AO_ (4 ;%%8_P#PEND_\_?_ )#?_"C_ (2W2?\ G[_\AO\
MX4 ;%%8__"6Z3_S]_P#D-_\ "C_A+=)_Y^__ "&_^% &Q16/_P );I/_ #]_
M^0W_ ,*/^$MTG_G[_P#(;_X4 ;%%8_\ PEND_P#/W_Y#?_"C_A+=)_Y^_P#R
M&_\ A0!L45C_ /"6Z3_S]_\ D-_\*/\ A+=)_P"?O_R&_P#A0!L45C_\);I/
M_/W_ .0W_P */^$MTG_G[_\ (;_X4 ;%%8__  END_\ /W_Y#?\ PH_X2W2?
M^?O_ ,AO_A0!L45C_P#"6Z3_ ,_?_D-_\*/^$MTG_G[_ /(;_P"% &Q16/\
M\);I/_/W_P"0W_PH_P"$MTG_ )^__(;_ .% &Q16/_PEND_\_?\ Y#?_  H_
MX2W2?^?O_P AO_A0!L45C_\ "6Z3_P _?_D-_P#"C_A+=)_Y^_\ R&_^% &Q
M16/_ ,);I/\ S]_^0W_PH_X2W2?^?O\ \AO_ (4 ;%%8_P#PEND_\_?_ )#?
M_"C_ (2W2?\ G[_\AO\ X4 ;%%8__"6Z3_S]_P#D-_\ "C_A+=)_Y^__ "&_
M^% &Q16/_P );I/_ #]_^0W_ ,*='XJTN6146[&YC@91A_,4 :U%(&! (Y%%
M "2,5'%0>8AYW;6Z5).I91CU]J^*_'1*^-O$((4EM1N"#SP!(<"OG<XS9Y5&
M$^3F4G;<Y<1B%AXW/M!95/ E;/T'^%+O_P"FK?I_A7PGN]E_6C=[+^M?++C*
MVGL/Q_X#.+^T8KH?=F__ *:M^G^%&_\ Z:M^G^%?">[V7]:-WLOZT_\ 7+_I
MQ_Y-_P#:A_:4?Y3[LW_]-6_3_"C?_P!-6_3_  KX3W>R_K1N]E_6C_7+_IQ_
MY-_]J']I1_E/NS?_ --6_3_"C?\ ]-6_3_"OA/=[+^M&[V7]:/\ 7+_IQ_Y-
M_P#:A_:4?Y3[JDPZX+*X])!D?RJLVGV3-N^R6Y;N2@_PKX>W>R_K1N]E_6C_
M %R?_/E?^!/_ .1#^TH_RGW!_9]G_P ^=K_WP/\ XFC^S[/_ )\[7_O@?_$U
M\/[O9?UHW>R_K1_KB_\ GRO_  )__(A_:4?Y3[@_L^S_ .?.U_[X'_Q-']GV
M?_/G:_\ ? _^)KX?W>R_K1N]E_6C_7%_\^5_X$__ )$/[2C_ "GW!_9]G_SY
MVO\ WP/_ (FC^S[/_GSM?^^!_P#$U\/[O9?UHW>R_K1_KB_^?*_\"?\ \B']
MI1_E/N#^S[/_ )\[7_O@?_$T?V?9_P#/G:_]\#_XFOA_=[+^M&[V7]:/]<7_
M ,^5_P"!/_Y$/[2C_*?<']GV?_/G:_\ ? _^)H_L^S_Y\[7_ +X'_P 37P_N
M]E_6C=[+^M'^N+_Y\K_P)_\ R(?VE'^4^X/[/L_^?.U_[X'_ ,31_9]G_P ^
M=K_WP/\ XFOA_=[+^M&[V7]:/]<7_P ^5_X$_P#Y$/[2C_*?<']GV?\ SYVO
M_? _^)H_L^S_ .?.U_[X'_Q-?#^[V7]:-WLOZT?ZXO\ Y\K_ ,"?_P B']I1
M_E/N#^S[/_GSM?\ O@?_ !-']GV?_/G:_P#? _\ B:^']WLOZT;O9?UH_P!<
M7_SY7_@3_P#D0_M*/\I]P?V?9_\ /G:_]\#_ .)H_L^S_P"?.U_[X'_Q-?#^
M[V7]:-WLOZT?ZXO_ )\K_P "?_R(?VE'^4^X/[/L_P#GSM?^^!_\31_9]G_S
MYVO_ 'P/_B:^']WLOZT;O9?UH_UQ?_/E?^!/_P"1#^TH_P I]P?V?9_\^=K_
M -\#_P")H_L^S_Y\[7_O@?\ Q-?#^[V7]:-WLOZT?ZXO_GRO_ G_ /(A_:4?
MY3[@_L^S_P"?.U_[X'_Q-']GV?\ SYVO_? _^)KX?W>R_K1N]E_6C_7%_P#/
ME?\ @3_^1#^TH_RGW!_9]G_SYVO_ 'P/_B:5=-M&Z65J?^ #_P")KX>W>R_K
M7J_[->3X\O,;?^0=)TS_ ,]8J[<#Q,L9B84/8VYNM_\ @(UI8Y5)<MCZ,72K
M8_\ +C:_]\+_ /$T[^R;;_GQM?\ OA?_ (FKJTZOO3TBA_9-M_SXVO\ WPO_
M ,31_9-M_P ^-K_WPO\ \35^B@"A_9-M_P ^-K_WPO\ \31_9-M_SXVO_?"_
M_$U?HH H?V3;?\^-K_WPO_Q-']DVW_/C:_\ ?"__ !-7Z* *']DVW_/C:_\
M?"__ !-']DVW_/C:_P#?"_\ Q-7Z* *']DVW_/C:_P#?"_\ Q-']DVW_ #XV
MO_?"_P#Q-7Z* *']DVW_ #XVO_?"_P#Q-']DVW_/C:_]\+_\35^B@"A_9-M_
MSXVO_?"__$T?V3;?\^-K_P!\+_\ $U?HH H?V3;?\^-K_P!\+_\ $T?V3;?\
M^-K_ -\+_P#$U?HH H?V3;?\^-K_ -\+_P#$T?V3;?\ /C:_]\+_ /$U?HH
MH?V3;?\ /C:_]\+_ /$T?V3;?\^-K_WPO_Q-7Z* *']DVW_/C:_]\+_\31_9
M-M_SXVO_ 'PO_P 35^B@"A_9-M_SXVO_ 'PO_P 31_9-M_SXVO\ WPO_ ,35
M^B@"A_9-M_SXVO\ WPO_ ,31_9-M_P ^-K_WPO\ \35^B@"A_9-M_P ^-K_W
MPO\ \31_9-M_SXVO_?"__$U?HH H?V3;?\^-K_WPO_Q-']DVW_/C:_\ ?"__
M !-7Z* *']DVW_/C:_\ ?"__ !-']DVW_/C:_P#?"_\ Q-7Z* *']DVW_/C:
M_P#?"_\ Q-']DVW_ #XVO_?"_P#Q-7Z* *']DVW_ #XVO_?"_P#Q-']DVW_/
MC:_]\+_\35^B@"A_9-M_SXVO_?"__$T?V3;?\^-K_P!\+_\ $U?HH H?V3;?
M\^-K_P!\+_\ $T?V3;?\^-K_ -\+_P#$U?HH H?V3;?\^-K_ -\+_P#$T?V3
M;?\ /C:_]\+_ /$U?HH H?V3;?\ /C:_]\+_ /$T?V3;?\^-K_WPO_Q-7Z*
M*']DVW_/C:_]\+_\31_9-M_SXVO_ 'PO_P 35^B@"A_9-M_SXVO_ 'PO_P 3
M1_9-M_SXVO\ WPO_ ,35^B@"A_9-M_SXVO\ WPO_ ,31_9-M_P ^-K_WPO\
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M_$U?HH H?V3;?\^-K_WPO_Q-']DVW_/C:_\ ?"__ !-7Z* *']DVW_/C:_\
M?"__ !-']DVW_/C:_P#?"_\ Q-7Z* *']DVW_/C:_P#?"_\ Q-']DVW_ #XV
MO_?"_P#Q-7Z* *']DVW_ #XVO_?"_P#Q-']DVW_/C:_]\+_\35^B@"A_9-M_
MSXVO_?"__$T?V3;?\^-K_P!\+_\ $U?HH H?V3;?\^-K_P!\+_\ $T?V3;?\
M^-K_ -\+_P#$U?HH H?V3;?\^-K_ -\+_P#$T?V3;?\ /C:_]\+_ /$U?HH
MH?V3;?\ /C:_]\+_ /$T?V3;?\^-K_WPO_Q-7Z* *']DVW_/C:_]\+_\31_9
M-M_SXVO_ 'PO_P 35^B@"A_9-M_SXVO_ 'PO_P 31_9-M_SXVO\ WPO_ ,35
M^B@"A_9-M_SXVO\ WPO_ ,31_9-M_P ^-K_WPO\ \35^B@"A_9-M_P ^-K_W
MPO\ \31_9-M_SXVO_?"__$U?HH S9-"LKA=LEE !G/[L;3^@%0?\(GIO_/L%
M^DC?T(K9HH QO^$3TW_G@?\ O[)_\51_PB>F_P#/ _\ ?V3_ .*K9HH QO\
MA$]-_P">!_[^R?\ Q5'_  B>F_\ / _]_9/_ (JMFB@#&_X1/3?^>!_[^R?_
M !5'_")Z;_SP/_?V3_XJMFB@#&_X1/3?^>!_[^R?_%4?\(GIO_/ _P#?V3_X
MJMFB@#&_X1/3?^>!_P"_LG_Q5'_")Z;_ ,\#_P!_9/\ XJMFB@#&_P"$3TW_
M )X'_O[)_P#%4?\ ")Z;_P \#_W]D_\ BJV:* ,;_A$]-_YX'_O[)_\ %4?\
M(GIO_/ _]_9/_BJV:* ,;_A$]-_YX'_O[)_\51_PB>F_\\#_ -_9/_BJV:*
M,;_A$]-_YX'_ +^R?_%4?\(GIO\ SP/_ ']D_P#BJV:* ,;_ (1/3?\ G@?^
M_LG_ ,51_P (GIO_ #P/_?V3_P"*K9HH QO^$3TW_G@?^_LG_P 51_PB>F_\
M\#_W]D_^*K9HH QO^$3TW_G@?^_LG_Q5'_")Z;_SP/\ W]D_^*K9HH QO^$3
MTW_G@?\ O[)_\51_PB>F_P#/ _\ ?V3_ .*K9HH QO\ A$]-_P">!_[^R?\
MQ5'_  B>F_\ / _]_9/_ (JMFB@#&_X1/3?^>!_[^R?_ !5'_")Z;_SP/_?V
M3_XJMFB@#&_X1/3?^>!_[^R?_%4?\(GIO_/ _P#?V3_XJMFB@#&_X1/3?^>!
M_P"_LG_Q5'_")Z;_ ,\#_P!_9/\ XJMFB@#&_P"$3TW_ )X'_O[)_P#%4?\
M")Z;_P \#_W]D_\ BJV:* ,;_A$]-_YX'_O[)_\ %4?\(GIO_/ _]_9/_BJV
M:* ,;_A$]-_YX'_O[)_\51_PB>F_\\#_ -_9/_BJV:* ,;_A$]-_YX'_ +^R
M?_%4?\(GIO\ SP/_ ']D_P#BJV:* ,;_ (1/3?\ G@?^_LG_ ,51_P (GIO_
M #P/_?V3_P"*K9HH QO^$3TW_G@?^_LG_P 51_PB>F_\\#_W]D_^*K9HH QO
M^$3TW_G@?^_LG_Q5'_")Z;_SP/\ W]D_^*K9HH QO^$3TW_G@?\ O[)_\51_
MPB>F_P#/ _\ ?V3_ .*K9HH QO\ A$]-_P">!_[^R?\ Q5'_  B>F_\ / _]
M_9/_ (JMFB@#&_X1/3?^>!_[^R?_ !5'_")Z;_SP/_?V3_XJMFB@#&_X1/3?
M^>!_[^R?_%4?\(GIO_/ _P#?V3_XJMFB@#&_X1/3?^>!_P"_LG_Q5'_")Z;_
M ,\#_P!_9/\ XJMFB@#&_P"$3TW_ )X'_O[)_P#%4?\ ")Z;_P \#_W]D_\
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M**\QM/C-KJ_MCM\)'M; >'3X"_X2L7!20WGVHZA]F*%]^SRPN3C9G)'S8&"
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MT4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4
M+129%&10 M%)D49% "T4F11D4 +129%%*X"T444P"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%13NB!RH!]3>#_%.F>,O"^D>(-'N3?:1J]G#?V=YM=1-#,JO&P1OG4%65L,
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MG]P?7L/W/IC=[T;O>OF?_AI/Q-_SX:;_ -^9?_BJ/^&D_$W_ #X:;_WYE_\
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M?_BJ/]:,N_F?W!]>P_<^F-WO1N]Z^9_^&D_$W_/AIO\ WYE_^*H_X:3\3?\
M/AIO_?F7_P"*H_UHR[^9_<'U[#]SZ8W>]&[WKYG_ .&D_$W_ #X:;_WYE_\
MBJ/^&D_$W_/AIO\ WYE_^*H_UHR[^9_<'U[#]SZ8W>]&[WKYG_X:3\3?\^&F
M_P#?F7_XJC_AI/Q-_P ^&F_]^9?_ (JC_6C+OYG]P?7L/W/IC=[T;O>OF?\
MX:3\3?\ /AIO_?F7_P"*H_X:3\3?\^&F_P#?F7_XJC_6C+OYG]P?7L/W/IC=
M[T;O>OF?_AI/Q-_SX:;_ -^9?_BJ/^&D_$W_ #X:;_WYE_\ BJ/]:,N_F?W!
M]>P_<^F-WO1N]Z^9_P#AI/Q-_P ^&F_]^9?_ (JC_AI/Q-_SX:;_ -^9?_BJ
M/]:,N_F?W!]>P_<^F-WO1N]Z^9_^&D_$W_/AIO\ WYE_^*H_X:3\3?\ /AIO
M_?F7_P"*H_UHR[^9_<'U[#]SZ8W>]&[WKYG_ .&D_$W_ #X:;_WYE_\ BJ/^
M&D_$W_/AIO\ WYE_^*H_UHR[^9_<'U[#]SZ8W>]&[WKYG_X:3\3?\^&F_P#?
MF7_XJC_AI/Q-_P ^&F_]^9?_ (JC_6C+OYG]P?7L/W/IC=[T;O>OF?\ X:3\
M3?\ /AIO_?F7_P"*H_X:3\3?\^&F_P#?F7_XJC_6C+OYG]P?7L/W/IC=[T;O
M>OF?_AI/Q-_SX:;_ -^9?_BJ/^&D_$W_ #X:;_WYE_\ BJ/]:,N_F?W!]>P_
M<^F-WO1N]Z^9_P#AI/Q-_P ^&F_]^9?_ (JC_AI/Q-_SX:;_ -^9?_BJ/]:,
MN_F?W!]>P_<^F-WO1N]Z^9_^&D_$W_/AIO\ WYE_^*H_X:3\3?\ /AIO_?F7
M_P"*H_UHR[^9_<'U[#]SZ8W>]&[WKYG_ .&D_$W_ #X:;_WYE_\ BJ/^&D_$
MW_/AIO\ WYE_^*H_UHR[^9_<'U[#]SZ8W>]&[WKYG_X:3\3?\^&F_P#?F7_X
MJC_AI/Q-_P ^&F_]^9?_ (JC_6C+OYG]P?7L/W/IC=[T;O>OF?\ X:3\3?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -;[
MM?%'C[_D>=?_ .O^X_\ 1AK[7;[M?%'C[_D>=?\ ^O\ N/\ T8:_/N,/X-'_
M !/\CR,PVB86/>C'O1CWHQ[U^5QV/#>X8]Z,>]&/>C'O5 &/>C'O1CWHQ[T
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M:_$__/UI/_?U_P#XU7TW^%'X4?ZK9=_)^(?4Z78^9/\ AFOQ/_S]:3_W]?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&1P<$>G5IX*M0PT<2VGR)?B;RC3<8*>]D7_B-;CPI\*_"WA>X8'4UD-W+&C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -;[
MM?%'C[_D>=?_ .O^X_\ 1AK[7;[M?%'C[_D>=?\ ^O\ N/\ T8:_/N,/X-'_
M !/\CR,PVB86/>C'O1CWHQ[U^5QV/#>X8]Z,>]&/>C'O5 &/>C'O1CWHQ[T
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MCWHQ[T &/>C'O1CWHQ[T &/>C'O1CWHQ[T &/>C'O1CWHQ[T &/>O6OV9_\
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M/RKG8Z-C])X80J[!)&#&W7 )R3^A.2./7%?._P"UWX3U[1=<^%GQD\-Z-?\
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M]U^PT?PU?^ 9-7U&ZO\ 2H;[^RY/M%Q$+V)&DB:23>MO"$+L@\TLT;!3B_\
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M6LEO/<KIUG<PW%T$88\EY'PK [OW;AU0KBOIK7O%&B>'/^"H.ER:SJUCH_\
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M[+^1I_ZY/_GQ_P"3/_Y$/[17\I]X><O]ZCSE_O5\'[O9?R-&[V7\C1_KD_\
MGQ_Y,_\ Y$/[17\I]X><O]ZCSE_O5\'[O9?R-.4,^=JJ<#)X/'N:7^N73V'_
M ),__D1?VE'^4^[O.7^]1YR_WJ^$?<>6R_WE.1],@XI/^_?YT?ZY6WH?^3/_
M .1#^TH_RGW?YR_WJ/.7^]7PA_W[_.C_ +]_G1_KE_TX_P#)G_\ (C_M&/\
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M%C>&/^ABTK_P-C_QH_X6-X8_Z&+2O_ V/_&OB_=_G/\ ]E1N_P Y_P#LJ/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #6^[7Q1X^_Y'G7_ /K_ +C_ -&&OM=ONU\4>/O^1YU__K_N
M/_1AK\^XP_@T?\3_ "/(S#:)A8]Z,>]&/>C'O7Y7'8\-[ACWHQ[T8]Z,>]4
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M3"XCL]8LHKJ))0K*)%60$!@KN-PYPS#N:Z*B@#R8?LI_!B,;5^#W@,H1M/\
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MW_T+^E_^ D?^%= %Q2X]JZ8X6A%64%]Q7*OY4<]_P@'AO_H7]+_\!(_\*/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% #6^[7Q1X^_Y'G7_^O^X_]&&OM=NE?%'C[_D>=?\
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>vnda-20201231_g5.jpg
<TEXT>
begin 644 vnda-20201231_g5.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /X0OVL/^3IOB7_V4#6?_2Z:BC]K#_DZ;XE_]E U
MG_TNFHH _;__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>O
MW^H **** "BBB@ HHHH **** "BBN<^+OQ4\'?!#X8Z[\7?B!?M;:-X=TR6^
MU"1%W.41<[$&1N=CA57/+,!WJ9RC"+E)V2W+ITYU:BA!7;=DN[>R.CHK\4?C
M+_P7J_;4\:>-KC4_A->Z/X,T))S]ATJ+2(+V5HL_+YTMPC;GQU*!!Z#O7VC_
M ,$IO^"K.H?MI:A>_!CXSZ)8:=XXTZP-[9WFF*8[;5K92JR$1L3Y<R%E)4$A
M@2P"A2*^?P?%&58[%_5Z;:;V;5D_3_@I'V.9\!<0Y3ESQM:,7%:R2=Y17FK6
MTZV;MZ'V[1117T1\6%%%% !13+B".ZMY+68-LD0J^URIP1@X(Y'U'-?C?_P4
M ^,'[77_  2=_P""INM?M2_LV:KX_P#'?P$\,?#'PSK'QV^%^L>.-0UA=/M-
M7U36K-]3TV&]ED%L(#I$4AV, K2D';"\AC /V3HKXV_X*-_%;X9_M-?\$?/'
MO[5?[.WQ?U@Z?+\,+WQ#X%\9>"?%%YIEQ#((MZ2+);21N'1TVO%)G:RNCJ#N
M6O>?&GQ4_9U_8F\ Z!H7CGQO>Z;::GJ::3X9T^[N=0US5M9O74L+>VB'VB]O
MIBJLQ5!(V%9CP": /4**\V_9]_:[_9W_ &HYO$MA\$_B&-2U'P;J:Z?XOT+4
M-*N]-U/1+EE+)'=V5[%#<6Y8*Q4R1J&"MM)P<<UI?_!1C]CW6->\/:#8?%"]
M*>+]=CT;P?K$O@_5H])\07TCE$AL-1>U%I>Y*L0T$KKM1GSM4L #VZBO-?C;
M^U3\!/@KK]G\-OB'XLU*3Q!K6F3WEEX9\*>']2UC5Y+*,[);L6FEP37,<"LP
M7S]BH'(4-N(%?!7_  0,^)/PMU#XP_MP?$CPK\4YM3\#VWQN^UZ=XE\0^(KB
MZ$.FI9-)OENKZ1I52-=V?.;,84AL;3@ _3^BO"? ?_!2W]BGXD>.?"7P\\-?
M&*6+4/B!'+)X N-9\+:IIMCXI6-=['3+V\MHK;4/E(8?9Y)-RLK+D,">X^-7
M[3WP1_9]NM*TCXF^+YH]6UTR_P!A>&]$T:\U;5]3$0!E:VT^PBFNITC!4N\<
M3*FY=Q&1D [ZBO)_V;?VX_V5?VO-<\2^%OV=OB[:^(M5\&I:'Q=I*V%U:W>B
MO<O<I##=PW,4<EO.6L[@&%U61/+!=5#(6I?\%!_"5KXK_8K^*$AUW7-*O-+\
M :UJ&DZIX=\07>FW=E=Q:?.T4T<UK)&X9&PP!)7(&0: /9:*_,__ ((Q_LJ^
M%_VO?^"1/PK^-'QI^.WQN?QOXJT*_GU3QKIWQ]\46U]'.FHW<23H%U#R5*)&
M@VF,QG;AD8$@[?\ P0,_;V^,7Q\_9J^,8_:K^--IXMT+X+_%?5?#&@?&G53#
M9P^(='M@K1W5Q*-L3.J%7:;(RDT>XE@78 _16BOF;_@EQ8?L"^&/V;=?N/\
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M'PMIOAOXD:7>>.?AU;>+[N;1-?TDR&&9OLMS*Z6\L'FBXS#Y8E6%E=9'$10
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M+Z_MN^$-/UO6KNPLO"O@"2RCUO7[O47M_/TZ2XE1)+J2214,LLCA-VU=Y"@
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M@74=2\.ZE9Z3XHE4 E-,U.XMTLM18Y&T6TTA;(VYS0![K1110 4444 %%%%
M!1110!_"%^UA_P G3?$O_LH&L_\ I=-11^UA_P G3?$O_LH&L_\ I=-10!^W
M_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !111
M0 4444 %<?\ '[X;^+/B_P#!OQ#\,_ OQ<UCP'J^LZ>;>P\8:!'&][I4A(/G
M0B0%2PP1SQS7844 ? /_  Y^_;K_ .D]/[0'_@ITO_XBC_AS]^W7_P!)Z?V@
M/_!3I?\ \17W]10!\ _\.?OVZ_\ I/3^T!_X*=+_ /B*XG]HW_@C]^W(GP-\
M3W=S_P %9?C)\5EM=*>Y'P\\1:98K::XT1$@A;R5#EP4#H%/,B(#D$BOTTHK
M'$4(8G#SHRVDFGZ-6.G!8JI@<93Q,/BA)25^\6FOR/Y=98I(9&AFC9'1BKHP
MP5(Z@CM7TO\ \$P/V-/CM^UI\8]0D^#GQT\4?"M/#VEO+=_$3PM:QR75E))\
MB6T?F@H6E4R @@_(KGKBOU_^,'_!-']ACX\>,9OB!\3OV=]*O-8N93+=WUC>
M75@US(3DO*+66,2L3U9P2>YKU'X5_"+X8?!#P=!\/_A%X%TSP[HULQ:/3]+M
M5B0N<9=L<NYP,NQ+'')-?"Y9P;B,'F,:U6HG&#NK7NVMK]%][/UG/?$W!YCD
MM3"X>C)5*D7%\UN5)Z.S3N]-%=1[^1\2?\.?OVZ_^D]/[0'_ (*=+_\ B*/^
M'/W[=?\ TGI_: _\%.E__$5]_45^@'XZ? /_  Y^_;K_ .D]/[0'_@ITO_XB
MNO\ @#_P3&_:_P#A!\9/#WQ,\=?\%C?C1X\TC1M06XO_  ?X@TW3TLM5C (\
MF8QH&"G(/'/%?9]% !7S-X=T/1?$W_!5WXQ^&_$FD6VH:=J'[,W@&VO["]@6
M6&YADUWQHKQ2(P*NC*2I4@@@D&OIFO*_#'[%_P  O!_[0VJ_M4Z%I_BE?'.M
MZ7;Z;JNJ7/Q&URX@N;.W>22"W:SEO&M?+C>:9D41 *9I" -[9 /QD_X*"_#_
M .,7_!!7PA\7_P!F'PGH^K>)/V1OVD=!U6T\!(KM/)\.?%=S Q%B68_\>LQ&
M%#'+(-X+203&;]'_ /@H=X^^"B?MX?LP_"?3?A'9^*/CY>ZAXDO_ (1ZGKNN
M7-GI/A>U33L:IJ%VD#9O3Y"A8K4*3(Z']Y  9*^G/VA?V>_@_P#M4_!S7/@)
M\>?!5KX@\+>(K40:GIMUD9PP=)$88:.1'57212&1T5@00*X/]L/_ ()U?LH?
MMV:GX/\ $G[0W@?4KG6_ .H2WG@_Q'X>\37^C:EI;RA1*(KJQFBE57")E=W5
M 1@C- 'Q+^Q!H=YI_P#P68_X*">&/CM\3(=56Z^'7@7_ (2W7=$TPZ;&4;0Y
M0[0P)),T7EQ.43<\L@"C+.Q)/$>#_&W[;W_!(JR^#G[./[9?A[PO^T+^R;<>
M-/#FB_"OXP>' UIKWA"3[1$=%-[;HVV:*,I$JM'N#1@J97WK;M]Y>"?^"2?_
M  3_ /AQ\;]9_:)\#? *WTSQ5KWAI=$U.\@U>\,4L(A> SF!I3&;MHI'5KLJ
M9VWR$ONDD+V_A[_P3%_97^'&F>#_  CI]KXNU7PI\/=3MM1\"^"O$_CO4M5T
MG1+NVS]EEBANII#)Y&<PI*TB0D*T:HR(5 /F/_@DO\5+OQY_P5W_ &^-'^+5
M\J^.M+\;:!8Z/97AVSQ^%[:WN8['R%/2 AUE;9P7N5=N9 3XW^SCXP_9C^#O
MAS_@JIXF_:E\,W%Y\,H?BYJ*>,=%T4M%<:A;75FT4EO$8G0I+/)-L#[DP\FX
MLO)'WO\ M'?\$JOV.?VG?C]I7[57C#PSXE\/?$C2K$6 \;_#OQQJ?AS4[RRZ
M?9KB?3IX7E3'RY)WA0%#!1BJ'P[_ .".G_!.KX8Z5\3]$\.?L]0RV?QCBFA^
M(5MJ6N7US'J<4BE2NV28B)AN8B6/;+N8OO+'=0!\'_MNZ?\ %==/_P"";OB7
MQ##X8\)^$I?VC? L'@+X9^&O.O9-!TO[(!!'<ZK/)OOY5@$4;&.*&,%F!\[Y
M93[[^P_\6++Q7_P< _ME^"_BSJD:^*M&\'^!K+X96-Y,"\?AD6,ES>_9,\F)
M[RY@FEQD;Y$!^[7IL?\ P0>_X)E-\,/"WPFU7X*ZWJ6G^"O$-GK'A6^U/X@:
MS/J.E2VH<06]M>-=>?;6J!VQ;1.D.[#[-X#CIOVIO^"/?[ G[7WCKP?\4?BC
M\(+K3?$W@73HM-\.>(?!/B*]T&\@TZ,$)8F6PEB8P*&8*N<H&8(5#-D \&_X
M)>RV$W_!<#_@HV^FR0M&-6^&*L8""OF#0[\.#C^(.&![Y!SS7V+^V\0O[%WQ
M>9B !\+]?R3_ -@Z>O@S_@CQ)\#/AU_P6%_;?\$_">?2--\->('^'T?P\BL)
M +76(M/T:\COFLY3D79BED'FNK.Q9F9B26:OT4^.GP+^''[2'PPU;X-_%NRU
M2[\.:[92V>L6.E>)+_2WN[:6-HY87FL9X93&Z.RLF_# \@T ?FG_ ,$3_P#@
MF?\ LD?M8?\ !#KX3Z?\9/#GBNX'BKPWJ*ZN=+^).N6*.3J5Y'E8;>\2%1M4
M?)Y>QB/F5LG,_P#P;>_&/XI>&OBC^TK_ ,$UWUVQ\5_"_P#9U\=+H_PU\9V6
MD6MJYMY+F]C:SG:UC2*XE'V=9&DVE][2EF8-&%^MO G_  1\_8;^%WPLB^!W
MPWTKXIZ#X,@A>&#PKI'[17C>WT^*)V+21);IK C5&9F+( %8LV0=QSZI\ /V
M/OV:?V5?@Z_P$_9M^$>F^!_"TK2/-8>&7EM)999%"O.]S&XG><@*/.:0R85?
MF^48 /Q=\(:Q\4O!7_!KQ^US<? Q+BWU"/XU^*+2Y_LY2'ATF37+&'4-H'1/
ML3W ;TC+GM7W!_P50TCX"?&O_@W%\6Z[H\>GMX13X&Z5KG@J:!%"6TEO!:SZ
M<8<?ZL[UBC &#ARO0D5]2_LP_P#!/C]DC]CKX;>(/@Y\ OAC=:?X5\57EU=^
M(?#^M^*M4UNTO9KE0ERS1ZE<W"CS5&) ,!^=P.37'_#G_@DG^QA\+M"L?A[X
M=\.>*9_ >DZVNKZ+\,-7\=ZG>^&K"[6?[0C)I\T[1-&D_P"^2"0/"DF'6,,J
MD 'R!\0KKXJR_M??\$D+OX_3W!\;R>#_ !0?&#WY/GMJC>#++[3YN>?,,Q?=
M_M$UUW@GXG7>M?\ !PE\>/@3X]_:0U[P'K&N_"3P;+\(%TN+2'_M?2;9+R34
M((3J5C<Y(O+F63RX2I<0RLP<1#R_L3]KK]@7]EW]N0^$;C]HOP+>ZC>^!-:;
M5?"6KZ/XCOM)OM-N'4)+Y5S8S12JDBJH=0V#M4]54CC/VR?^"0G_  3_ /V[
MO"_A/PS\?O@7#(_@.UCM?!NK^'M1GTR^TBV0 +;Q3VSHQA&T8C;<JGY@ W-
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MC3/"LMMXKU*"QTZUG55FC33XKA;,[U1 S-"6(C09^1< 'RG_ ,$)?CU/X_\
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M7/X=^%K+9\*?)OKG1[%/^/2/7;SPY?W&L)"!\JMF6U$BC[H$0 &*_1'XM?\
M!/#]F[XL?'^']JN.R\1>$OB2-'_LB^\9^ O%5WHUYJFGY!%K>?9W5+M%*H5,
MJLR;$VLNT8UX_P!AK]F*W_9NUK]DNR^']W:^!O$T=ZOB:PL?$VHV]YK+7F[[
M9+=W\5PMY<RS[W\V629GDW$,Q% 'YE?M&^$/"EG_ ,&:EA:V?AFPACD^"/A7
M4'CAM$4-=M?Z?(UP0!S(7^8O]XDY)KT;_@M/X=T#PU_P3?\ V28/#FB6FGII
M?[0?PU?3$LK98A:,8Y<F(*!L)R>5QU-?8NM?\$L?V(O$/[(=O^P9K/PV\03_
M  EMHHX8O!S?$OQ (O)CD66. S"_$[0JZ(RQ-(8P5&%JS\:O^"97[''[17PF
M\(? [XS^"?$^N^&/ E]:WOA;3I_BAXBC:TN;966WG::*_66>2(,P1Y7=ESP1
M@4 ?,7QJ\#> _%/_  <]?"B^\6^&]/OKBQ_91U*[TPWT*OY=U#KK^5(@;C>B
MR2E3U7)(P0"/+OCQ\,/'GP;_ ."_OQG\??L1Z&;77]?_ &%=5\0>*[+2;?$5
MQXE^V3P:9(ZJ-IN9'M;4J,;V"2MSO;.I^TAI7P'^)/\ P<8_"_PSKGQ%U:QT
M_P +_LY7FCV/BW1_%UU;RZ9XA_M>7RK)]027)NV@$JO!.[&59MKH_F8/Z)?
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M# E5)!X.!FN[^.=O!8?\'-OP,O[*%8I[[]F;Q#;WLL8PT\4=](Z(Y'WE5B6
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MILO"?AY?@7XVO+BWMYI9YKRZ?0[H/<7%Q.[RW$K!5!>1V.%500% 'JW[-O\
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M6+Q9\+-/:Q^'=]I'CG6=.@T"V: 0/#;6MI>1VZ(\($;KY>)$&UMPXH ^7/\
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MW@R+PMJ>M'5KAHI--26.41BW+^4K;H8LN%SB,>K;O6J "BBB@ HHHH ****
M/X0OVL/^3IOB7_V4#6?_ $NFHH_:P_Y.F^)?_90-9_\ 2Z:B@#]O_P#@TV_Y
M2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#^$+]K#_DZ;XE_]E UG_P!+IJ*/VL/^3IOB7_V4#6?_ $NFHH _;_\
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M1!(C95AD$=Q2T ?PA?M8?\G3?$O_ +*!K/\ Z7344?M8?\G3?$O_ +*!K/\
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MP/\ ^Q[E_P#29J]TH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
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M^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH ****
M"BBB@ HHHH **** /"_VL/\ DMGP/_['N7_TF:O=*\+_ &L/^2V? _\ ['N7
M_P!)FKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /X0OVL/^3IOB
M7_V4#6?_ $NFHH_:P_Y.F^)?_90-9_\ 2Z:B@#]O_P#@TV_Y2F?M=_\ ;Q_Z
M?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J "BBB@ HHHH **** "BBB@ HH
MHH \+_:P_P"2V? __L>Y?_29J]TKPO\ :P_Y+9\#_P#L>Y?_ $F:O=* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /X0OVL/^3IOB7_V4#6?_ $NFHH_:
MP_Y.F^)?_90-9_\ 2Z:B@#]O_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
ME*9^UW_V\?\ I\GK]_J "BBB@ HHHH **** "BBB@ HHHH \+_:P_P"2V? _
M_L>Y?_29J]TKPO\ :P_Y+9\#_P#L>Y?_ $F:O=* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _A"_:P_Y.F^)?_90-9_]+IJ*/VL/^3IOB7_V4#6?_2Z:
MB@#]O_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ H
MHHH **** "BBB@ HHHH **** /"_VL/^2V? _P#['N7_ -)FKW2O"_VL/^2V
M? __ +'N7_TF:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 >%_M8?\EL^!__ &/<O_I,U>Z5X7^UA_R6SX'_ /8]R_\ I,U>Z4 %%%%
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M"-OT\W[=!]EU>;'O>K&N1Z<U^@U !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '\(7[6'_ "=-\2_^R@:S_P"ETU%'[6'_ "=-\2_^R@:S_P"ETU%
M'[?_ /!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %
M%%% !1110 4444 %%%% !1110!X7^UA_R6SX'_\ 8]R_^DS5[I7A?[6'_);/
M@?\ ]CW+_P"DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ K\0O^"OO_!7W_@HE^RY_P %$OB'\"O@5^T-_87A70O[)_LK2O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /-OVO\ ]J?X5_L3?LT>,OVIOC1JGV;P]X,T62^NU5@)+J3A8;6+
M/!EFE:.) >"\BYP.:^:?^"*O[*_Q4\,> /%O_!0C]KK2BGQQ_:/U*/Q'XGMI
MU.[PYHP7&E:'%N^:-(+8H64@,&8(^3$#7FWQ_ _X+ _\%5=-_9 T_P#TWX _
MLL:K;>(OB](#FU\3^-"&.GZ*>JRQ6HW2S)RN[S(I%!\MJ_2B@ HHHH ****
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M@/XHSV36_CO5)/#VG:=J5KYT&I7#V=S<-:NI4IM>"VN.'^5L;.2RJ?QE\8_
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
M"#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\
M_-[_ .!;5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?
M\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO
M_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _
M-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;
M5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!
M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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MQ[E_])FKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[HACDY'0R<]17Z"T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%%
M!1110!X7^UA_R6SX'_\ 8]R_^DS5[I7A?[6'_);/@?\ ]CW+_P"DS5[I0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[_P44OKS_@J=^W]X5_X(_>"+R67X8^ #8^.OVI-0M)"(YX$=9=*\-LP_BN)
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MSX'_ /8]R_\ I,U>Z5X7^UA_R6SX'_\ 8]R_^DS5[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X-_P4S_;5T+_ ()]_L2>._VH=1MDO-3T;2_L_A31R"S:IK5P
MP@L;54'S/NG="P7)$:NV/EKEO^"/?[%.N?L-_L.^'O 7Q*G:\^(_BRZN/%_Q
M9UB<J9K_ ,2:BPGNS(R\.8LI;AAPP@#=S7@_[0)'_!3+_@M1X+_94LV%[\*?
MV28+;Q[\2E!#V^H>,[I&&BV#CD%K>+S+GTYFC8 @5^C5 !1110 4444 %%%%
M !1110 4444 %%%% '@/_!5']G7_ (:R_P""<?QI_9^M['[3>^(/AYJ(T:';
MG=J,,1N+/CVN883^%5?^"2O[1G_#6/\ P32^"7Q[N+[[3>ZU\/;"+6;C?NWZ
MC:Q_9+PY_P"OF";W'0U]$5^?/_! <#X+:1^T=_P3ZN?W7_"C?VA=:@\.6?\
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M4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH **** "BBB@#PO]K#_DMGP/\
M^Q[E_P#29J]TKPO]K#_DMGP/_P"Q[E_])FKW2@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9?CCQOX/\ AIX-U3XA_$'Q-9:+H6B6$M]K&KZE
M<+#;V=M$A>261V("JJ@DD]A5W4]3TW1--N-9UG4(+2SM('FN[NZE6.*&)%+,
M[LQ 50 223@ 9K\OM5O_ !C_ ,'$WQTE\+:#=:CH_P"P_P##OQ %U?4H))+:
M;XS:S:RY-O&1AAH\$B#<PP9&7*G?@VP!^6?[+O\ P2K_ &_OVSO@WIW[0/[.
M7[.M]KGA#5Y)4TK6;S6;#3!>"-BC211WUQ#))'N! D52C%6VL<''H7_#@/\
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M\52VUQ\SZ1X9C4Q:'IJMC)1+3$@/=9HPPRE?>=0:5I>F:'IEMHFBZ?#:6=G
MD%I:6T02.&)%"JB*.%4   #@ 5/0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'Y\_L^G_AFK_@XD^.OP@?_1]*_:#^#&@?$'2T(Q$=1TF5])N8
MX_21T8S..I !/:OT&K\^?^"NV/V?OV_/V)OV[8 (+33?BU=_#7Q1<#A7L_$E
MFT$#3'M'#-"S@G@,X)[5^@U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4C,J*7=@ !DDG@"EK\V?VQ_P!H7XQ?\%9_VAM=_P""5W[ WCJZT+X<
M>&YUMOVG/CEHTG_'E"Q(?PUI4O*R7LRADFD&5B7<K9PZ, 8_QT^)?Q!_X+U_
M'O6?V)_V9/%U]HG[*?@35_L?QU^*VBW)CD\>7T9#-X;TF9?O6PX^T7"Y5E(P
M=AC%Q^D7PS^&?@#X,_#W1OA1\*O"%CH'AOP[IT5AHFC:9 (H+.VC4*D:*.@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445\)_P#!2G]OCXV>(OC#9_\ !+#_ ()G
MSVVH?'OQ;8K/XK\7,/,T_P"%NA/@2:K>L,@711AY$!^8ET<@[HDE ,'_ (*
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M+DM$\0W4WB34]4FNTMO-\E=^H7,[1JOG2':A4$MD@X& #Y:_X)Z?&WPEHO\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M9Q\4WVE_LU_#G5TA_:/^)NCSE#XJOXV#CPIILR]4R ;F53P..%"+< &%\/?
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
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M\.?L*_L-Z/:^)OVEOBW$\/@[3),/;>%=.Y6?Q!J/#".WA4.4# ^8Z'"N$92
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MUA_R6SX'_P#8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P""<W_!=;Q5\%)R++X:?MC:++XN\)*?E@L_'&FH!JENO0!KJV(N68G+2&-
M*_1:OC/_ (+I?LQ^._CI^Q%<?&+X$1M'\5O@3KUK\2/AG=0QEI#?:83--; +
M@R+-;"9/*SAW\K(.*^@OV.OVG/ G[9_[+?@/]J?X;2J='\<^&K;5(8!*':TE
M=<36KD<&2&820O\ [4;4 >E4444 %%%% !1110 4444 %%%% !1110 4444
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MB@ HHHH _A"_:P_Y.F^)?_90-9_]+IJ*/VL/^3IOB7_V4#6?_2Z:B@#]O_\
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M!X1TKQ[X+UF#4='UO38+_2=0MFW1W5M-&LD4J'NK(RL#Z&M*@ HHHH ****
M"BBB@ HHHH **** "BBB@ KAOVD/VDO@E^R-\%M=_:$_:(^(%EX9\)>'+0W&
MJ:K?,<#G"QQHH+2RNQ")&@+NS!5!)Q4/[3_[3_P._8V^!VO?M%_M%^/;3PYX
M3\.6AFO[^Z.6=CPD,2#YI9I&PB1J"S,0 *^$?V>/V7_C9_P63^-'A[_@H/\
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M^"?_  1T\ ZE/'=?'?Q@FJ?$R:S<A[#P3I#K=WQ9AS$T\D<<<;'AVB=.=V*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2OVD/@[$\WAO=A8/&>C\M=>';[D"2.52_E%B-DC'#1[S(GLO_!/3]O'X3_\
M!13]FG2OV@_AA#/IMT97T[Q=X3U$XOO#6LPX6ZTZY0@,LD;'@E5WHR/@!L
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MO'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH
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MR-UDED<M(\A^9W=F/)-=S0 4444 %%%% !1110 4444 %%%% !1110 4444
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M(QU9V8Y:21FRSR.6=V)9B22:_+3_ (-COVW?/M/$/["'CG5_F@\W7_ GG/\
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M_P 1%R3_ )]U/NC_ /)G]*5%%%?"'WP4444 %%%?B%_P5]_X*^_\%$OV7/\
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MOPB\76>O>&/$VEPZCH>L6$FZ*ZMY5#(X[@X."I *D$$ @BNBK\O_  1?7_\
MP0 _;!@^#OB.[E3]C;XW^)G_ .$(U2Y<F#X4>*;AB[Z;*Y_U6F73;FC8_+$V
M2=NR:23]0 01D&@ HHKQC_@H?^V!X7_8)_8J^(O[6?BD0R+X/\.2W&EV<S86
M^U*0B&RM>#G][<R0QDCD!B>U 'REX)_XV(?\%YM=^(;G[9\-OV,_#;Z#H9(W
M07?CK5X\WLJ]G-K:((&4C,<R(P/(S^BE?*7_  1<_8_\3_L;?L!>%?#/Q4::
M?XC>-KBX\;?%2_NU N+GQ#JC"YN1-@#,D2F*W)[_ &?/>OJV@ HHHH ****
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MBM^S*UYX9:9K:]_:3^,%C/IGABVP=KOIMHRBYU.1><': KJ \94YKM_V</\
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M"?Q"\,0?$'X 74WBO5K?[/"A,.K:1OAND\YXY1YR!]SK#&69CN%?<'_#@/\
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M!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\
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M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
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MJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J /DO\ X+^?\HD?BS_W ?\
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M==1"VNL[1C"A;Y(E4+QA3TZ#]!O^$Q\,?]!J#_OJ@#2KXY_X+^?\HD?BS_W
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M&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\
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MVO!;7'#_ "MC9R653^,OC'X$_$+_ ((W?M'>)OVV?^">_C*;2/AQJ'[3^G>
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M@/\ X*W?]&F_^7YH/_R=7[<_\$AOV=/BA^S%_P $[_A[\#OCUX(BT7Q9H?\
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M[_1(YS;ZI8#@'[18SA+B$ \;F0*2#@F@#VC^SM/_ .?&'_OT*_-G]K"UM?\
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MO^)$R1@(VCZ]$R6LTYQQ#;72-+G/#2+USBOT)_L[3_\ GQA_[]"OG7_@KO\
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M0!^W_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U
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MX_N7,NJ?%'Q]>-K7B.^F(P\K7DX)A9OXA L2MW6OIZBOYC/ZD"BBB@ HHHH
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M:5H:-YEA\,]";)BT6P7)"R[7/GS DLS.H)W323?<E%% !1110 4444 %%%%
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M[SK:***]0]L**** "BBB@ HHHH *_/3_ ((P8_9@_:F_:O\ ^"8E_P#Z/9^
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M='1MR,.S(P[5Q95BG6I.$GJOR/-R+'2Q-!TYN\H_BG_7Y'6T445ZI[P4444
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M45^5'ZT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444
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MNUTM@HHHKC.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% '\(7[6'_)TWQ+_[*!K/_I=-11^UA_R=-\2_^R@:S_Z7344
M?M__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4
M%%%% !1110 4444 %%%% !1110!X7^UA_P EL^!__8]R_P#I,U>Z5X7^UA_R
M6SX'_P#8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1110 5YY^UA^U#
M\(_V+_V=?%O[3WQTU\:=X8\'Z2][?R#'F3L,+%;Q*2-\TLC)%&N1N>11QG->
MAU^:/B?_ (W<?\%)_P#A (/]._9<_98\4++XB<?/9_$#Q_$,I:?W9K33PV7'
M*M(V"'29&4 ]#_X(\?LO?%SQ#JGBW_@JW^VKH!M?C1\=X8I=-T&XR?\ A!O"
M*D/IVB1!@#&Q01S3\*6?9O42(Y;[KHHH **** "BBB@ HHHH \<_;^_:S_X8
M9_9(\6_M3?\ " ?\)1_PB_V#_B1?VK]A^T_:;^WM/]=Y4NS;]HW_ '&SLQQG
M(_-;_B+._P"K _\ S*G_ -ZZ^QO^"_G_ "B1^+/_ ' ?_3]IU?S6U^D\'9!E
M&:Y9.KBJ?-)3:O>2TY8OHUW9^9<:<0YQE.:0HX2KRQ<$[<L7KS275-[)'[W_
M + /_!PU_P -S?M;^$OV6?\ AD+_ (1?_A*/M_\ Q/?^$_\ MWV;[-87%W_J
M?L$6_=]GV??7&_/.,']*:_EM_P""4[_M2Q_M\> F_8KA\!2?$W_B:#PROQ.:
M]&A#.EW8N#=?8?\ 2,"V\\IY?)D$>?ES7[)CX6_\','BH_\ $_\ VJ/V3?"F
MX\_\(OX'UN_V?3[8PST[^I]!7A<8Y9@<JS.%+"PY8N"=KMZ\TEU;[(]_@S-,
M=FV5SK8N?-)3:O9+3EB^B2W;/O\ HKX _P"&%_\ @O?XJX\2_P#!='PWX;1C
M^]A\+_LT:/<DKW57NILKP?O=00*!_P $D_\ @HSXCP?B5_P7V^,]T2/WG_"+
M^"M(T8$^WE!]O/Z<5\F?7'W_ $5^?_\ PX6U+7QN^)7_  63_;<UH$8DM;?X
MW"RMG'O%%:>F._KZTO\ Q#>?L'ZS_P E+^+?Q]\:%O\ 6'Q1\;-4E\SZ^4T?
MN?\ @1H _GFHHHK^G#^6S]^D_P""?'_!2O\ X*=L-?\ ^"KO[01^%GPSNSOC
M_9M^"6K-$;N$](=;UE27NB1\LD,!,38#(T3<5]P?LW_LM?LZ_L@_#2V^#_[,
MGP;T'P3X<M>5TW0K%8A*^,&69^7GE/>21F=N[&N^HK^8S^I HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^?OVX?\ @I_^
MQ?\ \$]M'MG_ &BOBS%%X@U,*/#W@/0(3J&OZU(S;42VL8LR-N;"AVV1Y(!<
M4 ><?\%G?VX?'7[('P*T?PW\)=0^P>*O'-Y<6UGJP4%["T@1#<2Q9R!+F:%%
M)'RAV8895-?B^GQC^+D7C'_A8<?Q2\1KK_G>=_;8UN?[7YG7?YV_?GWS7W=^
MUI\._P#@JQ_P5E\*Q_'[7OV(=.^%/@#P7874_@/P5XGUEY?'&N_:'@\V>:VC
M'DVJ^7 "+5RLP92 9=RU\#I\-_B))XP_X5['X"UIM?\ .\G^PUTN8WGF9QL\
MG;OW9[8S7Y3QB\P6;>]?DLN3>VVOSO?SV\C^@_#2.3OA[W.7VMY>TO:^^E[Z
M\O+;RO?K<_;/_@C;^V[XV_;#^ &IZ7\5[T7OBOP5?166H:IL"M?VTJ,UO-(!
M@>;^[E1B!SY8;JQKZ_K\T/\ @WQ\1?#;X?ZU\8OV7/&?]J>'/C3H.MV=SXH\
M$>)-/:SNAI MT-I>6ZN<SP%[B4-(OW2\>0 \;/\ I?7Z%DOUO^RJ7UF_/;6^
M_E?SM:_F?C?%*RY<08CZA;V7-I;;97MTMS7M;2VV@4445ZAX 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!X/_ ,%"OVX_"_["/P./Q&O]'75M=U2Z^P^&=%:78MS<[2S22,.5
MBC4;F(Y)*J""X8?EDG_!=G_@H,OC'_A)6\8>'&L?.W_\(\?#$'V3;_<W#_2,
M>_FY]Z^J?^#C#X5^)?$/P<^'WQ?TWYM,\+ZU>V.JH&^X;Y;?RI"/0-;%/K*O
MK7Y'U^8\5YOFN'S5T:<W"$4FK:7NM6^^MUVT/WCP^X<R#&\/K$UJ4:M23DI<
MR3Y;.R2OMI9W6NN^Q_0W_P $_P#]MKPI^W5\"H_B?I&DC2M7L+LV'B31?.WB
MTN@JMN1C@M$ZL&4D?WE.2I->XU^/W_!"3]L7]F;]F[Q_XE_9[^/_ ,5X_!7B
MWXD+IM_X&LO%=I+866N6\1N8F-I>3*L$TIE?9Y8?<Q4!0Q#!?V!K[K)<3B,7
ME=*M77O-:^?9_-:_,_)>*,%@\NS_ !&&PCO3C+3K;1-K_MUW7R"BBBO4/!"N
M/_:"\0?%KPM\$_$^O? ;P'_PDWC2#1YO^$7T,WD%NMS?,NV+?)<21QJBL0[;
MF&51@,D@'L**35U84ES1:O8_G%\1?\$+O^"P7BWQ!?>*O$W[,DU]J6IWDMWJ
M%[<>/=":2XGD<O)(Q^W<LS$DGU-?>_\ P0;_ &2O^"DO[#'Q#\4?#']HSX S
M:3\.O%5H+U+\>+-)NUT[580%5_*M[MY-LT68V*J?FBAS@ D?J'17GT<LHT*J
MJ1D[KT_R/(PV28;"UU5A*5UYK_(***^'/^"LG[;'QEL?%/AK_@F)^P%?I+^T
M'\8+5S_;*$F'X?\ AS)2[U^Z*\QLJ[D@'5I 2N65$D]$]@\Q_:\\6>)O^"U7
M[8M__P $QO@GK]W:?L^?"S58+C]IWQOI5PR#Q#J$;B2'PE:3(>?G0-=,IRFP
MKE6C"S?I#X2\)^&/ 7A;3? _@GP_9Z3HVCV$-EI6EZ?;K%!9VT2!(X8T4 (B
MJH4*!@  5YA^PI^Q1\&?^"?7[,WA[]F+X'Z>XTW1HC+J6JW8!N]:U"3!N=0N
MG'WYI7&2>B@*BX5% ]?H **** "BBB@ HHHH ^<_^"C?_!-OX1_\%$/AKIVG
M:_K5]X0^(/@^\_M3X8?%+PZ?*U;PKJ:X:.:*12K/"65/,@+!7"@@JZHZ^2?\
M$^?^"DOQ>MOC*_\ P32_X*@Z+8^$OVA-$M2WA[Q!:KY6B_%#3D!QJ>EN55?.
MVJ3+; *58.55=LD4/W/7@W_!0;_@GE\"_P#@HM\&4^&?Q82\TG7-&NAJ/@/Q
M]H,GD:QX3U5"&BO;.=2&1@R(63(5PHS@A64 ]YK!^*7Q-\#?!;X:Z_\ %_XG
M>(H-(\.>%]'N=5UW5+DXCM;2"-I99#CDX12<#D]!S7Y]? 7_ (*S_%+]AG5=
M=_8G_P""QZ16'Q&\)^&KS5/A[\3M.M]FE?%C2K2(L'@/W8=4PH$EL<99@0!N
M ;G?V]?VAM#_ ."Q'Q$^"'_!+[]FGQ'<2>#?B5H]G\2/V@-6L)\2:5X/MI5:
M+2960_N[BZNU$++]Z,QH2"CM4\\>;EOKN1SPY^2^MKV\CT'_ ((F_#/QS^T/
MXB^(?_!9S]H7P[-8^+OC_<+!\.='OA^\\-^ K9\:;:KV5KG:MS(5^63$4@P6
M85^@E5-!T+1?"^AV7AGPWI5O8Z=IUI':V%C:1".*WAC4(D:*.%55   X  %6
MZHL**** "BBB@ HHHH **** "BBB@#^$+]K#_DZ;XE_]E UG_P!+IJ*/VL/^
M3IOB7_V4#6?_ $NFHH _;_\ X--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F
M?M=_]O'_ *?)Z_?Z@ JMI^L:1JTES#I>J6UR]E<FWO%MYU<P3!58QN ?E;:R
MG:<'# ]Q7Q]_P7D_:1^-/[*?_!/'5_BY\&[W7=.AA\6:):>-_$'A>/.I:-X=
MFO8TU"ZM6P?*F\H^4LN,QF;>"K*&7RW]A3]GOX+?'*SU[]J7]@?X[^)HK*P_
M:&L+W3]9T?XBZI=:?XG\/"UT8W]GJ$-U<2)=LT,ER=\RFYCG0 NI#J0#]'**
M^-?^"^DOQ/\ #W_!*OXO?$SX3?'GQCX#U?POX4DOK>Z\':A':2W1$T(,<DWE
MF=%V[U_<R1$B1LEL#'JOPF^-6D?!+_@F=X9_:+^(EU<7-AX1^!5EXCUV9Y=T
MLL-KHR74S%FZL5C8Y/<Y- 'NM%?EI^SIX%^-7[6W_!'O7?\ @IWXQ^+/BC3_
M -H3Q7X;UWQYX*\0:7XDNXK7PP;66YETO2+2T$GV?^S_ ";>&.:%XW%QY\S2
M^8S B#XQ_P#!6KXB?M:_L;?L7>$/@QXBNO!GB[]L/Q;:Z1XJUOP[<M#=:'IF
MGRI'XC.GRY+0S>9F&*7[T:2%@5<*P /U2HK\]_VAO&T'_!+#_@HA^S7X;^$F
MI:K;_"KX_P"LWO@3QGX1U+7;N^M[76PL+:3JEK]JED:&XDEE>"<JP$R%6</(
MBL/T(H ***X/X@_M/? #X5>(V\)?$3XJ:7I&I)"DK6=W(P<(W*MP#P: .'_:
MP_Y+9\#_ /L>Y?\ TF:O=*^5/CE^TA\#/BG\<?@W!\/?B9INK/8>-FDO%M)&
M/E(T!12<@<%B!7TS_P )CX8_Z#4'_?5 &E7S7\?_ /@K[_P3M_9<^+FK? KX
MZ_M#?V%XJT+R/[5TK_A$M7NO(\ZWCN(OWMO:21MF*6-OE8XW8.""!]!?\)CX
M8_Z#4'_?5?S>_P#!>JXMM4_X*T_%:YLIUDB?^PL.O0XT'3P?U%>[D& R_'5Z
MKQLW&G3IRFVFD]&NZ?1L^;XGS;&9/@J=7"Q4I2FHVDFUJI/HUV/V//\ P7Z_
MX))#K^UCU'_0AZ]_\@U]*? #X_\ PC_:C^$FD_'7X%>+?[=\*Z[Y_P#96J_8
M+BU\_P FXDMY?W5Q''(N)8I%^91G;D9!!/\ )#>H@B\PD#;QDGM7[R_\$.?^
M"A_[!_PS_P""=WPZ^ 7Q*_;$^&WASQKHK:N-3\+>(/&-G97T!FU>]N(LQ32*
MQW12QN, \.#4O#Y1BN&X9EA7+G=3DE&33MI)](K=)/YG!D>?YGC\XGA,3&*B
MH.2<4TWK%=9/NS]*J*YOPQ\8?A7XVTU=8\&_$/1]7LVQMNM,OTN(SGIAD)%:
M7_"8^&/^@U!_WU7B'V9I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%>)_
MM1_\%%OV-/V+_P"PO^&E/C,GAW_A)?M7]B[-"O[[[1]G\KSO^/2"79M\^+[^
MW.[C.#CR7_A_Y_P21_Z.R_\ +#U[_P"0:[Z.5YGB:2J4J$Y1>S49-/IND<%?
M-<KPU5TZU>$9+=.44UUV;OL?8U%>)_LN?\%%OV-/VT/[=_X9K^,R>(O^$:^R
M_P!M;]"O['[/]H\WR?\ C[@BW[O(E^YNQMYQD9VOVIOVQO@+^Q[^S[XK_:4^
M-'C*&R\.>$M)DO;TQD&6X886*WB4XWS2R%(D7(R[J,CK7+6H5L-5=.K%QDMT
MTTUUV9U4*]#$TE4HR4HO9III]-UIN?.W_!8?]K_XN>%-+\)?\$[/V*M2'_"_
M?C]-+IGAZ\B8D>$=" (U'Q!.5YC6&(2"(\$R!F3<T10_0_[%'[('PC_8._9B
M\)?LK_!+33#H?A731";J91Y^HW3$O<7LY'WIII6>1CT!;  4 #Y7_P""/?P,
M\;Z[J_B[_@JO^VQ#%:_&GX[11R:=H-PQ;_A!O"2D-I^B0[AF-B@CFGX4L^S>
MHD1RWW5_PF/AC_H-0?\ ?59&II45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5
M &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45YO\ 'O\ :_\ V7_V7/ %
MQ\4?VB/CKX;\':!;Y#:CKNI+ LCXSY<:GYII#CB- SMV!KXBU/\ X*^_MD_M
MZ74GA+_@CU^R7M\,SL8S^T)\=(9M'\/(A_Y;6%@!]KU 8.5;: K+AXR#0!^@
M7Q7^,'PH^!'@6]^)_P :_B3H7A+PYIJ;K_7/$>JQ65I .VZ65E4$] ,Y)X&3
M7PCK?_!:7XV_MCZQ<_#K_@BO^QYJOQ8V3M;77QJ\?PSZ%X&TUP2K.DLH2XU$
MHPPT4*HV"&4N*L?"G_@BG\$O'?CRR^/_ /P5,_:7U[]J/XA6DGG65MXT M?"
MFC.3DI8Z)"?LZK_"1+O1\!O+4U]V:'JOP]\,Z/:^'?#;:=I^GV,"P65C8P+%
M#;Q*,*B(@"HH      H _.7XD_\ !!/]I#]L_P %7OC'_@H?_P %+_%/B[XE
M3>7)X;L?#VD"U\&>$G,B>:+?24DB-[(81+ +B5XVQ+O9&90:\J_XA,?^K_/_
M #%?_P!]*_7K_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJO8R_/\ -\JHNEA:G+%N
M]K1>MDNJ?9'BYCP]D^;5U6Q=+FDE:_-):7;Z-+=L_.C]@'_@WE_X89_:W\)?
MM3?\->_\)1_PB_V__B1?\(!]A^T_:;"XM/\ 7?;Y=FW[1O\ N-G9CC.1^E-9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5<V89GCLUK*KBI\TDK7LEI=OHEW9UY=
ME>!RF@Z.$ARQ;O:[>MDNK;V2-*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZK
M@.\TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC
M_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$
MQ\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M6IQE;:Z3MZ7.S"YAC\"I+#590YM^63C?ULU<X']I7]BS]E3]L'X/'X"?M(_
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M_P#:2^-GB?X\?$7_ (*.P3:SXIUB:_O,?# E8M[?)"F=4X2- L:CLJ*.U/\
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M3?\ "4?\(O\ \)!_;O\ Q/K"Q^S?:?[-\G_C[GBW[OL\WW-V-G.,C/YK?\.
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M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM
M/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L
M[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT
M*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_
M .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*-1U'3](T^?5M6OH;6
MUM86EN;FXE"1Q1J"6=F; 50 22> !7@R?\%3O^"?,GC'_A!E_:E\.?;O.\KS
MB)Q:;O\ K[,?V?'^UYF/>L*V*PV':]K-1OM=I7]+G7AL!CL:I/#TI3Y=^6+=
MO6R=CWG^SM/_ .?&'_OT*/[.T_\ Y\8?^_0I;&^LM3LH=2TV\BN+>XB66WN(
M) Z2HPRK*PX8$$$$<$&L#XJ_&+X2? KP?<?$+XV?%#P]X0T&U_X^=:\3ZS!8
M6L9P3AI9V5 >#QGM6^YR--,WO[.T_P#Y\8?^_0H_L[3_ /GQA_[]"O@GQ;_P
M<&?L\?$#Q'=?#;_@G-^SW\3_ -I_Q1;3>1,WPV\,RP:%93=A=ZM=JD,*'C$J
M+(G(YK-'PG_X."OVV\2?%WX\_#K]DKP?='$OAWX;V*^*/%;1'K%-J$Y%K _8
M36QR,9VGN ?:?QT_: _9N_9B\'/\0/VBOBYX1\$:*@.-1\4:O;V4<A ^ZAE8
M>8_3"+EB2  2:_.G]LG_ (*O?"#_ (*0?!/Q/^RC_P $X?V;_BW\81K$MM'J
M'Q)\+> YK7PWI:VUY#<2[[R[$32N1"4$:(=^3M+< ^\_ O\ X( ?\$[?AAXP
MC^+GQH\'>(/CQ\0.#<>._CSXAE\27DK Y'[F?_15PQ)4^3N7CYN,U]H:1I&D
M^']+M]$T'2[>RLK2)8K6SM(%CBAC48"(B@!5 X  P*QQ%"&)P\Z,MI)I^C5C
MIP6*J8'&4\3#XH24E?O%IK\C^7V6*2&1H9HV1T8JZ,,%2.H([5]'?\$T?A-^
MW9XE^,MQ\9?V$/!/@?5O$7@BR>6=?B5=7=OHTZ7"- UL9+52_P!H:-Y'C!(4
M&(LQP-K?L1\8/^":/[#'QX\8S?$#XG?L[Z5>:Q<RF6[OK&\NK!KF0G)>46LL
M8E8GJS@D]S7J/PK^$7PP^"'@Z#X?_"+P+IGAW1K9BT>GZ7:K$A<XR[8Y=S@9
M=B6..2:^%RS@W$8/,8UJM1.,'=6O=M;7Z+[V?K.>^)N#S'):F%P]&2J5(N+Y
MK<J3T=FG=Z:*ZCW\CX8_X>4?\%6?@D#'^U5_P0H\4:I90_ZSQ!\#_'^G>(_M
M [F/3\)<+[!FR:N:'_P<;?\ !,C3-5A\-_M(6?Q+^!NKSR>7'I/QB^$NI:9*
M'[JSPQ3Q(1@\LX'O7W]537-!T+Q/I<VA^)=%M-0LKA=MQ9WULLT4J^C(X(8?
M45^@'XZ>2? []O3]@?\ :6$,?P"_:R^&'BVXGQLL-$\76,UV#QPUN)/-0\CA
ME!YKV#^SM/\ ^?&'_OT*^8?CA_P1,_X),_M$^;+\4/V _AN\]QGS[[0-"&C7
M,I/5FGTXP2,W^T6S[UX^?^#>WX2_# >?^Q;^WM^TO\$C"N+31_"OQ5GO-'7T
M$EG>K+YJCL#(* /O[^SM/_Y\8?\ OT*\4^+_ /P4)_84^!'B^3P#\4?CSX?L
M-9@D,=UI]M;RWDELXZI-]FCD$+#^Z^TCTKXQ_:<^&G_!;;]@WX%>(_BK??\
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M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
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M9D8=JZVN]-25T>K&2E%-;,****8PHHHH **** "BBB@ HHHH **** "BBB@
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MM9?MB?LV_L.?!V^^._[4?Q7TSPGX<L?E6XOI"9KR;!*V]M"N9+B9L'$<:LV
M3@ $CY[_ &W?^"OOA_X0?%<_L5_L/?"RY^.W[15[&1'X#\.W &G^&@<#[7K=
M[GR[*)"P)C+"0Y4-Y0D5ZQ/V3/\ @D'K^K_&&Q_;F_X*L?%.V^-WQPA/FZ!I
M[VY'A3P$I8,+?1[%QM+H0O\ I4J[RR*X"N&D< \S7PC_ ,%"O^"ZF+SXFP^*
M/V9_V3[P[H/"L4@MO'/Q(M#T-XXS_95C(O6(9>16(/FHZ2)]_?LY_LT_ ?\
M9(^$FE_ O]F[X7:3X0\*:/'MLM(TBWV*6.-TLC'+S2MC+2R%G<\LQ/-=S10
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MP^%7PC\/DOJ/B&]/&]MH/V>UC)W23L-JJI W-Q7XE_!+]I_X]_L[>-K?Q_\
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MNZ7<Z)K>G07=E>6[P7=I<Q!XYHG4JZ.IX92"00>"#5BBAI-#3:=T?G3\9?\
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MW]L:_<73VMM#&L<<:-*[$ *H'X9KZC_8^_: _P""A_[9$VD?\$Y_ '[;=]X
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M-NUKMV6RO96ZO<****^C/B0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0F2,L.M?-?\ PV5_P6:_X*"'[%^PE^QS9_L\> ;PXC^+/[1,.[6IH3_RULM
MA+&.0##*;DO$X;J.M?0/[&/_  2._8$_80NV\4? OX#V4WB^=VDU'XA^*I6U
M;Q!>S-_K)7OKG=)&7/++%Y:$\[:^DZ_53^?3X0^$W_! S]G/4O'%I\<O^"AO
MQ:\8_M2_$.V;S(M4^*U[OT2P<X++9:+&?LL$)(SY3B50>1BON30/#^@^%-%M
M?#?A?1+33=.L85ALK"PMEA@MXU&%1$0!44#H  !5NB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#^$+]K#_DZ;XE_]E UG_TNFHH_:P_Y.F^)?_90-9_]+IJ* /V__P"#
M3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH
M**** "BBB@ HHHH \+_:P_Y+9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\#_\ L>Y?
M_29J]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /X0OVL/
M^3IOB7_V4#6?_2Z:BC]K#_DZ;XE_]E UG_TNFHH _;__ (--O^4IG[7?_;Q_
MZ?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH **** "BB
MB@#PO]K#_DMGP/\ ^Q[E_P#29J]TKPO]K#_DMGP/_P"Q[E_])FKW2@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _A"_:P_Y.F^)?_90-9_]
M+IJ*/VL/^3IOB7_V4#6?_2Z:B@#]O_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@T
MV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** /"_VL/^2V?
M_P#['N7_ -)FKW2O"_VL/^2V? __ +'N7_TF:O=* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ)I.M?'+Q[8>$+OQN^LR3:Y:>&=/2W_M6ZCO')D^WR120I]I/S@S22 A]K
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MZD_^(H ]:HKR7_AN[]D/_HO&B?\ ?4G_ ,11_P -W?LA_P#1>-$_[ZD_^(H
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MQHG_ 'U)_P#$4 >M45Y+_P -W?LA_P#1>-$_[ZD_^(J.#]O7]D"Y0R1_';2
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ME8_@ A)H ]=HKR1?V\/V0W4./CQHN",C/F _D4I?^&[OV0_^B\:)_P!]2?\
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M[<%0IGN]/CD<@=!N92<5J44 81^%WPS((/PZT+!&#_Q*(?\ XFF?\*F^%?\
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M44 ?.?[4GP\\ :=\9/@O:Z?X&T>"*[\;RQW4<.F1*LR?9F.UP%PPSV->V?\
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M$T'_ ,11_P *F^%?_1-/#_\ X)H/_B*Z"B@#G_\ A4WPK_Z)IX?_ /!-!_\
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M1_PJ;X5_]$T\/_\ @F@_^(KH** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\
MT33P_P#^":#_ .(KH** .?\ ^%3?"O\ Z)IX?_\ !-!_\17B?@7X>> )OV\O
M'>C3>!M'>SA\$:7)#:-ID1C1S(V6"[< GN17T97-Z9\*?".D?%'5/C!9PSC6
MM7TV"QO7:<F,PQ$E $[')Z]Z )/^%3?"O_HFGA__ ,$T'_Q%'_"IOA7_ -$T
M\/\ _@F@_P#B*Z"B@#G_ /A4WPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\
M^":#_P"(KH** .?_ .%3?"O_ *)IX?\ _!-!_P#$4?\ "IOA7_T33P__ .":
M#_XBN@HH ^<_VI/AYX T[XR?!>UT_P #:/!%=^-Y8[J.'3(E69/LS':X"X89
M[&O;/^%3?"O_ *)IX?\ _!-!_P#$5'XW^%/A'X@^(O#GBCQ'#.UWX6U)K[23
M#.459BA0EA_$,'I724 <_P#\*F^%?_1-/#__ ()H/_B*/^%3?"O_ *)IX?\
M_!-!_P#$5T%% '/_ /"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_ /!-
M!_\ $5T%% '/_P#"IOA7_P!$T\/_ /@F@_\ B*\N_;7^&_P[TG]E/QSJ6E>
MM%MKB'0W:*>WTN%'0[EY#!<@_2O<:Q/B1\/O#GQ5\"ZG\._%T4KZ;JUL8+Q8
M)2CE"0>&'0\4 <_\-/A9\,;CX<>'YY_AQH+N^B6C.[Z/ 2Q,*DDDKR:V_P#A
M4WPK_P"B:>'_ /P30?\ Q%:^C:5::#H]IH>GJP@LK:." .V2$10JY/<X JS0
M!S__  J;X5_]$T\/_P#@F@_^(H_X5-\*_P#HFGA__P $T'_Q%=!10!S_ /PJ
M;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17044 <_\ \*F^%?\
MT33P_P#^":#_ .(KQ/\ 8*^'G@#6?@WJMUK'@;1[N5?&^KQK)<Z9%(P1;DA5
M!92< =!VKZ,KF_A;\*?"/P>\.S^%_!<,Z6EQJ5Q?2"XG,C>=,^]SD]L]!VH
MD_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_ .(KH** .?\ ^%3?
M"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (BN@HH Y_\ X5-\*_\
MHFGA_P#\$T'_ ,11_P *F^%?_1-/#_\ X)H/_B*Z"B@#YS\"_#SP!-^WEX[T
M:;P-H[V</@C2Y(;1M,B,:.9&RP7;@$]R*]L_X5-\*_\ HFGA_P#\$T'_ ,14
M>F?"GPCI'Q1U3XP6<,XUK5]-@L;UVG)C,,1)0!.QR>O>NDH Y_\ X5-\*_\
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M%?\ T33P_P#^":#_ .(KH** .?\ ^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\
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M064G '0=J^C*YOX6_"GPC\'O#L_A?P7#.EI<:E<7T@N)S(WG3/O<Y/;/0=J
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M$T'_ ,11_P *F^%?_1-/#_\ X)H/_B*Z"B@#G_\ A4WPK_Z)IX?_ /!-!_\
M$5XGX%^'G@";]O+QWHTW@;1WLX?!&ER0VC:9$8T<R-E@NW )[D5]&5S>F?"G
MPCI'Q1U3XP6<,XUK5]-@L;UVG)C,,1)0!.QR>O>@"3_A4WPK_P"B:>'_ /P3
M0?\ Q%'_  J;X5_]$T\/_P#@F@_^(KH** .?_P"%3?"O_HFGA_\ \$T'_P 1
M1_PJ;X5_]$T\/_\ @F@_^(KH** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\
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M_P#PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%=!10!S_\
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MX;_%OPO9+;67C31(KF&VNA+"B(D-Y;2W-J'147*S@[2 LLP!]PT444 %%%%
M!7R%\ ?^"SG[+W[1_P"W[XH_86^'5MJ$\>B1SV6A_$3&=&\1Z[9J)=4T>SE"
M[9)[6"2"4D,=Z^<0 L:O+W__  5'^%W[2'QH_8&^)GPS_9,^(UWX6\=:KX?,
M>EZIIT'F730B1&NK>#!!2::V$T,;J0RO(I!4@,.%^('_  27^#?AC_@GSX?_
M &./V1X8? ^M?#&:VU_X1^+=@:XTWQ1:$RPZE<.!^^-Q(9([G(Q)#<S(  5
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M** "BBB@ K)\=^//!OPP\'ZAX_\ B%XEL]'T72K<SZAJ5_,(XH(QQDD]R2
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M<2M-\6_@GX[U+X=?$2_>0L=2O-/\IHKW<1F3SK:>!C+TE<.XQNP #[$HHHH
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M/QYX:\8:\VL6WQ36WM]$\?Z9?:E<WL&KQ3W8%O.;B*=&>.4AR^X@$9">*?\
M!./5-&_X)\_\%0K3PI^R!K,^I?L9_M/^+=;T;X=I'J;7>G:7XHTRQCN);JP=
ML_Z'/,E[9Q,I83"V#;F2&-B ?LQ1110 4444 %>3?M/?MT_LF?L9V,5_^TK\
M:]-\,":T:[2WD@GNK@6RL%:Y:&VCDD2 ,0IE90@)P6S7K-?G_P#&7]M31/\
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M?"1N!:F68L2QN;:5X8Y-Q9_WP#%]@FE /T"HHHH **** "OFC7?^"QO_  3
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M2_\ LH&L_P#I=-11^UA_R=-\2_\ LH&L_P#I=-10!^W_ /P:;?\ *4S]KO\
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M>%_@G\5?BW+XZU7PM9R:;%XKNK/R+B_L8II%LC<#<V^X6U$"2RY_>2H[X&[
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MYTJ\LYBTDFT_)%,S'"C#3L0C 'G'P%_;J_;"_P""0/CKP]^Q]_P6=\7+XO\
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MN&1&"R/'<L&$G ^(_P#@FQ^TY_P3[_;,\/>/O^".WCC1_#G@/XM^)98_BO\
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MM^$'[*W[(W[#WA#Q%KG[-7[,'A?P5;SVSWNM6WP_\'PPW>I>2C,J;+:,27#
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MOV ?VO;O]DC]GGX_+K/[*"Z1#XALK?QS82WNL>#)&N74:!IETS!)H9O*=B9
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M\)VSG7_A_J+^98:]:JOSWFFRL2)HBIWF/<_[M@Z23('=0#VW4OA%_P $X?\
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M/Q<^,7Q _:LTO]AGX#?'O3_ACKEQ\-[GQG=^)I_#$.K7MU"E]'91V]I!<L(
MJ,SO,[*[8>!5"[F<?)'Q(_X**?\ !0S_ ()%?''1Y?\ @K1X#\-?%/X)ZM<M
MI6B?M+?#CPHUC?\ AXW$D9,6JV"%UA1VBA+)#@-Y:E&N'3RE .X_9(_8Y\3_
M /!/S]I*_P#^";?Q+^*7B#XP?LW?&OP/J5UX$T_XH3IJ=UH.IV7E#4-#E<H%
MEM;FTN#<1C:H!M90$#;Y),GX-?\ !)C]JS_@G9\8-<M_^"0O[</A^U^'UU?"
M]UW]GOXS6=SJNE:1)/EA):75M(+JT# -M&W+;09'G*C'N'_!3+]J[X+?LZ_
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M -E UG_TNFHH _;_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\
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MWAOP5XW\=?$K]MWP98?8)OC,^BOXKT'45']IZ!KVCVLFD7VE7)4;?]&:V1,
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MB]!HEOXR\.:C@ZEX>U_1(KC2[[3)RHVE8#'&@P2"XF=<I(A(!\<?&C6/&?\
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MIHY3D3BWO//6&<?*PMXW3Y2E?:M,M;6VL;:.RLK>.&&&,)%%$@544# 4 <
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MIG[7T7["-Y^UOH ^)\VJC2ET)+6Z:!=1+;!8M>K$;5;DO\GDF4/YG[O&\A:
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MK?P&^)"R(VIZ;IEQ;1WT%@[,I5GBCEN[.92H22VO60(L;JH_1&@!%544(B@
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M?#WX;:!X#UOQQJ?B:\T71K:QNO$6M&/[9J<D42HUS/Y:JAD<KN8JH&6/%;M
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M^ETU%'[6'_)TWQ+_ .R@:S_Z7344 ?M__P &FW_*4S]KO_MX_P#3Y/7[_5^
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MHB_8KR.WN4;2HHK>*&07%X-U^'D:)BL1B5I$S&&]"\7_ !\^$7[1OPQ\'_\
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M&?4O'WPM:WMI-:O2!-XHT&;?_9>MG& 7ECBD@N,  7EG=8 0QY /C70O'/\
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M&J7DK;8;2TMH09)YG;HJC  9V*HC,ORKX6_X+S_LBVG[0NF_LR?M.?"CXM_
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M1CXIU3^S?!GC/Q5X/DL-"\079?8D-M<NQ<,[85?.CB!9E7(9@#[9\8<?L?\
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M#9B];PWI]QY=U?6\;JUPMO\ *WF7 @$K118'FR*D>Y-^]<?]K#]K/X _L1?
MO6?VC?VF/B!;^&_"FAJ@NKV6)Y9)I7;;'!#%&"\TKL0%103U)P 2/G[]@/\
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M_P#@HU\</A[=ZWJ=[!X \-?#;QU'9:=X(BM9VAMXKNS@&Z:]D6-+J=GE1_\
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MT7X:#3O#K.B1PW/BI(<P:T\D@'ER_P!H[;UY<%U.XC<0 ?KRB@#\S_A_I/\
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MA^T3I\0&C7,3[= ^(UJ,JM_I$[85G?:2UM]X$-M *R10@'I7QU^!_A;X6_\
M!1_X,_MD>!M(@TW5_&YU3X;_ !$N;6,)_:UC)IESJFGS7&.))(+K2E@C<_-M
MO2N2H 7G_%WQP\$_M,?\%(KOX'_L[ZW!!\3?V>;'1=2\0>(?+EDTZ[TC6+F2
M+6/#=W+$C".86UO97L2$Y-Q';G&V"<5VW_!4_P"%_P"U5\5/V2Y]+_8@FTZW
M^*UAXMT*\\'ZAJS(+?3I/[1@AN+R3?D,L%K-<3%<,6$9 20D1MK_ /!/']@?
MX6_\$\/V>[?X-^!+^YUO6]1O)-7\?>.-6)?4?%6N3_-=:A<N26+.^0JECL0*
MN6(+, >[4444 %%%% !1110 4444 %%%% !1110!_"%^UA_R=-\2_P#LH&L_
M^ETU%'[6'_)TWQ+_ .R@:S_Z7344 ?M__P &FW_*4S]KO_MX_P#3Y/7[_5^
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M>]L;R!98;B%U*O&Z,"KJRD@J0002#5FB@#X7_9'_ ."3'B']C#]M_P 5Z_\
MLT?'+Q;X+_9RU.UMM9;X+VU[$^G3>)VFD:5K1VW3V5BB+"SP1F,32.(V+P1^
M4?NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH X_X]_ #X-?M0_"36O@5\?\ X=Z;XJ\)^(;0V^JZ-JL&
M^.5>H92,-'(K ,DB$.C*&5@P!'S=_P $LO\ @GW\;OV&K3Q7X&\<_M1^-O%7
MPZTCQ%=V7P3\#^);Z&9O#VA94#[1/$-]TS,A$$;L4@@"%4CDED2/[!HH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O"O\ @H+_ ,$_?V;_ /@HA\"[CX4?M!^"KF\ET\O>^%?$.ARK!K.@
M7ZKE+FPN#CRI=RKPQ\M\ ."!Q[K10!X'_P $W_V?_P!IO]GS]F+P_P"&?VQ_
MVD];^)_Q&?38$US6M4>,16B1AO*M(EB 65HU8B2Z??/</EGD91$D?OE%% !1
M110 4444 %%%% !1110 4444 %%%% '\(7[6'_)TWQ+_ .R@:S_Z7344?M8?
M\G3?$O\ [*!K/_I=-10!^W__  :;?\I3/VN_^WC_ -/D]?O]7\GO_!+O_@L+
M\-O^"/?_  4#_:*^)'Q(^#NN>,8/&.N7^FVUMH=_# ]N\6K3REV,HP00<8%?
MH)_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZB
MOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X4
M5C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\
MA1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZB
MOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X4
M5C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\
MA1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZB
MOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X4
M5C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\
MA1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZB
MOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X4
M5C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\
MA1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZB
MOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X4
M5C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\
MA1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZB
MOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X4
M5C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\
MA1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O
M/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ
M_P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\
M"BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _
M;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZB
MOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\
MB-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]
MEG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X
M@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _ #]K#_DZ;XE_P#90-9_]+IJ
L*Q/C'XWM?B;\7?%7Q(L;&2U@\0^)+[4H;:9@7A2>X>4(Q'!(#X)'I10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>vnda-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vnda="http://www.vandapharmaceuticals.com/20201231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vnda-20201231.xsd" xlink:type="simple"/>
    <context id="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic58a5d7276774436bb7a5273a227e621_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0cdd21bdc0c645ba84491ec3d4e3be0e_I20210204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib28d7508f88c4efabda9793b54a8f6f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f26062015ff434da5708800b4290055_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i257e050f9fc943cca28700c4122282b1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if5abb4b8a9434ae69f1ef6beffbc0493_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0074f63a213243feae2eb63ef3b3d8bc_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idfa64fe61cad4642af1fceb2198e6bcb_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i926bf00cb18047ab87ba70c56d7331bb_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i35541c52d30540b0bcc5d1c03313822b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2695d91d6f1c481d8edf3b68ee2898f3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic059f611bf8f4dfe887222e34e6e559c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2b61d51b346e4a2da4ff3d0965c86883_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id3b05afd51b244beb8e0ce8e0775250b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id26474ada35c4b5583a6d5ff5c85bdcf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i96bafcfa87c1497a9ba610e7dafdc2a8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i085e6c9dd96d4b038e51f519dc41e37d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib44c3f48cda746eb8848faa815ee7b25_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i72e49fdf29e54b778aae30d4a1501e76_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9dd9bd75bf594c4abbd1eedddf97813d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2876e1911793496ab09397265fb99368_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4633d2c610df4f1b8efd83504abf4563_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f91365a2a7f4aa084ca1a085338e9fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i765bec0d716f47f7ba015545f962331b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6908a347bbd14f9887021a5ce0273e9e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e47e23e944242d4a81577603ac3211a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9fc5301b024c4390bc0aabe019ad7ed3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i992cb2bfa5d0475fa5bbaab433093f86_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia96fe03637474cd5998b5de2ac3a4f41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i019a056c228946c5ac4dd9f6f794a1d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7446888cd5f945f79f3d4520f7511af9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia77cfbc0f34e4893bd812347680c5cf4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i424e0c1a909c43918460f4dd87afab4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99b78e259ae349ce94d9e93829b687d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e03ba7540db4ef69e680c9d993fb6a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vnda:NoncurrentInventoryAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d0645b788e347848286b67c1d3bd108_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vnda:NoncurrentInventoryAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6797cc9249a14561aeec1ea22885a66a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57f83003f7bb4ea681811d4c44d82646_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf54b4365b834d72b6c65f6179255cf7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia7d2c26d1a8c4ef7843d0e6970eeee5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23995355e19f4d9ca86f91468591e135_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2aa1c343c0de46f5a4a09cdf2ebcc104_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2a6f1b4c76e9497aaa45532e1227ad8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78c8ef22e15348c99b08db2c9df24f2c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i644a9e8beacf4148bf19d98813c87d7d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iea7d114004f648229f473f8282cbda31_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ee0973839d144cf8989e256f4f67b49_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa0d780548074d448d8fa037c0529ec7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i79728196d61b4e99b2d02bfd59fa48b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64e8e24272914f67bf876ad95f66ccdd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2d06651aaae742ed909bbbb905f9bc60_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib5fdfee666e741d38bae37b3799ca556_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd2ad127c2804ac9a3a22c5e5cd6fd79_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i893a60e2f07e4beabea78d9092e5f827_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icb1cae17f9d144cfbac6ede34e4e28ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5fd1a532a29483fbd96f12b34922d1e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icb4fc5098f424b22bcd541acb7773579_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7520c5fde90b48c1b3be4f65d3e11085_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4aff6df1bae41c89733b2e7a1d327f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c607b03683846a192234cafe043197c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f400e70454f47359d4725431a87a437_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief538f6767dd4ce0b60f4fd839aebbf9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57b2e8bf447542a48106681a8f18fd2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfbcdcb15332468b82f91cdeca7c2d90_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vnda:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieccc14d91ff74e1695188703bf8f103e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i40340870e2a2486992b608dd3ae40740_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i21fd1609a04e49b0bb22ec6b8e33dadc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib01d7291558c49ab8183941f323312e1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89fc42978e1140569719239aff32634c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7f4a59b89dd4fc5b2a51c78dbf422c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia69b9f546af14feab861a844ee2190df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">vnda:SECSchedule1209AllowanceProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i526157fae9164658829ef8c67feeb4e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bd2be23072740898c45df963bd01f36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f20c258cb11480789b0ddc9a38ebb80_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i95233a42c2d2400c9e832af0546a849c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83bee279dbf04510bbc505415f41b886_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1cee81eae3834f8a91784e60ea88cdd9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1931a9cde2641aead7a75d77a370fb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedd654c3e3074ac5beb9219888a8397d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaaf5512406d242b3b334cdf95473932e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfd2b9acca2e4a7e89256bcac7794b71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i590279da68dd44789a39b09a2a7b4e5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0aff0dba35f64b73909e86bb8cbb00e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4fa1365e34d44fc9764447fd2ec2e24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1521ac6ce4c4e3faa831a373c4b2943_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i39e789b5b4e8447591662fec5bda3261_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id26713507297483babfde81db7b9fa28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia84837f39b7f470cb64a3244ed1fc84c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3b552a7bd9b47038ad2a7e5c99411fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c688c60d8564383bf26445621f9ca74_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd3faacc11ff44169093da58889d764b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4362e7304366445d990ded2bb3505b1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i792f4aa473234968ae82e33224c68d6c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0242a482bf8f427e89cb520b935b8dec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i572e6e7f0ee349d2b27aafb167ab28ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad2ca748413447168432f3afa16e0405_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7112e733b494f1a982cc5aac77faeae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27df4ba463ab4d5b86c334633ea1634e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba732339a56e4213b11aa8a21ae766e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnda:ComputerHardwareAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf7b6f3b209b460b89808f786605b838_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnda:ComputerHardwareAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b8918e05b554009ab234e53619bc90e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnda:ComputerHardwareAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b1c97ddaaee4131822793e4b11a1fc3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b9c76d935aa454e9830545d747a662d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26247ebfe7eb4525a836402ffc21ca64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia34b88e9659246eea1386afd588f2793_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b9bd57d44144fa28e3d7c0a1cc6d107_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e6096930e004a5cb3b64a1d96cd3a18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a58cc236b3a4b2aa61a7e28fe9c07da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i686659adf6bc48a2a6282c2af72dab52_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice34ccdece6648b48a6896c3974844b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98d5263305ac4d87882e5502fb408e09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:SubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib295f3c8735849ada24ac840f8aa6e79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia30bb33a28694ca0b45ea8f0d52a84cc_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="if6745c8d49094756a3fd1e677133183b_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ib4a98ad86cb947b6b61d3738c4361015_D20150101-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ib8b929e9cab449588933c3ffe31bc66f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9498b806f5e43439515d6d38d221880_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i712a2982fd6d4ab8ac21ead0059a6ab2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07f9ce99f5d440829beb69d57b267e2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia48b1e08808c4068b45beac65e2fc47e_D20040201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-02-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2321f5ecabd74d08919f170010c86d17_D20141231-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vnda:StatementScenarioSecondaryAxis">vnda:ScenarioFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iae6fb1507ec54a02b3ed9ec15779f92e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icce1828699d04ca897051ef167bc2cf9_D20120401-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a443bc8c89e453aab29432964b30663_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:PreNDAApprovalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4c827b82caa44a79a4cef10d4761150_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81b735133e1949cd9c6e0aeb4f8be530_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04c1d7fb8dfe49699863ca274c5642ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib097b437c4ec4ac8a415c8716b033089_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37dcfaf9fa1c4d21a01c3abfb80350e7_D20170301-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c5916a7919c4f108df3dcee675165a5_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3bb19f1abf4e4d15b43df2933d3b57bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f739a8080b94ee0acf1864cc98cfab3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:FutureRegulatoryApprovalAndSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if67d682d4b8343aabcab512b8d833546_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d164c813b754d099714d4875c7405de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1f829f974634d488f1643966850c384_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d9544bb0d4445a097ccc5fa7f50cd38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:VQW765Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec535a14efca43c882d02e3f9ef3b063_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vnda:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ib81f399dfe554faa998124d94d076956_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i418ff91379b846d3988ba7db10522717_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vnda:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i0ce88e2ed3eb4664882da8188a70d03a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd61525c1c634dbc97c9cb4caa360206_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9396936ca284498ea1ea5d4f7a73b747_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:ServiceOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id82d67047689492daa3dc90ebad4142a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:ServiceOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5dffeb908a7c4343be9d34ab1b2dd23a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9ea30e5f62224d9baf5e2ab37d1f16cb_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ic569076d0e77486fbda62273057abb7d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idf7edbea6dae4c4584d42f4bfaada83b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5cafed82f414158a6563a9d462e2f6f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4accca8a781b42bc8a5a731e56f0eec6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie623210fe21f455fba6a25bfe1712547_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id14b5fd7c713420383f8b6f8cdaf4438_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5cbcabe269184dbcb50a511cf3bdb9fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iefdf2eff6cd54e0ea9ebdad5ee519b38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5dba30ea1414af0bf583a5a09975a52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a749d60ade74a138ef81f76767e56e9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5bd51d5e4edf48f2ad3197f761187562_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id823e499960c408ba259173b9f02984b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia5dd64fe80b642d18d3588ccecb6c437_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i533bb21627594019891d85b5903ed825_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">vnda:IncomeBeforeIncomeTaxesCurrentYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3af2a96bce0440ec840b163636430f9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">vnda:IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1209ef3dad5a4c70b22c2b5ea6d9c116_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">vnda:EstimatedRealizabilityofDeferredTaxAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia35ff2ef50ed4a898205b8960a640489_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia324b88c017e451d84714c225aa51f90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">vnda:OrphanDrugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i868e756c16d248bf88fef93ad48e1708_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:DC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0312bfa2fd454fdd90ab881abbadfeaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnda:UnitedStatesExcludingDistrictOfColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icff6f745ed084863aae10666b4b2b891_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i94da092e27b14db4aff38691563ff026_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>vnda:segment</measure>
    </unit>
    <unit id="product">
        <measure>vnda:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="installment">
        <measure>vnda:installment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF80L2ZyYWc6YTc1MzljYzkzMWZjNDA2YWFmY2MwYTNlMzdjOTAxNjEvdGFibGU6MjRmYjY4MDJjNmZjNDZlOWEwNTZjNTUzYjQ5MDM4M2IvdGFibGVyYW5nZToyNGZiNjgwMmM2ZmM0NmU5YTA1NmM1NTNiNDkwMzgzYl80LTEtMS0xLTA_ee6f13e2-16f2-41d3-814f-66bcdd3a4bb5">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF80L2ZyYWc6YTc1MzljYzkzMWZjNDA2YWFmY2MwYTNlMzdjOTAxNjEvdGFibGU6MjRmYjY4MDJjNmZjNDZlOWEwNTZjNTUzYjQ5MDM4M2IvdGFibGVyYW5nZToyNGZiNjgwMmM2ZmM0NmU5YTA1NmM1NTNiNDkwMzgzYl82LTEtMS0xLTA_c30be886-3f79-4765-9da3-930a981dee8f">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF80L2ZyYWc6YTc1MzljYzkzMWZjNDA2YWFmY2MwYTNlMzdjOTAxNjEvdGFibGU6MjRmYjY4MDJjNmZjNDZlOWEwNTZjNTUzYjQ5MDM4M2IvdGFibGVyYW5nZToyNGZiNjgwMmM2ZmM0NmU5YTA1NmM1NTNiNDkwMzgzYl83LTEtMS0xLTA_e9088875-b84d-44ba-8877-26a732f6f59c">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF80L2ZyYWc6YTc1MzljYzkzMWZjNDA2YWFmY2MwYTNlMzdjOTAxNjEvdGFibGU6MjRmYjY4MDJjNmZjNDZlOWEwNTZjNTUzYjQ5MDM4M2IvdGFibGVyYW5nZToyNGZiNjgwMmM2ZmM0NmU5YTA1NmM1NTNiNDkwMzgzYl8xMC0xLTEtMS0w_9cf2f35e-c293-42bf-a057-c4020cf30b1c">0001347178</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ2_ffdab0b6-b157-49a4-9cfe-51d0c9bd3f00">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ3_b1ad988a-b034-4ece-a56b-8cfe68ef72f6">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAxMTY5_e78d48e6-51b2-488c-8e3f-9499fac7663c">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAxMTY5_5c6de3c0-1264-4e59-ba38-57c408cffe40">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQz_f409b14b-9f13-440c-ad5e-05cc58036736">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4_5d783477-7a9f-4f9f-9124-6313a4eba6f6">001-34186</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODUx_aeb12bd7-1eed-4e11-bbf4-72064518ff26">VANDA PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjQ1Yzk0YTc3MTdlNGJmMWE1NDM4MGU5NTU3NGYzZDcvdGFibGVyYW5nZToyNDVjOTRhNzcxN2U0YmYxYTU0MzgwZTk1NTc0ZjNkN18wLTAtMS0xLTA_ffc620e9-1c7f-4d10-a653-6f4df29ebbfd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjQ1Yzk0YTc3MTdlNGJmMWE1NDM4MGU5NTU3NGYzZDcvdGFibGVyYW5nZToyNDVjOTRhNzcxN2U0YmYxYTU0MzgwZTk1NTc0ZjNkN18wLTEtMS0xLTA_91a477d6-d976-4bd8-a95a-2df168a2d5f5">03-0491827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU2_c9ba8822-a6cb-4421-b08e-0a078d463ef7">2200 Pennsylvania Avenue NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODUy_bf1488bb-7705-4c8f-ac69-1a1a805fd9cc">Suite 300 E</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ5_6ad97c98-dca5-4357-8589-8367bcdccd5c">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODUz_0c9f8d86-77f8-4fbc-8cfa-ce58b22a3c27">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU3_5dc119e8-7f14-41df-b515-f0b6805b0abe">20037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ0_a36c9522-9ec8-4ece-b1f3-21c431bf6b2b">202</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODUw_00ea8787-0594-4eeb-9997-ff7fbaef8cdd">734-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MDIwNmUzMTE4NzFmNGM3YzkyMWQxMDgzYjc5OTRjODUvdGFibGVyYW5nZTowMjA2ZTMxMTg3MWY0YzdjOTIxZDEwODNiNzk5NGM4NV8xLTAtMS0xLTA_0051a7ff-9070-47cc-ba8e-a1fc342d9fab">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MDIwNmUzMTE4NzFmNGM3YzkyMWQxMDgzYjc5OTRjODUvdGFibGVyYW5nZTowMjA2ZTMxMTg3MWY0YzdjOTIxZDEwODNiNzk5NGM4NV8xLTEtMS0xLTA_e264c668-1898-460c-8fa8-cc796f141703">VNDA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MDIwNmUzMTE4NzFmNGM3YzkyMWQxMDgzYjc5OTRjODUvdGFibGVyYW5nZTowMjA2ZTMxMTg3MWY0YzdjOTIxZDEwODNiNzk5NGM4NV8xLTItMS0xLTA_0c9342c7-7f0d-4223-8524-6073e14fcc46">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzA0NTMy_8c3a35eb-4c19-412b-a69c-0c265cb2f65e">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU4_27995b06-2f02-4a0d-85f6-cd493d851d92">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU5_24f69eac-3f20-4b5d-8564-505623b6394c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU0_08f5a8eb-65b0-428f-82c9-d4383b7f6bca">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjI5NjY2MWJkMzdkNGI3YWE4N2Q4MTIzZmU0ODVlNzgvdGFibGVyYW5nZToyMjk2NjYxYmQzN2Q0YjdhYTg3ZDgxMjNmZTQ4NWU3OF8wLTAtMS0xLTA_29c4040f-d46f-475a-85d7-6551a771e158">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjI5NjY2MWJkMzdkNGI3YWE4N2Q4MTIzZmU0ODVlNzgvdGFibGVyYW5nZToyMjk2NjYxYmQzN2Q0YjdhYTg3ZDgxMjNmZTQ4NWU3OF8yLTYtMS0xLTA_1a179379-61dc-4182-bc23-cfa770d1f7b4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGFibGU6MjI5NjY2MWJkMzdkNGI3YWE4N2Q4MTIzZmU0ODVlNzgvdGFibGVyYW5nZToyMjk2NjYxYmQzN2Q0YjdhYTg3ZDgxMjNmZTQ4NWU3OF80LTYtMS0xLTA_b07c75c5-746d-4bf9-bf3c-5e1fc7af4907">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAyOTI3_46dc4fbc-e221-4c3d-b8c8-a478771e7666">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAyOTMw_52cb1950-f8f6-4a5b-b911-29039f8f8642">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ic58a5d7276774436bb7a5273a227e621_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODQ4MjkwNzAxMTE4_882d904a-4195-4b4b-ba4a-eecf0271a001"
      unitRef="usd">609800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0cdd21bdc0c645ba84491ec3d4e3be0e_I20210204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8xMDk5NTExNjM1MTAz_48c1e10e-7a98-41d5-b4fe-22360beee271"
      unitRef="shares">54882710</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xL2ZyYWc6NzQ5Njk5ODJlZjIwNGNmY2E0NTVjMjYyYThlZTYxMzgvdGV4dHJlZ2lvbjo3NDk2OTk4MmVmMjA0Y2ZjYTQ1NWMyNjJhOGVlNjEzOF8zODU1_5c94798d-6abf-4dc8-b2dc-cf642daa4a99">&lt;div style="margin-top:6pt;text-align:center;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specified portions of the registrant&#x2019;s proxy statement with respect to the registrant&#x2019;s 2021 Annual Meeting of Stockholders, which is to be filed pursuant to Regulation 14A within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMy0xLTEtMS0w_838ef56a-fb39-42ea-80e1-7eae5e4892fb"
      unitRef="usd">61031000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMy0zLTEtMS0w_ca1af1f4-f512-45bf-a44e-0761b59c8702"
      unitRef="usd">45072000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNC0xLTEtMS0w_27f97e2a-d8eb-466b-856f-db7218806f53"
      unitRef="usd">306709000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNC0zLTEtMS0w_0a6b699a-7a5b-4dcc-b743-407994ef40f3"
      unitRef="usd">267057000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNS0xLTEtMS0w_09823b04-9f62-434e-a5ab-e19a1e8ad97e"
      unitRef="usd">30036000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNS0zLTEtMS0w_905424e4-6310-49b4-b6a4-90a97019b1ad"
      unitRef="usd">26367000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNi0xLTEtMS0w_5df8cc7d-0587-4c6a-8eda-6eca6e30b0bc"
      unitRef="usd">1280000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNi0zLTEtMS0w_610b30c5-c1fb-49eb-8046-729abc3062a6"
      unitRef="usd">1140000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNy0xLTEtMS0w_f44aa9a6-ef6b-463b-8e69-0904033e26a7"
      unitRef="usd">10089000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfNy0zLTEtMS0w_436c9659-792a-44f0-bca6-a898098c182c"
      unitRef="usd">14500000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfOC0xLTEtMS0w_3766e902-2d2a-4cb1-8642-861d547bbdc6"
      unitRef="usd">409145000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfOC0zLTEtMS0w_9831953d-c491-4662-9307-7a492df3fa95"
      unitRef="usd">354136000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfOS0xLTEtMS0w_dbaae8fb-8361-4b88-a905-074e54a5e7f9"
      unitRef="usd">4136000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfOS0zLTEtMS0w_16ff9804-0b06-455c-b627-72d049f87fb8"
      unitRef="usd">3864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTAtMS0xLTEtMA_b235a46d-4793-462f-9f35-1fd9440dccd5"
      unitRef="usd">10459000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTAtMy0xLTEtMA_65d53a45-3cbb-4738-beea-8d8d9eb205ee"
      unitRef="usd">11180000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTEtMS0xLTEtMA_35d83f57-d1eb-49b7-85fa-4734481729fd"
      unitRef="usd">21559000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTEtMy0xLTEtMA_fbc7b382-1930-4a2b-96be-b92a4affea51"
      unitRef="usd">23037000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTItMS0xLTEtMA_12363c8d-c938-4ce5-8a17-a9c38c595956"
      unitRef="usd">81516000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTItMy0xLTEtMA_bc3dffab-ebf9-4a1f-a824-843f3b9abc0a"
      unitRef="usd">87680000</us-gaap:DeferredIncomeTaxAssetsNet>
    <vnda:InventoryAndOtherNonCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTMtMS0xLTEtMA_4ed47986-fcf3-47b8-8e93-a8e6770cfc1e"
      unitRef="usd">6641000</vnda:InventoryAndOtherNonCurrent>
    <vnda:InventoryAndOtherNonCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTMtMy0xLTEtMA_f5ee3360-c42a-4f2f-aa8c-2870fe164239"
      unitRef="usd">3851000</vnda:InventoryAndOtherNonCurrent>
    <us-gaap:Assets
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTQtMS0xLTEtMA_a00da9ae-f49d-49c9-84e2-101d876736de"
      unitRef="usd">533456000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTQtMy0xLTEtMA_e4ea8dfd-719c-4c8b-a216-00fda23d86bc"
      unitRef="usd">483748000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTctMS0xLTEtMA_ea96fbbf-272a-4ac3-a2dd-b8eb6ae21f8d"
      unitRef="usd">31509000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTctMy0xLTEtMA_25cffbd2-9f80-46a7-b8b4-5f4cb78b2f6e"
      unitRef="usd">27590000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <vnda:ProductRevenueAllowancesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTgtMS0xLTEtMA_5fda8476-4d81-49d7-b77e-cf70f5959abd"
      unitRef="usd">34427000</vnda:ProductRevenueAllowancesCurrent>
    <vnda:ProductRevenueAllowancesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMTgtMy0xLTEtMA_fd8a5d31-459f-4a63-8d81-de0c543ffb21"
      unitRef="usd">31915000</vnda:ProductRevenueAllowancesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjAtMS0xLTEtMA_b34b15b3-99c6-46cc-9416-c6f86717cae4"
      unitRef="usd">65936000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjAtMy0xLTEtMA_0410546f-5aa6-4301-97d9-80a16346b04c"
      unitRef="usd">59505000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjEtMS0xLTEtMA_8e39e393-e8f4-44da-a7e5-1ad5f94f76ba"
      unitRef="usd">11497000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjEtMy0xLTEtMA_a7d2b4d8-2fac-4fa0-9d66-9bf47a9f1015"
      unitRef="usd">12455000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjItMS0xLTEtMA_d8f66f6c-dcd8-4053-8099-45b5035394a9"
      unitRef="usd">2757000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjItMy0xLTEtMA_dad05e03-4075-465b-81ab-aa0625c9dee7"
      unitRef="usd">843000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjMtMS0xLTEtMA_cc37e2a5-c297-4455-8fca-6da1ba1bab91"
      unitRef="usd">80190000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjMtMy0xLTEtMA_31bd0e0e-67ab-46a3-a1cf-860fdd106f5c"
      unitRef="usd">72803000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjQtMS0xLTEtMA_ad25b386-412b-4f00-9d28-b4f494841d9b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjQtMy0xLTEtMA_0b143027-c709-4e90-8e38-c4c50e214e6f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzIx_73cfa972-487c-4aee-b39b-cc9485b4ff21"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzIx_a2bf32a0-85cd-4c68-9c64-5b6f4008cef2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzM1_1181fbac-b484-4dea-a701-63d76fc937aa"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzM1_faa4686a-e757-42e0-8a9a-11ec73d12151"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzYx_032dc89f-40e1-4b00-9e6c-2962600a2777"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzYx_785c46a1-1873-4cd2-841f-a33fffbd194e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzYx_93fd6316-2518-41af-becf-bdf44aca5901"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjMxNDczZmUyYTU1YzRkMDlhZGExMDU1Y2VmNDI1MGZjXzYx_e9aa8071-79c5-41f0-acff-a8970a0bc3e0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMS0xLTEtMA_06c487c7-3d77-4694-be8d-992f311f2ce2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjYtMy0xLTEtMA_1185ed23-aef6-41a3-bb7e-3819e656229d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzE4_a6b8c197-ad77-4eb8-a335-96818e2e30d6"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzE4_f2f376a1-fa6b-4e25-8da2-7adc33a6187b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzMy_3b10114a-3c9e-49eb-a7ab-0e46a2a2d994"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzMy_b651f812-cca4-423b-b664-fe906c2998f5"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzU0_24ebfd16-718c-4775-ace5-d9526067fc0e"
      unitRef="shares">54865092</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzU0_e079c981-1a08-4d78-946e-1786b6971efd"
      unitRef="shares">54865092</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzYx_ab8d36f2-7180-4652-b9c9-c68c30577f66"
      unitRef="shares">53549612</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjcxYTgyOTkxMDJmYTRjZDViNWUyZDEyNWYyMzJlOTI2XzYx_d8fcc0f2-d660-4e50-a2a1-e2ad8b7b9d72"
      unitRef="shares">53549612</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMS0xLTEtMA_99dc3f2e-0370-4464-a6ed-96ee137f25f8"
      unitRef="usd">55000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjctMy0xLTEtMA_85af2def-869f-4ca5-b452-8997173350a4"
      unitRef="usd">54000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjgtMS0xLTEtMA_cfa198e4-3f12-4317-88c1-de85aac1fdf3"
      unitRef="usd">650300000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjgtMy0xLTEtMA_c2107dbd-84f5-41dd-9fa9-7c5ed27f737d"
      unitRef="usd">631307000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjktMS0xLTEtMA_aa041062-c23c-4132-9468-8a1a3b4e79c3"
      unitRef="usd">239000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMjktMy0xLTEtMA_b2f36002-2576-4280-8290-8865a55bc98b"
      unitRef="usd">249000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzAtMS0xLTEtMA_993e56f4-b8b1-4bf9-85f1-1be8279f79f3"
      unitRef="usd">-197328000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzAtMy0xLTEtMA_72ca4358-0d21-429b-952a-7319b489c9c0"
      unitRef="usd">-220665000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzEtMS0xLTEtMA_61977e1c-5ab1-4a15-ac05-4d25dc20a731"
      unitRef="usd">453266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzEtMy0xLTEtMA_98f90aca-a4c4-4189-9183-940cd316dfc8"
      unitRef="usd">410945000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzItMS0xLTEtMA_23d66a6c-08a3-4050-a678-20ee592eb32b"
      unitRef="usd">533456000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85NC9mcmFnOjAyODJkYzhmZGU0ZjQ0NDM4NDFiYTQ3ZmQyMThhYzIxL3RhYmxlOjUzYWU2OTg2ZjE5YjRiMzQ5ODg5NzFmMGUyNzZhMDk3L3RhYmxlcmFuZ2U6NTNhZTY5ODZmMTliNGIzNDk4ODk3MWYwZTI3NmEwOTdfMzItMy0xLTEtMA_170024bf-1cd0-401e-a933-b1665c191bf9"
      unitRef="usd">483748000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMy0xLTEtMS0w_ddfba300-5144-4352-8d00-00ca17b732f1"
      unitRef="usd">248168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMy0zLTEtMS0w_1b961eea-e548-4ae3-8f9b-63a533caaee1"
      unitRef="usd">227188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMy01LTEtMS0w_034b5144-cda3-4f9a-abc1-156e1ce766c6"
      unitRef="usd">193118000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNC0xLTEtMS0w_05be2b99-d93d-4a2a-88ad-2c59c209f07e"
      unitRef="usd">248168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNC0zLTEtMS0w_b1f0d663-8cd8-4499-b4ce-77e481f3e8fa"
      unitRef="usd">227188000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNC01LTEtMS0w_7c535a77-5b98-46f6-9531-c508928184dc"
      unitRef="usd">193118000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNi0xLTEtMS0w_114bbc1d-c036-47ab-b4ba-17ccbf1bddfc"
      unitRef="usd">23364000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNi0zLTEtMS0w_ab14955b-c048-4fa6-9c19-d043c6722c44"
      unitRef="usd">24488000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNi01LTEtMS0w_5aa89ce6-c9ae-41aa-a9c4-ff503aed1e97"
      unitRef="usd">20508000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNy0xLTEtMS0w_9d497848-82bf-4a80-93d1-0903df10b8f4"
      unitRef="usd">55577000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNy0zLTEtMS0w_03c3bcd7-6953-4d82-864f-071f2fda55f7"
      unitRef="usd">48649000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfNy01LTEtMS0w_d1a6a6d3-fe8b-4878-beb0-884e0d01c482"
      unitRef="usd">43594000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOC0xLTEtMS0w_adb59108-6200-47bd-94ef-25361182815f"
      unitRef="usd">140510000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOC0zLTEtMS0w_37b48860-fe29-48d8-ab1b-df044edd4fba"
      unitRef="usd">129736000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOC01LTEtMS0w_a620ee56-8b0c-499a-a492-85455d88549f"
      unitRef="usd">105751000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOS0xLTEtMS0w_69f61c4e-995d-420b-95c3-372300ca072f"
      unitRef="usd">1478000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOS0zLTEtMS0w_2f7c0fa8-1009-4ae1-8280-d77c42a3e96c"
      unitRef="usd">1505000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfOS01LTEtMS0w_77852810-add6-4ce3-ad43-4e7b59171663"
      unitRef="usd">1527000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTAtMS0xLTEtMA_bf1e3876-5a6f-4d2a-b6dc-7446431b2255"
      unitRef="usd">220929000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTAtMy0xLTEtMA_8f2254d0-4290-4e45-bb40-a2ecd170ca6d"
      unitRef="usd">204378000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTAtNS0xLTEtMA_0414a5fe-010b-4a23-b370-f8e5f54930c0"
      unitRef="usd">171380000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTEtMS0xLTEtMA_add21153-e853-44e9-9b59-44d3c123ea7c"
      unitRef="usd">27239000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTEtMy0xLTEtMA_c3631768-9a3d-4be0-a0d4-de193cb60278"
      unitRef="usd">22810000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTEtNS0xLTEtMA_9200cd6f-c60d-4e1e-9629-e84ee08ef28d"
      unitRef="usd">21738000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTItMS0xLTEtMA_ce1fa5fb-a7a9-4213-9fba-305a5afa33d9"
      unitRef="usd">4416000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTItMy0xLTEtMA_2097fb28-79c6-46ff-98ed-8ba4e8e20b0a"
      unitRef="usd">6218000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTItNS0xLTEtMA_cbd75ddc-4831-4ad9-8985-9a6ef0992daf"
      unitRef="usd">3608000</us-gaap:OtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTMtMS0xLTEtMA_4a3230b6-061e-4a57-9e5a-dd59c9b072bf"
      unitRef="usd">31655000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTMtMy0xLTEtMA_8c041085-3126-421e-8293-3eb09c8e2154"
      unitRef="usd">29028000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTMtNS0xLTEtMA_f047edf1-0f89-4399-945a-78a192ffa68e"
      unitRef="usd">25346000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTQtMS0xLTEtMA_854eb8aa-5ebf-4791-a118-1674f51ec100"
      unitRef="usd">8318000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTQtMy0xLTEtMA_b7ed4616-e28b-4a29-8702-92b2bbb92773"
      unitRef="usd">-86525000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTQtNS0xLTEtMA_62276639-3960-4c9e-b662-b11b980a08fd"
      unitRef="usd">138000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTUtMS0xLTEtMA_d077e7b9-66ca-4421-8a9a-f43016b3700f"
      unitRef="usd">23337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTUtMy0xLTEtMA_9c2ca608-2d60-405a-8e38-bc36e624e598"
      unitRef="usd">115553000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTUtNS0xLTEtMA_03748a27-e4ab-4f26-b637-a0b802774418"
      unitRef="usd">25208000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTctMS0xLTEtMA_96818a8f-58aa-4b5f-be05-c9989909e9d4"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTctMy0xLTEtMA_f29d9d8b-3fcc-4076-8d61-fd75bdfde413"
      unitRef="usdPerShare">2.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTctNS0xLTEtMA_6e01228e-fabb-48cd-ad92-a1a37324abf7"
      unitRef="usdPerShare">0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTgtMS0xLTEtMA_7d4e7329-f8e5-423f-84a6-6abe43e9022b"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTgtMy0xLTEtMA_9dc8a7bb-bf42-4d87-b6d0-dcebd9198ac8"
      unitRef="usdPerShare">2.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMTgtNS0xLTEtMA_4f38b2e0-f07b-40d8-869d-a0e92c5eead8"
      unitRef="usdPerShare">0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjAtMS0xLTEtMA_00db5c04-c5f3-42de-b27b-4a32b71cf2c7"
      unitRef="shares">54427683</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjAtMy0xLTEtMA_22586b31-8691-4663-a31a-2d71ce214619"
      unitRef="shares">53137562</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjAtNS0xLTEtMA_b32027b4-9290-4d43-98e9-3637bd8a9073"
      unitRef="shares">50859947</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjEtMS0xLTEtMA_7af833bf-32e2-411c-8aa3-956eab0e599e"
      unitRef="shares">55190802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjEtMy0xLTEtMA_c43f18f3-cdc5-48f7-bc10-78662795e084"
      unitRef="shares">54847060</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF85Ny9mcmFnOjc5NmE0MTk1MjM5MjRhN2FhOTEwYTZmMDI3ZGFkYjQ5L3RhYmxlOjRkY2FmMjZiZTI3ZjRiM2Q4ODYxYTlkMDRjOTgwYjc5L3RhYmxlcmFuZ2U6NGRjYWYyNmJlMjdmNGIzZDg4NjFhOWQwNGM5ODBiNzlfMjEtNS0xLTEtMA_03c0b88c-95e9-40c2-9083-248022b33216"
      unitRef="shares">53045257</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzItMS0xLTEtMA_3025687f-5541-4fef-aef9-84b58ebefe60"
      unitRef="usd">23337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzItMy0xLTEtMA_4dd97932-15c8-43df-b94e-076d85659bb5"
      unitRef="usd">115553000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzItNS0xLTEtMA_2c683bad-97ce-4943-af8d-03ce7227b5fb"
      unitRef="usd">25208000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzQtMS0xLTEtMA_4b1d2219-2fdf-4319-ab10-59091e547170"
      unitRef="usd">68000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzQtMy0xLTEtMA_64c13c29-df03-4e29-aba5-495062f8c1d0"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzQtNS0xLTEtMA_1cc01928-0949-427d-8419-5bb943b9cdff"
      unitRef="usd">-22000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzUtMS0xLTEtMA_8a66ed27-25e0-46ba-8004-c6ab965a5db8"
      unitRef="usd">-102000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzUtMy0xLTEtMA_5c957ca7-fb69-4318-9a69-8de602866534"
      unitRef="usd">313000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzUtNS0xLTEtMA_f3b29caa-eada-4272-b971-ba86b1230232"
      unitRef="usd">57000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzYtMS0xLTEtMA_9a2beb2f-da50-4ee4-a77b-5aa7a7c68d09"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzYtMy0xLTEtMA_a910e31a-bead-4129-81f7-01d4bdd7f330"
      unitRef="usd">71000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzYtNS0xLTEtMA_dcd9c549-35b1-4fc4-bc89-8dc673f12562"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzctMS0xLTEtMA_b8ff4cc4-5aec-4bfa-b73f-22c17e592008"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzctMy0xLTEtMA_423a567d-9bf6-4471-806f-431755b88ba3"
      unitRef="usd">248000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzctNS0xLTEtMA_e2ee6e9d-b0dd-4de3-92af-7b504623f111"
      unitRef="usd">35000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzgtMS0xLTEtMA_dfc740aa-3bc0-44aa-9235-103ca0b81e1e"
      unitRef="usd">23327000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzgtMy0xLTEtMA_b737f126-aeda-41df-9f62-10d28f03e96f"
      unitRef="usd">115801000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDAvZnJhZzpkMmRjOGExZTkwNTI0YWRiOGI3Y2M2NWMyYzczMGQ5MC90YWJsZTowYzYwNDgyNzY3M2E0MzNiOGIzNWUxNTcwODk4MWM0Yy90YWJsZXJhbmdlOjBjNjA0ODI3NjczYTQzM2I4YjM1ZTE1NzA4OTgxYzRjXzgtNS0xLTEtMA_763321cf-790b-48ac-aa85-97d2a228c784"
      unitRef="usd">25243000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i257e050f9fc943cca28700c4122282b1_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItMS0xLTEtMA_d3336ced-eeed-4036-8860-b0dbf1ed84ca"
      unitRef="shares">44938133</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i257e050f9fc943cca28700c4122282b1_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItMy0xLTEtMA_ab936e4a-698c-41cf-a768-1c38ba150e12"
      unitRef="usd">45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if5abb4b8a9434ae69f1ef6beffbc0493_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItNS0xLTEtMA_f81b3cc8-dc7e-4926-9390-544124c270d7"
      unitRef="usd">492802000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0074f63a213243feae2eb63ef3b3d8bc_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItNy0xLTEtMA_7c51400f-4456-4f71-a743-9f62a7105252"
      unitRef="usd">-34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idfa64fe61cad4642af1fceb2198e6bcb_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItOS0xLTEtMA_9eb40d8e-8145-4376-9727-196b685735da"
      unitRef="usd">-361426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i926bf00cb18047ab87ba70c56d7331bb_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzItMTEtMS0xLTA_57d5caad-8f1f-4841-88dd-ab124381f073"
      unitRef="usd">131387000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMS0xLTEtOTc_8401820f-d5a6-44cb-905c-47746cca21af"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMy0xLTEtOTc_2ce36f26-54a7-4efb-a5cc-228f62c52b50"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i35541c52d30540b0bcc5d1c03313822b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtNS0xLTEtOTc_b26bad67-522c-455f-a18e-289922527ca6"
      unitRef="usd">100864000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMTEtMS0xLTk3_52a26162-dee7-4bfa-81ab-11e9816274b3"
      unitRef="usd">100870000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMS0xLTEtMA_264d2389-efa3-427e-8081-59a809906334"
      unitRef="shares">1214460</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id004579c1da24db7ab618dd6d996aa89_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMy0xLTEtMA_380bb5d4-5772-4691-918c-878d6f812e5d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i35541c52d30540b0bcc5d1c03313822b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtNS0xLTEtMA_c816de43-bfca-4a68-84fc-3b4b4bca76df"
      unitRef="usd">6255000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzMtMTEtMS0xLTA_6489c5bb-9fc0-4d03-9c02-5143d15cd0dd"
      unitRef="usd">6256000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i35541c52d30540b0bcc5d1c03313822b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzQtNS0xLTEtMA_3c352a85-8f83-43d1-9c1a-5811f0c3b249"
      unitRef="usd">11666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzQtMTEtMS0xLTA_6cf3c6f4-1031-4cb9-85d8-a0e9f355c2eb"
      unitRef="usd">11666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i2695d91d6f1c481d8edf3b68ee2898f3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzUtOS0xLTEtMA_ce96c610-c578-47e4-b46c-a831cbb29d82"
      unitRef="usd">25208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzUtMTEtMS0xLTA_08aa0917-4491-42e7-9a39-7652788aaee0"
      unitRef="usd">25208000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic059f611bf8f4dfe887222e34e6e559c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzYtNy0xLTEtMA_4fd12791-5e6a-4d2a-9d73-978480605e34"
      unitRef="usd">35000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzYtMTEtMS0xLTA_5cf93399-2924-4874-9d7b-166b843be289"
      unitRef="usd">35000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2b61d51b346e4a2da4ff3d0965c86883_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctMS0xLTEtMA_ade17f84-f413-4abc-8c9f-782e31ae6622"
      unitRef="shares">52477593</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2b61d51b346e4a2da4ff3d0965c86883_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctMy0xLTEtMA_910b7a96-54be-41d9-a52b-f211ff2e2317"
      unitRef="usd">52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3b05afd51b244beb8e0ce8e0775250b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctNS0xLTEtMA_000b453e-fe67-4fe5-a4cb-41dba53f48f9"
      unitRef="usd">611587000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id26474ada35c4b5583a6d5ff5c85bdcf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctNy0xLTEtMA_68522caa-ff0c-4396-ad24-1ffe1b53ff75"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96bafcfa87c1497a9ba610e7dafdc2a8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctOS0xLTEtMA_77e1c10e-70f9-425d-afaf-6fb5b7559f19"
      unitRef="usd">-336218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzctMTEtMS0xLTA_cb0727b4-eefc-463f-a710-50af385ee198"
      unitRef="usd">275422000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i085e6c9dd96d4b038e51f519dc41e37d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzktMS0xLTEtMA_a762df80-345e-4c52-8877-a9a5e1427483"
      unitRef="shares">1072019</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i085e6c9dd96d4b038e51f519dc41e37d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzktMy0xLTEtMA_43bf0449-510c-42d1-ba2c-88254c9ae0ba"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib44c3f48cda746eb8848faa815ee7b25_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzktNS0xLTEtMA_f8b337cf-0186-4a5f-89f0-cd68c5bc1b8f"
      unitRef="usd">6262000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzktMTEtMS0xLTA_a3c6982b-f9b6-4a13-9192-b9a1f0f0e8c7"
      unitRef="usd">6264000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib44c3f48cda746eb8848faa815ee7b25_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEwLTUtMS0xLTA_e634e43a-e64c-4f38-9429-d16a9b9f7939"
      unitRef="usd">13458000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEwLTExLTEtMS0w_25354198-ff64-4327-8c28-de97b25b9e59"
      unitRef="usd">13458000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i72e49fdf29e54b778aae30d4a1501e76_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzExLTktMS0xLTA_4b7f1b1a-2525-4767-aafa-c5e5ad43ed02"
      unitRef="usd">115553000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzExLTExLTEtMS0w_620fe29c-032d-4dcd-9b22-6191ac085151"
      unitRef="usd">115553000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9dd9bd75bf594c4abbd1eedddf97813d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEyLTctMS0xLTA_2f63f1f8-b0fa-4562-a0fb-2b67a426d922"
      unitRef="usd">248000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEyLTExLTEtMS0w_2eed0598-f31d-4646-ab2d-72275f9602d9"
      unitRef="usd">248000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2876e1911793496ab09397265fb99368_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTEtMS0xLTA_625edc05-2b73-4265-a050-7ab57a7e7a99"
      unitRef="shares">53549612</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2876e1911793496ab09397265fb99368_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTMtMS0xLTA_24b73bfc-5b18-4850-bfc3-83a7e63193cb"
      unitRef="usd">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4633d2c610df4f1b8efd83504abf4563_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTUtMS0xLTA_0c1fa7be-09dd-4f86-be91-03888d821475"
      unitRef="usd">631307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f91365a2a7f4aa084ca1a085338e9fa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTctMS0xLTA_d5ff06b8-3268-439b-91de-7f27f68be17f"
      unitRef="usd">249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i765bec0d716f47f7ba015545f962331b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTktMS0xLTA_d71cd8b3-86dd-4ead-892d-6f1767c71c4c"
      unitRef="usd">-220665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzEzLTExLTEtMS0w_d03411bc-b730-4420-b8b4-ca13a4f7be96"
      unitRef="usd">410945000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6908a347bbd14f9887021a5ce0273e9e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE1LTEtMS0xLTA_a429372c-ee5b-436d-a585-00eda758b1e9"
      unitRef="shares">1315480</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6908a347bbd14f9887021a5ce0273e9e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE1LTMtMS0xLTA_cfa79c53-a930-4d76-92b7-ca0995612b3f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5e47e23e944242d4a81577603ac3211a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE1LTUtMS0xLTA_6d2f71f0-68e8-4a60-8263-f1db79be86d2"
      unitRef="usd">5633000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE1LTExLTEtMS0w_188acb37-803e-4802-8da5-68e4b1d2a1ce"
      unitRef="usd">5634000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e47e23e944242d4a81577603ac3211a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE2LTUtMS0xLTA_e7486afd-e774-4988-b983-df3c0f1a4024"
      unitRef="usd">13360000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE2LTExLTEtMS0w_f403e407-fc66-4116-a438-ac0637f0e026"
      unitRef="usd">13360000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i9fc5301b024c4390bc0aabe019ad7ed3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE3LTktMS0xLTA_e8ee9989-b486-4bad-bbb7-a07f2508627c"
      unitRef="usd">23337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE3LTExLTEtMS0w_847b43e6-f003-4a38-944e-f33114b4c1d7"
      unitRef="usd">23337000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i992cb2bfa5d0475fa5bbaab433093f86_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE4LTctMS0xLTA_6cee5a3a-7861-4d1b-a7bd-0f120fa53d2c"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE4LTExLTEtMS0w_a1e4478e-a754-453e-916f-eba02fbc1283"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia96fe03637474cd5998b5de2ac3a4f41_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTEtMS0xLTA_92067aff-4e8f-4ae1-add4-977327c6db33"
      unitRef="shares">54865092</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia96fe03637474cd5998b5de2ac3a4f41_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTMtMS0xLTA_21ce7ada-2a57-4dbb-a9f0-087f714eccc3"
      unitRef="usd">55000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i019a056c228946c5ac4dd9f6f794a1d0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTUtMS0xLTA_6848ab68-ac5d-4a6a-a0f0-d8da500cc029"
      unitRef="usd">650300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7446888cd5f945f79f3d4520f7511af9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTctMS0xLTA_e1c08ccb-ae8c-427c-a095-5d1e2d2490a0"
      unitRef="usd">239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia77cfbc0f34e4893bd812347680c5cf4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTktMS0xLTA_f0ed2a15-c2bd-4bc6-beac-9fd8519e144e"
      unitRef="usd">-197328000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDMvZnJhZzo0ODQxMjg3MDYxMmY0OWNjOWM3YmI4MzUxZGI2OTc2Zi90YWJsZTpjMTM0YzE4ZWIyOTA0NjE2ODUzYTdlZGY4YzU1NjBmOC90YWJsZXJhbmdlOmMxMzRjMThlYjI5MDQ2MTY4NTNhN2VkZjhjNTU2MGY4XzE5LTExLTEtMS0w_ff8a9e47-f920-4a63-ace8-b86ac3230cbb"
      unitRef="usd">453266000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMtMS0xLTEtMA_bb74b4ad-52cf-4595-b9ea-b9a4cf77da70"
      unitRef="usd">23337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMtMy0xLTEtMA_1f024b97-2e09-4461-85c8-6e04edc331fa"
      unitRef="usd">115553000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMtNS0xLTEtMA_020b26e9-822d-41c3-9e61-3ddf68ed8b9a"
      unitRef="usd">25208000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzUtMS0xLTEtMA_00983092-b6fd-45dc-8e7c-2123e4a284d6"
      unitRef="usd">1386000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzUtMy0xLTEtMA_9e60edb2-4fbc-4c7b-8cca-e09ba859e196"
      unitRef="usd">1387000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzUtNS0xLTEtMA_7ac6d36d-6750-485e-98dd-29bdb958cdab"
      unitRef="usd">1429000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzYtMS0xLTEtMA_fd88eada-feed-4b22-b95a-c6e59b3a863d"
      unitRef="usd">13360000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzYtMy0xLTEtMA_e653321f-5916-42a1-8565-b84200a904d4"
      unitRef="usd">13458000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzYtNS0xLTEtMA_c35afff9-2da3-4745-9e05-5f2413f6a1a7"
      unitRef="usd">11666000</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzctMS0xLTEtMA_fee5d027-4f0e-4da1-8772-470640b91d0f"
      unitRef="usd">-179000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzctMy0xLTEtMA_6ec023ff-8f84-4cca-a9f6-bef9cde7c139"
      unitRef="usd">3099000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzctNS0xLTEtMA_d8e85f7f-151e-442c-afed-54c983af72b6"
      unitRef="usd">2221000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtMS0xLTEtMzgw_26d8c964-fbb9-46a1-8d95-afc8db3687e7"
      unitRef="usd">229000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtMy0xLTEtMzgz_83de0310-9059-4bdf-9b55-923e378e18a8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtNS0xLTEtMzg1_2c810fd2-88f4-4641-9f2b-586c4374d450"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtMS0xLTEtMA_c5bcd95a-ad52-4aa6-85df-43614e0562bc"
      unitRef="usd">1478000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtMy0xLTEtMA_eb5585be-9307-45ae-b10b-271503bf7c38"
      unitRef="usd">1505000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzgtNS0xLTEtMA_0525645e-13d1-4c22-8c72-3d686611e2c2"
      unitRef="usd">1527000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzktMS0xLTEtMA_a752dec0-3c84-48e7-beb7-83ada68a823c"
      unitRef="usd">6189000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzktMy0xLTEtMA_148dbe46-bc45-4f4d-bbe2-f8c4c9a6b96e"
      unitRef="usd">-87767000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzktNS0xLTEtMA_9c07b580-1a08-4614-b8af-94dd98b70037"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEwLTEtMS0xLTA_f2b372ef-bd31-4116-b1d9-7325eb22e16f"
      unitRef="usd">-1758000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEwLTMtMS0xLTA_26d84c4c-0079-4d9d-97a6-c71a7196e97b"
      unitRef="usd">-1785000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEwLTUtMS0xLTA_204a7cc7-ff6b-44bc-8965-1f8a6da018e7"
      unitRef="usd">-167000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEyLTEtMS0xLTA_771a3cf4-b608-4863-8511-75a62cd061f0"
      unitRef="usd">3767000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEyLTMtMS0xLTA_650d9887-d6b4-4850-989c-1f73bd4e2484"
      unitRef="usd">-2342000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEyLTUtMS0xLTA_d18ef5bd-7037-49e7-b30e-9cd90dc00d66"
      unitRef="usd">11207000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEzLTEtMS0xLTA_27b5f19a-801e-49db-9501-d91d289282b3"
      unitRef="usd">-4068000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEzLTMtMS0xLTA_34be71c1-25ff-48d6-9f3b-bb586202571b"
      unitRef="usd">2764000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzEzLTUtMS0xLTA_33358e7b-fd9f-420d-9789-2e5326211ec9"
      unitRef="usd">4258000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE0LTEtMS0xLTA_28bc4d1e-eff0-4324-85ff-dc60f760a546"
      unitRef="usd">2876000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE0LTMtMS0xLTA_e9f38e05-0024-4675-bc4f-ae7952753c12"
      unitRef="usd">722000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE0LTUtMS0xLTA_a7789fac-9e14-4f06-870a-8ea144192039"
      unitRef="usd">-70000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE1LTEtMS0xLTA_3640b21a-cf2e-4086-9b77-74577c255cb7"
      unitRef="usd">3759000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE1LTMtMS0xLTA_26b4a066-9f8d-4cd5-a34e-8e0f36371fcf"
      unitRef="usd">3508000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE1LTUtMS0xLTA_a987c7ec-ca7e-46fa-9857-cdaaaf57d9e5"
      unitRef="usd">-618000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <vnda:IncreaseDecreaseProductRevenueAllowances
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE2LTEtMS0xLTA_b7ac9953-80e7-442a-8bd8-37adec7600a7"
      unitRef="usd">3133000</vnda:IncreaseDecreaseProductRevenueAllowances>
    <vnda:IncreaseDecreaseProductRevenueAllowances
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE2LTMtMS0xLTA_23c9e059-f677-4056-bd15-420a2ee275c6"
      unitRef="usd">761000</vnda:IncreaseDecreaseProductRevenueAllowances>
    <vnda:IncreaseDecreaseProductRevenueAllowances
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE2LTUtMS0xLTA_f2bbb580-1491-4f14-99df-4326899f46a5"
      unitRef="usd">8223000</vnda:IncreaseDecreaseProductRevenueAllowances>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE3LTEtMS0xLTA_5fd683dd-dba3-48ef-88df-fdca3cccbe49"
      unitRef="usd">51775000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE3LTMtMS0xLTA_9208a184-a8e2-428d-8612-46a53c4d44e2"
      unitRef="usd">45947000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE3LTUtMS0xLTA_48189378-53a2-46d8-aebd-d27b0eeb3145"
      unitRef="usd">29986000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE5LTEtMS0xLTA_bc62ca33-caca-47fe-97ef-8e2c34852290"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE5LTMtMS0xLTA_789c589c-c7f4-4742-aab5-131146e16bff"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzE5LTUtMS0xLTA_90104aff-97ba-4f2e-b436-d5f87f8dc96e"
      unitRef="usd">25000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIwLTEtMS0xLTA_2bbe56a9-1192-4b64-90e1-81c98c308737"
      unitRef="usd">1795000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIwLTMtMS0xLTA_1f523228-e867-4711-b1c6-a463cdad521f"
      unitRef="usd">1019000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIwLTUtMS0xLTA_31650a4a-369e-44e3-94e1-37a86221fabe"
      unitRef="usd">368000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIxLTEtMS0xLTA_439e25f7-2804-4980-bf29-9fc457058c74"
      unitRef="usd">346622000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIxLTMtMS0xLTA_b035630c-89ab-4f79-b598-d7ad059d98b8"
      unitRef="usd">394517000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIxLTUtMS0xLTA_92dc42a9-1ae8-4b1a-90ed-d3c0969b00ee"
      unitRef="usd">282395000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIyLTEtMS0xLTA_00040dbd-56e3-402c-8a2a-cf299fd5c50e"
      unitRef="usd">306918000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIyLTMtMS0xLTA_fc0f6780-ef5a-4c19-a9b0-49244f7d4ab8"
      unitRef="usd">327227000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIyLTUtMS0xLTA_6f077cbe-f702-45e2-a797-2eec4591d093"
      unitRef="usd">198103000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIzLTEtMS0xLTA_db90ad6b-b777-4c04-a345-d5f7137ece57"
      unitRef="usd">-41499000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIzLTMtMS0xLTA_2006bd02-bff0-42fa-9141-d9fd627b795d"
      unitRef="usd">-68309000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzIzLTUtMS0xLTA_e46ef1b7-18ee-429e-9405-67366891f217"
      unitRef="usd">-109660000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI1LTEtMS0xLTA_f15daeee-6227-44a2-84b4-8eef5500d42d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI1LTMtMS0xLTA_26f50c6a-914b-4db9-8d3e-350f1c3b9222"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI1LTUtMS0xLTA_996f9c09-c14f-4a53-a35d-a74dad077aca"
      unitRef="usd">100870000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI2LTEtMS0xLTA_b933e915-be62-48b3-a866-b89cd425e1b4"
      unitRef="usd">5634000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI2LTMtMS0xLTA_498c5ced-f0ff-4f0b-8010-f95cd547bce0"
      unitRef="usd">6264000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI2LTUtMS0xLTA_d7ddc9aa-0703-4ab7-8b73-b02188468df0"
      unitRef="usd">6256000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI3LTEtMS0xLTA_f589462d-1f4b-4489-a6aa-007431380b0d"
      unitRef="usd">5634000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI3LTMtMS0xLTA_67d2ac52-52b2-4b12-bf45-0533d55a8e3e"
      unitRef="usd">6264000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI3LTUtMS0xLTA_43269751-c267-4580-aec9-76f2986be33d"
      unitRef="usd">107126000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI4LTEtMS0xLTA_0bb5fb1a-fc8b-4b04-8dc3-0dbd30914f1e"
      unitRef="usd">53000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI4LTMtMS0xLTA_51c6782c-38c9-46ed-8d38-11d564059fc8"
      unitRef="usd">-1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI4LTUtMS0xLTA_696937ae-dbc0-43a8-a5bb-a8fe60982085"
      unitRef="usd">-38000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI5LTEtMS0xLTA_d9d013df-5464-4e0a-93f2-a2108c6f48e6"
      unitRef="usd">15963000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI5LTMtMS0xLTA_ea9e3266-561a-4408-9c36-a906b1d4bc5d"
      unitRef="usd">-16099000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzI5LTUtMS0xLTA_43dd6a20-8b0b-4a5e-812a-895a2d015d1e"
      unitRef="usd">27414000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMxLTEtMS0xLTA_b5ecca45-8a0c-47fe-b2f8-c2c103641915"
      unitRef="usd">45650000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMxLTMtMS0xLTA_a67e0da4-91fa-45d2-a602-a5332b46e500"
      unitRef="usd">61749000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i926bf00cb18047ab87ba70c56d7331bb_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMxLTUtMS0xLTA_e79ad148-897e-4739-9442-b6ba0cd9f10f"
      unitRef="usd">34335000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMyLTEtMS0xLTA_599beb7a-72f8-4434-8e8f-7bbd7a1f09fd"
      unitRef="usd">61613000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMyLTMtMS0xLTA_0f1af580-1038-4a54-9f46-3028f474c38b"
      unitRef="usd">45650000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMDYvZnJhZzo1NDliZTI0OWQxMzE0MTM1YjNlYjcwMTAzOGRjY2JhMS90YWJsZTo5MmIwZDJlODZlNWY0NmVjOWM3N2Q2YmEwZmI5YTA4Ny90YWJsZXJhbmdlOjkyYjBkMmU4NmU1ZjQ2ZWM5Yzc3ZDZiYTBmYjlhMDg3XzMyLTUtMS0xLTA_c8f21f79-c9d6-44bf-96e9-ac66ee3bb8b7"
      unitRef="usd">61749000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0Xzk2NA_50939536-59e6-4ee6-885c-c7313ffb5f45">Business Organization and Presentation&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vanda Pharmaceuticals Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s commercial portfolio is currently comprised of two products, HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of schizophrenia. HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is the first treatment for patients with Non-24 and SMS approved by the United States Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (tasimelteon) for the treatment of jet lag disorder, pediatric Non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <vnda:DescriptionOfBusinessPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0Xzk2MQ_81f15a05-a7b2-4427-8519-91cd11189a4e">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vanda Pharmaceuticals Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s commercial portfolio is currently comprised of two products, HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of schizophrenia. HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is the first treatment for patients with Non-24 and SMS approved by the United States Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (tasimelteon) for the treatment of jet lag disorder, pediatric Non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders.&lt;/span&gt;&lt;/div&gt;</vnda:DescriptionOfBusinessPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0XzE3NA_d1c7c320-1794-4425-9a2f-7f16642cdb22"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <vnda:NumberOfProductsInPortfolio
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0XzI1OA_f00968f5-cc36-440b-87c0-d96c80a75660"
      unitRef="product">2</vnda:NumberOfProductsInPortfolio>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTIvZnJhZzpkYjQyNjlmODBiODk0NzM2YjcyNGQ3YWExNzUxYmM0NC90ZXh0cmVnaW9uOmRiNDI2OWY4MGI4OTQ3MzZiNzI0ZDdhYTE3NTFiYzQ0Xzk2Mg_485f223e-e8b3-4651-a3fb-9fabf56fb613">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTg3_b75e0583-373d-4d8d-bfc2-0b29f41fc971">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#x2019;s evaluation could change. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#x2019;s Washington, D.C. headquarters.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current inventory and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its marketable securities as available-for-sale securities. The Company&#x2019;s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders&#x2019; equity in accumulated other comprehensive income. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value. The Company also reviews its available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is the result of a change in creditworthiness or other factors. If declines in the value of available for-sale securities are determined to be credit-related, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the Consolidated Statements of Operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next 12 months. The Company classifies the estimate of such inventory as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as research and development expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the estimated useful life is through July 2035, which is the estimated economic useful life of the related product patents. Intangible assets related Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been fully amortized on a straight-line basis to November 2016. The useful life estimate for Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (ASC) 842,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing office leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For all office leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable and Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management&#x2019;s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i)&#160;an evaluation by the project manager of the work that has been completed during the period, (ii)&#160;measurement of progress prepared internally and/or provided by the third-party service provider, (iii)&#160;analyses of data that justify the progress, and (iv)&#160;management&#x2019;s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company&#x2019;s reported expenses for such period would be too low or too high.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from Net Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product sales consist of sales of HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Net sales by product for the years ended December 31, 2020, 2019 and 2018 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;in&#160;thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available in the United States (U.S.) for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., the Company sells HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in Germany and has a distribution agreement for the commercialization of Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in Israel. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents each major customer that represented more than 10% of total revenues for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent of Net Product Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents each major customer that represented more than 10% of accounts receivable, net, as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent of Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company&#x2019;s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company&#x2019;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.&#160;Reserves for variable consideration are classified as product revenue allowances on the Consolidated Balance Sheets, with the exception of prompt-pay discounts that are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns that are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Prompt-pay:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Rebates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Medicare Part D Coverage Gap:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Medicare Part&#160;D prescription drug benefit requires manufacturers to fund approximately 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model.&#160;Estimates for expected Medicare Part&#160;D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when the Company has validated the insurance benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Service Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Co-payment Assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company&#x2019;s third-party administrator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Product Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company generally offers direct customers a limited right to return as contractually defined with its customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of December 31, 2020 or 2019. The following table summarizes activity for product returns as of and for the years ended December 31, 2020, 2019 and 2018, all of which relates to sales of Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reserve for Product Returns&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold includes royalties payable, the cost of inventory sold, costs to write down inventory to net realizable value, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the Company&#x2019;s distribution partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company&#x2019;s research and development efforts and has no alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award&#x2019;s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were&#160;$12.6 million, $3.2 million and $0.9 million for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reporting currency of the Company is the U.S. dollar. The functional currency of the Company&#x2019;s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transactions denominated in currencies other than subsidiaries&#x2019; functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the Consolidated Balance Sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions. Foreign currency transaction gains and losses are included in other income and were not material for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Certain Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outbreak of the novel coronavirus known as COVID-19 has resulted in government-imposed quarantines, travel restrictions and other public health safety measures. As this pandemic endures, the extent to which COVID-19 may impact the Company's business, financial condition and results of operations is uncertain and will depend on many factors outside of the Company's control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s products under development require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the products will receive the necessary clearance. If the Company is denied clearance or clearance is delayed, it may have a material adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s products are concentrated in rapidly changing, highly competitive markets, which are characterized by rapid technological advances, changes in customer requirements and evolving regulatory requirements and industry standards. Any failure by the Company to anticipate or to respond adequately to technological developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards or any significant delays in the development or introduction of products or services could have a material adverse effect on the Company&#x2019;s business, operating results and future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company depends on single source suppliers for critical raw materials for manufacturing, as well as other components required for the administration of its products. The loss of these suppliers could delay the clinical trials or prevent or delay commercialization of the products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly rated financial institutions. At December 31, 2020, the Company maintained all of its cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in one reporting segment and, accordingly, no segment disclosures are presented herein. Foreign sales were not material for each of the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which clarifies and simplifies certain aspects of the accounting for income taxes.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The standard is effective &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The adoption of this standard on January 1, 2021 is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses, &lt;/span&gt;which changed the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#x201c;expected loss&#x201d; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's consolidated financial results.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTg4_482c6929-815b-4745-92c5-3e63f55763b2">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#x2019;s evaluation could change. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTY5_9077b070-ad4a-4322-9980-a8ab8f8caaaf">Cash, Cash Equivalents and Restricted CashFor purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#x2019;s Washington, D.C. headquarters.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDE0_f01077e0-21b5-4c35-9893-d5b66a8b7817">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current inventory and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzItMS0xLTEtMA_838ef56a-fb39-42ea-80e1-7eae5e4892fb"
      unitRef="usd">61031000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzItMy0xLTEtMA_ca1af1f4-f512-45bf-a44e-0761b59c8702"
      unitRef="usd">45072000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i424e0c1a909c43918460f4dd87afab4a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzQtMS0xLTEtMA_5e4df526-6255-4617-9e9d-10c1fa2fb49c"
      unitRef="usd">57000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i99b78e259ae349ce94d9e93829b687d8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzQtMy0xLTEtMA_79a65fc6-6e62-4f8f-a0d8-c83f0d5b0815"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i5e03ba7540db4ef69e680c9d993fb6a6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzUtMS0xLTEtMA_e144f8d5-545f-4a7d-b05a-fcf8d543e8be"
      unitRef="usd">525000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i8d0645b788e347848286b67c1d3bd108_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzUtMy0xLTEtMA_6a359e17-9ce2-42b9-8442-e57fb7284064"
      unitRef="usd">578000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzYtMS0xLTEtMA_892d55dd-8c4f-45c4-9384-69adaf55dedf"
      unitRef="usd">61613000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTplZDI3ZDU4ZWI4ZTY0M2UxODE3NWEwM2JiNTJkYzYyMy90YWJsZXJhbmdlOmVkMjdkNThlYjhlNjQzZTE4MTc1YTAzYmI1MmRjNjIzXzYtMy0xLTEtMA_b181914f-b0ae-459a-8de1-8be6811e67d9"
      unitRef="usd">45650000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDI2_288a5564-0a02-4045-82b1-2b375fe2fbce">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its marketable securities as available-for-sale securities. The Company&#x2019;s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders&#x2019; equity in accumulated other comprehensive income. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value. The Company also reviews its available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is the result of a change in creditworthiness or other factors. If declines in the value of available for-sale securities are determined to be credit-related, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the Consolidated Statements of Operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTc2_5f0c43d1-1cd6-42a8-bbc1-a80e0919ca46">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next 12 months. The Company classifies the estimate of such inventory as non-current.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDM2_9b6298d6-37cd-4d26-9e36-f2dce79f0953">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as research and development expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the estimated useful life is through July 2035, which is the estimated economic useful life of the related product patents. Intangible assets related Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been fully amortized on a straight-line basis to November 2016. The useful life estimate for Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTg5_c0e3120e-5337-416e-88f3-6329998352bc">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a &lt;/span&gt;&lt;/div&gt;straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTk5_c8cc145b-c731-484a-af82-d3ffaaf1167b">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (ASC) 842,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing office leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For all office leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <vnda:AccountsPayableAndAccruedLiabilitiesPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTgx_322fab2c-f124-4363-89cd-12f237f23351">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable and Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management&#x2019;s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i)&#160;an evaluation by the project manager of the work that has been completed during the period, (ii)&#160;measurement of progress prepared internally and/or provided by the third-party service provider, (iii)&#160;analyses of data that justify the progress, and (iv)&#160;management&#x2019;s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company&#x2019;s reported expenses for such period would be too low or too high.&lt;/span&gt;&lt;/div&gt;</vnda:AccountsPayableAndAccruedLiabilitiesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTc3_b841889d-0bcc-48ce-9f1d-ace359deef97">Revenue from Net Product Sales&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt; (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTgy_b8019955-ef72-4eec-b953-1a4abe3030c2">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product sales consist of sales of HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Net sales by product for the years ended December 31, 2020, 2019 and 2018 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;in&#160;thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzItMS0xLTEtMA_ab6e8757-e24b-40d7-9f21-66d0045d1a62"
      unitRef="usd">160686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6797cc9249a14561aeec1ea22885a66a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzItMy0xLTEtMA_30a41898-d09d-4e4e-bb6b-c839f19278ea"
      unitRef="usd">142980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzItNS0xLTEtMA_78766f79-4450-455a-a5dd-e72182e7997d"
      unitRef="usd">115835000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzMtMS0xLTEtMA_fd87d0e9-cb7d-4fcd-9b7c-1e15f1fb0a50"
      unitRef="usd">87482000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57f83003f7bb4ea681811d4c44d82646_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzMtMy0xLTEtMA_8f1595ce-31fa-46e0-9277-d6a8ff7842d9"
      unitRef="usd">84208000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf54b4365b834d72b6c65f6179255cf7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzMtNS0xLTEtMA_9ed37148-c803-4fa3-bbcc-88779b554497"
      unitRef="usd">77283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzQtMS0xLTEtMA_77019e9c-fff3-4015-a46b-52617543593c"
      unitRef="usd">248168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzQtMy0xLTEtMA_8b967806-2eb5-494a-b8f6-f7d76027abd8"
      unitRef="usd">227188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo5MzBlZGI0NGNkZjI0ZTYxYjhlZGFjNThhZTMyNGE1NC90YWJsZXJhbmdlOjkzMGVkYjQ0Y2RmMjRlNjFiOGVkYWM1OGFlMzI0YTU0XzQtNS0xLTEtMA_dfa822e6-5ed1-43d8-9605-4c4be4d4cb70"
      unitRef="usd">193118000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:MajorCustomersPolicyPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDQ2_6776cd01-cd42-4fcf-aa40-f08d17e6d6b8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available in the United States (U.S.) for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., the Company sells HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in Germany and has a distribution agreement for the commercialization of Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&#160;in Israel. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.</us-gaap:MajorCustomersPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTky_d57543d0-89bb-49e8-a304-26bb16683b04">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents each major customer that represented more than 10% of total revenues for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent of Net Product Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia7d2c26d1a8c4ef7843d0e6970eeee5d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzItMS0xLTEtMA_6b5195ab-eb4d-4f7b-8671-2602c3ed292a"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i23995355e19f4d9ca86f91468591e135_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzItMy0xLTEtMA_610cebdd-cbd5-4234-94d7-6322113f8ed2"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2aa1c343c0de46f5a4a09cdf2ebcc104_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzItNS0xLTEtMA_89d6844b-9a77-4eff-ae04-0b2d45154c88"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2a6f1b4c76e9497aaa45532e1227ad8a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzMtMS0xLTEtMA_ea4390f1-6c8c-4ad1-a2a6-3feca18a7ad2"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i78c8ef22e15348c99b08db2c9df24f2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzMtMy0xLTEtMA_2ac5de78-a334-4003-ae5a-6e42e040985f"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i644a9e8beacf4148bf19d98813c87d7d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzMtNS0xLTEtMA_1463425b-a956-422f-870a-c3349c7d3508"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iea7d114004f648229f473f8282cbda31_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzQtMS0xLTEtMA_1494add8-0d65-4b94-83ec-6afdb4854eb3"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6ee0973839d144cf8989e256f4f67b49_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzQtMy0xLTEtMA_ab74549f-e923-46b3-9910-776d8fca5842"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa0d780548074d448d8fa037c0529ec7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzQtNS0xLTEtMA_7cc61a62-cd6d-4155-920d-7e6fec1559e0"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i79728196d61b4e99b2d02bfd59fa48b9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzUtMS0xLTEtMA_c8c9a4ab-8c81-47b4-9bde-2dcd4bb2a1c3"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i64e8e24272914f67bf876ad95f66ccdd_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzUtMy0xLTEtMA_1494399b-21c2-4c99-9a59-67db0f3110d2"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d06651aaae742ed909bbbb905f9bc60_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzUtNS0xLTEtMA_c32289de-9deb-4f83-a389-1f7a9bc8a0eb"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib5fdfee666e741d38bae37b3799ca556_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzYtMS0xLTEtMA_2aeca7be-940d-4146-af57-2f4f3ada34f4"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifd2ad127c2804ac9a3a22c5e5cd6fd79_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzYtMy0xLTEtMA_e6b41ff9-b9e5-4e93-9571-ea404bd53dae"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i893a60e2f07e4beabea78d9092e5f827_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpjZTRlOWNjYzc0NjY0M2EwYjE4NWZjMjAyZDMwNThmZC90YWJsZXJhbmdlOmNlNGU5Y2NjNzQ2NjQzYTBiMTg1ZmMyMDJkMzA1OGZkXzYtNS0xLTEtMA_201237a4-aa72-4786-abfc-c3e820bd7ed2"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <vnda:ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTkw_eb0d028b-0424-4686-9627-be0c382bda86">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents each major customer that represented more than 10% of accounts receivable, net, as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent of Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vnda:ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icb1cae17f9d144cfbac6ede34e4e28ea_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzItMS0xLTEtMA_c3164450-89e8-4a78-9365-f226ae366aef"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic5fd1a532a29483fbd96f12b34922d1e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzItMy0xLTEtMA_a96d3770-81ab-48ce-b022-dc7fd87dc72b"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icb4fc5098f424b22bcd541acb7773579_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMS0xLTEtNDcyNg_42f4f2ba-3e9f-42f7-830e-8edcc0eee3bb"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7520c5fde90b48c1b3be4f65d3e11085_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMy0xLTEtNDczMA_f53be92b-e252-41ab-9f96-a5a69ce35a0c"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if4aff6df1bae41c89733b2e7a1d327f4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMS0xLTEtMjM5NQ_5e4bf898-123d-4ee8-84dc-c8d42de404b7"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6c607b03683846a192234cafe043197c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMy0xLTEtMjM5NQ_bc54aa06-ffeb-4899-985b-bea09498547a"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5f400e70454f47359d4725431a87a437_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMS0xLTEtMA_2ce2d9e8-a29e-4987-af7f-8592c4077b9e"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ief538f6767dd4ce0b60f4fd839aebbf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzMtMy0xLTEtMA_c31e5115-b4a6-4bbf-afd3-88141d8f1ee8"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i57b2e8bf447542a48106681a8f18fd2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzUtMS0xLTEtMA_0e4e77c8-3407-40e2-b30e-419752c6f258"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icfbcdcb15332468b82f91cdeca7c2d90_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTpmOGU3NjVhMGM5YmU0OWFjODhiOWQyOGRlMzAyZDNhZC90YWJsZXJhbmdlOmY4ZTc2NWEwYzliZTQ5YWM4OGI5ZDI4ZGUzMDJkM2FkXzUtMy0xLTEtMA_c7e48c71-1bc7-4975-a815-304eaf22be13"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <vnda:ReservesForVariableConsiderationPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDMy_95cf26fe-85df-471e-927a-b0165db5bf14">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company&#x2019;s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company&#x2019;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.&#160;Reserves for variable consideration are classified as product revenue allowances on the Consolidated Balance Sheets, with the exception of prompt-pay discounts that are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns that are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Prompt-pay:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Rebates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Medicare Part D Coverage Gap:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Medicare Part&#160;D prescription drug benefit requires manufacturers to fund approximately 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model.&#160;Estimates for expected Medicare Part&#160;D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when the Company has validated the insurance benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Service Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Co-payment Assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company&#x2019;s third-party administrator.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Product Returns&lt;/span&gt;: The Company generally offers direct customers a limited right to return as contractually defined with its customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of December 31, 2020 or 2019.</vnda:ReservesForVariableConsiderationPolicyTextBlock>
    <vnda:PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzEwOTk1MTE2NzE1MTE_78b8099b-1d70-40cd-b96b-8d0841eb0968"
      unitRef="number">0.70</vnda:PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD>
    <vnda:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDIz_507da970-2044-4ae2-a50f-9ed77157a8b8">The following table summarizes activity for product returns as of and for the years ended December 31, 2020, 2019 and 2018, all of which relates to sales of Fanapt&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reserve for Product Returns&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vnda:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ieccc14d91ff74e1695188703bf8f103e_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzEtMS0xLTEtMA_80273d22-482c-4a5c-ae34-a2391fad9dd2"
      unitRef="usd">4119000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i40340870e2a2486992b608dd3ae40740_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzItMS0xLTEtMA_1d5d3a55-3770-416d-a99d-9defe017ff72"
      unitRef="usd">2684000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i40340870e2a2486992b608dd3ae40740_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzMtMS0xLTEtMA_ff83d382-5269-4ce1-b574-646762d8ddab"
      unitRef="usd">1616000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i21fd1609a04e49b0bb22ec6b8e33dadc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzQtMS0xLTEtMA_21b4f4bd-e21a-42a3-94a4-91fd66d768e8"
      unitRef="usd">5187000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ib01d7291558c49ab8183941f323312e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzUtMS0xLTEtMA_eff16f8d-1d0d-450c-b724-8ec3af6bb85c"
      unitRef="usd">3138000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib01d7291558c49ab8183941f323312e1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzYtMS0xLTEtMA_a8315bce-af39-4bbe-bbeb-130f3c4da950"
      unitRef="usd">2205000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i89fc42978e1140569719239aff32634c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzctMS0xLTEtMA_68c54c52-b39e-467c-ae05-08fd17e8890b"
      unitRef="usd">6120000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="id7f4a59b89dd4fc5b2a51c78dbf422c6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzgtMS0xLTEtMA_555d8a3e-9393-402e-b683-1a21e8b70790"
      unitRef="usd">3844000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="id7f4a59b89dd4fc5b2a51c78dbf422c6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzktMS0xLTEtMA_44a53bbf-d548-427b-bd1c-c7ce4569c026"
      unitRef="usd">5266000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia69b9f546af14feab861a844ee2190df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90YWJsZTo2NTE0MjE1ZGFkMGI0N2UyOTczOWQxZTFhYzA1NzNlMi90YWJsZXJhbmdlOjY1MTQyMTVkYWQwYjQ3ZTI5NzM5ZDFlMWFjMDU3M2UyXzEwLTEtMS0xLTA_d4ffb9b2-1e9e-4d53-83fb-f5e9edf9f8ef"
      unitRef="usd">4698000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDQy_818e2112-d40d-42cc-91c8-3d025cffe487">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold includes royalties payable, the cost of inventory sold, costs to write down inventory to net realizable value, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the Company&#x2019;s distribution partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDAy_b0908275-9cd3-4a07-93f0-54a1f41f70f8">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are &lt;/span&gt;&lt;/div&gt;capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company&#x2019;s research and development efforts and has no alternative future use.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDI5_d524dbe4-092d-45f2-a31a-915e07a5fce1">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTY3_982e98ef-b8a1-41a3-bf66-dbd405ea339e">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award&#x2019;s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTkz_a0794345-25fd-4881-980f-66c1adb962f8">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were&#160;$12.6 million, $3.2 million and $0.9 million for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzE5ODQ0_bbfb5eb6-173e-4962-8667-4c9e773e63dd"
      unitRef="usd">12600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzE5ODQ4_254269bf-f9d3-4e60-afff-b6567a014b03"
      unitRef="usd">3200000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzE5ODU1_0da47ddb-24e3-43c4-bde7-20e292275363"
      unitRef="usd">900000</us-gaap:AdvertisingExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI4OTY4_7a2c9eb8-4289-4a40-bc14-5312ad88586a">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reporting currency of the Company is the U.S. dollar. The functional currency of the Company&#x2019;s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;Transactions denominated in currencies other than subsidiaries&#x2019; functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the Consolidated Balance Sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDUw_ad6a0462-5c4a-418d-9bf0-50c3aafc57ce">Income TaxesThe Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI0MTU5_0a74c4d3-5827-426d-90d9-dd350fbbb3df"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTUvZnJhZzo4OWRjNzU0YmMwOGI0NjM1OThhZDMyMGViZWNhMTEyNi90ZXh0cmVnaW9uOjg5ZGM3NTRiYzA4YjQ2MzU5OGFkMzIwZWJlY2ExMTI2XzI5MDQx_d831c47c-c3ff-44a9-9e27-fbc3cca74305">&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which clarifies and simplifies certain aspects of the accounting for income taxes.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The standard is effective &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The adoption of this standard on January 1, 2021 is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses, &lt;/span&gt;which changed the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#x201c;expected loss&#x201d; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's consolidated financial results.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90ZXh0cmVnaW9uOmZiOTRlM2I4ZTRkOTQzZGY5ZDZhMjcxOTU5MWJhYzJiXzMzOA_cd6224eb-cd14-4b4a-95b2-8a75fd2b1929">Marketable SecuritiesThe following is a summary of the Company&#x2019;s available-for-sale marketable securities as of December 31, 2020, which all have contractual maturities of less than two years:&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of December 31, 2019, which all have contractual maturities of less than two years:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90ZXh0cmVnaW9uOmZiOTRlM2I4ZTRkOTQzZGY5ZDZhMjcxOTU5MWJhYzJiXzM0MA_8fc36d5f-7628-42ac-9872-608723c3cd6a">The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of December 31, 2020, which all have contractual maturities of less than two years:&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of December 31, 2019, which all have contractual maturities of less than two years:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzEtMS0xLTEtMA_80f28556-7044-492a-837b-0faf9f9d82ce"
      unitRef="usd">165966000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzEtMy0xLTEtMA_b1e5a636-1538-462c-9bcb-c94fe1fed404"
      unitRef="usd">129000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzEtNS0xLTEtMA_ec7ef38a-9585-408c-9700-722844266adc"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzEtNy0xLTEtMA_975ec8e8-c331-4277-b7c5-dce64e884eed"
      unitRef="usd">166092000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0bd2be23072740898c45df963bd01f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzItMS0xLTEtMA_db36133d-a0e4-4d34-ae3c-da2c6ccfaca3"
      unitRef="usd">140538000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0bd2be23072740898c45df963bd01f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzItMy0xLTEtMA_73d1a9d8-7505-45f0-9a7c-2eb52cd56c04"
      unitRef="usd">87000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0bd2be23072740898c45df963bd01f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzItNS0xLTEtMA_273eb9d4-4814-42e5-b951-351edd806747"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0bd2be23072740898c45df963bd01f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzItNy0xLTEtMA_89fbf157-b08f-4b97-9934-d3f61b9a6866"
      unitRef="usd">140617000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzQtMS0xLTEtMA_83cd50ab-0a63-4eaf-a892-817480928b10"
      unitRef="usd">306504000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzQtMy0xLTEtMA_6167e8a7-11cb-4a30-887b-d558d67694ca"
      unitRef="usd">216000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzQtNS0xLTEtMA_0963adf1-0d4c-49a7-ac5e-ece76312a93a"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTozNjFjYWM3NjBlZjk0ODVmYTExMzViYjc5M2IxNzUzMC90YWJsZXJhbmdlOjM2MWNhYzc2MGVmOTQ4NWZhMTEzNWJiNzkzYjE3NTMwXzQtNy0xLTEtMA_b628fb22-918c-4026-ad75-76fd8d956e67"
      unitRef="usd">306709000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzEtMS0xLTEtMA_ac616518-076b-492f-9745-ea2be551c1e1"
      unitRef="usd">88535000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzEtMy0xLTEtMA_be7b7383-f28f-4482-8c05-a6277a3d1d63"
      unitRef="usd">68000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzEtNS0xLTEtMA_dfe72d89-d474-4d0c-aa1b-6729083206bf"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzEtNy0xLTEtMA_3ae2a900-d4e9-40d4-8feb-80a353ae3bbc"
      unitRef="usd">88601000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzItMS0xLTEtMA_45af69ae-0fa2-4e5c-a0d4-d068cc364881"
      unitRef="usd">129860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzItMy0xLTEtMA_3881528f-fa23-4c44-97fe-436e19a5eeda"
      unitRef="usd">196000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzItNS0xLTEtMA_5fbc4aa3-a732-4f47-b14c-3aece7f8a7a2"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzItNy0xLTEtMA_09fecce9-cc52-48a9-85f9-b5e78170783a"
      unitRef="usd">130055000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzMtMS0xLTEtMA_6edc2931-c061-4b63-8314-b926af7a8966"
      unitRef="usd">48355000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzMtMy0xLTEtMA_80c334a1-1d4d-4b8c-af62-8cfa6e671853"
      unitRef="usd">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzMtNS0xLTEtMA_b1445103-e1b6-443f-ad91-3b40105923d7"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzMtNy0xLTEtMA_11594154-26ce-4e7f-b279-d4d8f03137fd"
      unitRef="usd">48401000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzQtMS0xLTEtMA_c1bf2fa3-4371-412d-8566-6fd80b265fc3"
      unitRef="usd">266750000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzQtMy0xLTEtMA_1f0747e6-abd8-446d-8b46-4e4c07dbb551"
      unitRef="usd">313000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzQtNS0xLTEtMA_15b9340a-68ef-4820-a42d-69f1415ec468"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMTgvZnJhZzpmYjk0ZTNiOGU0ZDk0M2RmOWQ2YTI3MTk1OTFiYWMyYi90YWJsZTowOWVlYTVjYjlkMGQ0YzAwYjAxZTA5ZmViMzk1ZGM2NC90YWJsZXJhbmdlOjA5ZWVhNWNiOWQwZDRjMDBiMDFlMDlmZWIzOTVkYzY0XzQtNy0xLTEtMA_50397430-3768-449e-bdce-f57817208470"
      unitRef="usd">267057000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90ZXh0cmVnaW9uOmY0OGQ1YTdhZTZiNzQ2ZTc4MTFjOGI3ZGE0ZTBmZDRmXzE5Nzk_76975e46-bb6d-4721-93df-2adf0e155b5b">Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2014; defined as observable inputs such as quoted prices in active markets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2014; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2014; defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's assets classified in Level&#160;1 and Level&#160;2 as of December 31, 2020 and 2019 consist of cash equivalents and available-for-sale marketable securities. The valuation of Level&#160;1 instruments is determined using a market approach and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of Level&#160;2 instruments is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level&#160;2 securities include certificates of deposit, commercial paper, corporate notes and asset-backed securities that use as their basis readily observable market parameters. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2020, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement as of December 31, 2020 Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&#160;for&lt;br/&gt;Identical&#160;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2019, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement as of December 31, 2019 Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&#160;for&lt;br/&gt;Identical&#160;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value as of December 31, 2020 include no cash equivalents. Total assets measured at fair value as of December 31, 2019 include $7.0 million of cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances, and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90ZXh0cmVnaW9uOmY0OGQ1YTdhZTZiNzQ2ZTc4MTFjOGI3ZGE0ZTBmZDRmXzE5ODI_16e5ea35-c086-4563-84c9-f46d09b23b4f">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2020, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement as of December 31, 2020 Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&#160;for&lt;br/&gt;Identical&#160;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2019, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement as of December 31, 2019 Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&#160;for&lt;br/&gt;Identical&#160;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i526157fae9164658829ef8c67feeb4e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzItMS0xLTEtMA_378000ac-93c6-4da8-9867-c845716a332d"
      unitRef="usd">166092000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i83bee279dbf04510bbc505415f41b886_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzItMy0xLTEtMA_59ed92a6-0e1c-4e50-8d37-2b9c0d550565"
      unitRef="usd">166092000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1cee81eae3834f8a91784e60ea88cdd9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzItNS0xLTEtMA_3324c392-78a6-469d-9a58-bd1fa4a8eae2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic1931a9cde2641aead7a75d77a370fb5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzItNy0xLTEtMA_02c8ab30-f2ce-46cf-b862-bc450c1057c8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0bd2be23072740898c45df963bd01f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzMtMS0xLTEtMA_cacfb031-0be2-44ec-ad9c-fab207f69da9"
      unitRef="usd">140617000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iedd654c3e3074ac5beb9219888a8397d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzMtMy0xLTEtMA_47c519d0-3ee4-431c-a5a7-609dfa19e339"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaaf5512406d242b3b334cdf95473932e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzMtNS0xLTEtMA_35d0537d-eb44-4592-b1c9-1226336bacfc"
      unitRef="usd">140617000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icfd2b9acca2e4a7e89256bcac7794b71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzMtNy0xLTEtMA_8d7c9d7b-6bb2-4c86-bd22-da45cf3e2322"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzUtMS0xLTEtMA_2cf2b227-ac51-4c9d-87ed-798a6a81a44e"
      unitRef="usd">306709000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i590279da68dd44789a39b09a2a7b4e5c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzUtMy0xLTEtMA_08afd42f-ed5d-4e24-a391-b91d1c7763ba"
      unitRef="usd">166092000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0aff0dba35f64b73909e86bb8cbb00e0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzUtNS0xLTEtMA_314ffbd7-ffd4-48d7-a540-ea35f729a21d"
      unitRef="usd">140617000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia4fa1365e34d44fc9764447fd2ec2e24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyY2I1ZGYzMjMxOTY0MmZkOTlmODZjN2EzYTBiYWVhOC90YWJsZXJhbmdlOjJjYjVkZjMyMzE5NjQyZmQ5OWY4NmM3YTNhMGJhZWE4XzUtNy0xLTEtMA_955d0bae-c14c-4540-91c1-3963b34bc302"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5f20c258cb11480789b0ddc9a38ebb80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzItMS0xLTEtMA_5a2a504b-8d31-401d-b3bb-84ea92a4b82e"
      unitRef="usd">88601000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia1521ac6ce4c4e3faa831a373c4b2943_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzItMy0xLTEtMA_fd928cb0-0118-48ed-abdd-1b58a5455e1a"
      unitRef="usd">88601000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i39e789b5b4e8447591662fec5bda3261_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzItNS0xLTEtMA_3f0c5b40-def8-4484-a5f4-46311cbd83a0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id26713507297483babfde81db7b9fa28_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzItNy0xLTEtMA_2b2143b9-4e6c-41da-822c-bdc545280975"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i95233a42c2d2400c9e832af0546a849c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzMtMS0xLTEtMA_66816511-e398-4042-997f-d14e2dc9074d"
      unitRef="usd">137025000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia84837f39b7f470cb64a3244ed1fc84c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzMtMy0xLTEtMA_d1c94cc9-da21-4f28-86a5-0629076b27b2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib3b552a7bd9b47038ad2a7e5c99411fa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzMtNS0xLTEtMA_8f17fa6e-c91b-4e4d-8705-a36afdb85a68"
      unitRef="usd">137025000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c688c60d8564383bf26445621f9ca74_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzMtNy0xLTEtMA_9b21b0dc-8dd6-48ad-a074-90ba55bc52d7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c16c9f16e3a4d18b24a1abddffccf95_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzQtMS0xLTEtMA_501ab422-69b5-41f8-8d82-1a57a30d93ee"
      unitRef="usd">48401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifd3faacc11ff44169093da58889d764b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzQtMy0xLTEtMA_c1b5b706-26a5-42b6-bd4b-4e90531090cd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4362e7304366445d990ded2bb3505b1b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzQtNS0xLTEtMA_404ff35a-8294-4ff3-9351-fd57b9d676ed"
      unitRef="usd">48401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i792f4aa473234968ae82e33224c68d6c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzQtNy0xLTEtMA_a716c86d-9d41-4c33-8f5d-d5ff78526122"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzUtMS0xLTEtMA_3d5c3ab3-507c-4807-8eb0-68c0358694b6"
      unitRef="usd">274027000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0242a482bf8f427e89cb520b935b8dec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzUtMy0xLTEtMA_3913f415-fff7-49e5-b552-cfec90c285da"
      unitRef="usd">88601000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i572e6e7f0ee349d2b27aafb167ab28ed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzUtNS0xLTEtMA_d506a304-10a3-439a-b9f1-0130a416424b"
      unitRef="usd">185426000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iad2ca748413447168432f3afa16e0405_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90YWJsZToyZDcxMmY4ZDI1YjI0NWE2OGZlZDJjMmUyODkxMzAyMS90YWJsZXJhbmdlOjJkNzEyZjhkMjViMjQ1YTY4ZmVkMmMyZTI4OTEzMDIxXzUtNy0xLTEtMA_8095db2f-132e-44b5-83ac-1e4f4eab4d91"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7112e733b494f1a982cc5aac77faeae_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90ZXh0cmVnaW9uOmY0OGQ1YTdhZTZiNzQ2ZTc4MTFjOGI3ZGE0ZTBmZDRmXzY1OTcwNjk3NjkzODA_7b1a1be1-3d6d-462d-bbf5-6d1fcbd4a419"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i27df4ba463ab4d5b86c334633ea1634e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjEvZnJhZzpmNDhkNWE3YWU2Yjc0NmU3ODExYzhiN2RhNGUwZmQ0Zi90ZXh0cmVnaW9uOmY0OGQ1YTdhZTZiNzQ2ZTc4MTFjOGI3ZGE0ZTBmZDRmXzEwOTk1MTE2MzAxNDc_a9647cc5-c535-4a1f-9dbf-87a39bc51646"
      unitRef="usd">7000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90ZXh0cmVnaW9uOjA1Yjk5NzQ5NGFjNzQxMTc5ZDA0ODI2ZGY1MDQwZjMzXzY0NQ_b0a0ee9c-d0f0-48e3-9f46-c29bd7c42951">Inventory&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <vnda:ScheduleOfInventoriesTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90ZXh0cmVnaW9uOjA1Yjk5NzQ5NGFjNzQxMTc5ZDA0ODI2ZGY1MDQwZjMzXzY0Mg_8caaea7c-9ed3-42b9-9d43-1b55562544d4">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vnda:ScheduleOfInventoriesTableTextBlock>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzItMS0xLTEtMA_1afed492-313c-435b-8ec7-79028401dca6"
      unitRef="usd">66000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzItMy0xLTEtMA_5f2ba9cf-12bc-4c7f-8295-857efbda46af"
      unitRef="usd">0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzMtMS0xLTEtMA_5edc9c26-b548-413f-b654-609d68e6d6cb"
      unitRef="usd">1214000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzMtMy0xLTEtMA_3334da2a-a089-41df-91bf-077f463123db"
      unitRef="usd">1140000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzQtMS0xLTEtMA_052f1ab8-1ab8-445c-b8f8-7d527376d07c"
      unitRef="usd">1280000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzQtMy0xLTEtMA_aaecb227-7819-441b-a6b5-6473ca9bdadd"
      unitRef="usd">1140000</us-gaap:InventoryNet>
    <vnda:InventoryRawMaterialsNetOfReservesNonCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzYtMS0xLTEtMA_59f35877-0565-4b30-becb-80cd2e8bdc8f"
      unitRef="usd">744000</vnda:InventoryRawMaterialsNetOfReservesNonCurrent>
    <vnda:InventoryRawMaterialsNetOfReservesNonCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzYtMy0xLTEtMA_b34e7e01-d272-4d1c-bf90-d4aea680c515"
      unitRef="usd">659000</vnda:InventoryRawMaterialsNetOfReservesNonCurrent>
    <vnda:InventoryWorkInProcessNetOfReservesNonCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzctMS0xLTEtMA_51d66da1-5944-46e2-b64d-d32ba7e975e6"
      unitRef="usd">4045000</vnda:InventoryWorkInProcessNetOfReservesNonCurrent>
    <vnda:InventoryWorkInProcessNetOfReservesNonCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzctMy0xLTEtMA_d7a93963-4382-49bf-824e-a5c63f22bdb7"
      unitRef="usd">1109000</vnda:InventoryWorkInProcessNetOfReservesNonCurrent>
    <vnda:InventoryFinishedGoodsNetOfReservesNonCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzgtMS0xLTEtMA_63ffdb95-0ed2-4ad7-a311-0e91445ebbe3"
      unitRef="usd">302000</vnda:InventoryFinishedGoodsNetOfReservesNonCurrent>
    <vnda:InventoryFinishedGoodsNetOfReservesNonCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzgtMy0xLTEtMA_298e776c-c666-4098-8737-7cf6a03e8091"
      unitRef="usd">1056000</vnda:InventoryFinishedGoodsNetOfReservesNonCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzktMS0xLTEtMA_885f69bb-2d3a-4040-9071-e46ea76fb808"
      unitRef="usd">5091000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzktMy0xLTEtMA_fea94ccc-3c57-4b90-8397-c1bdb46d4c3f"
      unitRef="usd">2824000</us-gaap:InventoryNoncurrent>
    <vnda:Inventory
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzEwLTEtMS0xLTUwOQ_37b05e5f-56b7-4e02-bd56-4efafa1b0bcc"
      unitRef="usd">6371000</vnda:Inventory>
    <vnda:Inventory
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjQvZnJhZzowNWI5OTc0OTRhYzc0MTE3OWQwNDgyNmRmNTA0MGYzMy90YWJsZTpkNTNmYmEzMDA1MmI0YmNhYWY1ZjliMTE0OTEyZDQwMC90YWJsZXJhbmdlOmQ1M2ZiYTMwMDUyYjRiY2FhZjVmOWIxMTQ5MTJkNDAwXzEwLTMtMS0xLTUxMQ_5ee5347a-bcee-455c-a966-08b87a827b0e"
      unitRef="usd">3964000</vnda:Inventory>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzIyMA_5a8d9ca4-329d-474f-9c5c-788a3d2e18c3">Property and Equipment&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s property and equipment, at cost, as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful&#160;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $1.4 million for each of the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzIxNg_1507e6cf-437f-47ba-bcd2-24f09b51d026">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s property and equipment, at cost, as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful&#160;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iba732339a56e4213b11aa8a21ae766e1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzEtMS0xLTEtMA_1aecca5e-7478-44a2-8427-8408e013742d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibf7b6f3b209b460b89808f786605b838_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzEtMy0xLTEtMA_554f059e-cf92-4878-8d3a-7f86c62e5ea9"
      unitRef="usd">5212000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3b8918e05b554009ab234e53619bc90e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzEtNS0xLTEtMA_72b5243d-e29d-4fc8-9677-f8cb3ea4383f"
      unitRef="usd">4398000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8b1c97ddaaee4131822793e4b11a1fc3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzItMS0xLTEtMC90ZXh0cmVnaW9uOmIzMDg2Mzc5NzdkMzQxOTBhNzljNTEyZWY0ODk4MTIwXzQ_7e23e5e7-6d82-49c1-b287-64b8a0c902e7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3b9c76d935aa454e9830545d747a662d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzItMS0xLTEtMC90ZXh0cmVnaW9uOmIzMDg2Mzc5NzdkMzQxOTBhNzljNTEyZWY0ODk4MTIwXzk_0756e23f-7822-4c54-b5eb-ce1406d3ebcb">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i26247ebfe7eb4525a836402ffc21ca64_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzItMy0xLTEtMA_564957b7-bf30-47b8-be67-2df04d31d5a0"
      unitRef="usd">1495000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia34b88e9659246eea1386afd588f2793_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzItNS0xLTEtMA_99e53394-100f-40a7-bec0-63b552e3895b"
      unitRef="usd">1491000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0b9bd57d44144fa28e3d7c0a1cc6d107_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjZhMWUwMTlkM2NkNjRhZWE4N2VhZDMxMTUxOWYwZjEwXzQ_8385c956-7586-4930-9c0f-45c9480540d2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1e6096930e004a5cb3b64a1d96cd3a18_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjZhMWUwMTlkM2NkNjRhZWE4N2VhZDMxMTUxOWYwZjEwXzk_63da4bea-cbf1-4ee8-984e-9b05cdd1a699">P11Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2a58cc236b3a4b2aa61a7e28fe9c07da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzMtMy0xLTEtMA_456a8333-c2dd-41f9-b08d-e21f3eb12b03"
      unitRef="usd">5457000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i686659adf6bc48a2a6282c2af72dab52_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzMtNS0xLTEtMA_ba0f6ce5-b649-4d38-9af6-b1c6dc5f8cd8"
      unitRef="usd">4587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzQtMy0xLTEtMA_b480cc8a-de98-4df3-b8c3-bd33f6fc4eb0"
      unitRef="usd">12164000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzQtNS0xLTEtMA_6628c9a0-8e45-437a-9dd6-ef553ae57694"
      unitRef="usd">10476000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzUtMy0xLTEtMA_6ab8a104-5403-48a1-a5eb-4ff8af2301f3"
      unitRef="usd">8028000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzUtNS0xLTEtMA_561964b5-6ca1-4af2-a189-19bf47a37cb6"
      unitRef="usd">6612000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzYtMy0xLTEtMA_d357ac4b-a47a-47b0-b41d-35d75a9ed441"
      unitRef="usd">4136000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90YWJsZTpiNmI5MDdjYWUxOTk0ZjUwOGU1ZWQzNzE3MDc3OGZlOS90YWJsZXJhbmdlOmI2YjkwN2NhZTE5OTRmNTA4ZTVlZDM3MTcwNzc4ZmU5XzYtNS0xLTEtMA_3fcd8835-c413-475f-a46d-6b543bca9aed"
      unitRef="usd">3864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzE1Mg_697afb6a-dabc-469a-ad21-52c67e141961"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzE1Mg_9488321c-87e6-4694-802a-cd5aeb90e12c"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMjcvZnJhZzo1ZjYzYTMxMWMzZDk0N2Y1OGQxOGFmZjcyOGQ2YWE5Zi90ZXh0cmVnaW9uOjVmNjNhMzExYzNkOTQ3ZjU4ZDE4YWZmNzI4ZDZhYTlmXzE1Mg_fd4d3c98-561f-4a6c-b23b-5686d8f77a42"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzMyMzI_e523838a-6980-4ee1-87ba-38f83829d8f4">Leases&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's long-term leases primarily include operating leases and subleases for office space in Washington, D.C. and London, England. The Company recognized ROU assets and lease liabilities related to fixed payments for these long-term operating leases in its Consolidated Balance Sheet as of December 31, 2020 and 2019. The Company also has short-term leases, including office space in Berlin, Germany.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2011, the Company entered into an operating lease agreement under which it leases 33,534 square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. Subject to the prior rights of other tenants, the Company has the right to renew the lease for five years following its expiration in July 2028. As of December 31, 2020, the renewal period has not been included in the lease term. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions. The lease may be terminated early by the Company or the landlord under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into a sublease agreement under which it subleases an additional 9,928 square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. The sublease term began in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January&#160;2017 and ends in July&#160;2026 but may be terminated earlier by either party under certain circumstances. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, the Company entered into an operating lease agreement under which it leases 2,880 square feet of office space in London, England. In November 2020, the Company extended the non-cancellable portion of the lease term from 2021 to 2023 and has the option to renew the lease for an additional three years following its expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s ROU assets and operating lease liabilities as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the years ended December 31, 2020 and 2019, the Company recognized operating lease cost of $2.3 million and short-term operating lease cost of $0.4 million. The Company also recognized $1.5 million and $1.4 million, respectively, of expense related to non-lease elements, such as building maintenance services and utilities, and executory costs associated with the operating leases. For existing leases as of January 1, 2019, executory costs are excluded from operating lease expense, which is consistent with the Company's accounting under ASC 840. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices. For the year ended December 31, 2018, the Company recognized $3.6 million of rent expense, inclusive of lease expense, non-lease elements, and executory costs for short and long-term operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities is included in operating cash flows and was $2.6 million and $2.5 million for the years ended December 31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current obligations under leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ice34ccdece6648b48a6896c3974844b0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzQ4OQ_16491732-d181-4668-86d5-a95c8434d528"
      unitRef="sqft">33534</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ice34ccdece6648b48a6896c3974844b0_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzY5MA_45a2a569-b765-42f3-8e8d-b5712d6a1be0">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i98d5263305ac4d87882e5502fb408e09_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzExMDk_227e81f9-322d-41ae-913e-eb47e446b2f2"
      unitRef="sqft">9928</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ib295f3c8735849ada24ac840f8aa6e79_I20201231"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzE1NTY_aab8cca9-be3e-49ca-9086-a2531c89b3c4"
      unitRef="sqft">2880</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ib295f3c8735849ada24ac840f8aa6e79_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzE2NTY_ef96d2c6-192f-423a-99d6-793766a8483e">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzMyMzM_6bf2b453-5bbc-451e-850c-5b5b6a302e7d">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s ROU assets and operating lease liabilities as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.&lt;/span&gt;&lt;/div&gt;</vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzItNC0xLTEtMTg0_371a8b36-a0db-424d-ba8c-8935330ef3d4"
      unitRef="usd">10459000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzItNC0xLTEtMA_7e8757ce-90af-413d-a3bd-99c01460ae89"
      unitRef="usd">11180000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzUtNC0xLTEtMTg0_eec139cf-8ca2-4e08-ae9f-6c4096012cae"
      unitRef="usd">2117000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzUtNC0xLTEtMA_eab89f54-d832-4e47-99e4-aa7c90dec123"
      unitRef="usd">2147000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzYtNC0xLTEtMTg0_fa0528c9-7459-481e-adb2-32ccce4a22fe"
      unitRef="usd">11497000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzYtNC0xLTEtMA_e702fa52-89c5-4ecc-89dc-b0bfd2f6eba9"
      unitRef="usd">12455000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzctNC0xLTEtMTg0_ccdc4cd4-7f62-4386-a10a-bd565995cac2"
      unitRef="usd">13614000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzctNC0xLTEtMA_7918dac6-7bb2-4d87-8177-a282ee3bc30d"
      unitRef="usd">14602000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzktNC0xLTEtMTg0_6189cdbd-ae35-40ef-9610-9a6a22e37b96">P7Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzktNC0xLTEtMA_5730478e-f4e8-4ab0-86e9-daece8c67698">P8Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzEwLTQtMS0xLTE4NA_2fab0def-fde0-4b66-ac32-25f98956adca"
      unitRef="number">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTplMDUzZTc1ZjczYmY0NTIwYmVlM2I3Mzk1MGFjZWYwMy90YWJsZXJhbmdlOmUwNTNlNzVmNzNiZjQ1MjBiZWUzYjczOTUwYWNlZjAzXzEwLTQtMS0xLTA_062a6144-6b9f-4a28-ad4d-5b558d84030f"
      unitRef="number">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIwNTY_012a3b36-ec4a-417e-a9f8-2f8509195d3b"
      unitRef="usd">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIwNTY_a91ac197-80d2-4d12-8b83-a1f746cdbe30"
      unitRef="usd">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIwOTg_13d6836b-e8ff-43d0-8a94-4b77c84a3493"
      unitRef="usd">400000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIwOTg_735312ef-b3c6-4b87-93ec-8f5f52077046"
      unitRef="usd">400000</us-gaap:ShortTermLeaseCost>
    <vnda:OperatingLeaseNonLeaseComponentExpense
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzIxMzA_59cfc69d-385b-4425-84b2-6385f9b26c0f"
      unitRef="usd">1500000</vnda:OperatingLeaseNonLeaseComponentExpense>
    <vnda:OperatingLeaseNonLeaseComponentExpense
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzEwOTk1MTE2MzExNjM_10e900f1-1634-4098-aa83-1d8c671a3963"
      unitRef="usd">1400000</vnda:OperatingLeaseNonLeaseComponentExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzI2NzE_de21d912-5bb5-47f5-8d0c-4c236ec39555"
      unitRef="usd">3600000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzI5NDg_6da415d6-1f27-4053-a85b-47828564c496"
      unitRef="usd">2600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzEwOTk1MTE2MzExOTk_e71910d2-27ba-4547-a90e-0a090006541b"
      unitRef="usd">2500000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90ZXh0cmVnaW9uOmM5ZTNmNzBmYzc2NDQyODRiNTg5ZjEyOTcyM2Y0NGJmXzMyMzA_45fdd03d-26ba-461e-acf2-e89e1b15b8cf">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current obligations under leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzItMi0xLTEtMA_cf145d20-88f6-4acb-a7e9-deab2abc149b"
      unitRef="usd">2290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzMtMi0xLTEtMA_7597e8c8-1989-43fd-a108-3c77c22a7a6e"
      unitRef="usd">2611000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzQtMi0xLTEtMA_4ba6af70-eee7-4c73-99d9-f1588beeec47"
      unitRef="usd">2462000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzUtMi0xLTEtMA_e8850b8b-63c2-4bf8-8b9e-9517083fdd51"
      unitRef="usd">2488000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzYtMi0xLTEtMA_52b4bcfe-b904-477a-a4a8-d0e8f1d5249d"
      unitRef="usd">2557000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzctMi0xLTEtMA_cb5e9bc9-1e1d-4939-87f5-4e8643e86ab3"
      unitRef="usd">5624000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzgtMi0xLTEtMA_eccd9845-e77a-49ce-81f5-a95306a4ef7f"
      unitRef="usd">18032000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzktMi0xLTEtMA_87875e11-ce44-4442-8811-8ea8f79937da"
      unitRef="usd">4418000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzEwLTItMS0xLTA_f49769fb-9ee8-497f-8145-f739d1ae3314"
      unitRef="usd">13614000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzExLTItMS0xLTA_e44b8345-776e-4e3f-9394-c0f8c224da89"
      unitRef="usd">2117000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzMvZnJhZzpjOWUzZjcwZmM3NjQ0Mjg0YjU4OWYxMjk3MjNmNDRiZi90YWJsZTo5YmFkZTQ4NjdmNGU0NDY2YWU5Y2VlZTQxZGE1N2M5ZC90YWJsZXJhbmdlOjliYWRlNDg2N2Y0ZTQ0NjZhZTljZWVlNDFkYTU3YzlkXzEyLTItMS0xLTA_1b145223-6845-40be-b9de-261177a8dd27"
      unitRef="usd">11497000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzIwOTA_14921203-d109-43f3-a4a4-5002ece0d417">Intangible Assets&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of $8.0 million to BMS. The $8.0 million is being amortized on a straight-line basis over the estimated economic useful life of the related product patents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company met its final milestone under its license agreement with BMS when cumulative worldwide sales of HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;reached $250.0 million. As a result of the achievement of this milestone, the Company made a payment to BMS of $25.0 million in 2018. The $25.0&#160;million, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated economic useful life of both the $8.0 million and the $25.0 million intangible assets were changed from February 2035 to July 2035 based on the July 2035 expiration date of U.S. patent number 10,376,487&#160;(&#x2018;487 Patent) issued by the U.S. Patent and Trademark Office in August 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s intangible assets as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s intangible assets as of December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 and 2019, the Company also had $27.9 million of fully amortized intangible assets related to Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense for the years ended December 31, 2020, 2019 and 2018 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the future intangible asset amortization schedule as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ia30bb33a28694ca0b45ea8f0d52a84cc_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzMxOQ_96515887-6230-48c3-acd8-4c73f8e6f431"
      unitRef="usd">8000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ia30bb33a28694ca0b45ea8f0d52a84cc_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzMzNA_96c82b45-b548-44aa-a99a-83437f1c348f"
      unitRef="usd">8000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <vnda:CumulativeNetSalesToAchieveMilestone
      contextRef="if6745c8d49094756a3fd1e677133183b_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzYyMA_48c36b46-6a1d-48a4-83d5-d4adf7802850"
      unitRef="usd">250000000.0</vnda:CumulativeNetSalesToAchieveMilestone>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzcxMQ_b8d2b77d-9c44-47ac-9ea5-919ad874b03f"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="ib4a98ad86cb947b6b61d3738c4361015_D20150101-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzM4NDgyOTA2OTk2MDU_91604661-2b52-4a97-b498-f54418dd5983"
      unitRef="usd">25000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ia30bb33a28694ca0b45ea8f0d52a84cc_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzExMDg_96515887-6230-48c3-acd8-4c73f8e6f431"
      unitRef="usd">8000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzExMTk_5f4ed619-8942-48d6-8ad3-32eff6118d82"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzIwOTI_88dae927-51a2-4cf5-a681-5bfb1761dbde">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s intangible assets as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s intangible assets as of December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo5OWQwYmM5ZTU4MWQ0ZjJhYjg3MWVkZDNmZWZhMTNmMi90YWJsZXJhbmdlOjk5ZDBiYzllNTgxZDRmMmFiODcxZWRkM2ZlZmExM2YyXzItMy0xLTEtMA_282c58f7-3218-47f5-a190-017c890d043f"
      unitRef="usd">33000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo5OWQwYmM5ZTU4MWQ0ZjJhYjg3MWVkZDNmZWZhMTNmMi90YWJsZXJhbmdlOjk5ZDBiYzllNTgxZDRmMmFiODcxZWRkM2ZlZmExM2YyXzItNS0xLTEtMA_a2367aa7-e0a9-47b2-a1bd-b685bc93a745"
      unitRef="usd">11441000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo5OWQwYmM5ZTU4MWQ0ZjJhYjg3MWVkZDNmZWZhMTNmMi90YWJsZXJhbmdlOjk5ZDBiYzllNTgxZDRmMmFiODcxZWRkM2ZlZmExM2YyXzItNy0xLTEtMA_7a81a528-ab22-4067-9dfa-bd674a40de79"
      unitRef="usd">21559000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie9498b806f5e43439515d6d38d221880_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmZTBiMGI4NTZlNDQ0N2MwOTZmMDg3YThlMTZmMzY5ZS90YWJsZXJhbmdlOmZlMGIwYjg1NmU0NDQ3YzA5NmYwODdhOGUxNmYzNjllXzItMy0xLTEtMA_5b7b8d26-5a5b-41ca-a518-b2556386c551"
      unitRef="usd">33000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie9498b806f5e43439515d6d38d221880_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmZTBiMGI4NTZlNDQ0N2MwOTZmMDg3YThlMTZmMzY5ZS90YWJsZXJhbmdlOmZlMGIwYjg1NmU0NDQ3YzA5NmYwODdhOGUxNmYzNjllXzItNS0xLTEtMA_fb6af6ff-4f16-4627-8ce3-c113ba5d4a8a"
      unitRef="usd">9963000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie9498b806f5e43439515d6d38d221880_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmZTBiMGI4NTZlNDQ0N2MwOTZmMDg3YThlMTZmMzY5ZS90YWJsZXJhbmdlOmZlMGIwYjg1NmU0NDQ3YzA5NmYwODdhOGUxNmYzNjllXzItNy0xLTEtMA_7aafc9fd-1af4-48b5-992d-f03848e8a375"
      unitRef="usd">23037000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i712a2982fd6d4ab8ac21ead0059a6ab2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzE3NTk_00f81edd-0a27-4981-a99a-d3bb3a42f383"
      unitRef="usd">27900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i07f9ce99f5d440829beb69d57b267e2c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzE3NTk_cd584af0-edd6-46bf-8611-622d6060b7e9"
      unitRef="usd">27900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzIwOTQ_85c49e50-8dd6-4e62-9dc9-6d0ced2bee0b">Amortization expense for the years ended December 31, 2020, 2019 and 2018 was as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo4OTMwMjdkZjc4Mjg0NjVlYTVjZTgwZGIxMmExMDgxZS90YWJsZXJhbmdlOjg5MzAyN2RmNzgyODQ2NWVhNWNlODBkYjEyYTEwODFlXzItMS0xLTEtMA_d548e3bc-4b78-45d1-bf87-20476ddec036"
      unitRef="usd">1478000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6797cc9249a14561aeec1ea22885a66a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo4OTMwMjdkZjc4Mjg0NjVlYTVjZTgwZGIxMmExMDgxZS90YWJsZXJhbmdlOjg5MzAyN2RmNzgyODQ2NWVhNWNlODBkYjEyYTEwODFlXzItMy0xLTEtMA_3db608cf-276d-4055-b06b-f3b5a0fbcb42"
      unitRef="usd">1505000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5f152054f8a64a16a3697766345d4c85_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTo4OTMwMjdkZjc4Mjg0NjVlYTVjZTgwZGIxMmExMDgxZS90YWJsZXJhbmdlOjg5MzAyN2RmNzgyODQ2NWVhNWNlODBkYjEyYTEwODFlXzItNS0xLTEtMA_750b9d33-bff2-4c92-b559-14fb5c484ec4"
      unitRef="usd">1527000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90ZXh0cmVnaW9uOjI3MjU4NDc0MWIxODRjYjU5MGE5NmI1YWQ0ZjZlMmM5XzIxMDE_2b673cb8-fb43-4702-8f2b-dd1fb7d51fd1">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the future intangible asset amortization schedule as of December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtMS0xLTEtMA_767a7cb1-3b91-4c77-8cf3-1733705d673b"
      unitRef="usd">21559000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtMy0xLTEtMA_9a399459-7ebd-4db7-a8ae-0a2c68e5dc65"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtNS0xLTEtMA_7ea13130-5bd7-4b55-b94b-898da4d8ed1a"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtNy0xLTEtMA_a2c9ec8e-a2b0-43d1-96da-2238147b9454"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtOS0xLTEtMA_268a98f4-75ec-4c50-86e9-4eaa2d2c3d8e"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtMTEtMS0xLTA_6501e0e6-f6a7-458f-a804-6ada3829ea22"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ib8b929e9cab449588933c3ffe31bc66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzYvZnJhZzoyNzI1ODQ3NDFiMTg0Y2I1OTBhOTZiNWFkNGY2ZTJjOS90YWJsZTpmMGQ3M2E1ZmM2MWI0OWViYWRiZmM5ODkxOTg1YWUxZC90YWJsZXJhbmdlOmYwZDczYTVmYzYxYjQ5ZWJhZGJmYzk4OTE5ODVhZTFkXzEtMTMtMS0xLTA_6135fb36-e2fc-4852-a6c6-fdea02d278dd"
      unitRef="usd">14169000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90ZXh0cmVnaW9uOmZkOTQxNTY0MDQ3MTQzNTk5ODRkMDliY2U3NmQ2YTFiXzE1Mg_2004f8f4-9d38-46ba-89bb-b2cc9db93996">Accounts Payable and Accrued Liabilities&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s accounts payable and accrued liabilities as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consulting and other professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone obligations under license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90ZXh0cmVnaW9uOmZkOTQxNTY0MDQ3MTQzNTk5ODRkMDliY2U3NmQ2YTFiXzE1Mw_84710270-4e86-4c33-897c-0f2edcb68d94">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s accounts payable and accrued liabilities as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consulting and other professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone obligations under license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzEtMS0xLTEtMA_1c2cf754-ef42-453d-aa37-f3285ac4f4e3"
      unitRef="usd">10951000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzEtMy0xLTEtMA_99175834-bea6-4b88-8b56-9ea77fb2c27e"
      unitRef="usd">6597000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <vnda:AccruedResearchAndDevelopmentExpense
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzMtMS0xLTEtMA_64a822a0-9117-4768-bcba-e334263c09a9"
      unitRef="usd">6173000</vnda:AccruedResearchAndDevelopmentExpense>
    <vnda:AccruedResearchAndDevelopmentExpense
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzMtMy0xLTEtMA_63628f4a-0289-44ab-ab4e-18888a949afe"
      unitRef="usd">5893000</vnda:AccruedResearchAndDevelopmentExpense>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzItMS0xLTEtMA_bcd064e3-1e62-462d-b916-f7491efa94d9"
      unitRef="usd">5817000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzItMy0xLTEtMA_572ed289-ab61-4521-b524-ad2a6ccfba37"
      unitRef="usd">5904000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzQtMS0xLTEtMA_7e4d40ef-b44a-438f-8f4e-ffff734ec823"
      unitRef="usd">5052000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzQtMy0xLTEtMA_271e72a8-e084-4a75-a8a9-46ed51491d2e"
      unitRef="usd">5376000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzUtMS0xLTEtMA_73df8e49-4195-4130-8d31-d74bd4543915"
      unitRef="usd">2117000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzUtMy0xLTEtMA_f5743c0c-396d-4989-9e1c-5a954601ee7a"
      unitRef="usd">2147000</us-gaap:OperatingLeaseLiabilityCurrent>
    <vnda:AccruedMilestoneObligationsUnderLicenseAgreements
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzYtMS0xLTEtNTY1OQ_d71d29a1-a7b9-4f29-a1d7-4a5f54b1f77b"
      unitRef="usd">350000</vnda:AccruedMilestoneObligationsUnderLicenseAgreements>
    <vnda:AccruedMilestoneObligationsUnderLicenseAgreements
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzYtMy0xLTEtNTY1OQ_b9e43e89-d73a-4446-8c65-f36e55138952"
      unitRef="usd">0</vnda:AccruedMilestoneObligationsUnderLicenseAgreements>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzYtMS0xLTEtMA_1e6f98c1-0966-43f8-b4dc-ab7c119e0276"
      unitRef="usd">1049000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzYtMy0xLTEtMA_6e764860-714f-4a15-b7e0-872dda6e309a"
      unitRef="usd">1673000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzctMS0xLTEtMA_e20b8a34-9110-4709-8e50-abd167215fc3"
      unitRef="usd">31509000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xMzkvZnJhZzpmZDk0MTU2NDA0NzE0MzU5OTg0ZDA5YmNlNzZkNmExYi90YWJsZTpjYTMxMjcyYjliY2I0Yzg0YjhjMGY2ZWY2MTdmNDU0YS90YWJsZXJhbmdlOmNhMzEyNzJiOWJjYjRjODRiOGMwZjZlZjYxN2Y0NTRhXzctMy0xLTEtMA_6d4cabc6-1a39-4c31-bf45-3ff3739e194c"
      unitRef="usd">27590000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1Xzc2NzY_f9643456-2da7-443a-a644-cdf1453bc03e">Commitments and Contingencies&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#x2019;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#x2019;s products. The term of these indemnification agreements is generally perpetual from the date of execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December 31, 2020, the Company has paid BMS $37.5 million in upfront fees and milestone obligations, including $33.0 million of regulatory approval and commercial milestones capitalized as intangible assets (see Note 8). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;net sales to BMS in any territory where the Company commercializes HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;for a period equal to the greater of 10 years following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a 10% royalty on net sales in that territory.&#160;The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the&#160;mid-twenties.&#160;The Company is obligated&#160;to use its commercially reasonable efforts to develop and commercialize HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pursuant to the terms of a settlement agreement with Novartis Pharma AG (Novartis), Novartis transferred all U.S. and Canadian rights in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; franchise to the Company on December&#160;31, 2014. The Company paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December&#160;2019 related to manufacturing know-how. The Company is also obligated to pay Sanofi a fixed royalty on Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;net sales equal to 6% on Sanofi&#160;know-how&#160;not related to manufacturing under certain conditions for a period of up to 10 years in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tradipitant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an&#160;NK-1R&#160;antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. As of December 31, 2020, the Company has paid Lilly $3.0 million in upfront fees and development milestones. As of December 31, 2020, remaining milestone obligations include a $2.0 million development milestone due upon the filing of the first marketing authorization for tradipitant in either the U.S. or European Union (E.U.), $10.0 million and $5.0 million for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to $80.0 million for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Portfolio of CFTR activators and inhibitors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as single-digit royalties on net sales. As of December 31, 2020, the Company has paid UCSF $1.2 million in upfront fees and development milestones, including a $0.2 million development milestone payment in March 2019. As of December 31, 2020, remaining milestone obligations include &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.2 million for development milestones and $33.0 million for future regulatory approval and sales milestones. Included in the $12.2 million of development milestones is a $350,000 milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed $1.1 million in total for the CFTR portfolio.  In the fourth quarter of 2020, the Company determined the $350,000 milestone to be probable and accrued it as a current liability as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VQW-765.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with a settlement agreement with Novartis relating to Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize VQW-765 and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company&#x2019;s current agreements for clinical, marketing and other services may be terminated on generally 90 days&#x2019; notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company&#x2019;s contractors in closing out work in progress as of the effective date of termination.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ia48b1e08808c4068b45beac65e2fc47e_D20040201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzE2MDM_d2b330d1-6b05-464b-ba68-3af5e6b33028"
      unitRef="usd">37500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="ia48b1e08808c4068b45beac65e2fc47e_D20040201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzE2NTk_edab482a-da08-402d-802f-7582bddec127"
      unitRef="usd">33000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <vnda:RoyaltyPeriod
      contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzIwMDY_30503168-d996-49c6-b519-f279a4ab9b8e">P10Y</vnda:RoyaltyPeriod>
    <vnda:RoyaltyPayableOnNetSalesPercentage
      contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzIyNDE_610c7927-bc2c-4386-9f89-2d09b77c5cfe"
      unitRef="number">0.10</vnda:RoyaltyPayableOnNetSalesPercentage>
    <vnda:RoyaltyPeriod
      contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzM4NDgyOTA3MDUyMDI_30503168-d996-49c6-b519-f279a4ab9b8e">P10Y</vnda:RoyaltyPeriod>
    <vnda:PercentageOfFutureSublicenseFeesPayable
      contextRef="i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1Xzc2NzI_350dd093-9937-474f-b28a-8c69b264db2b">mid-twenties</vnda:PercentageOfFutureSublicenseFeesPayable>
    <vnda:RoyaltyPayableOnNetSalesPercentage
      contextRef="i2321f5ecabd74d08919f170010c86d17_D20141231-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzMxNDg_c63f78c8-d7e5-4658-9174-74e8baa901cd"
      unitRef="number">0.03</vnda:RoyaltyPayableOnNetSalesPercentage>
    <vnda:RoyaltyPayableOnNetSalesPercentage
      contextRef="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzMzMzg_2696597c-dc5f-4c8e-b4ec-f6b7ba9c950a"
      unitRef="number">0.06</vnda:RoyaltyPayableOnNetSalesPercentage>
    <vnda:RoyaltyPeriod
      contextRef="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzM0MzY_cdf6cd88-bbc7-4254-afd0-af8a448c612d">P10Y</vnda:RoyaltyPeriod>
    <vnda:RoyaltyPayableOnNetSalesPercentage
      contextRef="i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzM4NDgyOTA3MDUxOTE_2696597c-dc5f-4c8e-b4ec-f6b7ba9c950a"
      unitRef="number">0.06</vnda:RoyaltyPayableOnNetSalesPercentage>
    <vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
      contextRef="iae6fb1507ec54a02b3ed9ec15779f92e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1Xzc2NzM_7070ed21-3c74-4caf-beed-cffb57fc074c">low double digits</vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales>
    <vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty
      contextRef="icce1828699d04ca897051ef167bc2cf9_D20120401-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQyMzE_6441d925-e22d-4888-b08d-438281a00b54"
      unitRef="usd">3000000.0</vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="i9a443bc8c89e453aab29432964b30663_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQ0NTk_cdb68c44-7956-48b2-bf81-5a81278b0327"
      unitRef="usd">2000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="ic4c827b82caa44a79a4cef10d4761150_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQ2MDI_84981153-95fb-4212-8191-f5c1f6eef4e8"
      unitRef="usd">10000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="i81b735133e1949cd9c6e0aeb4f8be530_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQ2MDk_56629265-f636-485c-9344-8bb43a3efbb1"
      unitRef="usd">5000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="i04c1d7fb8dfe49699863ca274c5642ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzQ3MjY_4fbd5c70-f228-4cc2-8583-0e176ff97206"
      unitRef="usd">80000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:TieredRoyaltiesPayableOnFutureNetSales
      contextRef="ib097b437c4ec4ac8a415c8716b033089_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1Xzc2NzQ_0ab16059-b256-4798-b60b-c83ef837477b">single-digit</vnda:TieredRoyaltiesPayableOnFutureNetSales>
    <vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty
      contextRef="i37dcfaf9fa1c4d21a01c3abfb80350e7_D20170301-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzYyOTk_c3d332fd-c58e-4cb8-a0ae-1f473a6c99a6"
      unitRef="usd">1200000</vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty>
    <vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty
      contextRef="i7c5916a7919c4f108df3dcee675165a5_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY0MDc_8e2f5bc6-5737-4adc-9791-afc22d515ffb"
      unitRef="usd">200000</vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="i3bb19f1abf4e4d15b43df2933d3b57bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY1MDk_b33ffe36-52cd-477b-8bb0-86b10793633b"
      unitRef="usd">12200000</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="i4f739a8080b94ee0acf1864cc98cfab3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY1NDM_aa43c6f4-c7f5-41bd-9a8c-54e7632a6d24"
      unitRef="usd">33000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="i3bb19f1abf4e4d15b43df2933d3b57bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY2MTU_d8808419-b1ee-4e2b-867e-a33d17686657"
      unitRef="usd">12200000</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="if67d682d4b8343aabcab512b8d833546_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY2NDk_57701e95-e4b4-42e4-81f0-8fb9fa38d573"
      unitRef="usd">350000</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="i5d164c813b754d099714d4875c7405de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzY3NDk_be33caf9-db3f-4f7e-b629-878179b035e2"
      unitRef="usd">1100000</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:AccruedMilestoneObligationsUnderLicenseAgreements
      contextRef="ia1f829f974634d488f1643966850c384_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzM4NDgyOTA3MDY3NDI_0b30e1d2-c668-4e28-b009-2a2c506ea32c"
      unitRef="usd">350000</vnda:AccruedMilestoneObligationsUnderLicenseAgreements>
    <vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
      contextRef="i7d9544bb0d4445a097ccc5fa7f50cd38_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzYwNDczMTM5NjQyMjg_2a8f41f6-c2a3-45e7-a6f9-811f4ba4c01d">mid-teens</vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales>
    <vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDIvZnJhZzo3NTlhNTcyZDc4ZWM0OWRhODVjMzgzMDUwZDJkZDQwNS90ZXh0cmVnaW9uOjc1OWE1NzJkNzhlYzQ5ZGE4NWMzODMwNTBkMmRkNDA1XzcxMzM_b6ce530e-b406-4a91-8b38-ea850b3bcdb2">P90D</vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod>
    <vnda:PublicOfferingOfCommonStockTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8zODQ4MjkwNjk4ODcy_133ce68a-7e6d-4aa4-8d8c-d9d5d5f5ca6d">Public Offering of Common StockIn March 2018, the Company completed a public offering of 6,325,000 shares of its common stock, including the exercise of the underwriters&#x2019; option to purchase an additional 825,000 shares of common stock, at a price to the public of $17.00 per share. Net cash proceeds from the public offering were $100.9&#160;million, after deducting the underwriting discounts and commissions and offering expenses.</vnda:PublicOfferingOfCommonStockTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iec535a14efca43c882d02e3f9ef3b063_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8zODQ4MjkwNjk4ODg0_b358a4a7-3079-4265-8aea-d199574a6f8e"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib81f399dfe554faa998124d94d076956_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8xMDk5NTExNjI5Mzk3_ed591b41-b810-45e6-969a-62b141a285ca"
      unitRef="shares">825000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i418ff91379b846d3988ba7db10522717_I20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8xMDk5NTExNjI5NDA2_2f893677-ca54-4b38-bd6c-52c269b68200"
      unitRef="usdPerShare">17.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iec535a14efca43c882d02e3f9ef3b063_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDM5L2ZyYWc6MTU3NTkwNjRlZDQyNDBjN2JmMmUxNzY4N2EwNGM3MWQvdGV4dHJlZ2lvbjoxNTc1OTA2NGVkNDI0MGM3YmYyZTE3Njg3YTA0YzcxZF8zODQ4MjkwNjk4OTEw_8f9abbb4-5238-4241-93e0-5a44800697c7"
      unitRef="usd">100900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90ZXh0cmVnaW9uOjEyMzUyYjY3OTI0NjRkNzRhMDMyYzljMzRmNGQ2OWIzXzI3NQ_48b1258f-f2dc-41bb-95c8-5cb9fcd4d4f1">Accumulated Other Comprehensive Income&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90ZXh0cmVnaW9uOjEyMzUyYjY3OTI0NjRkNzRhMDMyYzljMzRmNGQ2OWIzXzI3Ng_d943deb0-10ed-4a06-b26f-ece9862e46f9">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzEtMS0xLTEtMA_333470c1-6a3f-4324-8ddb-34dfa8a0c615"
      unitRef="usd">81000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzEtMy0xLTEtMA_f5acf39a-e090-47be-9fc3-58267eda233a"
      unitRef="usd">13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzItMS0xLTEtMA_0b2ad8d9-f6e5-4f45-a1aa-d72b53ff61cc"
      unitRef="usd">158000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzItMy0xLTEtMA_5628f4f0-0f79-4417-8972-1427bb6f6dd7"
      unitRef="usd">236000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzMtMS0xLTEtMA_35b2c1f7-c59a-4f6c-91ba-550d63774b7b"
      unitRef="usd">239000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNDgvZnJhZzoxMjM1MmI2NzkyNDY0ZDc0YTAzMmM5YzM0ZjRkNjliMy90YWJsZTpmODQ0NGRjNDhmZTg0NzA0OWIzYWM0NjcyYzVjYTgyOC90YWJsZXJhbmdlOmY4NDQ0ZGM0OGZlODQ3MDQ5YjNhYzQ2NzJjNWNhODI4XzMtMy0xLTEtMA_4180d1da-77e4-4b15-bc50-402fc8dc1542"
      unitRef="usd">249000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ2MDI_33446724-64cb-410c-97e1-3e9a1a07cea7">Stock-Based Compensation&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, there were 5,246,381 shares subject to outstanding options and RSUs under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April&#160;2016, and the Company adopted the 2016 Plan. Outstanding options under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company&#x2019;s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated three times to increase the number of shares reserved for issuance, among other administrative changes. Each of the amendments and restatements of the 2016 Plan was approved by the Company's stockholders. There is a total of 8,790,000 shares of common stock authorized for issuance under the 2016 Plan, 3,991,612 shares of which remained available for future grant as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over four years, with the first 25% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the service option awards in 36 equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards granted to employees and executive officers provide for partial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acceleration of vesting if the employee or executive officer is subject to an involuntary termination, and full acceleration of vesting if the employee or executive officer is subject to an involuntary termination within 24 months after a change in control of the Company. Service option awards granted to directors provide for accelerated vesting if there is a change in control of the Company or if the director's service terminates as a result of the director's death or total and permanent disability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, $6.9 million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of 1.2 years. No option awards are classified as a liability as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in&#160;thousands,&#160;except&#160;for&#160;share&#160;and&#160;per&#160;share&#160;amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise&#160;Price&#160;at Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Remaining&#160;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,719,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(685,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(546,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,495,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,606,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value of options granted was $5.53, $10.19 and $10.66 per share for the years ended December 31, 2020, 2019 and 2018, respectively. Proceeds from the exercise of stock options amounted to $5.6 million, $6.3 million and $6.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An RSU is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#x2019;s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that are subject to terms and conditions established by the compensation committee of the board of directors. Service RSUs granted to employees vest in four equal annual installments provided that the employee remains employed with the Company. Certain service RSUs granted to employees and executive officers provide for accelerated vesting if the employee or executive officer is subject to an involuntary termination within 24 months after a change in control. Annual service RSUs granted to directors vest on the first anniversary of the grant date and provide for accelerated vesting if there is a change in control of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, $18.3 million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of 1.6 years. No RSUs are classified as a liability as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value for the 581,757 shares underlying RSUs that vested during the year ended December 31, 2020 was $9.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for the years ended December 31, 2020, 2019 and 2018 comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company&#x2019;s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December 31, 2020, 2019 and 2018 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber
      contextRef="i0ce88e2ed3eb4664882da8188a70d03a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzU1_c85efbd3-1399-4742-8349-f5abdd57863b"
      unitRef="shares">5246381</vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idd61525c1c634dbc97c9cb4caa360206_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzg2Ng_b7119f14-b48e-4067-b981-9daa58fd6c4b"
      unitRef="shares">8790000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="idd61525c1c634dbc97c9cb4caa360206_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzkzNQ_20aa4a7e-f1bf-491a-9097-2774fdec1a1b"
      unitRef="shares">3991612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vnda:ShareBasedCompensationOptionAwardsContractualTerm
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzEyNTM_1985ae73-2651-4045-a150-7c2a03233e33">P10Y</vnda:ShareBasedCompensationOptionAwardsContractualTerm>
    <vnda:ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzEzOTQ_622c2c14-3f28-4b87-aa23-6d7ff10bc413">P4Y</vnda:ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors>
    <vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzE0MTM_e3514478-382e-46a2-84e1-cf7dc2c97317"
      unitRef="number">0.25</vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards>
    <vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzE1MzI_2636bbbc-c498-4096-afbe-9c4b99a9f59e"
      unitRef="number">0.75</vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards>
    <vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzE1ODk_a8d18acd-5630-4fc8-9380-be196ae4817e"
      unitRef="installment">36</vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments>
    <vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl
      contextRef="i9396936ca284498ea1ea5d4f7a73b747_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM4NDgyOTA3MDU5NTA_f86d052f-fd75-4158-aabd-d7b6c7040894">P24M</vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="id82d67047689492daa3dc90ebad4142a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzIxNDk_dbefdfb0-4994-4ff8-a062-06a7344212a2"
      unitRef="usd">6900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9396936ca284498ea1ea5d4f7a73b747_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzIzMDE_40ea8348-926e-40a7-b028-cd265c56eaa5">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ2MDQ_831f5825-edd6-4fb5-a0b8-236aab61b134">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in&#160;thousands,&#160;except&#160;for&#160;share&#160;and&#160;per&#160;share&#160;amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise&#160;Price&#160;at Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Remaining&#160;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,719,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(685,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(546,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,495,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,606,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5dffeb908a7c4343be9d34ab1b2dd23a_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEtMS0xLTEtMA_c959dbbb-2293-4d67-83ad-790d5f3b0e9d"
      unitRef="shares">4719784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5dffeb908a7c4343be9d34ab1b2dd23a_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEtMy0xLTEtMA_ca621e4f-f9d8-4294-ad35-f18e9ea92538"
      unitRef="usdPerShare">10.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9ea30e5f62224d9baf5e2ab37d1f16cb_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEtNS0xLTEtMA_eeeab621-5bd8-40d3-9622-9165c8221da9">P5Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5dffeb908a7c4343be9d34ab1b2dd23a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEtNy0xLTEtMA_d2c89c3b-95a9-43a1-9286-13e37f510528"
      unitRef="usd">24421000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzItMS0xLTEtMA_c1979845-dd7c-48ef-b146-031840e368c1"
      unitRef="shares">567500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzItMy0xLTEtMA_0d047d38-325f-49ab-a697-1a528f96b1f1"
      unitRef="usdPerShare">19.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzMtMS0xLTEtMA_51b36024-6a83-436d-9c96-eac82f27e1f9"
      unitRef="shares">232527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzMtMy0xLTEtMA_7044a0ef-b441-4081-a646-c9b66d51ca5e"
      unitRef="usdPerShare">13.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzUtMS0xLTEtMA_e144a7eb-8272-450e-8a4d-aa5899019510"
      unitRef="shares">685715</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzUtMy0xLTEtMA_08f5c4a9-58c7-4b12-b1ee-6706a08d19c4"
      unitRef="usdPerShare">9.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzUtNy0xLTEtMA_8a5eedeb-ac0f-49e2-85a5-e4da2747fa5a"
      unitRef="usd">5945000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idf7edbea6dae4c4584d42f4bfaada83b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzYtMS0xLTEtMA_c766c9bb-8180-4778-9078-f7b89cc2f390"
      unitRef="shares">4369042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idf7edbea6dae4c4584d42f4bfaada83b_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzYtMy0xLTEtMA_e4c5df00-47c6-47b1-8cd0-f082d15680ec"
      unitRef="usdPerShare">11.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic569076d0e77486fbda62273057abb7d_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzYtNS0xLTEtMA_4fe9e8e2-748d-40c7-b87e-327d68fcd0d9">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="idf7edbea6dae4c4584d42f4bfaada83b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzYtNy0xLTEtMA_f090f237-709a-4dfb-94e7-875c09fe12fd"
      unitRef="usd">65438000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzctMS0xLTEtMA_af1ead16-7795-4755-9857-c1676ec756f3"
      unitRef="shares">687500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzctMy0xLTEtMA_6e68b90d-4818-4da3-9dee-63d3c0679e33"
      unitRef="usdPerShare">18.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzgtMS0xLTEtMA_4db5b119-9290-4955-94d2-2ce638cdcd38"
      unitRef="shares">53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzgtMy0xLTEtMA_b0b5bfd7-576e-4fc9-ba0c-04117aaee0f6"
      unitRef="usdPerShare">7.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzktMS0xLTEtMA_12779eda-40da-4be0-952b-0a9123c7bd0a"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzktMy0xLTEtMA_04a651ce-1b3c-4991-a3c4-cb6f829ded49"
      unitRef="usdPerShare">14.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEwLTEtMS0xLTA_99d3607c-47c0-4c75-a284-95fbffae7524"
      unitRef="shares">546344</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEwLTMtMS0xLTA_198e51ba-8d9b-4756-b196-503883348ca2"
      unitRef="usdPerShare">11.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEwLTctMS0xLTA_c28a1515-9ea5-4e70-aa4a-90998d158ea2"
      unitRef="usd">2482000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if5cafed82f414158a6563a9d462e2f6f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzExLTEtMS0xLTA_1d054b7a-615c-4eee-a6bb-06c808e0d36a"
      unitRef="shares">4495145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if5cafed82f414158a6563a9d462e2f6f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzExLTMtMS0xLTA_3e1bed2d-a662-47a4-a542-2ce363bf6c8b"
      unitRef="usdPerShare">12.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia396e251e4474cfebcd294c8cdb2a54b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzExLTUtMS0xLTA_84e7a4e5-f3ff-4480-88b5-38047ed55f64">P5Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if5cafed82f414158a6563a9d462e2f6f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzExLTctMS0xLTA_4e6f0ab2-a84c-45ea-8a73-aff250d645ea"
      unitRef="usd">22148000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEyLTEtMS0xLTA_383f6ae9-cac9-4585-b4fa-ead3b68f35b1"
      unitRef="shares">627500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEyLTMtMS0xLTA_e44a4cd5-1744-4913-89e2-1e04aac5dfe6"
      unitRef="usdPerShare">11.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEzLTEtMS0xLTA_00fe8311-f964-4d80-b907-60de217ba5cd"
      unitRef="shares">225000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzEzLTMtMS0xLTA_15ca6432-37da-4999-a54b-2ec45632d8bf"
      unitRef="usdPerShare">18.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE0LTEtMS0xLTA_ebb75f44-bec4-4915-9523-e527e910b8bb"
      unitRef="shares">557604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE0LTMtMS0xLTA_d68e8a5b-4e55-4d82-a657-1980ba1a7d43"
      unitRef="usdPerShare">14.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE1LTEtMS0xLTA_38fae373-22fa-479b-9dbc-37f6ab77f8e0"
      unitRef="shares">733223</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE1LTMtMS0xLTA_ac4074a9-44a0-48d9-a2de-9d46cbf775e5"
      unitRef="usdPerShare">7.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE1LTctMS0xLTA_34e89fa0-3f5a-40c8-98af-08d7a8b885c8"
      unitRef="usd">2868000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE2LTEtMS0xLTA_0e3d546f-d6a8-4562-99f4-1966be989257"
      unitRef="shares">3606818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE2LTMtMS0xLTA_4af933ca-388c-49f8-9f34-741e5e565bd4"
      unitRef="usdPerShare">12.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE2LTUtMS0xLTA_7e0f41bf-4c07-4869-932c-0340a1da7907">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE2LTctMS0xLTA_9155dfe9-0594-4709-9bc2-f60051879145"
      unitRef="usd">8511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE3LTEtMS0xLTA_8e1b8a6e-3bd6-48b8-ac39-b8ac31ab9f0e"
      unitRef="shares">2556394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE3LTMtMS0xLTA_0543dba3-2347-4c0e-82f2-86dc9de9de93"
      unitRef="usdPerShare">11.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE3LTUtMS0xLTA_a1b55d6f-cf96-46b0-ac95-811c6d406a78">P4Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE3LTctMS0xLTA_179a58ba-256d-4680-8527-af74aaaa8797"
      unitRef="usd">7302000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE4LTEtMS0xLTA_8c643304-07e4-4efa-8aa9-541c5a37db31"
      unitRef="shares">3482804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE4LTMtMS0xLTA_ae670489-2d19-414e-acb5-48153ccbcca7"
      unitRef="usdPerShare">12.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE4LTUtMS0xLTA_0826057a-1d00-4f6b-a9c7-53e8e90b2ee8">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i8f32a8cb20304b4aa8420ecde3f099a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo4ODI5Nzc2M2I1NTA0ZTM1Yjc0NjUwMGYwNTY1ZjE2MS90YWJsZXJhbmdlOjg4Mjk3NzYzYjU1MDRlMzViNzQ2NTAwZjA1NjVmMTYxXzE4LTctMS0xLTA_7ead12b5-1f0c-4d1b-b75f-063ba988c693"
      unitRef="usd">8337000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI1NTQ_097bced1-a02e-45aa-8e5b-09d99d698856"
      unitRef="usdPerShare">5.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI1NTg_e901ff75-b112-49e1-9fee-bbd8416fbe76"
      unitRef="usdPerShare">10.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI1NjU_74ea45ff-708c-4d9e-8409-7f46f9349023"
      unitRef="usdPerShare">10.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI2ODM_918cd001-c3a4-4fbf-8820-6053505ba51b"
      unitRef="usd">5600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI2ODc_036c6769-2799-430c-b442-0740d65f8885"
      unitRef="usd">6300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzI2OTQ_dd47e056-4165-4652-9ac0-3d39c6c6c9d6"
      unitRef="usd">6300000</us-gaap:ProceedsFromStockOptionsExercised>
    <vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzMwODU_9204ebdc-2d08-4204-9285-32810838b8b2"
      unitRef="installment">4</vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments>
    <vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM4NDgyOTA3MDU5NjQ_e51c4a64-0d64-406d-882b-f51909100e71">P24M</vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i4accca8a781b42bc8a5a731e56f0eec6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzMyNzY_94898266-2ad9-4c16-99da-f298fe3b08d2"
      unitRef="usd">18300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM0MTE_c15f8099-8b42-43df-8011-53501141bfc5">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ2MDU_bc5f8437-f020-4e5c-87f3-bc6af9df07ea">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie623210fe21f455fba6a25bfe1712547_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEtMS0xLTEtMA_cfa0ceda-73d4-4b93-af56-e057087b9227"
      unitRef="shares">1357838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie623210fe21f455fba6a25bfe1712547_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEtMy0xLTEtMA_a8023356-e708-494d-9124-932d6af9a58d"
      unitRef="usdPerShare">12.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzItMS0xLTEtMA_82a6fe15-cd13-4c8a-844a-34272712de9b"
      unitRef="shares">714086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzItMy0xLTEtMA_38a05259-2ded-4f83-b80a-b3ac4244febd"
      unitRef="usdPerShare">18.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzMtMS0xLTEtMA_531f1777-7205-4759-8825-7fefd93ff236"
      unitRef="shares">229603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzMtMy0xLTEtMA_82c86926-fe40-4451-9b21-f0ac0ac9be1c"
      unitRef="usdPerShare">15.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzQtMS0xLTEtMA_d89bcce5-5f0e-4af5-813d-eabe76e36fba"
      unitRef="shares">528745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib704b69eb14d48b9b7ecc593829bfe69_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzQtMy0xLTEtMA_5aebac0c-8d14-433e-8cdf-8c357a40860a"
      unitRef="usdPerShare">12.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id14b5fd7c713420383f8b6f8cdaf4438_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzUtMS0xLTEtMA_2f9282f1-2a83-4b96-a3ae-d90cf59cc16a"
      unitRef="shares">1313576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id14b5fd7c713420383f8b6f8cdaf4438_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzUtMy0xLTEtMA_02942d78-4a73-4780-a4ce-4928dbd9db3f"
      unitRef="usdPerShare">15.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzYtMS0xLTEtMA_c6f6934b-3bc6-414d-8566-037bd3ed01eb"
      unitRef="shares">937328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzYtMy0xLTEtMA_5d8b766e-d60f-449b-8d7e-81ea7a25c8b2"
      unitRef="usdPerShare">19.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzctMS0xLTEtMA_4fb07eb3-18dc-4ef0-9206-bde5a34d645e"
      unitRef="shares">75444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzctMy0xLTEtMA_aed1f9bf-b2ee-409b-ab51-573682ecca04"
      unitRef="usdPerShare">18.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzgtMS0xLTEtMA_bf3a3a7b-3ba0-4c63-a1d9-d0df6b7e25a3"
      unitRef="shares">526175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i622f4d1e9f7c47449e3648fb2f310e2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzgtMy0xLTEtMA_c441696b-fd60-4b93-9f5c-b9434acd5e12"
      unitRef="usdPerShare">14.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5cbcabe269184dbcb50a511cf3bdb9fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzktMS0xLTEtMA_c976fb23-1258-482f-8b66-7103e37e0dd0"
      unitRef="shares">1649285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5cbcabe269184dbcb50a511cf3bdb9fd_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzktMy0xLTEtMA_1433199c-da24-4c99-9485-402ef5b656f3"
      unitRef="usdPerShare">18.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEwLTEtMS0xLTA_0284c4c4-4bd4-4da4-bbda-be3c4032de8b"
      unitRef="shares">832162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEwLTMtMS0xLTA_e5cceaab-be55-4f62-aad3-6c0212408cc3"
      unitRef="usdPerShare">11.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzExLTEtMS0xLTA_47ecff7f-abdd-494d-9f7b-033a1d9ac7e2"
      unitRef="shares">260127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzExLTMtMS0xLTA_7315368c-b914-410f-99dd-ec39c1089f0b"
      unitRef="usdPerShare">17.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEyLTEtMS0xLTA_57828b8e-1222-4d8c-924f-f1815084acb2"
      unitRef="shares">581757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEyLTMtMS0xLTA_a333d708-279f-4821-b616-89dab21d488c"
      unitRef="usdPerShare">16.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4accca8a781b42bc8a5a731e56f0eec6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEzLTEtMS0xLTA_d559895a-e843-4e83-abc7-35bdfaf71bef"
      unitRef="shares">1639563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4accca8a781b42bc8a5a731e56f0eec6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTpiMTRjYTVlYTEyYTE0YjFhOTFhMzkyMzMxOTA0N2JlYy90YWJsZXJhbmdlOmIxNGNhNWVhMTJhMTRiMWE5MWEzOTIzMzE5MDQ3YmVjXzEzLTMtMS0xLTA_d06f2107-5b9c-4abb-8dab-c15da0c2f5ef"
      unitRef="usdPerShare">15.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM2MjA_ac145e3a-9cb6-4326-8457-4f2fa0f5e9ec"
      unitRef="shares">581757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i121f6fd163194e94a507e63b36007dfa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzM2ODc_a41a7f18-92ec-4445-bc6a-821228647856"
      unitRef="usd">9600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ2MTA_bde01d94-1809-4f5f-96ab-063bb73bfe72">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for the years ended December 31, 2020, 2019 and 2018 comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iefdf2eff6cd54e0ea9ebdad5ee519b38_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzItMS0xLTEtMA_16982bed-ae69-4e45-9dbc-5d604ee5e7fc"
      unitRef="usd">3804000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie5dba30ea1414af0bf583a5a09975a52_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzItMy0xLTEtMA_ad39c14e-9dd1-418f-ac13-f14fcd03bef7"
      unitRef="usd">3207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a749d60ade74a138ef81f76767e56e9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzItNS0xLTEtMA_2bb0bb77-59da-4891-9a0d-eea30e0974eb"
      unitRef="usd">1290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5bd51d5e4edf48f2ad3197f761187562_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzMtMS0xLTEtMA_376cad25-1bdc-4ecd-be5a-e989da403a71"
      unitRef="usd">9556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id823e499960c408ba259173b9f02984b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzMtMy0xLTEtMA_ee516790-deed-4a6f-8600-53803d76dc65"
      unitRef="usd">10251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5dd64fe80b642d18d3588ccecb6c437_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzMtNS0xLTEtMA_9ff02fc1-18e1-4045-9f4e-7b1636fe8f1a"
      unitRef="usd">10376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzQtMS0xLTEtMA_20798eb2-46be-45aa-afeb-a460a21dcbd0"
      unitRef="usd">13360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzQtMy0xLTEtMA_ef743c1c-7c73-42a9-9c88-566fedea11a5"
      unitRef="usd">13458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZToxYjI3NTVlMzQ1ZTk0OTkzYWI2Y2M0ZTc3M2VkZmNlNC90YWJsZXJhbmdlOjFiMjc1NWUzNDVlOTQ5OTNhYjZjYzRlNzczZWRmY2U0XzQtNS0xLTEtMA_22570d8e-db3e-43bb-bd9e-528c49ed037d"
      unitRef="usd">11666000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90ZXh0cmVnaW9uOjM3YWYxNmI1OWU3YjQ2YzU4MDcxZTdkMDNhYTlhNjZhXzQ1OTg_dd710d64-07a4-4251-812c-a5462ead783d">Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December 31, 2020, 2019 and 2018 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzItMS0xLTEtMA_2fa1426a-d505-4ab9-a36d-874862fc99b6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzItMy0xLTEtMA_2430e352-b5ef-474b-b8aa-de27d6e665fb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzItNS0xLTEtMA_cb1df2a4-ba0c-48ba-bcca-cfe8c91d3c59"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzMtMS0xLTEtMA_f3f249f6-20c0-4b85-be06-9f979c01f261"
      unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzMtMy0xLTEtMA_dc34ebe2-285c-4217-b7a0-8041d09b191a"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzMtNS0xLTEtMA_6ec13857-4019-4c82-9070-fe1d24f1c63c"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzQtMS0xLTEtMA_934ed2bb-2c45-49b6-b58c-3609bfe0331b">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzQtMy0xLTEtMA_ba25ecf8-ed50-4000-99dd-2c43dc6e0853">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzQtNS0xLTEtMA_3384fef4-f1d7-4ef2-ba16-7ff09af124cb">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzUtMS0xLTEtMA_05d73b84-a3a6-46c2-af35-d75e58e639b5"
      unitRef="number">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzUtMy0xLTEtMA_63659c5a-d00b-40ba-8a13-82d1bedb83c8"
      unitRef="number">0.0226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTEvZnJhZzozN2FmMTZiNTllN2I0NmM1ODA3MWU3ZDAzYWE5YTY2YS90YWJsZTo5Mzc1ZWYwNjQ5Yjc0ODA2YjI5MWY0MTc4YzlmNzYxMC90YWJsZXJhbmdlOjkzNzVlZjA2NDliNzQ4MDZiMjkxZjQxNzhjOWY3NjEwXzUtNS0xLTEtMA_1a6465ad-307f-4abc-869e-c22348a6b750"
      unitRef="number">0.0268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzU2Mg_466585c4-68e9-47a5-8f04-fda69f157ac4">Employee Benefit PlanThe Company has a defined contribution plan under IRC Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Currently, the Company matches fifty percent up to the first six percent of employee contributions. All matching contributions have been paid by the Company. The Company match vests over a 4-year period and amounted to $0.9 million, $0.8 million and $0.9 million for the years ended December 31, 2020, 2019 and 2018, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzMxNQ_dffbfac5-035c-4729-8b39-fd53b182204f"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzM0Mg_15895c27-21af-42e9-8350-1caf06c77310"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <vnda:DefinedContributionPlanVestingPeriod
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzQ2OQ_93704d3c-8ee1-462e-a272-5d759722566f">P4Y</vnda:DefinedContributionPlanVestingPeriod>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzUwMA_256d6037-6122-4c3d-a4fe-fe4e0af2a43c"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzUwNA_7692b188-f88b-4aa8-874e-ffd7fc60948e"
      unitRef="usd">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTQvZnJhZzoxOTc3ZDQ2MWNmZmY0Njc1OTI1MGUyNmVhM2IwY2I3MS90ZXh0cmVnaW9uOjE5NzdkNDYxY2ZmZjQ2NzU5MjUwZTI2ZWEzYjBjYjcxXzUxMQ_7cd37b44-635c-4131-a6d1-01add7db18d3"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MTE_defb55b0-57d8-45dc-9df9-cdbf389f5c28">Income Taxes&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the domestic and foreign components of income before income taxes for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance was retained against certain District of Columbia state deferred tax assets as of December 31, 2020, and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is reconciliation between the federal statutory tax rate and the Company&#x2019;s effective tax rate for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other tax rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other changes in state deferred taxes (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(298.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.34pt"&gt;Reductions in 2020 valuation allowances are attributable to 2020 income before income taxes. Reductions in 2019 valuation allowances include $7.5 million related to 2019 U.S. income before income taxes, $10.7 related to adjustments for prior period credit carryforwards and uncertain tax positions and $85.6 million related to a change in &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;2019 activity includes adjustments to prior year credit carryforwards and prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Includes adjustments to state deferred taxes based on changes to filing jurisdictions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the components of the Company&#x2019;s net deferred tax assets and the related tax valuation allowance as of December 31, 2020 and 2019. Certain prior period amounts in the table have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for returns and credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and orphan drug credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of changes in the Company&#x2019;s tax valuation allowance for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;End of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has NOL and other tax credit carryforwards in several jurisdictions. As of December 31, 2020, the Company has $35.2 million of deferred tax assets relating to U.S. federal NOL carryforwards, along with deferred tax assets of $13.4 million and $24.4 million related to U.S. federal research and development credits and orphan drug credits, respectively. These tax attributes will begin to expire in 2031, 2024 and 2030, respectively. In addition, the Company has $8.4 million of deferred tax assets relating to U.S. state NOL carryforwards, which primarily relate to the District of Columbia. State NOLs for the District of Columbia will begin to expire in 2032 and other state NOLs will begin to expire in 2029. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of uncertain tax benefits that, if recognized, would impact the effective tax rate is $11.2 million. No material income tax interest or penalties have been recorded, and unrecognized tax benefits are not expected to change materially over the next 12 months. Income tax returns filed by the Company for all periods are open to examination by tax jurisdictions. As of December 31, 2020, the Company is not under examination by any federal or state tax jurisdiction.&lt;/span&gt;&lt;/div&gt;Certain tax attributes of the Company, including NOLs and credits, would be subject to a limitation should an ownership change as defined under the Internal Revenue Code of 1986, as amended (IRC), Section&#160;382, occur. The limitations resulting from a change in ownership could affect the Company&#x2019;s ability to utilize its NOLs and credit carryforward (tax attributes). Ownership changes occurred in the years ending December&#160;31, 2014 and December&#160;31, 2008. The Company believes that the ownership changes in 2014 and 2008 will not impact its ability to utilize NOL and credit carryforwards; however, future ownership changes may cause the Company&#x2019;s existing tax attributes to have additional limitations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MDA_bcecbb45-571e-4a79-b915-d2d89fa0e79c">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the domestic and foreign components of income before income taxes for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzItMS0xLTEtMA_1705abdf-0238-4410-840d-1b2099c96832"
      unitRef="usd">31667000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzItMy0xLTEtMA_9bb39440-4880-4a54-9112-88a055ce07ae"
      unitRef="usd">28794000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzItNS0xLTEtMA_2b3b3e0c-06fa-4e90-9775-341b2601990d"
      unitRef="usd">25123000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzMtMS0xLTEtMA_4e9d5b1e-615e-4179-bfb2-20c9459752e7"
      unitRef="usd">-12000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzMtMy0xLTEtMA_efdac534-de6c-4858-81fb-75d264973598"
      unitRef="usd">234000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzMtNS0xLTEtMA_446ffbb8-91e2-4fe4-b407-05eb32ff2414"
      unitRef="usd">223000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzQtMS0xLTEtMA_97270964-d84f-4aeb-8487-c39c372f7fce"
      unitRef="usd">31655000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzQtMy0xLTEtMA_39c249ce-2d52-4a65-aa2b-8c3238e3d627"
      unitRef="usd">29028000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo3OWVmNTBhM2JmMzA0MTA3OTI1YjQ5M2VlZWQwMGJlMS90YWJsZXJhbmdlOjc5ZWY1MGEzYmYzMDQxMDc5MjViNDkzZWVlZDAwYmUxXzQtNS0xLTEtMA_6f948f01-e0f5-42cf-81eb-f9143cf8cdf9"
      unitRef="usd">25346000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MDk_d5bc989d-fa49-463e-ad71-9a225ee65ef2">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzMtMS0xLTEtMA_65604aee-16ed-4421-aebb-887c29b90f48"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzMtMy0xLTEtMA_ef411c43-9f6f-4bf7-a746-196fd3ee3863"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzMtNS0xLTEtMA_33530d72-ae1e-463a-9d3a-168495f493e6"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzQtMS0xLTEtMA_0a2a22a1-73a4-4ce1-8901-32d1eaa1a2ef"
      unitRef="usd">2061000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzQtMy0xLTEtMA_ddc17e63-3817-4900-b9fa-3b5b63a3891e"
      unitRef="usd">1161000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzQtNS0xLTEtMA_8475e94d-19bb-4007-a8f1-d4e837d13524"
      unitRef="usd">53000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzUtMS0xLTEtMA_df6d5913-a607-4091-a6ac-bf713fcae3b9"
      unitRef="usd">68000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzUtMy0xLTEtMA_c224f72a-d651-44ab-9027-d26d0d067356"
      unitRef="usd">81000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzUtNS0xLTEtMA_0ffb86fe-3bf7-4ddf-a9bc-aeeb18aa8dfc"
      unitRef="usd">99000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzctMS0xLTEtMA_0be41c2e-c277-4acd-8834-2f0bf335373e"
      unitRef="usd">6076000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzctMy0xLTEtMA_526509b2-bd26-4dae-91cd-c1f0df207af8"
      unitRef="usd">-85624000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzctNS0xLTEtMA_9c0e00ae-ce56-4c01-92a2-ca63e9cc4a51"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzgtMS0xLTEtMA_1a4fc4bf-4032-48bb-9f80-2a566de25ea5"
      unitRef="usd">155000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzgtMy0xLTEtMA_9b2f172b-d816-466c-9428-2755e56164a9"
      unitRef="usd">-2127000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzgtNS0xLTEtMA_2a426915-df78-4e61-a395-75f05205b9ac"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzktMS0xLTEtMA_e213506c-437e-4470-8797-a433b50e44b5"
      unitRef="usd">-42000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzktMy0xLTEtMA_fdc0710a-1c58-4fa9-99c3-f241b39fdea8"
      unitRef="usd">-16000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzktNS0xLTEtMA_a7332ad5-b9e5-488d-af29-d44fae50e48b"
      unitRef="usd">-14000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzEwLTEtMS0xLTA_4215e5ae-339c-4ce6-b7be-bdfba49a2bb0"
      unitRef="usd">8318000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzEwLTMtMS0xLTA_568f1628-30a2-4f91-a736-9492d9d98505"
      unitRef="usd">-86525000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplNjIzZjk1OTUyYWE0OGU2OThjOTM5MWUzMGFjMmJhOC90YWJsZXJhbmdlOmU2MjNmOTU5NTJhYTQ4ZTY5OGM5MzkxZTMwYWMyYmE4XzEwLTUtMS0xLTA_73546325-9bce-4172-86b2-86f92cc74add"
      unitRef="usd">138000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MTA_3d97e914-677c-4d09-bdf2-169572e53b7a">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is reconciliation between the federal statutory tax rate and the Company&#x2019;s effective tax rate for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other tax rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other changes in state deferred taxes (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(298.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.34pt"&gt;Reductions in 2020 valuation allowances are attributable to 2020 income before income taxes. Reductions in 2019 valuation allowances include $7.5 million related to 2019 U.S. income before income taxes, $10.7 related to adjustments for prior period credit carryforwards and uncertain tax positions and $85.6 million related to a change in &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;2019 activity includes adjustments to prior year credit carryforwards and prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.&lt;/span&gt;&lt;/div&gt;(3)Includes adjustments to state deferred taxes based on changes to filing jurisdictions.</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzItMS0xLTEtMA_a8a47a6e-36ba-472b-bf71-0fa5980356e9"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzItMy0xLTEtMA_5083ce18-fe4c-48c9-9354-f2eb25ddd388"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzItNS0xLTEtMA_f627f61f-9ef9-47b0-930b-93c276a1d1d8"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzMtMS0xLTEtMA_b820c659-5874-4d70-bb6c-7662c57ee0f2"
      unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzMtMy0xLTEtMA_d880fad6-28b8-43ec-a577-e0dbd6cb7e5c"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzMtNS0xLTEtMA_507f6577-305c-4a5d-90de-6547cb766228"
      unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzYtMS0xLTEtMA_7ce85ddd-01b7-4e3e-9104-41a7e987c912"
      unitRef="number">-0.035</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzYtMy0xLTEtMA_ffc088cd-24aa-45d4-ae77-e88964a7a364"
      unitRef="number">-3.576</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzYtNS0xLTEtMA_78f5b808-79df-4a83-9aef-02c404a24363"
      unitRef="number">-0.164</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzctMS0xLTEtMA_1dc8f2ec-c913-438a-beb5-598d5100381b"
      unitRef="number">0.054</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzctMy0xLTEtMA_57f8617d-b524-4109-acf2-2a5f64706526"
      unitRef="number">0.109</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzctNS0xLTEtMA_d7cd59f1-83ac-46c6-a4d6-8834376f1849"
      unitRef="number">0.091</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzgtMS0xLTEtMA_a56ef349-69ec-40b7-89be-0b5c21dd994a"
      unitRef="number">-0.013</vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug>
    <vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzgtMy0xLTEtMA_1e271341-4195-4c26-adfd-b2f04fd72975"
      unitRef="number">0.171</vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug>
    <vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzgtNS0xLTEtMA_3b982dd7-4dfb-4941-be98-9da7c225d1a2"
      unitRef="number">-0.027</vnda:EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzktMS0xLTEtMA_acd051c1-b710-4568-a96d-eeb6aec98c8f"
      unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzktMy0xLTEtMA_bde49724-f62c-4bc9-bf69-7573a8da7b4d"
      unitRef="number">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzktNS0xLTEtMA_d89001c0-3169-4f77-bb65-97d9b714141b"
      unitRef="number">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEwLTEtMS0xLTA_e1ac5df6-5ea2-4397-b231-d6b82a9a7c6e"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEwLTMtMS0xLTA_39e7a53c-e0f0-4d89-b80e-36750981b70e"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEwLTUtMS0xLTA_300410ff-2fc8-4655-8259-8fb5805eb89a"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzExLTEtMS0xLTA_e665f627-2a58-45f7-8488-600f968a154c"
      unitRef="number">0</vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment>
    <vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzExLTMtMS0xLTA_9a3619c2-8c1d-4b54-85d9-8d32d4bb3180"
      unitRef="number">0</vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment>
    <vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzExLTUtMS0xLTA_a84a7f96-1db7-4866-a88f-7d98d6ae675d"
      unitRef="number">0.059</vnda:EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment>
    <vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEyLTEtMS0xLTA_0bd60511-1530-410a-af45-d8d56980bfad"
      unitRef="number">0.047</vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent>
    <vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEyLTMtMS0xLTA_6d459b85-e8f2-48ec-b39d-72f5fc94cde5"
      unitRef="number">0.263</vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent>
    <vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEyLTUtMS0xLTA_514e160c-1946-4aff-a530-049d2e70c434"
      unitRef="number">0</vnda:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEzLTEtMS0xLTA_9c07394c-2c33-48a8-8ead-f259f733be55"
      unitRef="number">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEzLTMtMS0xLTA_ca4fe5cd-b39f-4a39-976f-6477eafa3602"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzEzLTUtMS0xLTA_a406e420-9174-4e48-80fa-345caea53024"
      unitRef="number">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE0LTEtMS0xLTA_5d36cbeb-f929-4af2-82af-0bd007f09610"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE0LTMtMS0xLTA_57e6a250-5ea4-4086-98ad-c4eeec6ee2a4"
      unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE0LTUtMS0xLTA_ec715e03-bd0f-4ea1-9438-13a5aadceb42"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE1LTEtMS0xLTA_b56188d0-6c83-45f0-a4e4-6cbde031b911"
      unitRef="number">0.263</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE1LTMtMS0xLTA_280bc356-b779-46d7-a6e6-5fc234887a7f"
      unitRef="number">-2.981</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpjM2EzYThhMTU1OTY0ZjM4OTI1YjY1YjM4ODhhZDZlYi90YWJsZXJhbmdlOmMzYTNhOGExNTU5NjRmMzg5MjViNjViMzg4OGFkNmViXzE1LTUtMS0xLTA_2d7e8f72-4ae9-4add-82f2-188c2c075dd6"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i533bb21627594019891d85b5903ed825_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzI2MTY_e6bf5a71-19e3-4bcf-953a-4ecd0f37ac69"
      unitRef="usd">-7500000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3af2a96bce0440ec840b163636430f9b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzI2Njg_dda07a39-f8ca-4f5b-b167-a9c66d093ada"
      unitRef="usd">-10700000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1209ef3dad5a4c70b22c2b5ea6d9c116_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzI3NjQ_99a46f65-b50b-4cdd-8c2b-17a44b09e109"
      unitRef="usd">-85600000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY4OTg_c72aeae0-0659-4f9b-ac18-7445e39e223f">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the components of the Company&#x2019;s net deferred tax assets and the related tax valuation allowance as of December 31, 2020 and 2019. Certain prior period amounts in the table have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for returns and credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and orphan drug credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzItMS0xLTEtMA_f8150f85-1598-4714-a287-0cc3faa48c86"
      unitRef="usd">43623000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzItMy0xLTEtMA_bfa47f1c-79ae-49d7-8308-c6b4332c3648"
      unitRef="usd">52034000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzMtMS0xLTEtMA_d5360df4-e723-4af8-a1bb-f06ca1d4294d"
      unitRef="usd">4653000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzMtMy0xLTEtMA_bb437d9a-1b4b-4c1e-9b1d-ffcec0bff8dd"
      unitRef="usd">5298000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzQtMS0xLTEtMA_7dbf24d8-9ce0-4a99-b1e2-b8219159af7d"
      unitRef="usd">2429000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzQtMy0xLTEtMA_75b14d53-25cf-48a5-bb10-61af165e180d"
      unitRef="usd">1266000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzUtMS0xLTEtMA_edf8081f-7e88-4b1a-aeb4-ee91b293acc5"
      unitRef="usd">1169000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzUtMy0xLTEtMA_9e18a3e2-b4c2-4b9b-81a3-3e9065a1eba2"
      unitRef="usd">1468000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <vnda:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzYtMS0xLTEtMA_843d9e66-3453-4838-a2f7-0dcfaefcb4bb"
      unitRef="usd">37737000</vnda:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther>
    <vnda:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzYtMy0xLTEtMA_9ed084e5-6d64-4727-8f06-18dad9f03590"
      unitRef="usd">36041000</vnda:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzgtMS0xLTEtMA_3828bf1e-2cf3-47c8-92f6-4db976264450"
      unitRef="usd">3279000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzgtMy0xLTEtMA_20561800-5b5e-44c1-b899-77d4cc665034"
      unitRef="usd">4572000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzktMS0xLTEtMA_c95578b3-8e05-4501-8c39-f074bdd9034e"
      unitRef="usd">92890000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzktMy0xLTEtMA_5e447249-141e-45b1-9600-00f743229ed3"
      unitRef="usd">100679000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzExLTEtMS0xLTA_0ddd5146-c99e-4883-a56b-e86dd1ca1f71"
      unitRef="usd">1911000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzExLTMtMS0xLTA_4c46f6b2-3518-4d4c-a829-b28dfd5644bc"
      unitRef="usd">1994000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzEyLTEtMS0xLTA_3a9150f8-2cb6-414b-b1a1-220cb31b4c7a"
      unitRef="usd">2412000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzEyLTMtMS0xLTA_562aad5e-fc24-4c9f-870f-08d8f8c3c059"
      unitRef="usd">2850000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzEzLTEtMS0xLTA_f59827a7-cfc7-49d9-9fcd-a8b70401bb59"
      unitRef="usd">4323000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzEzLTMtMS0xLTA_b8ce215e-59f1-45b8-92ba-826b3f9a8e7a"
      unitRef="usd">4844000</us-gaap:DeferredIncomeTaxLiabilities>
    <vnda:DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE0LTEtMS0xLTA_03d076c6-19a9-4b1e-8d08-d2ad00c21d57"
      unitRef="usd">88567000</vnda:DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet>
    <vnda:DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE0LTMtMS0xLTA_b2a52267-d426-4082-b116-0d5264b82175"
      unitRef="usd">95835000</vnda:DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE1LTEtMS0xLTA_f936684d-3f3f-4cc6-8bdc-4a0524509cab"
      unitRef="usd">7051000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE1LTMtMS0xLTA_082f41c7-9491-4ed7-af88-efd8b032645d"
      unitRef="usd">8155000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE2LTEtMS0xLTA_25d500da-37d6-4f65-8973-aafdab28fab9"
      unitRef="usd">81516000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTpiZTlmMTMxYzVkMGE0ODgwODViNzQ4YjU0OTk1Mjk1Ny90YWJsZXJhbmdlOmJlOWYxMzFjNWQwYTQ4ODA4NWI3NDhiNTQ5OTUyOTU3XzE2LTMtMS0xLTA_83740f82-c7da-42e0-93e5-c2e9a9295001"
      unitRef="usd">87680000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY4OTU_24797887-a20d-48db-aff7-35c2b3103b83">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of changes in the Company&#x2019;s tax valuation allowance for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;End of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzItMS0xLTEtMA_89e8c73c-158a-488b-9e4a-bdc81fea27f6"
      unitRef="usd">8155000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <vnda:DeferredTaxAssetsValuationAllowanceIncrease
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzItMy0xLTEtMA_1e3a83c4-dbac-44b8-90a8-3fef9b5d28af"
      unitRef="usd">0</vnda:DeferredTaxAssetsValuationAllowanceIncrease>
    <vnda:DeferredTaxAssetsValuationAllowanceDecrease
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzItNS0xLTEtMA_2e2edb8c-22a1-4fd2-bdfe-8fa53c2b187c"
      unitRef="usd">1104000</vnda:DeferredTaxAssetsValuationAllowanceDecrease>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzItNy0xLTEtMA_3cf8bcd7-789f-4400-a3e5-3397b3fc7799"
      unitRef="usd">7051000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzMtMS0xLTEtMA_1e50bfcf-3ee7-4f30-8d78-1ec9da40053e"
      unitRef="usd">111950000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <vnda:DeferredTaxAssetsValuationAllowanceIncrease
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzMtMy0xLTEtMA_0473df1c-1f10-4526-9b5d-ec5589b827d9"
      unitRef="usd">0</vnda:DeferredTaxAssetsValuationAllowanceIncrease>
    <vnda:DeferredTaxAssetsValuationAllowanceDecrease
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzMtNS0xLTEtMA_ea4f92d7-4b36-4f96-887b-7aa42e146239"
      unitRef="usd">103795000</vnda:DeferredTaxAssetsValuationAllowanceDecrease>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzMtNy0xLTEtMA_09420a9b-0af8-4c4d-98d4-f0a172a0042f"
      unitRef="usd">8155000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i926bf00cb18047ab87ba70c56d7331bb_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzQtMS0xLTEtMA_c755a7db-6f10-47c1-be94-9a600bc415d9"
      unitRef="usd">116110000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <vnda:DeferredTaxAssetsValuationAllowanceIncrease
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzQtMy0xLTEtMA_787a1438-15e3-4782-80f5-36188779d487"
      unitRef="usd">4036000</vnda:DeferredTaxAssetsValuationAllowanceIncrease>
    <vnda:DeferredTaxAssetsValuationAllowanceDecrease
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzQtNS0xLTEtMA_dd0f9fbb-b7aa-4310-b5b8-5438dec29903"
      unitRef="usd">8196000</vnda:DeferredTaxAssetsValuationAllowanceDecrease>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTplMThjNjc3MzkzNjg0ZmU1YTQxODMwOTcyYjM2NGM3OC90YWJsZXJhbmdlOmUxOGM2NzczOTM2ODRmZTVhNDE4MzA5NzJiMzY0Yzc4XzQtNy0xLTEtMA_092f403b-6c3c-4b3f-a4b0-c6ac8aab500b"
      unitRef="usd">111950000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="ia35ff2ef50ed4a898205b8960a640489_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQxMjQ_4fb184fa-4e2d-424a-b2ac-ff3c2a3b56f7"
      unitRef="usd">35200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQyMjg_bbfe0b2e-b905-458c-ba36-431be6a3082c"
      unitRef="usd">13400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia324b88c017e451d84714c225aa51f90_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQyMzU_10ca9449-39c0-481c-9311-6cdacfc5d96c"
      unitRef="usd">24400000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <vnda:OperatingLossCarryforwardsBeginningExpirationYear
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQzNzk_a0e30678-bfa1-428b-8a66-7429747a44c9">2031</vnda:OperatingLossCarryforwardsBeginningExpirationYear>
    <vnda:ResearchAndDevelopmentCreditBeginningExpirationYear
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQzODM_edbe2586-5975-46fc-8cf7-e0461aa68add">2024</vnda:ResearchAndDevelopmentCreditBeginningExpirationYear>
    <vnda:OrphanDrugCreditBeginningExpirationYear
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQzOTA_731988dd-b8d3-4696-a6d6-379722a83009">2030</vnda:OrphanDrugCreditBeginningExpirationYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQ0Mzc_03bfe2d0-e5cd-4698-96c1-f3451a282642"
      unitRef="usd">8400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <vnda:OperatingLossCarryforwardsBeginningExpirationYear
      contextRef="i868e756c16d248bf88fef93ad48e1708_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQ2MjE_c0351d94-873e-4419-ace7-f250a5bd2971">2032</vnda:OperatingLossCarryforwardsBeginningExpirationYear>
    <vnda:OperatingLossCarryforwardsBeginningExpirationYear
      contextRef="i0312bfa2fd454fdd90ab881abbadfeaa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzQ2Njk_f88acc1a-3171-402f-a817-13f48c4e23b4">2029</vnda:OperatingLossCarryforwardsBeginningExpirationYear>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzY5MDY_a8341d87-f5aa-4058-b2e3-e904be990d5c">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzItMS0xLTEtMA_884a6e64-259b-47c3-806c-0f7066139d5f"
      unitRef="usd">9741000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzItMy0xLTEtMA_8663f4fd-aea3-45d7-b466-7966f1dcf2d4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i926bf00cb18047ab87ba70c56d7331bb_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzItNS0xLTEtMA_f0cfb24d-706d-4a3b-ae03-eb146ed59f4f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzMtMS0xLTEtMA_43ed39bb-1016-4d7b-ae10-0edf61bd84a7"
      unitRef="usd">121000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzMtMy0xLTEtMA_07e047b9-8fa7-4634-b9b7-e752f7dd0dcb"
      unitRef="usd">8223000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzMtNS0xLTEtMA_155378af-bd14-4cef-afaa-9499a3748584"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzQtMS0xLTEtMA_8530403c-c629-486f-863d-182e66ef118c"
      unitRef="usd">1613000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzQtMy0xLTEtMA_c38dd537-b987-4ce5-8d76-0eea8d7cf759"
      unitRef="usd">1518000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzQtNS0xLTEtMA_c6b26062-f86f-469c-9565-6ee6dfe21e59"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzUtMS0xLTEtMA_6bf22a1b-e18d-4a40-bb4b-75f9261149a1"
      unitRef="usd">11233000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib28d7508f88c4efabda9793b54a8f6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzUtMy0xLTEtMA_92814ea1-3375-4e0c-a535-b4d945cfed5c"
      unitRef="usd">9741000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i74f75e6998da4ac1a5f8b421e5dbe0da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90YWJsZTo2YmZhMGJkZWU4MGI0Y2IzYjUzZTgwZDRiYmU2ZWE4NS90YWJsZXJhbmdlOjZiZmEwYmRlZTgwYjRjYjNiNTNlODBkNGJiZTZlYTg1XzUtNS0xLTEtMA_0c53446b-1167-4c56-b9da-2639a43811f1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNTcvZnJhZzoxN2QzODY0M2Q1Yjc0ZWM1YTQzYWMyZDI0NDM0YTQ5ZC90ZXh0cmVnaW9uOjE3ZDM4NjQzZDViNzRlYzVhNDNhYzJkMjQ0MzRhNDlkXzUyNzU_204a3ac0-de22-4a01-b086-46519659341a"
      unitRef="usd">11200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90ZXh0cmVnaW9uOjExMWZhNTc1N2IzMTQ3NjQ5ZGI0MTQzMmI4ODczNmE1XzkwOQ_10a2eee7-18f3-4d0d-bc26-33a8110316ab">Earnings per ShareBasic earnings per share (EPS) is calculated by dividing the net income by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90ZXh0cmVnaW9uOjExMWZhNTc1N2IzMTQ3NjQ5ZGI0MTQzMmI4ODczNmE1XzkxNQ_7eeac429-2c36-4be6-b4e0-fe9ee636c614">Earnings per Share&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (EPS) is calculated by dividing the net income by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net income per share of common stock for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands, except for share and per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,427,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,137,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,859,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,185,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,190,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,847,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,045,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, basic and diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antidilutive securities excluded from calculations of diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,407,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90ZXh0cmVnaW9uOjExMWZhNTc1N2IzMTQ3NjQ5ZGI0MTQzMmI4ODczNmE1XzkxMw_668dc24f-27cc-4116-bee9-6499987cd582">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net income per share of common stock for the years ended December 31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands, except for share and per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,427,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,137,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,859,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,185,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,190,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,847,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,045,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, basic and diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antidilutive securities excluded from calculations of diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,407,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzMtMS0xLTEtMA_94ee4542-9bef-4f8a-b729-df2aadac7e8c"
      unitRef="usd">23337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzMtMy0xLTEtMA_5a8c2a7e-0263-47c3-8929-bb9a0f07f598"
      unitRef="usd">115553000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzMtNS0xLTEtMA_aebda3c2-42a5-4ac4-af2c-a0784b84c03e"
      unitRef="usd">25208000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzUtMS0xLTEtMA_aa77e604-17e3-45b1-a429-5a80a6269d7f"
      unitRef="shares">54427683</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzUtMy0xLTEtMA_bbb64841-92fa-4847-8318-c2b20542b8de"
      unitRef="shares">53137562</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzUtNS0xLTEtMA_e8433e2c-2651-49ec-a8ca-f393d76ad7bc"
      unitRef="shares">50859947</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzYtMS0xLTEtMA_719ff5ed-f7a9-4fd6-b658-455f3effa259"
      unitRef="shares">763119</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzYtMy0xLTEtMA_69526c25-88ab-4330-b60d-42c7069f034d"
      unitRef="shares">1709498</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzYtNS0xLTEtMA_4ba484bd-d35a-4ae2-8815-6e2c14f917ba"
      unitRef="shares">2185310</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzctMS0xLTEtMA_bc5f6f6d-805c-4283-8f98-39f810a2f7e5"
      unitRef="shares">55190802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzctMy0xLTEtMA_fb816534-12fc-4493-aa2d-968b00a81e6b"
      unitRef="shares">54847060</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzctNS0xLTEtMA_44f95a9f-d60a-4d5f-a2a6-d49f4f5ac67f"
      unitRef="shares">53045257</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzktMS0xLTEtMA_30112877-03dd-4084-8ba7-68d16b698b46"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzktMy0xLTEtMA_b1db36aa-bf9f-4b89-ba59-9325d202bdb2"
      unitRef="usdPerShare">2.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzktNS0xLTEtMA_195ba7f7-5076-48a4-af69-64b41525ddc4"
      unitRef="usdPerShare">0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzEwLTEtMS0xLTA_0d09719d-df4c-480b-97e8-56f7e94972ab"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzEwLTMtMS0xLTA_6875679d-88d5-429d-9cba-2bc5cf37169c"
      unitRef="usdPerShare">2.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzEwLTUtMS0xLTA_94e510b1-5f32-42b2-9a84-00c340c214f7"
      unitRef="usdPerShare">0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzExLTEtMS0xLTA_7d7dc96c-c4ce-4629-9d17-eac94d460ec4"
      unitRef="shares">3407409</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if08264d9bc0a43bbb74bc30b3820731c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzExLTMtMS0xLTA_09613840-3e6f-46b4-afa9-ab93357c9d21"
      unitRef="shares">1932024</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f26062015ff434da5708800b4290055_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjAvZnJhZzoxMTFmYTU3NTdiMzE0NzY0OWRiNDE0MzJiODg3MzZhNS90YWJsZTpkODRkOWRlYTc1MWQ0NGM2OGQxYmVjZTIzOGY0Y2U5YS90YWJsZXJhbmdlOmQ4NGQ5ZGVhNzUxZDQ0YzY4ZDFiZWNlMjM4ZjRjZTlhXzExLTUtMS0xLTA_835a1d8d-2a89-49fe-88a4-20f4fc854f1d"
      unitRef="shares">903265</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjYvZnJhZzpkNGJkYzJhYWQ4Mzg0MDcwYjNlNmM0NjRlNWU0NzBhOS90ZXh0cmVnaW9uOmQ0YmRjMmFhZDgzODQwNzBiM2U2YzQ2NGU1ZTQ3MGE5XzE0Nzcy_77689815-9999-4fe3-acfc-1253d7946032">Legal Matters&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In 2014 and 2015, Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex) (collectively, the Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Defendants) each submitted an Abbreviated New Drug Applications (ANDA) to the FDA seeking approval to market generic versions of Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;prior to the expiration of certain of the Company&#x2019;s patents covering Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, including U.S. Patent No. 8,586,610 (&#x2018;610 Patent) and U.S. Patent No. 9,138,432 (&#x2018;432 Patent). In response, the Company filed separate lawsuits in 2014 and 2015 against each of the Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Defendants in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2016, the Delaware District Court ruled in the Company&#x2019;s favor, permanently enjoining Roxane from manufacturing, using, selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ANDA until the expiration of the &#x2018;610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. This ruling was affirmed on appeal by the Federal Circuit Court of Appeals in April 2018. West-Ward, having replaced Roxane as defendant following the acquisition of Roxane by West-Ward&#x2019;s parent company, Hikma Pharmaceuticals PLC (Hikma), petitioned the U.S. Supreme Court for a writ of certiorari, which was denied in January 2020. The Company&#x2019;s lawsuit against Hikma regarding the &#x2018;432 Patent remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into separate license agreements with each of Taro, Apotex and Lupin resolving these lawsuits in October 2016, December 2016 and July 2020, respectively. The license agreements grant Taro, Apotex and Lupin non-exclusive licenses to manufacture and commercialize a version of Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. effective as of the expiration of the &#x2018;610 Patent or earlier under certain limited circumstances. The Company entered into a confidential stipulation with Inventia regarding any potential launch of its generic versions of Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, but the Company&#x2019;s lawsuit against Inventia regarding the &#x2018;610 and &#x2018;432 Patents remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Between April and February 2021, the Company filed numerous patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Defendants) after having received multiple Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Defendants alleging that the Company&#x2019;s patents covering HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, U.S. Patent Nos. RE46,604, 9,060,995, 9,539,234, 9,549,913, 9,730,910, 9,844,241, 10,071,977, 10,149,829, 10,376,487, 10,449,176, 10,610,510, 10,610,511, and 10,829,465, were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as described in the ANDAs submitted to the FDA by each of the HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Defendants. These lawsuits have been consolidated and are schedule for trial in March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In February 2019, a qui tam action filed against the Company was unsealed by order of the U.S. District Court for the District of Columbia (DC District Court). The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint alleged that the Company violated these laws through the promotion and marketing of its products Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys&#x2019; fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. In May 2020, the DC District Court dismissed the plaintiff&#x2019;s complaint in its entirety, without prejudice. In June 2020, the plaintiff filed a second amended complaint with similar allegations and seeking the same relief. In July 2020, the Company filed another motion to dismiss and in October 2020 the plaintiff filed a reply. The DC District Court will hear the Company's motion to dismiss on February 24, 2021. The Company intends to continue to vigorously defend itself in the case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, a securities class action, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gordon v. Vanda Pharmaceuticals Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company&#x2019;s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, HETLIOZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the Company&#x2019;s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. In March 2020, the Company filed a motion to dismiss the complaint. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, a shareholder derivative complaint, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Samuel Williams v. Mihael Polymeropoulos, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Michael Bavaro v. Mihael Polymeropoulos, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bavaro &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;case to the Eastern District of New York, where the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gordon &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Williams&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases are pending. In March 2020, the Delaware District Court transferred the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bavaro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; case to the Eastern District of New York, consolidating the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Williams&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bavaro &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cases, and the plaintiffs filed a consolidated complaint in April 2020. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company&#x2019;s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  In July 2017, the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion recommending against approval of Fanaptum&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA&#x2019;s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the E.U. General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. In February 2020, the Company filed an appeal of this judgment with the Court of Justice of the E.U.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90ZXh0cmVnaW9uOjI0M2IzZDlkNTdhODRmYjM5YTYwOTUwZWY0YzgwYjE3XzI2Mg_b1c95306-08c2-4ae0-ba9c-6e205c9b1452">Quarterly Financial Data (Unaudited)&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of quarterly financial data for the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands, except for per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Gross profit includes revenues less cost of goods sold excluding amortization, and less intangible asset amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="ic85969e83c184734a768b7cbcef5635f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90ZXh0cmVnaW9uOjI0M2IzZDlkNTdhODRmYjM5YTYwOTUwZWY0YzgwYjE3XzI1OA_341a30d5-4539-4831-b79b-a1431d6822e5">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of quarterly financial data for the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands, except for per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Gross profit includes revenues less cost of goods sold excluding amortization, and less intangible asset amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzItMS0xLTEtMA_b9d827b7-ddbe-4b16-8415-c2ba87e6d793"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzItMy0xLTEtMA_2aa52874-89a8-4cc5-a59f-5684ae418258"
      unitRef="usd">62207000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzItNS0xLTEtMA_3efac7ad-c8da-4ce9-89ef-93ec625fc779"
      unitRef="usd">60308000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzItNy0xLTEtMA_d1d58758-f726-469c-b53c-2cfe2566f51e"
      unitRef="usd">67653000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzMtMS0xLTEtMA_53f14944-0dcb-4c51-9c54-53f531039a47"
      unitRef="usd">52423000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzMtMy0xLTEtMA_f63b7a42-6bf1-406f-8662-98ac198ff942"
      unitRef="usd">55991000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzMtNS0xLTEtMA_f71a1f18-fcb9-432e-b1a2-c36db756be1f"
      unitRef="usd">54041000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzMtNy0xLTEtMA_b94961eb-44fc-42a5-b754-c5c348775574"
      unitRef="usd">60871000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzQtMS0xLTEtMA_192cd0d2-d800-47cc-af50-e52262aff355"
      unitRef="usd">-125000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzQtMy0xLTEtMA_58cafc8b-a4c7-4321-9106-5a5d02bcc2f6"
      unitRef="usd">9171000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzQtNS0xLTEtMA_b523cc24-a910-4efb-9a37-55a15d9869fc"
      unitRef="usd">7742000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzQtNy0xLTEtMA_9cb9271d-1557-47dd-a860-9d015ce8de0c"
      unitRef="usd">10451000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzUtMS0xLTEtMA_a32bb925-e668-47c2-8280-ca62115421aa"
      unitRef="usd">486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzUtMy0xLTEtMA_9eca9503-222c-4664-b111-3415884db239"
      unitRef="usd">8714000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzUtNS0xLTEtMA_d34ac4d5-3265-4fbe-8b5e-fd77666e0422"
      unitRef="usd">5947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzUtNy0xLTEtMA_7a0495aa-4605-4acd-a4a2-c75634d15d6f"
      unitRef="usd">8190000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzYtMS0xLTEtMA_34ca6e56-43b5-4fc7-bb02-d13d53749389"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzYtMy0xLTEtMA_47be521c-3b59-431a-af87-a89e2d9ece65"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzYtNS0xLTEtMA_cdc51af2-75ac-4f90-9733-078c9e96f2d6"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzYtNy0xLTEtMA_52fd6738-be13-497f-aa29-3074ac964199"
      unitRef="usdPerShare">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic306fa221ddd4b6fbcd662815361e72f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzctMS0xLTEtMA_5b752e8e-5cd9-46c9-bdba-f5d705d41f15"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i735de1a344cd4c63b3728fd1db9bbde3_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzctMy0xLTEtMA_1e687618-bbc1-42e5-908c-3a535685863b"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia411e9be7291429db78e5b99f0babfb1_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzctNS0xLTEtMA_3808848d-053e-4145-a666-83580f5dd221"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icff6f745ed084863aae10666b4b2b891_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzctNy0xLTEtMA_5fcc695b-c155-4380-a4cf-9929cfb770e8"
      unitRef="usdPerShare">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:Revenues
      contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzktMS0xLTEtMA_ab70f9a9-d6ad-4608-bcd0-e6fee3ceded7"
      unitRef="usd">47713000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzktMy0xLTEtMA_077580e0-969c-4931-a28b-5ca38fb3c611"
      unitRef="usd">59060000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzktNS0xLTEtMA_4cf44668-4d7d-42a5-ad86-fedc876aeb4f"
      unitRef="usd">59485000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzktNy0xLTEtMA_80c9b7db-d489-4460-a797-47e8d8df0389"
      unitRef="usd">60930000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEwLTEtMS0xLTA_cd966508-7495-450b-976f-52aba2a4eda7"
      unitRef="usd">42220000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEwLTMtMS0xLTA_59c7bbf1-cd7a-40a2-9df7-571908d10151"
      unitRef="usd">52313000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEwLTUtMS0xLTA_3f903f62-164a-44ba-b6a4-5259e022c7f5"
      unitRef="usd">52327000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEwLTctMS0xLTA_e3ad0128-cd63-49a9-9a39-afd9efae2a2e"
      unitRef="usd">54335000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzExLTEtMS0xLTA_d1cf26a2-af8f-40f2-966a-42bc49d722c3"
      unitRef="usd">-2087000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzExLTMtMS0xLTA_3fd73572-cac2-4471-9553-17843806d567"
      unitRef="usd">9895000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzExLTUtMS0xLTA_33e7ce66-be5e-4fcd-96f5-b82ec84024fa"
      unitRef="usd">10759000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzExLTctMS0xLTA_4212e848-4dc9-4382-bdca-6c8fd8c3f121"
      unitRef="usd">4243000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEyLTEtMS0xLTA_3e55bd2e-2811-48eb-9584-bd67353c84dd"
      unitRef="usd">-612000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEyLTMtMS0xLTA_09d7e8ef-1d50-4902-a78a-6c0860141cb3"
      unitRef="usd">11526000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEyLTUtMS0xLTA_85aa6df7-c48c-49d2-9cdf-9cf44b45ac13"
      unitRef="usd">100423000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEyLTctMS0xLTA_23e31a77-6273-49f5-a992-8282c9d0803e"
      unitRef="usd">4216000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEzLTEtMS0xLTA_2686f812-cf99-4fa2-bcd7-4978220cbc6b"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEzLTMtMS0xLTA_4c573962-a6ea-4586-8074-1c54cdb15979"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEzLTUtMS0xLTA_ef39a259-4a97-4dc2-9603-1dce39345c2c"
      unitRef="usdPerShare">1.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzEzLTctMS0xLTA_db90c662-46c7-448a-98da-59603f04292c"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i464b78e16c5a420dbb2ee78f4ce27867_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzE0LTEtMS0xLTA_5f6f9150-28f5-4ffd-88d7-455f8a9fb653"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i57bc8f8aa9494a238a0e0643a88e0f45_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzE0LTMtMS0xLTA_b68864bd-c526-4cd7-889f-f3acfd935abd"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i94da092e27b14db4aff38691563ff026_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzE0LTUtMS0xLTA_23fd98d4-0cb4-4796-9e2d-337c9a4d0a4b"
      unitRef="usdPerShare">1.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie3a62439e4374ed9ac9b1ad5d8358b4d_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4ZTdlOTQzYTY0ODQ0OGQ5ODEzMDRlNjEyZTY4MTE0L3NlYzo3OGU3ZTk0M2E2NDg0NDhkOTgxMzA0ZTYxMmU2ODExNF8xNjkvZnJhZzoyNDNiM2Q5ZDU3YTg0ZmIzOWE2MDk1MGVmNGM4MGIxNy90YWJsZTplZWUyOWFmNGEwYjM0YTIwYWNmMzI2NGM2NWIwOTJjNS90YWJsZXJhbmdlOmVlZTI5YWY0YTBiMzRhMjBhY2YzMjY0YzY1YjA5MmM1XzE0LTctMS0xLTA_007ceda5-0b98-4dbf-9c45-f18b682b1f39"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548768527576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 04, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VANDA PHARMACEUTICALS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0491827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Pennsylvania Avenue NW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300 E<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">734-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNDA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,882,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified portions of the registrant&#8217;s proxy statement with respect to the registrant&#8217;s 2021 Annual Meeting of Stockholders, which is to be filed pursuant to Regulation 14A within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001347178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772358072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,031<span></span>
</td>
<td class="nump">$ 45,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">306,709<span></span>
</td>
<td class="nump">267,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">30,036<span></span>
</td>
<td class="nump">26,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,089<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">409,145<span></span>
</td>
<td class="nump">354,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,136<span></span>
</td>
<td class="nump">3,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">10,459<span></span>
</td>
<td class="nump">11,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">21,559<span></span>
</td>
<td class="nump">23,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">81,516<span></span>
</td>
<td class="nump">87,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_InventoryAndOtherNonCurrent', window );">Non-current inventory and other</a></td>
<td class="nump">6,641<span></span>
</td>
<td class="nump">3,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">533,456<span></span>
</td>
<td class="nump">483,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">31,509<span></span>
</td>
<td class="nump">27,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ProductRevenueAllowancesCurrent', window );">Product revenue allowances</a></td>
<td class="nump">34,427<span></span>
</td>
<td class="nump">31,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">65,936<span></span>
</td>
<td class="nump">59,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease non-current liabilities</a></td>
<td class="nump">11,497<span></span>
</td>
<td class="nump">12,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2,757<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">80,190<span></span>
</td>
<td class="nump">72,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 10 and 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 150,000,000 shares authorized; 54,865,092 and 53,549,612 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">650,300<span></span>
</td>
<td class="nump">631,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(197,328)<span></span>
</td>
<td class="num">(220,665)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">453,266<span></span>
</td>
<td class="nump">410,945<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 533,456<span></span>
</td>
<td class="nump">$ 483,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_InventoryAndOtherNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_InventoryAndOtherNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ProductRevenueAllowancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Revenue Allowances, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ProductRevenueAllowancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769081352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">54,865,092<span></span>
</td>
<td class="nump">53,549,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">54,865,092<span></span>
</td>
<td class="nump">53,549,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548782207608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 248,168<span></span>
</td>
<td class="nump">$ 227,188<span></span>
</td>
<td class="nump">$ 193,118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">248,168<span></span>
</td>
<td class="nump">227,188<span></span>
</td>
<td class="nump">193,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of goods sold excluding amortization</a></td>
<td class="nump">23,364<span></span>
</td>
<td class="nump">24,488<span></span>
</td>
<td class="nump">20,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">55,577<span></span>
</td>
<td class="nump">48,649<span></span>
</td>
<td class="nump">43,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">140,510<span></span>
</td>
<td class="nump">129,736<span></span>
</td>
<td class="nump">105,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">220,929<span></span>
</td>
<td class="nump">204,378<span></span>
</td>
<td class="nump">171,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">27,239<span></span>
</td>
<td class="nump">22,810<span></span>
</td>
<td class="nump">21,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">4,416<span></span>
</td>
<td class="nump">6,218<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">31,655<span></span>
</td>
<td class="nump">29,028<span></span>
</td>
<td class="nump">25,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">8,318<span></span>
</td>
<td class="num">(86,525)<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 23,337<span></span>
</td>
<td class="nump">$ 115,553<span></span>
</td>
<td class="nump">$ 25,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">54,427,683<span></span>
</td>
<td class="nump">53,137,562<span></span>
</td>
<td class="nump">50,859,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">55,190,802<span></span>
</td>
<td class="nump">54,847,060<span></span>
</td>
<td class="nump">53,045,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548773031912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 23,337<span></span>
</td>
<td class="nump">$ 115,553<span></span>
</td>
<td class="nump">$ 25,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Change in net unrealized gain (loss) on marketable securities</a></td>
<td class="num">(102)<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax benefit (provision) on other comprehensive income</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 23,327<span></span>
</td>
<td class="nump">$ 115,801<span></span>
</td>
<td class="nump">$ 25,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118948100&amp;loc=d3e30304-110892<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548777330968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,938,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 131,387<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 492,802<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">$ (361,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from public offering of common stock</a></td>
<td class="nump">100,870<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">100,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from public offering of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</a></td>
<td class="nump">6,256<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,214,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">11,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">25,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,477,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">275,422<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">611,587<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(336,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</a></td>
<td class="nump">6,264<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">6,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,072,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">115,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">53,549,612<span></span>
</td>
<td class="nump">53,549,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 410,945<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">631,307<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="num">(220,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</a></td>
<td class="nump">5,634<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,315,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">23,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">54,865,092<span></span>
</td>
<td class="nump">54,865,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 453,266<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 650,300<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
<td class="num">$ (197,328)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548773162824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 23,337<span></span>
</td>
<td class="nump">$ 115,553<span></span>
</td>
<td class="nump">$ 25,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">13,360<span></span>
</td>
<td class="nump">13,458<span></span>
</td>
<td class="nump">11,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premiums and accretion of discounts on marketable securities</a></td>
<td class="nump">179<span></span>
</td>
<td class="num">(3,099)<span></span>
</td>
<td class="num">(2,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Gain on sale of marketable securities</a></td>
<td class="num">(229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">6,189<span></span>
</td>
<td class="num">(87,767)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash adjustments, net</a></td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,767)<span></span>
</td>
<td class="nump">2,342<span></span>
</td>
<td class="num">(11,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">4,068<span></span>
</td>
<td class="num">(2,764)<span></span>
</td>
<td class="num">(4,258)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,876)<span></span>
</td>
<td class="num">(722)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">3,508<span></span>
</td>
<td class="num">(618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_IncreaseDecreaseProductRevenueAllowances', window );">Product revenue allowances</a></td>
<td class="nump">3,133<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">8,223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">51,775<span></span>
</td>
<td class="nump">45,947<span></span>
</td>
<td class="nump">29,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,795)<span></span>
</td>
<td class="num">(1,019)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(346,622)<span></span>
</td>
<td class="num">(394,517)<span></span>
</td>
<td class="num">(282,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">306,918<span></span>
</td>
<td class="nump">327,227<span></span>
</td>
<td class="nump">198,103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(41,499)<span></span>
</td>
<td class="num">(68,309)<span></span>
</td>
<td class="num">(109,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5,634<span></span>
</td>
<td class="nump">6,264<span></span>
</td>
<td class="nump">6,256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,634<span></span>
</td>
<td class="nump">6,264<span></span>
</td>
<td class="nump">107,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">15,963<span></span>
</td>
<td class="num">(16,099)<span></span>
</td>
<td class="nump">27,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of year</a></td>
<td class="nump">45,650<span></span>
</td>
<td class="nump">61,749<span></span>
</td>
<td class="nump">34,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of year</a></td>
<td class="nump">$ 61,613<span></span>
</td>
<td class="nump">$ 45,650<span></span>
</td>
<td class="nump">$ 61,749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_IncreaseDecreaseProductRevenueAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_IncreaseDecreaseProductRevenueAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765725208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Organization and Presentation</a></td>
<td class="text">Business Organization and Presentation<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Organization</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commercial portfolio is currently comprised of two products, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of schizophrenia. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first treatment for patients with Non-24 and SMS approved by the United States Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tasimelteon) for the treatment of jet lag disorder, pediatric Non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD);</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia;</span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). All intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765973096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#8217;s evaluation could change. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#8217;s Washington, D.C. headquarters.&#160;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventory and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its marketable securities as available-for-sale securities. The Company&#8217;s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders&#8217; equity in accumulated other comprehensive income. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value. The Company also reviews its available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is the result of a change in creditworthiness or other factors. If declines in the value of available for-sale securities are determined to be credit-related, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the Consolidated Statements of Operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next 12 months. The Company classifies the estimate of such inventory as non-current.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as research and development expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the estimated useful life is through July 2035, which is the estimated economic useful life of the related product patents. Intangible assets related Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been fully amortized on a straight-line basis to November 2016. The useful life estimate for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (ASC) 842,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing office leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For all office leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#8217;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management&#8217;s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i)&#160;an evaluation by the project manager of the work that has been completed during the period, (ii)&#160;measurement of progress prepared internally and/or provided by the third-party service provider, (iii)&#160;analyses of data that justify the progress, and (iv)&#160;management&#8217;s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company&#8217;s reported expenses for such period would be too low or too high.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Net Product Sales</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist of sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net sales by product for the years ended December 31, 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in&#160;thousands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available in the United States (U.S.) for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., the Company sells HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Germany and has a distribution agreement for the commercialization of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Israel. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates. &#160;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents each major customer that represented more than 10% of total revenues for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Net Product Sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents each major customer that represented more than 10% of accounts receivable, net, as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Accounts Receivable, Net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company&#8217;s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.&#160;Reserves for variable consideration are classified as product revenue allowances on the Consolidated Balance Sheets, with the exception of prompt-pay discounts that are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns that are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Prompt-pay:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Part D Coverage Gap:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Medicare Part&#160;D prescription drug benefit requires manufacturers to fund approximately 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model.&#160;Estimates for expected Medicare Part&#160;D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when the Company has validated the insurance benefits.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Service Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-payment Assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company&#8217;s third-party administrator.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Product Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company generally offers direct customers a limited right to return as contractually defined with its customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of December 31, 2020 or 2019. The following table summarizes activity for product returns as of and for the years ended December 31, 2020, 2019 and 2018, all of which relates to sales of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reserve for Product Returns</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes royalties payable, the cost of inventory sold, costs to write down inventory to net realizable value, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Company&#8217;s distribution partners.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company&#8217;s research and development efforts and has no alternative future use.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award&#8217;s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were&#160;$12.6 million, $3.2 million and $0.9 million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reporting currency of the Company is the U.S. dollar. The functional currency of the Company&#8217;s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in accumulated other comprehensive income.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions denominated in currencies other than subsidiaries&#8217; functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the Consolidated Balance Sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions. Foreign currency transaction gains and losses are included in other income and were not material for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the novel coronavirus known as COVID-19 has resulted in government-imposed quarantines, travel restrictions and other public health safety measures. As this pandemic endures, the extent to which COVID-19 may impact the Company's business, financial condition and results of operations is uncertain and will depend on many factors outside of the Company's control.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products under development require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the products will receive the necessary clearance. If the Company is denied clearance or clearance is delayed, it may have a material adverse impact on the Company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products are concentrated in rapidly changing, highly competitive markets, which are characterized by rapid technological advances, changes in customer requirements and evolving regulatory requirements and industry standards. Any failure by the Company to anticipate or to respond adequately to technological developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards or any significant delays in the development or introduction of products or services could have a material adverse effect on the Company&#8217;s business, operating results and future cash flows.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company depends on single source suppliers for critical raw materials for manufacturing, as well as other components required for the administration of its products. The loss of these suppliers could delay the clinical trials or prevent or delay commercialization of the products.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly rated financial institutions. At December 31, 2020, the Company maintained all of its cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographic Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one reporting segment and, accordingly, no segment disclosures are presented herein. Foreign sales were not material for each of the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which clarifies and simplifies certain aspects of the accounting for income taxes.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The standard is effective </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The adoption of this standard on January 1, 2021 is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses, </span>which changed the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#8220;expected loss&#8221; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's consolidated financial results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548795769000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable SecuritiesThe following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2020, which all have contractual maturities of less than two years:<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,504&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2019, which all have contractual maturities of less than two years:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,057&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767131016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8212; defined as observable inputs such as quoted prices in active markets</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8212; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8212; defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's assets classified in Level&#160;1 and Level&#160;2 as of December 31, 2020 and 2019 consist of cash equivalents and available-for-sale marketable securities. The valuation of Level&#160;1 instruments is determined using a market approach and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of Level&#160;2 instruments is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level&#160;2 securities include certificates of deposit, commercial paper, corporate notes and asset-backed securities that use as their basis readily observable market parameters. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2020, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:39.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement as of December 31, 2020 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets&#160;for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2019, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:39.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement as of December 31, 2019 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets&#160;for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,426&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value as of December 31, 2020 include no cash equivalents. Total assets measured at fair value as of December 31, 2019 include $7.0 million of cash equivalents.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances, and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765903240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,964&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767420264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s property and equipment, at cost, as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful&#160;Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and other equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 11</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,476&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $1.4 million for each of the years ended December 31, 2020, 2019 and 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767749624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term leases primarily include operating leases and subleases for office space in Washington, D.C. and London, England. The Company recognized ROU assets and lease liabilities related to fixed payments for these long-term operating leases in its Consolidated Balance Sheet as of December 31, 2020 and 2019. The Company also has short-term leases, including office space in Berlin, Germany.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2011, the Company entered into an operating lease agreement under which it leases 33,534 square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. Subject to the prior rights of other tenants, the Company has the right to renew the lease for five years following its expiration in July 2028. As of December 31, 2020, the renewal period has not been included in the lease term. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions. The lease may be terminated early by the Company or the landlord under certain circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into a sublease agreement under which it subleases an additional 9,928 square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. The sublease term began in </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;2017 and ends in July&#160;2026 but may be terminated earlier by either party under certain circumstances. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into an operating lease agreement under which it leases 2,880 square feet of office space in London, England. In November 2020, the Company extended the non-cancellable portion of the lease term from 2021 to 2023 and has the option to renew the lease for an additional three years following its expiration.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s ROU assets and operating lease liabilities as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the years ended December 31, 2020 and 2019, the Company recognized operating lease cost of $2.3 million and short-term operating lease cost of $0.4 million. The Company also recognized $1.5 million and $1.4 million, respectively, of expense related to non-lease elements, such as building maintenance services and utilities, and executory costs associated with the operating leases. For existing leases as of January 1, 2019, executory costs are excluded from operating lease expense, which is consistent with the Company's accounting under ASC 840. For all leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices. For the year ended December 31, 2018, the Company recognized $3.6 million of rent expense, inclusive of lease expense, non-lease elements, and executory costs for short and long-term operating leases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities is included in operating cash flows and was $2.6 million and $2.5 million for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of December 31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current obligations under leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767420264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of $8.0 million to BMS. The $8.0 million is being amortized on a straight-line basis over the estimated economic useful life of the related product patents. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company met its final milestone under its license agreement with BMS when cumulative worldwide sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;reached $250.0 million. As a result of the achievement of this milestone, the Company made a payment to BMS of $25.0 million in 2018. The $25.0&#160;million, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated economic useful life of both the $8.0 million and the $25.0 million intangible assets were changed from February 2035 to July 2035 based on the July 2035 expiration date of U.S. patent number 10,376,487&#160;(&#8216;487 Patent) issued by the U.S. Patent and Trademark Office in August 2019.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s intangible assets as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s intangible assets as of December 31, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company also had $27.9 million of fully amortized intangible assets related to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense for the years ended December 31, 2020, 2019 and 2018 was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the future intangible asset amortization schedule as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767132456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts Payable and Accrued Liabilities<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s accounts payable and accrued liabilities as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and other professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone obligations under license agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,590&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548766254600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#8217;s products. The term of these indemnification agreements is generally perpetual from the date of execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2020, the Company has paid BMS $37.5 million in upfront fees and milestone obligations, including $33.0 million of regulatory approval and commercial milestones capitalized as intangible assets (see Note 8). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net sales to BMS in any territory where the Company commercializes HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for a period equal to the greater of 10 years following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a 10% royalty on net sales in that territory.&#160;The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the&#160;mid-twenties.&#160;The Company is obligated&#160;to use its commercially reasonable efforts to develop and commercialize HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to the terms of a settlement agreement with Novartis Pharma AG (Novartis), Novartis transferred all U.S. and Canadian rights in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> franchise to the Company on December&#160;31, 2014. The Company paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December&#160;2019 related to manufacturing know-how. The Company is also obligated to pay Sanofi a fixed royalty on Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;net sales equal to 6% on Sanofi&#160;know-how&#160;not related to manufacturing under certain conditions for a period of up to 10 years in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tradipitant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an&#160;NK-1R&#160;antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. As of December 31, 2020, the Company has paid Lilly $3.0 million in upfront fees and development milestones. As of December 31, 2020, remaining milestone obligations include a $2.0 million development milestone due upon the filing of the first marketing authorization for tradipitant in either the U.S. or European Union (E.U.), $10.0 million and $5.0 million for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to $80.0 million for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Portfolio of CFTR activators and inhibitors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as single-digit royalties on net sales. As of December 31, 2020, the Company has paid UCSF $1.2 million in upfront fees and development milestones, including a $0.2 million development milestone payment in March 2019. As of December 31, 2020, remaining milestone obligations include </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.2 million for development milestones and $33.0 million for future regulatory approval and sales milestones. Included in the $12.2 million of development milestones is a $350,000 milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed $1.1 million in total for the CFTR portfolio.  In the fourth quarter of 2020, the Company determined the $350,000 milestone to be probable and accrued it as a current liability as of December 31, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VQW-765.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with a settlement agreement with Novartis relating to Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize VQW-765 and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div>In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company&#8217;s current agreements for clinical, marketing and other services may be terminated on generally 90 days&#8217; notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company&#8217;s contractors in closing out work in progress as of the effective date of termination.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767047304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_PublicOfferingOfCommonStockTextBlock', window );">Public Offering of Common Stock</a></td>
<td class="text">Public Offering of Common StockIn March 2018, the Company completed a public offering of 6,325,000 shares of its common stock, including the exercise of the underwriters&#8217; option to purchase an additional 825,000 shares of common stock, at a price to the public of $17.00 per share. Net cash proceeds from the public offering were $100.9&#160;million, after deducting the underwriting discounts and commissions and offering expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_PublicOfferingOfCommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public Offering Of Common Stock [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_PublicOfferingOfCommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767429096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">Accumulated Other Comprehensive Income<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548766010584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there were 5,246,381 shares subject to outstanding options and RSUs under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April&#160;2016, and the Company adopted the 2016 Plan. Outstanding options under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company&#8217;s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated three times to increase the number of shares reserved for issuance, among other administrative changes. Each of the amendments and restatements of the 2016 Plan was approved by the Company's stockholders. There is a total of 8,790,000 shares of common stock authorized for issuance under the 2016 Plan, 3,991,612 shares of which remained available for future grant as of December 31, 2020.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over four years, with the first 25% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the service option awards in 36 equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards granted to employees and executive officers provide for partial </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceleration of vesting if the employee or executive officer is subject to an involuntary termination, and full acceleration of vesting if the employee or executive officer is subject to an involuntary termination within 24 months after a change in control of the Company. Service option awards granted to directors provide for accelerated vesting if there is a change in control of the Company or if the director's service terminates as a result of the director's death or total and permanent disability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $6.9 million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of 1.2 years. No option awards are classified as a liability as of December 31, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.797%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;for&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise&#160;Price&#160;at Grant Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Remaining&#160;Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,719,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(685,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546,344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,495,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,394&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of options granted was $5.53, $10.19 and $10.66 per share for the years ended December 31, 2020, 2019 and 2018, respectively. Proceeds from the exercise of stock options amounted to $5.6 million, $6.3 million and $6.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An RSU is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#8217;s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that are subject to terms and conditions established by the compensation committee of the board of directors. Service RSUs granted to employees vest in four equal annual installments provided that the employee remains employed with the Company. Certain service RSUs granted to employees and executive officers provide for accelerated vesting if the employee or executive officer is subject to an involuntary termination within 24 months after a change in control. Annual service RSUs granted to directors vest on the first anniversary of the grant date and provide for accelerated vesting if there is a change in control of the Company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $18.3 million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of 1.6 years. No RSUs are classified as a liability as of December 31, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value for the 581,757 shares underlying RSUs that vested during the year ended December 31, 2020 was $9.6 million.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the years ended December 31, 2020, 2019 and 2018 comprised of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company&#8217;s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December 31, 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767343144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanThe Company has a defined contribution plan under IRC Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Currently, the Company matches fifty percent up to the first six percent of employee contributions. All matching contributions have been paid by the Company. The Company match vests over a 4-year period and amounted to $0.9 million, $0.8 million and $0.9 million for the years ended December 31, 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765690424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the domestic and foreign components of income before income taxes for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,525)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance was retained against certain District of Columbia state deferred tax assets as of December 31, 2020, and 2019. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is reconciliation between the federal statutory tax rate and the Company&#8217;s effective tax rate for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other tax rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in state deferred taxes (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.34pt">Reductions in 2020 valuation allowances are attributable to 2020 income before income taxes. Reductions in 2019 valuation allowances include $7.5 million related to 2019 U.S. income before income taxes, $10.7 related to adjustments for prior period credit carryforwards and uncertain tax positions and $85.6 million related to a change in </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">2019 activity includes adjustments to prior year credit carryforwards and prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Includes adjustments to state deferred taxes based on changes to filing jurisdictions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the components of the Company&#8217;s net deferred tax assets and the related tax valuation allowance as of December 31, 2020 and 2019. Certain prior period amounts in the table have been reclassified to conform to the current period presentation.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for returns and credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and orphan drug credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,890&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,323)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,844)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of changes in the Company&#8217;s tax valuation allowance for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:41.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has NOL and other tax credit carryforwards in several jurisdictions. As of December 31, 2020, the Company has $35.2 million of deferred tax assets relating to U.S. federal NOL carryforwards, along with deferred tax assets of $13.4 million and $24.4 million related to U.S. federal research and development credits and orphan drug credits, respectively. These tax attributes will begin to expire in 2031, 2024 and 2030, respectively. In addition, the Company has $8.4 million of deferred tax assets relating to U.S. state NOL carryforwards, which primarily relate to the District of Columbia. State NOLs for the District of Columbia will begin to expire in 2032 and other state NOLs will begin to expire in 2029. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of uncertain tax benefits that, if recognized, would impact the effective tax rate is $11.2 million. No material income tax interest or penalties have been recorded, and unrecognized tax benefits are not expected to change materially over the next 12 months. Income tax returns filed by the Company for all periods are open to examination by tax jurisdictions. As of December 31, 2020, the Company is not under examination by any federal or state tax jurisdiction.</span></div>Certain tax attributes of the Company, including NOLs and credits, would be subject to a limitation should an ownership change as defined under the Internal Revenue Code of 1986, as amended (IRC), Section&#160;382, occur. The limitations resulting from a change in ownership could affect the Company&#8217;s ability to utilize its NOLs and credit carryforward (tax attributes). Ownership changes occurred in the years ending December&#160;31, 2014 and December&#160;31, 2008. The Company believes that the ownership changes in 2014 and 2008 will not impact its ability to utilize NOL and credit carryforwards; however, future ownership changes may cause the Company&#8217;s existing tax attributes to have additional limitations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548766029416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) is calculated by dividing the net income by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income per share of common stock for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for share and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,427,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,137,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,859,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,190,802&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,847,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,045,257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive securities excluded from calculations of diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,407,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767879320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text">Legal Matters<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In 2014 and 2015, Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex) (collectively, the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Defendants) each submitted an Abbreviated New Drug Applications (ANDA) to the FDA seeking approval to market generic versions of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;prior to the expiration of certain of the Company&#8217;s patents covering Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, including U.S. Patent No. 8,586,610 (&#8216;610 Patent) and U.S. Patent No. 9,138,432 (&#8216;432 Patent). In response, the Company filed separate lawsuits in 2014 and 2015 against each of the Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Defendants in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2016, the Delaware District Court ruled in the Company&#8217;s favor, permanently enjoining Roxane from manufacturing, using, selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane&#8217;s </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ANDA until the expiration of the &#8216;610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. This ruling was affirmed on appeal by the Federal Circuit Court of Appeals in April 2018. West-Ward, having replaced Roxane as defendant following the acquisition of Roxane by West-Ward&#8217;s parent company, Hikma Pharmaceuticals PLC (Hikma), petitioned the U.S. Supreme Court for a writ of certiorari, which was denied in January 2020. The Company&#8217;s lawsuit against Hikma regarding the &#8216;432 Patent remains pending.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into separate license agreements with each of Taro, Apotex and Lupin resolving these lawsuits in October 2016, December 2016 and July 2020, respectively. The license agreements grant Taro, Apotex and Lupin non-exclusive licenses to manufacture and commercialize a version of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. effective as of the expiration of the &#8216;610 Patent or earlier under certain limited circumstances. The Company entered into a confidential stipulation with Inventia regarding any potential launch of its generic versions of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but the Company&#8217;s lawsuit against Inventia regarding the &#8216;610 and &#8216;432 Patents remains pending.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Between April and February 2021, the Company filed numerous patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Defendants) after having received multiple Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Defendants alleging that the Company&#8217;s patents covering HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, U.S. Patent Nos. RE46,604, 9,060,995, 9,539,234, 9,549,913, 9,730,910, 9,844,241, 10,071,977, 10,149,829, 10,376,487, 10,449,176, 10,610,510, 10,610,511, and 10,829,465, were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as described in the ANDAs submitted to the FDA by each of the HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Defendants. These lawsuits have been consolidated and are schedule for trial in March 2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In February 2019, a qui tam action filed against the Company was unsealed by order of the U.S. District Court for the District of Columbia (DC District Court). The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint alleged that the Company violated these laws through the promotion and marketing of its products Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys&#8217; fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. In May 2020, the DC District Court dismissed the plaintiff&#8217;s complaint in its entirety, without prejudice. In June 2020, the plaintiff filed a second amended complaint with similar allegations and seeking the same relief. In July 2020, the Company filed another motion to dismiss and in October 2020 the plaintiff filed a reply. The DC District Court will hear the Company's motion to dismiss on February 24, 2021. The Company intends to continue to vigorously defend itself in the case.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, a securities class action, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gordon v. Vanda Pharmaceuticals Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company&#8217;s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Company&#8217;s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. In March 2020, the Company filed a motion to dismiss the complaint. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, a shareholder derivative complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samuel Williams v. Mihael Polymeropoulos, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael Bavaro v. Mihael Polymeropoulos, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bavaro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">case to the Eastern District of New York, where the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gordon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Williams</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are pending. In March 2020, the Delaware District Court transferred the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bavaro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case to the Eastern District of New York, consolidating the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Williams</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bavaro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cases, and the plaintiffs filed a consolidated complaint in April 2020. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company&#8217;s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In July 2017, the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion recommending against approval of Fanaptum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA&#8217;s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the E.U. General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. In February 2020, the Company filed an appeal of this judgment with the Court of Justice of the E.U.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765904376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text">Quarterly Financial Data (Unaudited)<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of quarterly financial data for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Gross profit includes revenues less cost of goods sold excluding amortization, and less intangible asset amortization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548773140408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DescriptionOfBusinessPolicyTextBlock', window );">Business Organization</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Organization</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commercial portfolio is currently comprised of two products, HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of schizophrenia. HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first treatment for patients with Non-24 and SMS approved by the United States Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tasimelteon) for the treatment of jet lag disorder, pediatric Non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD);</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia;</span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). All intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#8217;s evaluation could change. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashFor purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#8217;s Washington, D.C. headquarters.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its marketable securities as available-for-sale securities. The Company&#8217;s investment policy requires the selection of high-quality issuers. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders&#8217; equity in accumulated other comprehensive income. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value. The Company also reviews its available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is the result of a change in creditworthiness or other factors. If declines in the value of available for-sale securities are determined to be credit-related, a loss is recorded in earnings in the current period. Interest and dividend income is recorded when earned and included in other income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to earliest call date and maturity, respectively, and included in other income. The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the Consolidated Statements of Operations when generated. All available-for-sale marketable securities are available for use in current operations and are classified as current.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next 12 months. The Company classifies the estimate of such inventory as non-current.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as research and development expense. Obligations for milestone payments to other pharmaceutical companies that may result in a capitalized intangible asset are recognized when it is deemed probable that the milestone event will occur. In the event a product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized on a straight-line basis over the estimated useful economic life of the of the related product patents. For intangible assets related to HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the estimated useful life is through July 2035, which is the estimated economic useful life of the related product patents. Intangible assets related Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been fully amortized on a straight-line basis to November 2016. The useful life estimate for Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents solely owned by the Company with varying expiration dates, the latest of which is December 2031.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized using a </span></div>straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of operations for that period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (ASC) 842,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, effective January 1, 2019, the Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company does not combine lease and non-lease elements for office leases. For existing office leases as of January 1, 2019, executory costs are excluded from lease expense, which is consistent with the Company's accounting under ASC 840,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For all office leases entered into after January 1, 2019, executory costs are allocated between lease and non-lease elements based upon their relative stand-alone prices.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#8217;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date in the financial statements. Accrued liabilities include research and development expenses, such as accrued costs under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, consulting and professional fees, such as lawyers and fees for marketing and other commercialization activities, accrued compensation and employee benefits, such as accrued bonus, royalties payable under licensing agreements, and other accrued fees. Pursuant to management&#8217;s assessment of the services that have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i)&#160;an evaluation by the project manager of the work that has been completed during the period, (ii)&#160;measurement of progress prepared internally and/or provided by the third-party service provider, (iii)&#160;analyses of data that justify the progress, and (iv)&#160;management&#8217;s judgment. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company&#8217;s reported expenses for such period would be too low or too high.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue from Net Product Sales</a></td>
<td class="text">Revenue from Net Product Sales<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span> (ASC 606), which the Company adopted January 1, 2018, the Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company recognizes revenue when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value add taxes, and usage-based taxes are excluded from revenues.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Major Customers</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available in the United States (U.S.) for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Specialty pharmacy customers include Diplomat Pharmacy, Inc. (a subsidiary of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UnitedHealth Group) and Accredo (a subsidiary of Express Scripts). Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. Wholesaler customers include Cardinal Health, Inc., AmerisourceBergen Drug Corporation, and McKesson Corporation. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., the Company sells HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Germany and has a distribution agreement for the commercialization of Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>&#160;in Israel. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ReservesForVariableConsiderationPolicyTextBlock', window );">Reserves for Variable Consideration</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is determined based upon the consideration to which the Company will be entitled in exchange for transferring product to the customer. The Company&#8217;s product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. The Company estimates the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and updates its estimate at each reporting date. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.&#160;Reserves for variable consideration are classified as product revenue allowances on the Consolidated Balance Sheets, with the exception of prompt-pay discounts that are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns that are resolved during the product expiry period specified in the customer contract. The Company currently records sales allowances for the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Prompt-pay:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Specialty pharmacies and wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Part D Coverage Gap:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Medicare Part&#160;D prescription drug benefit requires manufacturers to fund approximately 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. Vanda accounts for the Medicare Part D coverage gap using a point of sale model.&#160;Estimates for expected Medicare Part&#160;D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when the Company has validated the insurance benefits.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Service Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company receives sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-payment Assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by the Company&#8217;s third-party administrator.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Product Returns</span>: The Company generally offers direct customers a limited right to return as contractually defined with its customers. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. The Company does not expect returned goods to be resalable. There was no right of return asset as of December 31, 2020 or 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes royalties payable, the cost of inventory sold, costs to write down inventory to net realizable value, manufacturing and supply chain costs and product shipping and handling costs related to sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Company&#8217;s distribution partners.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are </span></div>capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company&#8217;s research and development efforts and has no alternative future use.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. Selling, general and administrative expenses are associated with the activities of the corporate, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Affordable Care Act fee.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. The Company recognizes the expense over the award&#8217;s vesting period. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line method. As stock-based compensation expense recognized in the Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expense</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses, recorded in selling, general and administrative expenses, were&#160;$12.6 million, $3.2 million and $0.9 million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reporting currency of the Company is the U.S. dollar. The functional currency of the Company&#8217;s international subsidiaries is the local currency. Assets and liabilities denominated in foreign currencies, including intercompany balances for which settlement is anticipated in the foreseeable future, are translated at exchange rates in effect at the balance sheet date. Foreign currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in accumulated other comprehensive income.</span></div>Transactions denominated in currencies other than subsidiaries&#8217; functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the Consolidated Balance Sheets related to these items will result in unrealized foreign currency transaction gains and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carryforwards that can be utilized in the future to offset taxable income. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which clarifies and simplifies certain aspects of the accounting for income taxes.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The standard is effective </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The adoption of this standard on January 1, 2021 is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses, </span>which changed the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#8220;expected loss&#8221; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's consolidated financial results.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per ShareBasic earnings per share (EPS) is calculated by dividing the net income by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9054-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable and Accrued Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DescriptionOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of Business</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DescriptionOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ReservesForVariableConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reserves for variable consideration policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ReservesForVariableConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772945368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventory and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Net Product Sales</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist of sales of HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net sales by product for the years ended December 31, 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in&#160;thousands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Major Customers that Represented More Than 10% of Total Revenues</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents each major customer that represented more than 10% of total revenues for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Net Product Sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents each major customer that represented more than 10% of accounts receivable, net, as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Accounts Receivable, Net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of Product Return Allowance</a></td>
<td class="text">The following table summarizes activity for product returns as of and for the years ended December 31, 2020, 2019 and 2018, all of which relates to sales of Fanapt<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reserve for Product Returns</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Schedule Of Valuation And Qualifying Accounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767879320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Marketable Securities</a></td>
<td class="text">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2020, which all have contractual maturities of less than two years:<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,504&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2019, which all have contractual maturities of less than two years:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,057&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765904376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2020, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:39.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement as of December 31, 2020 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets&#160;for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2019, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:39.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement as of December 31, 2019 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets&#160;for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,426&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765764728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ScheduleOfInventoriesTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, current</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,964&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ScheduleOfInventoriesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ScheduleOfInventoriesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765953240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment-at Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s property and equipment, at cost, as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful&#160;Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and other equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 11</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,476&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548795769000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Lease Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s ROU assets and operating lease liabilities as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Reconciliation of Future Cash Obligations to Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the Company's future cash obligations to operating lease liabilities recorded on the balance sheet as of December 31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current obligations under leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Lease Assets And Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772403624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s intangible assets as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s intangible assets as of December 31, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Summary of Amortization Expense</a></td>
<td class="text">Amortization expense for the years ended December 31, 2020, 2019 and 2018 was as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Summary of Future Intangible Asset Amortization</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the future intangible asset amortization schedule as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769743320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s accounts payable and accrued liabilities as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and other professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone obligations under license agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,590&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548766054264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772711576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.797%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;for&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise&#160;Price&#160;at Grant Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Remaining&#160;Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,719,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(685,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546,344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,495,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,394&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the Plans for the years ended December 31, 2020, 2019, and 2018 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the years ended December 31, 2020, 2019 and 2018 comprised of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted</a></td>
<td class="text">Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December 31, 2020, 2019 and 2018 were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772212056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of the Domestic and Foreign Components of Income Before Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the domestic and foreign components of income before income taxes for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Provision (Benefit) for Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,525)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Statutory Tax Rate and Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is reconciliation between the federal statutory tax rate and the Company&#8217;s effective tax rate for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other tax rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in state deferred taxes (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.34pt">Reductions in 2020 valuation allowances are attributable to 2020 income before income taxes. Reductions in 2019 valuation allowances include $7.5 million related to 2019 U.S. income before income taxes, $10.7 related to adjustments for prior period credit carryforwards and uncertain tax positions and $85.6 million related to a change in </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">beginning-of-the-year balances that resulted from a change in circumstances that caused a change in judgment about the realizability of U.S. deferred tax assets in future years. Reductions in 2018 valuation allowances are attributable to 2018 income before income taxes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">2019 activity includes adjustments to prior year credit carryforwards and prior year tax positions. As a result of the tax valuation allowance previously recorded against deferred tax assets in the U.S., these adjustments resulted in no change in tax expense.</span></div>(3)Includes adjustments to state deferred taxes based on changes to filing jurisdictions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets and Related Valuation Allowance</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the components of the Company&#8217;s net deferred tax assets and the related tax valuation allowance as of December 31, 2020 and 2019. Certain prior period amounts in the table have been reclassified to conform to the current period presentation.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for returns and credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and orphan drug credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,890&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,323)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,844)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Changes in Tax Valuation Allowance</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of changes in the Company&#8217;s tax valuation allowance for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:41.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765748872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income Per Share of Common Stock</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income per share of common stock for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for share and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,427,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,137,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,859,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,190,802&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,847,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,045,257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive securities excluded from calculations of diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,407,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767177800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of quarterly financial data for the years ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands, except for per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Gross profit includes revenues less cost of goods sold excluding amortization, and less intangible asset amortization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765734024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Presentation (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>segment </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_NumberOfProductsInPortfolio', window );">Number of products in portfolio | product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_NumberOfProductsInPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Products In Portfolio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_NumberOfProductsInPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769273016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,031<span></span>
</td>
<td class="nump">$ 45,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted cash included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">61,613<span></span>
</td>
<td class="nump">45,650<span></span>
</td>
<td class="nump">$ 61,749<span></span>
</td>
<td class="nump">$ 34,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted cash included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=vnda_NoncurrentInventoryAndOtherMember', window );">Non-current inventory and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted cash included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vnda_NoncurrentInventoryAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vnda_NoncurrentInventoryAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548777295976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Sales by Product (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 248,168<span></span>
</td>
<td class="nump">$ 227,188<span></span>
</td>
<td class="nump">$ 193,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">160,686<span></span>
</td>
<td class="nump">142,980<span></span>
</td>
<td class="nump">115,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_FanaptMember', window );">Fanapt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 87,482<span></span>
</td>
<td class="nump">$ 84,208<span></span>
</td>
<td class="nump">$ 77,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_FanaptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_FanaptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772969400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail) - Customer Concentration Risk - Sales Revenue, Net<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Distributor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Distributor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Distributor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Distributor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Distributor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548771859256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail) - Credit Concentration Risk - Accounts Receivable<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Distributor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Distributor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Distributor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Distributor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Distributor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vnda_CustomerFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vnda_CustomerFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772446232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD', window );">Percentage of insurance coverage gap allocated for prescription drugs under Medicare Part D</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses | $</a></td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of responsibility for patient's cost of branded prescription taken by the manufacturers under Medicare Part D.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765671864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail) - Reserve for Product Returns - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 6,120<span></span>
</td>
<td class="nump">$ 5,187<span></span>
</td>
<td class="nump">$ 4,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions</a></td>
<td class="nump">3,844<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments</a></td>
<td class="num">(5,266)<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="num">(1,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 4,698<span></span>
</td>
<td class="nump">$ 6,120<span></span>
</td>
<td class="nump">$ 5,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=vnda_SECSchedule1209AllowanceProductReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=vnda_SECSchedule1209AllowanceProductReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769157752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Available-For-Sale Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 306,504<span></span>
</td>
<td class="nump">$ 266,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">306,709<span></span>
</td>
<td class="nump">267,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">165,966<span></span>
</td>
<td class="nump">88,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">166,092<span></span>
</td>
<td class="nump">88,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">140,538<span></span>
</td>
<td class="nump">129,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 140,617<span></span>
</td>
<td class="nump">130,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769594968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 306,709,000<span></span>
</td>
<td class="nump">$ 274,027,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">166,092,000<span></span>
</td>
<td class="nump">88,601,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">140,617,000<span></span>
</td>
<td class="nump">137,025,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,401,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;Prices&#160;in Active&#160;Markets&#160;for Identical&#160;Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">166,092,000<span></span>
</td>
<td class="nump">88,601,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;Prices&#160;in Active&#160;Markets&#160;for Identical&#160;Assets (Level 1) | U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">166,092,000<span></span>
</td>
<td class="nump">88,601,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;Prices&#160;in Active&#160;Markets&#160;for Identical&#160;Assets (Level 1) | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;Prices&#160;in Active&#160;Markets&#160;for Identical&#160;Assets (Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;Other Observable&#160;Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">140,617,000<span></span>
</td>
<td class="nump">185,426,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;Other Observable&#160;Inputs (Level 2) | U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;Other Observable&#160;Inputs (Level 2) | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">140,617,000<span></span>
</td>
<td class="nump">137,025,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;Other Observable&#160;Inputs (Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,401,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767464520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, current</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrentAbstract', window );"><strong>Non-Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_InventoryRawMaterialsNetOfReservesNonCurrent', window );">Raw materials</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_InventoryWorkInProcessNetOfReservesNonCurrent', window );">Work-in-process</a></td>
<td class="nump">4,045<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent', window );">Finished goods</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Total inventory, non-current</a></td>
<td class="nump">5,091<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_Inventory', window );">Total inventory</a></td>
<td class="nump">$ 6,371<span></span>
</td>
<td class="nump">$ 3,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_Inventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_Inventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_InventoryFinishedGoodsNetOfReservesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_InventoryRawMaterialsNetOfReservesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_InventoryRawMaterialsNetOfReservesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_InventoryWorkInProcessNetOfReservesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_InventoryWorkInProcessNetOfReservesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548768658360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Property and Equipment-at Cost (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 12,164<span></span>
</td>
<td class="nump">$ 10,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(8,028)<span></span>
</td>
<td class="num">(6,612)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 4,136<span></span>
</td>
<td class="nump">3,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vnda_ComputerHardwareAndOtherEquipmentMember', window );">Computer and other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful&#160;Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 5,212<span></span>
</td>
<td class="nump">4,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful&#160;Life (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful&#160;Life (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 5,457<span></span>
</td>
<td class="nump">$ 4,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful&#160;Life (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful&#160;Life (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vnda_ComputerHardwareAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vnda_ComputerHardwareAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548766025800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">$ 1,387<span></span>
</td>
<td class="nump">$ 1,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548777383320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_OperatingLeaseNonLeaseComponentExpense', window );">Non-lease component expense</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_DC', window );">Washington, D.C. Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Leased square footage | ft&#178;</a></td>
<td class="nump">33,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of lease agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">London Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Leased square footage | ft&#178;</a></td>
<td class="nump">2,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of lease agreement</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vnda_SubleaseMember', window );">Sublease | Washington, D.C. Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Leased square footage | ft&#178;</a></td>
<td class="nump">9,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_OperatingLeaseNonLeaseComponentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Non-Lease Component Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_OperatingLeaseNonLeaseComponentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_DC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_DC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vnda_SubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vnda_SubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772693736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 10,459<span></span>
</td>
<td class="nump">$ 11,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">2,117<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease non-current liabilities</a></td>
<td class="nump">11,497<span></span>
</td>
<td class="nump">12,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 13,614<span></span>
</td>
<td class="nump">$ 14,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772658744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">2,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">2,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">18,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount of lease payments representing interest</a></td>
<td class="num">(4,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">13,614<span></span>
</td>
<td class="nump">$ 14,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current obligations under leases</a></td>
<td class="num">(2,117)<span></span>
</td>
<td class="num">(2,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease non-current liabilities</a></td>
<td class="nump">$ 11,497<span></span>
</td>
<td class="nump">$ 12,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548768700472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - HETLIOZ - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">203 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CumulativeNetSalesToAchieveMilestone', window );">Cumulative worldwide sales milestone</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Intangible assets capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CumulativeNetSalesToAchieveMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CumulativeNetSalesToAchieveMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767756296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Fanapt - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_FanaptMember', window );">Fanapt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Fully amortized intangible assets</a></td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_FanaptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_FanaptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772902920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Summary of Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 21,559<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">11,441<span></span>
</td>
<td class="nump">9,963<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 21,559<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772399208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Summary of Amortization Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">$ 1,478<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="nump">$ 1,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">$ 1,478<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="nump">$ 1,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767930584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Summary of Future Intangible Asset Amortization (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 21,559<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">21,559<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 14,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772208024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">$ 10,951<span></span>
</td>
<td class="nump">$ 6,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_AccruedResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">6,173<span></span>
</td>
<td class="nump">5,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">5,817<span></span>
</td>
<td class="nump">5,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting and other professional fees</a></td>
<td class="nump">5,052<span></span>
</td>
<td class="nump">5,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,117<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_AccruedMilestoneObligationsUnderLicenseAgreements', window );">Milestone obligations under license agreements</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 31,509<span></span>
</td>
<td class="nump">$ 27,590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_AccruedMilestoneObligationsUnderLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Obligations Under License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_AccruedMilestoneObligationsUnderLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772859384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - HETLIOZ - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">203 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_HetliozAbstract', window );"><strong>HETLIOZ</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_HetliozAbstract', window );"><strong>HETLIOZ</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Intangible assets capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPeriod', window );">Royalty payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPayableOnNetSalesPercentage', window );">Royalty payable percentage on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_PercentageOfFutureSublicenseFeesPayable', window );">Percentage of future sublicense fees payable to third-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">mid-twenties<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_HetliozAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hetlioz [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_HetliozAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_PercentageOfFutureSublicenseFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_PercentageOfFutureSublicenseFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_RoyaltyPayableOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_RoyaltyPayableOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_RoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_RoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772305512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Fanapt - Additional Information (Detail) - Fanapt&#174;<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FanaptAbstract', window );"><strong>Fanapt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPayableOnNetSalesPercentage', window );">Royalty payable percentage on net sales</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPeriod', window );">Royalty payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_FanaptMember', window );">November 16,2016 through December 31,2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FanaptAbstract', window );"><strong>Fanapt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPayableOnNetSalesPercentage', window );">Royalty payable percentage on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_FanaptAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fanapt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_FanaptAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_RoyaltyPayableOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_RoyaltyPayableOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_RoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_RoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_FanaptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_FanaptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_StatementScenarioSecondaryAxis=vnda_ScenarioFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_StatementScenarioSecondaryAxis=vnda_ScenarioFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772425880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Tradipitant - Additional Information (Detail) - Tradipitant - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">105 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales', window );">Future percentage of royalty payments based net sales</a></td>
<td class="text">low double digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty', window );">Development and milestone payments to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember', window );">Pre-NDA Approval Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payment</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember', window );">Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payment</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Regulatory Approval Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payment</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">E.U. | Regulatory Approval Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payment</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Milestone Obligations Paid To Third Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Percentage Of Royalty Payments Based On Net Sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_PreNDAApprovalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_PreNDAApprovalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548776931176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">46 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_AccruedMilestoneObligationsUnderLicenseAgreements', window );">Milestone obligations under license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_CftrActivatorsAndInhibitorsMember', window );">CFTR Activators and Inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_TieredRoyaltiesPayableOnFutureNetSales', window );">Tiered royalties payable on future net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">single-digit<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty', window );">Development and milestone payments to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember', window );">Regulatory Approval Milestone | CFTR Activators and Inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember', window );">Future Regulatory Approval And Sales Milestones | CFTR Activators and Inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember', window );">Development And Milestone Payment, Conclusion Of Phase I Study | CFTR Activators and Inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty', window );">Development and milestone payments to third party</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_AccruedMilestoneObligationsUnderLicenseAgreements', window );">Milestone obligations under license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Development And Milestone Payment, Conclusion Of Phase I Study | CFTR Activators and Inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_AccruedMilestoneObligationsUnderLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Obligations Under License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_AccruedMilestoneObligationsUnderLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CftrActivatorsAndInhibitorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CFTR activators and inhibitors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CftrActivatorsAndInhibitorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Milestone Obligations Paid To Third Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_TieredRoyaltiesPayableOnFutureNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered royalties potentially due to third party under license agreement based on future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_TieredRoyaltiesPayableOnFutureNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_CftrActivatorsAndInhibitorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_CftrActivatorsAndInhibitorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767733656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - VQW-765 - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vnda_VQW765Member', window );">VQW-765</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales', window );">Future percentage of royalty payments based net sales</a></td>
<td class="text">mid-teens<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Percentage Of Royalty Payments Based On Net Sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vnda_VQW765Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vnda_VQW765Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765959624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Commitments (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod', window );">Agreements for clinical and marketing services, termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreements For Clinical And Marketing Services, Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772688856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering of Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vnda_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock (in shares)</a></td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering of common stock (in dollars per shares)</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offering</a></td>
<td class="nump">$ 100,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock (in shares)</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vnda_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vnda_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767270312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=116690757&amp;loc=SL116692626-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772314664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember', window );">2006 Plan and 2016 Plan | Outstanding options and RSUs granted (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber', window );">Shares subject to outstanding options and RSUs (in shares)</a></td>
<td class="nump">5,246,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixteenPlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized for issuance (in shares)</a></td>
<td class="nump">8,790,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares of common stock available for future grant (in shares)</a></td>
<td class="nump">3,991,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnda_StockOptionsAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnda_StockOptionsAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnda_TwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769041624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationOptionAwardsContractualTerm', window );">Share based compensation option awards contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors', window );">Vesting period for subsequent stock options granted to directors</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards', window );">Portion of initial stock options granted to employees that vests on employee's first anniversary</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards', window );">Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments', window );">Number of vesting equal installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, weighted average fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.53<span></span>
</td>
<td class="nump">$ 10.19<span></span>
</td>
<td class="nump">$ 10.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 5,634<span></span>
</td>
<td class="nump">$ 6,264<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnda_ServiceOptionAwardsMember', window );">Service option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl', window );">Full acceleration of vesting, employee or executive officer subject to involuntary termination, period post change of control of the Company</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expenses</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expenses, weighted average period</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of new hire stock option award that vests after one year of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of new hire stock option award that vests monthly after one year of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Service Option Awards, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationOptionAwardsContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual term of stock option awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationOptionAwardsContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnda_ServiceOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnda_ServiceOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769422488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments', window );">Number of vesting equal installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments', window );">Number of vesting equal installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl', window );">Full acceleration of vesting, employee or executive officer subject to involuntary termination, period post change of control of the Company</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expenses related to unvested RSUs | $</a></td>
<td class="nump">$ 18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expenses, weighted average period</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Grant date fair value of common stock vested (in shares) | shares</a></td>
<td class="nump">581,757<span></span>
</td>
<td class="nump">526,175<span></span>
</td>
<td class="nump">528,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value of common stock vested | $</a></td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Service Option Awards, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769216632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Option Activity (Detail) - 2006 Plan and 2016 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">4,495,145<span></span>
</td>
<td class="nump">4,369,042<span></span>
</td>
<td class="nump">4,719,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">627,500<span></span>
</td>
<td class="nump">687,500<span></span>
</td>
<td class="nump">567,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(225,000)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(232,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(557,604)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(733,223)<span></span>
</td>
<td class="num">(546,344)<span></span>
</td>
<td class="num">(685,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,606,818<span></span>
</td>
<td class="nump">4,495,145<span></span>
</td>
<td class="nump">4,369,042<span></span>
</td>
<td class="nump">4,719,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">2,556,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at end of period (in shares)</a></td>
<td class="nump">3,482,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise&#160;Price&#160;at Grant Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 12.21<span></span>
</td>
<td class="nump">$ 11.15<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.27<span></span>
</td>
<td class="nump">18.38<span></span>
</td>
<td class="nump">19.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">18.83<span></span>
</td>
<td class="nump">7.94<span></span>
</td>
<td class="nump">13.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">14.21<span></span>
</td>
<td class="nump">14.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.68<span></span>
</td>
<td class="nump">11.47<span></span>
</td>
<td class="nump">9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">12.24<span></span>
</td>
<td class="nump">$ 12.21<span></span>
</td>
<td class="nump">$ 11.15<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">11.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at end of period (in dollars per share)</a></td>
<td class="nump">$ 12.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted&#160;Average Remaining&#160;Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Term</a></td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">5 years 6 months 29 days<span></span>
</td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">4 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at end of period</a></td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 22,148<span></span>
</td>
<td class="nump">$ 65,438<span></span>
</td>
<td class="nump">$ 24,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">2,868<span></span>
</td>
<td class="nump">2,482<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">8,511<span></span>
</td>
<td class="nump">$ 22,148<span></span>
</td>
<td class="nump">$ 65,438<span></span>
</td>
<td class="nump">$ 24,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period</a></td>
<td class="nump">7,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at end of period</a></td>
<td class="nump">$ 8,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772368936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity Plan (Detail) - Restricted Stock Units (RSU) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,649,285<span></span>
</td>
<td class="nump">1,313,576<span></span>
</td>
<td class="nump">1,357,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">832,162<span></span>
</td>
<td class="nump">937,328<span></span>
</td>
<td class="nump">714,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(260,127)<span></span>
</td>
<td class="num">(75,444)<span></span>
</td>
<td class="num">(229,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(581,757)<span></span>
</td>
<td class="num">(526,175)<span></span>
</td>
<td class="num">(528,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,639,563<span></span>
</td>
<td class="nump">1,649,285<span></span>
</td>
<td class="nump">1,313,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 18.04<span></span>
</td>
<td class="nump">$ 15.68<span></span>
</td>
<td class="nump">$ 12.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.28<span></span>
</td>
<td class="nump">19.46<span></span>
</td>
<td class="nump">18.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">17.35<span></span>
</td>
<td class="nump">18.93<span></span>
</td>
<td class="nump">15.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">16.54<span></span>
</td>
<td class="nump">14.54<span></span>
</td>
<td class="nump">12.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 15.26<span></span>
</td>
<td class="nump">$ 18.04<span></span>
</td>
<td class="nump">$ 15.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772375688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 13,360<span></span>
</td>
<td class="nump">$ 13,458<span></span>
</td>
<td class="nump">$ 11,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,804<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,556<span></span>
</td>
<td class="nump">$ 10,251<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772313816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average expected volatility</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted average expected term (years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free rate</a></td>
<td class="nump">1.14%<span></span>
</td>
<td class="nump">2.26%<span></span>
</td>
<td class="nump">2.68%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772213976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan employer matching percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan maximum employee contribution percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DefinedContributionPlanVestingPeriod', window );">Defined contribution plan vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan matching amount</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DefinedContributionPlanVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to employer matching contribution to defined contribution plan is no longer contingent on satisfaction of a service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DefinedContributionPlanVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767956824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Domestic and Foreign Components of Income Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 31,667<span></span>
</td>
<td class="nump">$ 28,794<span></span>
</td>
<td class="nump">$ 25,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 31,655<span></span>
</td>
<td class="nump">$ 29,028<span></span>
</td>
<td class="nump">$ 25,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772735256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">2,061<span></span>
</td>
<td class="nump">1,161<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">6,076<span></span>
</td>
<td class="num">(85,624)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">155<span></span>
</td>
<td class="num">(2,127)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 8,318<span></span>
</td>
<td class="num">$ (86,525)<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769464728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="num">(357.60%)<span></span>
</td>
<td class="num">(16.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(5.40%)<span></span>
</td>
<td class="num">(10.90%)<span></span>
</td>
<td class="num">(9.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug', window );">Orphan drug credit</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">17.10%<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Section 162(m) limitation</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Other tax rate changes</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment', window );">Other changes in state deferred taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent', window );">Uncertain tax positions</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">26.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other items</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">26.30%<span></span>
</td>
<td class="num">(298.10%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_IncomeBeforeIncomeTaxesCurrentYearMember', window );">Income Before Income Taxes, Current Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Reduction in valuation allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember', window );">Income Tax Credit Carryforwards and Uncertain Tax Positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Reduction in valuation allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_EstimatedRealizabilityofDeferredTaxAssetMember', window );">Estimated Realizability of Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Reduction in valuation allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117330312&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_IncomeBeforeIncomeTaxesCurrentYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_IncomeBeforeIncomeTaxesCurrentYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_EstimatedRealizabilityofDeferredTaxAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=vnda_EstimatedRealizabilityofDeferredTaxAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548769581064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets and Related Valuation Allowance (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 43,623<span></span>
</td>
<td class="nump">$ 52,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation</a></td>
<td class="nump">4,653<span></span>
</td>
<td class="nump">5,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for returns and credit losses</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther', window );">Research and development and orphan drug credit carryforwards</a></td>
<td class="nump">37,737<span></span>
</td>
<td class="nump">36,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">92,890<span></span>
</td>
<td class="nump">100,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(1,911)<span></span>
</td>
<td class="num">(1,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(2,412)<span></span>
</td>
<td class="num">(2,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(4,323)<span></span>
</td>
<td class="num">(4,844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet', window );">Deferred tax assets, net</a></td>
<td class="nump">88,567<span></span>
</td>
<td class="nump">95,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="nump">7,051<span></span>
</td>
<td class="nump">8,155<span></span>
</td>
<td class="nump">$ 111,950<span></span>
</td>
<td class="nump">$ 116,110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 81,516<span></span>
</td>
<td class="nump">$ 87,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit and other tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548772303736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DeferredTaxAssetsValuationAllowanceRollForward', window );"><strong>Deferred Tax Assets, Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 8,155<span></span>
</td>
<td class="nump">$ 111,950<span></span>
</td>
<td class="nump">$ 116,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DeferredTaxAssetsValuationAllowanceIncrease', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DeferredTaxAssetsValuationAllowanceDecrease', window );">Reductions</a></td>
<td class="num">(1,104)<span></span>
</td>
<td class="num">(103,795)<span></span>
</td>
<td class="num">(8,196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at End of Year</a></td>
<td class="nump">$ 7,051<span></span>
</td>
<td class="nump">$ 8,155<span></span>
</td>
<td class="nump">$ 111,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DeferredTaxAssetsValuationAllowanceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the period related to valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DeferredTaxAssetsValuationAllowanceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DeferredTaxAssetsValuationAllowanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the period related to valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DeferredTaxAssetsValuationAllowanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DeferredTaxAssetsValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DeferredTaxAssetsValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548768959208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 43,623<span></span>
</td>
<td class="nump">$ 52,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred tax assets related to U.S. federal research and development credits</a></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_OperatingLossCarryforwardsBeginningExpirationYear', window );">Net operating loss carryforwards beginning expiration year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear', window );">U.S. research and development credit beginning expiration year</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_OrphanDrugCreditBeginningExpirationYear', window );">Orphan drug credit beginning expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets relating to U.S. state NOL carryforwards</a></td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforwards</a></td>
<td class="nump">35,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=vnda_OrphanDrugMember', window );">Orphan Drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 24,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_DC', window );">District of Columbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_OperatingLossCarryforwardsBeginningExpirationYear', window );">Net operating loss carryforwards beginning expiration year</a></td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vnda_UnitedStatesExcludingDistrictOfColumbiaMember', window );">Other States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_OperatingLossCarryforwardsBeginningExpirationYear', window );">Net operating loss carryforwards beginning expiration year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_OperatingLossCarryforwardsBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The year in which operating loss carryforwards begin to expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_OperatingLossCarryforwardsBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_OrphanDrugCreditBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Orphan Drug Credit , Beginning Expiration Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_OrphanDrugCreditBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ResearchAndDevelopmentCreditBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development, Credit Beginning, Expiration Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ResearchAndDevelopmentCreditBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=vnda_OrphanDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=vnda_OrphanDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_DC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_DC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vnda_UnitedStatesExcludingDistrictOfColumbiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vnda_UnitedStatesExcludingDistrictOfColumbiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548765882728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at the beginning of the year</a></td>
<td class="nump">$ 9,741<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,223<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">1,613<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at the end of the year</a></td>
<td class="nump">$ 11,233<span></span>
</td>
<td class="nump">$ 9,741<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548767917944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 8,190<span></span>
</td>
<td class="nump">$ 5,947<span></span>
</td>
<td class="nump">$ 8,714<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 4,216<span></span>
</td>
<td class="nump">$ 100,423<span></span>
</td>
<td class="nump">$ 11,526<span></span>
</td>
<td class="num">$ (612)<span></span>
</td>
<td class="nump">$ 23,337<span></span>
</td>
<td class="nump">$ 115,553<span></span>
</td>
<td class="nump">$ 25,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,427,683<span></span>
</td>
<td class="nump">53,137,562<span></span>
</td>
<td class="nump">50,859,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763,119<span></span>
</td>
<td class="nump">1,709,498<span></span>
</td>
<td class="nump">2,185,310<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,190,802<span></span>
</td>
<td class="nump">54,847,060<span></span>
</td>
<td class="nump">53,045,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculations of diluted net income per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,407,409<span></span>
</td>
<td class="nump">1,932,024<span></span>
</td>
<td class="nump">903,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140548782148584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 67,653<span></span>
</td>
<td class="nump">$ 60,308<span></span>
</td>
<td class="nump">$ 62,207<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 60,930<span></span>
</td>
<td class="nump">$ 59,485<span></span>
</td>
<td class="nump">$ 59,060<span></span>
</td>
<td class="nump">$ 47,713<span></span>
</td>
<td class="nump">$ 248,168<span></span>
</td>
<td class="nump">$ 227,188<span></span>
</td>
<td class="nump">$ 193,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">60,871<span></span>
</td>
<td class="nump">54,041<span></span>
</td>
<td class="nump">55,991<span></span>
</td>
<td class="nump">52,423<span></span>
</td>
<td class="nump">54,335<span></span>
</td>
<td class="nump">52,327<span></span>
</td>
<td class="nump">52,313<span></span>
</td>
<td class="nump">42,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">10,451<span></span>
</td>
<td class="nump">7,742<span></span>
</td>
<td class="nump">9,171<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">4,243<span></span>
</td>
<td class="nump">10,759<span></span>
</td>
<td class="nump">9,895<span></span>
</td>
<td class="num">(2,087)<span></span>
</td>
<td class="nump">27,239<span></span>
</td>
<td class="nump">22,810<span></span>
</td>
<td class="nump">21,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 8,190<span></span>
</td>
<td class="nump">$ 5,947<span></span>
</td>
<td class="nump">$ 8,714<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 4,216<span></span>
</td>
<td class="nump">$ 100,423<span></span>
</td>
<td class="nump">$ 11,526<span></span>
</td>
<td class="num">$ (612)<span></span>
</td>
<td class="nump">$ 23,337<span></span>
</td>
<td class="nump">$ 115,553<span></span>
</td>
<td class="nump">$ 25,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ML/X62X593-CB$'7S(/4^BRWJ5DG=VDL]Y&FJ=\]_E'GKJ#(_9+4%WR[AVR?
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M9PF7I<#\OA9"O]V4 S0G7M/_ %!+ P04    " "%.$M2E<#60W<#  !N"@
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MT ;P_Y9S];;0#NH1<_(_4$L#!!0    ( (4X2U(DG@B?XP4  $H;   8
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M+O-2&_7/49!DK@YY50<IS3(M7YZL5965![O!X!HT\9LTZ1WLL$IF!XWD8>.
MQ%]T/'?H^Y@I#^8.:HF@&&,4IS_OZ,]'Z?\,G8#E4Z7 !$B>S&N.K<8EYH.<
MR"_'$*\(T: 7L&"4TJ?"I,6]LA32JH*$3X]"C I4@"1)[.R^!8:*@LCA@Z)8
M/,#I2)3I&Z5D([6&?'LI9>D3'I9VG./Y!4W<N""H:1+'PJT>"&XH/*RGPD:I
MW)BMU*0HBVE=B-.^<+^SY1DEQ9 D<LO# D4E7H 0E!B*3R_2] V5WL*6DY7M
MA8[4Q.Z^II#L5'JG=F\J"^WEFH[K]676UB)0&*D>;,*BG@N1TN+%>8' & ^9
MZSID,$I9,.2]7KMI-$KF5LM]JD 3GZR6R,9E9;U/&A^BU")O-6$@O$WAHZ8L
M%J%+#8&%+!IH2FC? =#Q%N!3\0 [N]3/* -?G*<LB5V=QV Q\X+CH^*A7.V%
MGHXK?;?+]NESK0E]8(YV-,K-%VL>1UX=0E!1X.H^@IH*.A2;7OCIN/+?ZG)]
MR QD$,3H -QVT&6G139 R)=?#JV,2\A'Q8*Z?'Q0PA@?X-,K.1V7\B^G]K8H
M/5^((QK'D<O/AX71//1TPX>Q^3P9:-58+^TL^*[#D(+TJDX_#+%>;]FXWEYF
MT)Y7ZJ7U4TY+@7F0C6EE>_!\$[)$(%,6!<% *K->=MFX[-X>=+9-;7']KI,(
M\^5R"@VLNR]06'U^?LT.@7$QD,FL5U_&3^=V<@?;#OIZ,:$0;FE=H,!Y"/GA
MTD. +&'\R%VO&?9RS\;E?@7M>2.+>6I:3M]'UM=N'H@Y=?42PS%0&X^JCZ/S
MA 8#58SUO0 ;[P6Z*G:HZG;WA!QO&6(23D/W&+7 <"*!\Y;+$,'18"[$4"KV
M30$3WU7%-JH V3F]BO7RS<;EV_H24CV3<OWR]F@#YP@[$^P=.$CD]N1G3_.H
M0WW9]0K:FY E J%!D SU)JR7;_:F?!\1DT]29ZJJS[ U(U ^6[WQK>(+<"1X
MZ)+S48)YG2.*BH:4KA=S]A_$_.V-TO)#Q!SAYZ,P?CZ*!C%E PQYK^5\_)A^
M#5L1NB^(EWS*ZN,3@4Y%DJP]2L'6M YXU[C!BM0#%,&B/5!IJ E:9<:^@H+G
MF!>X?Q1WWT4N$,S4;=<P#!_0+-YW&'R\PZ@#W-!6_YNIWS30:"X\LDAO087_
MH@G!L1A*Z0#EO@7A[,VZ]U](OI[NZ,7Y>%=P)>]54;3%[EFF&G6=+]EA)"*W
MT"$P0>/0\YP/XR'G _+/>_GGX_)_;8]=(R3\5^J""NK%WX<A7)?H:,=<&Q*S
MHV],N=3W];>ZBM0'QN9C37>W^QYX67\%<^Y?T0_+YJM>/TSSD?%SJB&$%=G)
M#0P9O(]!DG7SW:ZY,.6^_I)U5QI3YO7/K4S74EL /-^4I7FYL!-T7T\O_@50
M2P,$%     @ A3A+4OLTVGPJ!@  W T  !@   !X;"]W;W)K<VAE971S+W-H
M965T."YX;6RM5]MRVS80_94=92:59W2W8R?Q94:VZMIM7*N6XTS;Z0-$0B)B
M$& !,([R]3T+TK24*FX?\B*)(';W[.[!6>CHP;I[GTD9Z'.NC3]N92$4;_M]
MGV0R%[YG"VGP9F%=+@(>W;+O"R=%&HURW1\-!OO]7"C3.CF*:U-W<F3+H)61
M4T>^S'/A5J=2VX?CUK#UN'"CEEG@A?[)42&6<B;#^V+J\-1OO*0JE\8K:\C)
MQ7%K/'Q[NL?[XX8[)1_\VF_B3.;6WO/#97K<&C @J642V(/ UR=Y)K5F1X#Q
M=^VSU81DP_7?C][/8^[(92Z\/+/Z@TI#=MQZW:)4+D2IPXU]N)!U/J_87V*U
MCY_T4.\=M"@I?;!Y;0P$N3+5M_A<U^'_&(QJ@U'$706**"<BB),C9Q_(\6YX
MXQ\QU6@-<,IP4V;!X:V"73@Y+3U6O*=KMQ1&?1%5K4Q*4R>]-"$N'/4#8K%%
M/ZG]GE9^1]_P.QS1E34A\_2C266ZZ: /D W2T2/2T]&S'B<RZ='NL$.CP6CP
MC+_=)O/=Z&_W&_[6$^[0F37>:I5NSY_L@LZ5$2910M,,BQ+$#)[^',]]<*#6
M7\\@VFL0[45$>]^]%]_#+VW?=H=]@J:9P!%(9!E4(K2G2X-FM$,F4;B\$&:U
M0\J3H*6V<U1HKFRQ84%)M8T6%J26*<$S6Z?R$W2AX&)&0-B62\=5?HR/RBMC
M["?!IY=MG"B4]!0LB31UC#?#R:/2Y)"P7*8QG)$R]=&CR@MG*TO2<.'98P%O
MW+\>W3ZE4 4W"= IM!:ZYR($#P @W6 W^JN695RT1D*8"NN",DOR<LEY;/A\
M^>+U:'APZ-<2(]Z_ -<LERPIG8.1CM$+IV)M%A0>+ %W6B;!=^CBQ]MWE]=_
MT,L7PX.]0]30Q70"5#C$TL'B5VNZH[WNA2T=S;241?>#N)<T4=ZZ5#IJ5QMV
M8A*&M2I 7,GS5DJ5#Z6;@]]58K-<A:Q[!54VP#A;F=19;&[/KF:5@W-A1!&>
M!83YH;Z !DA/B=[7.< M6RR4\V'-CCT]-@=*&+(ZKQ@4T4D4L9TIS5?1P7NC
M I[BD?1T;FT:MTY<N:1Q"L%4?#XCD]KGD_%.#]1EXJCJV*\QF#+!##9E/D>Y
MD$ *'[$::R3MX#G198I^OR5N[FC_\.O4VD%XE%8':<W.]MI\!%6U6'+=8W<Z
M5("X(CB5U EW$%6+%5*K.H3CY&6SG]J3V712M4+@A/F<?($YY\I\;<]X-MDY
M;%!NMJRM-#-9I>#P-T#.56&U<$\.HV((=Z\@E>8'SR\DHRK\*LFL1TO;T\FT
M1D7:XDSPT,67,A^!3LPU./1N?!D#YJ6N^O+?['E*XM:)5!4J".QJW[W[O;O_
M>G^G@V@^%UI3;C'M2T0QLG060)7I#G%$$UD$RV?@E^[PA@$&L;1,C<[VZ$L!
MUMA"0%X4SE]N(U"ODGL62,0+MD"K4!3<"T E7D+29]=WEY/N\ T5B)_;#>1W
MMS?=T9N#+5@SX& E227D,JPTE[1],1F?05--IN:*H6^%R1>T8+5= @M\JF6<
M4+(2OGAZ"ANPEU4'JDN1X)N'S8/;#J^M2=C1"B%90:/N/8&?-I*%J&<K#TW'
M/)R[V'3TQ/A<YG-\\VDRK%HL)70CE]QDKOS9^2T7GN]@O%!K\V-Z?NU<T=WL
MY^YP.-B><NI6)%>RDF*4#_Q49J%%GC]-M=/I=7=T\ U>R<1)1%R!O<*Y3(J&
MWQL@0&B-PAQ&ATT/?_O0/=A_M8UO*@%'\$E5#]E<Q>E04P]<BFUH>+>E/5L!
MQ\-52T.#M$>G@DN/]QLCG">/2.I9&]-HKC50DD5S@_%/-Y@J95G),=N6O K'
MSPS^V#L6:&2I5UW[8%BGRKE77-1' F8"8W<NI<$DDWR6N.$QA$LC/6()ZI ,
M%N,/\ H->PP>IB7&(MZC@I7MOP4?.,>8J\!&[9_&XRGT?8R^*!,P;&M=;Y)B
M4(')*I)JKC\AE%IA5H@Z3K)^&>QMN]GUUV[<B+^,_RMXRB-0=?EN5IN_+N/J
MQOZTO?K?<R7<$HI*6BY@.N@=O&J1J_Y+5 _0FGA_G]N ?P/Q)V@+&O &O%]8
ML*A^X #-'[J3?P!02P,$%     @ A3A+4F1TZW"N)   ,'(  !@   !X;"]W
M;W)K<VAE971S+W-H965T.2YX;6RU75ESVTB2_BL(;\^.'0'1(B7+LOJ(D.7N
M'L_VX;#LZ=C=V <0*))H@P ;!4CF_/K-+S/K  C*=L?,BRT2A:JLK+R/XC?W
M3?O!;HSIDH_;JK;?/MITW>[JZ5.;;\PVL[-F9VIZLFK:;=;1QW;]U.Y:DQ7\
MTK9ZNC@]O7BZS<KZT7??\'=OVN^^:?JN*FOSIDULO]UF[?ZEJ9K[;Q_-'[DO
MWI;K38<OGG[WS2Y;FUO3O=^]:>G34S]+46Y-;<NF3EJS^O;1]?SJY3G&\X!_
ME.;>1G\GV,FR:3[@P^OBVT>G ,A4)N\P0T;_W9D;4U68B,#X0^=\Y)?$B_'?
M;O8?>.^TEV5FS4U3_586W>;;1Y>/DL*LLK[JWC;W?S.ZGV>8+V\JR_\F]S+V
M_.Q1DO>V:[;Z,D&P+6OY/_NH>(A>N#P]\L)"7U@PW+(00_DJZ[+OOFF;^Z3%
M:)H-?_!6^6T"KJQQ*+==2T]+>J_[[E8.(VE6R6VYKLM5F6=UEUSG>=/775FO
MDS=-5>:EL=\\[6@]O/4TU[E?RMR+(W//%\G/3=UM;/)]79AB.,%3 M1#NW#0
MOEP\..,KD\^2LWF:+$X7IP_,=^9W?\;SG1V9;V*;R?]>+VW7$K7\WP,+G/L%
MSGF!\W\+>A^<&^QZ97=9;KY]1/QH37MG'GW!@LE[:S#L>]N51-WTQ;N-26BF
M7=9FS#'T<%7669V76978CL80-W8V*>LD;VH(A++;$[UVF^3'Z^LWQ*-_]"5!
M0O19$T-C<-(U].F#28Q?I=MD79*M5L26]+>AMW9-VYDBR;8 T6+9S%I#?V5U
MD51EMBRKL@/$F;Q1T#P8A;^G $R3HK1YU=B^Y7$$+'8.<*8G3OF+8\"TYL[4
MO>$QYB-)0TN@%'T+9(9W\&EGVK(I9LG/8?^R=I]5U9X&GIB[K.H9#25-[I&2
M)K_WQ5JPBV4(S'Z[PR$H; &C__D?EXOY\Z_I99D*!T5G6Q5)OLEHDS,ZZX[6
MH]4L22:K#XN2,-XFJ[;9$M"-C4YDEMQD=I/RO\GW=(0TL8?D+0UKRQPHX><D
M"I-=W^X:($'/X(; )*+"L13)RZRB S')+422S#%X?AOHB%Z7.4DST#YS_&VB
M]0FQH&O"XH9D:[4_J4IZ6A#]W1%4,@=37T;XZ>A B!H#;;3&)%L1/P1S9>P!
M_= ^"&?6" (8U ,8RCJO^L(,UB3ZIXG-GE9M/Y#>7/5UH9#DS79K6J;'959_
MD/T'&BUK0GK71P<;O;#+B'X %W9[\@>=(3:4-X3L%A"71!2FI>.*SH3A;4W%
M)+5KZ4#;DBB-N,X1\,94H">:I\*HEA9:,3XZ^L!GD+>F*#O]-L.YXL]F1:+#
M)"Q@'.)NFNTNJ_>>!'^CU8GNNZ9.DU>SFQDMEA4$>-LQG) G*UJVN6=6R985
MY$MS5Q;@90*;F",G%O32)F<Z/#@#X*D]V+,R*M!.!_(I.B2,8$C7=(0 0Q/B
M_)E=_Z6K>NH>$O=50IK+;)=TOM!>C_G5IK>TAGW"RHS^F;]X@ Z_2B[FZ>G9
MG/XX?Y:>/E\<4(%2*MCC*GD#,5Y&\@J3-@1N2T9%VT:B\-GSA,]S\77R2U.?
MN*>@][IK2).$-Y\MGM'PR^0=(_$+T,; 7\S/!/B+9Z<D(<$Y3!&W)@?KEJJ
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M/96P(GW#?GR%NP=]V^.F)W;R\@_A#<G"S+R% -L]_1('*TZ-U,.68495C=L
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M'2X76H3KO7WK_+'[(B1#Q-WB7L0!JF7F+M9E&"6"Z"E.UM+R;8NK;%Q]OD.
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MB]9.257,1JIB;+8R+'C9L[;LWG4;5 /#/\ ]9Z1 \$0O4/O8:7A/#$T/(WA
M[_B*S.2_6A\:2:/C\MTBSDGE*_^'MQF5-J);5G2@/"E@U,LE]S['V&B3S]!(
M_ZMUW48/ELJ[,K4X<*9>?FBR]>EPO4[/Z>'8^H^OQ%RK/>9CIG$P"+$>EZE3
MQD=DSKHL=50VY$TBR40SR3@W-,DKD[62BWY]X-F088G:2C^&B\7\!QY097MV
M;:7@EK/F6; CV#6TX>JV047')S!ZT)R%OKEL5Q:2R*G7[%'*#R1(" $%5W?N
M KI!T6JXN>:?HG%XHA!_D_!8<<?N1>KE=E3@,<SLLT^!"T7D&F!_9@>#2J)\
M8J&]W+,B"O&:J:ZL()5'=]/!$O:>EK2<L_)MV%^FR26* 8MW 'I$=PRU7",D
M2W_&=IHV'G-L/VRMC;<C]T+N!Y7^3!63B06Y<7%P%8<_[SA-)3_=<8R:U(,\
M=C>+EQ9!<3KYP$DAO346]_.OT!L\2I:S>.#R=UBC2%M+B)1SB"7*$Z0_KNS4
MW;R/DEER$TB4ITCCRM3@T7')>!0)]*&^*"BBB8'HVER]2:NQ3M?9&"S]O1,@
M?RIUETCQV9V[H(['3?8<QK*#RRB5!UV5ON2,64<E/PQ^XD.OC7*LYR\:)IHE
M__-W,Q3MG%.-Z"8_6$F[$''9<CJ=XGS@QQ@F+[\>'O:NRG)MH?G2B<2%5?$C
M FKZYT[X<MX)YRE&!%]"*+90])L/7PP2..Z^.0K'*\-&C/XT2M3K.JAGA1R/
M;@B.72.G7.+K)MG0+73FF4O]\'WM4D/N%L6\;/MH)HUM'[G>.OP,D;_]VE1(
MGEDI5V=SBHAY"WX#U>%F,7_3.D/@8D/(ZZQ].]>/!H7?.R)&<D=#WB4F 1$2
M:H_7<<C/AHE2O<\# H%V5C?^8?C!)7<MC6M[!.!E'9QUK9>?]+6Y9TLY[TM\
M;FD#'OW,%=F!3:\7O_%=)-'=I>ZBQ<"VD_<XOFSHO^3Q#]>W+Y_(KWX4TP/?
M<Q,:KBMY_X2G/YDOTJ'K__@=^6YY\OS\]$F:W/*->'+[%N"()@4>XA=]A3;R
M?2OGD%J9@+/PSK*STB_A+A$=3AD[]%HJK=#S?=_^/DJ,%=0O#9D6-;L>W ?@
MT3=_Y@Y!5#L.<.LC]UH\IFDN]^TG)].*_:+9!?%;V@ D?3>XYV4Q=S<MQ-&)
ML:J<-+B\BLSCJ-KTQ6%$-G_OB1UP'["2#!&#IX7;]_SD9'Z61K3T.KHYD!>;
M?^V4Q4_,KFDR]=-R3Z-?\=OB'H,;;JGG8Y0?]//?)N[G$*_E5P##</DMQ9_)
M&4/XJS(K>O5T]OS9(ZE@<Q^Z9L>_";AL.C*$^$_\=I-I,8">KQK26?H!"_@?
MB?SN_P%02P,$%     @ A3A+4M6^1PU  P  O <  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&ULS57=;]LX#/]7"-]P:  W_G:<+@F0MMO='@84:W?W
M,.Q!L9E8J"UEDIRL]]<?)2=NAK5Y.>"P%YNDR!^_1&JVE^I1UX@&OK>-T'.O
M-F9[%02ZK+%E>BRW*.AD+57+#+%J$^BM0E8YH[8)XC#,@Y9QX2UF3G:G%C/9
MF88+O%.@N[9EZND:&[F?>Y%W%'SBF]I80;"8;=D&[]%\WMXIXH(!I>(M"LVE
M (7KN;>,KJY3J^\4_N*XUR<TV$Q64CY:YD,U]T(;$#98&HO Z+?#&VP:"T1A
M?#M@>H-+:WA*']'?N]PIEQ73>".;OWEEZKE7>%#AFG6-^23W?^(AG\SBE;+1
M[@O[7C<CCV6GC6P/QL2W7/1_]OU0AQ.#(GS%(#X8Q"[NWI&+\I89MI@IN0=E
MM0G-$BY59TW!<6&;<F\4G7*R,XN/3#VB8:L&X1[+3G'#4<\"0]!6(2@/,-<]
M3/P*3!3#1RE,K>&=J+#Z$2"@F(; XF-@U_%9Q%LLQY!$/L1A')[!2X9$$X>7
MO(+W0>Q0&[I.1OMPBRL#3%3P[EO'S=-)ZO!EN=)&T67Y>L9I.CA-G=/TOU;W
M+(P=S"N]927./9H\C6J'WLO8#S7"6C8T:EQL@&M@QW$#N09#IS>RW3+Q]/MO
M11Q-WI+"CO'&HES2A%]J1G#M,[)^+@S3%H+:@NT*U= :'_8U+VM@30,UVR&4
M= ]L_3K6$)(YFI-M@UI3#$R V4MX0J;T%5QP8FO9:6J''L&RE<KP?[""/Y0D
M]?[[GG$%G\?W8WB@S:,[2L=V;R-WJ(3M*= "$:7U\P:B//.G>6ZI>$K?BV3D
MI+D?3F/*7VVE8@9I=ND21&GH9TD!Q00NBI%C\V@"#]*X\%\JQ!M(PMS/PI2H
M.+)^+J)H=!!/PBG\WTV(IK]>$XJ"RIH1D1>V0/&HE^5A]%,'XJE?Y"%$TYP*
M22U(0C_,,EAJC>9RQ<I'BN.D!&GA)W2<3EUCB4L)\WR_8NK]) MMBZ+$AI./
MG'1"CB;PTIP')QNU1;5Q[X:FLG;"],MUD Y/T[+?R,_J_;M&<[KA0E/AUV0:
MCB>9!ZI_*WK&R*W;SRMI:-L[LJ;G%955H/.UE.;(6 ?#@[WX%U!+ P04
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MDVMCD=B9[;3P[W=.VM 5Z*2]Q.?S?=]]Y_ANO%;ZP>2(%A[+0IJ)EUM;C8+
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MOV[JG^# VQIAHR6])Z&V("SPPYL"O0%'I]>Z:;FZ__>?(F.SIQ;:8R \ ,7
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M[S:19WG!+)M/M=J =MZ$YB:^5!]-Y+ATAW)C->URBK/S19ZKM;0&EFS+,H'
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M83B.58FX6*=#T[N 43"ZU)(:BKBBOJM=;,3>AXO;*R1Q>&S\&L+;3DJB^O(
MK \L:UXNQV2!1&]+!"W='G*^=(PGU!P37\N2PT(+KU*V3+C#$V5XH0%2LFI?
MEY@Z?5/3P#X=5!);SY>DTY>!2% ZOA$#/XIL:>#-U3Z3I=A,N8^E4'9M=Q)-
MOX)!AY$%%8X'0C9381,D4M'5T@]_ 0_O3J8#W822S08''EQZJT"+FQ0^U K7
M>>HZZ$U:"ES6#U\>4$\#*?0?CT?C\?BA%H$!D2LZ2)(TZP/.U\+Y.@FOH!6
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MM #/4V-\>T$*NB_[9_\'4$L#!!0    ( (4X2U(I=\V>M0(   <&   9
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MBT;C%>B\U-KM-MY!U_1G?P!02P,$%     @ A3A+4@,@)BT9"P  @R   !D
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MEH)RW2G\M<*^[N5U)XM/YZ]@5\E>RP:QUIS<]?RB@W1:<U$,DEY92<$127[
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M-$5OS!F;NF-";?&9^K&51?&I !Z9:1-0L]/QV<[V,^SD0 1LL^9A\YR",A-
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M4C ]5 --X1#9XUE WVM G8)R18'VW>+7T5EPILWI@&[)5AC&GVB'?WOJ\<$
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MN5Z #V 2*9#0A9<5#R'@HB'*4X#VXY]R:PO4EV50J+$$N%&HKZU%KTW95F.
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M'@&VX2@I[W2OG)UBNL8Z>!251OR'1IH:[G1O7 ._8[CA]+P0[4%\$:H7%GZ
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MU!$ZTZV30Z9Q+HY#Z_!&F1*?GP&JSISJO3#NV$8J FNF-/DN"G1$;8R2#:G
MGWUV<6S1#-0U4$,#RKS XUHITW@B15&FQ9+J*C":2O,O>&NM@"996%N'QQ[%
M,]J_J(V!U,4<;&W^&8P'-*ID2\0K"!^9"!VY*>B48^B!G72]P=CA#7(0?$?9
MV69@NV^ /UA0<-03>;+O8:(>(8B.XIE6KM(=X3X NXZ<5F2"0@,E;M' O-UH
M @P('6T-Y%KX';!>HH@P*_H!3MPV&/[XK)&)0.)GE6U9IZ;PW1H8MM3^!(LP
M%9]DSO)HJ5<X&YBVX(AS@ ^)"A@3]!F"FUOPZ9=H%X*WO<JT(0A%LN8P!R@\
M!>/7JBG8.VSI.!J_L+<!:&V$7K>3'@R!^L86Q1&W\!9,FA5@$N),1#9$+_V0
M#UB2%E4UAF1Y%W_YR2#<PQ$2_6!E2Z:+Z&&RDDANW<+&-AR/0ZE%4ZW 7K0-
M8[70.8H#Y\U1VAQ-Y7>0'6*G ",=\%++BF<L;XL).>\,)1XR>!QDC&K5@#^]
M#BM*Z"K8+Z_1U@590*Q7F!M3:/+QD$=Z<P%F>#9=B!M("HD6X8UZQ@*?8FNZ
MK9,IG7<*JD,B#'8728)LHAS]/=P4@(8A$N#;<C?!C0,$I4%X<Q2-I$'9:&*]
M.QQQ'-*4J#KGA1\,Q[AWAJAH*0).= +TO+%BX&_KCJS P^)+0J5TDA0-#6H;
M9-_&@-RY)6-MJ7OP[9DQ?3/E70QOTGFPHP/OL>,RP@='4)Z2'+FRN#4ACR2.
M2@>"\MQK)=;@_.(QO?I=T*O?'56(KP$W%7KW8[KT*X=FX9-';TJ[(C'!O&.1
M1F('-EV!P.<C)#R(:NKYM/PJ2D'3%&<8$$!SJ^J0J]DOH* &D54!4C!OA>;D
M"XZ7N(GC!8H,0_;K&$D],V"Q\"?;M4)G?>*,O@1X)0:VVQCW&:.IWC- 9UV.
MCBR]KD6'2(+1(#NV^)1$!07D0YP:M5ZY B6S&K##LC,EJ"49B;H#K#O8R7)'
M_BWP!FU>A!NX[X!R!;2]A!V@FD*/N"59-<DL1:M*;P&$^,G$/W$;(+#PC7UV
MTLFXMD26 6MJ/0 R5QA51 YDDX9)05#NG 5S%F$@6P/UA _.9UU-240)=.TD
M0 W6*'+5A/)Z!0NL/5_,>V\3C^3][ =F" 1', W,O"3R\HZGC /BK.P6Y,P2
MF'C%&A]]SKP-(MZ+E^=,8+?& 98(U;)'G(;=5&)*]%)4D[,+D03 IY$]P*J&
MQS)4J*H(02RVT[W X@%D< 1A!9*)$2J9E!TL2+94KIM6H00S6W1RB=]PJ?YD
M.6AB_2776E A=(4JUK_L.6YM+1 @K>?!J_27-IO-Q9V:'C*:\57O\I*]B!B+
M, "B*EN=?84$FYW'M.GY'8(("'9M\)@O*.XPFA/]QCE@;XY=/P25T1!(&)EL
MA]PRR*V\NKK(A&5%$E;@?Y6@Y2MF?B$_%/CZB_%D%&7E83+RM#;-WBU+LQ;]
M@ MM#?BU% ^OU8ZU%5 P2\71G*+QT:&MVGF+"NVTA*51B :$4# G +JNZ'=2
M@<PXA08N37@M6,D1,@SMM&PM6W 1&DHJ$:G0#RJ(1$PI45AO#+46,RIWX!,Q
M$J:;H #S<AE<+41@PK[I?DG3!D,(X^(9YL$P[7=&@6FVE%&<]F@<-8I>=644
M*2C/O>TN_XF=&';)4 $3821EB&D77H=C'&3*)N-KTY)D(C>V6V^R7SKP6N;G
M#QXE"KD_,$";SG 7M*\/0MI/E<7@+$R-@>"[\0I;_15P2YG$^?GL,<N7%+@@
M5/"$^^O=(M&H)$GNE1VF$')38^Z+-3MG;#"B!%[5DJGK8G&9/3U_%(*3#7MK
MA=7,Z/"]]$%4 _R3L_\A&5'@JCXP@BT4GN@[<H1=B#BZC: 4;U1#@7ZR*EAY
M%1RD)/F-'VFE<()7.O<(>C [*CJ3BI/94;%WW:"Q"685[AVC?B1K1N7GT8FP
M8.D918A^N$?QNN9&WSLP>]9[K,-CY$@*+I/-2)J( W9)3*' :"!:%AC=!X3$
M;XBI+8ZIQV<W9(&@B_6GN#L40I"F)N*?9F\P2(:Q$%\S(9'EGD_%!J?*CIW7
M/)[7_.AYT8KC^NUK!E(J?Y#%28IMP-^I"M44J/R*Z'R= (><9D\?SB>93#/)
M-"464 3_ @8Y5BU1^<_LNW[\)CC.#B,K*+R;!KWV$+-GUXW#C7CLH&]US:=+
M56EG=G6&TOWD_;N/IU'J^)APLM:_PW,<@:*$4K<8=@ KL"0F8QWF;1E>#D%C
MS4!?TPS(H15LT+TAX\*#@^I5X!V0<<X9 -7R"RSJ):HJ\6I:?XVI2Z(Z #B8
M5Y,,]GLP/=/7Q-[!(CA\10XAF#STGF",=.WW%Z(@@WT$5HBX8IF<X*[GK-G:
MHP4,12WF-K^<V JP6P="<XGE.]YH'<;3]!<TZ9T8$E;(X3><)/C-?3(+\0..
MD6]K+!IKO4\O$-L0#QGNE5RR!!W!.LEIX":94H+PI!B. 6/8=N3('"8"; /,
M3F&+WJ&8BJLY*1,?@@+'CS3-NM<=4&2..C8,AE<443HF&IHN29$X\ LQ_Y^#
M50AJ#+Q(K$MPDWX8KN7TY#'JZ%O_05,"I$N<0;@9RZ; UN=ONA3IF*04F!V8
M-<A\PQWU?D.+&%;?DS% (GF7.ISDC$DHAUA/5F6C.3&#R#ET+9NC@),^?R<I
M;1(>;!P\/ ^2CX'ES$ *IZ90'IG-8/&OD*._"FB8R>;$D$O=WJ+)=!1Y3#?D
M00/@IHEA!8>R^TR5Y <T -G1M,LLEF+.'AQ5'!<^!7^M=L&3AH<-!E/>1*DT
MJI/^FJE'LRA)[IO$2HR_!T-1R50]V>G(*O2:'+1V3@'CE63D272/Y+J9XF5J
M,3?&Y@=/UY9H*D@ <\=UCLT-G@@+M*2X0C?(_5$\#S>YU!M5KH)E6@4 )(05
M_'99(9G1!SR24 R95#V'EISS !WSVH&\C!>FX\BY&$4%9TWO\FC=Q$>P D:9
M/Y@#T4I :>63JR46#2FL)*JD$(H$7D(/-JG&]653& %&S8WQ,JZK^+VK.,W6
MG[9M8&\PZ4ISR:Q?/@D\Z@-S"$&ASR04$H%5E,+!B5$ @<?MHY<P8 44R)X$
M+AJQ4:K;G9;"+P*'O'UR;?JQS_TH&)6-^9J+@-0MXCM6?6E0:G:GM0^"C1S$
MTE8=/&[L#KQN/-1:6)7/AEUJ @;L&%\5$@'STR#TT^RZ:URG?+'*7G"/<WV^
MBHN35U_!-X.3ZZ%%**>OGX/I1"9#5!+$ +UE%8=QR6F89@O$34)F$=Y ZQR"
MQ6'],.RS[,1@$65:3"(N(<R/E9XR<4CZ8?^$W[9$1/#\2DU>4"R*X532!.:'
M!;:@+#I)!I)$LVLJ]TZ*N"AT0CYY5=SGD!;[1 ).&FH/0H7?:6@5VH<J=U+Z
M0;Q'</[>.91W?E.T,M/"B;DY/1;-'02#]I*LP;[P,C68CBPG4NI8=Y7$;X.@
M$YL_F&=(N6>4(@03]RPMF-H7J"ZEM28D)5R(;/KW)J/R.^31 XD%J<L'%V.[
MK;68(Z%5X",F_H\J\-CJ,#O>I/!>RJK(*OI5D_M-89V%*@^H[?_+A*,N)AA1
MC\\?@U.3#KWL"_9+:K !>7=LU[%4<W:\R/*M^ATP>6!.V>;Q&?;+[Z.)/5K0
M>/)QNIAR93AV!S1FV;%')$$Y%01"K)BG?">(UIV/U(8JN:&/@6LV&JB^3%X%
MH32<8">=2JRD6 -?&1#T0.2^)'0WD784%4L_J2J!-_2SA@DWV4\ =GT:C#)=
MV/T!+[_4)&$6>6/JUIU.!\&P4:P!FKX-2UBLJC&CVH1LWEUX^2T,&<'')951
M@,K@G3(V)ER.ZFS7Y/J%;M8@<JDIXE**KZC] 9=_F_\3]@PP)[_T/2*T EF#
M4.8/N<&%^D;QAET$;#)*!UR3'K<^H=IHM/5]8%9B#'VIC<7MY-9EMR#S-[;K
MN3\DG:U!]=7*4U*3ELI&J,1VI1NQI+EF@8&<>N9UODJ ;7>&B<UW2L@!UR-?
MA]P?Z]BPUVGVKFLQ/1=HH:^=L8+%[?6^5-E/V#E0[:0\&6-&/?()]D>(\8PV
M1O6H\YB@B>7!L^/5O>\YV,F2_1,X$(2*2TE!'BP1OV/6#U34'NJ=V:/C7$NH
M1.G[@B'K&:)3?+ICU4JH1=M2:E2^2!T-X<V?/]=T,Y7M$<*8.Q92VJ0#>DDM
M3/2CMU1C"(6PXU\.%;_@!-]R*U7,G#4>L>3;.RRC,.".] I@8H4+,L>2H^<8
MW5C#E_PS,I;8,&Q9YQ:8A*K*C$N2W $<,.XK7SF-SGD$&>&Z@=,%=LK6:#A4
M(QUX:!U3M5&O?*!G8,0D[XVGE<'!X>)N<Z@^99\H@/Z!PKT]2"%P*5N3M:1V
M!D'MZF*O*!H% ?E\L;X:7YI&8NX#:-Q7 &56D\R,^[0QAV]\5#Y)&X*"25I?
M);V'=-(XQ1EJS@6@&/3DP[Z(\  [:T3IJ#\EVWC1I[ Q6I&SW".01@\YS8 #
MU]"/WG'R5CN&/3V?>*$KY!O2"8A@:F!JR&L13XT$&P[1:740.F]49$YD"K,S
M7U+VJHX9X'U.1PD)KH;4,8T#C1(]D5T'Z'&_^N@(]]J1(JI^+?@DNLI8BE![
MP0R3;NN6D!^KU@(C]@$ [=1)&PA'88::B!E0!$B:N0\LWL>:_Q7SX4@T5/V!
M+TJ81'EK'2LCTGB]+\*(FG@L<)(PS'X]+;NJ24W$((9R%T*G8+2).R29BY [
M/G*BL4D'L(0!J\#+4K1-=I[^HY.Z4MF_)AH=/<"WU$=LBLA;D?P+C;1+=42>
MAUILVEFS<0?FD&,3&A;=8I!=F^VR:YRDB4IEMF(5'Q3581NI;RPO2]F6[$%*
M#.../<,&Z3&H;0G]QMZ0$QW7%RE<48//>IVNUX&NG^W;ZB-&'FW&8@^)3NLW
MA89A*A^#'R@9JEURT7?^&H-2LBVJJ09S)PN35 I)<>RQY0H8KJ7"LL>@T-C0
M2V FGK"8_>A;!W3B3; F>]FL:<#<>Z:C9P=D=S !L$:.<\-AY:@0 E62)<]3
MXIFL&[5%9KS%>FGJB>"CUYY^.82AMN*<2C6-J'>9)_0NW2)GKUI9<T6N!4!3
M2VPLQIJ]/:5"W5D-O-RK4QCH&P\8*8$08^-FEC5U'X7Z;P&5,T)8<(I=E&$=
MB>$D,3Z/&Z:D0,Y])">%%<BCG+ZP38JPD%7C+G^*+,8THR\@)"M%7"5_Q)=1
M^SY+O[#0Z*L!4N1,.LG:L=0S.'F^H4<J0H%OB1"_AB&F(28Q.K47:>D-!)1,
M2OIML*V3#T"\Z(48H&G7CT1T"^K!2:Q)LLLIRLI[0.*Y,8KKG^3U10=&Z0X<
M;C"%.[00HB@/.T^IC6PJCTO*^P(T?.1[**&3C?A@$P[DK+>3D!CRSS0]][EI
MMB<X<<6K\EX-EI@B2,A[$EJ\:[F0LAA"R[.(&W+G++):0B31<_&$QZ0/1':-
MN: K.':LD@4GZ"=5/R/<#-](C2ZZYR!P5MJ-F20(L(6B0T<9Z]B^$#< /IZ<
M_YL7!\,5HH&6>VC6JA;)/UA<2C,QV54:+L@*=T"0P1(=%WI]*BW!P5;R&FL(
M1&]I7[G"\0*,5E%1NRUT.4W:65>4O97:V:,31MEF*DG#57^E+4S2X=O-8$\5
MGE5?:50[J7J5P(M7_7RY0XQH2PI*6BYB4"($D4D"A:!U#(5\()5)N9V(&]N3
M<.CNQSZ SQ6VYXCB&33F4*[%]3Q>7TA %Y<D+;:B;SFDQ16@W%:4J6A=BUF>
MNO6A>S<,)PN\VDN%[B:@A*EZBYT\%4P+MJ<+2O;#Q%AHG-&M"@*U-Z2#509
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M@/Z4J2Z1;+M 3U<-A>YY?)<-Y*5>FZHBJJ=2DH"^V2-O*G/E*T:!M\%)DNN
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MO+K!%^#WE05TR1=<(/S)J1__%U!+ P04    " "%.$M24S8G;GD%  #!#P
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MI,L'8_EC5>$>:0MEL6BX;H9O;*YI <XOE;*['S)0O]I'_P)02P,$%     @
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M>:]HI*Y6C"K_8A->JOW%('9^K_6.%3CW:$ UJCUZBX<*82-K&CXNML UL-,
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M \/N,$5/N^'QY-Z-X NF<BXTE)A1J#^9'SN@NK'6&4;6[2B)I:'!U"X+^A)
M91WH/)/4RMZP!,.WQ>8_4$L#!!0    ( (4X2U(RZ;/^M (  .@%   9
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MO*YL<XWGK%1F OY?UK7>=HR!X8%\^A]02P,$%     @ A3A+4KU8JP95"
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M:F-Z8*E1[5/7(V_V;A8E-K>^&\,;ZJ;FFL#U9L6:)187\LBJUL:$8;A8DW-
M#2 G< $";^ >)6YL5C1V0US<P=9E,E\9/PK^" /3&L8?37* ;ZD!EL >6=HI
M]=S,+#*7XOU7N0;=I)#M<H>>N@'^3!.7(K7O)OAXW\U$-/:G]2FIRKK4UEKK
MAV^N@>'Y%<(OMPG)C8N*>*Z/ KW.'<\*ML0;&HB#,O$JNDW8!6X:;#?7F\$J
M<C.X/D"LI&98*D#I6J@2+5/&G]":%[O!#N.]%OGGMSB=%:9WP=!HW8FLVY [
M&W0;-&MEJ7FMP&'?N.J9)&)"W[]$8:=PZF>I#3>X;>2>0M:*-K<&@L4&8".Y
MA_(+38=I+<MYJW'*(EI8ZL-]R7TA'( [*ARXJK;@Y"0!N^JRJNS(7('MA54$
MG _NO7M$FT-. %3)D(T5?\ $6ILY #?B6I9XY7 K-BC+F93/\.,3DX4RT&T/
MY ]_.TDCB/&(A:P##?HYY\NR::#"O!6+MY"JM[CY8?:NK+-Z!7L5^AS,W<"[
MD*+>X<Y+F;<UX&Y+G+,6D3&D^J,MEF9SL3D<54R)@3--5?[%YE#-M&F2)F!#
MZ!*F%-<F%XM6X_QHRM)(GM)_ @*@/@8"Q+VM;XA*M*U+M]I)$(BR^3'1.IB=
M <U.>EQRA3."C>MF1$"*L4H&8\9C"6V\>C8=0&*A94M(N=*' H;B,* .KA3?
M,;U/)M U8I E%,&_X';F[I&&F?0-,SG:OG:'[U_@R+N9#DQ/O++&8I3N.F1^
MZIV_VC@_UC6/JGWM?+8[A(_URX:/AWO37_O]=2"-S$A^V2&[1IJYY*;;R3L[
MG]6B;;99M4A>L4?$+\==G5=@2+DH[=:&"0$_'N#2N&6GO(TP$Y'&=A]W?T!\
M:=K>&[H=\ 8!.#.Y%: !Q$)TX;"G]K;""0D#F/\"6$0P0L))X6 /">%H$)#(
M@>)/KO)<MD#0@1)F "?T,Q@__3C>0L042\FA0G1EK]N-: ?PX+"*/"$,J0>;
M/CZ+ETU]UXL@<9(@(0&,M"'MVEK@^$D&1D>)WYU\QB"2^4Z:>81ZGA,G>T&$
M:<X4P9)#)#] ;IIEB2GN6*?4R2B.,G#/8!JQ:F%H#O'0!?<T@FX[HGH@%V9I
M)_!A#(![&H:G8UET#+[3U(G@J)=%3AI$Y">NP*9/(UA.'"^B,&SC /_+@7T!
MPSAU(AKC(G'BU#LVA:=]44F_]7AWLYU[L)Y\8_$X*OXUQ6,P?HU5C4/5X'6C
M]MZ.O;9=&L?IZTT;1YO,1'Y5%-TL,&B8 X[WB/F.=CO"GXV4@9,NT\-S(>"1
M>B&>KRP67I8*2@&RD=?SP!0=.$D&$ZR5ML^1 D?L4.K!=O("/#,Z-(.A?2/G
M"'JR'CW9/SG#@??_DEBM'AILK,NF_*MK3MWW@M'/ T=5C"/H:O_HUK68?O8R
M*080F*4I^$BR-,:U0^,03MWY5QDHJ@Z:ZK7? 1X.BF=ZS\C.:C/.G)#,2: ,
MCGTK^-! _618?*<%[Y:GP_GST%B$7Y(HX@,_)+V4-I"PZ6LC,J@3TX!@Z4E[
M&5]UDMO-,' /4.<'P8B?8SB<#;X)UUPNS9=OZ(*82?MYN'_;?UR_LM^4M^3V
MR_S/3$*\%:GX ECAC!!-B+1?N^V#%FOSA7DNM!:U6:XX@[,U$L#O"R'TY@$5
M]'\Y7/X-4$L#!!0    ( (4X2U*^<K,Q;0,  &,'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,X+GAM;(U5;6_;-A#^*P>A'UJ B"A*LF3#-A G&=8/+8*F
M6S$,^T!+)YN()'HD%:?_?D?*5ETLR?;!,E_NGGONE<NC-H]VC^C@N6M[NXKV
MSAT6<6RK/7;27ND#]G33:--)1UNSB^W!H*R#4M?&@O-9W$G51^ME.+LWZZ4>
M7*MZO#=@AZZ3YOL&6WU<14ET/OBB=GOG#^+U\B!W^(#NM\.]H5T\H=2JP]XJ
MW8/!9A5=)XM-YN6#P.\*C_9B#=Z3K=:/?O.Q7D7<$\(6*^<1)/T]X0VVK0<B
M&G^?,*/)I%>\7)_1?PF^DR];:?%&M]]4[?:KJ(R@QD8.K?NBC[_BR9_<XU6Z
MM>$+QU$VSR.H!NMT=U(F!IWJQW_Y?(K#A4+)7U$0)P41>(^& LM;Z>1Z:?01
MC)<F-+\(K@9M(J=ZGY0'9^A6D9Y;WTG3JWYGX8 &'O;2(+S_*K<MV@_+V)$!
M+Q97)[#-""9> 4L$?-*]VUNXZVNL?P:(B=E$3YSI;<2;B+=874&:,!!<\#?P
MTLG=-."E_^7N_>3NG]=;ZPQ5QU]OX&<3?A;PLU?P-]*J"F1?PZUJ!X<U?*;&
M^MA7NL,+F[J!&]UU5)4/3E>/+T7Z33N^51?V("M<1=2+%LT31NNO>X1&M]1G
MY"(XGT4(M[VSX.BRDFTUM#*T U'83F3K$]F>R*J1K*\'>R9;C62M)TLF3$#[
MCM)80)]IH#QAMR65<Z[\-YD'<%J4"_B#I,>R^%GXO>H)30^61"T#?*[PX(*-
MT;I'^,%%=GH@;SX$&Z,)#P^?APZ-=-HL0L!//KP#D;(T+6B1)#G+\]0?Y4SP
MDDCTFOIIU/D6FI>HR2>"V>%HS0)-,>N( <63G<*59RP3!9N5*>0I2]*"Y3,!
M.6=E/F?SK("[IJ&)XZ,6HDHS!RQ6@U%.$6(Q(R5BG;""SUDV+T&PI,Q9FO#_
MQ^*<JCQGR9RL<N$IE5G!^(Q[2CPC!_/B,@Y3_-B_<[Z L6;? ;_*0GRNDB+L
M<CX5<;@4XV4R[DJX[IUZR45*83OX/#=&=Y<U9Z>@O%9J*<MX03\?GWDJ&!<9
MS'G*Q"R'E[HSOAA\5 "[,-XME2L5R3@#I]/I!;D>!^</\?'Y^23-3A'%%AM2
MY5<%#6PSCO1QX_0AC-&M=C24PW)/KR :+T#WC=;NO/$&IG=U_0]02P,$%
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M[_*EHH3!6""Y+ HL_MX!Y>N>XSN;%Q,RSY5YX?:["SR'*:C'Q5CHF5NK9*0
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MKA/]3Q#E':*<*+ZPA^035_K(M<-<W[M &(!>GW&N-A-S[M8WN?X_4$L#!!0
M   ( (4X2U*#V]0Z\0(  .P(   9    >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;+U6:T_;,!3]*U:&)I V\FR2LK82;4%4@JVBL$F;]L%-G,8BL3/;:>'?
MSW;24+*T0T+B2^O'/>?>XY/X9K"A[(&G" GPF&>$#XU4B.+,-'F4HASR4UH@
M(G<2RG(HY)2M3%XP!&,-RC/3L2S?S"$FQFB@U^9L-*"ER#!!<P9XF>>0/8U1
M1C=#PS:V"[=XE0JU8(X&!5RA!1+WQ9S)F=FPQ#A'A&-* $/)T#BWSZ:VI0 Z
MXCM&&[XS!DK*DM('-9G%0\-2%:$,14)10/FW1A.498I)UO&G)C6:G JX.]ZR
M7VKQ4LP2<C2AV0\<BW1HA :(40++3-S2S16J!?447T0SKG_!IHZU#!"57-"\
M!LL*<DRJ?_A8'\0.P/;W )P:X+0!WAZ 6P/<UP*\&N#IDZFDZ'.80@%' T8W
M@*EHR:8&^C U6LK'1/F^$$SN8HD3HT7E-Z )6. 5P0F.(!'@/(IH200F*S"G
M&8XPXN S^"J?PP7,Y'CY!.:,QF4DP/$4"8BS$[E_OYB"XZ,3< 0P 7<I+3DD
M,1^80A:JTIE17=2X*LK94Y3M@!M*1,K!!8E1_)+ E H;F<Y6YM@YR#A%T2EP
M[4_ L1RKHZ#)J^%VOP,^?3T\/*#&;4QS-9^[A^\6K1$I$4@8S<'%HT",P Q,
M]-."&/AU+>/!3*"<_SZ0S6NR>3J;MR>;<KVHS>;*_2Y#*XI 4ZB[9CURO-#V
MI=KU[C%WA#F!';;"IO^&V7W7MI_#7@CI-4)Z!X5<7=Q=S[[]_/C!#KPO!P[&
M;_C\=[ A:+(%;[>AHO!W#\ZW_-!OV= 1YCG]T&K9T!%F]T*WUVU#V @)#PJY
MA 06XK\N]!NZ_CNX8%O/%Z;U=A]JCMTG. R\T&GYT!7F.5;[=>@("P(G=%L^
MF#MM0$I?Z7;*@;[)JZNR66U:]KEN5*WUL6KENKT\TU3? 3>0K3#A($.)I+1.
M _G&L:JU5A-!"]ULEE3(\]?#5'Z.(*8"Y'Y"J=A.5(+F V?T%U!+ P04
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MI_T1XBB.GA93N+RX,IB1;.V1].[?#=:^K<&.H$S?CW)S%.6 ::?I8\?#=D[
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M^9&Y1\MK[U^8\A)^(M+L&P4,ER9D<-<QW2'+BZT<:+%Q1_U":'-QN,>U^19
M:0'F_5((O1_8!>JOB\%?4$L#!!0    ( (4X2U+\7_K1X ,   P0   9
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M[%:3$H7@(18%<V"7-.P25VPU +>R,86M ."&6U.XVG&J[$"7R6ZKU^H <>M
M;=H:D$]BJSYI91N+6"4@S;:Q+DBUC?6<7J?)+DXK",0M",?06ULP2>E-0BN[
M6,26>-)P%XM46U,5'ETFNSAMI2?N2G\,C\=+(K%5GK2R]42L,)!F6T]C4NTG
M'6++%G_B+OYCJI;@MV]K;JZ:O*MUO2RSE;K7RH9/SQ;M7L,-GSQ>X-A+>TR2
M6]/J_4JW]((]^7?##94+'BL0LKGQ]$X#LREE]H>!;*#%*GWG/A%:BR@]7#(Z
M8S(Q,+_/A=!/@^0U?O&WC=%_4$L#!!0    ( (4X2U+/<5PKO0(  /$(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;*66RVZC,!2&7\5"7;124VQN
M22J"-$U431<SJGJ9KEUP@E6P&=M)VK<?VU"&!HA:=0,VG/_W=^QC3+SGXD7F
MA"CP6A9,+IQ<J>K2=66:DQ++"UX1IM^LN2BQTEVQ<64E",ZLJ"Q<#\+(+3%E
M3A+;9[<BB?E6%9216P'DMBRQ>+LB!=\O'.2\/[BCFUR9!VX25WA#[HEZK&Z%
M[KFM2T9+PB3E# BR7C@_T.4268&-^$/)7G;:P*3RS/F+Z=QD"P<:(E*05!D+
MK&\[LB1%89PTQ]_&U&G'-,)N^]W]VB:ODWG&DBQY\40SE2^<F0,RLL;;0MWQ
M_4_2)!0:OY07TE[!OHX- @>D6ZEXV8@U04E9?<>OS41T!&A,X#4"[[,"OQ'X
M-M&:S*:UP@HGL>![($RT=C,-.S=6K;.AS"SCO1+Z+=4ZE=RP'6&*BS=PNB(*
MT^(,3,#C_0J<GIR!$T 9>,CY5F*6R=A5>D C<]/&_*HV]T;,5R2] #XZ!Q[T
MX(!\^6DYFG^4NSK--E>OS=6S?OZ(WW(KA$X68"F)DD<,_=;0MX;!B.&3KM )
M99-*\)3(P0FJ#:;6P&RI71)%L;OK3D(_!+81'[""%BLXBG5-&=45D8$-Y\/+
M5NNCSI#(0\$!UT 0"D;0PA8M/(KVP!4N=%4U17>N2]RNR1!D.  Y@P>0 T&C
MD%$+&1VMD]^<33Y=*]/6='HT\SN\U_M6$4%Q,;@FTUXFT^!P2?HQ43@?3G;6
M<LV^6\.SWJ@!#,(#M'X00G"$;=ZRS;]9R//>J#[T#LCZ,0B&T3 9@O^_F_!K
ME<QTU1RIYL:NBQ'".3I@'8CR9EXP MOYR*.OP [RH?Z7RI_V^/I1_CPZY',[
MYY'Y&?B%Q88R"0JRUC)X,=6[5M3G:]U1O+)'U#-7^L"SS5S_DQ!A O3[->?J
MO6-.O?8O)_D'4$L#!!0    ( (4X2U*)9_0 \P,  (@1   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;+U886^;.!C^*Q8WG5JI+=@00G9)I#;MM$FM
M%*WK3J?3?7#!"=8 9[9IVM/]^-F& $F),^V4?DD,O._CYWW\^DG,>,WX-Y$2
M(L%SGA5BXJ12KMZ[KHA3DF-QP5:D4$\6C.=8JDN^=,6*$YR8I#QSD>>%;HYI
MX4S'YMZ<3\>LE!DMR)P#4>8YYB]7)&/KB0.=S8W/=)E*?<.=CE=X2>Z)?%C-
MN;IR&Y2$YJ00E!6 D\7$N83O9RC2"2;B*R5KT1D#7<HC8]_TQ:=DXGB:$<E(
M+#4$5E]/9$:R3",I'M]K4*>94R=VQQOT#Z9X5<PC%F3&LC]I(M.)$SD@(0M<
M9O(S6W\D=4$#C1>S3)A/L*YC/0?$I9 LKY,5@YP6U3=^KH7H),!P3P*J$]!N
M0K GP:\3?%-HQ<R4=8TEGHXY6P.NHQ6:'AAM3+:JAA9Z&>\E5T^IRI/3.5<=
MP>4+P$4";KZ7=*762()ST/_@'$LP8T*"DVLB,<U.5>3#_34X>7<*W@%:@"\I
M*X5*$6-7*GIZ$C>NJ5Q55- >*A"!.U;(5(";(B')-H"KZFJ*0YOBKI 5\9K$
M%\"'9P!YR.LA-/OI=#BRT/$;K7V#YQ_0^@S,,ZQ$WI;\[UL5#CY)DHM_+),%
MS62!F2S8,]D7)G$&5MU5))NYSL"2,]&[1!7HT(!J"WA2RP+#8.P^=77KB?*"
M8=A$;3$>-(P'5L:7<5SF988E2=1&5*844UQM=<4=YXQ+^J^YT<>[@@X[C,XC
M#T4[O'NBPA"B?MYAPSO\'TH71/;Q#5\I&$ _W*$;OJ+K1YVUV&([;-@.K6QG
M+%^5DG##D\E4C1JVEK:+&OCH^#T^:B8;66NY$9+FIE\>!%F4V>^_P=#[XY8N
M"#CYBV N3ONDMV/ZX$5G6MA!K_56[QA[L$;M-L< =;JT:HXZJML=@3^*^KL#
M=GX/H)7SAY(75):<&+H+^JS'5CE0"XV.WQNP=5OH'T5]_[6Y!:/!KOK^*_55
M%-RC?FO:T.[:_>J#_\ =+6A>YC9A6I^%@S=8A]8>H=T??VV7'@ ='-ZFK2-"
MNR7N%QT_'Q*]]47X!L8(6V>$Q[#& Z##@Z*CUAN1W1MOB?KSG;(L 317>_2)
M:!VLT*V%(7A\J5%K:P@=PV=JU"V7#P;#'9_IB0H&T;#?9U#KC<CNC?WJ_Y3/
MH-;,4/ &Z]#:&K+_?_RUEC\ >MAG4&N$R.Y9^T4_Z#.H-3,T? /16UM#T3%$
MMX-"N%]UMW/6S0E?FE<  L2L+&1U[&WN-J\9+LWAVFW#JW<4=Y@O:2% 1A8J
MU;L8JE;@U;&_NI!L94[.CTRJ<[@9I@0GA.L ]7S!F-Q<Z F:ER_3'U!+ P04
M    " "%.$M2 FU#-EH"  #$!0  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6R-5%U/VS 4_2M6M >0&,X7GTHCM81I/"!5,+:':0]N<MM8.':P'0K_
M?M=.FA74,EX27_N>XWM\[9.ME7XT-8 E+XV09A+4UK:7E)JRAH:98]6"Q)6E
MT@VS&.H5-:T&5GE0(V@<AJ>T85P&>>;GYCK/5&<%ES#7Q'1-P_3K#(1:3X(H
MV$S<\55MW03-LY:MX![L0SO7&-&1I>(-2,.5)!J6DV :71:IR_<)/SFLS=:8
M."4+I1Y=<%--@M 5! )*ZQ@8_I[A"H1P1%C&T\ 9C%LZX/9XP_[-:T<M"V;@
M2HE?O++U)#@/2 5+U@E[I];?8=!SXOA*)8S_DO60&P:D[(Q5S0#&"AHN^S][
M&<YA"Q"=[@'$ R!^#TCW )(!D'P6D X ?]2TE^+/H6"6Y9E6:Z)=-K*Y@3],
MCT;Y7+JVWUN-JQQQ-I]KO$':OA(F*W+]U/$6>VK)5S*M*NXZPP2YD?WU<GTZ
M*, R+@XQX^&^( =?#LD7PB7Y4:O.((?)J,6R'#DMAQ)F?0GQGA*BF-PJ:6M#
MKF4%U5L"BGI&4?%&U"S^D+& \I@DT1&)PSC<4=#5I^'1Q0YX\7GX^0=JDK%%
MB>=+_M.B(S(7#'OSME._IPMC-3Z?/Q]LE8Y;I7ZK=&_IZ!TE[UL-+^@M!G8U
MM&<Y\RS.6)[S*#D_S>CS]B'O3#I[FU3L2$KCBS&I5T&W[G<#>N5]PI!2==+V
MMV*<':UHZE_@N_D96E3O*/]H>G^[97K%I2$"ED@9'I^=!$3WGM$'5K7^%2V4
MQ3?IAS7:+&B7@.M+I>PF<!N,QIW_!5!+ P04    " "%.$M2CU\6YJD#  #'
M#0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6S-5U%OXC@0_BM6;G7:
ME5H2)P3"'B 5N--5VNY51;O[L+H'-QE(M(F=LTUII?WQ9SLA 1I,MT]] =OQ
M?//-^//8'F\9_R%2 (D>BYR*B9-*67YT71&G4!#18R50]67%>$&DZO*U*TH.
M)#%&1>[ZGC=P"Y)19SHV8[=\.F8;F6<4;CD2FZ(@_&D&.=M.'.SL!NZR=2KU
M@#L=EV0-2Y!?RENN>FZ#DF0%4)$QBCBL)LX5_KC (VU@9GS-8"OVVDB'<L_8
M#]VY3B:.IQE!#K'4$$3]/< <\EPC*1[_U:!.XU,;[K=WZ'^9X%4P]T3 G.7?
MLD2F$R=R4 (KLLGE'=O^#75 H<:+62[,+]I6<X=#!\4;(5E1&RL&14:K?_)8
M)V+/P.^?,/!K __8 )\P"&J#X*4&_=J@;S)3A6+RL""23,><;1'7LQ6:;IAD
M&FL5?D;UNB\E5U\S92>GGT E3:!+=)4DF5X)DJ-K6NE)K\O[!4B2Y>(#>H<R
MBFZR/%?#8NQ*Y5Q#N''M:%8Y\D\XPCZZ852F OU)$T@. 5S%NJ'N[ZC/?"OB
M N(>"O %\CW?^[)<H/?O/JSD[[_A8?1'![_YB]'PJ$;K0%F\'"7J1#D(-6A6
M*3"PP0G8SVK_7,4QVU"9T36ZY8RJ=@QJ TJ!&$?SE- UZ!4ZF);1."MS0-\_
M*4!T+:$0_UKH]!LZ?4.G?X+./R5P8ESD6CXH9D)V*:)""0V*+D /4[\7C-V'
M_56QSSF@%S;T0BN]9<JXO)3 BS/\*ACL[3GW>OTC@F<F'3 <- P'5H:?&;W<
M42M*1M4R(GA4M5Q %\_!<PJX%Q[Q[)QT@N>PX3FT\KRS$UL,GRU>T!MTNXP:
ME]&O:.L"E>3)R+PK,5&'> 9'>>F:$W9S'#4<1U:.WXA(%4/)Z 5:].8]9*JH
M96-AKRW'WEO8Z7CO?,#66$UHB3J/-X0#6C$FU74 _4262CNK(0?[N@C"X(08
ML=]R\<_)$;;J@#);FZWJW4W6'$Q^.JG8$4/T!(0+6Z;:&HT#>Z883=2)>58+
M;97%_3>AA;:N8GMA?946PF=:\*/(.R&%MH!B>P5]C13LB,%Y*;1E$]OKYG)S
M7Q'ZB7Z]5K25$D=O0A]M6<3VNO@J?8R>Z6,T\J,C?;A[-]P"^-J\% 0R054W
MQF:T>8U<F3OXT?A,OU+,S;F%J9XX-X2O,RJ4DE8*TNL-E7!Y]6JH.I*5YAY]
MSZ2ZE9MFJEY:P/4$]5W'N^MH!\W;;?H_4$L#!!0    ( (4X2U(*#,54O (
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M)]/J..Y>CS#]^2<6:\*DOBDK+>0-$OVBB;KGU1/%2]LVEESI)F2'N?Y- &$
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M)B$L,%5&@>C7(YYA41@AG<:/6M-I0AKBYGBM?F&]:R]3(O&,%U]HIO*!<^)
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M.Q"% >CO,\[5>F("-+=J_!M02P,$%     @ A3A+4@#1_WNT @  FP@  !D
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M@@H0V$)+9;:L(5$D[@F^1,)$ZVQF8+VQ:%T-9>8QCI70NU3C5#QBBK YG62
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M<7*B@WSO=1QX9YD>F525B/=3H3Z8"KB="N]40>O@\"(*_<@[QK>(!8GJLJ,
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M6<(6S#8OT#B*F"DYX=!?$M<0X/.4:L+X%QCQ8SY%GS]]09\0R]!3(@H%1M3
MU^"^<<)?5J[>EJZ&)US%Z#LXERATET4T.H*?O((/7S,P=1OH]AT&?$A\G?UP
ME_W;T&GQ.Y&7J(._HC# -\<B<L.G=+F#A\&Q>#X&OWLS_*7S>\GHU%3L6'N=
M4U0T5"/[5&,UU1P3=.L)NG:"[JEL,TYA0644B05GL26J0@744B+.EJ!^%)%8
M4FJ7P[%RE/:OK'TCP>M1IP>96[=S_H8Q=X=CFA%[H?7JT'K.T-S+U)&[?CU!
M_SS%N:HGN')&\,2HI!&28DNX-MJ3DRU9<*A5AE:%+B1%&>R;BD -CY7&;5V!
MIG%Z$;&8:8>SU[6SUTYS4[J&+38W/+&92&MF@=>EF&J!=,)D!#U2;X\MSG**
M?HL$&+;WXSRXJ1V[<3KV2.."FPIMT3C/I5B#+#>T__6*G#LR@X-F0PG.PQ3<
MVK.P,\J94(H9;E3$.$S_T=T!'ZPZ')[,. X;;T*G-_>E$\=2/X;8YX:Q31'4
MAZK0:"D^DYCB1DVQ6T[?687N >T[G>!D%1H!Q&X%;"])D_:&];/2FZ_F;+/D
MA3WB_KU"LP3.E^@!S741;3]4E$9#\9E$%#<JBMU"]SN4Z;::H[U23J^31C.Q
M6S3?R9=#F6SOI_N^-#*)W3KY\:- -<$IOZKSY(WS,+!_9FP4-@S<SI-GEA8I
M</;/D3YLQ#K$YR%]V"APZ%;@]S&K,KJW'^ #FONMNU5*96POM0HM19'I\II5
M]]87Y[&]+OK-\/+6#:?]F '-.%T!-+B\ D63Y46V;&B1VYO:0FBX]]G7!"[_
M5)H!\'TEA-XUS 3UWPFC_P%02P,$%     @ A3A+4M.!23<S @  _@0  !D
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M3FV^8NO'"\R5,/X7-FWL(("\-E95+9@45%PV3_;4YJ$'B(8[ '$+B#\*2%I
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M"V;9=*S5 ;1[36ANX9WII<E\+EW<'ZVF6TYR=OIH5?QT-2?/)7"C4DHGPWQ
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M9H<6C@B?4,8=96PIXPN44[IF=<WJM4XGO=$%!3>L;C?P@VL'&SILZ4R5>9U
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MC 935*2;7M%,K*K]Z[E2%M]B/ZRPO8)V!KA?*F7W$^>@:]CI7U!+ P04
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MQ][Z3-\?3;O_)]-</O=$K"F3J(25EO2NQCK-HFGHS43QVK:X)5>Z8=IAH>]
M$ :@OZ\X5[N)V:"[59._4$L#!!0    ( (4X2U*P>4P0#@,  %4*   9
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M+,$O";[9F2(4LP\QD60RXNR(N$8K-?UB-M.P5?@IU>>^D%Q]315/3A[IBN6
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MTOY'A^K;J(>2O50\K\"Z!SDKRE_ZLQ+B!(#'+0!2 <A3P+ %,*@ @Y<"AA7
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MRM._\D;QG3T/N^=*\=Q>;H&F(,P'^OV:<W6\,0W49["+?P!02P,$%     @
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M\JHE>?5C.>Q([I+86,QI\O'A_?ERO#K(V?')E*51I^:1/P.DAD0MI?C:,%V
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M55Z!B4'.9?EGZRH.6X"H>P005X!X'] Y FA7@/:Y@$X%Z/C(E%)\'*;,LM%
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MEDJJ'?_6HH.FSI)X^+Q7OZN"5\&\$4%O6?H[B>7Z>A ,0$R7I$CE+[9]H'5
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M;S"\WN&J3R3;5;L,STQ*EE>'6QHGE)> ^GW#F#R<E [:;<;1?U!+ P04
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M<F]P<R]A<' N>&UL4$L! A0#%     @ A3A+4MFW D/O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ A3A+
M4IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "%.$M2H6FL6,T&  #L&@  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ A3A+
M4HO#6RH"!@  2A<  !@              ("!$0\  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( (4X2U*YS0D#X (  +T)   8
M      " @4D5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" "%.$M2/E?(Z08%  #]$@  &               @(%?&   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ A3A+4I7 UD-W P  ;@H  !@
M             ("!FQT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( (4X2U(DG@B?XP4  $H;   8              " @4@A  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "%.$M2%LO.=/T&  !)
M'0  &               @(%A)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ A3A+4OLTVGPJ!@  W T  !@              ("!E"X
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( (4X2U)D=.MP
MKB0  #!R   8              " @?0T  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " "%.$M2U;Y'#4 #  "\!P  &0
M@('860  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (4X
M2U*N/)!'H04  'T/   9              " @4]=  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ A3A+4E+ %C:O @  Z04  !D
M         ("!)V,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " "%.$M2$S$.)/P"  "B!@  &0              @($-9@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (4X2U)/&S##CP<  -(4
M   9              " @4!I  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ A3A+4K/F/5" !0  ^PT  !D              ("!!G$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "%.$M2>P'(
MZ0\#  #)!@  &0              @(&]=@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( (4X2U*'+]CU7PH  .4?   9
M  " @0-Z  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MA3A+4BEWS9ZU @  !P8  !D              ("!F80  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " "%.$M2#1+>(:P"    !@  &0
M            @(&%AP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( (4X2U(#("8M&0L  (,@   9              " @6B*  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ A3A+4O,(R009 P
MJP8  !D              ("!N)4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " "%.$M2SK!-W1D+  !B'P  &0              @($(
MF0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (4X2U(0
MACO Y ,  !<)   9              " @5BD  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ A3A+4L.01B3"#@  4BH  !D
M     ("!<Z@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (4X2U)MES!K, ,  &<(   9              "
M@9_F  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ A3A+
M4C+IL_ZT @  Z 4  !D              ("!!NH  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " "%.$M2=#:3.?0"  !9!@  &0
M        @('Q[   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( (4X2U+/M 8%( 0   4*   9              " @1SP  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ A3A+4I L[E14 P  * D
M !D              ("!<_0  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " "%.$M20;,D=1P#  "T!@  &0              @('^]P
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( (4X2U*)_<$>
MPP(  !H&   9              " @5'[  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ A3A+4J8&2[3J!0  + \  !D
M ("!2_X  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "%
M.$M2O5BK!E4(  !^&   &0              @(%L! $ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( (4X2U*^<K,Q;0,  &,'   9
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M970T,BYX;6Q02P$"% ,4    " "%.$M2U1T_74(#  #1#0  &0
M    @(%P'0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M (4X2U*5P >X$@,  #8,   9              " @>D@ 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ A3A+4D.!=E7> @  0P<  !D
M             ("!,B0! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " "%.$M2"NY>R0L#  !I"   &0              @(%')P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( (4X2U+\7_K1X ,
M  P0   9              " @8DJ 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ A3A+4BW<Z 0&!0  PB$  !D              ("!
MH"X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "%.$M2
MSW%<*[T"  #Q"   &0              @('=,P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (4X2U*)9_0 \P,  (@1   9
M      " @=$V 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ A3A+4@)M0S9: @  Q 4  !D              ("!^SH! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "%.$M2CU\6YJD#  #'#0
M&0              @(&,/0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( (4X2U(*#,54O (  (0(   9              " @6Q! 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ A3A+4L+U!O4"
M P  APD  !D              ("!7T0! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " "%.$M2Q16F"CT#   Y"P  &0
M@(&81P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( (4X
M2U)$\-F.*0(  .P$   9              " @0Q+ 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ A3A+4D-44UB+ @  .0<  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( (4X2U)_F(\.@ (  "4'   9
M  " @?)< 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
MA3A+4L$?G\1" P  C0L  !D              ("!J5\! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " "%.$M2QO[RK 0$  !:$   &0
M            @($B8P$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( (4X2U+3@4DW,P(  /X$   9              " @5UG 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ A3A+4G9 .JTJ @
MP@0  !D              ("!QVD! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " "%.$M2=#2VGQ@#  !8"@  &0              @($H
M; $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( (4X2U)D
MZ%RMC@(  #,&   9              " @7=O 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ A3A+4FCOUUG7 @  A@<  !D
M     ("!/'(! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
M" "%.$M2]80J[Y4$  "=#@  &0              @(%*=0$ >&PO=V]R:W-H
M965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( (4X2U)-$XVNT ,  '<+   9
M              " @19Z 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L!
M A0#%     @ A3A+4K#^BIW*!0  %AH  !D              ("!'7X! 'AL
M+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " "%.$M270V31-L#
M  #<#0  &0              @($>A $ >&PO=V]R:W-H965T<R]S:&5E=#<S
M+GAM;%!+ 0(4 Q0    ( (4X2U*0I>[7!P,  .4)   9              "
M@3"( 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ A3A+
M4N90=?CU @  :PD  !D              ("!;HL! 'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    " "%.$M26H,05:,"  "\!P  &0
M        @(&:C@$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( (4X2U+M\5?KL (  &$'   9              " @721 0!X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ A3A+4K!Y3! . P  50H
M !D              ("!6Y0! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q0
M2P$"% ,4    " "%.$M2Z'IK<0@%  "/%0  &0              @(&@EP$
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( (4X2U(B8*-_
M_ ,  "$.   9              " @=^< 0!X;"]W;W)K<VAE971S+W-H965T
M.# N>&UL4$L! A0#%     @ A3A+4N8VFEG9 @  ,@@  !D
M ("!$J$! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " "%
M.$M2W]=<DLT#  !=#@  &0              @($BI $ >&PO=V]R:W-H965T
M<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( (4X2U)!C ?E)P,  %P)   9
M          " @2:H 0!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#
M%     @ A3A+4A(P??>U!   3A,  !D              ("!A*L! 'AL+W=O
M<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " "%.$M2!1!UC=8$  !R
M%   &0              @(%PL $ >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM
M;%!+ 0(4 Q0    ( (4X2U)WHD+A40(  %P,   -              "  7VU
M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ A3A+4I>*NQS     $P(   L
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64$L%!@    != %T @AD  ''$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>188</ContextCount>
  <ElementCount>420</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Business Organization and Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation</Role>
      <ShortName>Business Organization and Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Public Offering of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock</Role>
      <ShortName>Public Offering of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2161114 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2163115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2172116 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2175117 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2176118 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/MarketableSecurities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/Inventory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/PropertyandEquipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/IntangibleAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353310 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2364311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2373312 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/EarningsperShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2377313 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Business Organization and Presentation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail</Role>
      <ShortName>Business Organization and Presentation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Sales by Product (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Marketable Securities - Available-For-Sale Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail</Role>
      <ShortName>Marketable Securities - Available-For-Sale Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/InventoryDetail</Role>
      <ShortName>Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/InventoryTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Property and Equipment - Property and Equipment-at Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail</Role>
      <ShortName>Property and Equipment - Property and Equipment-at Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Leases - Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Leases - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails</Role>
      <ShortName>Leases - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Intangible Assets - HETLIOZ - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - HETLIOZ - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Intangible Assets - Fanapt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Fanapt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets - Summary of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Intangible Assets - Summary of Amortization Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail</Role>
      <ShortName>Intangible Assets - Summary of Amortization Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail</Role>
      <ShortName>Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Commitments and Contingencies - HETLIOZ - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - HETLIOZ - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Commitments and Contingencies - Fanapt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Fanapt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Commitments and Contingencies - Tradipitant - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Tradipitant - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Commitments and Contingencies - VQW-765 - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - VQW-765 - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Commitments and Contingencies - Purchase Commitments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail</Role>
      <ShortName>Commitments and Contingencies - Purchase Commitments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Public Offering of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails</Role>
      <ShortName>Public Offering of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Stock-Based Compensation - Stock Option - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Option - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Stock-Based Compensation - RSU - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - RSU - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2459435 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2460436 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - Employee Benefit Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail</Role>
      <ShortName>Employee Benefit Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2465438 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Income Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Domestic and Foreign Components of Income Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2466439 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2467440 - Disclosure - Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2468441 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets and Related Valuation Allowance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets and Related Valuation Allowance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2469442 - Disclosure - Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2470443 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2471444 - Disclosure - Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2474445 - Disclosure - Earnings per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/EarningsperShareDetail</Role>
      <ShortName>Earnings per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/EarningsperShareTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="vnda-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2478446 - Disclosure - Quarterly Financial Data (Unaudited) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="vnda-20201231.htm">vnda-20201231.htm</File>
    <File>vnda-20201231.xsd</File>
    <File>vnda-20201231_cal.xml</File>
    <File>vnda-20201231_def.xml</File>
    <File>vnda-20201231_lab.xml</File>
    <File>vnda-20201231_pre.xml</File>
    <File>vnda12312020ex211.htm</File>
    <File>vnda12312020ex231.htm</File>
    <File>vnda12312020ex311.htm</File>
    <File>vnda12312020ex312.htm</File>
    <File>vnda12312020ex321.htm</File>
    <File>vndaex104012312020.htm</File>
    <File>vndaex104112312020.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vnda-20201231_g1.gif</File>
    <File>vnda-20201231_g2.jpg</File>
    <File>vnda-20201231_g3.gif</File>
    <File>vnda-20201231_g4.jpg</File>
    <File>vnda-20201231_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>110
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vnda-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 188,
   "dts": {
    "calculationLink": {
     "local": [
      "vnda-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vnda-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "vnda-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vnda-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnda-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vnda-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 558,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 4
   },
   "keyCustom": 47,
   "keyStandard": 373,
   "memberCustom": 30,
   "memberStandard": 29,
   "nsprefix": "vnda",
   "nsuri": "http://www.vandapharmaceuticals.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.vandapharmaceuticals.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Marketable Securities",
     "role": "http://www.vandapharmaceuticals.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Fair Value Measurements",
     "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Inventory",
     "role": "http://www.vandapharmaceuticals.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Property and Equipment",
     "role": "http://www.vandapharmaceuticals.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Leases",
     "role": "http://www.vandapharmaceuticals.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Intangible Assets",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Accounts Payable and Accrued Liabilities",
     "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:PublicOfferingOfCommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Public Offering of Common Stock",
     "role": "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock",
     "shortName": "Public Offering of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:PublicOfferingOfCommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Accumulated Other Comprehensive Income",
     "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Stock-Based Compensation",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161114 - Disclosure - Employee Benefit Plan",
     "role": "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163115 - Disclosure - Income Taxes",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172116 - Disclosure - Earnings per Share",
     "role": "http://www.vandapharmaceuticals.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175117 - Disclosure - Legal Matters",
     "role": "http://www.vandapharmaceuticals.com/role/LegalMatters",
     "shortName": "Legal Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2176118 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:DescriptionOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:DescriptionOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ScheduleOfInventoriesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Inventory (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ScheduleOfInventoriesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - Leases (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353310 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2373312 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2377313 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "vnda:DescriptionOfBusinessPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Business Organization and Presentation (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail",
     "shortName": "Business Organization and Presentation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "vnda:DescriptionOfBusinessPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i424e0c1a909c43918460f4dd87afab4a_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail",
     "shortName": "Summary of Significant Accounting Policies - Net Sales by Product (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ia7d2c26d1a8c4ef7843d0e6970eeee5d_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Total Revenues (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ia7d2c26d1a8c4ef7843d0e6970eeee5d_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vnda:ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "icb1cae17f9d144cfbac6ede34e4e28ea_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vnda:ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "icb1cae17f9d144cfbac6ede34e4e28ea_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "vnda:PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "vnda:PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i89fc42978e1140569719239aff32634c_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Product Return Allowance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ieccc14d91ff74e1695188703bf8f103e_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Marketable Securities - Available-For-Sale Marketable Securities (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail",
     "shortName": "Marketable Securities - Available-For-Sale Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vnda:ScheduleOfInventoriesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcessNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Inventory (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/InventoryDetail",
     "shortName": "Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vnda:ScheduleOfInventoriesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcessNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Property and Equipment - Property and Equipment-at Cost (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail",
     "shortName": "Property and Equipment - Property and Equipment-at Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseCost",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseCost",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Leases - Lease Assets and Liabilities (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vnda:ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Leases - Maturities (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails",
     "shortName": "Leases - Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Intangible Assets - HETLIOZ - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail",
     "shortName": "Intangible Assets - HETLIOZ - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "if6745c8d49094756a3fd1e677133183b_D20180401-20180430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "vnda:CumulativeNetSalesToAchieveMilestone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i712a2982fd6d4ab8ac21ead0059a6ab2_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Intangible Assets - Fanapt - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
     "shortName": "Intangible Assets - Fanapt - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i712a2982fd6d4ab8ac21ead0059a6ab2_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail",
     "shortName": "Intangible Assets - Summary of Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ib8b929e9cab449588933c3ffe31bc66f_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Intangible Assets - Summary of Amortization Expense (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail",
     "shortName": "Intangible Assets - Summary of Amortization Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail",
     "shortName": "Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ib8b929e9cab449588933c3ffe31bc66f_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i257e050f9fc943cca28700c4122282b1_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i257e050f9fc943cca28700c4122282b1_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Accounts Payable and Accrued Liabilities (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail",
     "shortName": "Accounts Payable and Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Commitments and Contingencies - HETLIOZ - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - HETLIOZ - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i6d211de579c0497c934d4ecf5fa12295_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "vnda:RoyaltyPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "vnda:RoyaltyPayableOnNetSalesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Commitments and Contingencies - Fanapt - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Fanapt - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i8728d3d07a8d48cf8f36650d6ffe6026_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "vnda:RoyaltyPayableOnNetSalesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "iae6fb1507ec54a02b3ed9ec15779f92e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Commitments and Contingencies - Tradipitant - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Tradipitant - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "iae6fb1507ec54a02b3ed9ec15779f92e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vnda:AccruedMilestoneObligationsUnderLicenseAgreements",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ib097b437c4ec4ac8a415c8716b033089_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "vnda:TieredRoyaltiesPayableOnFutureNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i7d9544bb0d4445a097ccc5fa7f50cd38_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Commitments and Contingencies - VQW-765 - Additional Information (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - VQW-765 - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i7d9544bb0d4445a097ccc5fa7f50cd38_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Commitments and Contingencies - Purchase Commitments (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail",
     "shortName": "Commitments and Contingencies - Purchase Commitments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Public Offering of Common Stock (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails",
     "shortName": "Public Offering of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "iec535a14efca43c882d02e3f9ef3b063_D20180301-20180331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail",
     "shortName": "Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0ce88e2ed3eb4664882da8188a70d03a_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0ce88e2ed3eb4664882da8188a70d03a_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ShareBasedCompensationOptionAwardsContractualTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Stock-Based Compensation - Stock Option - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Stock Option - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ShareBasedCompensationOptionAwardsContractualTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments",
      "reportCount": 1,
      "unitRef": "installment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Stock-Based Compensation - RSU - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - RSU - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i121f6fd163194e94a507e63b36007dfa_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "if5cafed82f414158a6563a9d462e2f6f_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i6b55f4c45eee4e8f8f7faa228c1a8f38_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i5cbcabe269184dbcb50a511cf3bdb9fd_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ie623210fe21f455fba6a25bfe1712547_I20171231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459435 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460436 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail",
     "shortName": "Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - Employee Benefit Plan (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail",
     "shortName": "Employee Benefit Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465438 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Income Before Income Taxes (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Domestic and Foreign Components of Income Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466439 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail",
     "shortName": "Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467440 - Disclosure - Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail",
     "shortName": "Income Taxes - Reconciliation Between Statutory Tax Rate and Effective Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Business Organization and Presentation",
     "role": "http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation",
     "shortName": "Business Organization and Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468441 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets and Related Valuation Allowance (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail",
     "shortName": "Income Taxes - Components of Net Deferred Tax Assets and Related Valuation Allowance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ib28d7508f88c4efabda9793b54a8f6f6_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469442 - Disclosure - Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Valuation Allowance Activity on Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "vnda:DeferredTaxAssetsValuationAllowanceIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470443 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i0372a9ed43bd40eaba8d5c3dc96e86a9_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ib28d7508f88c4efabda9793b54a8f6f6_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471444 - Disclosure - Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Gross Unrecognized Income Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "i926bf00cb18047ab87ba70c56d7331bb_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "icff6f745ed084863aae10666b4b2b891_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474445 - Disclosure - Earnings per Share (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail",
     "shortName": "Earnings per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "icff6f745ed084863aae10666b4b2b891_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478446 - Disclosure - Quarterly Financial Data (Unaudited) (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail",
     "shortName": "Quarterly Financial Data (Unaudited) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "icff6f745ed084863aae10666b4b2b891_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20201231.htm",
      "contextRef": "ic85969e83c184734a768b7cbcef5635f_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "London Lease"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "E.U."
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r130",
      "r179",
      "r183",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r128",
      "r179",
      "r181",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r129",
      "r179",
      "r182",
      "r334",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_DC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DISTRICT OF COLUMBIA",
        "terseLabel": "District of Columbia",
        "verboseLabel": "Washington, D.C. Lease"
       }
      }
     },
     "localname": "DC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r17",
      "r131",
      "r132",
      "r180"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Consulting and other professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r169"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Unrealized gain on marketable securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r43",
      "r47",
      "r49",
      "r50",
      "r282",
      "r289",
      "r291"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "totalLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryofAccumulatedBalancesRelatedtoEachComponentofOtherComprehensiveIncomeLossDetail",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r50",
      "r51",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r192",
      "r194",
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r194",
      "r222",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r79",
      "r160",
      "r164"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible asset amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from calculations of diluted net income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Leased square footage"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails",
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r141",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities",
        "verboseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r313",
      "r323"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r42"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r137",
      "r149"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r134",
      "r138",
      "r149"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r136",
      "r149"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r196",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r92",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Business Organization and Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r27",
      "r81"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r82",
      "r84",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r81",
      "r83"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r288"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r174",
      "r317",
      "r328"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Notes 10 and 17)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 150,000,000 shares authorized; 54,865,092 and 53,549,612 shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r185",
      "r186",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r116",
      "r117",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r116",
      "r117",
      "r283",
      "r284",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r116",
      "r117",
      "r283",
      "r284",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r116",
      "r117",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r114",
      "r116",
      "r117",
      "r118",
      "r283",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r116",
      "r117",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r187",
      "r189",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt",
        "verboseLabel": "Corporate debt"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r61",
      "r62"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of goods sold excluding amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods Sold"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r262",
      "r267"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r264"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r262",
      "r267"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "negatedTerseLabel": "Gain on sale of marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r263",
      "r267"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r263",
      "r267"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r79",
      "r87",
      "r263",
      "r267"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r13",
      "r14",
      "r253",
      "r314",
      "r322"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 2.0,
       "parentTag": "vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r263",
      "r267"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 1.0,
       "parentTag": "vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r237",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r237",
      "r260",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred tax assets relating to U.S. state NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r259",
      "r260",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred tax assets related to U.S. federal research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r237",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r238",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r237",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r237",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Allowance for returns and credit losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "periodEndLabel": "Balance at End of Year",
        "periodStartLabel": "Balance at Beginning of Year",
        "terseLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail",
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r238",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r238",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan matching amount"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined contribution plan employer matching percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution plan maximum employee contribution percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r79",
      "r167"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation of property and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "U.S. Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r94",
      "r98",
      "r99",
      "r100",
      "r101",
      "r105",
      "r319",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income (loss) per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail",
      "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income per share, basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r64",
      "r94",
      "r98",
      "r99",
      "r100",
      "r101",
      "r105",
      "r319",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income (loss) per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail",
      "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r89",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Other tax rate changes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Section 162(m) limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r230",
      "r243"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expenses, weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expenses related to unvested RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expenses"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r278",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r278",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices\u00a0in Active\u00a0Markets\u00a0for Identical\u00a0Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r278",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant\u00a0Other Observable\u00a0Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r278",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r163",
      "r310"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount",
        "verboseLabel": "Fully amortized intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Intangible assets capitalized"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r287",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r125",
      "r269"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision (benefit) for income taxes",
        "totalLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofProvisionBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r84",
      "r241",
      "r242",
      "r251",
      "r252",
      "r258",
      "r271",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r240",
      "r243",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedTerseLabel": "Reduction in valuation allowances"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r84",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r23",
      "r158"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r39",
      "r155"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 2.0,
       "parentTag": "vnda_Inventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory, current"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 1.0,
       "parentTag": "vnda_Inventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "totalLabel": "Total inventory, non-current"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Noncurrent [Abstract]",
        "terseLabel": "Non-Current assets"
       }
      }
     },
     "localname": "InventoryNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r40",
      "r84",
      "r107",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r24",
      "r158"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization of premiums and accretion of discounts on marketable securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r143",
      "r311",
      "r321",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LegalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Reconciliation of Future Cash Obligations to Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount of lease payments representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term of lease agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r315",
      "r326"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MajorCustomersPolicyPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r116",
      "r117",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.",
        "label": "Major Customers, Policy [Policy Text Block]",
        "terseLabel": "Major Customers"
       }
      }
     },
     "localname": "MajorCustomersPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r52",
      "r55",
      "r63",
      "r80",
      "r103",
      "r318",
      "r329"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail",
      "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r93",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (loss) from operations",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r297",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails",
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current obligations under leases",
        "terseLabel": "Operating lease current liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail",
      "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails",
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease non-current liabilities",
        "verboseLabel": "Operating lease non-current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails",
      "http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r294",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r300",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r44",
      "r45",
      "r47"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax",
        "terseLabel": "Change in net unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r43",
      "r47",
      "r286",
      "r290"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r56",
      "r59",
      "r176"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r48",
      "r268",
      "r270"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedLabel": "Tax benefit (provision) on other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r71",
      "r73",
      "r135"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisition of intangible asset",
        "terseLabel": "Acquisition of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r196",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from offering of common stock",
        "verboseLabel": "Net proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r71",
      "r72",
      "r135"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r225"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r168"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r170",
      "r327"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r84",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment-at Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful\u00a0Life (Years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r234",
      "r342"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r84",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r10",
      "r81",
      "r83",
      "r312",
      "r324"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Restricted cash included in:"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r177",
      "r325"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue from Net Product Sales"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r60",
      "r123",
      "r124",
      "r127"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering of common stock (in dollars per shares)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of Provision (Benefit) for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Net Deferred Tax Assets and Related Valuation Allowance"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income Per Share of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Statutory Tax Rate and Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r194",
      "r221",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r194",
      "r221",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Net Product Sales"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of the Domestic and Foreign Components of Income Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of Major Customers that Represented More Than 10% of Total Revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r196",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r200",
      "r211",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r250",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Future Intangible Asset Amortization"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67",
      "r154"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant\u00a0Date Fair\u00a0Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "terseLabel": "Grant date fair value of common stock vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Grant date fair value of common stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted average risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted average expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares of common stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares of common stock available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted, weighted average fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r202",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise\u00a0Price\u00a0at Grant Date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r193",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r84",
      "r196",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r217",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Weighted average expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelforStockOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r298",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Net proceeds from public offering of common stock (in shares)",
        "verboseLabel": "Public offering of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r176",
      "r177",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r176",
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from public offering of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r177",
      "r195",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock from the exercise of stock options and settlement of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r133"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Changes in Tax Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails",
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r187",
      "r316",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government agencies"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r239",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits at the end of the year",
        "periodStartLabel": "Unrecognized tax benefits at the beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Increases (decreases) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases (decreases) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesSummaryofGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]",
        "terseLabel": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]",
        "terseLabel": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Credits/payments"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r97",
      "r101"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r96",
      "r101"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.vandapharmaceuticals.com/role/EarningsperShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnda_AccountsPayableAndAccruedLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable and Accrued Liabilities [Policy Text Block]",
        "label": "Accounts Payable and Accrued Liabilities [Policy Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_AccruedMilestoneObligationsUnderLicenseAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Milestone Obligations Under License Agreements",
        "label": "Accrued Milestone Obligations Under License Agreements",
        "terseLabel": "Milestone obligations under license agreements"
       }
      }
     },
     "localname": "AccruedMilestoneObligationsUnderLicenseAgreements",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_AccruedResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpense",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements For Clinical And Marketing Services, Termination Notice Period",
        "label": "Agreements For Clinical And Marketing Services, Termination Notice Period",
        "terseLabel": "Agreements for clinical and marketing services, termination notice period"
       }
      }
     },
     "localname": "AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_CftrActivatorsAndInhibitorsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CFTR activators and inhibitors [Abstract]",
        "label": "CFTR activators and inhibitors [Abstract]",
        "terseLabel": "CFTR activators and inhibitors"
       }
      }
     },
     "localname": "CftrActivatorsAndInhibitorsAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_CftrActivatorsAndInhibitorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CFTR activators and inhibitors [Member]",
        "label": "CFTR activators and inhibitors [Member]",
        "terseLabel": "CFTR Activators and Inhibitors"
       }
      }
     },
     "localname": "CftrActivatorsAndInhibitorsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments and Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments and Contingencies [Table]",
        "terseLabel": "Commitments and Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ComputerHardwareAndOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Hardware and Other Equipment [Member]",
        "label": "Computer Hardware and Other Equipment [Member]",
        "terseLabel": "Computer and other equipment"
       }
      }
     },
     "localname": "ComputerHardwareAndOtherEquipmentMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_CumulativeNetSalesToAchieveMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation.",
        "label": "Cumulative Net Sales To Achieve Milestone",
        "terseLabel": "Cumulative worldwide sales milestone"
       }
      }
     },
     "localname": "CumulativeNetSalesToAchieveMilestone",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_CustomerFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 5 [Member]",
        "label": "Customer 5 [Member]",
        "terseLabel": "Distributor E"
       }
      }
     },
     "localname": "CustomerFiveMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_CustomerFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 4 [Member]",
        "label": "Customer 4 [Member]",
        "terseLabel": "Distributor D"
       }
      }
     },
     "localname": "CustomerFourMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 1 [Member]",
        "label": "Customer 1 [Member]",
        "terseLabel": "Distributor A"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 3 [Member]",
        "label": "Customer 3 [Member]",
        "terseLabel": "Distributor C"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 2 [Member]",
        "label": "Customer 2 [Member]",
        "terseLabel": "Distributor B"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofAccountsReceivableNetDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofMajorCustomersthatRepresentedMoreThan10ofTotalRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets Liabilities Before Valuation Allowance Net",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit and other tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research and Other",
        "terseLabel": "Research and development and orphan drug credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesComponentsofNetDeferredTaxAssetsandRelatedValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_DeferredTaxAssetsValuationAllowanceDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the period related to valuation allowance for deferred tax assets.",
        "label": "Deferred Tax Assets Valuation Allowance, Decrease",
        "negatedLabel": "Reductions"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceDecrease",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_DeferredTaxAssetsValuationAllowanceIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the period related to valuation allowance for deferred tax assets.",
        "label": "Deferred Tax Assets Valuation Allowance, Increase",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceIncrease",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_DeferredTaxAssetsValuationAllowanceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Valuation Allowance",
        "label": "Deferred Tax Assets, Valuation Allowance [Roll Forward]",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance [Roll Forward]"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceRollForward",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesValuationAllowanceActivityonDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_DefinedContributionPlanVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which an employee's right to employer matching contribution to defined contribution plan is no longer contingent on satisfaction of a service condition.",
        "label": "Defined Contribution Plan Vesting Period",
        "terseLabel": "Defined contribution plan vesting period"
       }
      }
     },
     "localname": "DefinedContributionPlanVestingPeriod",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EmployeeBenefitPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_DescriptionOfBusinessPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Business",
        "label": "Description of Business [Policy Text Block]",
        "terseLabel": "Business Organization"
       }
      }
     },
     "localname": "DescriptionOfBusinessPolicyTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Milestone Obligations Paid To Third Party",
        "label": "Development And Milestone Obligations Paid To Third Party",
        "terseLabel": "Development and milestone payments to third party"
       }
      }
     },
     "localname": "DevelopmentAndMilestoneObligationsPaidToThirdParty",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Milestone Payment, Conclusion Of Phase I Study [Member]",
        "label": "Development And Milestone Payment, Conclusion Of Phase I Study [Member]",
        "terseLabel": "Development And Milestone Payment, Conclusion Of Phase I Study"
       }
      }
     },
     "localname": "DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.",
        "label": "Development And Milestone Payments Potentially Due To Third Party",
        "terseLabel": "Possible future milestone payment",
        "verboseLabel": "Possible future milestone payments"
       }
      }
     },
     "localname": "DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment",
        "label": "Effective Income Tax Rate Reconciliation, Effective Tax Rate Adjustment",
        "terseLabel": "Other changes in state deferred taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug",
        "terseLabel": "Orphan drug credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_EstimatedRealizabilityofDeferredTaxAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Realizability of Deferred Tax Asset [Member]",
        "label": "Estimated Realizability of Deferred Tax Asset [Member]",
        "terseLabel": "Estimated Realizability of Deferred Tax Asset"
       }
      }
     },
     "localname": "EstimatedRealizabilityofDeferredTaxAssetMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_FanaptAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fanapt [Abstract]",
        "label": "Fanapt [Abstract]",
        "terseLabel": "Fanapt"
       }
      }
     },
     "localname": "FanaptAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_FanaptMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fanapt.",
        "label": "Fanapt [Member]",
        "verboseLabel": "Fanapt\u00ae"
       }
      }
     },
     "localname": "FanaptMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Percentage Of Royalty Payments Based On Net Sales.",
        "label": "Future Percentage Of Royalty Payments Based On Net Sales",
        "terseLabel": "Future percentage of royalty payments based net sales"
       }
      }
     },
     "localname": "FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_FutureRegulatoryApprovalAndSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Regulatory Approval And Sales Milestones [Member]",
        "label": "Future Regulatory Approval And Sales Milestones [Member]",
        "terseLabel": "Future Regulatory Approval And Sales Milestones"
       }
      }
     },
     "localname": "FutureRegulatoryApprovalAndSalesMilestonesMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_HetliozAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hetlioz [Abstract]",
        "label": "Hetlioz [Abstract]",
        "terseLabel": "HETLIOZ"
       }
      }
     },
     "localname": "HetliozAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_HetliozMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hetlioz [Member]",
        "label": "Hetlioz [Member]",
        "verboseLabel": "HETLIOZ\u00ae"
       }
      }
     },
     "localname": "HetliozMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHETLIOZAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofAmortizationExpenseDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryofIntangibleAssetsDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesNetSalesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_IncomeBeforeIncomeTaxesCurrentYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Before Income Taxes, Current Year [Member]",
        "label": "Income Before Income Taxes, Current Year [Member]",
        "terseLabel": "Income Before Income Taxes, Current Year"
       }
      }
     },
     "localname": "IncomeBeforeIncomeTaxesCurrentYearMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Credit Carryforwards and Uncertain Tax Positions [Member]",
        "label": "Income Tax Credit Carryforwards and Uncertain Tax Positions [Member]",
        "terseLabel": "Income Tax Credit Carryforwards and Uncertain Tax Positions"
       }
      }
     },
     "localname": "IncomeTaxCreditCarryforwardsandUncertainTaxPositionsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesReconciliationBetweenStatutoryTaxRateandEffectiveTaxRateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_IncreaseDecreaseProductRevenueAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances.",
        "label": "Increase (Decrease) Product Revenue Allowances",
        "terseLabel": "Product revenue allowances"
       }
      }
     },
     "localname": "IncreaseDecreaseProductRevenueAllowances",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_Inventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory",
        "label": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventory",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_InventoryAndOtherNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets.",
        "label": "Inventory and Other Non Current",
        "terseLabel": "Non-current inventory and other"
       }
      }
     },
     "localname": "InventoryAndOtherNonCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_InventoryFinishedGoodsNetOfReservesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Finished Goods, Net of Reserves, Non Current",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReservesNonCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_InventoryRawMaterialsNetOfReservesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Raw Materials, Net of Reserves, Non Current",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReservesNonCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_InventoryWorkInProcessNetOfReservesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Work in Process, Net of Reserves, Non Current",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReservesNonCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_NoncurrentInventoryAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Inventory and Other [Member]",
        "label": "Noncurrent Inventory and Other [Member]",
        "terseLabel": "Non-current inventory and other"
       }
      }
     },
     "localname": "NoncurrentInventoryAndOtherMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesReconciliationCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_NumberOfProductsInPortfolio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Products In Portfolio",
        "label": "Number Of Products In Portfolio",
        "terseLabel": "Number of products in portfolio"
       }
      }
     },
     "localname": "NumberOfProductsInPortfolio",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "vnda_OperatingLeaseNonLeaseComponentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Non-Lease Component Expense",
        "label": "Operating Lease, Non-Lease Component Expense",
        "terseLabel": "Non-lease component expense"
       }
      }
     },
     "localname": "OperatingLeaseNonLeaseComponentExpense",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_OperatingLossCarryforwardsBeginningExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The year in which operating loss carryforwards begin to expire.",
        "label": "Operating Loss Carryforwards, Beginning Expiration Year",
        "terseLabel": "Net operating loss carryforwards beginning expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeginningExpirationYear",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "vnda_OrphanDrugCreditBeginningExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan Drug Credit , Beginning Expiration Year",
        "label": "Orphan Drug Credit , Beginning Expiration Year",
        "terseLabel": "Orphan drug credit beginning expiration year"
       }
      }
     },
     "localname": "OrphanDrugCreditBeginningExpirationYear",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "vnda_OrphanDrugMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan Drug [Member]",
        "label": "Orphan Drug [Member]",
        "terseLabel": "Orphan Drug"
       }
      }
     },
     "localname": "OrphanDrugMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_PercentageOfFutureSublicenseFeesPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property.",
        "label": "Percentage Of Future Sublicense Fees Payable",
        "terseLabel": "Percentage of future sublicense fees payable to third-party"
       }
      }
     },
     "localname": "PercentageOfFutureSublicenseFeesPayable",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of responsibility for patient's cost of branded prescription taken by the manufacturers under Medicare Part D.",
        "label": "Percentage of Responsibility for Patients Cost of Branded Prescription under Medicare Part D",
        "terseLabel": "Percentage of insurance coverage gap allocated for prescription drugs under Medicare Part D"
       }
      }
     },
     "localname": "PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_PreNDAApprovalMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-NDA Approval Milestones [Member]",
        "label": "Pre-NDA Approval Milestones [Member]",
        "terseLabel": "Pre-NDA Approval Milestones"
       }
      }
     },
     "localname": "PreNDAApprovalMilestonesMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_ProductRevenueAllowancesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Revenue Allowances, Current",
        "label": "Product Revenue Allowances, Current",
        "terseLabel": "Product revenue allowances"
       }
      }
     },
     "localname": "ProductRevenueAllowancesCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_PublicOfferingOfCommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering Of Common Stock [Text Block]",
        "label": "Public Offering Of Common Stock [Text Block]",
        "terseLabel": "Public Offering of Common Stock"
       }
      }
     },
     "localname": "PublicOfferingOfCommonStockTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/PublicOfferingofCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_RegulatoryApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Approval Milestone [Member]",
        "label": "Regulatory Approval Milestone [Member]",
        "terseLabel": "Regulatory Approval Milestone"
       }
      }
     },
     "localname": "RegulatoryApprovalMilestoneMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_ResearchAndDevelopmentCreditBeginningExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development, Credit Beginning, Expiration Year",
        "label": "Research and Development, Credit Beginning, Expiration Year",
        "terseLabel": "U.S. research and development credit beginning expiration year"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCreditBeginningExpirationYear",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "vnda_ReservesForVariableConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserves for variable consideration policy.",
        "label": "Reserves for Variable Consideration [Policy Text Block]",
        "terseLabel": "Reserves for Variable Consideration"
       }
      }
     },
     "localname": "ReservesForVariableConsiderationPolicyTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_RoyaltyPayableOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.",
        "label": "Royalty Payable On Net Sales Percentage",
        "terseLabel": "Royalty payable percentage on net sales"
       }
      }
     },
     "localname": "RoyaltyPayableOnNetSalesPercentage",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_RoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Period",
        "label": "Royalty Period",
        "terseLabel": "Royalty payment period"
       }
      }
     },
     "localname": "RoyaltyPeriod",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_SECSchedule1209AllowanceProductReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule, 12-09, Allowance, Product Returns [Member]",
        "label": "SEC Schedule, 12-09, Allowance, Product Returns [Member]",
        "terseLabel": "Reserve for Product Returns"
       }
      }
     },
     "localname": "SECSchedule1209AllowanceProductReturnsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesSummaryofProductReturnAllowanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule, 12-09, Schedule Of Valuation And Qualifying Accounts",
        "label": "SEC Schedule, 12-09, Schedule Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of Product Return Allowance"
       }
      }
     },
     "localname": "SECSchedule1209ScheduleOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone [Member]",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_ScenarioFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario 4 [Member]",
        "label": "Scenario 4 [Member]",
        "terseLabel": "November 16,2016 through December 31,2019"
       }
      }
     },
     "localname": "ScenarioFourMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block]",
        "label": "Schedule Of Accounts Receivable By Major Customers By Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of Major Customers that Represented More Than 10% of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_ScheduleOfInventoriesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of inventories.",
        "label": "Schedule Of Inventories [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoriesTableTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Lease Assets And Liabilities [Table Text Block]",
        "label": "Schedule Of Lease Assets And Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Lease Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]",
        "label": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]",
        "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]",
        "label": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]",
        "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofRSUActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ServiceOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Option Awards [Member]",
        "label": "Service Option Awards [Member]",
        "terseLabel": "Service option awards"
       }
      }
     },
     "localname": "ServiceOptionAwardsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options and Restricted Stock Units (RSUs) Outstanding Number",
        "terseLabel": "Shares subject to outstanding options and RSUs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted\u00a0Average Remaining\u00a0Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of new hire stock option award that vests after one year of service.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards",
        "terseLabel": "Portion of initial stock options granted to employees that vests on employee's first anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of new hire stock option award that vests monthly after one year of service.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards",
        "terseLabel": "Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Service Option Awards, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Service Option Awards, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control",
        "terseLabel": "Full acceleration of vesting, employee or executive officer subject to involuntary termination, period post change of control of the Company"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Annual Award Vesting Period Employees and New Directors",
        "terseLabel": "Vesting period for subsequent stock options granted to directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_ShareBasedCompensationOptionAwardsContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of stock option awards.",
        "label": "Share Based Compensation Option Awards Contractual Term",
        "terseLabel": "Share based compensation option awards contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAwardsContractualTerm",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments",
        "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments",
        "terseLabel": "Number of vesting equal installments"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRSUAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "vnda_StatementScenarioSecondaryAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement, Scenario Secondary [Axis]",
        "label": "Statement, Scenario Secondary [Axis]",
        "terseLabel": "Statement, Scenario Secondary [Axis]"
       }
      }
     },
     "localname": "StatementScenarioSecondaryAxis",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_StatementScenarioSecondaryDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement, Scenario Secondary [Domain]",
        "label": "Statement, Scenario Secondary [Domain]",
        "terseLabel": "Statement, Scenario Secondary [Domain]"
       }
      }
     },
     "localname": "StatementScenarioSecondaryDomain",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_StockOptionsAndRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options and Restricted Stock Units (RSUs) [Member]",
        "label": "Stock Options and Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Outstanding options and RSUs granted (RSUs)"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_SubleaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease [Member]",
        "label": "Sublease [Member]",
        "terseLabel": "Sublease"
       }
      }
     },
     "localname": "SubleaseMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_TieredRoyaltiesPayableOnFutureNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered royalties potentially due to third party under license agreement based on future net sales.",
        "label": "Tiered Royalties Payable on Future Net Sales",
        "terseLabel": "Tiered royalties payable on future net sales"
       }
      }
     },
     "localname": "TieredRoyaltiesPayableOnFutureNetSales",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_TradipitantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tradipitant [Member]",
        "label": "Tradipitant [Member]",
        "terseLabel": "Tradipitant"
       }
      }
     },
     "localname": "TradipitantMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]",
        "label": "Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]",
        "terseLabel": "2006 Plan and 2016 Plan"
       }
      }
     },
     "localname": "TwoThousandSixPlanAndTwoThousandSixteenPlanMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_TwoThousandSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Sixteen Plan [Member]",
        "label": "Two Thousand Sixteen Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenPlanMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_UnitedStatesExcludingDistrictOfColumbiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States, Excluding District Of Columbia",
        "label": "United States, Excluding District Of Columbia [Member]",
        "terseLabel": "Other States"
       }
      }
     },
     "localname": "UnitedStatesExcludingDistrictOfColumbiaMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_VQW765Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VQW-765",
        "label": "VQW-765 [Member]",
        "terseLabel": "VQW-765"
       }
      }
     },
     "localname": "VQW765Member",
     "nsuri": "http://www.vandapharmaceuticals.com/20201231",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765AdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r343": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r344": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r345": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r346": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r347": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r348": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r349": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r351": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0001347178-21-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001347178-21-000005-xbrl.zip
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M>< T8QOX_D FF5;>>"6X051R);5B*'7< K49K,32@.Q1;>#[@P^GGF>.22E
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MZ!T13M7??C@!0"^FX+J7HV'Y(OPPOGC\_?ASN/I6H!M'J E-K!UC5&B .Q/
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M!EQ-QG'!<A(L" #&4\J9D%2",%#$AOZ@6EF**%Z KC$S ][#3(VVH%!HF8)
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MR(+9LIG73OX]OU%T1SV=JV5T/QB2,@ P1M9:JIG7QC*&!<H(0X[CZ[W7'J-
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MGIB+'Z^O&M;-F7N^?F3R\U4CDY\?W'!X\\M7S_U!<QM9_OJ-^JONJ 7WX3W
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M@P<F7"JD%,;_HK9%T8=M\SI@"4C.-YRGPU8ZLZCTN0,+9=!$LL+H#.A7?%6
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M?0\1J<3,B=;#ZU*FF(5HC(DQ&MK-J>5F#=?Y6;9'U3EK5(,*W Z (<Z3&M;
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M1.1ZO4$;>(X5"2JKN92\U:,BQ #4,EV.!!+7@PT<USRLW@451QQLK>=\(Z:
MRG6%K@X4IX6IZQ=H,'*P H@NWS 7S"Q]:!ZZ<43YG98>:?0 4'>;V&G!'JOH
M2 XCDJJ)\QI;BFEK5=E)@,G.__ELN'MI!LR7#<TBVQ[Y/_>]AS1A6:6;@UJK
M4\&9=L@(393?UB H]W:!&;H TPT@.=IE#ME]<6#\8@6CI6!%;JYI&>\L>^4^
MV>GG\Y:E\JHUWB +%PN$R= JO%RQ8@M":56WQM[?#G\?B +YY]YNLR U?;-8
M__:B^R<;NY=U./9B1^XK5M58$G38M);A@'LK!3,4J4K\GKE*%_)J:9'<"<8<
MV9!YM7UUZP"LM_@G%U#\QJ$PFPM9LPAK7HB8\&)B[1<L1<5L6LFN7F2\G'/)
M_:PXYJEE/>]]7QM-,]<,IO5UR7Y=\GY?E]S7)3_"3?1UR=]0"BSE%T3*K\PP
M#/P"46O2D216Q2"12!@=*P,F#!>EQ::L<0#,%+;'KCP!G_(KFI$WS]-\'Q:D
MU]%__Q6>)MN5&<-8**#<$=&2=#_P4DYI'^\0S4[** ^V?C\Z?;<]Z)9C7M?Q
MO-PY9/#L:Q[-,.@F1Y8VUXS5N<1(G7;[KY<:TAESN3 6@#IQ6$]IJS6+'EQ6
MY66E-*TN2D&;$J,<4*U)&VS!1G O&%2I]1ZBZMDPP#D\6E\8E3>IV6%?]G+'
M>!A\SC%9QPS<D#'V>'E[_]P;[M_ X;VIE_G/O7WO?3RG:>7S^=7_?.9[X_BP
M4GT=[9:]KN-,A_RH?=U^?[+&SU6LLW\^>[$[('&RS@$FV1W)Z'"1^!:5HG'2
MV0-PVD4E_X!#WD G^,*=B'0$>_Z2*L;QM_XLWQQW:9W3L@HK0V$#8B/NB<(B
MK-B%S#^AY8S85.+;%T4%X $3C4_HY:'%V[%YX>H#WS@PIKMP.V_F._*%VV37
M<<E.PHY(O.B6I$*0OJXI'1Z>)>80=M4$W&UNR9-71;=B$8BO U MS"3BR=1K
M5NSR]*WE/P';:3,;S(^7ZT09Q^/*$@K)_>D(L#[K=O,3&&Q$SXYRMP\WK*%=
MP2)0H^PK 0FN:ZG>?036(@-\E07;ZIA9V2<CD-;NCJPQ0F^1#_&JL0T1ZKO4
MXM\\>-P4BSTE(\"'_;A^O*2AQ4U#)GKU'GLG]8DG7$](2 *8"GV;G_AL?@I^
M#:MHNO-G^ 7)6/I )3ITP_3_G\;5ZH0JI>:REW:'-;>8U)G-P_&<9N.ZIL%#
M$D63%IO*7:ZE-NT($.OLXDC9D><3SAT1V;"DAY.#F,0Z(Y[N2V1XC:KV!C85
MZ3B[W<K-#Y%!297W0AXIWL ,0!D6VL[(*YXD8OUBGE(2\>3FN7?\<C7)CXXB
M'J<TP1=+$TG=DUN:MRT>CFOGT#9[]+7S\@O8DP6(6:G0E29UD0F6,H!JD^EP
MV-[DVC4MCT@7]*T'MS(;6T.:B)6<2>/=,@CLH[>MSK)+3<;.;+VD\++H@L;.
M\V;I[HLOW8"N>16+#8][&+^X>U4+#)5+=]Y]_D1&X(J%:!P%IJ"=^TEJ+A98
M4AWN.C=9S/-J[?1COW"R=.N@>]D[*+=H<F&+5TM0!STI5ZW\]?4H^9#'*'?&
MW0H1#LV5UDLS#!RH3][IXT2@MNEH]9I'NU)CY9V%DC3W38"OQ 1<#Y;S(/<L
M')'4[HA5&_D?,[P2C_)1Z2:9"T4L CHHIL-"["<6^YP(?J8&'4#UW%/%Z[<B
M^KZ[<C?W4E_[W.AF]%+Q7GIJO\O:IF=];5-?V_0(-_%]UC8]%F_YD/MB"C,%
M>L<Y[++2SH-@>\#B)7(5M <WXZ(OB3^12^..C\L>.^2B +)J>)3&B5TXYYT^
M\_1AAN4+WOY5)Q;'_:VB_9+/^/"]4UL?V2@.?L[SLVUW(JL.0P?M<.>G SVV
MH$#2,F?2_&(8O.>TO<V8EC;Z%? N8.JY!E+I")39[^P7"Z1/,]3&@O$DAJ.[
M&%I6!F]Y:@^OYU\A$>[J>G15K7(39*U.Z0)#>8=HSD-)?K3_^(E,TWD:+GY,
M,J8<?ZEKD=!]4]WT^C59/,^@GJJ"_B^VCU?--63-]4,5K_C;P?#@U<':/^\.
M]V[XMU?[SV_TS<L6^^S5</_5B\U9[(M7Z__L/_8'/C4Y.>( ,--__N/9/QK#
MA2'B?]R??PGVK'CUS:XE4Y7Y[:ZE[JNKD@!L(*D,<E="]W[)MG:QJ7]<ZZ,;
M08$/+#Z^@@ K=H5I  ^SIR5AO=O%,[[=SA[?>7U>S$UK3U=<1V0#)P60D7=T
MA5%D#!ET*LS9#)I7 3E/21S8Y=_TL"]S*>Y+/^\^AES#[MW"LUS"K6L/]"LD
MU)TSQ>I[0H_Y]L8TL\/OIW+[7PQ>O7@Y>+'_^AIBX$K"/K!\N.;6OU+X/7E6
MH,<(,2S0IOPD:)NWDZ1C_I_;7;Q[>,8&',KOI\'KP>[+W<'KUR]NQ*0WW?)F
M7\W-.^CWIIKFVAR>CQ7BTD[IN1,[YB[4WET^8P,.A6_?BV>O!_O/GO>*\0D?
M]#W>OE[WW>[V/7\]>.UE@GK=]_0.NM=]C_!0^/8=/"/+<V^WUWU/^*![W?<(
M#X5OWZL7+P;[S_=ZW?>$#_K;Z;YKAJCO@11?DXRX"Z'[_6CH3V^?OWRYV_NF
M3_F8>_W\" ^%[M[>[F#W8&_P^N#@+E35=T(W+F@JZY%TL/:^W4-R[]YS,C'O
M)N/WG=!-1#&7D/4"^%&P\,'KP=[>S5CX^Z3;G;-P+X5OQ\+/#EX.GK^ZF0WQ
M?=*ME\*/YBB$A9^3(;%W\+*7PKT4WCQI(BS\DO[OQ=TD.KX3NO52^-$<A<_"
M=Y(M^$[HUDOA1W,4PL*O]E\/GK^\6:'C]TFWNXRGZ05^6OT.#XQ'\)#M#G<H
MU-?RQ";=%9(QKP8O7KV$INQSZM\E"_259H_P4/A>OGRQ/SBX80RASV1OQD'W
MF>Q'>"A\^UZ_?CUX^>Q5KQ6?\$'WNN\1'HKT]QV0[GN^W^N^)WS0O>Y[A(>B
MM^_Y8/_%S6HH>]VW&0?=Z[Y'>"C>[;N3D.]W<OLV[Z![W?<(#\6[?7=2N?&=
MW+[-.^A>]SW"0^';M_?LU>#YL][O>\H'??^Z3Q,SBD:Z/F7[T+KQNNO<@$.5
MV_OB8+"W?ZMZFSLGR6;?[J?'*%]Y^W]@0.#_??7P5R7!#FHN'M?TUV^%+_E5
MR[K+$HQ'/\GN8UW8V6DZA\X;226#4;))/^GDUI-.[*R?E5-D95@-3_P*H[_J
MQ)_T%[I10@SH_O/[TV%_'+<^CD2@_V>8-B@3:#'R$"CY=$W/@!R/3V%@&R/%
M\W!G'>R9CP$.;^AT2H<JG]!K)C),X&*:1-/+AKDE]"^3RBRIB!1:Q:.'W-#B
M(3#[^TMXYZ<ND]@PN3)X8R(>#Q#L[^[OV_$!&  QT-/##.+,SG7E6:UC^M?.
MPH2%C.DL<;"3(LQPB,U(V=9PT\.(S_IC5.7RKKU7P^ H+V1F,D\:6#_]3^?&
MX0&S'!,K> PA\R:FC7W6!;L9@,2LGXLP-OA$\!$C. T_1Z<;[.T'L^7RY=80
MC)Z[;L-=,A(9(V'EY.C&5Q>X]/N[SY[Q\= _9&YV=9$'<:L0UYW#TE,2?L +
MGJ#-TRI84>A,2AU7L6H>I9,9<NIE^]AUKK>EMOPU+(D@:66( ;?NDQ=>#F_'
M"H^=$Y9F^&T'>4&ZOJS+N0B.S1LY>YSIP).!S#8,+^ST%9$=>[L!9",S$L_M
MM5.Q$[)MMMANP??F>:5C>7E6?.:/UF/9FD#4ZG!% RG<3._F;P0E'7="P@W#
M6S/:&Y%&>7Z[,P%0![2L7::(TM9">?!,,9_2PIKG8F9QR6-?,#_=D8%WF1>K
M'L/WUPX/["<&WN'58AZH@M2$I!'=8?*,[9!G((4I<4'53 C*RS+A\=R0J\R!
MS7$T]C4&MT=6C&XE0T-V0&A_YJ_JUTK\6D:;8 :0, 7_*L),:4RR'_&L=O>Q
M0:",W@AGL2?T[]L-3\$63&-,%&<+(U:>K^=X+LP/W>YHP3N!8F?=P8\K:WH!
MS^(,6Q/!@PC'B0M3F6#K].2(KHE,Q$H-3)<3NFLA&: 179YS4U;)1-9XDM*B
MMTZ.3[9U6>.Z8*4C:POH25W6;E_G,OE"ADM637F<.!:\XJ: 4MGRE9,AQJ0E
M.^*![9ZZ!,EI9;HP-Z63R$3N/<A!QLY5UWS5:\6JDL/ ;'HY?\^6LO8>#V=?
M4KI!3 H[:L:YDN(.9I,?XG 1Q'G)9GWB'(8E';\O@YV=N,(#P)>E72Y1?!A\
MO%+Q>R**A*FN>$!D6! UQO1ECZ:];+K#89S]+$Z/&GO/V^3H9W'VLS@?Q2;Z
M69P/&VNN2NAJ&VYAE=>RJ%?9T=!1O7*ZG>$,$QD!3EAZL/Y,E3B]?TXF(\P)
MF7C)5I.83[&QEH;.M)=HY6+CW-=#S^9983/YAAOYZ!'LY:!,C9EC.#RG%R4<
M3'_OQE/4#DLX?,..;L^IMS@IMEHE9CD(+EH&?M>$YTFLGI_.)[0JW#5HX@[I
M0AT8'!LXVI!-+/&:Y3#LG+:0Q^WPL!56>%<[)'NM._&J<R<>52[V&_6^]ZG8
M=<S?R?N R1\8CV##98DD<[Q4RO[NWDO_0DLJD'^_B__*E79).7H"N?WY14;?
M'BV"TS#+QXGSPC5FSV[["JTBY(*<R?MCO%5 O3#-&?Q!Y ZO'K;]V"R0G@%N
MP0"DU,-1GB85;N3=)^WIWE\G9W\=(P IB _YN4TN[SU#K)(%C8TN\P\.5V2[
M97N&W1SMLG'9\]$M^ B+B>'+$-?DU6)N6+QKAISH7[O@^E6I]58PU^H9/"Q-
M2BGRX<=\+,)L8H*?\_P,O_I7F-4(SQ-CO!@@25&:"N]MQX';YFH[[F[-5EZ?
M,!U^U36->RZY12 W\+S%RVHFFI(MY:"N7;&6%P:!RXBB)JRLA ,TBX!,3;M&
MY=G>YBF\/XT0B/-P)&F)$&PH(:^$N /+WE8RXK(J!I"*Q#H.(D$ZN$CB/#/!
M5L_H=UNH\-OA<4O!6B$H62C.XB51D9=S$DFF^VF<3G\@-S\0':#M*X/G2T+%
M5JR5^<RF5+VDW_)YA7_5!C8/GUM4+$KRN\O^Y.[]Y)ZM<C/7'9H5EM>JZ%HC
M"R^7KJU'.3LH3DIY+)%B%G)@GFLB\EJJ);3Z1M0>/YL4(0R?69Z:J$[-QD6"
MOZ:0J3 3W(^\6-RBG(G)B&*_KRUF^I"[@#V=4&G+]/IK>@N-=V$K;.C6S))*
MW:Z1O9.X% 6ZA^(@KMU=TZN#Y.<:CF@"Q5RJZRI(7!QI&%R:^2H3VBRQB_?X
M>1B=A1.S'(XNN92#EAR>A_0EK$JJ.354SLFRGDD>,%=6SSO9LNO9[H\Z-0#_
M-YG3Q[TVM,V(J?^6P(O.+S@_Y$?7R5F_,&F*_UZ5$YSGZ6*&<C%B"%A-./9!
M-]TT"\]88C24:E=\>3<9@8+EN)(U$CHQZ$YC2&FN##PWCJDV#FEP8WUCB;=H
MOTWB<%XD*1LS \@[,^_$P2[8"TB:[V1$'(Y:(-A19X9-V(&+P2'$E2V\!@JN
MK51Y1N0V)"8NZZ9H#"5U*"_W'M>;.2K=\4KZ4EG5,1.:];IW?IM_;__X_&EG
M__7!AMU97367\08E.,H9G,&O;PZ/B+VFR2BIT&R%,VOL,-C%(;[5A&LX54R&
M%TKP\PQ;F"S:Y=TWM;[M,A^QY?VHF?,D+ZIQGB8Y-G?T[O,GB4C  "I5&.HQ
MEQO&P.BIG5]_=RP"16H7>1@[BY-X28NDXYC$:\F<I:8'GCJE5Y*X)"4D/1/$
M;9DQ<3F0YC5FYHCX*B.]%<-F79"Q&1$?5LD\E"X)J+9H42*%<I;$F5F ,PUQ
M*7UP2JQ65ER#C/66)BH,&Z=Q$A;%E#XU%,>7+E"7_^^0Z5GE:=$]N4IQ@@CI
M4ZBW^..__]PY\,97; 9O?\C)!JZ2\I8VE6<YU<S82HV!_4<GT:<M:Z,D"UW+
MFOTD*P$QFS2F.9^&9(E$IF8OPPMQ2HJ.[D!F;3'KS)>FJJ2#(@CIT_(O_JO;
M<9_1O[/"#,_>H_=;9]HTQJYK>A=S$&TL:*RYPO;U<[+Z &[+6=ET/\!?5.98
M_IJ9(B)#@C;3,&08G$R)>L'QL8B[,"7VVCF0'TBVYL03)#^)W8B,D)KH7</V
MYK!0YN =V $3DL-EM62$K[*=N_'#&]6=?9=]!QUIVO<=]'T'CV(3WV'?P:.V
MO5HE?!MF@1UR))G#E&VXGM)3#[1L%_VQ?X7]79?X33@B.YS5L. )<->JA+\E
MM-*IE;I$X0HZQ5AK8)K8DSR'E-@9.15-SLOZ)8UJ\ZTJ[JP46[^T_9!=P[_=
MYGW1B@BY9>?>^:XORT1B!IH7T3ER,[)*U&^40J&CB54B0Z*SHS1,9J6J93('
MR"A,KD$AKD3S+=\N\,(LK$@'M7PV>9.+.>AFE"Z#KG7;>F G*EF73R)20,8/
M>8W<VWR6Y1<[T_QBPR[MNYQ/<&D;$@--A NYB9T^@A*@<5XLAXX'MM?<M+"&
M+ <RIZ% K4ZEL"RC#T62(4+D51C)B)O#_($+9]WR1=/(SFO*SO/TW*Q>-7?#
MF&B:23R-OX#78Q?\,*G672DQZ,IR>H6M7;J."VXO0H6=QAC\6+G8Y=DXB27$
MAXB(\\_8MK=)+VP%=C[=Y$JB>H5A**T  43=JYG-TWQA4$A*;S;G(8?!LY((
M%MI+',;GZ/HIA8(5"U.^M^M602^SD7 <I $-02VT$TVY>KEN'WZ"<YEIZ44A
MG6_BQ&J:D)T&+)*_21Y%M,"CX3>'9W[N+\_2A3VNYIG8!3]4*2#5I1&W_2?E
M5(,M)?]E7A<D/81'^&GT"R +2+@^B.L*G>-+N]<<%Q8J89J\=,N^ML2Y][NX
M6IR\=X63V/1IF)I-,P'Z'K/;9'BC<$X7'AD?W%I!#NG4;]KRJ2:/0$S^(<]V
MI"3+J^1]SDS4'\B=' @+H3984N>05AY,AH=5M*2F:[.JBQ'@4=A@.WU_VH5]
MVVW2\IMT6/>SZ.O7]#8A,M(4:5AGT=0\ >Y_4++Z<L?+NN\]]TO1T\5@\\G\
M.(3,2JG_=OC[E5*? 8:([T?T=)B)9#264NJ02E,'Y!>CA!W6DYK<8K0;LKW[
M1*_-@YXGD?D70Q9OMA@&O]#"Y1RERX*.K2D*\'O$>YRCN\C=(%_-;@(<$,,P
M>'DAYC_Y=>4TF3<%Z'Y2MYMD<<7G_9'<KJS55HAM6CEVGT6]Q;&SH<PC *JO
M=F7*:)K\G<^GA<F2$!]_'T*%[;[NW%%?777L%,\'VN5P2T1+3C*2"=+2F.;:
M@MLJ:ZZFG3<$^1RE,G76-R_>%4_XG3VNH)1.X?K0LP\9F_DW\< 164\Y,<BF
MQ65XF (I/+H%$HZ50"<B_YROL>F,,K3>+CY$%P=9<_D<QP$9A2A,T5L@L7X.
M!C89@C<)7:]96*$R 7\FY^ XBX;!5LB@T@DJM#AL]SM=*Q/_:NA9T^"7(J_G
MV_S:PR@J3)PO?^'M%Z1"RN T*I)Y56Y+R<$%UX+1HHO6,H["@OY+'"<OD$4,
M@D,ZN:3,ZR(R/YN"2!"\00?,45[,-1,I3WT?_1>]BIC4^XLM<GY!1@8X(;*<
M$)@PFG(0LV80SK&U.BJ@>.[M_@>'(1D"U)T /@-?7^QR+@S%")DY@K^:\:$G
MO7ZQ[KN07H+YSG"L-GX@E1_/]@822'CD-^JH:6'8L-N$K-M2)5=,#%$LV,OB
M<'-$DJ[@;GJ40Y*^<BT;YT;K+,&NN&Y>Z20*&T>(A=.QTO<G\M%9$O,"!1T]
MS%Q5^ 2ZTR YFH49;N9 LA^\)D[\$8>BJ P,))Q?"F/:_"174#;]7K1.^TQ/
M%2;9N AI>R0BZJ+S!/00.;CITDS$H$9WM=N@+7/FDFDD>NBY$TXH-KOA.#U7
MR24(U7O928 -Y'3=I%83B8<*A*E<\E;%5<B)(U+P4(.EKJM)3D*6M<-UW@9K
M%)8RKI^<DLXT<6E;:*IPSH?=V"NE(-=*1DERK_:,\X*3+TEJ0*81Z6$B@>1#
M6JED?B6?@RTD&X?G)'&00AG3:T!M]#@DI4L+H"'/6P)<'H<I#0$9QD@>A1.D
MA]MAFJ[7@]03JV#N W19L\0L96NU]A;9Z',XKTCE('T4177!F6!DV<C%G2=(
M-4>N(\1[FZRT,%PUUZ(!Y)G_[AQ%73@"^D.&RGAW;3;.C?C3/WN0+YE!G7E<
MTCO^=S(UI[?-;XEC%8(3TS2_*'^\?L'@S9;U\BM:UZ^Z\%H2BD>V9LF]>-X1
M CO?Q-!9MY57^_LO'_",.W/VGF-4B51^]/-4;A7G71>39SU]=>Z/53(N'Q>H
M!._>'#8&BM@^;8/BU,1,H9U?%_,L[]@B;-&H$2%OM)/=&JQ8M<C@"8T2D_7'
M?H-CW_H[3\G.,;/M!GHQV&I\3R%M</2II^[74Y?<^M_J#$Y03[V;\*8I_\[G
M293FF1'VK+/\G.>FM-S54@,BI^0:]*2^H1@(4S,G0C.=3\;TW4*I^BFG?YM9
M3]:;D+4(==@;T_5S>$8Z;XE[CSANL A^2V8)CY$Y)4\[RXN>Y#<A>9Q_,?-$
M&=D46?(%[KN-=Y2#X&>3EOFLZ 7%C<A;UN=Y8;Z$P+$C"K\W172F,\;#V?PG
M8N:A#5!;=!<7&V$L>?+-K,TQ0#WRW[D#UM*CT_X[(L,.690[$HI&Q!_MUZ9Y
MS,\F"^-BD?8'><,XP^<%Y$P:G+SO2?CU)'3]*J4TF&#U>08< >E!+9N0<:]#
MO[D._2-,29R$O5=X(YH3"\^D@TLM;U.<)VB?.DJ**"3/L"?K3<A*!O9D!VDA
M'AFL\H()_,'413);8NO?JE@0JQ";&>=Y[(V@;)YP"?;9=]F>_K)O3^_;TQ_A
M)KZO]O3+LAD/)!E.I\FX0B'G&0M5H.V5#(C"(6;Z>%FZ^+(?C59#+OA0GR>3
MI'<X;F93%+,\#L=)EJ12'74"2.">G#<DIT=,NFE3MHW->=<R)E><2WG@-[,Q
MT><@[S<'>8^Y^Z?.TJM2D*T*:BGZ":O%7"O"JF1>+J(IDH=EJPX%.<A/23DW
M11SV\N5F;C>3CU'OM_UJ5!Q!=["!(S7YX5F?[KIY1.XX.S>3GGPW8M@Y+>K:
M'-L3^L:$/B5[PF193[P;]?5Q?3W9:A^+:IKOO(\^F"3=^1<]LC1+>6V;2/F_
MBSE2+CW!;R(6\C3,_@[AW%TI%'HZWYS.GTR*>NKSS2/>Y_O)?GVU1. 9"@.$
MVO._:M-;K3>UH2P!@__3%ZW=2&(2\:I$)";X\K"LBO#_FLQ$87#RV]$@. 1D
M^GC1$_=F4;!DGLQ1]I *>3]697T62C=?M")\PZU^0O'@?0CHM=[TNAGI5ZG\
M?-RS\RT*7%EOU5D\,M'9#]?AY%\,RGUZ6M^$?_^&W"C%OUTJTSP-Y],B*7O*
MWD@HD_/E*3RT=4YH'?,T&@2_A54=]Q+W9O4.=8MAKZC?_F2^U&F5]*2^":E'
M!48<^(;%]>2R0Q,@X5&%/:/?WJH#E$N1?T%B3L;)FW@'*+AH.4XRC&CC6@8/
M>Y%ESIDI9FB/9J'S1Q$NTK"O +_1840X#3H+*\^OD18=H%0<+^P5Z*V315_!
M]70*"2F$0IC^*)RGB\U-'CTHNB6IVEDXKPR=@M6VQ\"ZV3DR:0KL#FV"8(0;
M1$G<Z-4TE^CHP)\KQ7G8U6G6:6C'8:>87D;;FQ>T_K_Y$=643C.)]2=&XZC3
M>5( ;7M+ <(%3=W!]B31]C5GMSXB* 2 <=C)<3IL !@/91VAHFA< ]&+T3!D
M8*V%4;&0']Y721[Q'"0&D1 9E8,N3&O&/&E^F<_L+QGCPD>_<$ A/(>)$<3'
MBX']R "0[S51O, >2AD1&NM "A\Y3!IV89*-!4E_EO#8L X^C.OH&)DQP($8
M>$.R[GS+O8E//DZ,_9J F5R+?@P&HD1<)EY8$8M'@GA8&&D6/J.O\;RK6(B2
MF"PR'G1,%T<D7[T4._]Y/):1$F1)A37+LI((6?A#0(CIBW@'YPOHM47.K<DR
MA3X*2T:,,6<"<Q_1VS!PVIMO&4U-.$=I=;==9J W189.,R)]"VDD97P4H<"U
MX40>$G(LJ\<A('>(H38,(@FP>W51R.@2>V/#X#PI>-09UV1C_(JW0[FF"6R,
M4<VAIF@*_J3_E6.],$&<\R0'&0Y#1YM? #$G B_",.$Y!/:1I@7F5S334^@%
M=@F,-S/6>2L,*+;Z':UE-2_LWHSFVQQUC/UKS3U8WEHA+M!_8:'7M)8G ZS7
MN,;Z,5&FK$P8*U1O)E=7)P/2#;)S#1PFF+=Y^@X)EVG.0PSISG*!)OV=[A+$
MWR"@"YQ:JA-7I-Y<B]9N=4#%5=-O-DT?$8-"V,GT9Q\AD@=_ (%(YW]XHLHC
M;['$;*Q@@%E7A9F.-ADS!AW_P9$/1\75AXX=UP/1,AS?,/@UOP" 5@LMP@)3
MX>T\$@304B+WK-2M3%'4<X$75N;2:]<Y4C_)ZVFVPIPGYJ*$R0+L8GX(OF9A
MQ!CHSK_  S#.O*XL.%G8(MA AC@I3AFT0F65" \;\D@["%J&CVPK,Q.V+S$*
M:38/=; *#*MFM@A^T[RB,!B?LI&L*=!LS3@96$,I61-"V).0#G--4$CJA/4#
M@KUH;S=H-[!_VQXT (LJ!6'OSO+@'=#GBN T2M@F2LC/6"%?>G3D.QTNL>D
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M;+GA:E@.;P:$UV]&ADI6N>Z*5?:77T9H2?<+:@):HT."$RT,*(.MZ)?WG=(
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MNK36?]M6??M)M.AO7N:Z#=K8'0W3N@0K[0H=N[Y\#Z[A1G2G15SWI6*AALX
M]J*+?AAC*@UP31@]]":HT&H9R]MY<"YFN:#UG@'L5N9CQ*AM]1#>-8[ <8GV
M'-KV(X$?!IQ8>BSG]S&"*+%1V*1 C*20;-@L+T9)G,@=GP&"+V6\B.NMS-_@
M-1[;E,4N[ZB2@"J/SP'^:9U5+LI5\)**4/[+EQP2PB(#BM?D>X2<KY.(;&)?
MG,)29EP%I$(E-^; N5&#O!88>TU-_U0$;E/WW6I.8)M]%?\H*&73^,N0("9-
M=SAUA&Z4^(H<F&7\*]ZD+.W5:1@7-O$R<G,W/K7K6+H6$]LVT.I3Z:RQF39L
MNQAMTU&8L">.<]0V1&4@']E/&6%-,T6C:%QS70?(?.U]I7<U!8"2+7/Y<IOV
MZG1__/_LO5ES&TF2+?Q78'UGYI/,0+:6VM1E]X%-25WJ;E5I)%7+[+XE@ "9
MI40F.A=2Z%__A1]WC_#(3%!4J2@14C[,M(H <HG%PY?CYT@1C&DI,WGO-M^8
MOD<#-B^RKO0_[36%')HMQ@%(?,*T'+F:E#:UO8JPF6=EZ4<3?Z6VQX "0S<?
M=3V?58PO6,DR'2/81W#C#7/5G:' 7F?;W#6!;M^(2P6;;!+\([_>V6.8&B,2
M%1#GWF(EV6P4RV<$W90F$KR,75X?+4\Q!\818XXI)Y 25BC5UFW*:IL&>S:#
MZBS-/SH'9CEDXJ%P(?2I(]WH]K"U"33+$66=09 0NW=Y(&OF^4*%>(0X@/C:
MC5NIQY.I#-@;19$$58RJ%F U6@7U/--EWN.E3Q.,H4LGMC>F>3ND3M<.**QF
M;B$B> ',9:,U).!FLB@D3=TT5.'@&[]O$3()R@IC1OD>[W5VPDFTJ"B),V:O
M>#83_S)8IZP,J1WMP[3<O=QAN8Y]K%'MNB9OH)6^=[-TC?=,1*$C+]2CXKBL
MZK=)E@@)U/$DO/*?H)GJ^LF'F[)S][_U=N[IGK396#+KO?.[JKCB"70OST-
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M)N.VU=4G1PDA72S!%*FXH("0E%!]Q-'5S@A&'IR#]-.S%R<G!^@52?CRC"8
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M&CF;]^B!ZA>-(FETN9!H5GUC+G#R3F2WVV^C)2_%1MW8Y )4U(<NUCJ'"R
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M/.98EYT)2?@6L8YAZW+]AD;4EGR([>-C'Z M4%K8V:9 &G?T3U2EAD\XH%&
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M3G,_*'D;\OF0H:LHC+U_</D*7FB#"6Q&%L#[9OGJ>?TC@],Y>PIU?E:!-B<
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M&OV^U#+7=:AF2Q2?A5-J]HJ/ EA">R5M@R8-#WI8<V%Z7;\1_)]%'M5'2:)
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M,T.=G/?.D(M3;1))D%1@^J8LJ0KH32MU6JF?>0"MV499B QOI00U% ":2H_
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MN_.6*-U9)IW-QLBGJ'(FZX)3<G ;(9F_2S*T_DTAN9K7*RQ";7=4S$A4G,\
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M-%D27= ]3C';M;=6:;8>LWJH+HNG3-UPHYQ(]$'Z0IPNIK]'_]B;*[^DH;M
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MX^JL:3@@7Z+>8>P3'"L<8J!3@H#U[*<GK__Y[)?_=R-EEV^/?_CV=[W>B)-
M,W+T\/@^7=!/+6(L.>DI9N.CY7_^S_WOO[GI9I8/G"@-LJB2'S/>124J$"6G
M'ZK:Q;!C=/*8"C!/)' ,[>$TCS<]CR&92:$BC(Y:&_\'QGE]J(FY16T)GVK]
M7-D*=HM7RY6#1SGP*)XX,+,JNW%M0VU,QNQD3'J1[A?_"QD8^99_ZO![45&4
M[#*+Z42^!-6^ X"DKLI\:7+S>KJR'I[&T=GLW+\UJ_QPMHB!+<X?U[&W4HO5
M?E@SUJ3@"HDT4.YY8VA(-"$=*>W-[TN%P-?0>L0^TTD9I6$/_!^\5+Z[9K\E
M:;6^SS9(Y#NUCOZ.UE&K5]2AWMO5DN07E;=QB 4?KI1J*=NJSE7F-^[4"*(Z
M9[FB#CMK,IP?8SC5#E&0H+QRTXA^Q(A.MN4&;4M-!YT34^%$EZD2:O:8<>7T
M>QU@D)H+!YJ$[)-U)?M?GE;_M/IOY^KG>LU%)7B[6#5)*#.PGJ=%_%'1!+OO
MWB/N-E*4HMJD_!D@L76=;12)<\G%K64[K?X;7/T+ C&I6&'C%U2SWIEJGLW%
M0GTM6/WF.DPQT\S\_IE9LO+W-=3?;FE98$!5ER8%H5 \%M>N*G@3ZZY8$V9"
M%7 94=&-+<HYHQG6(F.H (ALY0-\'R3!':FIXBVQSCRF'8-0,P,U@IKS*K0^
MZ%7HH7+"LU,CBPC9?+I$\Q=Y)(B65I2-5WCM7%*1"S=H4R7(]!L]&OBDR%OY
M.C,+IIR/0;L=!PS#-"X="#V0_5E);UE!W(G77*)?0*'E%\NFB2K7TZS,MNV4
M:;^Q3+O4/TT[],H1> <M$(+#O#*I"B%J^EH=NN4@W22S2 B9=4'RH62M,*?>
M<-4MRW?+/P\M@>^W.ESO3[0ZOT@S2X!>/[LY]<Y=L;QZ2$^SVI+,O<EY7_F+
M/R;S?<4MIOSW5^0-_X'Y[Y7;D/&$@8SKR>B ++H=_70R.7]P!GP:T"D%>"N-
MRZ=(@$^+?UK\MW+Q?T#^>UK#4_K[RUK\4_K[ML[,P:>_3P*Q<+$3E+B3KC^@
MFYL-]?V-9G>4< IJ-B&_0WV_[TOOQ$Y/$%!P(+,%@0IWIG-4;>[5Y^Y:I[V"
M]JDHKX['()XEO(.$7OZF.;8&\584Q?QCFL,B.M[@4$>2P(>?@GWC6+#'Y 01
M,[E6YH*QBJF>/!L?[00&!K(><"8:PJEU5<>4=M,MZ4A?=V!O.O>#X$^9575H
M.4'*7:\[M#S*&W%W+:=3M2O"$( 8F@?I)?11:0:B^##@:/.G-F;BH4//K!_T
MK?2JI.3S=(_T!D0GT>9K)IF5N;',XI&-YY]^1(D3J2ND>_F,25OV<0C,9R[G
MAOM"BA-M=68XNOR8%SZZ%CJ;V/6"SI$TVWQ6.]I19CNF':+\DU@[,3\A3Z3.
M09D1EXU__"G]]I6<QL;>7%MO<QKOWS_>:"5LL[<\X"X2<;@F4(CT11RG^;BY
M^8CDBOMYW(+N._.9\2:Y4EGSJ^PA_V'J(9]ZR&_A2WQ=/>338?#[#X-].N6!
MI,:Z20>7MV Z[$AB1O$G4[40?\X%H0CH/?_=Y<NWPL9+99(+BE%,]%-6U$V7
M<EHNI;_T;:HG,*OH\'*M.X9 !PJWFC/1^(R8E.A)$/ Q 6D\D[<9& V%)Q^Q
M,U'9Y1=Z8!,H4+0Z1D[LL1"ZZ4";9A^R#K3G>*21.)NCZ=EKMSPO_6R=P3LS
MNE7:[GRM9UJ#2Y_NF&T1%EJ24;0Z@EP]>0X:H?W#RXQP\@U_X0UG!58Y<:92
M?L'/I= MV4S!7#-"'Z.S,)[K01U^F!TZN#WS2T)*E:_33$M*VQ9(7=?)L@/^
M:\Z)#%YAR@YF<H3$3-D$$K5L2_M3Z-N*G:4N7QF1 J9XW62_#4GPHR.[R&GO
M\++=Q=U_//NEKVT@5-SF"4NF.!5RB_ X3(YIEC\]AN2OA%J\9Q^8XZDA5MFF
MX4R#7<C'49>'Z,D"F+<]S^O5$>4^=I2:K.HP1-(=C!'=="5E:Y1WCAASMZCA
M^K& Q(FL\F3K6*IEG3APC$RXWX_"_4Z5Q(^H)&H"LD\_C-S]BCC\R[!8YPJG
MSY;G8'RTX&CEUL-6R$#6_A%6.V*VK\[<,VM_*G5UV\C[_ZI*-^"3OD]J]S$Q
M_UDGGTZ-3+7#$OYLPGCN$H>)OGN3ANI[DHO_W3OMF^,'![#1;M!2?>'#=WQW
MOU3I+?7CTIJM:/:B2&<*<UQ[]4Y/XMJ!7Y-(EH.S\FM@ZO\I:Y?G1V^R=_X!
M6>^5?QU<P>C761^?_0[0B?$],U##=@@4F-4984)5'DD$%$-184&]\"X/0[;[
MS^ #5?<6U5P?0VQ8;\*^Y&)GE':,.)+_07C5U)E,9(I0%2M;#(;#(^;E6@6L
M"*C;"/D$\Q?O4\R!'U<1;W]1.**GY5^PJ%6=05Y@K[#3L\#)VI71(:<BM5Y/
MM-A/?B;M Y8$@DH2'8ZB8C"<NZ4/@_WHAV&@ TZ)WU-VVEC 75"M]Z*JV1?/
M2:#2!3>U[[W.]2=%UI7^;BL3)A2!K95/V[1>]_OXFF[3#GQ=25RO\Q(C8C[Y
M=-1IRS"7B?Y%%"#\WG(K7MCGU>4^\0"TC34Z=T:$ DSK>4,!$36(^1N[N!A>
MJJK-[)\^]/83 RWG.R__^?@N[3+_L\XO'L/1VXP^(:LPX$[V-H0%:+L5@CIH
ME&#KM4UX+'V*?SZ>Z\ZH'0:+N Q]8,1:C$2 I& /^C*+.Q#03*M'E%*'->E6
M8%UBTJ36C0@<AKZ/P/^?75("P019E,V(@G5$ATTTZY*8\*=7QJ@1;QNH8*["
M-G8BA^H=7-8'*(M?!TZGCPW%I-HA%9/54T;S[_O4+>J.G*(']^X_,J_R4T7
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M YJ[UK0B7[]S?Z;Y$7YKJS,I-PFM<6;7;S+:7%)T3ZZPF"Z"GS.&A33[04*
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MM"<TCDF2-\G$UB@;E_PCQY)?7&BM(+54J-$OG0-TZF7'$Q:;1\%T8PC'-(.
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M36 R>5*_H^XU.D7=BU#OVXV09RE#]1;8@X_:%4! @'4-^#6]8.XS1&3:+$9
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MM/_3[:/A8/=@[W;VT=T^VQ_O]8/M!WM?@]V_W8!^KDU/ZN%GWV%'WU)M@P[
M7=.>'QW>9E(4-WJ<:74;]?\+X<"S;N.L;<QOLG=V],V[N'L%7N!5E=?ZH7$9
M:L,+6GM2/]%YQ'0M2V7^"_L>E2]OX=CQE86VF'XB&C.!3'"K-@GX&C]KP@.8
M[B_/9N&T;_9B^--VRW-;O"-8O!>C?OV^<_T.^_7[H?4[Z%J_;]R$DVCZY;*
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M);O" <6>)R:3RW&I8DU\C*-*N>. 7O@3;*MT(E\4\QL !*VKA2EI&W@?4FO
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MP>$E@.R9P)I$M(NHS#'H"T4L)L_.$1XS[HQ#D&PW<[%;PJ;DIP4)@2IY*=F
MUH]BB=ZQF*#- N#0D+Q$J8F12=2([+*P[QEJ1+8:D=W 0Z@1V=M,_A\NFC*D
MAL$\@'T%\\R?!I,!I $Z7> W@I"=H.,QQ;G0,E(A#<!8FAH."W/'NJKY0+G
M(FCCWZ AI$W'\\0'<R>D['XR2]VY!J(5'9)?N,,PQC'"G"0HD(K%*?83L!M4
M)0'([)A,TVP_8(<RTM5H8:&-R"88LR;_$,"G:W=<+H$'+L=@,O<#?P]"V_<
M.FC;@,Z1FA"U4Z9_<TLP-^BU<_PZ@;\FXM@2#KHV2F?T-G0L W_B"UW[H_;>
M_R!B6P TCF$586J1*<VS$ (:%R";X\S#O8OBKT+%YSZ>P!5%!X0%4H2C='A)
M]A89]")="HO!^F!^)&CY<##:22&3-@T _8#+?PI3K&3><V'BM]#$G]^C 'I5
M<2(6S!.9-V S)G:,%_Y\+S\>O5[0S7O_-MLE'1<W^9__,3"-_D\)_,R]P0_:
MVHFP"(4Y0TL".J7+CCXZK>Z @<+\+$@H076+H9:;E)SZ4<G@A$/>26NEA?_
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MO FB$080%WLH3K&Q=Y0F8MZXF,"QT&P0&]W[ <^[#F?C4.6N1/MW[/A(T]4
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MS_ ?)=L+A;%H[SN9\-CQA<%(ID39#,/U59/TC94R0CEQQO[W: ID&OI,.A%
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MBD-HZ(TE#W7$PJ]BEP4SH1CU9S2C#3Q7\8K"I653D9+ 4[7^!G[R:4)3/,5
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M_DT[.#P\_PSB&3\X/\O^>7+V*_V@$.Q%[GL?)?A9%#Y0?+4' JZK!)P2<$+
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M/K2U D>X-MX!(3; VGY@3?J\6D#P^!ZT$8E26<\8Q3Y@"6\$QFS"[Z+X:P$
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M13<%?U:S;\JMBXUO' +J=U3\5^FN>MUE[I7N A'Z^?+D^D_M_(\S<$A^.[D
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M=TQ:\4=_!J3DK(#N\ZD?^G+0#$*@SK B&)P@38;P.=AALS@*M A,I-+C@FZ
M'+8/@@<Q_0?7QNR6:RQU_1G-1X:_ RU/8"]SI&:G;&>.9/XW$?G?!W$OYO'
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MP@;0T?>YXT"W\.?"*Y#PD:*E>\O*KNHZ)UE+=1<'%@*#-&\H5"[)'OQ@/5M
MD&(>"@.L"X)@!4'><?:5K S^#71>(AUL!!R]_A[T78X %FI9^-QE$VBIO9+K
M8<(@;0O^C3MZ /$EDDZ05"/B@1+!$@8)(T"3J%)#<&23!%N19'3GQTXZ0?#!
M%Z3Y1SSP^:T4WB6= ,LB90-L2H)ZE%N\)=^\"7)M3<O]B -]B(@+8NZ3/_%G
MA>K?EZC[@>8LV)=K,%^"]B"2%E"P(')AHF5T4:N^JS(P!M)BT@X&L-;&6Z3Y
M!))ERN)<L-2J&HI:?9,'F*;Q-)+>XZ+M4A-SJA62;>U)$!)LF4@=,@4AZ&26
MXJ+&>>]_$-5OP,)D_$ACEHP&'M+6X=@Q)D-=\1N*;)6 ['+X8:#C25*,X@0B
M72 BC1B*#,A(QF@>X")A3A']PTOW,L"8:W:4.64]3U#X"3::[_0A/-.AJN\A
M2QZWC]!.2I(':89CG' E)#\!G5DPE#2\P_VI5+]+N?1-%JX8RPM75 U*8_:B
M:E!V:O-KUZ!LV3+@WS#$XL](0U5U $GR$4?12DY"% :UP1:6@MZ+RRG 4CQ1
M:)VLFF-1R>"WH&A6TC2%10': PQJH3QB#1P95(&@%;F3*90TS#9%*N+OU!?2
M64=O2,=?E33APJYR T J1E(CH&0"5V:R"Q=!6/>9\5[K\C3<,/R%.PQ DB4+
M_1#\"$1;4-C!^AJ6T(3-L9X@PQ !FO!2<>\3D=C3T3CZPIV<;)#F,J=*H*7J
M/H']X*5(J3(G*6R-)!U]*44%"U].[C:A78TX74"$/;O\;W@!4G9^]%)-!D;%
M_*R,(Y;F#7EW-S*PA&0"UFPE/I:;?%'%"\,7X_EALVBH-8 8UO2.#C'FZ>#D
M8G+:3]D,#K,+N0TGV[B(-DQHXXBZ21K"YU1;Q(/H3G@W\FL&M$.A[C@2D4JP
MKXD;9 H\CURL%A 305"65%\;Q8MQ[LK7DHK%JYR\YB*W9\%_D)4[(J269=&$
M2,N#2R*8$?-"5JV:Q,MD\@?@AMLHN)7Q80I<^F1[ [<$ 0]O*) BN0]8E/B%
MF(-_T[ZD[HUD]>MQ^8B2L6OQ ^YE!'M' <*"F<@7HDS 0I)2E"&3MZOD(]E7
M'J(3PK2[<11P&> 560YXCXZ1K]+FI+M:3SU$,+IT>\EEU1+AQO![6ZM= (,E
M83E2=Q]M49$@E5AN+_=:JN6;V.UJ^W*DGB5/N0O@\%WMDH^(=-&#_PA6PG3V
M(H4'O79W%9OOOI^'D&M9].O%%F4LX<(Y %NE;_^TU8()_$_#I? !!8N $49/
MJ"4 01/=4822*":6U",#+FAGBA60AP1#B3PL_C:GN:,XO9&$IUW$T4W,)N4(
M-YD)C!)A8GWD<'PH$?I=QE;9' S8=K9.%M2/[M# 1,<X-P$#LBVQ\%-$I450
M*\)<&TELD",A]S (@LDQD!] 9?X4@_)D;U,X.)U&8;ZQ%.4(6A^RUA3+)6[(
M["(U(CZEK<JL;4+6=O$>857'B2Z"Q7#F##9".N=0K@(Y*6+3B)<4UIP+&9\#
M+(.[%M-/*"HN,PLN'&WFH_9,9WX@O0/QOBQQ.V9)$2G*0$268UI!/0#Q!\MN
MVV!$!@%%:I?59L&G0GZR2K9#8*NB-ZN$I431QJ(H9S-)-PTP<A^U#F6D4'@T
ME"$I=21"2X.,]@DP,]DK9$S59Q$%MM!L$')-$=*S$9(PS>LM*48U!KS"Y)G)
M64UF9HGAQ:<GG*')18^D( <H&(]5.IG1"RK+!5$4H&5WLZ",=%D4GU3$5"&^
M240EZ60JJ$JNPT5ATX,"$LU+^#8&^ J5 S+OFRC<A8WY(*(#=O,3O-L7">0T
M#D$;B+IC;0S@+#FJ!#%8(0-,R5C/KAB ?XTU3[!2/7DOI#D%#DIY[B#S641Q
MUD,G*T&DQJ3=+#K\4@1I=-& <=VXE".6E)?3QR8 $_&%4,:I2&5G:Y!_(Y/K
MZ_HYI%437ENPD"6L:XOG\@C)HAAKE'H$;.RB5",BNB?5RK=P<O!3/$WFXG*I
M074;6-(BN4H*G$S-WL=YI41 1Z,'Z0JM5W@KQ@U*\@P@42ZOR]\A[56%\&=#
M.*HC(08%&_JQVT*C'U4-,K\0CB516JL52OX*X@?$/TAVTHNS&'"81]8K6B*/
MY%!D.\[$0"WBX<63^S6QV==M,+8KNK!VC5PV(K&5!8^("LV$W*%J3TI=._/<
M/ZK1%R#O6!:**X F8LTRPTN'RUXDG3<G8/XDR0H6*O>7T.DH\U^E@ <S]_*W
MGG!R$BQU#9UY$>:M>&3P_MS_1&LQQ\%#CN=FJF_S+U_;BJ/1TD"8_ [CCN,(
MA-AAA.50B?;IT\7S'_[5\R4L &*/8JYKIRR>@P?OKAB>ZVW-X\F&4(D<6S:)
M:ADNMG4A&'Y^*PI&ZLKA,UL6S#&0;F:G8]WW,S>X\C[(D;+6SWHO_+,W68YB
M/DL?%5OU45$U+-L_Q!NI86E*UY3?#\Z.#K2+WPXN3P\.CS]?GQP>?+K23LX.
MET<CF[+UP_.SJ_-/)T<'U\='VB\'GP[.#H^UJ]^.CZ^O=GCJ4M]L]X:KS4=:
M9UG#:/>L_D;+/OQ=UWJAS0[W;T;4ZC4DI#C?TX4#\ 3 5L9;,M^P<I=\K&1,
MEPW%%9WL7R*Q]F'?IDS=2U:]S+33782%,:S XA%>&#'GZTT,1.*VY'8=AW/0
MJFLRR6O,OJT__L'555FX/S"!:ME15QI-M0+5/ K+IZRQ_B;7QKQ'_UG$O$9_
M#IM, H>RL$R4F/ZX$2TL''XC5+WT&L_$RX11J]\,C-;/1J3.UZC*J+D.5F;<
MLJ R.K-J ZQT](ZV"]/<?WC2$<M'BW'51IWMO_QO/X91^#$6MYNT-/1GE^A)
MI8G[CN+!L'OZP.]8?9,-N6M;(]?N<#9B [?K6*XS[/%!CPW_[P35OF%:QCL-
M?#1_PH+DO]^U@!M$&@"6^#;[,4PG;C23W[_30C;A^++6#6/3'Y'(#D(7_S@N
M*.Q@=LCB&)OG_<Z"%'R]!(#'B<\H:.):O\]'1]'M)_/R]D_K-'6_'-_^]>OP
MR_D7Q_[KV@W.K__]_<_K/SOG1__NG/_Z[^[YT?'WTZ/+X.S+\?ROZS_MT^OC
MSB?K+/CS>V2=__K9^NOZ:^?4/#;/CFXZ9T?CK^?7-]].OQ]TX-EOIY//)OS^
MV]G'0??L<#AQ)A_#\R\'\_.C__GZY_?QY*]?/W?^^O)O^-VI?7;TT?_S^M_6
M7Y-_ST^OQ^,_OY]\^V1=CO^<? O.OWS^_N<?L-;UC?G7E^/NGU\N_=/ON+>;
M[MGWCY/37S_/S[[_-3X]^FIEOX%WI7^9GWMGUV=CV L\^]?D]#KPSWX]^7YV
M]-4^AV=/__CS[J_K$^ML<GQW?NUZI_/.MT_7Q[/3J\[=_PVL ?>Z/=;R1M:P
M99N<M08=;K3ZG/$NMP=#TQN]^[EGZ!W+^*]_5BECR7#4303=&BSQG+I=":8]
M%4PC<^#VNYV!-Q@X-O?8R&7#_M :=6TV\'I>#P63,52"J6F"Z7LNF!QF,,_P
M[);7-<R6W1UY+6;;O-7I]XQ1=^@,^AWSW<]V5^]@%+TQ@NDY[?EF6W^G+/[*
M900N[Q2TU*HWUP-!K;#=:8GT"J;2P2WS T3(QRB^ JE3-' ZXJ-9\2_IB2G9
MM(9L.CLL&4UFWQOVN<E:[H"/6G:O-VH-NCVOY8[ZIC$8='I>UWKWL]7IZ?W.
M\*G"Z0$!\5)6TZHN\IMGZE<P,Q13ORA3%P9'A_5&O>&0M?JL"TSM.DYKU+>M
MEMWI#X> 7+OC 5.;O;[>Z?8;Q-1O)]YTD-T@I 8GM\@4NA;RV49&QZH>WD[+
MI]<P.B12+G.<G/&9$D8;"*.KDH71&0Y,:]2Q6T.O!]Z/!8X/Z[)1BQM#9O !
M<\'^0 M#[UB]!GD_SYUR>?,,_!H&AF+@9V/@PIH8=KJV:7.[U;.,3LL>CNS6
MJ,> GSN 0$#9R& N6A.ZU7NR,:'"%QLPX4F(W5JB>*Y"%ENT'G(L@,Q1PF8=
M8>.7K(6NZPT<I^^V.MU!OV4[/=8:<)>U>MQA/6YU1IV1\^YG0S<'G08Y+BH:
ML7O&@N+7S?FU, YZ1F=D=9QNRS&\$1@'?-0:=.Q>JV\.V<BQ.CV3]9!?#;M)
M_/IV @T7V*K5Q\[GV--$7G$6/5&<2A63BCQLT7:06#H62#H(W7/$T $A1ODO
M&XBH<EV(9]N,#5FOQ;T>IC@L$%&\-VQUAAV[8UG<[+$^B*B.WAD\.<.A A#-
MY>-7L"D4'S\['Q>FAFWU0.1VAZW^T&0MV_8ZK1$X!2TV& XZPX%C#$QT#6R]
MVWFRK='0.$3/$#<;&VMN7$<S;,OT=,M" F&E*O3]%%>OD?!0@FE#P71>KJ&P
M^KT>'W;,ENFB8')&1FO0LTWX'\/MVOW1R'7 ![([0_""NL_D!:W,&#L4TGC#
MS/X:R1'%[)LS>RD;,K",8=<"VK6'!A9,F:VAU>FW^LP>FJYG>6S8??>SU;5U
MX^GYS-=B]N>,AS3EZM:R> BVL\GZY_V=^E/16T_57FP[ B+P<A&P< :.TW&&
M&A6=75-8E6LOW!%C?."-6@.K!\)J-!BTV+#3;77Z-@?5TN5];PB6R7.(*A7Y
M:"[_ODKD0_'O<_%O86P8/<\;#CIVJS/J]%IVM^NT1CT3C W3[=A#;]#W1@,P
M-G1P-QK$O_MX$;R>!\_S2:$!9S1_%KYK15X+)],\/?JQWU+I%:R*'#^?$#V7
MN,]S[W/"R1=28FF="VW7!RB2A&EQ\'\CT^HRN^>V;- CX 697FOH6=V6X;E#
MV^ZXCN-V*:=B=]6MD3WFX5>P+!0//RL/SW,>[G7=KL7L;LMR1B-@9&O0&G&\
M-.\.W"$?F9TNY\##AFXTJM;J[<0J3L(9"V]\.4>18]MD%:;8KD'Q$:>-\T_^
M+7<+[(C(JG)TUI5&QV6+PNJZ \OK]ENN@1=1AZ-^:]#U&,HEVQX8?7/H896Y
MH7>?;E&H6$5SF?@5+ K%Q,_+Q(5)X8V<_L@:F"UC:'5:-C-'K6%OQ%NCH<EL
MYGF<=0U@8DL'4=T@)G[M@,56>?&(>SRF\:7LFXI1;-^DR/!Q$N*(XVOV34FB
MS2312=F< )3T+&< U#H$O\9V>+<U8$:_Q8:.-7"Z0_B_WKN?!V!.&,^5I54!
MB@8R\"N8$XJ!GX^!"U-B!%+6\_">^,@;@BEA>"TV,.W6P+8\:X272SH,&+BO
M]]YT=&*K?'@6A:VLUM//KE,5-TQ4I&(+9L5MZ++B;EM6@@Z84I5?F\BDT[)1
M80/&^L-!K^4YGM6R^Z-!:\"'%@@FWNOW.X[G&/S=SSV]9^]A@U'%O:]@4RCN
M?6[N+04GNIQ;5J_3<FPLT_9,L"C8P&F9@W['XT;/-JTA%5-TF\2];_#Z2'U0
MXF6KQQMG6ZW>_7CM\^^-('ZU*S)*[*XE=O]=-II8IP/ZD?&69P_=ECUTAN##
M<;-E= QWT._UK9X+1E/7LG2[NS,%\\\4IU$R3<FT;=T$4C)M79E6F)+<YJ!J
M/+?5-X9.RW8&HQ8SC5ZKT_%<9EKNH(==BNR!I??MP:[(M+V?W/7IY."7DT\G
MUR?'5]K!V9%V=7U^^*_?SC\='5]>R5'%VO&_/Y]<__E,T[TLP(0;I5C T^#Q
M7JON<A_+NA^>[Q7X;.0'U)-:#?G:_5Y(>=/E*9O3L >,5#/'B5/NEG&M9GZ]
MD=$ZK]A3^D*0W$'H'@B"^U30FXKM;6*0.64GD[-ASQN-O);9Q]@><RPPR%RW
M-1KP48]QT_ &[KN?+4/O/GV*1?-"\TI [:F >L6>V4I O8" *CQ&L^MXWL@U
M6T-OT&G9/=8'V32R6UW/=D;]P<CT>OS=SV9?[P[WM7E5LXW#BSAR4V>FQ?R6
MARG8AD$0W;'048/ ME?&('%R*5!RD&-$R:--Y-%-V6#J>BX;V/U>RW8'1LL>
MNB"/^GW><KQ^Q\/R2- U8##9NFTV:4*0JH_<'0M#L?!+L'"IGL$=L*YK ?=V
MAQ[X/#T+KVX:+9=WG*YM@;EA&N3S#(WGZCKW"B:%ZR?3@,UQL_QAKG^M)Y\S
M0+8C%1C._0#H4XHYEZ8N]ERXOD)\27EI3Q.I7ZIM+2Q[9'1'5FLX=, TZCE.
M:V@;O9;3\P:]OM%W&+??_=SKZL-G:YBU&F_L4.WG6V7V5XC5*&9_.K,7]E/'
M-CI=N^>UNHP!LUL=HS7LN\/6H,.,GF7W1AW;>?=S=ZAW.T^VGUZ%V9\I6+-R
M8-CU;[.UZ2=^Z ))_FCU2'8TH1]76+J@4F?+P F44]B SER98)N?1:&C)-L&
MDJW22V/ K2'\O]7B \]NV;;+6JS/NRV#N5UO:'O]WHA19Q][J(([>\S'K]Z=
M2_'Q,_!Q8:&POFN.;'?0,CWFM&R/=5I#M]=K#4>>W6=#S^@8V&7/U.WN#D5X
MGJN0L,EV" U8>W[KXTU<KWL-ZP/Q4_*FE+C:4%Q5>FZXH%1 JS@MUP&997>Z
M%OA2PV'+[HZZ':MK#6TV?/>SJ?>[36K^HZ['-L;J4$SZ4DQ:V!0N<SM=WK&
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M8XE.DK]@P"] 817 3PCXD6QR).$@)8@E'T V<8"^XSXBI2+7)+&HDYV9;"J
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MI-^/U]1Q@[I@W!#$$^'(F*H% )7:F,2E!9V@FY36:3%^]@S%>.TOE(M_U4=
M[,5^HZH$=M[M?&V%&!KN<OR@/]CFZ]1I"]?IAMA%\)2O\SCU.J>MT+AZMM7F
MMWGF-,"6FV#*MT-+_GKYOI>K'^Y?67/CVIB%Y"8C.3:N.$0*4K,04'"6Y<K$
M"6D-))>"M\Q[[R(W:^N"-)6:NL[0I !:HOCG"R:%>:9 "BD\(RF,Q(RA6%N@
M>&1UI"!A=$!:$IJ;J@KF>> \TK5U+IJ&3UW'J)#"*I+"/ ]H%%)X1E(8R2&N
MB39,:228S500-++1@>- E<,Q.D8XR"%JFD;?W1!=4U*84PGE>2@B=7_!LZR&
MTFGG6Z^1NIVS1JO]-?8>*X8>,1"/LM"3*H<]-NCT<F]R3BV%%KD%\?\N6KU6
MM=9T$LS=F_U(R][#.>GTAWH2O+675;'UPTYEJ6XL;<ZF6V_%C5R@EQ0T.$/>
M>HNX2A$9E>5YI)YQ+2AX4G5L2U!V']5;8!<TSP_-(TFMM/$B%TCS*K<[5YPB
M:YU A!'"9232I530O*QHKFOM@H+IV6-ZI(@SYW*;$JS+#E;H?!# <291$$FK
MI(.ONG]1T83)MU)[">LK&=Y>=/V)S>710#"<=W/NKW]9'5V*,/_/,QA>V%["
MNA8NN$--;X?6>GMJV_V-=MB^,ECAJ(DX:N=&8R#J7!32&D2(H8@[R9'!D2!-
MO-'@16J5FYN1IC)WTWOE9/1*H'J>";J"ZF=$]4A-D"0HHU2CJ*4"-4$(<L1+
M9+ED/M@@**G:?8$Y"ZI7$]4SD!$%NG.#[EAM,R(%\+!%##PMQ'EDR'!8D)FR
M6E+ K74@&M@])4J7N<#RDBB&,]O]$OM5N8->]!?=EUCC8&D$P\97VSK-MGK3
MZ1X 'QU<6VPKND)2$Y+4]W'5P)F)5"2%J,8<<:,Q<HD:9)+GL,X([14'DN*R
M*:>JJ%0"E34&]T)U0P'WC,$]$@\.,R!GG!L36H=X4@8Y830*R@8L3.YYK@'<
MAC<%F:;-0P%WC<&]T"Q$ ?>,P3V6DZ#!<YKC?39JQ!VQ.=X74& >@ZOF,(XY
M)Z%IDTT5\2M)B<?C,D_Q0;\6P,MPHL]6;2QOR*.N8J/;@0D>>F^ZG;-LOHUV
MV!W8[G(_/4Q?A;HFHZX;K2)AHG$<7$!"1H8XIN"A6%I56#,F!>$%SI$1+)OF
MGMHLY1CUR@!]KL*C 'U.0!\)D.1QDDIC!,1M$??$( N>">*&<I C@=M*@%#5
MI+1.?=(+T)?XE% !^KR /A(C,F$%#EI$26&*N(@46644HC%Z+@P)V+"U=6)T
MD^!5K:% 3)VER77%A(M>#(U6>[(#0B_P#.2<LR.3]YU\X#3DSI5=RVG(IU+;
MC5Z3P1EL@W3(J5SOR6.>*\.*O/=3$::BCT*MK7/2Y&::+1CE=/1*,L,,%$YA
MAEHQPU@E.(RE"^#ON*IO%,WE90G/76A3D%0Y94186Y>ZR7!AAL(,SUAINC!#
M'9AA)(<BES$1IQ#1,0(SF(@,QP))Q:34AB1*\EYL;)I2SN# 2*F>,.OJ":G5
MMFU?JB>LPDVN_,;&+.W/AT&OP?3MI 27@MG;2?#(9V>=?$\=_^6%;7"L82&%
ML=CD3J]WD6NW[J?-RD0'V4)EV9ULV;W1JBD1$6R$%5=2FHNJ6XHT=QS!(IR$
MP#AP&LK1ZQ> YGD54BAHGCF:QULR)8&]K$2U0SPX@W1@$3&!$_',&4II0?,+
M0/.BDH<%TK.!]-B>12.3\=@@3WA"W J&+!,!6056#5@IZVW6Q;BIIV\&6S8N
M3M20:4P^Q.^QZUN]F.5#I1L:G?-L@;)EL7Y;%K-Y]@?6V1Z:+12.FHRC;G9F
M,HQ%0P1R45+$M0..TE(BIXT' 2$B<7QM730EXS7:R%!V+-5;0A1 SQG0(QW!
MC?;"QX 23BDWGW<H.XLH&>&#X HX&J^MRR:8NP!Z=0&]L"V(!= S ?1(1005
M@C?6(JPP Q7A% )?BR&'*=&:2QW2 -!BZO+D]=MJ^#@-$5I?KRX\_#S*;W[-
MY-45QOLZ+7I+XG@3I[_-O,%CE8T&-58F#VPO>'-ET[*]X*D$>*.54Q+:<$D#
M(BE'1KDVR,K,AUAQ1IC&#H<9292R^6@5.:$&G9P*)\R"$T8J1ZI K1<4">IR
M^4>2MR5R@;!@+ AA=61Q1BJG<,(J<D(-&CD53I@%)XPU<F)4&B4(\C07C\P=
M;FWT!BF9J-'21:"&G&Y134)+)Z=)=)2Y+:/,PE34=DK1]W.J)G[W)[9]'!M=
MVX^-P<^]!J ^BZSF0&KEXMA? 5#M_J!.13?V^MV6[X/XRJ]/H;0FV9^WF@PZ
M Z5UDR8'IMU/VT/#O@.[[K<S<^;_;X],^>[:BOF%C7:X^8NQ=Q8^G8Q/^8VZ
M%<Z)E OM)*]!=SG,D0Z>H5S+@F%#>"+@8XE9'7"MC8,UPQCSJM'#HLZ"%:*H
M'U&,Q)@@7BI-/6(:W"TN8\A;US0B) C)L3! (.!X35_XMU#$:E'$+ ^%%8JH
M'T6,5<P 5Y$I&U& Y0!Q9C6RPCED=8H2&U@2M%A;9S,H#EX_1;:,!VR&TJKU
M)#55(E%US5A-18!O82@Z8:?MN]'VXE8<_ W_/KW(YAFGV@']%L:<C#%OM$D-
M)F#"0D*"2XYXQ!89EBBRE&#M9>(Z2G"J1-/(J158"7$O#;'4OAI'H9B:4\Q(
MMT5K(J-2(B&)19QCC8QG$EF#I2,!)DNNZ$%D$Y=:/R^#76J:0"N<4G-.&4_"
MA2 MQ4@[[/*9IXC ]A9I(RP%CT:$'#2FJLG)TF3F5^@\U,/U0*;4>'.JA['R
MUUCYZ,*O\;C5;@^K=5Q&VRU5.AY:8AW500FLD]:>QV1=L$89Y@2W.LDD/^U,
MO5VM1$3GMU#NWFA%YD3TWG*!M,4><94B<C1IY*DGF$D.AA5KZUPTI:C3V>!R
MW'_&(%<\*1&E,3I8;CVQ(FGPH4D4P44<; 7R!;K/!>03@WRDL*U4V88<&9)
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M?-IQH,)<JW-^XQ.-H;IKI(ZONM<#1/.G0_P:3SOG6;!5@,^=[G)]91C@(0V
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M'2#)EGU5T#'%^,*$S<.;6MU>?VR0\[!?^6J-;S"]AXBIIC/,ZX8]K[R[JNU
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M)R&?*@!XF'S#@4?U')9< 0!KF '*4IB!=188ZM9H&I+.CULQM4LJO=5^4Q\
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MT6^/_II7]5RUU;Q/>4+'Z+W65!7#T;[CW*SLW-*R-)2S+$AW.DZ0[1?27#@
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MJ$P2/MQ*WS*P[1DRK%>"4I<3[FQ*6&8%D7D"L&N8=LPRHXODP<-49EMI>G?
M-MA!_A$"*"^7LB>E9Z8LN<8P_%WU:5IUD?4QY<V]3WS#=Q^_I!_SHLB-A;4S
MEE&\3O-$*980D ]M6KC<YEJLIH8I4IHJIU-OE&#&*NES*[2@F7+*Y8J="L"_
MB=CDFX[*N-6!W9C(8Y$BN4F1^'82TKZ]GH448K^]W7Z]_7N(];9E/:M*/6]R
MBL0ZF*K+$P?L2L?D;_41%H08ST[:4K)EF]1C-4<T]EFY&7SJ/;H]>KW:P$F7
M.F21F/%Q>32&)9B-_FJ>V1H]GYCMT6\JI&PI;8E9:$+UFD7RG:7,2QV@#96<
M>D0ADA6WDZ&2TU#):1,F<>\J.5U8F6F%85M')<MSGA6*L\1K)1-G,_C+9[+(
M,WUV6FAZ=D*YBZ6 E4$4-,F,R!+'+4NA<\:-HB)-E,VIP.N^&T&UR-7^VP%7
M.1@] ]YU]'N77MK9Z6FN\>3K4<@Y^MI4Y=&L_GU[2"%SY9(&B!:7DRR.#Z9C
MAU>535[AU5;7R!+ONE?6R!"/5 5*DAJ/(F%$"6)KM(,20CV=5\;]Z:I]-QD]
MKN;[HT?3ZJB!@2C.[)K_#T@$QMS[93GK&R;4CLEX0S4OS&BXDO\-:V)T ]M:
M*SN%EWM3W\*6'&;T[U+QM+6V^FEOQ]/]6,IB=*PJAQD:W$JQ\J-IB9F 9\VW
M;2JZ\W//;8\:VT/=U@*+&?WBF&+>]BJDH$,QI@JYN]L$T_6B&=B:%_,99JGK
M:&$Y52 0[[B^ULQ7^?;/';H-/W/1Z@"GXID#0IK$DFXAP>+R@>N27W<9G4YG
MY(:S=XWP]PLW8I,S<%[,.KLM?5Y7RHWQ*+:'KJT@6%5E4_X(CW!CM S5/H*_
M!R;^Q\Q;(:$E[C>ROW(6*O A7.Z<_2/B0I.9NRV3>P!T-*U"_O)0PJ\*.N-2
M<26U'^O7]/"AS6IO6M2$!T)FZUC^JE\B$08!X&7)>#K]'(J'M[FMUZ5\7#&S
M_=+$CPTF_GFR;(3Z\^152)@-8W_M0FKP.LCB]]@@A?4!3SY:C@X!-B%":DT8
M; -1(#03FFN=YKG(='+:P'0Y8^--I7B,J>U"=OO #9NR476L37&(]+%(Y-KD
M;FV>@6-S.*U<4_<L^3\A*VSPU6I3G?Y0UKTAR][M3UQWJP8[9-F[.UGVXM1"
MJKWXSQO)MW<#D_\+1."F LF:-/Y7DSOL5E#!D&5NR#)W/[+,W9Q'_N-6(P?Q
M;N=,FCDO5NA*LF'<(O^;:!5<<<%1A:6&YC95PC"'062@8[A<%HF#_W%[@7,Y
M757P'G56+,SC7]:?&Z:@]EW:^=,0>DNUN.A0<_3IPYM7XQ?O]CZ]_V;@^??8
MY_'[3T_8WKL/GW8_[9S N\=[;PX./ZPZU!SNC?>>O>7OZ1[T^1+^Q/G]6>Z^
MV4\_'$)_C_\%&N!.^N+9A\\KJ;]RS5/)E29.,XSO+301>0&[DB?4X 6'I.K!
M0_;344&_(,/#39R*__,];.6R3I$#S'POS-!,2IYQ[E+IF95&B=S+E.6"R]2E
M&;_ K7J F>N%F863=)XFQFD+U*LM)XQFC$AF"Y)GE*9IY@4@S8.'V16[[ TP
M,\#,E<",4JG)6&82ZUCNN6(JD<9ZZK0Q:<(N<"@>8.9:8:;G'BRDS05CFDA5
M% 0$3T^42QA)-+6,IYP9(0!FB@%FO@-F?E&RK,W0]?[\(5WO#N:%. , <Y]J
M9HK<228+I13C/*,NI;105JA!G;LY %Q*U^04RV3B4Y(;80A3-B4*-H]DWAF5
M"@6[A9F<Y68D>;AYC!N2R%P]6!3"".<IH //F#!2ZD1838T$@8EY>E&LZP 6
MUPL6"Z6,*L.M*_#&'_0QV/H,I"6N2.X8!:DID8+[!P_IAF2$&<#B+H)%SIB2
M3FBGC&<I$]JGTDHATLR(PA9V4*UN$BQZJE7*\HQ1KHF2/">,4D]$D2AB #ND
M*6S&$U"MTI]6K>X*6-RKF[)'/W-3=N<QSJG"IBFTQ'S.!*72LR+S@@IJM%59
M.FA/-X=Q2WF34LS>8:T@B<TY85HR(C)G2*Z\U4QPYG0&&/?3B6[7'_7;AW$W
M8(B^\V"1.Y?((A.9M"ECQ@LII*,\]P >A69RT)YN%"Q.>D6S"L:9],1)FA&6
MZXQ(F2:D*'(KO%%<,#J Q0 6U^IFHQ);B(0SD13,8LRK\"K)"I-P*IVY*&7O
M !;7"A;]:BK&Y%A%CQB;6\)2SHFDB26%R[TS\%$ZS%O#!K"XAW=/CX>[I_/,
MR;*@(I6YS5/-G)2:VH1J;[GTB@DM!^WIYC#N;5][,L)(Q90FPHB4,!!6B=36
M$6J-95I3]*' BE&#A6@P)U^?.=D)1QDMJ$R#PN1%D2LKN<]S8ZP=M*<;!8N3
M)5-+!F!.:&HH849*(A67)"^L3GR6IHF]$NUI (L!+,[T:K%)GO-4*>4*1IV5
MB=3P/YEP+[7)DT%[NDFPZ&E/)J-42! EX#]-F!<949F0)/6%@IT2*G%Z (M[
M>O?T9+A[.@?C-/?6.Y?G.6!<:C.AE<L*G152&L7Y1:49!XR[1HQ[W]>>J')&
M%1HPCB5H(6(Y49X7A'KF,V55QCP#C+NJHN.W'N,&<_+5@X6W5-F4%H:*A"G0
MYC-%J>&.&YM[6PQW3S<+%@OMR>6:I=Y+HJ7CA#F9$<F+E#C%$J8MSZQR5V%J
M&<!B (NSP$+(3.6)HSXI'--.P?\+@3H4==P+.MP]W2A8]+2G(-45BA&E"DI8
M(4"RT-X0DSE!$VT+=S6FEKL"%A=H3VW"+5@I=WX>D-O\Y'>4G+B>E'Y?)E;U
M\OGM-&E-%PD6A]1^WY7:[_BCTXE-J- D8901EL.YESDMB':)R0355HE\2.T7
M,G&>SIV[A5DZMT:JQM]/Y?5K,_K)VYS1KZ#;N1R2Y.69')+D]><D;V>.O'N8
M#J]ECKWTPUN8(V_(BC<D=_N!K'CWZMI@2.[VPYJ_T:E1+BU\XZ(.RY0[ZS+F
MF*/"#=D UFG^A]C7WJ>_#W:?[?+WAV^3%^^>?GKQ^*!\\>[ER8MGK\;0)VC_
M>P>G-?_W,"]#]]X].7[_;5Q^>/.2OW^WRZ!?_N'Q<_;AV=MO0?NG3U>3NYDL
MS1GCF-S;"0):F" RRSGQE.;*93G\@0&^5Z7YW^UT*$/6I5\-,]S;5('4KZAD
M(O/:RMRG5&=,4FI3-]Q&W"C,]")A9&ZSH@"8294F3!A'=$(IL:;P5A3P%]4
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M=Q&PXB4ZYK7/X*@7'\(#8W42?-IF@=H.@,A!LNP,7L'5!8V*D0JGDWX/=XL
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MSRG\-?KMZ<[K/W\'J:'&3"AK'WQ[%&)6?]MY_?;WT#Q)Z=;HFE-5GKFA9ZW
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M:<Y309(BUYC!Q1-9,$Z<HMIQGIK4I0\>"K'%,WY; MV&\-X!_#8-_(8;] V
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M Z .@'K/ '6S#0&#G?>JT'0AI?(DDP7+$I(5.4JITA%MC2.>HX\7300K$C0
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M:SP&BS&>&^&!@CQZGI]Q&/+-23F\,Y\=3(&]P3)\<:/]>6G5Q#A88@2MLC[
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M>H<GM4)9:7X43"+*?IK7B%3+@.41AG"O4.MLE^D4BIT_1+HZ1#6NI]\SSMX
M3X^J+H$J5'7FF+:0T",0-P>A@]K>&0DMS34(H#!%-0:D15G2S\?C$0ZOK80!
M!PPD57B@-Y7MY3GVRE\TDN7(H+;N8>5FL:B%=4?3NIQM 6D<@IX0VCL"Y:+"
M;]J<)Y,I/AT(9'U$5)P'R+E(@C XD&XU>HS H56V7.(5[8H>J0JT1Y@0[-29
M![5_,"G;+OB-G<W1*?7I5VC2(0"M;K0Z^V+R"E<<,3#XX]QGY?K%X^<?T]QQ
MIS).3")R HIG1@0SDGB6VT1JFFGF5Y7ELZAK,V!_=.#&-IQ154Y:&.DP(G)
M.'C ]K1KU$EDLK.^5@K(I.#1AE":<W@&9]C"'V+!G<VH95,DQ8_4LLGDMN3\
M6HJ8\/Q:*JYD5S_8;)OG/U;(91CLQ8/]/C*X5;5LSKVA6G_C<,_F=&;T2<IO
M;\&1T[;B,Q6'MR@%7Z86R6810VAP*-;4#VA8$,#5EMVYS$WB9J_3RZ#61:CX
M*^AV\=_E))3GV0D:7?PJ5NUI?@>U+3SPO%5-X]=1A ^__!:4LU'Z/:3U7>MY
MK_;E-0P@:*Z365S9%ZA(AX5]T6F7\9?G0;GNKSD=UOPGU[RIW]4S^@9B/[72
MV>^7X1>W/T?,4+OJ*OW [G%V;YJGO/#*R31G.1>"2N>%R0OOG&:.746EZ<"*
MUKAI;(Y?UP]:DAJ_KI/W]'GZX=G[;[N?=K^^@/'M'GZ OL:'_S][;]K42)*L
M"_\5&>><]_:8$4SL2\\89G1!U:5O2W154<T17[!80:"%T=(LO_[UR)1 B*58
M! C(LU2#4&9&1K@_OH3'XUOKNX<-N@%C_JW5W/GK8.M:7=?OA\W#OXYV#^MG
M]5RZ<?CU#.XMMG::O-&IL^9VXZ#^!<:UL\%G*'*9TB!#UB/#O$0\6(V,E@IY
MS84BTC)&P](JD7(9F^O]"Q:4S[MJ8E#!W// G&8N1JI,< EG\@KGO,""$Y$X
M<5K+"N86">:FRE=-#(9:B7 D/C.!8Z0#4X@ZXW$0L(925#!7P5P%<P7,$7AS
M3:*-3#.>M#5$:1XECE9K'X*Y'\R=QWXOV,%!A7#/A7!3QYW 4>.>&8J4!ICC
MT@1DK-#(!9(LMQH6DY9%.(3^JT*X"N$^-L)Y8ABQQH=()2<VVJ"L$B%WJ%0X
M.5$AW((@W!3/-/7:.H91HIEJ2OJ$G)84.<\%]@0+Y?6;0[AW3T15M9ZZ'R!A
M%ZB+E&%%%<?::)#JD(QD+F"26!59+@XJ72&9]M8GAQE!&%8/<1Y]9K'T($^.
M8I7 #[,&(DN.ER69U\'(!3HS7BGP1(%C"%* "QY!A;GUPD5G*#%::ZN94:'R
M*!9$=R\]"JZ\("9@Q&+DB#,"NBNL0A*;D"PQD3$S-X^BTMW%U5UKDQ"$<BP#
MY=0QQQCW8'T%5\PP&BOCNT */)WT$ $+I@**CH,""P/1 /$&$4HE8Q*D.?G*
M^'X !?8)O&=CO;<T<JNB-E1(![Z94H8[12KCNR"Z.]7,(2AO@G)(.@>.L]<2
M00A$4;!<^,0@%*+S2UB^7-NHR9D!&&R\6]VK;U[]YKNOM2I+6,?'8FX^_O+(
M_-0C*'(^4%[[R;/S;LPD9HI:$P-G+G <K;,Z",^"-S)J:>^YKU?YN2]@*W],
M)YFH3]11JI"%@!5LI0E(JQB0,MI*JXGE'&"48;FL\+RZ'\U)>=[&UE\%H!6
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M(M0!'GF5\BEB@;10,<%*<FE3Q1ST"@KXN=5M#0YB[B#6"Q5AT#/X/??>8;R
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MUI-L=1MQ^#V#&HAMWENW^Y?>!*(?3XK/&NL;>Y)@KPQ5R'GJ,_N31"9I@VC
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M'U.*NUS#EK+;0H6>CVU6PSU7 6@%H$NK-U< ^E  '>G$G&@<2+!(J9B#=8E
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MI*[N3BN\C]T>4 >P<$%''V%FW?<?/AY<]+H]V\K0O-_OR[TL"3%/SLH?R3$
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MRW2R_7).<N?)F5U#C^I4MX)T(#ARIC^8ESSJI)-*UE*J/;$Z,9WU"HK[>@4
M694SN]H(=CGN86":)6FC0=YZ PBF!7(\611M8$["]@M'-K8E74C2[!(?\;PP
M(+C=A3 G&E1)LRL%!"-_ EB5EOL@$%&<(VX(0SJ7("41<VMS=:XHBY/>*>V"
MU@<&5OT9+R?W8KZLV=4U2V>,T5LIY:Y*J)T;TZ_&E3N,4]2,$)2,!$P/&B-G
ML$(2ATB)<E;XD,W3*O]BQ4!@'?2Z*JWVL8%@+(Q/>"LYHXBIG(=EC,F'10[1
M" 0A&0W:I:(DBI[,KG^1AT5+^8R7X[:;)[%V=:WU=5;MJL3:N1$=CZMVT3D%
MN\^1 PC/YKK(F;4,14%5- 0[[=S&MA!J4^(J/V.%0& =5+LJM?:Q@6"DV@6I
MH[;"(1Z%R#8>158*A8C1V%EB5>"LR*V=/PYHB;%@U9_Q<OQV51_:)53NJMS:
M1X9L<OW,-=G(%$.4)K#&E7'(!.?!.$_2.J62CGAC6S&V2>D\U>Z6V!1?3QY?
M#]VMRJU]3!@8:6[6<ZQR)UK.+49<!X,L#1'EN$'ODE(BBESL3BY3Z-BR^,(J
M0%IP#.N<0%2EUJX^-(WB6AE0@$F 2BR)7+S-:V2T30CKH*QV6@NO<VJM7BIL
M>N&M:"FN6M$^- 86$(Y:[1W%#'/'K=6<XNA#9 D;8VF.X']N%WJ56CLGQ-%K
ML1&1!<%E0D%:C;B0%!F3.")&2A>--E2HC6VV*;'<U&11':^6)K6V<K+/:*@]
M#"&JU-J5@8:18<9M,HQYBYC6N5QE NTG,8X4)Q%L,BE<X&5J;56&?#U2:Q]D
M_%2IM2O/\Z/46A5QXL0EQ#U6B&MID&'4(\PXMB189;#*J;5*5MUHG](M\3"Q
M6Z76KBA#CEP0AHB<<V(0%H8CKC PI/,4)8FQ(%H9PL7&MMX49)G.M=>HNM<O
MCV^M:\;%N2 FZPXQ6/_0OLAOJ7P02^2#&-O^R@?Q$(QCXSX('8G35D;$7)"@
M=#B-K&<&P8>>$>M,PC&[6860FVS^GD<SL]FR'!*]O,.9Y79"C*% Y818*#:,
MG!!8<!:<98@RKK)5$I&FB2(M@S<AYO^S(A]7S%W==#V.AU>)YU?."7$[Q]_F
MA" 5S]^3YT=."$N !(),R"<#^H!T&/0!(Y FQ,O L;1*;VSSK5$/U*J^USHY
M(1;#H->=$*3R0LS,D2,O!%'&"NTLHD(&X,A<<4]0A6Q20 9 ",JHC6VUR? R
M2>$U"H28SKN?8A<D4,VV0BW^/(\^_])KU[[#QX\5&%&N\#2+J7);++W;HJ27
MG59XTZ>6PW;^J(JHF!,K^35OAI>< 0T@K")'/*9<#-$:)#CQPC(5')# -LO]
M&#;UE*3$N2(J%L&>RW+R^O(.?9;;W7$W>E1>D(5BREB,?)0*<VT0#<0@3G@$
MB\@)Q#41S'OGO55E*,8R]7BI0C'6TPLR,Q!4SI%YH6#D',&:2BR4121@C'B2
M#EGC%1(LZFBPHS'J'*$A>16AL8[.D4<5X#M?OW;B5]N+503'G SKQT*J;" 4
MA#5)V",>B$.Y9@G"DCEK-)@+^01#;S*V3!5%"]_)[[WL2(-_0^/[]@2<P(>#
MH9S9SM=&JXSGI@.F;K0"$. K)@O$>&+VI9E]#T]B[4=?%-5L*8MJ7W,A712
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MV]\;&?,+%BA,ACX5 C;DPY[NX(-0,M,8NV[57L=.#ZZI=>^DZ#*T*?J++#.
M'Q)<WAF^OI!"UOO8!"LSW_N])(U:(UT?$UPV\90,,6-\"\#;:'UO-\&ZL9W+
M@HT;K9([\P1&7#7UN.Y![#/EN.XL4_ DMSS$+N_#1<DTQ2?=MQ?-YLY@N>#3
M@]3GI;W1S ]'$R\Y[.]VM_?Z)+_M(!7G=^WFRV,E#F.Z/#B$Y^Y^%/NG[XZC
M()Y;R5%N;XHXEB%;4 XE 7:,(1A'13:VZ<0A7*W882#L!!0&$M<7*YM!VY=K
MNU7;*?GM-N882H02[OO2+C4Z.>BOU0(*[W0S!?<E27%G*0PS,]V/<T"D%?K
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M=K?7/83!_0NN^?;B"/P=K8-ZY$+$)!B.B,8&,%<D9"2H1QAPS"GF4E2@$T>
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M;S^_G+[[N7]U<GKP^8C!_'[<R(6ER1).I45!8)$K9!IDF0Q(*ZXE3=X8)[-
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MEYXBFYA 08DH=)3,N%QM88O,W1QC+=P'E<]RN0Y**K19 ;09&0F226&\L"B
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M:N]^W?7A24&"ATE8X@A/1%N:,!",IBE[)UQXA-R(VXI^ES/_5\R5QT?$!_^
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M-I80V"W>WXG=:#NP=?F7 %<WV^=Y>6J95;_#!L4N;,5%)[<>R_KK9LVFO,,
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MR%B@IDI:$A60$S1[AK!!UB>:^PDER166@DK0JO#69#?M"D0J$%D*XZT"D><
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M;W)2Y5)Q!Y>0H>L?A;F51FY]?/T^\)!N'0P$7*;=[?=GK=.;''M?&JEU=VO
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MIUM=N>K<L^\I@6@"T:W@R E$KP.B$U*L6,YQJ2BR.2 IIQXCS;Q EGIM--6
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M5A0I7 K$) %3(=>.JSRD7\;LQ@DEDEJOL>F_3GJ=3/]KZO64Z>\<+G59%*@
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M%_#[Y5/UZ>C%R<>C-^UP[<<O;[Y\_+)?[;_;;[]Z_NO7_=__K#Z]^]3^^.Z
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M;AL>U>L>=X?M;G^IOV"I3T!?@,*FTQF:]MQ^&-SUH[VP:>\MCBTG"7O7'J1
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MZ//Z$WBO$./C69="!#)$<Y"//_\R>LCG$@HA-I4##@&/#3B?FN#PPW]*8Q/
M-!114^%5?SG?K;!#RK6Q,; ^B=]W6^U7]HM(*NZ,E=SUMI4LL9K_,.A565\/
MGL>#QX?[SJ1W?]=Y[#QW>^//O=YD7*CO4XE)L% %%BT 8 R=B ,P(J04GY;B
M$3NA,QD/$8-6+;! X*!0;5.6X\:'?G[<E!^W:/]44QS'$_CYU'N>C ?]P; W
MZDP>X&U9#%.HRO%K-YN:#+\-46705S9D3\CUNX.GX:CWN?<\?OC:>WB&/WN'
MA#")O!Q+#2*@_%ANT5<\!B=4^]W/G>=?>^.'Y_%DT/WGY\'C?6\T[OWVY6'R
M[X.B*V$C1_FBV;S< V6/#^"K1#G]C^+Q.@'>[W;&G_N/@V\'M;\;HG(P+YO-
MJSW !*J*(%LCW.Y<FUC8M@=LCBSREY &,!E&&E4$N3QD)=BUU*:J>N$#L763
MVB[#\$= 58F258"N$B5\0B_:&_?80:20!YN?N Q)K0G_%412^=%C4"=/=NPN
MEXBMZ6Q,YA:9 2:6T]%% I18\R$UB4ZP703/G)3EP[*MBDAR"TR?L$)G2H2T
MLJ&M!,1/..[T]OOCF0O75E-KQ0=I?EPA\O1_.PW570 F:&J^)\ ^?1F\[>9%
MNQR\'I,3N+N=/\(ZM71B$B%M%]D+_G_O3Y>\(!,:;P/ (VP[C.@.-O@[;T9[
M1WTH+I)\&K_4REA^*+PMF,(Y_RQ^*A'AA ^P$<][[[L!)_V+@?V,G3%TG#U=
M#QDU7-TI[NZ58RC7G2M-Y#&+ZPZP501?9;I6?,XG[S -)+[-RG!-3&=/Z _*
MNJ[MT"5FMK- S@C[/8"-)\KP9($LM4EG$^H@<X1?L.5B^[V5Z$#RR77N6A.Y
MU^(Z%TC)2PLYE5!0A4NJ1$15N*P*%U91F__-:PB!E4#BDZX>4!=\(GRFPS!O
M@&<"YN$(=58FIUQW;S21:ZY*=P/!E8WD/PL3?-+B%.WH&(9@B,P':T9!S\JE
M7LHSE>J7VM1$EKNX?FU8*Q'>)_U(M1Y!*=]W&6''95;'-.DKWVKY[L8K%WNY
MSJB:2*:7L$F;PH$'Y\FAA(+448&>$/L.C08;.\:ZRXA3,!V42$>:S%-Y/F\7
MT@T994.GYG 43^%(J$D3-FJ['8^V$Z&I8VXFJ5<[+V W^*,^93Q23"I3W,R6
MY"BWK!H$*_FPAHDW8-H K@W.-DTMZF=)^XBPK\AT\1-&O!OYDF^A49M,2&Y+
M+]1XN,GI*(*0$J54=TB*FU,9.;D]O6S'I[H4>.IH41,[MF/;V+'])P9RPD+4
M&G%#P\#!NT,V*6%7#\)7;EVO()S.BSS85\$[>&HH$"I'"D.($TJ@"!'J:&<?
MK!<0GK)U$<0WE>7V]%J-IT#"NG7L[.)6<Y>$W%+>M.,364BACK8Q;'QQ,[=+
M0FJQ6DU-;4H0J)_!&7HG:];0QWRI<,6-=1$8$NE(S1 8HGBF+" CUBI#0C7'
MH[AYDE"36JH6W]>0#YLZFJVD;DUZAIPNM4LLGQ3B(S> ;4V-[59) 3;M10,<
M-\[O9"Z]_CCP L6^+.1X:YH:2W:EXGU:>@AP?H0@I9C)]6O*I[X+-9[P]RK6
MKH^+3VY;]>73V64[[FIXU>LX?7DME]B4$G!(J<I-U96FQO)(/DA9IJF&\(F?
M7DH%8'DD:$K,2%Z\!(29E.4P7FMJ+,@-812_!)D@/OU$R-<8S"?D;*UJE$ O
M3DH.UXVFQCS]$*X-L1,XFQ[]73T@/+^K)X!*Y(\<9,T)3.">22F60-JA(77=
MVDTUOJ*X(>&;MAI#4":7FDA)ZMFU 9"8)QV#HXY.WFYO?NY-'A\&_WO@8+4
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M:$VT*MBY?]]%M)8,K3MDVP]%:S <[[./'4$8V4ZXH*":HZ;P6E(<B#Q3+(?
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M)NU( Q%X9$E;$7/QPNDNK(1!W?%1KG*,YV&V!>50+GS<;==?J<E!"R=-=+0
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M>5&[0T.]&:A38%E(+7@ H]KT!^HJX&.RM$% :G"BN/8&K$E]EIAWW!N#.K)
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M)B@Z!*,0L71A2GW+<7(OG.^+D_OH>[0@J8M0CRU.[@54IVAI&RV/ERJ1.NN
MG'E:(9E&09LABL)(*N>4!A=3EUOOAPA]WSAY>.3[*+=MG!RCB,[8P&I]5Z:M
M3"Q$RPFE4&3V6L<8[@NA#C=.[J7GS7%R'R4=4)S\_'1Y>J."PE4?N$'4W'7,
ML6+HK72P%E$GY%E+[VWP3JO@@RU<>=0E:ND"^LT1==?11XBON33>DA4S4RR]
M"AX\"])Q)D)RMKA02IM6)'MFQ=3S3V$S6NX\R[Q6K8P0&7EI@>44G/ QA*S&
M+K]PN.?0?>RDYSET'QQ&YL/<S'R]HD7@W>]X_!E_I<CKPV*27)4_%^9M(>D%
ME[5 A&?&DP>0(E9.W-C<F/O%?EQ6-C2.XW)F;I'^/Q'F[WZ?3624!@*46GA7
M,ETTA9Q>D;Y,*1PERBC&YC1NEO;1V]PVJ#4@WFPA--D.3C)X=$)S9IW3]5J?
M8R'%R%Q2)3A9/,A#,;8J[W=SVPJY 7MJ;B_V\]GI?(*2PB@N.,L6,_D%UI#4
M)=;;8BHIKA/8 [&W*NYW<]L&MP:].;>0FCX[B2"X$A:9$;JR(4MF097*?Y"(
MPDG T0\:[Q#WN[5M@UN##I_]I'Y2ECC_*KH,$;C-CJ$DT] H#/,FUTZV J(O
MID1W *'#-9D?O=UMCV"#GJ$]#J=(!;8H%9@U55(3:J<NI!C'><UU-,&UJ5;[
M0(^&=S&H1J@<[-&PDL7H+)'Y& K3R;C:'%6RK#(W0:%+KDO=F6_Y:+@7SO<=
M#??1]VCG@EV$>FQ'P[V ZG1 N(V6QRL+Z931FM;,*#WY7\Z3<)&^"K+D>E&
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MW6L;U 73Z]E_T_[U*WEA'XZ_O#A9+.'X>!6W3Q)($9WRC.M$&Q77BGD/G@D
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M_P?K*?SO/.I=#>%.'G4?0!X*!;7+G+[SJ/OSJ'O9RAA<U&V ?BA&G+TV,JO
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MO.$!Q;@J!Q[/X_.<NLB<.@]K8RK&>9#5NV/.KWQZ&X7RDK9@(47MQIEKQ9O
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M7E&1<RO)U7.AU+IOCOG ;2VLD+6S$31ODJ/<,Q]GNV)W(]%2\"@A&PU.HI?
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MM-+GNGU@J-.7\6X/'E8W'1;Y:"'&3&Z \:[V2XP&:[%)FSBM6T"^0V>^-NY
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M)((X,1A0B(!"(D@2@X DL66!0@Q(8H$L!&2) ^(JUA@0Q^(080X&!@$.B".
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MG T@X_.9H2C)X\SC*;V%?U/3&T6B%/W3US2<;YEQ= Q^Z95$$#)3SW$:758
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MR'#XV_9@!%B3][]G%<UO[M^MM!^98QC:9[[\EA5F>5 A?OJM?/]5<UE=@Z#
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M7;9Y>J#8*^B##<U^(_9>/!;7V9#+Q1O'JN(Q0FV/1'_[A2/731AGTB;@]'.
M'W7Z76I$VE[@_J!E0PZ\+C H'8:3I8=;X)E\39?J?#57S4O7?^13555?69N(
M/@</(I#_U;@)[2#%[\!;-^/T_R09FJ#J,8_(+XTBKUO7*0\N.+1+F\O[7;7[
M]/$*1.$7)&>J[ 5VMDR]"DZ]7)828_<4'[-A\SCP<<"^G8-F.U)?BK=E%R>T
MO2_BSIBU-UAL&EGOYA!FR[$\3'%:=:,5M 61A.!C'F%<0*4.[VL,^[B2M#>A
MU*=$,E;/D4=%6O_]D;F3$F\;../N[QJ6?1X$E#$X_F6FM!W#8/"D\U+-$),S
M6%HXJ*(ZO[Z2D:& :9H\$UZZW$:J)E"L:94LOA+:DU:,- T:]XL4!>?2:CCB
M@/ .B7>X6ELNM@@643]<G\M @&OFQ.2RY=N[\:?2&E]HV]M5;UV"+P->KJ(J
MM^F$ ?PNQG/E>SA\_37#%>5);T^;TT!Y=#N50P\8!A<RX=_A5>1$6!5B/-PI
MY%-XD'G]WI_9OD;=NGHF\_"7;$@ECK++L *P<Z;KI'E2PHS:4%GC$7!'U?]I
M9T.H#U.$B5U6_,9+/:(-[;+QCG4W;8*&!V25 96Z1[!F;.M^[/P8O1&4\HR6
MO57Q(<SR/KS)@=D=Z;>K5;8M4\>( -OX7VGC<?94JU@_0_&YS02<D)'\8*!@
M'!I&[@OXHQ/%):A9)H].[WH09=[3M=3U[9X#[A.4*0(_M]L80I"P;R=C15#[
MNW "OR5^$0ZA7#M.%8<1'2N.>DTN*F@B*\X6G\]PP9RNSEV& :J"<8VV#!W,
M$(D#1 )( <")#>DBPEIY?TO#Q5:T%2(_\JO1B68*C2E7=,*]3T[TM+@*Z9Z3
MATDSG-#GA['NN'$-^O/=:A#^PN('/JXAI-Y22Q9?KME-.DZL(#P(B:V91S,T
M&&W93XH3U+/,Q;E4CHM:-SB$WS=8^5.V]FIAKAY,C7'PJS_*XMD0'^0DMIO$
M!9]]KV_U**0OGT"U@>X-+9.:\I(;/D),?>NK\%[NV+B[8_$Y[2+N[8035T[_
M5%H'BRHW_VY!F=;FHSQ-6G::X1G:H58XU! ^%T%:'] X5Q,KR'E[Y9/AASRT
MM4)N=)Z-I<CFT=;LC*$-U\RMGR&5V. ,9C@B:\QKD CKHYFS>,O.4()_SR0R
MW7=SV!#D('&MC<#'AGBP(:DX82,5E&<'29"EB;Y0017)$TEKU[Y78<+?.3!0
MUY@QIYS9T>#W_BE70-+BJQ.3XXH$*+;5&NX]K4(NZT 2GUC1L+&NP&GJVMSE
M&9$GY&\Y6G59;(AE[*J!Q]/;X4ZH6J26M%' 64;JP"L5G;TY! >6&.*C2JZM
M:-'-[1E&9/]N6JD&6(@VHXV4F9>IGDF-Y]Y,KN;\:5_Q+]7D75;,OI(SIY5J
M?L-HY8D+^5:4K9*$DM:V'ZV;_G&WW#"<UD=O^&X$97I1_SQJY&#H^.Q9FKQ4
M1RV)V>TJD*C1D#ZU*3 ;XQ*\I+$Y-<N9>CT?& +]*@(P&%;,JX#I+"XF3Y]*
M:)UVZ,3M467!OFRMT,=&?+,KVZ ,;='ZV(#R5U.S;\3=$X,<_J!.BX?D3+]C
M#ONL[/:]OB%:FE]3U+M")"7L:,$H!K->6.]:EH!V?1%-#LF/;7/*T:O"+0^S
MAOTP7X]-++ AI=SH)I8G=PUEJ8'(O$'EH9#GZ+L-5;@TI^-42C%&>Y@-<6TR
MO=4\(B//I:-3@Y%MO'I6S^MMEIDHZ]JE=]%[(G:0Z[\9_IAO<%[,,<P <;G3
M*MY)FK8<1?"Q%*"S^BRKOE**<]LV[G+OODYX&ZLGV'-R7Y_*%_@HLR7&8[1:
MB\=WO6R;LH8$CHFLZ9GTE+PD<)&RLMD0%5Q1E>U<VCK81G+OV2W_A9V8G$52
MI.?+DO+$:3KMV'CH0;]&\5 R!SE")2(IUY907YE%VW".U4EU]_76?N>)%"K_
M8B=("35.:QA8&IM&_KRX->PO& I*PR0KOTE\S*?\YL%_.[:767R#[QQ]<51+
M>,JG2:7G<L E>I!&6H;FS\,LOF(LWX[4V_KJU)U1,X]4O=?/+YE+?W /E><Z
MB))-/>7C8YJG!BN-?;JJ:VD9$L9(Z[*:5*%'41&="$ 6L=Y$W6QC*8,=77RC
MW]RYV30!^Q]$S%N1/T41?D@^QXLT%7&$FEF__RU(<:^@@N<4%MP$26$D",&+
M !S'IOZ:%/GV&\:]__;]T8%6E3#5TO1(_8OW?L9ZM<SG^:X*1D.I9H,3A%E8
MMUZS LJ*#(\+P4E:R/5FO[%(F*\,E;B)QV=<C)IZ^+5=RI53= VS=S</+4J=
M[')2IPG$D:>-VNV &,,P(_GZJ_W$JO2W%V//=J2*/KL#.64E^J[N+F64#4F#
ML2%RKM(%9;\)V[A8(V'J8(P6+A5:#NW:E$"#Y3OF-6UD#I^V'@I6C]#:&9C@
MN"2GZ@MMGP[[;I%4>7D^G5B^C^K5.RI@H5<%I2&(/UE?7+L0O;U-2'.P0L,Q
M_?H"9=JO7:EP\N[+7V/4U?-+1W1--34ZYBZ<KM5+,'YP[ZB-PH'"EC);0)*A
M"2C1?65.R? .8<M-T]"6$?-'0B)+(]+P/OA<HZ% QA@6ALW"-:3=]4W+O'C%
M/ B_\:-ZI)KRAD&X6E6:NUZ]V4Q(V"J@\##\@*390:88O@5WP/#&W*Y..X&K
MT9TZ:H&K\!FE!]Q:E5J>A!TL("Y::?2?ZN:+O_#:07Y!L8Y)W"W13.$A#ZXW
M@"%UBBK8QBCR+8O6-ZJ<;;*UJ!GQ%YN_\NF;6JC#Q:9;VN@/G$I/;83W$)4N
MNQ#\X#YLR'@$V8K2.0N$P!/S]H^@'0HF]QZ4=,\ASDUIR.MW&PH\D:LTE72W
MY4CV,C.X* OH,+C11P!.*L]5P(&,B&L^,L+D+.JB^>@;?JU>L,^IYT)6:2[.
M!-VX$2Q_NNUA'K>W5(*#9693:!-IX7+AS,YFV?NLD9W-*>;N;A7V[FU!L,.E
MVJH(QL_PUG]EAL$?8CU571$.!KY?Z7\DPOV=4\T/&7"E4Y!74Z4E9'$G@!OS
M5OM9_=BJL+9(XUEH8@@=B&#<1NG8C:+=J6-7OIGLXF)@(Z;BEH%[ED/K[&X_
M+HJY4[/5)?+QX[F=4"H(.\,91JR!YM/(@RAQ,CRZ4:O8W-WHI6)G?H.';S@;
M,MI!?E94%-+.^;"E9:Z":0!&1S>@Q#BSXJ0Q9B2!5J*FQ3*=2[W&:LS#7;W$
M@CP2QOI2GJ4?=#E[5#M*U]#&YD,3[L3ZV R8RNB+?PY)68%MH'(1"YJP??L5
MTXHZEDJ838=_@D5780]ZW<].+,:<\;ZX;(IO3K0 M!&K'QFO^9L"_/UV4I\<
M_=$RENV$XIS=C(;/OB3)&%K3!#OR],?0S@5,^V]5SYK%[-'&V<;X406_\Q#!
M<6WS^@LI^;G8IQ,,(W4^VDXD..\@,(HM 2C=8_<%1@JH[(;N0^N]8J*&**5=
M;PNM1'1TZ!5GOG=U"5_<%'_F-RU^_\CD%8UOMD-Y<N![]]"\-,]N"VQ"3EH;
M@F,:19]9<"JM(5XXOVKQP"9A0=;%W.9CNGQ4[]E6T9)+V>BF0\C-0*8F\]+B
M]YY0/'F A7VX_?,5&_(9SN(K8T,0X 9[7Y3X,U+' 4SI251Q\F ;_+!/CFTK
M080I#HC.;DJC]L]=\U4I6$T("LFU<[\!JSS5-<FYCX3:3JS(\/U=Q))@D%_%
MS6FZMNG[%'2VX\1CO'GH*UM$V RY=ELR>W%RM Z:B*5>%ISX,W\OAJRJTXGC
M91XMM0?$+6N&JHX&^US.$M->J]GO+'N4J"#9IN<N_6Q>X4D?U]P(1:+LQ75;
MQF_M#]MOQG*Q$5=(0?A^IA^6".]$@, FJ:Q9%M4G#.3:[2:BS^?$?,8S=)L8
ML/AJ%>=[UR'*.;I<W1 U!05(+>>4&NLXX#F'^?LOP/74S5BFR>LU(CV)+*GP
M[>Y)V)O:VI$.&>EJ\\:%F\?42T0^&M]9.KZ7]V+WZL5TQB&FRE>CTQ/ 3G>K
MO24N(6231S".7F&\I/BR)OJ81I)(%3_=/=G,JE^.5/5TNG*Q&!F%I5Z!/816
MAJ7\MA)&"9*MHIA*I;X'SU1WSN06G%23"XQ+/:6;<"O@YJE7?TJ*>JQN-)6P
M(?G8YX-7<I,=];5),V\(QEN^;?"MTH+U)#;$_2.)#;EVQH40HO*Y!'N'$"V&
MX$1K4$=A>[Q69A$\/DDE/XAGO=$I1K\]LV:OQ-VCM-GE8\PE@YT:K@]L!&WC
M_WPH^TK$_#:%JV!46:]-1&P>_*^:D&L&Q6;]_:(V;AD!D/RR9V#3T*P//)Q%
M DJF'6G #98432D1[5=Z*T6L:^3\2"ELT\7A_<$!=1/_ W5F.><E,?.BKBV:
M'-M_&-RL,=;)W0KL[-P9XVXH4>H-4WVT2A5YF1I:7H>M<+KEO0ZB*V\SX)K"
MLTO;LH\I<LN+9;7H8# [_MA]VGP8[?B]D;\8?4VL68%*+P]][3.ZW$XL3+M<
M7Y/;\\Q"N69K5.O)"?<IU]F7D^?D?T)GE2@/H>N%C'#,X,T=G?5!AN5D.W60
MK$6*Q9(/XUI5Q>-#Z]Z]7*S]]J::E!VS%"YCR@79:!==L94Y,*QE!1Q;9HK,
M[<Q;C"PU@W6I8>XU/1M_75N.8"XG36O8M][_5I<[X8AEZ+?W33G8/O&??W)V
MD<#A7PO3-P27?!<W"G9N[<KL@KXJQ582*.FT1]>H2NVX!/NP^$;+]]V:[TGK
MMC?+I]_I_K2?L7MCMLS[ G<\=W&[Z_I2J4$;E.JT.:'339+6!(%V/;PS-]*T
MT[ZKFB>NBA$1R6.3L7]MXOTM.;,-L?&V&^_<K8_1H$?Q?MM%"\CD/(D1M#3C
M$AO2>@9;_HMQ1"FLS4KD(J9[3VLF8E_O*D'Y,(_''0,QI4*M-J8Z=3>&P!1^
MPN*=#SV2\B+,@M9NVM''E\#S?$Z/:)4KN9U8B+SV5J\SZ+AIS0 L]XGMY.<?
M@>@7:Q^1&[9&:V"Z^8F.^&ZT#]2EB[8N /SGO-#N-#7Z8 M+QLSA[IBX[3 E
M)'D!O32MMD]/0O;PMV9U\)TLUA<"U2)2O!7+A9%%7_BFBK8CIPFL9)TB8IU7
M<S)'WT1I1>FA/]])=\LX'Q,_@U!*S]!89D/POMAV:U"3)\%#\%%OA:,7B5\5
MACD)1"G"&P1YMT)&C8JSK<OZ)CRY?DL60>/6M08!$&AT=C655S9Z8;B[/GC&
MN(U+;1UL<3OL%A!IHE7QDS#U9/>Z>!B1%.&-L92IGH4!:G'KA33C>:LX)L<K
M].WA4)@PZNUZS_MW]R-7B0.J+=</\ =\C7_[/.GC=I!Z1=W6.*_1I6TDBY\E
M 9H%IH]6DR:6XFLC-H2F0Q-%[0$L+E6 -[@P _4=^OXX,7 K[Y_PQQ"S?N#W
M( "S:K/&00UI?'C@&T\]8J(^1 7<R[/@V#:W98HXL'JO85=(':&DF&0GJ1(3
M(FE;2V?G6:\5\0-A;0[Q>J?<1,0VSU_$V@3ROSO0[31!N@$-D4B8+8$*8G0=
M'+V*9C?Y &$VI-WV<4_ W'9IP<MWY]/7E5V)%\T#SJW[=KP&IV^/OF0U3J+W
M4SF=4%8,W_G-M-!-8<#C7*3.!+FZ^:5"]&V=)\\6( =[$V<#HWQ_J266AO7T
M#(\RD=M/>NN^7RDD+?MB3-NPHJ!Q.)D3S4 WXSBJVZ;YZQTJK@6^9^V^3O)S
M?W<=*_I+R+A_U3DA8>7(CBSE\\D/K$2W"T",ZP"\)A-X,1VL_;ESXJU(";1
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MY&[-XV_-XW#+XF[-Y&K-YG#,Y6_,XV[+XV[,Y&[,Y6[,XV_/Y
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MJAL>5:*/XCYZ*IXCZ@L#= 4_D9^.D9]=$IZ>(Z'&="O=\Z!EJJ4FDJ2YH:*
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MS_M#,:S0B<V<!U/>&PP:-+70V]RQT<\>)">HD08/(@SBW8-#M)9B_JC?? )
M;6><OCLY^*'QMIN%6Y1S,W=6AE4_WC"+3L!',CYY\!04<]4L#4=M50KKDRJ%
MO5I\QX5UJ8VE'VM<Y:_U27;SKV_>#E:!&L2O4R^NX?5AF&MI\ VB* ) K$L
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MBPF 0S^B?;D*AX.O%J2:J@SJ-'AHN>&[GA( Y)#KWBYJ2FTK,PJ+'T*,]1"
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MS!A"Q?9MR6J  '0U?V]D&&R&1(X2@(]7P*T3"-OU ^WQ/@Q3Y+IU%$P7Y&?
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MR[T"Q,2)"$O3SVOSQ!6R"8TGX]V;9*T#IY/;)3=X+"C1.7Y&5TT,C(SXBRJ
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M[-]D@$UDUS(A.K70\7B(,P(S$P+=:5_X]A%FN"@!&/@V0'T^=@+_S!!_?HL
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M\4H^]@SJ4&3=*9U7CH?:"]8%IE"84XZWD9/)1?X>8O.!+["/'CCW#QNR6A,
M30S+ Z]73>0=1KXT;#G);41;9;)W#:A2\[7NSUMUE&0:YI]C2C'.7U[#=R*I
M3/".O\Z";^P?)2>PX?V%^ +;@^YK= /QE&]HR@X)+N<B:<@8 ?@[.9Z8[K<$
M20@:-G@=\9<3I#^[E7^GT/ O8PA_I"G"2\?A;?\T14#N;THK F"Z\%_C*'_=
M*_Q;!_A_ Y[G)0&)14!>7RJJSYW+DD%_*2ML1_*W-1K=],^I.^/S6(8'..(F
M#71.0F*1D-<\19_RG$*DT5\3"QNK/E6@>LQOVJ\]BISVI1$[)!\7;C)CLL3S
M('ZPK&ZNN6RHKE]=OO\*W6NKF'6UY=$\V""JF=3* W=+5(;MNO/J8A;PI=K8
M %(2#+^_[/EFUDBQ>#."_05,[]A6/,80\277[P)BV&=_4?3_P6X'HR44%__-
ML*R^+>\KU%.'-_X#LT+<A<[F\4,$X.\H5NN+#'[VEYC[_N_1^!O6[GUVO]W,
MNKAVW&G_P==/O*7^7E;UZVT8,),H_S]%@7\E@,;^QTK;?_8Q"-#'<!. !%SM
M7V5/4)8=T<U?D]M_^>VX_^6YS!AR4'Q"RQS1\ $=?P6"R?HF\5PE\C8[ _IK
MF$.I8^VISUZ?CJ(?#SE*596?=Y7Q%GK$;4OUMH#;/.-&L  Z%/[1N=2P<+R,
M&UHJVHQHJ,7@2MXFXD'-D%V-NQ1Y)[,Y?H=,.\,;YW2'/J4A9KY+W_5^_TJC
MG9'HX4)%HZ_%2,NR9;9]\F,2KH9KWE]#X?^ R0_\R.27O]WC6)]ZFRI;_[=T
MF/;;756$<_S?H^%_9-%=0W_'W?_I+LW_KGCS=WRB@'QTOYPXN*FU]KWBSSGQ
MRE_1(7F2BK0<T>[^W7%WW#>? OO;^=2?=W38_Z8=_=]B3.T1:OEORPZ5;_7M
MMW=U@#+(\TQ"(*.++^&WO4K45)[1N'A3:[7,W&0K8*M2SREH2-!56$1'?91+
MC),Z.9QK&D,_O-H>(K""&CC*!.\_-H5H/3EK]I7</;=!569JHU3>V(!&4C'$
M[B7<?R2LK<BRJ-JCY,%>?#EB(EN1*69V4C<\C8)U$=2=Y^ _4-Z8YP?\6EY]
MS5-@01583.Y-^_G&J>L6F1SV^L05->,/PW\K-@C?(P!+^VHD "83OWK&OY6,
M_$:C_W?$E_\:ER< /1@$*$'</R>!UKYG^K]%EO[=W;OKT/ZO@,?6?Q/!Y#EL
M/W6X5*B2-U<K@_Y:4O AF2DSLIAT7>.&QN"MF3B )W001?/ZY_D$SBYQ_H2L
M] T]3RHM]9;5.FSK1)RJ&M2LJ5:;58''2'-+ZA&RI\2,<4<*9F%E/D :*5"_
M]?AQA';U8,$5<^L8ZZSI+]$[QSYY+B\':S$@BEUS0P+!J9O >H-$"$ U$C]H
M,G=A;&%H'IY% -!&[9M(&MA7'@+P(G5I!KER49YU%M>F5D?;FY3Z\K/)_)%A
M[!/>Q]%*_(6V=:09##?$_$B1'0;M[YG/,A:TTKBIZ8S%.OI)-?I>$UN-C)A8
M9+&\N6U:&Z5[\U)_N$EJ@Y!;SI1@'$7 ;I(KYC3LG?80YRI%^#U1TH:^;66;
M-C<=P=UQGPW)#Y<9-,,TLRO;!IEEJU-&I*NLIL_)LM^?S:(]%=#<M#(0U8P
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M$@ G+=>(L[Y]*P^U2AQ\A-WELJ\N5<<-O_*/?G0>(K.:HD"4A^^'DW@)#Q"
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MYY.=ZH33-'^G:<@O-^4-?U%*(RNE,2VHVG\2_:C*T-P5$GN#('DD@0286]>
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M5.\')4$$U'!?.FU^QMR$_2)D$\BPWZ\P:M?IUC1S7#&1P7,>_N@NZ6BP\:\
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M9MI $%7@V^PUJ"'G+6F 4+(YB\_.EWW?Q?<__:%$@CK'5GDWP_$ #G(4#(<
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M:K8L$[W?PP.:CL18HL-=1'WDGAW-L$2=T VGOY)ECC<Z#E^./$TBZXFA6 )
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M[P8X"T9]EL3&VD&0*=^BYQ6/,[YK+,+[:[07YMKQHX[ZJT<_/HFY\-U\_C@
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MV> %%Q($C@=1@/O@8?2$\O'Z7=<&?3D:M%),6A?Z00'$2 D[-V:IC@;\*F0
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MVWAF2L<5+4*_X@K\K.Z5.HW.W5_2L_ WDB7RJY)A%&#5G@+@I&B^WHT> E.
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MGN ]P7N"]P3O"=X3O"?X_P'!ZDJBPVSBI0\/S3!=!ZTR>[P8%Y?0_2WRX;Q
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M(/=CQQ%;6H$8E#O3!+?6M#(-WOPF%KJ<@.UO&NE^6?YE'3D\K=._XD0<<&/
MW;O!6[1^5I==\X#6_MAC<D7^#3OP9LBP\:1/Q"ML0&XP!;"G ,.-@VC]]R4F
MY?8B*U/]8UIG1RRN6?N;Y]W(K-+0;-)<.>=:0,@&=E*G^9=5)Q'!Z<>QY ]Y
M5I (&YQ:L[@O_"JVI'!CL]K6YM!@!)MP5(GFU[<*NNO7M;78[D%H*,"]'@98
MX*"BVM2HDJP5UB5Z_3@BS]>@E05R:V"03LWSQ9UC7Z.? SW"%T*#0.PN''B?
M(GOD<8C32MA6BDY0*384U< FC3[J(-G 412W&86?1C,(FCJ-C=X/[>2YX>TL
M*/0:/[8;HUUIO-3B81=EWGVGOWDG,%,D_]"6=YPI7V^#), 0QY?[T= ZU%V3
M_24]F [N4GR0Z#E0J^0R!:$E7JGNWW#0>;/3AW?*Z2_+7X6[>2B*8F1X.Q22
MW4^ER\0ES(\>:",RJ4[=<TP9206Q3. Y-6H#E*GN_MG8X*$ZKDB5 D+%^\<O
M/LWY3NOS*HQH#FMI&"D;$LXO8Y%$QG#3P3)3UJN#/Q2E,3%ZRX-RP0O:68XM
MV@_//)DSU)Q2V6X_\7*_$_-Z[E+35 #C_*8VWC*S*].A.'LA\-@[5C.'2J.*
M*H+:*Z56_&CXFI46ATY]LJBV3;J*(NVF!'YJ2FQXGGRX=!+.[EN'6_8<A2X?
MPE1&.+]'O9>/&=5P<GZ^/7/_N%S]D=G.UQ(\G['AFZW8GI;B"$;\L<6F"1&\
MUS1=*2$@/6JZ6XAP85X_Q#.RVYFVPGO;!GF=*^\V5ZCR4?PULMP F8G<-"(6
M;-,[-W3W RXLPRD;_RY7_DJET19CK<?')S&M)G%S]FD,!6]/14^2F'&T]= R
M4&3@*>+IP<"S^/#)W$?"ZV!V4SU;^"LH='C!9Y^Z#5*G(LE+Z/3[*%?Q?8KC
MD9RA+T%J>%5"H*_DM'=NQJ4IO0-$U?2F&VG#8XZ.4SE(G;XB=Y7*ZG36)Z=O
MSU08N!](D;D+1;H,L)0<EJQ\<A#T\5A_&O-T;PB4ZG$UB'IRZ@AM"F$9-KV]
M-U<7&._)LL:K.9^)]SM Q#WF.[6O9S9+NRK>NSG(]:!R6=B%-\VO8[O*/,'0
MP:"S?W>3[9.TZVP<@-EYV2,7!&CLL]HSSSRT,#M_0:#]I:@(TW,FF^NL+)'7
M(B\(T$>IG5-C9SK0\BKA3'3D/LQGK3AU-1JW7TH$597IV]R(4]DK^']1\&!T
MOTT<[^6/KID)#=(/,3U<]NF@\E@GJ^5;IB9OM-[6R-$J H?;4)?B>LZ4%.@S
M6??<&*:-O[K\@NY9AO;)(/GYR.OUTUPA5AJ@Y=-3X>]C>5WRK[!O;A<PV*IL
MM"XW^].DK(N!\*5:..EG=?UB:DM<1>OZ1^(^L;L]\?TAE !"--V!B@@^KNMX
MQ:O/Z!WUOE)-VH;!]?R7;QS_KLM)CM[3PV53*8=NNO)G'_(#!?C9C(;FW(*/
M9WQ#M+FA5Z253&ZH,8^YAOZ3$,"W=U\>^,RDUPJ!Q1FR_KH/I2^TBB8?]J#"
MH2V&?RUUHP#91HD[<5#D/'C%Y3,X9P;\0_M+&K*EF!;Y&$T/@T[B_$A("G#X
M8)Q/=D!IUYHB0IDUZN/H>Q\G=)J-';?C')J>W DODWU(E,ST]5 EY1MUJ?4)
M3[TMJ82 /+<5GYV^Q.60E.QQ_'6(L-9DVM!0]CO$ SLD#Z:F[I;W\DH*#I2I
M[%A+BER/$CM 5,)N1F'H%UWPZHI>+M.IR\:&80JC)/=9OB0MHSDO\1_Q>E(:
M\Q=*G2+%&X**]U7BCV)<(I&5%*!MA=$7C#'<:A)C];4FG_AV>N#TVZ@;P7.#
M\UK[?/DKXA)M%"8K;84U]9^/F/#R?WN4(#K8UAT=TK DQ]R)=YQ*#JL5FNYA
MQJ.N]9-[,!#FL\C-#Y/IQJQW!B69P+P25[Y&:_SXXE$CDA"BP@,GR).[N[%J
MBH8%B^EG:W$K")BE;[+R&9QHQO%'5H>:A$^T.;,G"4QK>!TYW(HY>,(Z1M&9
M0#Z\AHD"@Q;AH%I^',H"BVK0,=O(36XXG]/FY7&@K CAX7 L4SA,,]-[8M^2
M;5/ELU+6A(\$W;AG AW?57C 6.CFK?Y .J(F;BNB3('JY;PC:CAF#)O8H^QL
MR5U1UTIEXHK3^TIU/AQ2#*W?SS@:9?SL&_*M5>F4[P;HP#<*P.K5)?90=BC>
M4@^+<])(Z6TWG"W1N=;N?*8B7BV@,X@EUI0Y2J$V=[&W/HTV(?HS7Q3'+$I%
M"Q(*P'(S IO<\? IO29P^.:$I/%G,@]^58S5P8?10<&9OSS2;UY;;MANI,_E
M?8+DZY>G!%;#^4C7[GC;\N<JR9T">_13@$+]M@L=6[H/8M.?8MR&(H'ME<TG
MI!1%+5Q!&_08$3H%!1<W?8 WP$>..GE7<\GGICEC8L^+E[2_%H_H6CM/&&8[
M=:(-WL2,;\*P1BO*Y<%<\2@W7$B3%3ANY7ZMZ 1W>5_AN5J^^TFS=]Q+'UG6
MJ]?3QA_^VJ<A-OBZH30:MR"A*GXCH7[C)8@/3 LF<_C"H$XW9(H?P:>8.<Z8
MV?&AZ2O>KT6'<!%K9+S':R BOF'O";2^U8Y@)E]($Y)+6N\PD1MW+%MZMN?A
M&RGM@,'!M?9B#SL'7S;ILF.JH3&\$J_;#?LLWB<L%:(EP(BK]^.%!4UC ?;O
M"?4]5X'MM6G^I:A<H@JVI^D;#%R\ #X*T\8NJ:>?&)+J'N+7K5R=#C-WX(U7
M$>7U?:5V^E/@C23;"WSQ1#K2,R]D..2XXB4<*X:NF7/E,=6S+#>_N/YT,+M4
M1WFB1^]R\:9O(:\U1U*<3Q+X^NMN(>V5Q3/O3NNZM7&?]U#AT29<(!ZF &&>
M>/ 4*ES#$'HB!KPLX'6NE*7N@8Z7,%[B,-?1.C=HK4>P/Z96%_25UKS/L]"G
M7IZU%<GH"Y^T*E9<[9IT5+B871/&'N3@='L@QR[^HIE%_$/Q=@NYN_$:+N^,
MU.ZHR%& #<P+%;"@ ^IMX5-("32,S#".+]DB&#>QQM\;$8OV_)K2ZF]YQ:);
MD?4,4V)I:8^-(%18^58[P9(?2[?D4MB-<]3"1^&0&)VA5B=X$VX_=HQ5_HJ\
M95C">?<>=Y$I=X1L%\]0O>!-B3&C<U$+5P5H.U"VZ(>%A(NPD]BA)O1R0O%1
M9F<#@NI2\(#.W+C.1>7K/J,(6;#O/+MB&LCT'ZR8J!/SRPICUUMO,6UR"UJE
MA*M&#BA+^2IH#X@*__ R8.ZNC6&*VG2('30(OG"2.T 0A+<B'Z( +S]3@'HM
M"H"/W$:V/5.^.%1G2P$0! 0&C.;?B6S\;7<A2J2XY>*"H9W.91G=D5RR792B
MDWU']LE%Z,],(%/^>%YRB 8%H*&:.!BAF3>_VZ7XE@*82Z [P.\IP'/D4 %<
M4+F<ZK"L3")VCH*)^ZDC<D0FF145#/DF!<<RPLEGZJ[^;E>FP%^*/PMX4+F:
M^9\&@-@HY2;&$9#;X7O2]Z3O2?_?)STS*&O^E+NF7/V&<G!9&9IA8>3CO@#(
MM5I42&ZJ(^U59$JPD"9.UQH2E@;MH(Y"VNP1_E=V$+]#@?CCT$@^#F:D +VH
MUQ1@D@NYNQ\O")]*#B494P!@ABK7T64C2IH"((6H.)*W$S?>Z*V"K\$;M[ :
MI(,(\CX]"M!\@P+0HQO ZQP0_&$(=?*#2E* 1EJ,RP[K!I1(F[#[B9XJY23\
MKX0LLCA2 &5C,JW8&JCP#OS)CO7_!<[?<?@)ICT%,"F%;J^BL.SP9P&.)XGA
M_6#L!^()"G IDP($44'@F'Z/VO@C!?@CDT=TS>AUL044GHY_=_?B3DL*!>A)
MI'+H(C8MFB!GE)_]XVZV^P,+XBGE<Q0@ VY(K8L<!)\"&10>(L.*B0>A<V"S
M9@IP>KV-* ;?#^^E2I_DHP!$M9^!,Z]!_L!DB@8G2Z+?*2;3=.SNPR2_NXM:
MFX5/7J  XCN#_-N@G)_41^ GV,7/*<!//"C (=!CU#?H%SCVF![Y'.*O^SU\
M\!VD/4#BIX[6^ DXK.=G'G@5F X%N$PNH%;%'8Z3@K\Q+29N0_$,J(_*Y8_)
MJM__T-,_J_T<_ \\?M(MTIUN^'PGM;PM^?:>>NZIYYYZ[JGGGGKNJ>>>>OZG
MU)/? S?:H$,ON$#HF"PPZPZ&K$1N)[?PG*O#A;T3S<WK[!MKU[S9T['OX"D^
MZY*XD 4]*S]))(WOTWUZX1LJ0(\,5;FD(WJKM6<3G;8;;GP"68!58R>F!VN%
M^R7;K//S,,;"L 0-GG,?'%K.%QRJ80[11)R;4&^DH1LP-L:VM6P%,N#X)%L\
M*P83.@M@+T]R19C<O2R_0ANKI.-N:?&2X=,Q&<%X=*)YW_ISZ>ZK_7H12)D%
ME4BF5;_%]:UB3CK]<D&LY_CS;JU.YI-1RG.A45/5-I[D<NE+SKFSTS3J=!_T
MH+V>HT_/H*T7&R,%"O\M@1V.^O 8(2J)0[A1+F+;\F@>.,J: F2Q?)ED7J$
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M QQ*85*<<7YT"A%=)Z*]6_7,-CZ4.6T6\](U/1/F5M.7=?*1"&-)._OQ2?M
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M^\ULZYY!8=[(6Q%L"827#X?8B\M@C('<Y&$(7=UGCY=-'Y([D>*'9L(L/,(
M&R]%&^.9^Y)B3UY2  ]P!//.KD/6X8X^Z"6F5P%7M:IP",T-S^9X:OE\=I;M
M==7KDFSI7GR!'BFUG!UB_YS,KJCPS*I4'?;C0-)4=-ITNM+BNBQ&#=V$_CH_
MQ<!:[1.^=.M^E+G$)OS_L/<>4$U&V[IHD"928J&W@%0%07HG(E(4 07I)2I=
MFH)*"P1$>A-0NJ 4Z2+2:Z@)'>E2!))0I"?40$+R<.]WSSA[W_/>???L<\<^
M]]V3,6;&^$?^->=:\__7FO.;67,NJ7GWV*Y4OAR4VG.Q4*L 5S!>-*OOJ=:-
M7%93P7,0J#40>L7ZB,C"(I'9K@ZD:YZNV;:_+DWIEERQXAHUO&%2-)H,+=LI
MU']2;%*2VY#K6YY 9-9#]I:H(0I<"ZU=9OMK<GYB>@RT*2B_BNT J?%.?R"#
M0B<CF^U$,W]A->?'? 6))*M<]97[.1]O^E<N9A!=&H525M3R/"^4)PZY'D(.
M-1)AJ*QF!B!U=;TNAI1>@8]>D,LSI&=>^Z7RLU.HVY!-J:38#6I,D">"L*F1
M9(";)PCO:CQZM7ED/W6<N@">SJ=;:X.(/O]KN$\_4(OP *KU ^X IW#Q\:=]
M^W),;N)'581[L^_]O%9,8I)7*-S_S(1/&R^=-K?>H&R77H><6/&\@F$?N=5U
M0ABH39\V-GIT9(.]U;SKE=!/+B2]=N$T3@YGS<>PO%Q8\46&PA9S>>5J<&I-
MOAE<*CM,S2%"=>&C<O9&.F+!2CQ@SI,\#*0-1@WUQUMF2_UX6:JG9E.>-^Y6
M@8KH]2J-F%E\)0B[3LQ.7JWQ0CZE?FKX8C?KQ4%W4#>I][M,T #IDL)R)"MC
M(E^[*"5%.QE@3VFC%,^JJ, QYFF<(]JEQS9\8<0 24W@)(UD(+L_6EE@#XN_
M6,[,_4YI9ZC%T&CR]D1GG209$FE2#SM/2VH,@WF%?[PD,$K,'(IMF*;/./0#
M0"X $A6)917\C5Y+!)D3X\A'I7VXYZ@BVO  ? $#6RSFAM[".@/(@![UAV.Q
MQ_EDP%6QZ#C%1P@O@=;6JP6J# 7V-4K /X !B)2,;20UE5K-(LOT[:B47WU#
M&<GZWFFZRVYJ/R_S+G##^["B<62VS3]LU_Q8?BH9(1MCT>LW^J!_1<JQGUIP
MX*<@DPZ/V!*/^G: :Y%3;4-2G[U*BOG/4F!_1F6I:^.7&D')HG4VMNA/P54]
M5DY?U&OV=\ZCC'_]/#9)NS:ZE/7JFM(3#D:^]QYMCZ5BKR W'AIGQ0.4V&EQ
M:BXUOQ&J)<CH,_M@(2Z:&TWUQU $1OR;P8Y^&%YHF)C%U$(&/!U$DCY8FJUK
M!<&R8"WP.T&9[V -DJ;,QA9O8I.C6;7L@KT1OOL5%T^DQO_% .F:,S@&LT:[
M).H(GBINW/[V])9J:.@MIMR, 3:.8=7G=%L96HD6WY@,1X-!6G+VIHN\+N-G
MCH; 32U!+*TLH-J8H:20^EN@2DYA^?5_:1O]K*>\3?4'95%NNF ,+_VW![H/
M#(M_BU+L&ZLN#=&U(YYK X_1'\RE^'@UVC_1/M22&3)0]VCY\_N?S 6^'&SA
MOQ&+$N)@!E0;>3!GA@&4H_4[8J,!?TU<H_Y+;ML_^4+6XZQS9Z/#9 /Y#F5C
ME)4 "H.GH^?!'P!WM?@>+Y!*+/_Y=2C^DVQY\'MLU 0,E1# URP>VH61)NJ4
MR(#:X"D.XYDY/1=9;PT!35DW'L&X= M=):J+.G)QNGMC6::;:WE@Q_$<[829
MBH29^8^@=D.N6U.'_;(S-GTZ7/<^)3T*5CY)/)Y"IU[X*4[1?ZD'.2]7'(!V
M]S;:8R78CG_%U+N75<WUD &^\4I/I=Z)Y>(]L=E':*CE?FVJZ8E#>*BSQX[$
M=N3/J/#':G?YN;[X_SGW5U$A.+9 I&'+D7TU;3SA^HCU\LM?1NY<QG7P.J'E
MFA?2QTZJQ3U+ 6BX-5$%,TQ+FH!32U;7MM:&U03 A-<'16ATS3]VO5-"K" "
M6S\<VZ$JPOP3HFI YV<M!^T\LJ\VWIR!%2"6SZMX_2ZS\#(/7%2> %]QR9CJ
M@',]FZ'RKW(Y>JV@/7-7=IJ7VH>65OP\1KT0]$'<@#=;)O7#=.Y-Q>@TP3&S
MV(1BN0J\<'93P3K#J.^.=N5(X@ON,0^S.$K*-U;QH>6!3@0)6Z@J'K88 &?P
M=874-D?H-YQ;QZU2.*2=HNFVNH/TUWEE<<+EE+/S^ BC^BC$A;D%W9'$WO7!
MNMR<GDGWKZ5J5>]KQH7?*/!MUWHU(57=>?R0ZO,'P^*,T#O<U\<;=0*Y^U)X
MH>/%.9YXI,79DX^(]/4GSL^>AMFR*/ ^>T]UV5 )>>_(<+:T:T:BDJ"RGG)H
MV1(W3GIVB5OA?->BO"\-7(RIP.=&6\Z61.H]Z='[QP(_MD] EEJ-F0\N6<1,
M.UAP]6NYQ'/TKM]5I R=++%X^AZE0A1^.)!3]5$=$OG&D6&DP93Z?9&)D3]F
M%'X/OIA!XAO=SPD]>:N0$59>5AX8EWROR)=633_(!Y_7<=1Z<>(R8OWPU_)5
M)2)!)7)5-X3C@J7\D^2UK"FM(BAX<A\4QND3ES?^53NG9*'7,>6U0Q5S?Z]@
M/+"O?+1)JOZ5;:J(%#)U,INIHOK>ZFA.]6JW<Q!7T,P,).[&O6?RK!<[[ FJ
M(>U4CU=I%1&PZR=UZ)U0*#\! N6M&2N7BP2F]<.<9"_O)K$\U@SIH?1;#)F!
M\SO5NQ9;.C9F!$0!^V4KFKPH?IPIT59,1P>G_3E7,C5O(S5#Q_AZN^_(&XW5
ML,<ZNU^5&UY]INNP[-J_YEARN9CS76/B0109\.;5,*HI/ >AKC(BN\4$?@]/
M>[A$F<5PX$:YTQTX@G7MSJ8?"^)VS@B**IG6S/]I5?Y>VRJ,FOCMDI72-DV@
M*Z[0%.=842I*"*HKMBUNIW_AM7?M:&;SUF(V#-%8\99$.]DJ!'DV8QI5T5*S
MDOGLZ(=Y4^)A<)AFR:$(PYFUKNQ:/G#54DZ&&V$;/HBK! UEDP$K@0X$T3F=
M5P1?J'%]^)V,>:?Q#"6!QWT_6R(/3Z9^P&K!85 NG$)'(R2LV:1<YY/>JQ>K
M:U,R,E?3.QJ+!)G2?# SK=IG W./TMFB+J++W5T-9%TN7!49N-)&I[ZT32P=
MAR\65R;@M50O/W+4&@=HMG7Z>3U>K9NL+]')X3@O\EVG(*R<):18"?EZB+(3
MCM6WL7LX[C[[$!>?[)-W?2L@YK(>^^YYHB_+@0AB)V:>Y32;=+XUP:7(LF:K
MY8W%K*5X2 $'E]ZB4ZWK[LI4%Z]4%18_OCA1T^1^6=O5L%9H+K%[)?[>N?.K
MH5OM7UT?C%>\*D[1F^TOUT"O">TG"#CQ]-HA9 ;]C=K&NTP,"NZ,JO:L7,R[
M6R([D[P>>(;AJ%#XL$+G!595?=?R7YHNWN56,EHO9(/IS)O=O_&F"Y[-I."I
MQJ 94!4HDJ3V3%FB"E5N.S3WLVUR127"IEZ<SBUYZV1JM;8&.V7Z0YT=#T-S
M07)=_#]@+"V%LC(%HQWV%+S80<?V&&+T I8I%$,&1+^V%7271"C'M7R->.JQ
M?;6I)?-%K/0;J7I,$;%4N5YD*[#FFL7F?:F%^D.33]/]1'TLSTXGA.N9+2^\
M.?1!<\UL8X C-8V. !^Z0=[NQWBJF;M0>Y+%_-T5I=2!IP.#=7Q+?T[BLVQA
MB@A\D3N_CK/4E\^T7T]5>%AL'Y7^INBILOWW!$1KM$RSR?3>*P$_0M% _IR:
MBV,B&Z!VK(G6AWV1UWNL:,-(W-E8:9B@UT/<T)?7-GUO6A0?;8A67-/3R+P@
MFAOR#Z5-IW;#N6$=E7@K-!G ?AI*,"9=^L6[9T:XE-E[Y32;-M7QM+SN]8#'
MS,^AY\_ ;TFR9$!8.G:AG23K"MKL1#.R#AM;@67UE^@CC2"2 S/T[G,TFQ*^
MBV8*!'-8;SGTS!!6*EB<F3Z.XISO9W ]U@:O[%V=0/M[#C/9=XD8YQLQDETD
MHOU TTG@.5*$M@#D'),S+XIY[8T #^^Q[.9L72K!UZ&12$\Z(BW6)[H&1&%1
M^T$D%FK\=>V[K/+;6KJ7[[I=[!2A2+'!^MZ&1]?3L.:>47OJH/:ST4Q''&9@
M5SO5(&A@9)  _@KZ1MS^"34RJE!AIO9#T<_.*W/B4Y+![MFJW[>X%34J@_R$
M "=DP)!^4]3U>L$4JL= Z_T"BP^ISP5CG=B5B(U3RZOMGA>(CW'(35XR@,.3
MI.H[.M;%RQ%A,M6LY.X)_3YC;36C:X,>-T%?_L66-/D2HNQT)_X.Q>N=N!8,
MV@<Q#(+>QUMA@>VMER;=B3QG+U_LB=>O.7ST_+RAR/WJ& .KS#TWALQ)J&X,
MJW<B7/(*U3M X'N1V#<^T$_VE6L)UB?&$NGWA;@4GYO!"Z! )^P1VFSSE/ "
MRHJM7F C6F @$;S"RA,3*1_1:@9Z,=7U$?H#:UZ+%*H:S:F1.?5ZP3%[JG#?
M0;=8^BT5K-UQ90/"WXEO#^D/.$8B%FKE,Q?)@!F[^WC31N",;$+=6J-Z,=JD
MV1=>]<KF-E?4IMM@8X>EIQR?X3R_U!?<BO3BU.AS>&KP@R)*\9\"@IBL0.^<
M^V8K5Z%"GG$YE14(,B#^Y-7^8:LH#AB]3?1#M3S;,6Z()QA\&UU)47$V1]Q#
MRC[X^IE;0Z$D*I<KO&N7E(,?).B< <3#)V>S%G)^U@H/0\*85T=D ZD6@D@+
M]YO'\\SV1 )+=*.E)-BU%Y21:=-Z-P"!2B]___B@I,0Q(UVF4ZLT/-HL>??T
MTP$L4IT17UJ$IT6=(J-?P:GP7SPO6#D;K_\P;\V[45][97!5_C?J@L/[HN,H
M\XA?3J+-=9V&;W(NJ5,2/4?8[N%28X.$H3>G9#<B7^5AU%Z+I;\4Z[G7Z^[-
M]4TG28FY6OW1P_B[?CQO$&SH61C5.AE 2P8X@F8*$3,*71!>C=+?0:K-V'TJ
MU_@2_(3L@C1)/SI_OJ<)[1<*[=ELNI?U#CCY.TCGM:![+Y=Q3EJV%RVJ]_3Z
MZW2V4KLLH/=OM8VS%V/F\ C-L%"]L-F/2J# #QVU)VW4^?=,V%>G^7G/M%,W
M)VU'ZRY'NY@"J\\W__XI'E^XO!R"E0>Q$%E/O]:0 :%L0> IU8#%_AU:'8R>
M7@7[G-QVL9WT+QU'[&GI\P6N#T[7'UPGAMQ2M].E.#B:L4-X&6IT)(^3 3D%
M0-$A9D^'7K$L[L>'.\,L6(40* \.<HC$(NIPG9T+[ ?#Y]0_!][$!Z):Y#4]
MOW0[N;RZ+GE8!FJVR$_'!!)UBS\BA_3?B52=+49*1(MRW]E#)2Q-%?J&U8/)
M@\R0(K^CF8]SJ3)]; _JM7X)) V&F3Q,;K-FDKK%4]<E&3OJRX8I[(!%Z.5R
M+> -X#6OG]%#?\1<LO.HVKMX&^3KWJ)C$"@VR1_8S'R=C3\M]AR2ZIW*@2J!
M\]CU,#IA\+0>;K_<)L(K/F-H=YK."URUYJEXV\I']#JM)@.</<\>4L=/G,];
M$LCYT)\]  Q\=IN^*:"X_$DV\+LN[NY2%[0I63+%3L*"8IZNC78*S-*LA08Q
MX8'&XZH"*##> 'J7\DYM!MUX[IA^IVQ)6="(Z/7,!U5+H1_3N#/6RG]!D>Y]
MVC(URKN&BCQ>@%5X3=!S?!5ZJNL&F$2WAIN<) ,0J4=!U_'>&$G\[2U5JV>[
MY@O6&NY%YGP9.G?IZ3@<7SDQ-J1R]=>N>MJ<?B6)&Y9!GV*=VM-(PIU85^W&
ML>$HHA[:[^#\_FQ_C$G]):NU0S9]4?KGVU^M+]Z,CFMH\\VBW$RHUOFA*,)5
MORHP.T4&?+U6P9=(<;]RG_OF4?M^Q7 %!>G'#'BS'Q>^<RL!8X-$PL,M)T.*
M75/<7A6]:O'1;A[;8EWQ7<G2S>O-9E_:G0JV?]#$=KE7N"(BB(?X$N?4":8)
M^L%IEM"LCS:,],^?#+J:B1H,K^#FY6P=W68'?NMDZ"E]MN%TW=',)4W5H!,:
M^Q6@GH,[0F1Z4A$A> CVH'HCLUP3J:"<-#M'=^?FK([#L[%^@6R+Z824DD_N
M_#^3;E+ZVRM<*%$W9:>JZ_-NHDCH4]D-W$#MS%Y!\>-C" Y!0RFKB&PQ[,RS
MR<;3M$;L=M%D7.%I]M3@WHU,ETO](FEV'X8E8CC) $87HBZVMA -Y_5--L%/
MX8:M3G.JSQ]8N$'9/CL'28Q5P^K,.[FO6DW5(].?"R5?%C<B_O!X["7X"1AT
M6M2JI$E0)]+C0%TLHVQ="]-7)U(-K-K=5XZGI&Z=3[7;0J;7/[FK\EQ-YXNL
M5?RN_%9@GSRP)3GYC9K*P<88?'DABG33%<(&7DR!<%J9X6[BTK"K47P_7I(!
MS#5E*5.<->_99KRM?AE\EX))I1B4A_-)G ZW#%=!M?$@7 Z*K6.Z]2:LXP!'
MTW3F ]:6E[OZW]@/@XK!W#TIY;KS31_J\+8O(<-2 3T;]9'IG5T4^SEMD/@8
M7*YAI*UCQ.G;^2NXUP6H6X.OG0B/JZ]EQC^4IY$&O?.8K=OAGBKE^/%*<=M7
M-3!0#)7PTQ!C&@-J@\V T,.)?J?!JH%HT)73U+Y8&RY(E8;7(PIAQ'N$+H'@
M\YS+@]'/,^) KR(:PF3856YW.#A&%,+!S"^Y^IN%EQ&MW#U1O_AKD4(M8=TQ
M#4]-M'OUF-B):^I(&4#01\%>@<<*ZA_ID"^V#"N$3U.";O[97HR_M#@,RGSU
MO7YB4\K/+9$=HU=D[RRRV^[3%>1FY-8K;NSH1V56]N-?HARZ RQWU:B98V?-
MU)PI."J12B?&/H2<OGI@-(@9A((?.A'UR(#JH)^.?<=?U)KN+2Z)O?9(^WJ%
MQ'GF4/ZV .&Y%XC/FJT-O(,['AV:E%C:)NSKR-W7XO1,\32>KW-J(!:)EXZC
MFR^2QL[0^NTSG-&V0@9@'N5@QR^7GE-50,+V)\&$>PV@2PZOX=5$T#%'H ]P
M[NA'_W2Q3\#4X-E$JT8T"8T0>),=J&N5#003JPZH@*.?R(#P9)P"$>\"/UJ!
MD*Y_(P,L=B<*9<ZX6X!M.H_4TW[M:._X'^>0. V[%O907\B A708O@2,RB?J
MDP'JG)ZGQZEG[FG>J7,_//VT_6 3[+T6-[_O<?27O):_N^GOF4S&-AWGS(%L
M_S$Y"5MB:"W$AIJ03-L"=TR.!Z1<D32J+F1;ZZ][^/.8#/BQ!BOG\-P#UZNW
M1&P'2C;-Q\T?[(&)LCE1L-7A>V0 W N&>PGKO(M/)4'W*PA'(F0 F]ZI2[_9
M#.QY8 !P[L3.IX6K96,%AG<!7R8#AK,_D %!?[*4?O]%>9+$XS7(T;8A22+A
MH%2<Y'-$._7M=/B+0L!(T_R?+*2_O>7?X&'Y?7CUOR3]!TBR2:/HISC(-V7\
M$4HL7?$#NX"NJ+J5NA;D70KN2SJ#%0F35Z O<%52(A9Q&JKBKT<>![EF]$%-
M4CV^DNXT=T3_//D9<$D/(G V][&XBE,:V*XMZ$]BGRVO'!GP:9BDUTD&=$V!
M3WZ](5D$]A.[3S_KGJ"CCT$DMH@XV.^S*9.$_>M!O/^Z]4$3-?$[&= +&P!7
M7P-9/_P?L!\AU3V&IT".)8\C#L,$-J+%EASQRQ@3#M+T&0]G0U*_#E%2DM/M
MUVD-XL5@M1*Q=N7O)8Q KIY)V,<5GM+ =RW_*B'[# U]FB+I:9Y)&",#K&["
M>B6)J43DP4E@PM>BBD08RM]WC!0*.;X!_$NBG*0A)^R'*QD@]/FON7A6S__:
MH'-CGP"R>?@_D#!"JCWST9/^,HBIM4/U1E6[#6O#;F"D*8GZ3$/9+!Z2(NHV
MS4*5*>TJ"8%Y/#I%:Y.M4!!WL^, \+"5Z%W7$^*-?_\UH&M>?%(5XG=E?6HK
M0/#>'8VG6G=H.3ALZ1;->"5C;F['IO#(*<PC3*1P+ZH59.42HGFO3WJH'M<T
M9=KTZ21^Z<$BWF8=4-\]J35LV,I#&<;.BV"WNG@#B3/E&3VJ/1)9*M\$F7@:
MA@6*D9:H1QZWVY8HJ_>&@M['A1DM^ ;?@NPX+0OL"L/!\4^BWWYT,#6S_+D[
M>?7[,Z.4B-G6*SBABIAJ/7W+WA@K:^';]9UBE&_R S7*2[ YTSX/LM>'(2$%
M>^X"'X4B#ZG?AU.2\*#AEH":H-44=+8,_85!B^I N>O9HQ<TM)C-OCS[9_^'
M_9_A/W!F[YEH40J2H_SJ)Y6$;]RK^Q4PK'5O+@D)O^CYV4AD7,[5E<[^MB;[
MX5TD%2Q ;O'BQ_(F#J2G[<3.0M7I<DZ,^F7B [Q?0)&ERYAM[C-_:&K\18[<
MN-T20X[>ASO)OUTC..@,<AK]%:]IRYPYP%A,.Z=PA#M!9:/6](5P:;%K@:0'
M>\->1\S3\U0?Z^<"F9[INW:>T,1])7KAX[[^_H:/WKD[Q4JO)K%MP<KV(38_
M>?D;N*/%=W4V06T$YAPGHS<2=-FJ-4%]AWJA-_!E>[#5.TN!L"-A?L/1,X?>
MG7/[;!()YU2X2-OB]1"CI[7FN5#KF;Y6QQ^%A>I.D&=[+)R][J?6AP*1!57^
MKL>\+2CXFR *G [",]S_S>]*(!#?J5W?7#]Z/ZE,ZGZVZ>VE"(!?(5P)7<_C
MHX-%=E>\R;XZL:4JY8ER]^F<R6+]49LC.$Q(3VRGZMLTO'FHME&+I\=Y+: C
MMJXM-KE?[UIKY<'.IPH5Q)I1R:2-%]Y(0+N7#OHIQ+?*XKVUL+:E*$G [ZD,
M_W7EC'6SNHS,",=TU1\ET4RO'3)KGHBBE3:_OMI[<LQ]PKN!WGD3=&[D '@1
MK_( >Q2V7P&<=5%W#Z]4;_Y"LFI#*D4.Z/+XS@ %N!V;^Q$SL#?-E%@V5.!^
M$&-5,TXG]FR]V(^[K9?Y8?=VY'=FNG-+QS'#DPV>,1!.54:<ER%>]R!0P/8;
M+K)Z-UM%[(.>G[4H1>T'3%9.1T-%)(A=G&ARMI*@4L(\757M.N3+69 ?4Q64
M=OVY[2\M8T8;[70N3OP:LD [>P54JD=-DFCPP#OX-8R(.G>8J@)JF$FS6"L_
M?X UH-:]R'HUP%Z*4!B[%SV,XZL] _?J1-'P3NU:;#-G191(N!77M:7KH:ZL
M*OE/-1_['\GUV01-^9NL(@+UNJ5_)^FC!C5U]#D/$4K!]6T.5^V?9-^"$/T;
M%IB)4&RS.@4V(IPHD+?."OG)6;(N/_HL*2H4I2M4&6^ &;3''BR+J7R4ZGIR
M?/GG_I9K6] %7&TQ3J>-E?=*Y<ALA^G><,&ZZ9'AJN[3+&V$AL#6JL^3' ,9
M2^6@D$5#IKM8D=LP*A>S,3Q&-ZK&JK>@?E[F@M*3VOM.@F89^,+#).S;$=\%
M\S,514BZJ]I@1*G,]JRM:=\P:2K%Z=S_9GL0]X*@Y7*4@6P?O.5RY3P1^*4@
M;)2&/>OZI[E6,H#OU-5\I%R4L# 9SCL+I/OE%^24AQ=9M(U"^>!K2BU_-YJV
MO,KU37(7TZ^<JA@L;WY0-GIN=B FB<H74,MTM[W;X6M<+I[V,!\?$(!2VC_@
M_-BL[TV3^K+N@97!#_>4B^N#B?5U'%L9RV.'[T;D7"NB3IRB7NK?AM#A6T\/
M[K RE 8XK]S6,'VL<Y>KSM]SD^"*$B7)P#H>.@2\*/2UZY27AN@P-?AP6<NN
MG[N:=75;4(G0L&:!D O<]LHSBLU8)M6H!1S>;QPE<A&>0>]9;+OOM\C+E&B'
MHTWB+L;L ^RSO)2ZG\':[S6[?\)7=,YSU(S4$!AOH^?WI)%.+Y,NI2UQ;WED
MD=ZT"N/ 49*J6NBX@*ZKKC%^-:[37U=V[X("^UE$N-\8KIGOZF[F]P1[&#VJ
MMPN-!PH05QKY@U>*.0?W%9?3+)-S4XW7CXF00DM2A_]M:[R3X7ANIKDK!4.2
M@?JK>,_YHLL25LL"W*LBH6:M#,1+$=WSEP)ENA>8J@.O3E2KQ&2JV1%NZTJN
M/J84.,T<^O4-X(\ _EKE@29HX%O.//:."#(@+!#-J'Q<6 7G[(X[R.J[,F3F
M1LON]IE)@WU=YW.%UIF5?Y8 F-V(0<=4,&U$=+WX3:M-D+$NKF7@,S\J"<,(
M40S!8@H+93];?CPVGMLL5/:ZJZ<9H#]%5$,!IT50]9-$&7>T>3Y.MK:?ID"H
MZ^Y%!;9[]A0@P3"1"NX3=".0D:@\0N(^0X,MGI^Z996U%D)93^85Q-N;N^J\
MV.M4616IIA+Q/IBZ$,E6IM_J-#CYJ-)>SR_KN^M1ZCE7ERHSS,Q_?D^NCN"A
M+90M)SRTA/C.HB4JO//FK)!H?9:7,:(*H'U?C!1U[Z^Z#PFJ0&S1(]?^1S&'
MXYZO1WZ#F=1I\#X:>+]%KD&[SA/U^E:^L.V:<BO+25*W7+-%(D6(?D=H<&D;
M"SABIQH8 :Y:0#0QRFB,037L\C=&-"C5.I7G(K(!8=D*5(L*3D,O=FS50 A)
M6M\IE&%$\S5,BX*90BO(XFK->'74'4]Q:=U- 6B\&16HB,48-84P9,##4#OQ
M1-JR-<NR&9H6K[I+<Y:]H!E^^T1>^2$FV$3(6(MEY\1[GMF6'ZV5AA\5M2P'
MMBN(7+E6I&'_H(8SO^C\FJU8QOJU_,D:^IATT]WN@>U/?K?=NR0NGFO+XFUQ
M71[BWJ88<^HQNK_D/9N,Y*W9AM.3)/%L*-:X<MO?&;8M9 "=0:&34'5,T5"<
M4T,O5_Z#O!<7NNN'^<S"@//7%-^U'GD-SE5RD*P#7<<[$(^.QQJ6,->UK6/O
M7?-_,9_4M//2=_AY;O2UR'\P WVW8J:3I.^).=\NU,Q3)@JP3W+[ @AR;'7'
MTY(!U%=.LYO9L$!4741-!:@FNS(/[ZH_MO/8YLI#V%6TF#DZ4:&@P4A3C.&-
M!I*6>VK.C-WYD/O)T%C].>67JU.%F(?2B:)/8O<YN%>_:A )CLV:OX=C6Z6@
MM[[AC7&SJ(4M&:'RH\A69GQR>RG*1N=1Y7<'3E5C&Z'E@OV1K+Z1>];:=J(7
M[/#Y]E&S9PJ/S'#:BB*8XT40MA0U+3FHX8Y9?=V[Z)@8&9[6FJ(%#6;AH7FE
M>XJ7M%)=Y+':YR_\W@W,JERVN'->5[&3\1.&?=,+(!C$S.=L-Q#R(*77#3?U
M6>TDZ\7Q ]IV6%6Z-*R=7^Y)/7&>"6<.NN:9.C#._/@0 7ZX<1]WQ[(PN)6&
MU)O#Z_Y2;.?*&HRQ68YB2K9<7E#A7 =!)YICYU$*=7=KEV,".W]:E7;T$-Q_
M2SRRK)WDP*'JQ9Y%G-YG/U4Q"PT:X^7 PYD:L$=(R 4/FB9O5,!LSI8AQ1PD
MDUU5P_5Y% ?CM7<ZJ[=8TAF"P\2MSQGWOZ-<%3XM4I4AW(6UWPH"G*T70(?
M@#--,.5<U 1%?ZE)F9]ZT)!Z;T'V9FENSEQ8A#?W94>0Z(,$D598^VW25;U%
MPVE(M[QR8.DS93(@)AM,YV+YU')8MJYJ/OE*]^7NX?0EO\WTQ>_74774;G\V
M[S,&B1 ]\,>HA!@(,U&)#+C0-]8VZ6.J3/LF;\+]P*RAL2&V8&)SZJ$V("KW
M)J(2BGPIU'H+'' @.+E;1_'S2\=-.L;D!?X(N&?7 ]H^3B?B%=K#YV/[LU8!
M"Y3#98/<=-P988B:(K^J;UHT.N8KE[9?4W\KR1.Y4 \P&PYBQ;96G4E4L,%[
MH^(X">8XVLUEG*GD)9=YUB3:\#-X.,JZXK+U<9E/^#@IH-<D5WONFS:KS J_
MYY@Q/;$\EGIH*:ZR297@0P:H>?U$?;2;T7W-?<ZJJ&W(0$EIV!/["9BNSDWZ
M.>.T18>;O8-=[;AV@ZBUF,FCOOH0%P0/^/*KC>^U&$M<>57] V&G^8'O?*9Q
M5G;;.@]QP]T[7+]G()NK?PX*:$Y:[T0:0>\TXJ2=I^23!=0S)<H+RLPT^JAF
M^5^**G@X.#A0&V!.ND;Z!=P%Z.N)G;$,W#ZG,,,[5@_K0>)7M]JL@:EO;L)4
M [R'92GV:+=HVDAS"]^]E]PA>#U-;BP8;0'"1\>E ?'7+]\\KL3"/'LT^.&U
M&NW[B_'U&Q CN=9)*@&>_$L]ZXK#UKM [YFP.O%\Q?D&P=+'H1MCE LYE@#B
M 5Z'<-\EY]M"IXWA(B2&> -]0P]-&[8C5(NM"2O/D\)]:%E>&G91JXQ5[K"9
MBS :,F,W33%Q-IN&+Z8Y")Q&!''*<V@*%_XD=CTSLU'9!T6>F/$L_H2Y0L)X
M@1,D5AW4>1*_M>#4:TO);L(.FR87DK']!N/R1 'RHVR"QZC#NW/R79<T%U5S
M=$E#<*HMN!,L-)L;RQ*>]Z(,F=\I=K?(YGI^JMF5>WOWE[5?5Z0+N-L,F+Q^
M,Z"] M@%S5S0\IS-/#2D"+EVMC@ZHK)UB'K&=8M!];([TYMO3QO KL)/S]5C
MHXRS\PC2&HE;))9],F Z\[E@"GLG@X1,5G+/$-  CC%P?0W)4 <E]_(0KKR!
MG=X.!DN0A*'P;V3 5G%R]=DL0L,?=V&6E5,RI(&KMK.$Q[Z>G1 FL#.<ENB(
M3UXLA8&@,O4_P"C@I#XBF7%3G3=MGF[K@$[ ??/WBD[,A0;K15:_RR([<$]/
M %$/WXY]!Y7"TH:6U\S"6(:9_5-:_$K:76C"^9MJTH62V*A7S68E[E@XG#>8
M%,]M33&',)+B@U]=V.H]^W!L#R+K6@!0:I1Y,SWA(7X6@MUI6PAK9?Q!8D=^
M6E<6KL)I$:5X"OIMYBWTJ)Z[1%\6$0:K<NBY,\3VW7,44*N@(?U,G:?&@\_\
MP\6@J$^!"8?QE:1A; !>TZ2JJ:'ZVV[Z4]?98HSY^&RF>5R;L^5].CN^1C%%
MPN"3Y&?A-F5=*0YJBFI[PR+Q8(I;=6)[U]UL\HYN,2P"FZ9X0^O9U:LI<,-;
M'S"#7(L+6V($6:@&[M7XC&?H2Z7FN^Y%KK=' ]+*!>O'1E6<%_K-W'>9W1@N
M0QL,[SQ5C;B-$^D AD&X@Y1=<JII@[^JZN$D;7$VB )4VJLXP,:H:X;U6V2A
ME<NQA8!9W_$MD+A#;E2FE+36B7;MU]*PAQS4E36-H7/)PXI4&![OR0]E0YN,
M*]+3,R!GT*E'5F  ]P/:97#TP0T3V!/)F9/^+G]-O"&"$<?_*F"'OM^KRGHM
MZI7?%SV.OI!6@5I#"0<N0?-^_K;!@(3NA-E0'7P!UL<8;_,)+]+5B4F-?3FM
MJKS )%DF7-<PNM)8]]+OJU.*7&1'HJ.#EX9SGTS9/6ODD6&RP$5=VM;);>_L
M^0A/]5_75%.-CVBX=JC=[-20!L2<75'*Q8J?QHM]G009T@\8+?_DZBVH'1IX
M0:+^L%-UVFHFYC/O]D=VOJ!%#ZZ0"A6L(2)AFH""=31Y4A%OX2GSZY##C-TT
M(2\6:['Y;&:-AY^*N1\,I%[SZ-GPLE9'Z]UT_"EB%">RUM%&!JR3'G^N=Z-
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MIM_&]8H4V05V.O"%Y0P=J#Q*!ZHK?%PC);+A=2_@Y^(OH1@U($,,25Y=ZQV
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MAWE@A/$Z]@0-@2Z##_SG9:"S/I"U11J>UAYD.^\S.Z^W0LP-_06*$LB R<^
MJ;@!<Z,O]A2(B5\-(H9K0)T6X#=5<PL1Y^G +I9:^+)H%QJOLC'OR,<:C)[2
M> N.W$+A]/^ !2NXVD>&/R"?+_?)'/L+#OQ[35TZ<&S(D ZPV&U,R_2L0Y<F
MJ*/45(Z& 7+OP(^0_0XEX.&8XCK'#)PD+$UJIQ5OS+,K+D#F!>YI]PY7=+G
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MH2,(CV?S$G'_FOR1!7G6UXY:+@(EV?LG\^.D@P22^^C *6A;Q:L;7/JQLKW
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MK*HQ;6SR[+C;Y!E>3(:T19 <;Z!2%98)9P*#SB^5H4 @LY6)S> FNU<A?B2
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M3E=M_H.-SJC"W1ET9.]KG?S)EZ(VWA59RL<O=KM',,>?U^!<<F?S.A@/ 7S
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MG*$9Y7.?YKK?Z-<-M'@W52Q>?9($''NU ]X8[;*36_],9Z9VDGI^D3,K@+?
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M-2<Q)!N?[?HW8U B^BM)0.+&D0_3$-F+.\';NP6(F=$_7%P&ED<,J"K#'9(
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M5X%$RJQE6F]Z3[A*+ 88E.?,\='8*U#&!H L1_-DUV=0X:J;U2L1U[@K>XK
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MYP-,#B:3L C#J0#B-?E[( =H#=X^IMZ52%:@CHA[%W<":E%;*)F5FAHVWB@
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M1'#-FVN_356L>+*<T*3W?/<"W[W,:ZETB44#[U(4YGCBYRSTK4>X/^@CQE8
MYIA,GAWJ\V"6:^-=/TYCHL!<]-$%T<3[MBRUUN///S)$I!$?_A/?#ZTCAC]'
MD=M1[)\$<\A,).NC8_L(+(-S%=)8:,16.^-08G/Z_B#!X7L/'-?Q.1.W.L)^
MO'Q9XG>NI[12^KA"G#,HG17#L?+ATY&S%]H?'8*J!)WU/=\^91(,5Y\4T?SQ
M1&>@=*1 ](>6L5'2V33VQ\,27Y2="Q]H\ YN(D_B2PBL>-EI]GH4+5R@7UK$
M>Z IC9G-KO5'X]2A-5LG)Y/R)QW/&MN_7!(IHS6]P $\W+<.UH-T:%_9UO0/
M7X>;RZL1D0JJSM.,S(O)3]V3[/JR/A:QTTLWQV1DIWSV/9Y4<;*MPLWHP&YB
M\,!46QN2%6X*.0IWF 1#>%@QV]%E(L=;HR<MG VV82C$%XN\D6G1OE%TC:V-
M7MM7KV<?HD^17V'3&VX)M:)9:O=-$]I3KYZ"U4_KR=L6E'9GUW8$T,7)IKV5
M$2E3'BI+I+OT::JVIA7]03=$P1;+;8F]55<QM79894I71$'KM:^%J7Q0RM1!
M@TGR"-?#'DX#=1/!10V?VS0U50 ^#Z?[\,L([AW^CO-;IQ)\IDX9/AU[@ON6
MR^*6RX^^VURJB$0/OB_BDAJH2\\># G+*034%67#EM"LT(G7N][QMF[O'67'
MV;I7"ISSN[,2'"RN5!E=,SI0DG#F:K F'\/6,OD8*8Q(@Z&&HOVQTUW'=//N
M16<NRH<C<_ NAT5:8YT] AU.97=K$#,OFL1P1.K*WF7A9C6Y<$NI +.*GB@L
MPL9-X4)L\WQSFL?/]MZNK<(L?JD1Y>O-S]+R%8%7MF?$G=.Y]JCD F#]C)$O
MI7E8(1VC=:U.OBZ==B^)*S7E3JC4%;AU2LIBA],ZE'\8ZJF7.D*&U:K)N48.
MQ>%ND\(I@/<BW5/B465>)W5R^,3)VQ/V(:^P.P,1ODO4D+[$)P:T)UFW!K%@
MK3YX(8^KDK)SB,>^$:]P5E1@3_6=[1'GB2\[[Q,SI3VDO"\:ZAW-]JEK=)R-
M].HV-J(>%1QT$ONJHMJN K,Y+_^MO+@R$E$Q:/[&3W3DEDVDY(=S#+X<057
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MI;[\"8J7D$>N@>SA*4#2;VAS)IN9_@%=I&7P/'D;!OHT!A?3VKA'C .M)%&
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M"PD*__WP]R+_\ZF</%Q</()\O'R"_X\7NP<BQL_5PV/ Q:$"X13CX!+C8 ]
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MN^<4%K#;?,W2L#;GK??MH]RY(W*\<:9YZ8P),"6/L<:P,DP,BI #$V09( (
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MBDAN===O?.LHF'ONEF'9/,M?TD.V@F^MG\QU^/B:YZ85WX:2%!$N!R-4E#;
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MTKV4Y]&E_6;R5+,DDEVB<5W6S&3M@]HI<^5GP=(KT^_]'ELYW+PY^5CF+J+
MHXD0M:5*5T=^8$.:<G>VBBGCA \%T+A?T2%/!HQU7WLP-H/O%NEZ8_.^E-BT
M'[JA95 [[.\@Z^"@;$M70_6*_-THP#6H#T9CCS.X -7[P;7.MB98);0KU995
M$536U3OGU-#64;"68.'DLWOF.(_O%8(^)\<:K F>$K'/AK7_)O/E+^;Y"\TE
M=%L 2H1M;8[6S5:T[$HYVNFDCH5<3<STOA.-.<E\&*P3C%0 G77-!!8<K'A/
MB_ID^+A.X0$QWB=6CT;N_1R_Z3>O.(]7!NL^(08YMLK'?,6PI'M%P_N0:JT
MFD0^!?)Y,2"583GO+=-:)6DIY-;]O8T_WLFS]J9EYJMI9P]A\$PGY !.) *?
M]L<NL8N'5*-AIF\7#AOXB)/JLB+7V]Y1M-5JVN ISYE=<2%I#%[^1";%P0R[
M8@D3_-]Q%)_&X4H ;A?GCC@VU:*0LZ]0KR@Z<MDS1(%K/?^(6?CNG5.D[B)2
MZ0!.]#N<X@:V1LM^G-2V8K31%4"DSBAA&W/CMQZI((+FEJ>-U[*E76_+LC[=
M%!X_ODOCV6. DT5N!N<MRX;<!"EQLL>!?*+BQ:H2851:R<$?714%?LZ7\*&[
M[[2.U*1FECBK)M7A0-A'N5RZJ+6&Z<$)L2;@XET<5?AO2-Z.EDZ*V0O6D9G+
M3<3-SMNQ)>O3UP/>?[YF&<?U^^6C,L7X=,COTRQ!#D)WS 4V)#$!Y0E+@_($
MO_-0H?(E=X56,"[D+:-A_??R'MF*?UJK]0RJ?A?S=K>K"]'C"-_JC5WKUF<)
MG05QO\$,5GI)""VQ#&@19["*<66AQYD(=<VV&\KM3P\,(^8_E8(8R!N:B.-&
MA*.H7M;N47!J266%9<5J],004J5]MD6_<FC]0E.V6TIHT_+.Z7=7'EJBBOMA
M[UV@_&#.E>(;AWMP2WH@$&U!]^OQ;=(\S*A[3]@0@;SV2"J76Y?[C?-RZ1R&
M+>\_YVVIG',\]H6U=:<(I#@@I>+]^HEA ("\D-N( G^(<.>6'YE)23? I+4^
M>+Y[J!W[=C:T\%=HU)=":\]B][8?]CX3LIA4%A="%J!2X:Q]412?#H"%_T"Q
M&QJ)Q"4;AZ;I%4I2D44!F.9[QL8-PN[;(>YS2Z85[G,K%I+)\-F:"> 0;"NA
MQ(A:FHDX^!)HZW,$8:3NT@Y)/;E+9FW%SGK*Q/+N9JO+MHZ.WP670_ \IXSQ
MXYEI0CY-)!3%#<K+T*-,;-50<+2[U- M]WJ@C2 $+-NU =EF"M%(MR(,KW^>
MF)Q.R=34Q.V/Y1=SSNV>@X6'?DT:0$M!_!F>S%*6*6L91K$/70RG54Z;"0(9
M1$R*&:\S\,2>>J^2-+I5WHTMO=;4UIIAV98]1_+-#[)4M=54V9<BUI4YL!_,
M!=S?)F6*"[%+Q(% 5MA- 26D/8G09[ZX)(:H(W:?BZ1+5^K"OD[M^JY_>68@
MELVKU8.59PW#07:6'G7G!JKW(/8@<FJN5+)N/=E.>/.>T>K1QLDNTZ,W^]:N
MY;O&Z]B^8'X/MC&8+O-?L_!=VX N]=/J*&B&)&P()@J&&LWB8!8B#UM7W]B\
M]P Z@)*.+NH]O-R_A(S_:F[(_"F3_=E:U:U\,"#)*2CM>2Y']HD['&0XY;*-
M$"X5*T"%DUM(6IHJ,TCCZ$= HI7+QYKE:$_9P5>)^_EYSB\,Y&<^1#0%ZO_Z
M$!3#$@QB0S0^,<O8D*T4 ,R32WL.6W\N/WGE;^S0FO(B@++DXN+V4CJOE?HP
M6S;GW(LCV5)G(!!CCAOY9"ZZ*4.'6865#@0SW\P@H*,.+-)(ND!M9)V^#=7L
M>45LQ]SU8^/<C<X3PFB)\N.-TDMC Z)G#3A^5U)6;K:#=696SW7$JISF.6MW
M0%3.ZRWS+#1>:A35:].E240+HWH;4$U[#%6D<N,T:]B+TG:U^81CC<R3^T>;
M D)D_&5SEP)<_D&\\[EKK1W^1^8YJE>'#?%$"[-&C4K?O$JC[ T\8JACVX*"
MT'RE::L'HY,Z#;)IW_7A!6OQA4XZ@E8-K4B?D[)H$IPAWD2# OWT8T ,[020
M3\$/N+;UVPGIO/Z&E"DE1:4ZZ$PM.@0_&LLG!=B+IJI:*^69EOO+EHD4A&*/
MC(>!4_>2,^(8,(YXX^R,'(O:1TGX\!L7J<,<JI;,WUU.9$/T]'A:!FX[/9$J
MY^H9A%DU=WW$$3Z+9!FC^U>.+T0G[-&.O^EL-3=_O[(1R+I^B<!<2R5<*ADK
MG\(6,VMPA&>E(/XE%[^,-L.OH1-^%67Y$7_UE/::&4R;N%>Y1B=:/#EB8UYM
M>;3=\Z*FF1?6Y7PL0?8:<!XL\Y?,-#-!Y$<*:\Y, HBJ74589/13_7]$XP:0
MAK.&IY??BI_7?+QN4Y-B%*Z_==B%,<PIFWNQ-A#"-P2C6$*3V!!!, U?HBCF
M.OJ$830NJ%31K"#L96 )Z"O"6YDSV>ZGK\1TIH4P?A^>5M[0/.QG=,[IZ<BE
MSKUM/N4*>A!R%-;H-(@&5)T28=ZE*1WXU"YKH>\='@5T@R#;Z,:@\* [%OB%
MO;QI\J4+;X:F1D\*UMQ\,G*Q2OOT1#J,<D8$. 0?W%G2LV=6(MSH)PV0!^8Q
MR$52+.PB]="OO/SZ#_ 8TY6G^MKZH:C""TOBCJ,Y-YI"_BBX,9]@>:,3URJ3
M4/Y,F_[",BH\(:(H2[^O<3D:8Y\P?+FEV,$WRP"HEWZW<_W,NX]Y*@9ROV4@
M4$VPU@60IG9K;$@*3-Q,&/F1%G4"WHR/[PHSQ)&Y"P>^'UJOB[;,]ZH>&$N5
M[[,Y^3S]D\K#"XE<=U2LS78Q8FW@&(U@C=#@K?N^DLF5@)!;"X"I6ACVJ0)>
MS \O?;*)\H_G7+;QST^8L^++E_M1J%)@?OHN!R:DC#-=X[\.D8<F+F#0\IAM
MB/.D.COX%.C\=KBR08T;^5Q01K#NM,WT)<>PSCSG*T]'KW-K3)SDK/H/FR@8
M7%692!R*.(%O@S/5*VEQH%V7\]F0@:O_80L%RWH1!T.C918G*J.;KD]O8SYW
MYNVSB/[<\6S?[O&1GDZOS,?'D2W%\*FA<E"SOQCC\L;2PS_US^F:]_-E] V:
M1L'!,]=A=%K<F0"_>=?N8@I+D0^4S&%#RFW9D/%=#S;D\P8SP>R ]YAFC'%I
M!.JW/K4Z.JKXE-'_> #I!"6%(:Y%^SR#4*_8D,91W$O1>3EVE6?5[KWY[NH[
MXE!N+W:WH(>/Z[LKC/)U9QG#>C)-/X,B5-JP(22MG:S3=DU3$8!!G1E4=W5)
M*IU_3Z)%$E*N_J1'*3"0D7SYQVUF]I%)*X#OOV\M0?_#Y3:.7-1GJ)?C@9B^
M#K^47[;(-8>.AFEB6_NL;H_XJE6JU*L[)X4_2Y]<4YN/0_6>Q7V.8!:AMM9^
MXICZ088_8^^G#.,7=@F6Y%,8P&T +_L3([:Z FBYI[A2AFE.Z,CB(UHZYZ1R
MO#K$G-W[%49JM&O:9[,7Y1Z(:W 1X8 6?"N2.DP[R7Q^ '3T&JK7R,0@!!%
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M[<X-VHC47FD6PZ!$G^*!(?S64UZ)#-8EO:]7I4\*>'E_,AW:8DG]/D5W8'W
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M!N)?4X0&EAJ:_).^F0%=M+3OG-[W\PC+?<9X\[?]@1"C%Z.:UV;O6O5"T+H
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MV=%Z5 YI:M?^FNV2IO;#VE '(GG5'"+U(X5\_V]0F%4X_YW,)XQ+ 'A/GBM
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M)AL;]4XD&1LL1:68P )H[LI]L1=)Y#KB)V>+0^V/K5TL2)+Z2J\Y,S4@=[\
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MKZ@^EU\;3,HF2@LZ1-@9/E%*2[C$)SD:F<WD^TD[$-E$+?P,O<("B43:=KN
MQ5ITBQOSGT>FP4].G'%W:\13\5,AYF\M%B9K];R-C"Y8R8 VP4RA:J \E!*!
MM>_#B-)M6JTA:H.T4Y%YL&2#)DO&H;F%^&8S^13,H>XL\Z^]+?N2%"2$TC07
M$),CO=!:Z2XH8/BB9TN:>)$<M=1;(#:&"- Z:_$9SE?T;3@@\>S8I[=R*^.8
M@.1L0LV!ZA<M]W"7T]M<<'+K=7ULIPJ=1/2R0/5M%31WCTAH-W,W)3/YLBO=
MSS#&%%'A;]"F9K[<G-X:WVU]4YB2().M]A&3[98G31>59O(A<:0IME#75.82
MEN0B!7J-4=22MR5V*)A>)EQ%K++[T.9,I:>;RPY.6>*9(LEW>\"'Z;=&F"8K
M&/(U%X)#1=1GR!'RP"(*@44GV3,R<5H:MG>T5$5?U*S!5[[>0NW"AYHD.;54
M.\NT74 XK"ZP+>I.%[9FA [@[4&1$^[ ?D3%*EKHZYM@'M@XW>?E'&;V $79
MT?SN=?U^ZS*SA<+"CFN#8GO]QW9>7<8X?+M]MZVRU+YXUMK8_+JXI9*'I_7.
MZ(,=FLI7JM*7/Y@IF'%'0U78CB877$=*8('\P8#Z(%T">GJ,J0RL'CL)#/D$
M*\_Q4'J^WQ_NI6!XG V&U0\88"$[DS^-GY\8A3:$$()H>LPN,-D<.6V+S274
MD$OZ.Z,483%1!BVOFYKRW!9;FN_N6C[:T]/]?>V+3<<YZ:Q)G),9QS'%2IH!
MV\SK(2ZCIN3P?:EMALQ!YDZ*5"H> 0Z$AE"J7H12U&"CTA[-&,WD[Q=;VG+V
M%PF9=A_>J_3QRF7]Y>UDQAWP@XS2-M%5Y(XVO0##K<SX%NN+*CEO2U:8>UI'
MW*GC)_<K"^L_'+*Y?-/7V8[F9BW(^TSX'110YXFGZ^/L@<.Y[89MN\F,'*06
ML@N1Z-Y0-S5=Y&NR@JKORUD.YMRH&K%QVZK)2E93;1ME/*>'LG$UF.P*YJ+O
M 83(\]9(:LH(DR=0]BDFD^YR-W+:)<%42;M87EF 5S4MT.7&++F&)[K(9[8$
MM!/R?#X34#$D'*9H4NV&T1<S%>"Z%.YB\@MS*Z61%C"T>U!D<[\$]^&=6NIH
M<6M!"YF/UTUJ+<Y(.AF5M6W/D3KT4LBT.-X^-DJ7;L,&G:J4D&B]T")_B/H(
M<U^0<U[^2L^3O$^+:W(-!=_W>6?O\[MQLE80-RDBG+*]L..R!?E8)+#_:B(>
M)FY9Z=E'*>UY?[=,X&2,CIKQV<U:WFR-_"0U_T^ZL:</>['-/#>1K@4$!;.E
M[C:C .XB':T70O0(V87QF@E,+^F>./CEO.<72[WR_9[?2+*OKIB]-W>BO03]
MS.1 =.Q%8Y$(@8;!I&86J L1<R,R"I;B3 S!O[LI+!'H#O>R[=[WP.1DX^LT
M5SZ)BP/H'%=X$;%=83OC5ISY"5UKW^[->(+P0^T*:E,@G]JOX>:_,E]Y:8'@
M;!F@$%REK?VU8%0ZXLJ)?1<?9\7Z<_Z ,?D$L.Q(WIP]Y&GX#=<6G5+UT7I,
M<M<9 >\XXEZI31'KOL$&"?5/UT"<*0- )A;-:\;^:4!?0# NE;<0B<W)*OMT
M?WH?GPX7XQ7:/_C9U>S;%2&F#WCTM\#D%TR^4)H$?1<CO\6,MH^^'[B%/RJ'
MPZ28?QZG&_)T8T2:/VH[Y2PX^J$#GKN=:*3(E=WM;K0[?(:MIZY1W<;L& %,
M$"^CZU-V8OCVG4PWE6>!Q%K,%C;W:WRXOYLYN_38:<SUN/=:A[P6*%*8#5Z2
M8/P-(3,Z5$< 1M[ %2 KHX9LR;=9("<R,@WN4.%9DHT[NN/.D0MM;_.F^<Y\
M"_TPM'G=8\<]O$4 #J2[V8<+6^I%)<JBZ))M" Z L H6T1N0ZEP<=!NZ^;,N
M"X7&2;5D%3?%&EP6?RY<$V'R/<WG::T]!BG-EH\L3#6ZET*>7F);0V'XR>;,
M3@_5&K):DAXZ*6^VI/*B]P?)2KDS*01/.U&')C&;'K,+Q2<,PB%<;+D\"+V(
MGJJ89X&2H0'(6-B.*_5@2>#EIVF,4\[X%G8J/A9#6%5V#M[;E')6U"? 65>)
M3Z4_:LL3J\A#4P \F'QCM*N(#DZFQ#)400\F' 3F7D?&&^O051IS;S]LK%[)
M;;9K@07]\&UZ8'0I1[-,1;LC#F)M<B\Q0IP-?E.ZSK*CZ1AX!-F6/7"%%GOR
M)UHWNHX4C\3^;&TMR'D0*"5J%Z'_\[?+9^O>*$8@E8PRM#(ZAS9"1-+;AL@D
M)J\<6\!K@;.43;0_8@?S$_C2*+1QPBVN*Q4OM_A9ZZ?DM96;>1?S"1U#HX?V
MGY"_(E&XWTES&=&421?#4-D&,S8[P%T%R?8\24'23-DGQ612DMZLS1TAV],'
MS'PR%F?'J+IG3@6_.<0)DMD!@G@P*A"74%-]5!=&%AK[S)C4*9RBJ$W1R60J
MP25&6ZPI%ICS+0V1>Y^N#[AV&)_P"]IYT%9=6OL;]Z)3>A*H/(0-D&(?!&U)
M9M)E]Y([[PQX3>MGXW0Z_9]K':*O6:JF?4H=_/BAYIU-QC&+=?TM#YII5">L
M%D5H(.]@@:B7@:/DO.&)CJUA3V'1R6\N8IC^JJ-L6-N=6_>EKO_FFN6]RTK@
M^QJ"&B\S18;1V!@$^=0 %.O+ML_?P'QTRPI YUP>IG](GY3DWDJX[5GO4N,E
M8,NIU2_'Z^5_YMT>];68Q/#V=IX"1(==$@S0UJ&+/ZSA9*I")=CR.\G]X04#
MW?,;V_6!Z>)SS$F+7L_#^*0?V3RW,W=Y"V8\NWID"^F^!9O?H(MK4@\QBNE:
M;#S4"95@RF!,H0)AW"UDA>_I^$I;N[9A[S"GARJSE=VA61HO$[]\K0%EO]YQ
M )AA\KVE*=#-@ DL>%JN&RK4X-KB1JZS#P(G1DQ;9H0]-1;:,?5,Q-1@O#$W
M:Z;0=(_%Z@+^I)S'-7PTY#Q[6NW@OC7C"&PY"]3DUQF2LO7J.MPF%1_^Y%;I
M%$:AR5!1,J7[1.FMO6_\+UD('B>74%Q_:-M!IS<ZT60;S"2-ZO@9ZH=.@-:9
M&A/3242W%P$0+K)%+CYU1HZ/J73>5G+4T2[*^WY7D.@EU?8'1UI*[YF_,=#Y
M#&U$T$7[J#L8K1"- *@\$T)7;E'4&R*:%T$TR>@DDMZ=%:+%]9W#T[:[GX N
M<5QI+M=XQ;&O&9J*(=L.3GK,1Q#R7T1U0PP G@M(H1;#,"Y,POI1U37\!SN-
M[U+AMF7:>[-\K7\<*"Z>\SJAE]]_*_V^\ /82:#F.:+C'8(O#)P!$ZD7NMQM
MB*FEMHQTX2HE7QT@:$V<Y=IC=F#$5EW06]5-/L1HWY'$=\:PR1"FLRSC#9I@
M#[!C_9+;&T?5F+PDMO( PU%:@-K\:T M[!:>!>+PL-V5C1=RZ;G]=&%LX_&Y
M)_J[55_[CGZ1E+,;RO7GY]ZQQVL&AR)PT+3@^Q@E="?:)8"G8_IG:3=,_H0@
M1&OBNRFB<E:U7%XW"6<=[-=RYU+-OOBT6\<LN,6#05&7EYFZC$IV'(_@I/.5
MTIU'6DQHMLQ.\<C\KJW2V)9;I3P-%)W88-\Q+=)Z:GY2K]2:>E7>],DC)I/[
M<N\=.@&K&_OATH4"E#&$.^2^=B\P</CY2IMN*W 'YVDS<>9SE'QD7-]607&A
MAZ>'C6K,0.M'TF)1J/J3"UEY7/<UD[HTLM8K05$7F(/0M49H'YJFS]!A@6SJ
M;R\C+@@+ C=6F;OD&6BX;>@SM_=E*ULN74=>A<Q-G1I?,4PT>^+P[@./;J_K
M#L,KYY=VM!60F^CB E0],HSH4!XU Y$CVZ<\ UZ\FM3*J,1/ .5X(Y66>IAF
M\*L:R+.+D3Q9?*(2ZH*!X5^=2[M@@!J24$Y.9-O;=&B@?6*;&$4E,Q.RSTP"
MHC^!P4-:C<8>J)\ZF+PO[V<AM_JGR91GNH*W?*ZI<ZX)],DB,Z*V:[!L'X66
M4,'<>]\TR2*(K?-:QD%V6A_J996^Y<D;5I= OOH.+5G.[S"X3YOXEME-Y&3R
M#=)<HOJA?&QDJ)-4(#]D:LE6SZ[;C7%XU+UL=T];D:;1WG?U[XB.TR</G?)^
MM,?C[!OWXZ+WLV)&Z#NW3Z:V2X*<SIXG"<-5 9=;BD\HM@ZM:""^.#*N9ZNQ
M*0#EZ274%/K%K-S37L[Z$+WVX!G/R$N6DHN86A1=9(3)5TG;#8>ESONUHV(F
M<IH;XK\T>8'KQ^AGRP(-C"6&N86UGE9^')0X]"C<07MD7X7(J^<9QR UGC#K
MNV[U$F-: VL>KTC>:C#]2[X:ROM_BS_PBO/RSE@3IY0U3W'J7L9O+4=IOJO0
MIL5'V-7'3+75.<'4SNF"^K"@A!0[?94,!YDFG07-JPD'7I_'ZWZ;:0V,_OV3
MWO]%T'LZTUW,T_EX&..AD!\+9%M2F/FO+T1#V1J#'0G9M/$C1K! (> M> $:
M44'F80JQ8=W#DJ@)!)7" I6^7]W8^JN;_Z+_//W]%T9SR1[0,"0.L1W;*O4\
M>'=]I;!=VW@84FH%(D,F48E=7273<]^D-?EGO9KAJ\'\M[*/G#_,2^6VFYGX
M -D5N<KD-\.BP9'YW;+(WDP^N"V9FD\S<P7.]FPI+,4NC7R_4C_S^F;9](9M
MCLG4SOT[<PLN-C[QY=95NO4\\2/'AJ3D#Q0QK 318<M46HU0%&4DMH205W&?
MD$53!VJ!.CQW' 1ET'2[ZUIC4U/".0\/;\]"VV33][MG'^US4-P\0@*4T40&
MQ8_:Q$@SM:;$47O(SIG806GX(4IC*\X>_&7EU&KQ(.2!"U'Z<XBO)B_7HS9?
M#ESV3D%UT-;W%#J5#"9NT*Y%?896AZ0@L*_8 /ILET$4S_"+<?W!G7#%,5-3
M8@0>+!@0^C';-B)*%1-<=KXO^/H! 0E?F3K^9ON<0+:K"- !-&'W;D*GU+#(
M7NB4QZD:BG0J.B =8?XY2CC G>+3E+!Z9MJ[>51*==?>VN.]-RT$/9T/]K^]
M'7WWD3D\,8)V'A[$N(\()L6C:]6(E^<9:KWN/'U:)HZI[05&U>3E8;^1%K,+
M6?T&^6'\MLHA7-V'*CS>&;RK53K)O(K;Q[AUC$O"A8?"0RT .,@5W<$XG22D
MI%ZKDJ.5HW/=VZRX>U>=7O/$'5-8D%QLDV=4LT"^4.G5G#E9\D3O7=DUYII=
MSGCUAYZB*WZ<"^O<;S.!4W!=%LBL#$IZ"1HNK$/@=,E]#.YG+%!;&0MTKZ\+
MO"X;Q]QZ)J2A:<@4!PLB/@<*T[[]XOK%]8OK%]<OKE]<O[C^&;GVBXZ?%%/R
M<?46_>+XF8<<3W-%O!^!V[) M3%L5+1R<]3A#U?.\!!9(+IL, NT_Q2CB@4B
MLD,W^^P)TL\H$#L6*\&L/1R<)C'GH.N;1Z-8H#,\><P)6&UB.W+F#C6*PD/H
MH5E&.NAG\@.%DR?"KJJNE22<NZA\MF//HM&+F[M>'8YMB2V*VX32]L+#&)4(
M[#T62#X,&8U6:!! IX)K>YLHS5"N%19( N4]F&2J4C%P^8)6^M;7S?$$Z=@#
ML<>D%N[W'I]!?PLA)M..PL\ +! .QG\>+@K,@[M(T@"X=WQ.Y;-^/UI8R'D\
M0*FQN2'GT^+,8$Q1K+_V8C+5)H/3QU5$<_&I$I.O@78J:GA.>WP=.I/:!Y&L
M VZ%4,:%%?MQ4&[_6AY*_%CQHY3IW56JS0^G)P]0:7D3_8>MA@0_E$=CP>>C
MAB&\P I%#K<+A<5,C<S?S>U"26!F3)T5M5O)A:NJ[8_V6"O49Y],PS7>A]W&
M@A]^%=U$T [ CS->89A\NK1KB Y]IG%DA 4B&5S7%]-BB:/!1",=^PD4( _C
M,*2CHT7BUTB?"/W^P"67?TW_@PES_1UQ([<;%@\EGSW)* V#@N&2#%247 ^Y
MWZFZ*66FW<L0<-$G3,N_%WN5;1;A@PC2&GRRYY#DD^KG'[0/RKZUG\JG.I)+
M":3"R*IOM/.Y/8H:0")^=Q@IJ4!CE*B481>X974YFH-_X6)CRIQZ)2Y:3$P]
M83$B0/F:\$,$-O\V.IZ P,[8\ZR*VO*OC*/K<LHV4+T]_H3O+?2EH?%3M$6T
M$?0R6#!RIFN.DQT_'PF$B3Q_'"" )R7M=;\4KKSACGQ:>G6EO_.R[D^<AR(+
M5";K1Q>+P(?$0'UADH@.8Z8P<U@V*H8& 6HW',U'\KL<!_!'>4Z.^MY"K9O(
M==W8L^8=4"5EDGSAUMZ4\..UU6[28VQ\C@%4V0*)S(35&<8B_)"<I^!\AIV>
M+A;C[/ ESKI>'!VOKZ6L7OWH4OB.R$?2'QZH7ERT(!AJ!H>!-NV9 C/!+X.@
MC4BZ^'Q7V^XOTQ7,46?#YTJTQ0_3'D8ZPE5#NR+"^]P9AU'YIFHTT<@-O#0Q
M" >=L:5V S$XC%AD/JXM!E'\>]70>S=W$VZV[K+%)B/*=5^_+G#[OIBAEW0C
MJTM$0\H"$GQ7[1B7S[<Y7K)7:V284&BGK">QXTS)G5:(D7S,YZL^:I+EYB X
MC68#7.[RV@V,D3WAAKA5!5//R+F3S5(&R=*_%<XFN4QSXPJN!6&@=?4LT"8E
MD<G@IX#9\:&M7SL+1%-<8(&&?5$WG_$B_N7O?_'3O!10(LW$G@5"RB!(GU_\
MRS_+RWZQ_&+YQ?*+Y1?++Y9?+/]I%A#H@B#'Y_^R'793'6HU"_1@B@QE]KU!
MK#^IF-7L_+T=D!:2C;\(=W)9(.N\UN'_]EWM?S;ZM7C_Q/1K\?[35 6EQ@*S
M6.14$Q:9S#2%F[>LW0P1\/\!F[L8'1"N\Y[?K^+=PF6'V:>6M^W**FIL'-+.
M%[RC8]BAWCJBXQP\F'88?@,()A_&"B?!6R]W-O>@4N&7:DX=_RB1%5S2GQ%N
MO?O1UQ-C7F*:ZYE8G5[D3N80DMOT,&40-T!"%@*EEHEG:BY9+'=5N:OU65I\
M23,Y=) (^U!*Y**\[<74Y_8.BM,C@=1;2T&0_>.JZ)8NL9J0D <2@R?3=_2^
MJ"W,&-MJ8(&X^Z)FVNZ6)B$N"LM_8X'T%*^BL?9&+%!T%G7&?/"YYK67T-9K
MLQ5='8N[2@QL/&Q#<C"(17BO9[Y-H\^1][2ZF0\S=U<I4%A98<J&?=DO&?YG
MDV&@CRE@1KL$/P.HD(.ZT+4P0C[T*665&C<NUPD3?)9P'&R3/GH7[7[CD*.F
M2;C.(H*SV8C+H6(5+1O9WXG>!5>H@)M1QM%!Q?YY4OF0YZ\"<VOO)7P:EYFV
M]@V'ACE)/BYHEZ4SV!)O"1SN@37E$I7F0P!MGCZM'8OC,SV-:Y$NU&MD:JDB
M^#C9I^5C)=P!/?8%=DKQ^.U[.@UY1M$@L&M4+Y(][1VHR2:J(7F0X(%5V*]-
M-RJ,O%O/<+R3%/O^U>#!R[?"(,(ZIIF:U9^X&2_XGPGG(;!?6B.<R7T$'3QT
M<K4G8MBN,NH31J;%@;SV\[O<QH.>X*@-@[4[SU-6''BQ2:]78'<GE@8)69E3
M34P!&NT4<U ,K'0*F"!/="$EZ$>O1)H7#.5;C?(KDI2[K;I0_06QT5"SLO][
M&^BE@,CH/VR3H 08KZ!?&^'"+%#-=QA#-7##YK^]D>!_G%I2J21&+61W5#NB
M-C$-'8A)60L9:=$J?A*L-_E5P* "_M4RR$>:9R/[U'N9(R8GI* :#T 0<[;@
MU@-ONUF@IB6B(18)[!/N.!J^.&-/418!FJC9%.XGNBY#<'#((;W;U[(08X-W
M#Y[D)&E(J+@;>8"?S0F3$^.9X$A;6S(X5D\S6,=\2&_Y@%[ZH0][[D^[=\GV
M2>B6X1P<G(X10*@L!#8-5H/NQD1O?RIL1G-DCM4(9&;"ZKEK36$4BV^N']KR
ME&'K"I(<RD7.UPZF66;7S)GO?%D"Z7^V PU!8,M!S$$H^1QB$DF=B);18]CV
M&9=V(B0'T@ZL5$V#"5_#"6+?=BOOGH>BEO7AUBP0CS!<98*I@NA0ARA%=K4O
MNW1C!+U'Z'=Q%=7QZ<6]61$*7VK30K,"FY242KZ!:%=3%B"<= \R"]2'B9D3
M E9Q%CRVE-+XFXR(T].TQ*R(8(7.4,S"?1>7OZIP^U])_\AJNG]!BM+;._]7
M # +=/D+>NO4V/='.$1#(CUG,(8%HA[M9X&*!KQ6_MMFX7^;HH* ?*8A6Z>Y
M@A+;LT3OTDRC^IK7/%?[2.Z1=7B#D04/,"Y'RTA 6J'XP*O=JHY'T4P!.5I(
M)(EJQWBJ1TH U]TM&VTSHON/9W>@N===WQT2LI@7T"[L>EH]?9(9:M5>^"8)
M(IFL^(@%VOF-D=2R71CE!R/+5(VF R@2, -%[OF98JMKY3\:!BZ%+GK!/IQV
MR[.V#?YB[3JN]YY7G7-FF:V^FL+XD"[2+KH[$(P'QWL=;/Q1CQ3WC[A]NER8
MOM[X.AZ7A9 (EWQC#H)K;A?X8KLD*?;B[NQ@RVN'CJ+GK39U8#]^-@+7EYR
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MR1?6$A$3(N^5[\3L,'=,<VJLZ>A[CNB*WM[<PJP'H#>C_*'TI[!AP\26H\\
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MM/<.]0/$%V?*9=670>"SHU]_&X<2*+2C< 7&0Z8 <(<*!WBP=^QW ;:=5(&
MH@!GV[7"';8FNHO6"OTF[[KKWM;I*F=[%O^;T<X_(NWU3Z.J/ZJJRQ\5^F\.
M\[^'SM'-\4+BG5[@-HI+<H/5E9NSASYYM!ZGXJA](3O]O:QEJ$YGK"&QZ7&7
M4)FFH3AH H1G/$H9V#@?9_NYY6CQ^4#W3\4W)C.&AWGSW(I#IYPD']/X 4LF
M;P V1(KYV1 L@<:R?8.LGDFJO1AS*&K/8$S]*A8^(-XA)7AAF!AMJF0C6GH#
M?0#])KL<]1"BA^@XS51%=/C7F]@#*HF=R%V!QFQ\(-VF:QN$%Q9UG:D5,L%5
M/I/.%5:.N_<VZY+((ZAFPGX62$N3&M<!$20W=65R!X"%384+S4K\\W8]"2GU
MWPI^24P9'N<=5R\T8P_OG+"9VW %_^>S<<VZS[UR5!^4V\T>/IVB7BD4^^^!
MX'0$%JL3:XSN98$ 963/<HNZ=R:,[)LNG&YZ]!;H8V.3\='NVW'68)JOC*H9
M<[-/?QU!:**\M6(4HWV1B9AZB_AJ]\BECMN^K?P64Z*I;UV7I@CGWC@:Q_+J
MCT5V=>9)9]!57D:">Z0T0TN"C&]2C=/K;N;PO?#_>H+@E$0/PJ$!0W!/WL]2
MNGACR-2=W@GB=;S.% N$1R2WR05EJ@FW=3*^IBI5BYSOC&M4VOK,,U?_=Y,2
MV/9!@0TB)#.]8!_0M9U+S5[46+_!X#+X'4IPRB >+7WPAQX+%-\LCK5^.5?]
M3MI<YI8(^'&NY9[OR2J@#O:/HZ,F,0HLT!7H-/\/)I\T^Q;O**$!<QHT8V0F
M;#=AC8H1JD\^$N2O8(5Y^>EMEJBKWOFU5XJVB"K$Y9!)$M:2 *8=78;661)6
M</K#=)/G73^L]PJ'E<T>5 PCCD8+&^.=Y9Z^4WAT_.7+-)U)3BH?P!:+G00&
M\A63BZZ8LDC%!^6.FGK@9]U:!NR[I^M;O@1*/_BM_L';FSOOITA:[FAM_F_X
M?KBR=%76HE+EH[%7>? -JHOJ'"5XR>7@*4G77BSX46/MTU(>0>'K,#"BXQ8T
M )P.K472Q?M<@#?DJQN>(\\3>_)42M/I9KC('^7^<PIY5+U1[4H/G@_Y'R".
M_6F]OG/\M0DP+48\U \=BY%_]9,TG4OE 4AX_U>OH/Y! K-0MR'FOF^Y[HAD
MNJG6S<L(O[(38=?W>=:=4'F/.93_>.F80/FN(L[U&RF;MM0Z]@(&8:(P8+&?
M=]#3AZF9P*-GD7*V"7)03D 'ATQ;&+H0?E Y^UON(#_I3?./67R*H:KZBR9G
M?G<_5 %[0K+!]89]J"E[7"(QAHR@5@+]570[LA^A&/]V")<)!F*Q ^5>*P=7
M:@/%INQ-_ 9R>!\<R%&N..UR[YP3B*%;B-:"^MGOH <R*M'8S-LDN@2I%RH%
M=RAE?B[0),^]G1_DBHRSI:A\<6Z3,:C]TE^\(I43:\\>M-^F ;E/3T<N-1/B
MF_O1=Z<9)9/)/T81IS8PTM&72+QP&8KD1)RI)^TBT#AA17%NPLWD)*R>&-';
M=(2*/H6<STD(.7RP1V<N7?D _VMG$/CE.9<E-%%HWA^*S0&3'82G4%T(/GTM
M9PS.I8_AN]%><)B<45PUB_&87KUX,5CM7 /M7*V>H9BM9H>1\PYOC4^*)YW!
MS_^IMT!=%I?H\G&TJRQ09R;C"1O]^H1P!3)=DIBJWYGC:S#AX,*370.?C!3A
M,9<4GDA=A]V!1P KY!=4/P"*!V<BY.$! 3@2'^!A]X#F,4:"\>VTG>3H?ZM[
M[N09M]E'YZ0N""_V$5)IW.QP L\TB*Q@\C]A!W%<@%W9"@1$*4%R(\FV.*VY
MTK"@&WGRT&]A^9M['OED>,3D9LP9NL9^^.Y\?'7O4L_9"N>X>(/LNY],PPZ8
MPP^4#P48EK0VK_LM+-'%\ZEM8^B+F&E:)PP<G.<R3-2!].%3K1+L/N5"Q'#'
MF*I.W670I2)KV*AO7-4R4_TSH<46-VLC-PMUJ,_XUKLVV\6."M5O9EE]>U4D
M<B<.IHSHBD.S!7P]$+QY-PC#CDOLZ4J /18: Q/2@]T#"ZPGU[- PI&W>ZZL
MW^'[*9?:V!@3VJBKU=62]G+7_]N"#01:Z">_3MMW/=\.,L$"*67N;\>311]J
MU.-_.H<@\BPMS25<BN[\NR@<AH36"-,O)]*E/:C5C-P%52%#?%.\J1$EJ+/Q
MW@5O[A%]-\N-U%F",@M4AZF,BMM.\J%+^-FW 6SKS@5G:\25IX?&S4=,K<N#
M$/RF ==EP7.6Y3/)]467C#ENUQH(K[Q_7G]OVH; V-XLD/D_W4"?1S9M;'^6
M(WB8IAS91"UA@>YQ,L4R 7,FVUV(Z1!AU8Q2HB&5BEQM*0\/IEFP0*^GIC(.
M9VU6LD"B?H@QMN8LGF.!2)YWT]G#I[.MJQ7=C?TC82:R_ALS*&B]8->[0VD3
M!YZ>=X($[&^X\SZ@7WJHBD#O3S^2>.1#J)5#I]-":FSX0NI$GNW+$._,*3D=
MX,@J%<6H_IY+O<1(1%QL/7P*J)@_M3(G,AZ&3-JW-F+S*"8@9#%ZA<(G-L>5
M=Z.X)BEJE=%+(S'Y4&QGLP1L-SXD T?OX&@P,4^@"P].TT$W0C3HI\=KMW)3
M&B+ZK4VKNFL[7WW?EWB=]Y7U 9)2$VZ0+B+,=)PEYS/G,5L71X.V'%$":3<^
M[G)ZTIDC)5]S[?1$B%> =B75$MWQI,3$X,.2A_3OKZ-2>@!V,H<8SW;.JG>O
M_7N3_7<^U.'X2+>E)'8)B>HA..@.!>\KZ1$OK7%$D].CE?!E?<W$NC>O@UP<
MBPU:I";DH1\FI][[G 7ZY\$Q4!$T-AU3'Y&,#D8":NBTDF&(?""XGOD4*YP$
MKNL25\U^.86965DT23<X9'LB\L&L=;5V>.SSZV*F.ELL$,TFJA^Q$Q&4"9JF
M&P)$7-!3V],C/RN"+]ODVX]7K<^TFC@T';C0TMA<E[,?FW?HH]-0QV[]K^B=
M:&P.= =3!N[< G11!'J\U('T"H](/$P\\D@DIMLPMSHR:H5023RYNK.N_O#<
MR\Z9D*+,3TYWRUP$SW,.H_T',XTGNC#5]/V R0OW519(PM1IYXO.VUS]U4T-
MZ3:OFHMI:@-<\6_"#D&%E"1BM88_I,#M\9D$>RQ[-A$=!FTZS':D0(MW\T1W
M2!);W.&>Y8%YZ?0:[5+\W3N.38^TPX*2)I[EK$6.<'Y-%[R^GS\U%5$_01=A
MHZ0LVF6ZSRC"'SQ]%KNK!I\I'7B_1VB\XCH%VGV?*T$W"9<BHR^1PIM[X.3U
MPF<'^G9?L@^FB6]W84)<9$^OST2R#MN3#,9T=49 M&U/4H1&YY1'?UI7#<\,
MK+E$/0\UL:A8L@I_?L;6.RXF6C@'C2U RL%5"MDWJ+D-ZYZU6 DFMNRE08"$
M?I>4T ;LFY%GK0UYTF=C48OM+@%?<SA?HU*9O,R/8!&H]V LF&R%3@>+U;_-
MUSK<-6<R7H\6R2^:H?*U>-X,J1_2 3>_"W>>35-X>>TV\\UV=\!LVAX U2T[
MRZS$II_S]U*CR%!X4N"<P?C4Y1;]RL".K(&%\9P'J0%/YX[,G=R_8+>/3\4:
MO(AR!&;(FC@UHARY[ARPGX)J'[_- B7H/Y;2)&JOWN"LB>M3#MGMDN ZZS2?
M8^"2/N2VV\T,!.9$= 3!I5_2K[-Q3"JS';RC92_GE\!&I+RVZ77X_;3\8,.3
M4A&A_6H;(IGWQ=,_AF=$HH8#U]!QX)J^CI!8+V@KT%JDBL8+[\:L["_JGQ>6
M!?)(;J.%(P[TGIJ$H'+Y#K;#>OK@8*$EQ]>Y^;#;Q2#)!19($NV-2D#+M)QG
MZE$LT/C4.TTQ>W57($IYTPIE!W=U'QDL)WD]-P?!XRD15'?@%CEQ/K=C-5,P
MJ$#E=;!E;\+^W@K4P T)997>]J4%(_FLT>LPQ[_*) 7_<7?H;R=9_>?3LWYQ
M_N+\9^,<;3M (<69\DZ[ _W=X[<#QALB;[:J$;-WTCP)S]/"5Y M!-'J5G*0
M5^IS3Z_>OS4 3ET6",<S#%U:W&"!=DQG F;KF9N;K2Q0>V-EBCHGF"ER5XD9
M%8(@:Y7]52KE9&'T_VC.EU5-SR.A7>[ZF"2Z)9ZG>F2=YJ8=0D*%Z6C(^5]V
M'%3.Z-;85W; ]3YH9]YRQ0\EZE,@;KLPDR71Z!6BPP3J!Y; !"#J8%U//?<R
M7C!5EW\\A&B@T^,R^0/J=,Z]XUYT,MUUY$SJ-8YX\D9[!(9\39BH*]W#-HQN
M@>&8&D0G4@1-W^MN\&Q8C:Z%$O%X8S%:DDX^G7NU(T?O8K+<WMI3-3U;8=+1
MZU9*KA?SB*(2&OMF#_+S'.,)C.C"),[QLD&VIQ(NMPLFX.8?!?ZLMWQ%SQ-L
M%VW.];3>2NS("X=VIS.@RA10WU_-#_0OIJ91_9D@XB^FY\6_3$W%I?\_,M*U
M6*"X>$2P6TLHS74%6=?4"9/T["N&[W_M1M(FDEQS)V8$/Q4I"C5?25.LV/O8
MA3A!Y,(+IWI) 6IL+(,UC&9+GBJE2-840TY=]ET3"'O3YC,CM:FMG*%O?DFA
MZ>"'%QP/CD$'44EH;#R&[*HC!<32>KQ4&4]4VT8;3-Y?_2DPDZFX;*?2O69T
M2_DR];O;XP?VY2A-O4<1=F=+I4BMV:;RU,ARAW/^'6^_3=L11^RA[QAOV"X=
MSOP,X6<TL4#>:+ZHS^Y.7X8P@090/XI"FF%ZJI8C^,'B ;^]$>DK!:=N["5Y
MC?R5>F^RHVUNAAK1EK:'.8,10V"?0N69X('B#W.B#13?RB*[BFFKFXV7:D[<
MX;-^<O7B$U<S)8\GX=;R&K2#UVFBGJ_='VE\/AU0.KY4'%WIW"AUJ$*JN*ZY
ML97Y-[_$N*F0\#_*5O[B_(]P1KH09VFB 9C&4D(I'C65)YPT 9%!B#'^'_;>
M/![*_]\;'U%VLJ5LDRW)5K)49)*R)$TJ9,E4$A(J:S5FRAZA"$5,A20TV;-D
M[$NV[(QEMHIBN(8:%[/X73YGN;_W?<[WG/N<^_X]?K_SNW]_& \/\[ZN]_6^
M7LOS^7Z_EEBY;^EV&)V&_O" 4.ZK;MD7=9T3JV/RJX&/X6U+,7#@>!,CE2MD
MPI!G2H"AK'/A=9:0Z>HUMF?TMZ+ XP<4<\HQ;?2*H K9/.OV<8->XY=UI\IV
M+A]$U9(J ^CR9.2$./,FHX-^F*$?GJGQD&T87#33KJ#E=M<^Y8DR8GG0:4)2
MC*Z2]&<%Q=Z.9=YAD)J1XXD8!#LDJKI-C\C?ZH25Y"KWJWE>TC4TDIQT>8"Y
M9EV"?OI=237T"4QKO'N%3=KWYN>5&W?:ZH@#]R9T"YE6"<\!)C++R:$TJ"8O
M#=^KGC\Y-SA=WH6X @>-W>'C>&8Q@*<?1- Q7 VD:'C=$04,K]&V6?H.XQVX
M^39V@SL)@9VZN3#9?@=Q\K_S155[/]QL.=AQO3+-[<(:=.5K%77ADHM]]75:
MC=\-%!74#E^=IH?\*;OD>E_MWWA+3CPS_[7DYM\:N<4R8N^HH8;0*Y$<'^__
M(VM4XON7)HNX0J\9=1T(F3\$4&,#QI;DI32"V8R,TY4>M'Y95UL_SB. J60N
MY>9V9-+V7:E(J6NYGQ-_C^CW^@M999_RUJY.,)!LA<,;L*T\8_7A+/<Y% ]F
M.UCF>PE!IB^[VX9[& DR=CCT/$BF5IU]6OBK;%<;IAK;9(;PS>9GDC@I]>HL
M<Q\[D5!B8EPUY#0T$H[^Y3."A>L#3B][/!6_Q]8:_:N="N"T)#$OBU%FB"]T
M!X9CL8'J;7_^S+8JBCE_V!.BO6Q2N:;;TYK2FF*C-C:" RPOV3*?0^[)E3M.
M#%C8Q;H9)H85N(@.^E@S;"I0?2^_I+>XMC+^^LFD^W>O1=FH';),P&:>FD1G
M790#@.#;V$O/"K8]J\_))G2N/6YH0+!.G2\Z<^K@\KV0#9@JTS)^+SYH_<'?
MC^8!N[E".&A!!,!4P.D",+N@Q1*=8S;LX>0WZ+0"H,GI5'$_RB63-%RK7+*(
M:G6TQ3,1\>=SMSY(/'MPBP"<TR-VT+#T*XS?&[ F100Y6TDWU8Z14W@Y Z[8
MH'4Q8@!M#/Q^Y?]($<(.C[*_2)9:"@0YB0BE_FCY TG04Y8&>SLG#NO5+\KM
M(97W1^4.L ]0LI1%B]$&8^=R/&NS&Y5N+M=XA:JF>SR P:#[V9% #4)+ *CA
MU*@,=+>XC/0_0COC40WE#"WJ#GSZ,-JII'<%>=>D5*?Z]A4%SZ2V7\XOIALB
M_N.1;'T;,%#'$H=E*:*#0$5H?5X ?L_>B$>;*2,%T===+W;Y]O/]6HY32S_V
MZH595["*K5P0R8R*<>$(#?T1%G5I%G6R_1S_@_A#)IU(%>3-*_VX]=+%6XT1
M JH1HG=(%>*-&S 8=W #QHN^Q#K*/C=D-D8AR86%+%F.*L/\EW55O">>/ FI
M79PJ&7&^D'02G;P!XY,$232Z$]-YC'"%D)R9G,4P85YA7"")UY]!*>.#6.AL
MC;-G[Z!?%#>_.7 86WXP5)IG]>C_4F# !;F<_ )OHE][:1')PM?'A[<W./#V
M;FM*HOGU$(_F=[ 4)$P(QH9>?$2;G1Z]G'41O=EWYG#8O>M9-HST3X3M#<8=
M@IT)S7(GFJA560-Z>@Y7'3LDCV<G8N(L1!P9VMM/O(M[;2]Q2UH,!@N269N%
MGM%R*!A.'*(6=.B!VK&)VM?A0*VI(Q<.GLFX+>.+X)M;-BPI5WFYL[>'T:7]
MZ&O]/MJ2TUSP__3YY/]!!_PR8KGO?JY;XLQ*BE 6OKZ^PG:!@;?W6E,3S;47
M.G@NP&PT'FP-).W"&* U.3EF.WT1<F;&(.LT0(A&'[T^YM)74S05]ZHJ[G:7
M:;GD\?=[M1>^O!?>+CXK+>=%1VS ^$5\!=^!\7 I-)P3KUPC[I>??E]<$GW5
MX;)%;W).M_7-:WM-\L\_3?DR2I8CR2!N8HFA7&$-AOA%SC,L.8VK7P\@F^Q4
M_E0LQ9,JM?<_&2L^E&4+C*GV/2]L<>>-$JTY%2EEQR0L>+*DN'V(CQJ-= 03
MPWG.A;>\G@OQZJW+SNJI']$=YU'_/O7-/R>TL;L:!GLO(W,!,GA"7!FT$0@'
MEJQ &R"R<=TKAGWPE;/ZV\37<\R$K95Y6@/VTI=#U?ZH0:8W<VXO;#,\M0#Q
M42\&2WX#+_NSVKQG+*NE07\@X/48=V?8S'B96YAOJU'>Y_QO_@3]#TM/FY<]
M0MIW:L(M!H[!]T*BH@;Y5;P4AHCB,T3QHK%?95NPBF:2OPC 8[0/D/K.LFJ8
MNO7<NKJ"O&^EA<%-PAYTV[DF7GA1T4H+5X@ W*=:+9QGS&\6AIW!=.5(UPQ7
M(OA]"O,P TJ"0[*B-/%M_I=6S:U$[UZ%I5TS7;-/["U33%Q%-N$?(T0WVRI'
M*RF!) #;YD@D1;,=\LP+Y^Z5Y*(S=BR_NG93Z0*9\NS!E\9"6,1>WK?_JNTO
M!!-:Y32BZA'A5+S4C2?C/VL]7U;?BZ:WT)-F!+[6IQQ8>/\J)7SK700=RPK%
M]!%*D0LE[[AC)-EZ#_DPEYEFS8H+0\Z>G\8^:-B-5J7;X$AV9I:-AWAUV^R=
M(VH_1P??5XAE2Y.X0EH4%*C1T92E:&L#5,SH@Z]IB<>\L0(8.9\:WWXI7WV_
MBS0A@OYD>U^BP6>94^],IGF^$S;/3<\09#!?B%YQ&S"?)6)+VUEPC)D,5N^[
M 9<VO=ZH[ZPKW?9F/"3^R_C68X4/Z#L1P2K68 "X![G@RNBF9K3[+H%:T/UC
MS2\VZ(<1D$8D,33O8;T H*[ESI:K'Q]=%*T>S$W_E,'3\7SN>$8:<J:B_3^E
M:&M#K,N1F^<YT$OL96MP:HLW8%^Y2I@!YE.T)EB]>^U*]=B370:BEA9#]Q=\
MCR\<S[,O74*]&2'C@/.$<8+M7R$/+?#M6,_)1^=(%\8,/!#1AGO"8Y&C)<_=
M+KKQ*[QRC:.)7(BPSPY<D8.MUFK]0()JXO37[S'3V(_(2(Q>&%53ISXPKT,O
MIF&/3X9@F:^>A ^=>7_X*>)[ELF^/BG0,5CF]_1_WI( _6S9#EI TF_LA+$E
MYU$#WPTSI]9^8F!;.DF,K5.N7J+M'\<=:;@E8';:T7-@7*& *%'G-#6R-L8Z
M@&V'\"*Y&BN-\)U,9?;'$LKZ,C1:X#%]EG->#+LO:YE_%KQ>V@C)E/O?ZF0\
M[?/F740]@//5"[(,V6) \@(+:#G#THNMEZ5,'I6WBGI8UUD=?=7Q#G\/O3K0
MV/&ZVK(O_C^0#/!?,5E"JQ-[ [HKBHQ;"#!^^!IL*>8\!U?;C=:WO:AL7#[]
M@A2\YYZYQ('8 ,J*T^CG>X0L'*@S1J_;@(GB6#>AD4 "].$-!#PTGE.2628=
M0'ZO8=D1F68W&RFQ%VD)@Y]*Q_'O[7^X?DXV-NC@6(CW-.SYS4'^E(MGXS@/
M">1OI(F$%M*V>CV P*0KZ0(Q)6_&)WV,L=*Z;).C2[%_-)])Q_;55HDQ5W7C
MA(M+H_I0&$'A=5\@@$9H0A UFIZP3X*"C, 6C,%7_P/?;W!E1U\U5&OL(KKO
MN+PS]'R$R<-+!N\M*PT/+?0195['Y<H]F2C*OB1M[R(7_>^"$\=CC*5(\63Q
M9@;5%P%:.UG+O1ZHIS"32W>=/D[SNI1S6;-N+-XN;\_@U!A>B5--\"=,$+B"
M2X#E$JV:KDFS?_OSI\;$[_ ]?0@3^S&]BYC%+U^FM@_US3[8)F/I/+']H)@P
M5T@/@GWFH -KJT\MHH4.;ZZ-;44];CB$+4<;@(<I'C]NU-*;.IVOP8PG_*2+
M9#_=?B#!C-UW;$5\/)(K&,YP;27)^R'(N3C @23SDVL&+C*6@.3HXO8-F!AZ
M?Y5'S<W?G3:>*=_#2"&A!ZXLEV^__O0Q!2/";2%4=+!E<JDAB2Q/;)-;O;)&
MC)F\]VK".[0J)RWS*G/T4W]:85C"0V9=68'*Q /K)N*ONOQ'!!N=DI+BDMSR
M\FKKUX^VG)2VEK$_UGB6'\;3KOG[G\_^^9RJ'.]MQJWG^LBT?6ZU4P"0.X.>
M[KR2]@PPYXL0YY-C#W/2EP(0Y'@2<)8'LFJKC.CACY 35JJLRW9BWAU9='MN
MJD[5E.^I!^IJJ(?>AJSH/%35;K)<37%$#0DQ$.!>Y,)A *(4BBRML 2F-YAA
MD*[S3F4:]&T-2>"F43A7%2K?YOHWQCBKI+X[ES^0+<C3"[OO*<.H9DOR,[]!
M7&ZED;N'\Q1Q\Y#'$,([^:'QP!Q"2GO71\-WD'=_/3^ZQML3L;C[PT68<4K(
MFZZ=B&O_0S2N# U>[42GLR".UV1J)N"&#N"\09]C J;-0RU<^)"'U*\<94+
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MTB!XBPIS!2$;OE6$\7TVSDPI+!Y;RNW%P@W?PF[8)[Y!B-T8#!]?>L.G=N[
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MD5SAK*=&L)ZGFO%3.1LPK_Y[ZU7_X029_YH90>QESOOZ_DD+KG =H,=TKMZ
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M/Y1*=USZJU3Z;SC7')_?!;KN[P,^?!8\J;86_F.HUN9WPB*Z+QC"3B?C$X6
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M-DZ]6#@T^@D*.$,B)E-_E##&:/B%%4X=M22TDSLR@J7HC-#1&[ ],R9AA."
M4 7?N#>)&(==DZDI-@C;YHD^6;4>=?=:OT.?6%7^]+8_OJ4KIDXIU/*I6NF]
MIS0+"^_WYE_+J]7X4+"\BAK,V*S$9J_Z#Y78,,/>T*KP;*:"8>>&L,OL,<+:
MD88TD ?@I< 7:H!4FTW2UXP:=Y?Y6@]!I!(M^JJLNU7V;?56PN=/*3;R^MVJ
MZ)[;=9MM"9(TJ2\))MVTXU'7,E,RZE,<3]GFX0+;*&>D>^YHMP?/]XD>.L0J
MJ0ZAKK?YO!X?^[*99YP\B6_%EHHOU!8"KC9RI':]1RZM9N+@ <KS-'=;^CU@
M[7;/6>!JM<CU.R3E?7%MZ$;?7R;S\SKZ7_QLS]5# CFS)YU*O;M%S3I7NZ<C
M&K;%QA2FM1++%:1YWH?>\ 4.@6VW6?2/\3FO#*T#AHS-\'/2*R8_=2;]4 _<
M441U.,]VDM0RE[H,U];?+RI4B998Y_D#9TNI,J6!6;84@6D.+"VL>19E>[5J
M+__B(ABGB_N-XTS-@TYD5 ^:H/MK@#A7;96D_3:[4W]O_:?ZA#FX\B2LQQ*H
MM]2.GUA&_0X0P0QBQ2I(C\QV/&8(^68&RHN>$>!XIHD3<1-.!:<XPOC^ %!/
M[0ZFCUBP, ]-]]2@QP'C1KW'CD_"OC"VB6"DQXQ^UN98SW>[1O,_N*;QBV==
MZJ21YM4<]<Q=,@/#^D=>QO"_YO]4<)9?G&7#[</R0Y 6^S!'G?.RX6C8<='
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M/\^2_FO4Y@7'N,(_]5HW-_*;]G'UT*=!.\9LNQGO"%N/8J-7LEBO^,[*1V=
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M?<^/R_RK<P5)ZFM703?$4S@ 04'*&U[YO-0,L-2YAIB_P*B#QNF];+M4=P7
M/E-_M*B91K;1:-A5T#%X<-?#2L\EMBRV%8XXOS#NY8*]"Q=ID=(G3+.S#_W
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M:.6F;RQ'\Z)&C9C^2OO:I0)6UKN,^XD+FL6/TW5J99[$'GO1X.BH-,G>#H[
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M;G_KK-E:VMPH_X)_6IS8Q^+M189F7:L+P3=8!IB>?ONY_ATJX8!?H1T#/[]
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M=<(37=-X$MZ@L BE%)& K2'$S'-(DWO42,4 ";E#J.S[D%1B09C]P.;5PEU
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M.IOOE6VO\GX-[H%$RNK0,IA">O3D@1V0!RS9_7C#$/X6]JGN> O5F*):<G<
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MYC[@0O$:1/#[3[B)<5>I:?UY9SDD[6%MU<=G]AUJZ7 0@^-O8[=,%\(WKXO
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M?O(LW'0- IPD"X/!F8->[_?9LQXF306 ZQKD4'\S^$>-*#"<2B(3(;^Z6<)
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M+9DG!=C2H/%UIK14\68S#\#]A/^\6K.IM5NBE'H<<XMR9M\_G2'^M8#X2 S
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M@NRHC!(->NE1?TC&I33=?'@"E>GZ1.%!XK/R+6N0KPJL;D;J_ 3;>!JF7'>
M>L"J63[OK$,!NKUQ?X\WD=%6>65$;WDDT\O&314CYB96AU*8]Z! E=<[J^;R
M5+DO<)17N*U$7WT2]"R^A;@9JX#>&N#8@-V4#M'1,??*+BTBOE/2Q)5WID+.
M+]9ML=FKQ,#V'L<#FJCYRO/L:W[(*;(0UL#3CR<++%R-$O.]/>XR8LTTO'7H
M1D>A!_QD0*B= MQ9'L*&_^,=CS),,+U[$V<W _N4#A)23_7RWF6/7:/=+RZ[
M+FVF1>YILSO0L1UBJA:^04UXD)"#H+RH@E5@'S+N-"*VK4$NI49+8&R^8.4Q
MCOUUSC1H+&OEE4![0D6-;@DU7>0&Y=59*^/6]W-'; V^%O2X^VY7<ITC@PX@
MSDU?@UQ>2(2K C!&%&U3@;D?U7[G0B5!"%W8N%H05=3J-2>N-SCB7!7I=DZG
MT_R+BY.'@<W/[JHA>G8+&= BS+<S1U@+@ \SE.4!PKHDQZ.:R8J@0*6F!UWP
M,L8B."&[EW[]9_TV4C^>+5"OKL+/30HTC*%?"W^;G"-^=><);V"?XQP!2.2R
M=HZ4(TL,3\E.^0G;>G9V7+2NW]S=O\27MZ.\*FOS#WH*;?B^9:#0V_#[;O?+
M3+$0.0A;^.^ZX[]T\L2/!HB!G?D&) *-X@EGLD4! BN\!]1+F#Y=N@6KR3S^
M  ,S!GFTL;V'=DN Q(^TF_/'_+W*B-MOF"<\VGLM/U5ZD#>Z!A'A:6'\N<GP
MG9P=@.K+D6%T;4LN_Y?EA:V?@O>D:-1F#??M&VO?DY?QIF;"*DLQD=/,K2!2
M"G&5J#9R'&YKO>PHKE&@WL2WWI3AVMHMZ+_?Z!VML=!W[[LV_"M29]6M_4\3
MGF69W>_S5T\[F)QM&RMW8@-;U1J+XXB RGNTW@@<H\6,:O($TW-D!JYQ5W<3
MCA\-U@55N<H]F" J,9XEOWS;Y57(]M@VLE/D\!C-/B%GGPLNT\7NXHFWJ.SE
MC?]!<.%AW&<(2A'BS<)<(8U)68.DD+?IW41I.D<=&PBJJ=-\Z3&U>F!TQ/Q5
M*/<(B61O)G?:3F[8_$6CE\LYJ5C"DXOIIGEN%]+<Y"Q=G.]:3EFN/UR=1*R*
MFT>R=_':$1)@D(#HQ1%?H"VT9*<>81ZH*F1J-I(N>**1+;=DT\=&X977@R?>
M5#YHX6&*MNN5"5XXR7B/:D0"6CX@\E)D&[JW "-T5XZXQBHL&KZ%D9QTFU?Y
M'./1;PP5TW@0</F.QK.L(TWVL>)/[S67NI4G-WB'"\[D2^.I"*DIN"FCY $=
M*3RC%9(_*X\Q(06,GHO)'3\I84,1VRK\QGQU,.8WIBO]#5<)G>]@[^6UYZ#?
M U3:F(L<O&%H<9JGP,@J+/$8&=:6#NTH7AX)^59=Q;_;L/.5\LD7%YJE9S-_
M,9FSK$HN 4=YC*B"M1;?GN4)-3(=Z80HN-;,;1<")56&H]IODQ^8'V]TQU[H
MIO\4A!RP)5BF?\Q6<^>QIUJ-%P (&T>I;L/'X"J03<4B]+A&F,(P.J,I5^.-
M^QC4O?_1_9*G5Y*2&PSN6KK8;,C,S S?'O'%E9XZ)\?VP35>-!=@H(XS5N:"
M0.#<*8$QCZ(ADX*V!=0Y,*..]EW536Z/#Q*:[*-4WK,)2'[]2;=D+.4IY6+$
MW;QE-FLO]X418D26A>[AF?LI"PV:ZU_'&4^DU%(=Q9HGR%.W\S._5 4/2A)6
MJ&\C3W[>1'D:OJ'40OFIM933!O 0%&);\?KQ$*+70MPD+6Y>FFEOSRB(O^I"
M$BFVL=$/--/>';OYKE%&YRFENIJ!AY<-+PH?IJU!O%" EOZ<-ANM,((;UF<]
M8 PE$6Y^Y7RRM:W(L0\[2#*/^&[G<RWM<T)-S+CS5?1G-$$4]/!L[%".(T>R
MFM4 F++/<W",@KP0AN=L\SMR),>>5KR_\4=J9)#][&,X;<@IQT@@2;+X>=:/
M#R)Z VWV_+A[1,IKY:W<-) [ZBL#JJP:<$!CC#?#\Q7;!7!" F5#GH CX<QH
M1\BSKZ<=KE][UW(K/^I7WQW_;3%M0^GVC9)7[WP"T4?).@0Y=X!]=!I7A9S#
M,498A7U7)#Z9!U-FE3QI;7O5 _2\$XXR-H;L,*W[L$2^Y#_PMQ=27Z<J ^P&
M$"_,98LX-D F;=[,HL?(7;-VX.=C3Z;N_&N*95:ZG6*,-=];8P)R%QC92(X?
M4Y"R,-?Q%-N'%05\0ND!FE37EL<*K?7[&=B'8NETYYYB3\L;3!NR3KJ[41IR
M^Q7(X*YAA1L0XWH(>/ZY]04!6,5**PXXCA-8@_B3MUR&[_;#O$)M11:W/0P*
MUC L&]._$#]:JA@ALVASF'*I_AZADPCL;&_% SL6.#(^+*.J]T (\V/CF35(
M:_'%N4&<@'?/SVW%=3Z%Z,00:9WB3]6R:0V:02:;IR=>:ZN]=9;O)![&-8HC
M_'"I1&6<EZX]M7#^NK8#$T7!I_S4CT.*ZX\?;#]1U\\I2%RY+I?QN2IWD\%R
M9G--VQP$6OJ/%T&$(%XYOSQ7>"*!H"\_Z8?K$1KF75G?&*=RB>J]U3$$/8T[
MCED6(\(%3YAW3)HQ;]WBN^4(I[AOL3". T!@RW#< 23#A=%(AXICC(>,R"(?
M-!:)_9-O<O9MXJ3J&Q@D4R+?=E\&\IJ1C!,+P Y;CE0W2Y,((-@!,S@HAD\C
MXGG]8SHJ&BGY8WN?,4*([-YV(4>;_^''C)M'\R^D#ZU$"=<>7]H&X6I6UU37
M5:?\Z+N9I>5D?J*M,?-+4N1F2J19_^SB+$]T@;G>O-(4(()5+,,^E62P<*:V
MKP+&/PT3QPJ,H],^7CZ.1CA?<IR;??UR/OUSV-VRB]_N=MV)[]N...[['U1F
M$KK>X&D>U,08]RY<%==4L+X#A#\,BD:U".E<]_AJ+NN*/)_6<SAMM"- *HU4
MJ[)5YM+!4YFED4(KB%BR)%P)<Y$!?\@TI.JG+*=*HH-/5TM.G_D1]:(]V"]8
M;M^88ND>5SG^:^CM*0._QMA*N,9#B(OZL45,$9X0$DSWAE_,-2D(9;1_F_R2
MOPQ9:G"<?(C)>Q!6=':\\57K@:\R2P_C"VW0$RH??VP7OYNK!<I)'S!"@82>
M(RW<WX0OVU0.SV?+\?IYNH/+J#@_Y8*AV[>R:<D&;68)5U\KE?/BS#M"?22U
MSN^N$GV;ONUK.+;K/W8#S<#VDZL=YQZPY;ZVXMA'./[]F-T:%?X5U>E"/TH$
MRMZXO/4-R$L_%+Y'V-M[LU#CE:'70Y-KD#;DB/,A,+*#UR/@QS*,U-">S]'C
M/L<H/7-#*]",9V+*>BO'=,:L]-*"M;8ERKE,:]I>+%6^I1F7E@=978.P;G!?
M$2\122L-9$89[A(L!2[''(POVSSYGC%>K-0]_%QUAVG:,4"MW4Q-^.N\9Q3R
M/I[AA ?48"VXX05:-)%QTA'8\?P:6!CP$D4GD[#;INTF?)'B5Z06<H?G)<6+
MF\,/BU1Z7=F]^+UE8,5GSIU]'+!E#7 SS878SH"J0VY3<UL]+)%;\3'OP4UV
M[L6:BL"([-B;61K[Y/9D6"CC_X&Z2DPB*QPP9IN@#7DR@NW0>!=EI;[<;^[N
MG]!=?1['3CVRY-\3FTX[$;\PT?9ZY.*M-JFT9NQ'&.,X_BN*-5S[O@_G320%
M-M7K?ZD8T'WAF^7:IF0S;$GRM#=M.A8/54@4Z);[A-;D2$^R[C)A<Z+,.(H^
M1TJU!2OU?A K!9B<&JS399Z_.>ML3M+-K:K2#GC]$G),=[)4O!2VQ[X].>2>
MB^/\^G[>_$^X#T'BZ2G4@[NJ_S6/%HNG.":[5%V?16[!FJ*W+G1Z.%1=DGJ?
M3N;!SUV/7MKM'7_-9"?Z+-_".^T))*"&FL]D$EAON+D_4X6P@_6"R"V<*X #
M+:$.QKQH>WC@8L;QV)T3B3PQO%;LC-"%!T>P<UEA#QR><T_]K;#U!D;:>%N!
M *JN;3M9K,ZY<"I'(\UWY4Q!\<NQYS*LNR\^VJFE''P6,9KSA9 -HN6;*J2"
M+NY\F#\--<>FJM*0$IA]3$0<)Q 6?23]';<J^15IQD3F$*0E*W%L^&!D*]TB
M[]9./A\JE".=RA/ZQ.RGT3'\P'7V&> ,2CZA93> /)7N8<":L>K=GLC:ET.-
M_[:Y6L)4T;7G)X-X!RX.>NAN!.4;\FO4$0 OFEGU2GJ@R$.A=3\ZA=Q2O_E+
MPQ;6=\NLV,.CD3WU4]X*9P6=%0;U.1*R=,WYQPQ-NFT2@I).9#@M2-K1NF4!
MP>9>X X5V2JCXYB,4;LJ4)1UH:7T;54F-<6A%;_2L"<LTL\"8?'B'T7A]^1@
MGH@":* &1G7++"K:4XM;:2Z;/RO;5W'+8"8XW7UZY:CBTT7"-TN_[5OVII?=
MA2KYD^KA@&P+0@HN@!ZBXJ.#6'U!*'&T_8E^H_?'%8O*:VHJTW=^Y[\A;/;*
M*[ 58PH./@W0V=O7NPRL02Z8I7Z%L9H!I:>:+?HQ9\["I8%R1E2+B[WBZJFQ
M=)$].*]-RCOO%US,V2B_*>!AA/#G#:MR/B$^+X9;7_BM'.]&@36B9/-VK[1M
MWFZGKUGRB]F>22?J@+4I#L+K1S"LR".A3<0WV4EUN%< F^4,=+QT+.#(,97?
MFCP,H3B@K=5;;NLVT[DG9Q7O;(.HUKA:)R5\X17\%DN_Q1,CAGT:U]&/L5^#
ME$6\7H-,W_QR_ _?. F"3OUG[3&PD#]II?$?@_^_CK/M;;6(^'>IC61I/^)F
M/96XUFRXTONX9EE9@RN)2I:4H.JTD1?6]_+V*%(4-U[33N36XOPNLE6PG5AM
M[A,GOUF]I"H7UM#^AD!O'^.)^??W@ET/&BB.-*UH&SUULTLQV7"/ Y(V4NT1
M$ +G>1VL258L]P%O'Z#/NLO@/<+[,F6;E$*I''GE?.,WOY[O/S5P+_JCWNA<
MBL>GQ22AK]';%?7G?K+#L(-(QA%8?*XR-P$,BXI<C3M(1FRY@1](7Q"7:P^/
MW1RS8RZ>]L]?#- +A\U^4]LM\/B13K;TJG] 8$!H@-+$XR;[+2^4M2Y<ZYRQ
ML=JX;WM*(%(=^P%6!9T[ ":5K]SDRGGMDT#HIJ("Q\<*-%P34<Z=+_0)^:*&
M7$;L-F]]T<X T]1=)PZ/.7]"G(-^I;/8W!C$Y8"+K - $-NR$)3)VP%ZI&(0
M8Q)&]]AO3Q #L&X:&<KRY>]T2NTAIZ/J4DHNQ!XZ=#K7.CW\@#UE:S[[(G8
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M#+&*RQ.191U[8!J/"0NC@TL4I6J]8Q:C"]O=+J7..XX060&#Q #'81,7 ,G
MTR8Y.SS5<R?MAS@;Z'>D9(4*+I/"YN1C8GH@:6HVIU5%A_;4GE/6[D)<2!T)
M_6UG43JV Z[.&*QED$P/\CWEN ,(NK_3T#MIJLX6R38+=?NV3])-,6;/U$)N
MM$WEGF>+8EMAU:ESXNRS9-X''!_.5VH(YRUR0(.,[,MN6\54YY"CGX<^@#!^
M/+[9)>&K)FYHN"^07P=R>B)-_1[?,%84HPM>,Q%SK;_.E$H$=I: !-RACZ-?
M[$?Z] TA4GG@R*\ZQZ+I%?$QMZ,TUOB&PD;IT=T>(;X^P>F;AS"^2EZK67_?
MJY;0A4I<@U2X<J0->4*6S.Y68J7/O!W(1;;AO-<@BNB2A1.#RPM;#B[-X@7G
M/2]4_1#+8+U2KQ;[U;BUY>[ACQ,_:^;-S6A@S3$T_Y:]$W!G+7.C0%Z(CR,=
M'=?KLZE\AE%EFC3'^_1RTN<V/;A>I%-\*_OX_.Y/NZA;>FM.QF 7K,  _ Q.
MIOX,;Q@I5F?'AF*'<7S/ 03;&H"/M2?"%686OI_QW_O4AOUIO^V'7(GGIJGZ
M[&I7VQSS#Q#X,T9A,H\/.T(L#T1G4+-3=<S=*+!X3X6:JBBW7KTHVR"_ZY+-
M.YV3\L(_K[?G+7)QZK3XA6)Y<<$JAU)"A-9#<<U03C! 8&2TP*!&8WLXB +.
M^3=OO]@F_C""Y!Z]WE'POJ92EF?[H[6CQLM&1+7]1F/T(V@\>/9#6,4D1W*!
MU<5822524L;W]7),*8@[6/4L!*A107/W L=@ZF.!0U"U<972%"U5?Y\3:2VZ
M:3T@#7JR0^7_X>W/XZ%LW_\!>$)V)GN(*7NV45D*S52R):D4(2;)OK4)&3/V
M?8F*N]R:)-E"ULDZQEHD93>6650*DVNB<=4LGG%_OL\?S^OW__/'+"\O<\TU
MYWD>Q_%^'VL+_/.([MA*KT/+FZY)K:ZG8G=S@N>2K/.I"7$WO)6J!*\?/E55
MZP21U.&#2X!WK !L:HBE)K78U.*XF4-#QJA38Q+ZP4EI@1R34=_+D%A=^@ZX
ME6,,9ECZLOPP))04P@A$,D]S&C?A24?8ZHPJT'WN+(ZZ4-MN6'+7>%CO6UN7
MV>&4#$6EM7[IGJI3W6,*#_"%>X74>2I-L&FG42Y:@O-JF=..] G<7(>Q30!"
MZMIFKA3FX^T/JQ$T#YT/>#/WYJS$FYGG7=X:O?2V,G>'#YM>5-]T6MN9:L;/
M>4J@E")WJX&3K*-@ZT^?A/ &,+.W[=%U">?>Z5Z+M?70]P;B55;7?N4(?O'S
M"OXR.HOEBO&S[-!"G-=-!% ;R1->JFKR3O0O'Z5'Q?7GBACC@(RH^9_"]>IG
M[%O>^NF8YA_^I6M\4S[]Q@SO?A]CB2:6L93P=!Z#)9[C[4X!=S^"CU,24H9/
M]/CT>BWK*;SOG=_;'/B;E8*A4]%9'\OI_F$?PO+&KX\*"WE2D+-U7-%<EA;F
M,VS/YOIL;C]2N,,?\*?!LTV@\C^>1O9YNCK73Z(5*E=<)2(J7JJ-D0+6:[R^
MN=7*JP$M?]PB!P[3?R.[G1*9!/XN)0]0)0)'=_@1(49W]9J2>$'DE%:A/(>C
M8VZK73Q]9DMF:'BOOOJI"A%1"3<07H[V&L<H!5Y@WV>HYE6"/1ZW3 GPU-=/
MR>=2J%R_A,D;6E;BT3-UZHK[#+\10TLK_V^2B],.54'O^$?^03NW &;I6$H1
M:I\Q4G#5:W=G)T.PW)MVG.Y+>Y]_E(K_7"OG]#?=IX#^9,9;PT[T48B#_#1=
M@1&\9-N72QH;9^X%A1A;3J#WZ]P4IR6/46D':II)S.J[G!*F#J4YX6N?;EY#
MX]FUVL&/\:Y^;KE#SX[QOI4G/D1K B4/M;>I3I3WWH,-?\ZV!Q5IQQWU[V))
M%E1"ZHWZ0MOBCW(1V2:*8_J_^Z[\B=Q+HL9GGSB^P=S!8H_04KSG_ !5;<XC
M9" R\3P(6X*ET-T':?CN<%62[;&#<:I1TKX'*Z[8O]U#,>6OI38O11_'4X76
M:ECJF-[%/0SY5I8)YH.J G"Y@SD:4^.!1@)HHX45KS-'=$-:LNQO=H>)P"SK
M10\/(LQX9U*(]VUA:#[><VX4K!?;A.N%9D IJ R,PGCI)%>&'0V<'IIVN="@
M^&*1L0?^^H:K1I_'[AO7L]KG(G?R6B8)G$ZT/>O0=Z^CO$NDKR"4,P?;7A4+
M/2D!438Q1U]3'5G:;Z6EMR$AQ6XWGLC:RI[6")8^_.X*?PQ79)UEN0)KP*UY
M *L4^49OB5<ESZ.B!<M]0G6B:@R_1;Y])CQS\_V^AC8]2='GZHK],9K_"3,5
MV[)%WTT;35P'VJG^<1VH,M#' R0R-"U5RJ/:W<?[%[JREATF3*!&)VYD^SU#
MO8E]*NLWMWQUX$-MA<]-,1QP'L8CU_A!W&R,!VC"TD1[(R79P32QZJ,A'9C7
M7YN$?=XZI)=?LG'-*SY@2KWT^ZTXYG+0'SQSYU!5H-T [* 8#Z<OL^5Z>YY&
M]FY#<N(%,%!&;/E[*B%]BK+F46-^74Z]U2=[JN^@X<QE&RV!)4(0F23$%>.=
M38'*B9><$G1DS'/,)'97#;1HZ>@F2JC_>51[#S-Q?4'CWNO0GR79&+_8)(I*
MCX#@A4VAS(Y=O(]M\KY["].CY-4>+:MJ!&BG4\PPL&D#Z&QSN&30P<=P,4IG
M\1?X8]]CS@FO-;+?=*N6 +U,04X:0H3MU@XR "S3!KS%8[+D:$(@ Y%(F;/P
M&/^6H*EV94D\^5<D71US;NT;#VWZU"5L1"G3% 9AV5M*LG_=V:Y@#:>Y_,>6
M"UV\GN3V_6_8@X8VH]UG?_T87SAX5,NBXM>N=W5:O'MS99OLB!Q;KYT12<3-
M*2Q]*UK"I6Y#)'__N(M*Z3)N^_0EM0]AU'RE%'&O1"/GDFW(!R9UTG+V6_+\
MT&?=YL'91_^E%[B8]06B@X5Z%^YC4Z8*ME35')5^- D;?A&1+7RA]4MN!JBZ
M01(YOLNDASN':PK"O",W^.<2 M6]0V]SI8#-Z3?6Z+46VM6D[%<'-X0O+[B?
M(AA9A]S)^!/,+ 6FV0K.%,$,7!-JK9#E@$:"VY!RT@FX"2[)?1O2VQZKN$Y/
MFQ\\T]GT;WO7^#]+3V8HT&=^!_;RCR $N?.H%G^VU/3 (HSSD*="&U4/JQX%
M?6H=55)[ZTBU0XLH-8L$A*<%2J+U^</:N4)M73.+=P(-5EO0=!Z0Q<Y8+,'[
M/2V8)0S_M4I@L&_1B$^LTV)0X9ET?5M'85"B (TR<#;99GQ?4O[S@Q>-]-XC
MO4?G\$P+WH(N8H86=8#"M"Z%%_,>_E9@)Q ^:.K]<].BX8JQS,!*V:>.L.O_
MZA9_5E4O,#V] 9TI8N[GM!&NP4C,=:8=YQD&:=C(TC',@Z:%U+#O>!O\K*>\
M5_HZ$:#D.VYD7U(T=$_K!/?T5;J]I\:__#^*+2@?%G?&6N20N6/+O1ND.="'
MR@>:&YR+4A0L-?GY\FE2_>!;B1]A!5.#44/R'3>$[E[4917_7P05]02K2 B
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M5GO+YZ^%3H2N#73Q]T:G_6],/ZD;H1 K6KX1+C:0C7!0[]YC'B]Q 49Y J#
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M"=EHU&9?N!!I^$M%^^A;Y[7BH(/2N<E$P!.?1&Q&#G9'\L4%Q$7T,*_(BI"
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M_B:]H!$K^;S5FCUQ-Z;A7-_:MQNW#OUO(F^=06&:<XZ=QYQEB2UO0#CR7 W
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MHNGJD#.\-F>E<?"Y75*8)4!2HHM>>7.;\FTDM^@[(1<7@)L=(Q&!(V[9GGC
M917<95U[/028,)JGL&^ &Y 75>K1["P-V9#B+$J,>,2'"M\<D8.[>G36GE^
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M*LBNKEFC7=QDS9DG=.7S;7=Y%8/9GYOE@0D/[,\(QOJ18'@O@>;LUB2V&LN
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M,_,5A[;3<T9;(S"]?'.=%WX"2!V M10QA3D^%(PWKQHK]Q,'A6MQ3:?_&/9
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M-UR^>2:01EJJ<];727?J>@)44:6)6WG/\=-IJ!TX$8P_7UXO7J!37^*5&FX
MYSQ4M8#1-G>_A^9M[<]=_-G8M^2QGKDQ-\3M@99^_LJG,U%_XF@/]C-2O!/-
MSYW?=-X>(O1B<Y3BO^LW*5H<&V01N#*M[&7P+@O*S@/MF!(H]@UPKB3@CQ^9
M%+)8P$D,5I4X/J^H8M/V/$<6VRZ:,X0N=(!:N+48%F%2/Z>..S"1T3@8%SU
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MR#[H932<$LWIT<:EE(M:'Y#'Y3L<-\W[HI[WJM#5 >:^C'"0)A%D840ADE$
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MIDEJ(<&3(*>S$0>8)1XRRF(U01Z)0HA\0:":+@:Q+GN#PM0+9=C-TNO<L#;
MR'.TDFO ;>FV!_+8<Q-)@D7 /1C2U(,($4\7&I4P9)$(DY GRKZ?;_K:3V=>
M-C(--R=?]!B#G7V/<<K]/^4\>W*'UI,[GOX#'40/<N3\G(?+O0.V#WL]OU\V
M]<@#+)3QPF*U4,;*L,%1 *E'?!W%Y'.,(R&P5;JW<PFGYGAM"0A(#42[FK:+
M=_]=7_<3:T;;SSI= U.Y@X2A=4K0EIXST&HZ@92?2Y,PB>R=DT+^,1)Q+F'L
M+*?FXD ]>W9R7><[JY1+UIT5SJ7'PM1/$B@)EQ"EG$&:*LYG7A(GD1?YJ6=U
M?'<XQ-1(>TO"IA!Z;M]&\Q!&,X:]#IR!*7(;ETXZAQTJ3VKNM-WDX2CC]HX\
MJ>5!(\C35_:LSBYDEHMFEZQIUJ?H0^?=ZUK$NE[C;:[;2,[3A"0IB6.8\E1O
MDL<2IC)!,$(ICM6WGL2Q42\CJU&G1@"=T,TV^4IJ\* N ?>D9G?Z_2?WNHR<
M92UUHQDP(PKGN [,'2M(MP5NRG7,FK+U#LNAVP#CM.JYT<#C%C>WP>*@AKG5
MS=<<YNN.E6^4\.T&_E)]7EUI,V7@M#UMUZ>%HGJE?JCJC,U%&-*$1D)1D]"E
MQR(."4F)MDNHX))YR!=SQ:&TL#OQ[R6-S9>V+=. 'UPG69\(@'X38A,D,#C(
MX\01=/UO]9<'-JJ C2ZK9MZ;N -=)>+BW/0,.+@*5?<Q"?W$>8:PA:MP.Q[9
M<-TC>S1^6'7S>5.4?R5EICU"-7:5\6[4_3Q]ZOEQ'&$U>PF/(/(2'Z:I)-#W
MDSCPL$B4SV?<Z<%R\*G9>ROQ@9H7L%( [&A@T3O =B;.\^;0^ Y,E ;06M55
MN!YNB]X, \(^4C.&'?@?5_"S'?@?&BU<-6?KB=G9#@NVSQROI4)/;7=Z*/1]
M1L]#(;(0'V03FONQS)CX*,IFAW$N QDG7I#JW,,8(ASH1FQ"_1,AS'#,XB2Q
MRD\Z-=#4R+_K2%NL.M(64GT?]_=%WL;K'Z\E9WUB<PIUPX,7!U@.?7ZB1-38
M=7'YC9A R=D>F#@\_K@ A=-3C%-CC7L8<4'C@S.%2]?WL"[?+'5U+O4DIM>L
M6_7\3\4366RJC3<'%!_R]Z+6PU?S)(T\).( $I^$$-%([RB&(8S\1"08HT1&
M1LT<>XT^-8IIY=?LT2F@/Y2R50$\K%HTMF>*N:A!I96P,(&L9\? Y!P2\X&I
MJ(-[(SOX($$G_:8C9B,_^) WO88_#XVXA=4Y)/(CF9U]9\"5$=H7PK-6J/5#
MQS-#^^J[8X?V?DC/TA>DU)&_U6IY4D_/V$W.7V6+I2X N4K<CK!'N? 8#),0
M090F%*91XL$XI'[*>2C"V*YRDMFX4UM#]#>2M;N(:RMTIM<,9;OJ\$+>BF^9
M2F\Z"69FZ@#0#KQ4K"3>6*HS\&*-:2?W,$4Y[+!R6JW#<.AQRWC8X7%0W\/R
M]IZ<=?^P*)Z$^*P<=F59'X_>>5_DRIO7@^I G:J)UM[^NSY!>U_4_R6VSM$V
M3VIOVJ^0.U>NN,]2$4')E"F-E!$-<9QZD'LZ(H?0E#*K[-9GTV1JO/I;7JYE
MUX[_)O!O%?H#RJZ_>EV 90<(^/3Y-\N8H.=[=PS)^X_P1@R]B7&^?_L,K/5?
M%XG_SA9+WA[ZM5UM-03JNAH\J15[@\(,W)P/&;%?09Y[PIRN2<^FS+BKW'//
MV<&Z^>P"/4]NPU;)^;?YQR8>?^YSG-*(8NB'&$.$*8)$(@83F20^3SW! F;7
M*G@ *8W8<M3.PKMM5YXEH>'8;!KNK#_3#/WQDAJV--7=CUM=IY/6<&8BII38
M<$S,/U1JPQF<72<WG!NJWZKQ10U=2>55*,^P7?%T8(X\4D:\TBW(JN-_ZHKB
M,!$0CL(42A3KQ B$(4VB"'J!E'X8^<Q/K>J)N!1N:E[6L6+Y5<\J14XGT6R5
M>*ZI&?J@I-^L6'/[$/"Y)'6G\HW*YD,@NT_C@XQAQ]]<9//7>9W53W\M%LJ)
M)N73FVRA1)J+2%(/QPABR0E$''F0I!&%*6*$!L1GE!GEJYP<86I,V@H)UE*"
M5DPS"CV-XWD>=(+.T%OYEL 8L]A%Y3=45*VXJ!+LS[?%X\_JWI_U2:+^H3E2
MW&*?T\\=A4(NJK7B@<L7]G3A=83*VZI:"OYJJ4.O6A.OZ?)VW'2<)RQ0%I;N
MR20\"I%/B&XW+Z",HC3T:>)+:54?WUZ$J=&!%EYQK3@(6VMR$NH[ 42;(MQ<
MT?ZI:,WKYHBK$G6]:/U '9.RJ5'27KK,LS/E25Q-JZ&K/NADC>&)5Z 5?]:V
M 9T=][NW]YN)5"_1ENOMT-_NC:93=]I>BG&]Y=XH'3C#_9_4DU[9G>!+'0KX
MJJO'JZMM5NJ#UX;<NXS0;)'5F:B^Z(CCK<20!/M^* -(,?,ABB+EUG*&%-'J
MNEM!&'N^5;Y_3SFF1K1Z9HJ\<9 44>IHC)4Z;3791J&NT%-[7*BGMMMM6RR*
M;YJE+9FTYPP:TNGP\S(TIW8:Z DY-1E;>H"OC2;#M.^\$DVGG-I3E'&)]3J\
M#MCURL?942S3![GET_R7%W,L4^[[D7(]L1]#))A4GBCV8.R'D>=[:8BP49?0
MS2.G1GSOBIPK#GLGR)ER'Z?@.4]%_90>F%5^>__VR^M7X/^\??_+JP^_7L\0
MATJ>\1>[B_7'GJS^H;_S9.L[WWK@*)_LH0*KK^_(7_K9*LWAL%YA2W&GS)_L
M46RR:-ML6?4YMP:3^D.I7\57HOWOIG<:PR0280ICE*80,3^"*1,!Y EG"4T9
M8MPHX\"A3%/[E!N5FB"GM4ZKF-(?%SJ3W3)ZU,6TF1DK(T_&P!33SL...F"G
MHL!L53= 6S-#1)\ZQ-.EZ>)"K%'-&(<X[ILT+A_=NS-Z5HMW:F0U0JU>X$S9
M3IU1=5^4=?:/QKWIRE/MNY&!%Z6)+V$<A0E$0>A!G*( "BP#YC,4>QZW;)_>
M6YBI\?#GY?V]WJ%6?LNV[!>+JKF?)3/V'0O[X8\[E1IPH?4 &T56[N*QJ1C4
M9W0!J^,.\/WE&;M-_-7('>DE?_TS[8BV*NOYQ[+@2U9O#E?%*C0A%2P-@QA!
M(83R+U,1P]2+.221Y)X,P] +C(HMGQUE:M38"=KLW7226H:)G ?U/.$Y@VI@
M)NN%DC$_&:%PAGC4_5NDH_ZU3SCG!QB%28QT7%&$V<6]NV<^D(QWM*(?WQI^
M;1_/EG]^%6WU=2*9\$,$(YXH#Y<H0(F()61!Q#U/.;R<8LM&FH9#3X\E&LDW
M*3KZ0RA:[[9K@4L:\:V[:9K.A9GA- S"@Y-+"^[K;7 [E[4#M[.8OK:R.S2)
M[ %SW'W3=/2Q&W%:HG*D)Z?M$ZX]=3P>VML<@W;QO>L#,C7^\K[]W9Y_DB""
M*),"QEP7^92ICK$5$?0B91,%A&/FR7Z'D2[$FQHMOE@0]CM4.JH!*_BK*&OE
MR;3:- 5Y=)K:KP57TZ;+@:U2?[I4YU(P]6VV]7M64?_@EY+DM3@=YC_&.V![
MG#GVS(YXRGDF3V-GWF;;A\\;'4<Z 74Y <,<C#J1\)G.2UVB>_H8U>DH(Z?X
MZ0Y*]=-6[/%^[N%?FV3&54[)WT1V>Z>3&Q]%26Y%0WFO2"W>D*QLPG/FA/FI
M+SP)/9Y@B"CGD++$AWX:11Y)@S 55ID>D]%L:@M8*_[QDGMCI10Z?WL,UZ^I
MR#NEI>_Z],46G9W\EM:5J15 6\ME^^*M\QIG8(43Z(!J32&@H0(:JS:$<P+Y
MCT/-_R2R)ITK]\?(M1QJ3IUE: XFH#NO\X1&U2F5&MME[ODQ]Y$?04&4KXE2
MYD&,I =]+@AE(<9!8'5LZ4RRJ2W5I]R24SQ=G27JSC.QS 1U-^W]?<S!)_.9
MW,N!YM&)6WD5YD-[E/V$>W9G\BI,3?S(ZP;HMR[H<C0YRQ99,^H'N5WLZPOY
M_D+D0F9UM2[BU)9HTD7D:I+I>G)?BM??R;WN@Z0N_R3J99E7GY1G\J8HM8QS
MK$NF!P1!1E(!D5HJ8(KB5+TG24AD'!*46B5+#"WPU%:177TU!^W48]/A;RN=
MMVMM=6J#C=ZZ.-M*\^:V3G?P56L/.O4MUY?!7Q^S96=*+\7 J]%DW@?K=6JL
M27*Y? TN\ZBKVE@SL+_8C39NC[K]KZLZN]?9:)\$663_:--@GHJ#+)GN5#LA
M 8]\&4#&<:B6,UV_7T0$^C&)/4IH)&*CX[8>8T]M95I+#W;$/YYK9E$YWG)&
MSJ\0 ^,\,-E;07PYV.!JK"UJ] ^'^4@5^AUC;U>>OQ]Z9XOS6SYRO-+\_73=
M*<S?\Q$]EHOMXO]M.X#/37<D'33R1HA*^6?-=DD8Q8B'/(0ABG76H_!ARAF&
M2<"XIU80$9F%9=@,.K4%XN-.-Q?9=KRHUI(#J437S5V:$W=EC=9W6<GA RGK
M)PL*,YT1@W5B )R'CD3;Z1_2-179" VTU* 3>P!,+=:# ; =:2'8?8TOO;^@
M>7_!,E>$ DC;()VP>DD6@&R=R>GPHF5;<J86["XO%L6M6EM*D.6U6"Q$>\=#
M63PH(]A9ZT'+23B[GI@^:[R%Q%*[G17$]MZ>6;QMA]O\=I.H-A<TY0E-$%0_
M$(C4?1 CG"BW(A%1DC!&/6]>ZX+29AMD1\:P6AC6(PWW1769G$T!IF+=]-<R
ML_8(E&'(DY3K1FI4%V81V(,T"$)(J(>PI,@/$+)*<+X2RC&J6VTG)[M'U&S[
M[4J<!EXCU]+M9A [3!4^K;[3U-\CPXR;RGM:SX/4W#.7]K"Z_[>H%UGQC]4>
M#!(LIC2%3"011$D4P!3Y,0P#%A&?4)D$WOQ1E+0PLJYW'F[SWFX/,=SK^[]?
M?WGW]L/_^\]_\A/TKQ8VW"YF!M9O;QP&_GX[N?IL;^QB8&&M]L9B))O4&!,[
M^_"HVF>MP-T[QK/UCDJZ8]$=OZ)G](PRR169_2)R16N+FYS?\/LLSW0-@3I[
M%*NDD?U&ZD+0($D5F0<A4?8(#5.(I:<+KE"?XT RY!N5WKU.C*F9+)T6,]#I
MT617[&JRSJRRC';I-TUF1L[PX _,HS:XST"K!_C:_7>8A(BK('4:IM)/DG%C
M4JY"ZR  Y;JG]:U._OF>+!8OEE66"^5>2*:L-1\S*(54OB_R?4C3%$,9)4$2
MQR3PI5':P(GG3XWYN@+<C8Q@):1M7?)=!,]SEP-<AC[ALH*D1T7RHXI?78]\
M]ZDC5R,_JM)A+?+CEPT3/OQI71:[28#Z31?%;F+4;IAB$R7,?M9JX.EO'$%,
M](?/_ 22E"NL0TQ1'">*!"*70<26\DV-.+;*(7WZ_!M8">TV%MAV#@W-IN>;
MF:'MJ4NER3>J=;FG6KG9>O9&SS5U /N8H<&V(DXJ0+@GOK9APGV'Z=N/@M3-
MN_U.K2EOU8_5//0\$D:1#PD+ X@"JKX(J>::>9CZ(:,>PW:)GP=#3(Z+5Q*"
MKUI&T AIFY9Q"*0AFUX%S]"$:(=,CX8,IY1WVW#A8)21&RJ<TO*P8<+)*_LF
M SR*?"G>*)E>=N?6?\OJNY?+JB[N1;F)SZR49U@U835SE,3")]2#:8QU,P04
M0,K#! 8(ATD2$4_&5D6%>\@P-8;0K0\>NOIC%5G8[F+UF04S]A@8VX'II9.^
M/>1<R0^^*07 2H.=B/=."1VDYS*(O3>$;N/2[<48.=2\-TZ'T>/]']6/!W\I
M"OXM6^A=L?U"EZ^RBBV*:EENEU6GL<>\  K=5@^E*85$)@+&OO0#CW&64JL*
M3%:C3XW[5L(WF\N'%60W"I@4[78P.6;$.!CD U.B4[2MN; 7:BY9T$Z 4?FO
M%S;[S-?O(?TX[X8_BK+.*D6D+XNJ/C@D(RE+4(ICF":1@(CKM'^<)&I*HC3P
M@AA[H55LU87QIL9K6^+V*T)^"5\SHG*(VL#4M V8%G78DT1#7%R2SZ4A1Z4;
M0_WW"<;TMI[=$5:U2S9D5:T7YL1+D/0%@I2*!"+B4TA9ZD'"/18C2M+$SF\\
M-]C4R&13'6EKB:YZ6T1G<3;C%5?H#4PJ_8&S;SU@@(C3U@+GQANW=8"!Y@>M
M 4SNZ<<BKTFI4X!U-O!J#SQC<QE$$:-1 ",N8X@\I P37WE>7H@)88S3A%F5
ME3@ZRM1XHQ'*2>V_XZ!&H4^4STHAYTAYLEX80>72<H@HPQ[W&8O]Q"RPUAFL
MX\38ZAV[G39?&V!G@ Z,NAE#7XWDP-2\DD]7F&BK'\U (Z,[2CX+@4LN/C[0
MJ"1\5M=]]CU_<3_:?9L_BES-Q].&T3?."I+*Y>/(AQ%#J2(*&D!*U#]IB+D,
M@\A#OM6IW[G!ID;":UGMOOVS>)I1@"N4!F:"M9@[^T^#N'TFB+@DAK/CC<H/
M)IKOTX31/2-7HNZ*8;[^+DJ65:):U</\HM,0W^9UF>6*R]HRP6F<QAX+)0Q)
MD&JC1$+JA0*&*)6A%"&5R"YH; 2AI\9>*YEM&Q:,,;]F+#BU61N831U4>%[7
M<%ZKOEW&>:WY9.HU]YBH291BMI'[CU%EN<=,."N@W&?L?HO7RU+PK'ZIL<SK
M-G7Z4U;]WF4-ILSW_-"3$!%$( J#!)(HH9#0F*FYB%+J6=FZ9T>;VG+1"@MV
MI 5:7+OEXSS"9KSO#+>!"?LD9 ,T S/"Q"4WGA]P5%(STGV?C<QNLD]NNE&T
MQ35UO5F0VWF*PX@R'$%. UTBW:,P397=F@J!<>2'/F+"-*UIY\E3HX>U<$!+
M9Y[)M O7^>__*A"&/N0TT]\J;>FHKE<D+.T^;[14I:-J;"<I';_@>=S/#\NZ
MJDFNH\CV&C&LS _='$[,B4B"""E\9;,M+E,=[1Y2&,9^@E,_QDD<S1\:,^5S
M3<IZ'#_44'J;[V9?AP'/-,1MEC?UB"E1?V#B>7L;6;X0C <14>\$1(FG7HB(
M"MU\6D /I6'"!!&4!]T+\3KG?_#78:7!@+L3C=1_R#=AG,V+ >;V#[1_L:7]
MD?93*P2:1IX3VL>PG+,I;668BOZ'VLVPG _7&QJVP[N)FM@/-Y2I)Q-!)$PB
MIA:ND*>0IECHQND^2U.*DXA>$S\Q\7#.]6GUP^JT^KJ3_'[1G Y!>X;3_3$J
MQ!@B-.3A_[/&=1KJ?RD@P&U<I^:]4MPIZLL>15O@[[VH/TB=B$;B(%"F< R3
M5$K%*W&H#&+N0<%UG_+0]Q,1V50S/3.6%:>,4-5T1]0NG,ARF_0,L(:;I&[@
M&GJ+= >IG:J<,Z!CL0JIL_9FX*:NRXPNZU6%Y8_J7<Y/]Y*PWS^]#)?3W=,S
MPXV[=WI9[X.=4X-;^M')1_5NO%=OR\WWK)K[F 9QRD,H$T] %$0<$I)XD J2
M<!:$,6)6R73;#Y^:$:)E UHX\%6+9QGUO0.;&3OT!6-@.C#&P?K[/J:PRP]Z
MY_FC?L''--O_9(]>TW?)WSLQ>2%R=G=/RM]?%?<DR^<!B1/F2P$3G^I2E['R
M)V(/PX@F'L),<.I;Q6-?&G!JW_*1X[ZUQ.!K*[/E!WX1<U.3P!V2@]L%UX#8
M8_4W0\:M"7!AS)'M #,$#HT!P_MZU/KNO;_R2=RWW>*V>SDTEWY>TK\+5G\I
MVBV8YNIJS@3VU2OI0QY[D=Z[1S#5R?M!$$D:RI11$ANWZ!E+ZJGQWL>B7/6A
M5%K4&5F JJEU5K2[7>!6=S(77%OOXOYA43SIIBGU':G!HZCJ"JAW2%GW3Z!X
M%*7Z?2D$>!)ZPY]()3]0=N;#0JR&D%E9U<W?FU8LHGP\M]/[C._6>6J>[!LS
MQED >''^+.!%=Q;07;?;/'NM.]CM?-3>T>D/OA3=F4%[EV']G7'?$(MB]%-\
M4YZE]U(NOH&[3#<1VZ(80)HW8XM2[HN\OE.4TC)(D8M]QG#53FGLB3E;B7\T
M8<8K\C\VOCO] T8?O)]G]E[4+TEU][$L'C,N^(NGWY0X;_-U Y:N$&0F*ET\
M*<N7ZG<?UAV"-NGX+/ CR00,! H@XE$$J5 6;$S3Q%,NG1 QL?'?W(@U-6M'
MJP3DHOA6[;1:4LL16>MCY^0YFCXS5W#\21G8H-![Q<V<K%32D00_:JV4-?H3
MV'1^VF@V QO=P$:Y06H(N,7;I1OJ2+)1G56W:.Z[M(Z?WH_,W^D"=F(]YCNA
MUI9W6=?.MEMCJE=+\5Y\K[]\$XM'\:NV=90O&S,:^"&#J<\H1#'3<6@)@3QD
M<2QU:&)DU6FFKR!3(VQE)OEVA-Q["LPH> Q@!R;=5H79%KLV6LS 6H_9RFM3
M;*MT 5H9T&H#6G7<<>RU@+IDU=ZRC,JCUR*VSYQ7/^_*8N3*N-;NX%VQ4#=7
MK_][J89=&T:Q%R OQ1Y,PC"&"!'=$C3R81J+4$B/Q@FWLFN-1IT:"VX*<RL?
M>%OL?P&MX+U+3YE-@ADU.H=VZ-TL%ZCV+X)N@M(@=='/#OP\I=)-L#A9/=WH
MYFO;YKS1N^.*%A_%02G/O;8J(A+,3V,&.1>:L1(*4XH8C/Q$!(P$-$Z-CB6N
MD&%R_+5I?W-0Y+9O#QSS"3%DKV%A'IK+.NDUQ*W\L%'@2%'A<;K66(,X3&<:
M<S&>J?N,-4ZG.\S8/VK2R7J?BL5"%J6^<<Z]2-"4>A#YRC-&OI]"3"B%C*#$
MI[' W+.*=A]?A:E1\LGLFW_^DQ][_]J(W_Y(:O"+/@,&K]1Z.\G<K>TWQ9#L
M)SW_8YSB/D-&US#F]+/-Y!\PSVM;B_^)*5]'9NF9LK^.27)E$>YV)?]5$%WW
MC7_(/PFV+$LEAZX666W,71Z&2<P%AD&0$(CT_U"!?:A\$($0CB(:![T*<QL*
M,+65KC-[5W(#M9YME:'6<8HK/9IZIY8.B?7TF"U00X(^\/*R 7<&]K$_1'M0
M=Z0OBH/4!3>5X7EJA5LB=+)^N.US^I'BK\5C0]9O<SUH2^&+1?%-5QVH;G+^
M2>A((5%I&G[3688^2E.?>1)RENCBV)&$*<8$^H+%#-$4,6Q4U.<*&:9&C9]?
MOP0K_W$&_ !Z> 96>ND:@VO-P$:UIE?12CGP5:L'.OTL-Y_[S*(9?0X\-T,;
MZ*--BS6C7@&L2U+M(\:HO'H%3OO4>LVC>K:2>B390J_*ZG&?R4*\$K3^K'F\
M"9^XN=<AX__0!G15-ZP^#QFE'@^8<A:Q@ C[$211K.OI<.Q%'A:$I#9)P[8"
M6/'J")G$:PF;SDF6?:9LP3=CQ"$A'9@.M:A@(ZNR*E>Z0.5B0=VA5?W.#'+[
MQE0]<7/:J<I6AG%;5_5$Z*"75=_G].V/H%.@=<[ZJC'I?DS8"Z%>KRY5^@OY
M+JI?L[Q0TCR]S95Q)JJZ:>NW_93V[/%74=\57!=KK^HF=F*>^ D+9)# F$BD
M7'(/0QJ( &(:4A1ZC,74M^''$66?&K5VQ09HH]^JYTNM-;1MYS#>])LQ]$0G
M=6!RWRD>L6D-?1C?V\UX%YG1J@2V=)JMZE TR,S >\5>NMNPLHKTDU80N>Q=
M,?I\N6V%,9[X(W?6&'U>#AMUC"]"[U) ]T7>Q,\TV][;^]OS2$8^\S&' 4:)
M6K80A<3'$J9A&":^'XHHP78U 4X/-K6MD5;6-E%MUA:NK$"QD;>I;=G^VK*@
MY5G(!0V0I[PHZ(>!LA1D2" FL80B\7PF=+72,+0O4.L*^.>N*NL>[R!)=!:>
M@+'0'0(8"B&1)( B\"F-4HX1\VSKO[I%^UF*MKH'VLP&<@7=P$9+1PZ?6W)H
M)=TY"W=:X>HB(HY+7)T>;^P:5Q<U/U+DZO(]UX:"OE;+>?WTMXRK]5NMXO=M
M$0WQ*/*E:%;J[VJ!RLGBY5*M'O=JK7KQ]+$L^)+5>KON<YO"O'U@ZTN1^LH=
MY+HM"<(1AU@$,?11Q$G"DD!2J]R?P22=VAJMLP<[>8'>,>@=2^IZ1LW(;A+S
M-#!3=DJTCMU*#;#60X<9K31I#C!6NHP4I3H0\,/$LKH6]IDB7@?"_'1<[% #
M]EM']J*&WB]UYYJNOL#V<K5.O@E%*@C!'DS3.% N@6[3FB0!)$+B( V\F&&K
MRFRV DR-]==1AJ2+,CQTSOYBMQ!83XD9OP\)],"T?1#)V0K?)$JU:.\$?K[*
M%DM]]1 !GGU1=,G!UC*,2JU]$=IGS-[/N3*P\6W^H![^3A'RPN\ZR@4^%MC#
M,41)I-QR]4^HN0Y2S*@((C5+B54.U9FQID9O_[DLU!QL1>%7[<_**V]*&'11
M^;^2\G=1=W]3JQIXRX5:YQA9M+_J(N]^;%0%OJ4K?VYNS,C/$>(#\]QVK&(K
MZ QTB W0[<\ DT$B#X\,]SQ!AJ?U/AE/>.86.]JIRGK^*_E[4:[-O+9>=8JE
M1ST*<:R=;QY3G5D4P AY29(BS&-FU)/Z^..G1BXKX:P*5I] [CP/7(_'T'MX
MAE 8?^7G-3[S8:L;MSYJ]:_]#_K$DT?YAL]KM?IL+UQEWX^S]=E>-C5J%V]S
M+K[_'_$T]V48ISP)H40HTJD- E**")0L%)&(2<2%41K@R1&F]KVV0H).2M"(
M"92<YITZCP-Y_MMU L_ GZ\U,E8]/,]J?T4OS^//':VGYUFUMGM[GK^P9T>K
MKGIPMZ%R/!'K?=$<;2LGI*FMV/0*W_Z[COYZ7]3_)>I/@A6WN8X(:[;[N_2L
M>1AASKBO."$AFB*P@!A)#Z;40Y+XB8P\J^RG4:2>&NW\EI=K.9L*SNL44?%=
M_VR[TS[.U)LY)I.;T(&)\F@6[R;=L0F4:G7=3>Z=-8&TZJ^Z7G<--GHVL;9+
MEUU\1IT2IZW&1A%\W(9E8\[%0=NS40?OMXQ]4F.7&5/CZW*3-WGS'QV<]4@6
M3;1G&E$9([7N)*&0$(D$0YI$#,K4]Z6'$+/LS'AIP*DM'AMY 5.2VJT4%]$U
M(WF7F U^0KJ&JZF$JT]!FQ^VQ'5'M:; N&3)BV..2G"F".QSD_%]?5JFO'ZY
M.J[T P]OCBXW&5\Y_\\E663RJ2EER_0"O%_G*F!I+%$@(!&^;F[O13"5/(6A
M%(2G4M X8N;]4%R(-#5JVJI#MHH;^23J9;F51VG3:L+)K)TGM.>9BZ%-TF/Y
MK>L*9A_D=GZK8L.-9F"EFDUXR% 39], 9.P)'*F[Q_43Z:J1ATN SW?I<#+2
MB"TX7"*SVU_#Z9.O:SVZ:F*(*68RB"#BNBFZ%R60IBB"<9SXD@@21I'5YL_N
MXZ>VFFVUW>S5GW //#/+NC\D R\J%FCT;D,Z7%O!O1&>I17I^9:!)Z[J8>U^
M+,7[5S<W#P]EH6SG7[.%LJR+7%1=?$$2>R*-)(->2IN/F$+M4$-&/2]*:4"D
M,*K38C#6Y+[H4D E+EC)"S8"6Y@W%_ U,#C=H3;T1W\:L,OQ&];(65A\[A <
MJU';-4C:&6MFV)RUPBX\8CSSRDR7';O)\)8>Q/J&Y.2A7H70$>F3Q%?H-34'
M4D_H,H !C'F0Q$$:\8C)^:,H:6%$I-O/MGE]MT<8,HY+2_?/?_(3]*\6W_L.
M8 :\V!>$@5FP%:L/X>T 8$%O?8$8B<Q:\5QUB3RF[%EVVKEA/"XZ)N<.\QR]
MH)_C]5NE$RNJ.KLGM:CF"28)]K /)<.>3F%#$".NR";!(1(D1;ZPZM*R^_BI
MF6E*.KV%N);/SNW:@\[,[>H/R,#<LX_%#'PL%AE[ E^[_PZ2P74<#I<.V=X(
MHSIDQ[7;=\A.7#61[%:]RS/WL(<0BCF4*(@AXD)"PG$"11Q3S)D((O*\F:U:
MRJFQRY4ID[8-H :9>#-2>_;I'/QH=Z"9?/Z,UVVD)YWMV@CZQ\YTW<9Z\"S7
MG<%Z!GI**9I,I75YHT]JA=+!.#G+%EDCV(?Z3I0W_._+58TT)I''*5-K0XJ4
MN\H)4DL%\J"?1 &* S]1#[6*V^PAQ-16@L]:@R('?AS\>/\36&3W6>LY649?
M]ID/,P8?&N6!"7HM_E;M.* U +LJS$"C!-C20MFY;7=XAV&05X#I-*JQCQSC
M!BE>@=1!S.$US^I;=*W230MUQ9+62=H$%<2^D)3@& :1\"%*2 HIP@ARSEGD
M,1DFD6]7<NW44%,CNR;:6'F2OQ0%K\#G8L%MJT^=!-6,R]Q -3!C[:*T930.
MZV]?QL9M#:J3HXU<@>J2UH?UIR[>T;,D.V/+^^5",1-OR$@'/)?B3N35FKF:
M0I%%*;+;_.6R+$6N1B])7BW:6(PU>[T72D1%<_-8I!A'5$":> W7:.\\#*%'
M&?(%9^K_D0W7#"#CU$BJDQVP3GA0;Z2W+/,^P(2:\=PS3]/ !+FE76>T[>@'
M=NH-S\!J0E=J@BT]M\R]&="UQA3O*F4=UI8?;B:<EI\?0,QQ*]0/A_-!$?L!
MA^H9(E<6#Z*LGW3\CJXJK$/6'_3SWV6Y>%N+^VI..<*A##E,I>#*]TX#B%-"
MU:N08)I&NLROU3;MY2&GQNLKB957IV5N#*NUU."KEALT@MN&V%T&WXRTW4(Z
M, <[0-,^1,\8(*=A>Y=''3>4SQB%@_ ^\SO[\= [455"=!70\]MW@JBO.B-4
M^=AJU#8QM7JU%/,P":/4#WWE B>Z60:*%1M) @4CC(@PB-+ LVF683JP%2>-
MT.FB26P$]UF>W2_OP4*+#1XZ<>U8R!AZ,RX: M"!&:D5>0;60H-&ZAE8RSU;
M)4=7,Z!D=T=,MFBYI"?CL4<E*5M$]JG*^G['AM-F8TE&3"0"(TAP$D"$&(68
M\P1&810$+"*!<JR=&$Z3W;7;S:AKA-]=[B&I>S1!,\#^2KMIBIM[%^RF 2LB
MF\,TBO7T3/M]YB@86T_.&M[N%-=J]Q;WM[FYY_M)D%#($1.Z=PB'--(I%.J7
M1/@",VS%1@9C3HV.&I$W$1:6[6@-,#9C'<?(#4P[>Z"-$\%G 9'3QK$&PX[;
M*-8<AX/&L!:W]CYU:'(V/PDFLD>]_+P7=;MI5<\%"J(X""ED<9 J/TTF$(LH
M@"3& O$XYB@RJIQI,MC4>&:=AUZNA9V!7-BV>CT'K_%FOA/0AM^5;_'ZM(47
MD;6.J5A57@"ZBO'+4O"L!GJ/=-9MRKMLYFJ EN.=\]/CC;T%?E'S(WO9E^_I
MD::DGELN1=.W6MVH2ZF\TN5]B\9@>MT6F)LS+_592"2,XD09,RQ4[))P"A$-
M.0M1DD:A>3$3DQ&G1C$K81LO@&_$M2S!9X[X><(9!,?A64>+"]90ZB(46Q*#
M3F372%HD4KE&=*0$JY>D+)LZ'H^Z1C<@E=X J._$NHE<=2=$#;@.I5-_*>@B
MN^WZN&9Y<WC.F_?Z@3PU3JVF_O+2"P]^Y&JL;UE]E^6@R 5X4M<KVEG]2H^?
MZ\C7!2C6^WSLB:GG9Q(LBOQ6E#^Y2@JSF;BSR6)&#QHOB<Q&KYWD,JL;'>_(
MK1NS^-KXQ,HFY?K8 "7:)O4)A4+(T)-<>K'/G6S(3;4YSH4MI,O]67H"?^5N
MW 1;X%R-I+M-N"%;VUP>=!I;<)>:UYC?V(][=,OE7,W?TYLLS]3JQIL(S"9&
M0U->^2BJ.<8HDG[,8>R)$"*/,8A)$D _0F$01AY+F%6_9(,QI\8_*TG!K1;5
MCF5,(#;C&<? #<PT:VEG8 U?(_ ZZFPEM,OF]<8(N6TZ?WG8D9O%&^-PV.3=
M_-;>#3#.M53&/H\8\@,84,^#BF(DI&G"(8EH3"6C8<B,7&2SX:;&-*^[!A!'
M6C$;=6+N@_AY]G&/X\#$<RV$?5IJ6+6S[MM?X]E[6-LI?*3SAOL^UHV3]DI(
MH9WO+^1[VR!._=!NN38>O7+#FYKJ6TY<$\4Z%XGGB316_FN(!42<,YAZ*8()
M142F/!5)9.1772/$U CHY :=_G=1/MR1'/!R>0M8NZ?-MI6SV'+J.V<&^WDC
MS,3 %+;2H,G<;'68-3]W!PD[>LS SIPUNHPP$1;;@2-,R$@[A&V/$$"%DED
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M$1-W7G=$HH<+2 (]G]);C2-<ML?.ZHEYZX,":YK32BE'B\O9O_X"7"0J)5$
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MU%+VC!!3Z2;;CY%#(]D+-QKH8MP^/-#5TV?U=SK?UG716WMMW[%'FU%<QHI
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MT/UZEC*$"A)AF"2FN9Y(."1(+P^2TRA'.%5,6!5^&#;\U+8W>\MLN1?]7)<
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M,!'%.(HERC"UWNA9#CHYKJC$KGM]\DIPP%K)#7TTHH,G+;O#=LAV"BSVC &
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M*\]IEE-*8(8U_R*$&*2XB&&!D5*$,L)XXD*]_<--C5MK\=RH\0*@=MSG#Z;
MY%8+:HKS'YP2FSVFS]VE&RX^N>G"B*.2CYWVS]G%\JJ!]+'O\K)+N: LR0HL
M$!325-\4/('8M&)%4<IIHB*4I5;9R#UC3(XH]B(ZLL4)_"PIXCI40O/"7KH@
M:2H]VGM]^T\,,^XK?U[/H_>\YZM7'<=<['&Q/M?DPAP.;9X^++0TV]J<,1%N
MYOB@:7_Q59I4?M/WXMM&D]%OB[+Q/,T$EP5-2&3R6PJ(TH1#S2L)I#G)4L%Y
M%C$QX/SF)729&EEU#WPJ74%_7Y[UKC$/.-F8IT8&=*"Y:6)6JX.B7=^>/4"@
M0@A4$+EM0"<PG6XG3%-_X,8ZDOK_G[5A-#CD^&OJS]S8YV5_CF=OZ%';2\ZV
MY=G<BXCX$H=Y+SD79T[_7E2D@4&+;3!DS8$T5@526)N"G F()(I,V_H8QC3)
MA)!11NRJ6YV^_>2LLU:Z@<&&A]C9[26'(Q+:?+ &PSU(\*3.7D,!#T<8-^#O
MI'9'87VGOS6PJ$G=R.7]<B7+^\51Z929Q'FN4*I@G&7F%"\J("&Y@#3!7"6T
MX+QP.NV_,-[4WNM&3L>R)A<PM7N]/2(5^'UO) 6-J*?K+WDL=F('C->:)Q>&
M'+?TB9W^1Q50+"^[-F7A#5U_?S]?_O%M^_@XKWB*SM^6:SY?KK?ZJ7L6*8B*
M6&61HC KB@BBA"/(4H4AB21C/$TDCN-A&0Q.<DR-=[Y*\S"4\[+>[^B]D%'G
MIOJWVM+\H/-J\V."\CM;%_/WH7D.;A-G::.$GXX1?2$5^D:)&]!5 W3T"!*F
MZ0G-,!D3;J*\4 +%(+S.YU,,N]TP9FVS1^^6MUR_^"MY^X.6<S."IO)OF@:^
M2;Y=52<(;R7;S)(XRPD6$D81TANO0J20$J9I-1=Y$N>2%"*QZTPR4 *KEW?4
M!B5?](V^5P?<^B5^H*M_R$WUDJYW<KMQINN4V'%E")A'RA1K)#==,QK9@1$1
M["6^ 3MMH%JNX%KKXX\8!T+GDQ!=11B5" ?B\YP A]YF2/?E+9N7_+-2<E4N
M[C7C+A\>EHO*8[6W02C-I4@0@864>G,JLACB6&"8Y"1.9)%CQ*TZAEJ/.#4S
ML989M$)7-DHE=NW#=NDH;(.WQ1F:;Q1#,]<S #\? F@7$#4039<FS9Y1':M3
MLP]T'5LV.R#5W[?9YD8C-F]VT.NP@[/+A4,B3BZ=5)P[J&B.(V[O[U>5$?AA
MH3>QBW7)33<GN8NKPA%%--;,SI3(("*R@#32RV]>8%KP1&*26A57'D/8J2T/
M.W'!3MZJO9Q+&[G0\VL3ES&=60OM;#!JP/X#[]UY-SQYWKT[T#X[^3:A?>,_
M!RXQ$]-Y'L8*BIC*<^$8[C#.1/7',P268<2 A7'0/(Q(&&G,@:ZQ<V5-?EM+
MM9U_+)6<894E&9,8QHPHB#A%D!2F,6,:"\D2*5'L=(!I,>;4S(!WZTWY4&4N
MUS+^Z[_$>?3O1E+PRM1*7I\_G!L,NZ7+RR^8H3>+?061;AIP@1':HV?+'B&O
MWBR+8<?U8-GC<.2U<KCTBL9^=W\LFYQ^EDJE,B9@46BV08)12*A(H2()B7@1
MI;FTHIS3MY\:NW0;^[T>T,ENCYO%5N J-(*'032=ZY)K&OOMX1C0V&\0+&,W
M]K. 9UACOR/MK1K[[:\:O['?D<0G&_L=?VM@C,908^YB3.G?Y5J;%Q\67ZHF
MZG>FG/U[6JXJ6V^68\22F#-M=QDZ++091E-!(,5<8%7('!=N12I?1(VIT>XO
M*V.""+./4UK&JEM]%:3 :P_KNO*P_J@T<HP(>9G'Q,YBG/[D3]]%=)P2T61$
M; XR(FI 3(6+&I(;8/"XX$!TCVEYT0GU&A+S,IJ,&U'SHK-U%)#SLM*,O I_
MVAH;H,D-6=]N-]^7J_*?4LRB J<\I@QF#%.($IJ9(DL)I(S2&'$A>.14[L.[
MA%-;.VLYS6*YKB0]6C;I3G2@]+:F7*^W5+\?X)4FP_H21Y>)_TD/O%SZF,KI
MKX3[!Z'6$^P5G< *=VD.)K%XG17RS[$N7<+8VY)S<2#WIB"_TI_EP_:A<1=D
M'&OJQP6,)8Y-%^(<$H8(3#'A*>))(;A5[>RC.T^-O1OA[!M^'.+43YQ7:1^8
M\!JY/+I/SFI[;2>/PYN.UKWCI"[=CAVGOS#,D'OW\#A?/DGY3:Y^E%R>889Y
MA;[^Z;,R21WW"_/2UV9EU9/X8[F0'S;R83WCA**(FO#%C"IMQF6I<1MSF-(T
MHRDA!7/SDWB6;VHTX&'Y/[C,: M^-^J"2E_'%%[?3X.=??>"<SRB=;>;MOW,
MWK09AJ(ZAGM#'TN]1S-ZW8#;!U-ST6XNG:VY0(C[M.5\BSBJ)1<(W^=V7*AA
M!BXE2DF^V;6.O*,_O]*-/$P"K-*^;Q?BHQ9IOON>7,\D59F2J8 Y0APB3')(
M,8H@5G&<)(+*)'%J WF-,)-;)(R<8&-$<Z3S:V;$DKM'PCDP4>_4:-O;FO1O
MHPDX5.4&U)-AZ+I2I_-]DQ^D7RNNB=TC4WO URLM7R//N!SL ;DCPO5Q3W_5
MDMNZBT]M3M/;K32Q4'=ZQN4L%0E/<E.W)C,]+K!(M"6B?Y4($9I31@ESRDIW
MEF!J/)I$27I]1>5^T.U8,RB4@:GR3-WE&[!38-^H]P9H)8#1 E1JA"W';(5@
MZ K-_4*\>-%F*XQLZCC;W>C:.AQ^+-RZ(%6*B,(I8Z:6?*+_40PR'F=01JF(
M4JSM3T&&5>GP*.74.+-;.:)5$S1Z@G/>"[U[W2EK+MRKVYS"5WX*QYJ881\.
MRY.HEY[RZ?LKPG54#0!YF&(B/@5]H5(C ; ^7X@DQ&!7A#6PRP=C[$RFR.?M
M9KW1KX9>)/]+EO??-U+<_M"KYKW>(SS0TG2U>K-<5%DC6SJ_DZN'9*82D4FE
M%(Q9ENIE*2>F+IV$.,9""$DCA=R*1XVOP]06K59NT @.=I(#(^^ J(>1GPF'
MN(CISO3T(R=V48(=)&Y S]/3@:/_21H67_$R<^D] F-D-<:/T7B9>3H9Q?%"
MH@Q;7OLK[>Q_FV&1BSB)<LA4D4$D\@QB*06,XXAA+*.B0$ZG ;8#3VTAJV*5
M?ZUJ?;G4/'#&VVZ]"8%BX$5BU )>KOCX)%[KL4=E2U=$GE.<\_7#>.GM4C]!
MFY*_,5O8U5.; 9D54E)&(6-<0J1_@X01 1.<%5P1*FCL%)%\<I2I,<YO?_WV
M5_!>:NSHW(UL3H-HQRQ70Q.:1AKYJF/!)NQQ\Q2@/70O$#[YXO1 HY)#KZ[/
MF:#_RVZOO9"EOE^=+[HV)W2KQ^7*E!8PS>B57$DM_K["6<8*JO0F'2JL"HBH
M-D.8S!2,(H;BG&M&**Q:0#N-.C5:V D.NI*;[=5.=CNV<,.^GSV"(1J<32Z"
MZ;FJW""D]G2S;OEF+?E?[Y<__DW?[]],,K+YH<I*[C",VUBC,,X@]5L&&G;Q
M,$/DJUQ+?='WVX5X*W_(^;(J\=#9TK4;LKOE%[G2%NR#-HRJM*_UZZ<[/>;M
MSW(]2R1+!.8%%)PI;;@D,:0"2<A1FN)8*<X*IX,N+U)-C=%:I:J3C(Y:A^<=
MK6:F*'"C6Y5,56MW XQVX'>CG^,IEI^9MK.N1I^_P/PYWM0YVV]>H?9I[_D1
M;%3[T"N6S^U)OS<?QO:_+5:[@RR]L6AZF*SOOM/-?RVW<_'A0;\ FUW,61-M
MIO>EM$BP28J*)((H+S2]XX3I7RE*DCSGJ;+J3WN=&%/C\ZX6)E86L$8/4Q!@
M _XPFH"R4@7(7;2G^:)9S-W(>^#$V;%U^.D(3,\',V$VS*\/9J)2 M1:@'W<
M;1MPZX^+KP/2)_D.E&14MKT.K>?T>N7=!K:!H^OOG;9";04JQGF:"0[CPF06
M1(QK:QAG4"(N<92DN<S<FK^=&F5J;/B\Q9)C[[>30-K1U]7P!&:GH^93_IUX
MO1!X[>AV<J!Q^[CUZ7K4O:WWRT.WS!M:+J1X1U?FQ')]R_56?3LW&_2WFG-X
MN9DA)3*&TRK"IC*8,L@$2B!F<29$D9FH>+?]\*4AIT8''0F!J$5TW:Y>1-EV
M+^H3N^ ;S5I8T$H+7G61; 3VV!72'AV_>\.+HXZ\\;-%X7A79WVE^Y'!FW+S
M=+N2],U2R%F,TY1Q$4,D"*I];"0E'!88(131F.61583"\QM/C3F,;, (!XQT
M]C[^ [ NN_&'0A#:6+#3WLD/?TK5*USM![<;S9M^2HFNP_SDWX<M\/^YI2O]
MI,^?WI<+NN"E2:HS_I@JVFE_5*2-><(0S6$6%PE$4N209DC!% G]_XJK0CB%
MT=H-.[77=2<UV(D-WM(-!:]^6]"M*#41.A;]LH3?;O7W#VI@ CB%9T=DS\=T
MPV#R:0I8CCRJ.>"&QG.3P/'J81Q5.8;K7-]9G I2B(Q#H4D((IJ99O,X@6F.
M"<8I3U#BM-OHW'MJ;%,77"TKV=Q8I0N8'74,A"$P/]0(?.A'P/G]/Z&KSY>\
M>_M1W^03>CU_74]]Y04:NKG'1N]Z0"4HPIDB!4PR%$%4Q-H0282"14P%3XJ8
MR(*.UNMMN!Y3XYI6_+KORU%J1OVQ4<"M'<Q+/RW]Y/<G>@8"$VVE(7C=G^WS
MNLGV:;YWD.W3)OMT<WU<4GU>IN'<%4_6B+WHQGG"QFQ3-_4G;=P6=M?/;]#N
M=E>(]^=I?'?]''CMB>=!G.%!VW76][N%>&O"*BBB1/\O@4DB](9+L@QBPB*8
M,Y;F*55Y(JWR-,Z.,#53J!6R+:;QSH3!60>QG ?RLIOV:G@"6PG.R R*H#ZI
MO8=HZ</[CAX9?5*M4U'0I[\X]/CVAUQL95/1P5#+E^6\Y$^=_(M4;Z1(3&&6
M%)'QITA(!)8P9C'!&9&94$Z.W8LC3NUU;P0&9M; )ZD?[M52;/D&F(PXQ\B.
MRW#;'N-Z!#'X*6Z-W^^UB""(R]8:$+\'MY<&'?G<UA*#XV-;VPN'D<P'O6E8
MW)=L+F_7:[E9ORW7?+Y<;U?=-*\82<TE!$J."4219AA"HPPF640CGK"<2NE"
M,Q9C3HUH]B*#6F8W;K%!V8Y=/&,7F%^.8 -[>0,=$#D Y)-O;(8=E7$<<'C.
M.2Z7#JR'W02A:'.IVDJ]+>=;O4V:2412B4SA0:Q2B!1+(8XY@@5%>2R(2A!W
M:Y%P>IRIL4LC5M5^2BSG<[I:@T>YJEM1.1Y*GX,V0PQIZE804Z)M19(I2*,H
M@0@SAA(-=8&BF=ZFLN6(X';'"P>O,0SKDSCP2C_'Z[_LP;T!8@3L[:C= YZ!
MZ7P7ZZ=%K)U\-Z"1TF-9[WX8O%;L/C/4N,6X^_4]JK-]X>L#\P.ZGJZ%:,L.
M-LD)IK/ZOH7B:?_8WI!!19Z0' DH"R4A2E$!*5<"QFF,J"@B45 G<]&C;%,C
M_EW9V$898+1Q3$CP.'-V//5"\Q&8VP[.,TSV[,FY,07Q]JUTS];9"V/:!@#>
M:\J%1_'&3=3PC^M1>D> (=P;"IHZ::T(_[FE\U(]Z:7DEG-3.:9CYG_<=:F2
M14R*B!,81S+6!CEA$"-LO+0BPX+E&>%6$1N#1I\:6W][]P:TI7EO0)S B-R
MG585:>SU JUB!UO>CZ[MQX9-6S^1!Y^,T $/X\R#4Y?%P7A>VXG1?>#1NC4.
MQJ3;T7'X3899PFT?UZ_R<;G:F )[W^1]5>!FED@>%5D:09H8[T0B"LBX2"%E
MB2!2%3).L8MA>WZHJ3'?OH_R:B<K6#?"NMFK/?C:F9]^4 M,47O ]F*";Y<
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M+G_(U3YZGZ%(*9S"7.\63=7:%.),(<@Q5FG$(HJ(=5'J@SM/C>8KX9Q=W\>
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M-2:O1;2W .7@FX]7G?):_0]*5UY]L\%IPBOCGW\KZ_]^6'Q9R4=:BK;G;%L
MKBFH65>(FZF<Q1D2>G<48^,<3TUS2<1@A".49B2*:4QGBRH$RW*C/4P0JY>3
MU"]G5YQP[V8C=17UJ\5==Z(5Z@JOSDFP0^;'SBH.B/EH*;25X.!5J\)?0+D
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MF+#C%GD-C?E1Q=?@ _K*V:E\03MG75.,?-&U8#[)S2Z<,)8,HQPKJ'>RVEI
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MF=M77+]RZ[(O7TEH9E4IY)->6#;]8KXLELNK[S2?F0Q0;6.8S,][R?725!Y
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M^NU-YB[&P"W+.N-TV,FL^Z.Z\6@;G6_L*Y4D:6*\:BC,%,19PB%-<00C16F
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MM1*,TL?\)$NW*9V[M+(=X]1:%S<?F=PC6@IWZU*?K%_]H;5^=0U48\A74$U
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MNMWMMI LB]74E!ZAM3_S/]=TEJM7/4K=''7W],>$!DX%#Y,PI#%DV$2*!)F
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MLEA"BDTJ813BA'"W1N2]83],/_*#@XPZ-7DG'WD"V)!39&=D]@9[SVO P2E
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MJ@V)7FH_'1WP?2H]M>E^LJY3ZTT#IYM5LMS,EZNB/"]:WJZ>9/'P1.>W54;
MU\7\NUQJ$^=-$,1?]*-7UUJC31K!M\5L]GE1F*=.0YJ% D<9I)Q(B ."(0E1
M  4.&5(TC$*9#)*3UH]^8^/'@_BC4OI__9<P"?YL="C3EZI_M@>\_R%>+DNF
M'I?4(UH;/*3#U<O+#DB@1 FL-$S@MLF.VR!U)%&N1 MLWLX>$ZM'^B:,(KVN
M)Q7_&#EX_<ZOMT2]GL7L9G%\E;_5K1'TINBN6,SUCUQ6XA4?GXQ.-_/=*_(Y
MSU]F<GM&3(,HXFD:PX#HS0Q. P(S+#@,8Q*G,>$RYD[!*A=+-+9572L$MO*"
M?97T9(%**5/&;.^R6J\+#OXOGUR[-7K0*>MY51UDMIS7/F\(^URM+A=JT/7%
M&X9O5P1_#^[&X==2R:(H#[RJWLT[/6V^RM64QQ&2+.+0N 2@WKK%D$2:IA.$
MI5"*Q5$<NC#TF?'&Q[\K(&J1RR/]+A&%YS"V(TJ/R/5,@XVDY7%Z):O>!_@,
M);3$PB=AG1MR4#JRU/\MV=C>UO7P>L%_?5K,]!W+REZ=HB2*TB!!4$64FN!O
MO9<4@D$2"\Y0E'!DNE39]U\_',*), 9KP[[<D?-?_X5$8?KGLH2#<^V@(Y!*
M%08!93!32A.RU"\KE6D*$Q4J+)(H35$T?2D=$_<K6JR& /;M</W!NPE( HS.
M3$>0B_&,-(PH"@.(F6(0)R:N-4I22)(8)X*H(*2BQO/3W+)TM \TF\%Z] ]4
M36E] 6GK/+D$FKY/Q7:$^[?F@.MJM2IRMEZ5+2!7"W"G]^<MK>8Z.%%.(>+7
M<W(PRL#NDE-:'OI(3E[9L1GM\Z)8Y?\LCUI,/XV5GO+<]'$LE\ IBFB2\BR"
MB NI+=Q$P"S-&.0JBD6B4!+$3CG[[<.-S<#=RE>9MH#NB._83[8=9SM^\(=>
MSURQ*ZA)\MX!\JI]C^#>_M4*$Z]=7MM''+:9JY7V!SU;[>[J6,;,2#Y?50'1
MW_+EKP_Z.=>+9YK/IV$F(TZB#/* :WM"" XIC1(H>!;(A"6IS)Q:6+>,-38N
MV1,5&%F!$1;\4HGK> #9!K(=EWB"KF<BZ8Q:AW;W9_'P6H^L9;AAJY"=U_N@
M]IC%+>X5Q[[H*9K=/2WF=?V(J>()8YBD4*D0Z<U<3/6^0QL@. GU5B[0A&'7
M6^+8P\?&#J5\H!2PKHUB7TCL +AV K@4CIZ_> <DG.J#G5+Y@I)@!X\<K K8
M*65V"W^=O&9L$52?%X62^4J*FWD5,SJ-@Y2D*,U@&/(8XB RY06S$$:<Z2T'
MCX($2[=^50-*;_4M#=K]:B-B]V)60\Z^Y5G)R&;TOUMHTO:ET>],A<,?(>+H
MY.3],:*)#L7_;Q(I=')>AHL".BV")^^P<5?*D!,<Q RF-.1ZZ<(Q9#B44$E"
M4)RF^A?,Q:ES;)"QN77Z\0-?X/S]8WA\S<'8IHL[V+1Q[]$1/)3W]_U=OBY^
MWLN=NP<;X@^O'^2</SW3XM<R=R8D+$BS,(*1$A'$J4@A#7$"5:R(8C%#2#BU
MH#DWX-BVMT>.<3;R=DI5.HMXQT.P"W <_B3,&L++#\-.X-+KB=C;,=_W6.P$
M F?/QD[=UXUI-H'*U_F2SQ;+M7[%3%?*LBGEE%$3((P89)$V.; DFF802J$4
M--(+=,H5)2XTTSK:V#AF)TGB)TF-K*45Z,8K[?C:D8HWU'IFE!W =B0%O_32
MY=0*%)]TTC[@H%QBI?M;(K&[J:.]LBY,F,9GJ6^A,VT(??K=[+1DG=4]Q;$2
M-$T5E$%(H?Z7A"PD,11Q%&<4R8@$3MF)9\8;'9-4<CI:)&<PM31(_"'5MSU2
M20IJ4<O-32TL^*$6]_0AH[M%8@>,5X/DS)##VB-V^A^8(Y:W=;1&\GF^DE_R
M[^9,93^(X,LVC8F&L4R(A#(2IOE$$D(:2'- @E"L]*Z(4B>?O\V@HV.44F98
M"GT8#'-!(I+5#%B:+9YQ[=MZ\0"INQ7C@)%78\9FW&%M&@<D#DP;EWN[MBZ[
M$D*_;LOZ/^:YX101$:8"11 1<S@;8;U3"BG19DZ"0J%XF"JK?)W64<;&/96@
MH!9QTOP R@_D=FX9V]P.[/F( R]P]4PIG9'JT*BL!8F+FY0=>_; #<I:U#ML
M3M9VL;_//YH&&9(DC"F,)=6?/THCR"*>PE@@'(@P$%19!3.WCO*'^OP??EM<
M_OE'%WS^3G"]Y^??AI27SS_J\?./WO_SCUP^_ZCCY]\8&!NOVL:I]N'UK=NG
M]!((C+C"J809,H%&S'0&X<@T88G#%&$5"N%48L%VX+&1Q!$WI(DB.?1<=G+6
M6$^'W4:E#Y![IA9O^#KO6%S!\KEKL1Y[T)V+*R)O=R_.]W?H07+U6,C*??%Y
M47S45^6<SJ[FXB=:_"I-J8-[67S/N3D1+I[S>2G.U\5*_Z:.H0M9P 2*"22"
M(X@YU<2& PD)2C2E88$2+JT;DEPJS=C8;JL/4(L"\%JCLD?#<Z,36-9*3<!J
MJQ:8EWJ!E_: N!YFM)T;!Y^GG@ES9XH^F](PS11I;<!&'7"_F:(=C4"ETKF8
MQ1ZFR*&[R9!3-5"KD_ZGS*WQB2^(6[N@7#S(<"U1?.&QUQ_%VT.[[O,_/<OB
M48_SEV+QV^K)A(S2^>LT2HG"6:A@&!*FE[_8E"R0L;;KHS@5,B%A&KCM](^.
M,[:%K=[!-K*"2EA02^NZTS\.K>U>_V+ AMGMNV+58:_?BL3%N_WC3Q]XO]^J
MXN&.O_UR7WO^!U.48IHQA6+**12:NB$F4;F[5S#",@Z"1"+%K%KSG1EG;%1P
M;,?Y2RGIQ9OW"M>N>W5GM-YA:WX.* ^[\#T8^MUT5T.]\QY[3]_S6^K]RSOL
MH#^J57'%5_EW,S-+;9'<S)]REI?_:-J4IWHC+# U!;@"!7'$4IA%-(8Q98BD
M)&8"6UD)M@..C2,^?G[X!NA&YG+_FV^D=M@YV8!ML7_U#&'/Q-&.GDVA[FY
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MI"_ZI__S/YK?Z/\Q9OO_^1__#U!+ P04    " "%.$M2=!*FMJJB   II@<
M%0   '9N9&$M,C R,#$R,S%?<')E+GAM;.2]69-;28XF^CZ_(F_-ZT6E[TO;
M](QIS9*-4M)(JJZ9^T+S!2YQBB+5)$,I]:^_<,:^BLMQ'H_LLBI5!$6=@^5S
M. "' __M?WS_,OOE&RY7T\7\7__"_\K^\@O.TR)/YY_^]2]___@2W%_^QW__
M+__EO_T_ /_[Z?O7OSQ?I),O.%__\FR)88WYES^FZ\^__"/CZI^_E.7BRR__
M6"S_.?T6 /[[YA\]6WS]L9Q^^KS^13#!;_[M\E^RX2I)9D%Q[D 9SB&X+$$F
MYP./OCCK_M]/_\*+M5;E!(67 BH8#UZ+ ,DYH4,J)OK3A\ZF\W_^2_TCAA7^
M0LS-5YM?__4OG]?KK__RZZ]__/''7[_'Y>ROB^6G7P5C\M?S;__E[.O?;WW_
M#[GY-O?>_[KYVXNOKJ9W?9$>RW_]W[^__I ^XY< T_EJ'>:IOF U_9?5YL/7
MBQ36&YG_E*Y?[OU&_0W.OP;U(^ ")/_K]U7^RW__+[_\<BJ.Y6*&[['\4O__
M[^]?77OEMS#/X>OGL/P2$IZLIRG,5G]-BR^_UB__^FQ!T'@7/E72-X]:__B*
M__J7U?3+U]G%9Y^76/[U+]_H.42"8%R<$O!?+__QKY>T?%WBBN"SX?TU?7#V
MC/JVP^G"[VN<9SSE_?R-LT6Z]J59E?QB>?XO9R'B;//I).-TLGGRD[A:+T-:
M3Y0*6<2LP2FI0#E;P%O!P15D:)BWGNOK8J@LK(B'C:)6F/[Z:?'M5WKPKU4T
M]8>-C(#Q,S7]UULO/976?M2?K\Z/]-V)4QZEE9ZHM0840PF!LP3"&.ZLET6Y
M,@#Q5]]YG?:KNGZR3+\LEAF79&3.7QJ6Z9;>KP/\[!N_?@U+>A"DS]-9/O_7
MU=H,H;?U8@#YG2J'R/W++\1UP>42\^M3W=S+W(:S-9E>W'QS"+T_F<]/PNP]
M?ETLUY-2?,E%,P@^)E!:,HA&D3ABX%D+H7R4 ^K_ZKNWPH'H'P=[R[,3/+S#
MY7217\SS<]JK)U(JSK)P8)-BH#QM%]%8!CISB8:XR@D'!,2UEV^%"-D_(O:7
MZ,B0>':RK))Z.5W15OI_,"S/>3"%,:;(H1*8R,P9GR$D)R 8EK(*J)+(0^QQ
M][Q_*V"H?H$QB%P[,1<?EV&^FE;9GYD\KHJ14B!8$P6YW2+1%H@)C'%6^^ %
M"VI(%^+&^[?"ANX7&X/(=61LO)BOI^L?+Z<S?'/R)>)R0@:/D)LB%.DTV3RC
M("ID4#)Y_L&SD)(9 !,WW[L5%DR_6#A(CEU@X#U^FE8AS-=OPA<D#*<<O>1@
MR$L&)<@S#@8=^*A19Q9%\'8P'%Q_]U98L+UCX0!Y=H&'5_.T6)(YVPC^ \D?
MGRU.YNOECV>+C!//O*(]+D"QBKSE*")$F31H:T1(P191AC,3#Y*R%5I<[V@9
M3MI=@.=C^/XJD_BF97J:"#NSBM8DX6V@4#O96+TF3C\%!ZI$63!&RZP?##;W
M$+$58'SO@!E"PEU Y4G.I(+5V?^]GLZ13ZSDUAK.0&B.H%BDP M9S7T*[[47
M@;,X&$SN(&"[1!?K'2.'BK93?(B)EH8Y;0($R<BYLJR0@^W)UU+%\:24+&8X
M,W(' =OAH^-,Z#"B[0D?S^C'M\N/BS_F$Y39AL0+Y*PI-$^HP,GLP&+&HHPM
MQ@P1UM[S^NVPT7%V= BQ]H2,C3?U=OENN?@VG2><B."D9+%0.%XD[8M.0'1H
M &U100GIA!KBX.0A&K;#2,?YTL$$W!-0WBU6ZS#[_Z9?-SZWP&R53QP2]^0^
M9:\@1!E!)&0V>"%C''R/N4;!=B#I.'<ZD'#'SJQ7'I883@,QJ5UF4H O@6Q@
M3A(\R8)TZDMB!JU60VPM5]^Y'0PZ3I/N+<"1%5]K.&;O/B_FYRF]$H66'"7P
M*%0%K8$8M8<4;;&,9QW#$ =L-]^['0 ZSHT>),B10? !T\F2 ,Q%_#A=SZKE
M0IXRM^0:*[)<3%GPW'MRA0PGUUA[R<0 (+CYWNU T'%2]"!!C@R"C\M0*^8^
M_/@2%[.)B$(FK3Q%T(&1!(H&<G@2J*")DV2XX$-DQJ^]=#OU=YSEW%^$G1B
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M-0F_'B:K!Y]Z$# -*/T.S-+SL]?6*J0O^#%\O^3$*4[83P5R(E^.]GL$AZ&
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M!<YD:+(G_HRP<:OPCIWY/%PW@V%MC'Y+[S9*^8R;?W"=HP.;+UU_\O$Z,3W
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MT?V'C_3G[R_>?/SP]N7;=R_>/_GXBO[VT*3K/4]MFG#=AI.!DJVG!]07H+Q
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M-XN#-HMCXLCO#$%D"$757JFJSJLEACD711;+C1/-JL/V)7KD20IM,'@T+7:
MV-_#\I^XKC= +Z]^GG$BDDQ9%5W;E)TY!E$ATJ_1H!(4U_@FX?3])(T\#J$-
MV@;20 =8.F_5>&NW%U@\^90"@M44!0M-JT/8"$4)&VH?4=8F,7,?02./,&B#
MHT&DWP6*KG>P>3F=3]?X>OH-\]FR8)B]R<R#=;;VH24!A8+5EXP>+1*#J<DD
M@I]2-O)$@E:X&E(?'0#LWN8SMX*4XA/WF,$652L-L$ (QH(-J;B2M<$V UBV
M)7#D>0%MX-9$.QV@[C72ZL'7M>S_5O;%(M<4]GI(2D5:0-E"]-J!R8(KGVUB
MK$DSP =HV@I;_I%A:R@=C'URO4V7X9O\1>N2,W7Z$/>%XA(GP;',(4L=D1//
M6=RX@W]/%G6/EV^75&6/!$U'44$'%NNLI7 =!?.)MGS2UNTLGBX\!0="&V)(
M.0/5)H/6S,;B!7.\2>'C3RG;#G"/)8W?1B$=(.SW\'\7RV<GJ_7B"SWS[DQQ
M]$IS6C44]&826-8:O D)'$<TS"<1=1-G?PO:MD/98\O@#ZV4L3?+]Z26Y3=<
MO5PL_RTLI]5:UWJG:3YK#G K7(Z!V),4'R.O5;^!02SH(2>4MCC/8F9;;90[
MOG@[-#V6?'YST7=@OIXM5NNWI;;-N[75!RPI2U[[^?/:QI3B$B>*@&(SDR%(
M(VR;NU?WDK0=O!Y=JGX8%70 IKI6B(!ZL/"<]OG98A/TGLU@.D^T% IP P4E
M/F"MMLP)O$RTQZN2?=#"N#9YU"UHVPY>CRTW/[12.L#9!YS17WWZ#>=DA&<U
M;LE?IO-I%=9Z^NU\9NCM I&00A:H )6C\!AK&_'$"AB%,L<DF6ASQVD_<K=#
MXV/+\!]!=3T ]#/)^&E887ZV^%(Y.BU#/[^L]6J>2 /$;DT0GA^4643)E1-@
M-E+-%NM!F0*)R7+MDS6A20)M#UJW@^9C.R1HK;0.</DD?\/E>KHBT56OX]8R
MTSXK'C5M ;E>?3&R3LI1&2+Z8H7)VF)L4IKY,%W;X>VQG1(,J8P.L$4!$DX_
MS9^=T+OGQ,>25@F):-.Z;IXWO\Y..]G=9#3;$) 5#R::#,H&<CRT1$A6V,*+
MD@6;[,M[4[P='A_;R<)Q%-@!4D^'@7\,WV_%[M[Q9",YOZ=S8<G5\+)>__/:
M2(^1G(Q6,ROO)&B[ZMK'<N8PJ/@[@-$;_..*A):+.?V83N\6WIUQ+$9JE'6>
MAN)U&@%7X'WT0.&6*I;GE$6C>6F[$;H=[![;R4-3=74 QQ=A.2?.:IN^C2=[
MRTBS.B8K1F"F3A9(.D'4Y%/8(.L< YVT;W(Q_R=T;0>VQW8 ,:0R_CQWZC[6
M['G#&W5GSQ_I/MU=W+6_3>=\D-DH,DM>$I*LJK>>> +TWFC)T&5L,I>@X87A
M]!GSR0POFT9^./E*&*FF.LR>3U=IMEB=+,\$?KFFDBFB-@X#IWS:C$X!'U(!
M;GC0%$?%;)H$KWO2V^TMO5T0=2N'<@3==;#77K+Y@F2X_O&/:<97\[(@\U$5
M>%;D4&< O" #L)R'V<5A]-,?Y^TB**CZ@,MOTW3ULK5+R%%(2W*OTP%\]A#J
MY JT)6N6,_*;)[=#@WA@CKJ](3@,S,?4?U<+X8SGIS^NUUX\_?$>ORZ65QOL
MW%CZFBEF,7@PV2I:^@1/E\GA$MDDYTVTLDUQS.&D=WMY<1AH'T6C8U?67+)[
M7@WY'A-.OU6.=N<\&"X,X^2\BJ!/!1]%)-]>Q6!BS&CE3UW=X<GJ]H+C/C@=
M66NCX_7%LW/FN6#^4A"UK>]Y[ZO_=1)FT_)C,\_E5#PW.(Z:2T^\@16"=ADN
M+ 1G WC&G+;H78Y;XG0(<KJ]$KD_/H^NI3]/DJ"6!L_3=#8];>MVN\=TN-E5
M^K0G9L.\POXDC92*&$B&[;,7W*/&E"7%?:5.YI/T4]$&#)/,%FN="+*%\W>L
M[,7M*_:;-3Y1Z*1A=3 QUK:\44=PT6OPUI2L<K$J-^F3L!5UW68F=D'+PYF)
M(?320?CU-,SJM,L/GQ'7K^NWJXZ^3U<3DS0S(2G:N8JHO6GJKJ$+:.12%F$\
M3TV2_?<1-"ZD&NC^5LN@ 131*:">+[Z$Z7P2G7=&& VZU,)V%BQ))G)(2FI6
M7"PJ-$DTWT_2N* :1N5;X&@/^7> I'=+_!JF^;R@DQ;=V_5G7)Y6EZQ/K^'_
MCK6![D3$B"FQ %;SC< RQ,(2,%IV0<C$%&]T1WU;$OM#VCZ@N'5+O8F&QHZ0
MWY#G>\K"13>1<];.N+&,Y!()#T532*50UQN&TD.0@E:LD,IMVQC[9Z\:-_D]
M,&X:2+<#.W6W1T !&KY:XQ>RYER8X(4B^HL&%0KYG"E($)ZC%^1REM*D:.<G
M=(V+K/8.U9!JZ19E-X9R3835S@H308K:B9Z[>LU><6!8@JH7P8H]8O>\&]3U
M.*-O3SSL,TUR)^5T@+B?M?J["*J33UH:R0&S#Z L[>TN% .V2.3*DSE730S<
MM@3V.$UO&-PU4=$C@-[$I<2)=@6.E@XH92S0$E)0$C/%9^ETFR/?GQ$VKHEK
M X<=,;>3;CK VF$S*#F%+S%0(&.3(6:]$."EC,!DS,BDUB3*5AMNV_&BS<H.
M6F_$QU'F8-/&1S\N>X/K3>N >%Y7M/_DN\->.-)1UU;\MS_(LBEPRYV $I#7
M!J4>HG0.9.0Y89#1LR9;VC$.L@:J<=O$A-P*[@4/%!,Z1HL47=V[+/AHF/19
MJ&2PA9R:<-/M0=DN:&Q>V[BSWD=T*U;+]>2,A[?+,PXV2?W M0J."!9,4?1'
MNQS$Y"RXG+/VTCM>MKFC2L^_@EGZ[29>[R.@EP.TT3"Q&%!!?0#LJD#.TK))
M,)N-D.!+)(FH&,GY-AJ,SYJ30X4A;-,<9Q>4W:9B'*@-H]C;*#E0RF.?9OP-
MU[/IXC_.<NO,)<M9JG%9XK4O0*$P33&P46O.C,[DSVUU<G'ML:,K_% =+081
MV-ZJ_H;+N!A"V2_#/'Q=GY'NK$_(N09G%-'OA*OY1D]!?SVY4<$P#%OI^NI3
MQTFF-5+UWN(:5=,75T1WW$DO0^PDR7WCM4,JK^<J$A5XZTE^*NH026A9-3DO
MWYOB7@ZKQG9>CJOZ#K)S5WAZMIAO8I-_3->?S_EZ\3W-3G(M@%ZM:EOS_#%\
MGTA+O* 7@/4*B=(F$8LL@9 BI)!B,+K)#;@]:!W7*3\2BNYNX-Q,I7^>0O9S
MN[,HUR^DK#^']7L\HPOS[XLE?OP<YIPMRL>:73R3\*IU(F\@^D;*^[60[A'J
MW4N]_I8B+;IZHR121!-%0+".FR)URBXW.7 X;IIPQYN#D\($.8$R 1DA\M)9
M<>!9B6!,"EJ54"07+:0R .W=I@!W0=HV*<"6.NW 4Z&]K+9W/.WI_7ZZ^N?3
M'Q_IGVXR$,46%#H:VBX#R=,S!4%C@50W31-E$+Y)Y?,#-/67#FR*CUL=LX=1
M5H^XJXR<!<:,:\X8.6<V"EK"R#(%MQ@ F4$II+5>-3E3>H"FD8O AM+[S_"T
MIQ)ZP-/9PKO%TGF:Q'N7)%? >3TDQ\+(%<<,@B3F/+-2V3:8>IBNSG"UK_YO
MXFI 9?2 K=O+[RG.TV?RUO^Y68/>VV)-[9,6-XT?H@!7FX'&J+,L*14MC[51
M7B.LO_S3R+OE_FKK$H;GW)PO65J85A<%1F*=Y1DU1%02"LM!QFRY"VW*J']"
M6&=&[B 8_!1C!^BD XQM2HK.%ND;/#]CB$DZG= #-TY28.4#1*8":%$*:O2*
MAR:W:N^DIC<T':+PF_'GP=(?^83_NE4_75U<&BEM ;GIYN[(F0C!,LB!F-#*
MA@&/]F^_?MR:T;%VP %4,3*0WH0O)+5K/)R?FB:C8Y84Y:0Z)C$1 ASS#%S0
M/I:DG(W;=+O<"D_W4C%>Y<"A:ET,+>.Q"T7.27\[QS-[26O$.Y,<.%^CB\1H
M9[>& Q:1&6=):W\CU+NG@.#6H\=3^T"Z6@PFN%[4_O&/Q7E0*:7C)9$B0S64
MI@YCR*7^)%CD*F>4V\U^O/7H\8I'&JI]/\%UHW;2X#ELK42IA:,M42L!RHH,
MKM1Q;I:%: (ZK[9KZG;'P\?Q'UJK?D_A]:+\E]-OY^1S$Y.))8 T-4ME-)'/
M"V[F4*DDC99QNY8&MY\]3O?(QJK?4W3=:'YQ<MYN063RA[E6P$LTH'(0$$@V
M]*MD.EEBQ<?=-'_Q[''Z,K;6_'ZBZR G<2MVNB:?UQ?5/4$+$2W7D'1,H"(3
M=:RGAV!$3AQC3*EQ>>"#](W;C7;L9&P+)7: S5OIH'>XK!^$3\@GUAMO@F,@
M)'E72M4UZXH!R9S4,FE:Q4W*.QXBJI?2O0%1\+.4[+XJ^4]=D7>[O_0;;'[%
M=F Z'T^%WM;2;E^I%TH43A@&.M9L,ZT]<#K1'TQ$Y2,FA8^L,^WM4^[-;B8H
MSG'%&K FU4)V0UY0P$2FH ZZ8IJ%-D,/[R:GVWJZ7?#P\_J2G27?XQY_M?J&
M/**H<.,#D4O$N8-0C 5A9!+%"L$;E97T6B(WA,IWJ7K;0?X]0NE*P8T.ADD1
M."2#M<DS-^!C1/)^;-#$3HZQR?V/QUGUMHO>=ZAZVT4)/>")7CE=WU=FI6,(
M)0D#=60G*!$"..,YV.R*R@*#2KX)HAZBJC-,[:O[FY@:3!$]H.IG%3/*JY!$
M\N#"1E+D$T3G$F@F&28=+"]-ZD'ZKG<[SM:WOR:Z1-:-ZIFB,(BL&&F^*++K
MF.LH[ Q6.Q5+"=;SXVR"CZN$;2<8[%K"MHM..L#8[5CZ_*C+UREL"B$@JT)*
MM!"=+N!DP,QBU%XTV0[O(Z@W3!VB]D4#'?17RY:394&%6JCN2IV,K<$[GP =
M+3!E'0MAFVCO4=:R#;B[#2#=;LO3E!)>,.-!UGRU4B5!$,4#CUY@G;9GQ#9]
MWOY$Y6D[J76K\K1=9-S+R?5EE564DCF?':"BB$!%3Z&KPP+,9&DTEJS-#>?Y
M,9>G[:2KA\O3=A%<+VJ_K+)2%>ZA1I>Y4$Q9L%XPR+6ANL^V*!&9VZTJL>OR
MM(/5OI_@NE'[E0HKS%$P38Z3#IGLG[>Z3K,LX$V0(5F=HMVN=]DC*4\[7/5[
M"J\7Y5^IM-&9"56$!>F,K<?-":*F?5RJ["AB8]SYW4H3=RQ2.G)YVL&JWU-T
MW6C^:G6=02PQ0.!U9*,A#]D%8B2[V@I<A>)VK$;>L3#QR.5IAVM^/]%UD&^X
M%1B]OBAC<9RV*R8BR%1G"@AT$,E9 8;*!B8$HC)'R6:][J,([1@9TOVDWR..
MKM8M(<N<H3/ K)'$BTW@D!M(D7XT,6O;IG]2OZ5D0RE^E^JQ7;3PYZD>>Y+S
MM+XUS*[TVVM="O;02T>JZ]I:#D>8NF"*Y&0UH40,H+13=8OT$)-B67$6M&R9
MRAZP2&OC!%RNL;?E/:Z^+N:K:9S.INL?+Q?+=R3G6H/\;+%:ORU/EZ&*]AWI
M/2VG7ZL*_DX?D->826U+?!>6Z^<3B@V]RYD6:N84*2K/:\)9@;7!BVB3#F4[
M[VMHRKHM\]H%4=<<N%%UU\&V_21_P^5ZNB*AGDV4G7ADQ=-_ >OQB3*&0I<Z
MI\JSS())Y.6H-JOS%BGC'H@/#+>!)-X!9MZ<U$"GKI=ZSZ+ZP.<7+28N9J>C
MU2#(H2#TNP@^&0<F"*F9XEFG;:ZW[XR=^TD:]]BI$88&TL"?Q\F[^-99X^_W
MN#Y9SI_,9HL_ZBSEYI7_6[U^K(+^W65S!!<P*U0\<C N%E#.!HBZ.%!!LJBX
MEIB:#)0:W@6LF:4Z:O;4ILSS_SH)LVFI VC/RPB>3U=IMEB=+/$T8>"8"C;2
MZG1(JU/9C;EG$9(R/.;BN-UJ@]WJD'4GROIU[W9 R]5#V'9ZZ6 ;OF3N?"FO
M3@<MXO(;KBYJC;WB5M". $8RBOJ95> SF;GL-4N1,R-EDQLQVY$WWJ%O0VPL
MFBNJ>_B=)=8]HPB(W!K(FM%RE2R#+S8"K5OT@J5LVMPAW8:X<:U="U#LA+L]
M-#3V0=6'%\_.;R=RP?P%6]<<F]7Y#"E+D39M#$ .KR!'6 H(C%D0M)F0*UQB
M=.EGWM_.;^T94_LH?'$,Z8]<#;?M1G"9H8^&&."T#\3:J(SX2>"RX1!%23+2
MNI3!'MN!V^V,K$D]3?L=M;VZ.MA8?U]\PQK+OYH_O)[?+V:SEXOE'V&9)T5Q
MY%P@;1.N]C[3%F)Q$K05M)R-+!R;7#S8@];^/;X]D;,XKAH[0.K#C#T-L_K1
MQ,48M$^6O)?*%&H28DI84UX:DT6CU38S> ?V <^H&W?#;HZ1G3S"?12V-PJ_
MXG*ZR!_68;D^ A:??0[+3Y@_+NI1#GU^GGD71?!@5%W1QM>1:@@^& ,F:F=4
M3EJU*7'9B]IQCT/ZPNH0"NW>@C['ZEC3WZXF(4=N>>)00EV)D@5PFL(5[PTO
M7.N2U38NY]"!] 6!XQZS](7-/=6V.QS]*1SG^"FLS[Y[G"V=A6Q\U!G0,G%:
M+^D9.?".)4$N4RG&;],5?<0MO5F18%]0W$=A!V[I+^;Y.">#OX?E/_'L\#.=
M+*?K*:[V.>*[\SF#G]7]G-J!#MU>S4GOZ\UA\'.,F[WQWT^FZQ^7K[TX5G$Q
ML7K6#%Z6S;"'")Z[4N]=UQ!<%Z&;',)M3^*AYNS*FU[-S]YUJ8E;;YWG9[A<
MA^G\XS*<3\.]EKD@'3VEY_]SHK0).ID,.:0"];@>HI:%UFVR A.MVMRD2*85
M0^/&08TP>]-6=H&&QU!T<9>QVF3M!C.P9T\[BIF]B_+C&]L0K%&("DPA9% 8
MXL#7VFY-N[RV+B22V.,VMO7Q5Y[Z+4QG5?+DY=3)0!LM7"X9'VQ*R3FB6%.@
MYK6&H)B%D*VV7 2%N<FQ]"Y$/AJCN NV;AK%9EI[K(;NI@CN^L[^!64'OO$H
M!G-?"8Q@5'F1VD8"?F8)5*D-D3'4QM[H2W3,YJWZ53QNHSJQS&F-BCPAS6,=
MH53 )8HD<U1.RMH7NC09X+D%;8_'A.Z I#U,Z$XZZB Q^7(Z#_,TK9>%2$ G
M582;>A2G=(R.DUQRJC=E@X>HLH'L;8G!",]MDSSD/?2,"Z_!];X87@D=8(G"
MI_FJU(8Z\_P!E]^FB8*IM^4.[C9U3ZN[_^JL?$5:+#'6F]4\<"#6!3B/"-8K
MP:V7B*7)F(PAF1@7M8.@:M&)BCN ]]\_?%QB6)TL?Q#SORV^X7)>N3DKA,I<
M)(W$AU"\3KXI&9RF;0:+%=[Z$IAK<B/F0:K&!>!X8%FTTEP','RV6'Y=+,,:
MK^]*9\R$D&1Q(D.IG1"5KX/2?$KT1W32(;K$&LUX?X"J<0^TNX'A<)K;&X8$
M_;@8ZDII39,^#>F?F&\QXU'S@D&#V7A#LM >$Q,ML1"B%$4(5YHT@GB IG%/
MKKL!X5!:Z\ 27@X+N^F27W+V^J+&SP;.;#$!F*%PCP*_ (YI";P$%,H1Q[9)
M"=!.5(YK*5O'.>T4U@$:;[)T0YA?ZJBZ_\!<ZYB>AE4=#B$=#[Y(*,(@J%RO
M?#"N(4KFC6+!JC:GLKL2.JX3V1 S-RUC2P7N#]#%.LR. ="43KZ<S&J!T6_+
MQ6KU]SFYS+/*\&^TY3S%4N> A>\3KEUV&V\YU5+I$C)$CK7;*?TLT 6/36YZ
M#4+]N.:U&R@W4'7_!OA>IE_3;Y=,TYKF,N@ 0EA+/E"]T!2$!>.*S4J:4E23
M&Q:#4#^NC]L_OO=7=1=%F_>+];H )C*6P!VY[XXK10%"'5V@DH?,A>+,!TV.
MVC% ?!^!O0P9/C9.!U'88SAO?QFFRUJQBK]O\FYXVJ)GCV/TNQ\T^.GX%O0.
M=.A]\:;+^K(K16\^Q:)='5T=_7E]AU<0F#/(*]A8DWKKAX@Z^(3QCF=?%IIP
MEXQ"*>L5CESO(-'JBDR"5RP&CBF;K6:5#,)Q)_5 @R'DUC'C8)IXM"9H_^+&
MAQYW''/4L+SQ0<@585.1F8/3EB#'ZZ4K10&!),RI(H(H[O$:I=-:WS,QY[?S
M]W5/7D[GGS8A_N7J$!0+)4%+C@7A:T_=2!NTUL!]G<"H9>$L-!7"EH1V;+IV
MP=&]IJN%OAZM-;LNC+"^^-+BAESV+V,<Y+W'L8\'2>,8AM0P5C:5%CS5J7(*
M0SVV\1!%I-W5IZS:],([HB%],L^OIV'36'=SK'1KF=(7WBPH'K^V:C<'"TI&
M'3P/(#$)4+;D.DF#/)OBM>*$ J::'!D.QD''IG<7Y/W$]!Y)PQWD$\_N5'[X
MC+A^7;]=-5D+J(S+TEL*T0MW')2VAGQP<IR9-=8X([GU35*$]Q'4"?".BX]%
M V5U"KJS4W^,V9$+59-"S-1A\@6"L@[0A3J7U.CBFQC(^TD:%WC#J'P+'.TA
M_PZ0]"RL/M<J^&]A5KVCLQ*/XF)1D2%X&8D)YR($0TN.)>FU=]*JU.3X[DYJ
M^L///JJ^6>5UL-P[ ,^%47_ZX^+'OTUQ241]_O$:O^'LM)0XIR1%XA"R)ZZR
M$! XA5H6L^5&A!13D]O1VY$W[FEO'_MB T7V!,^K\=]M_LY6,W-:9>LT%*RM
M\K.F5<BC!!>=UKKV"LIM<S?;4-F)$S<@3.Y#XN ZZPF0K^9?3]:KC<3X^618
M9(E8J=,A12W9] *B%0YR+!J-83*))N'" S1U K;AD7 ?Y@Y42Z<($^=#2'V@
M7< GX-K)>J.'I*.,!2X$Y\033VTJ"1^@J9.]=Q2$[:.63A$FSU@Q19A0J\ R
M>A)1J FD+ WH*!/2VG&\' UALH=Z_G$1MH]:>D#8/3<22PA9A:#!NWHRI#F#
M((N#F)(-*J<L4YL=\H#+QNV1-6[<,("J.D#<H-=N; G*^8P@596G9PJ<2 %*
M]+4M"T<IFQC!/_^5Y)U0U?)*\BXJ[@#>#U]L]4H$U#P#E['>3\@.@G<%K'3,
M4BA7N&^2G?G/<B5Y)[#L="5Y%\UU ,.?7&Q55NO"'3&3R4DI NL.Q"%E8PO3
MH:!JTLGA/\N5Y$-@.)SF.H#A0U=;E=;"*F= J#IZ-=5ZH%K=R)24EESS9$N3
M]@S_.2XD'P+!H;36Q9WX(9SWUQ=7#YS-3 ;!@+SV.@2Q*/#%B;H( _U'EI2:
M6,Y!N1CWKD<GT=1HL.C%+%_F1B[KDR;.%)<R8X"V]D./B43J:7GGF(13DC/#
MVG6)N(NB3O+BQT?)73;Y8)4]AKK:VCEP3OC]L4]Q[.4_'KS"]1ZZ!NR\N7GZ
MI68O:@69#<BUX^"MH]@CA 0A%@.5<<.=344U:=C[ $U#=(>_\>C+2G$MF'(E
M25#&L#IS.$)TT0'JFGF(Q'IN8H0>(FK\;II#H..NMNR#J.%1&9;]KQS=?$0[
M(].X<_I]8')2.<>-HSA!!U H:MC +&3&@RU(OK]N$I0U,#6GDU,O+A:?O^&\
M*_TESG.VQJ#T%,AXVD!5#96XK;?N;*9/E. W^UK>-Z[VYR_KUXSLHOGKPVD'
M%O&C,B7[7^.Y^8AVIJ1QO_#[ *4"TLX4/7".!"CA)7B.=8>2B7.=I2Y-CA"/
MX;6\P?4%G]RCL-S32I'DT"N;:B.N%( 'F04YYK916]R[B.G7O.R"AGN]E'W%
MWD'(?<'#/Q;+?[Z:OULN$JY6Q-#;<CXQ;((F:*.,A"CTION) X^U'$HX7JP.
MPN@F_?"VH*T38.T-@/L0-9 V>@+8R^E\NJ(M^;?%(M]@21ENHA0:*&9PH'21
M$*2HS*%(@2%CK$EKARUH&_?TIQW !M)&3P C+B9(P69ADD-B48"*DAPZC8)^
ME5P'BY*YMB$Z$3'N:4T[R.PJWPX:&5[2OIC7W&>M(CF7"6W[3F"Q() DH8R@
M* !EAJ15<D%+;7RS03'WT-2)L6GF)AVFA!%MS2:@O.#C??CC]T /G5)<<\UT
M$H//3AF<E&0Y)^+!1RQD1%4!%[(%&26&D).,XH;/=$_POLM;>_&&#M3SXAA"
M[P9-][MZ5SA#Q8U0Q)3D+)/\ AEP:1D$G[5!)9,-;#<X;?/:3NQ1$SP-+O9N
M '6_:W>%LR!9D)+3 BD8024N:*D$!)DSYR*4P(O;#5#;O+87UZ@%H 87>U>^
M]87$)DDY[I0*8+7 Z@(:B-EH0+2\>&2T2IHT^;J#EG$+1H:&TU!"']'OOKXB
MR&LT6AGKR6BB!^54[7A.@65TSDHN.8\V[V9D.C$@ WG(!XAK,"4W/(V@S?4K
M+M<_PNF0Q:^U#G"?(XD[GS/XN<3/J1WH<.+\1>]F87X^@'+SM@LL:0(3<];4
M1L(&%%K"DO<&4L@E.)FUM4VNH?^4LD/WDWM?<-<Y?TDE,&F1;%[9G/QQ<,)R
M,"YSYEV0ILU=U5V('#?B&A9)-_>A9LIZ#">I=UF#_>LS'GC:4>Q8PZJ-+3#H
M5'&UOQ*3,53?9=.(F($FES?QR+))36HWQK-FE\LB!)L+2@5&$H'*D4<8:V\?
M)Z)5*:BL8Y/AN#\GK7O+M0-JMK9<^RGFL=JKNSX+ZSJ5:/_RD+W><Q0;MQNW
M1[-^!;GUI1006N=:8D1 XTZ"9*JHQ *Y]4W.-IM;O\OZJON7V^8ZA$R1.1<$
MF%*GIBK#ZA1AK,W24O*^A()-O-EM">S=$NZ"H/OGZ VHI X24_=R\_1'O8.V
MN2JN*6K6VM'FP3&!DDQ#4$&!PQ*J3RK1-CD+WH*V7@;E#0F*;??@/374,^@J
M0V?W&VDU6E%8@B0W(]-IG3JF/6C+)4_1%-1-[D1L05NG=FY?/&SM\^VGG+&/
M<YXMOGP]H6?]+2SS'R1A8NGM^C,N+_@ZGTF>12I&"$BT/D$9-."SUE"4\ZB+
MEB;XGSEUN[RP4Q3MJ^5%8Y%W8+9>GBSGT_7)AI^7T^_UI_-;T\P8;ER*8)(L
M-57-B1/ZB:'*Y&@8*]I,?[N?I'&/G%O!:V!5= "JUQA6^'DQRZ^^?%TNOIUV
M-3MO!B%B#'4D.!->D(1JD9@EWR$Q^M!XEKQLDO!Y@*9QSXU:PVHH98R(J]5R
M/7D?YI].'8$BD1=7 A#I]0A-2(A16)#!\)231<S;!,WTT"OHH=]N(N?:6WL9
M^=O *=]?NCU X@S)4B@AA5607:R3+YTF"VF);+3D'P9=%-_&K&P/BC$=G@,T
M=E/G>XAO9*W_/IU/OYQ\.2/<RIB#91YLKE%!20&"KE$!T](K'Y+8JE!W*[U?
M>_/(FM]';XLAA#BV]L/W*X1[J;34U@%W68-BK@ QG2DF5%&CY,*R;:ZQ;:?]
MJV\>9SL83/M["[$#Y_+>'?#U1<^2F(3P(10HNM;*\&S!>4'PEBK9G"-/P;7P
M,7].6B^3U<?([>VGGYX1]_<5EI/9ZVG!28R(248/@=7F$S8[<#+5MDXR$DNN
M8)LFF5O0UFE29D\X;(NV/773,]Q^6RY6JXE)FH<<(L04'=3Q ^"=(J-O:ULQ
MD9UKDY9YF*Q.4S.-0;:[1CK UY.43KZ<S,(:\W,D(M+T=&85?IWA1F'S_.3+
M8KF>_L?F\WN9GVC'4A)<@=62W$:/-2-O/$0OF:DU$LFT:88Y$ .=YGV&P>PH
M6MX=W?X4W7/\5"EM:S_K'56;/07'.9%WR\F?23Z"#]Z2<&62)4@I,C^J]=SV
M3G"SFPICV<Y=M?%8B]J?Y#RM[Z@-;\N"_MWI,ARRQNJA5QREO&IK'H]66668
M<IBY .8C13"."8C,!@@Y!4]P=KE-(Y_FE557C?E$(QGEZ.K\1Y7J32(!U5I#
M[7=L4W9*J"9<7B6BT_!B+R3<-%Y["_LQ5(5N#H;VJE@_^Y>#FY:[*!K(8IP^
M^@(4(A67<P@@M:DN^\9Y#P*R]$*BUD6D)D'4=3(./V==K1#?T@(@P<\_G3[\
MLHS99_+1DK/ \R8NL08B5QIR\59$1@L@-JEQ>YBL<>W% 3BX?; ZF/0?C[G8
M_YK+M7_?R'0TO,IR S@^2.2!,:@';+7N-D-@,0%%^]9IYRW/309@#V- ;O3
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M>Z5!1V$-DFB2;V)K[J"EJWL.AQB<0^7< 53NN:1Q/C-4I>(E5ZS.?_"U,W
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M&<J^"QT9;</Y4DTE-#GKM45?G6I:4V\?:PT&KM+:.K. C%8"VF*M:1-$*>8
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MM+G@VF5QX^9"&N\^S:0T@83'];G]Y^6K]-^7\Q5N4S9#LB,.DP$C'"F3C[7
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M$YBNV*^%_SN*H#__B6??\;?EXN+K^2S92F\NX$PA:CD3M3&/ ^TD8HJHE)O
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M9XG[#12$0TO[!$7EL?;BR\5!*$4#_=(+3[ZLXETTYLCZD320[4LM2/HP>AI
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M!Z'.PPA2U8)%&WR:IF[V)/1((\(C5="6*#P%+7WD).]9_K#(D\E6@-2IMHW
M!!XUQ2K,B^2RU-RR26II3T*/-(H\4BUMB<+3T-(KZKMQQ_BL;= (4JC:B! I
M#)!"0"S&:ZE(E&R<LMI!R3R9$^XCT=!6"#P&_1PH/M<94]%DMOBZ*XPPO*:I
M/?&&*5=2\5*'4\\)'<,9^R0T<@3,G=ZI_/.^?F!!F:)!:Q=!.4.^?B@,!,^*
MD^BRM$U:6QZ(OB/=(*=Q$-("0R>PT[U\(ON\WU[0E-J$22OK0=6QB\&( )IG
MCT(+E]TXT6-3LH]T7YR&(AX0<6.W<VCG$GS$VO: ?K]N?QW2Q64XJVVR;]K\
MY"2SB4H!7SOLD?Z(2BC D%7UY,F.;9U6#MUZ?6\:CGXF_"Y:=DRXF<KV%U_F
M5!R,4V+FF0KKJ$#:8LA#*!$"!<%0O E%694LE\WVO,/2.DY1P%'IP&.[XX0!
M>0(Z^[0G_Q2+^"R4$"(C[KA<YS'K.A2<PGNP'%E*:+7-[:JX#TOK./4"?V>=
M;0W($]#9WD[_TYR+0AD4&,$Q)TG21H/7 B$CF<$L>2#O:HJJ/!P+QBDX^#MK
M^$CP/?;X]=67+ZOU;<A?B GSQ?D\K9MXWXC4"9.E2YJTC4=05AH(3"8R@N3#
M>$>!:- '"5)?6&@GA7/_&XFV1<!4ML%AS-]]ALR8X]%PXT%GJVO:N7:59!&\
M+,JX&!*&J9\DWJ?HB$/'04';[I1P#P0=3ZUXWRJ&];B(+<Y(HU)A4@#7)#05
MR 0Z7P1MODD+P7W);2;>'8*X(X[VIJQF@^/JM#<O8:.P-H#TI@:S)H%#9\$'
M2=%M$C*:<2J]FVY>TXRPIJQ5PR!H2D4MPV2-[C.#SY1)17O#R%.OH_R84^#I
M5\!0Y1B<3ERUZ]35A*1QJJ^/0Z'&Q] );$XO9VB>D./,Y5KR8T@9#-:\DJ/8
MV')&ND%_8B%G>IJ1U\X4CU-&=ARZ.'D$GL!,NX^??K\>\E;':C0;:O?X>PX]
MU:X#M=,8:X<Y.5,T!_J3="<D!9'4"'Q*W*,0B;5QXL<9:W=EC@88T/'B.,N/
M9 16\VH0UDCY?3&_.+^:ZB%$\1XQ '.!UW-[53,VQ",5>#0I:Z_S2SHP 3J.
M>AQ>']3?SXP?#W8FX-Y=S;*A+Z^G>ZG"A)/107;*U&U:T^*-)5HR9R;3EFV:
M] B[MXHQ$]1'A)WE4(*<  IWY_8MV8N\-7HL)B=92A&$4<3-XG-MQZ_ *9^T
MR1FMG%B;@Z>)&=>4[X&MP6Y'#B3H"8#],?TG9W0SQ8X[GX7.$J2J _.,=!"L
M"8!92.6RT3(U*6)]=E43[T'5'#3+5A(<O9!DK WOM@3"QZ14'0D9+</:2DN3
MHQ<C1,Z8-IR5N'T(.#5G^]=QIQH>J^<R$:'U N $MH^=TV$OLNG=<O%]G2N[
MV_G<!LF*S@ZBR0J4EP5B+AYL)NN6<G0BMJOJ/!B9?\>88T<-&"H[VQZ.?P]E
MW31F+D9IQZT$P[#F2YP!;SW)T MR;GQQ7DZK'7Y?"B?N@XX(\\-KY Z8._[*
MMA?9<[]%Y8Q;3>;4)O L>5 Y>#*HNO:(Q2!CXD[%:34"[TG@D?8_/26%W -Q
M)[TY;GI18KYA38Q"<)(3*)T-J&0TN,AK/R%>BM/,(Y]6D_#^-!YIN]-3TL?]
M<'?<D\U>9,Y5'<8-9YR)7#I!+@,7-66@<FTJZ4'SZ&T4SELVK>+OG@0>:5_3
M4U+'/1!WXKJX[<G;4'PNB,!DK9-/)+K@%(.B0Y:B2)U*N]89DXD>I]>B[92T
M<1_,3:FTO"USMNXKKSW\UV11WH;Y:EV5>%?0 8-RKM2C)E\#\!C!FUA .XE,
M9\:Y.E:U[<.'O^.YR]%D;YL!^J0CV.[LFZ'2*;B4P;+@*.J7L<J??)N21 Y*
MF!*.S)'N3OS))X7;:<\$+4$O*/_M$LH=V&<B<U%$D)&I>@I/'J!'#8DB&^T0
M8\S3:OHZ- =./B5] N:@):A/VB6X,V#I9:Y%Y;/,'NNL>D9.863@<IV&IHWR
M(="G[L@.G_J0?_*I\!.P \W@?-)&X'Y*\V7&V11R<H6#J3=H%!,<?!0!LF(^
MAV"S2?&X[$!/#IQ\&OX$3$%+4)^T->@16C$GL)2 Q"2O09G (&A+05;B14;K
M5;(GFRH\^>3_"=B 1E >].#@X%?SU\VM'O^H-C-8G./0E_0[O_% U_5WX\ T
M+NX7IXTL)8$IJL[.E 6"59F<5FDHJ#56Y"8QV#@7]V],Q,V)R!N"X?('XB=<
M?9\G?,)VG*T?23^]+Q\Q+;\LYO]#BUIKWWJE5Q=,7-*2%24 O2--Y]5H<5[
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M3&8?I(9:NB<3 ZV"J6=: GS@"HKTA?;]P%.P1VY%7Q/+%U5#ZH"W>+E.-),
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M4(8A.!$S.(7T@2@H2K<KP#U>.DXN8VK0VDD$HW8H[V60N: X)TH(PEH*GK&
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M**L]+3<7D"6$%+).VCSB!I]?0^,<T__YLOS^;_5Q%1IN_5.%A;L+BZN7C0B
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M]1'5%-'X_'WZF47.,W<,*":DO35X7:]9>1#66,69\D:TOC_799W3"*\:H7!
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M:T8T(@\&FWAP.Z[W_W=W;:MMQ$#TO?\RH/OEI5!:^M1"+_39C$92,21.2>Q
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M3,\H+:B<!?@[,:E6+F&6@H\G SIMT8,QD72\,R8AZMTG%(@Y.I4P K?15*%
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MN@NN/57.-4PS2WI^+R!G2G^'<];2+=A<C#H],6W7,6TVB1/%YZ.8PSD!ONO
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MP89W9N\6><2H]Y=G.V!O1OVC'U!+ P04    " "%.$M2O'H,RSL#  #0"
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M0R'G$ ;M%Y *:=U>4B*!8J 3.* QG4>X4=VP99I@X()Y+;-1[TL55TC+/,=
MXE/.T/ %TYFE2_I7R20UO=+NUYT#A6D#N'K8;R;7*I&EE-CN4<WX"A.&SVB=
M=^%.M]<"DV*&D7&T?$YL>L48!,),=C .*Z9"2IA$VPI)E;&B93A(G@-*8C@Q
M)D@HT"S5LH*H28F<)?9ZD#).>&R8\'5B[R!V>10I<^>1**@D[A"LQL3[4%9$
M0FLQ'VS:O- DPK-0,41"8KJW,3]R4B@ZJ'\,$Z:*G"P'C-M=MD+#2Y.^F/=5
M6<5DJ^X+.SO>=K]KK@P:[PDZJ=57MPG/WB9\G=RG]0*OV^T]2 Z\\)-HH;<5
M=#]1\F%C^WVOO_DXM;X-A L&!E7A/CUK=!NU0$&2!.^#@TYQ!>%J+\YIJM\3
MZ:]_HNT=\)!&LB1R":$[GS=WJBH"G^^<R\YOY)^K#^[[\UQSEXSO9^?6UWK8
M1>RW<^^8983F<.3!F<B7<RI%(<I<8#4Z]@Z\%><?F;V!B4'C9\V%JG;:EEN@
ML::60VWE1R?*5_+\WAW5>OZ!U$#P=X:-B"4&T)JN-,H83;%I8@/5[)+"J;NZ
M&,;FF638R KL9/?H&^]+LMK7VJ"^ZU+_5>)]*NNO OZ_/+0_<@%_02_Q1GDL
M).&_JO5/7*UOYP%6W O*&4*;UUAA732N:W7+%6KW]K!&&.[QM$:;%99V/Z:2
M$E7*NZ7\(S3<D=F/8U%RC<%=$7I/)_ MQOB6T-9J'#"-6QP_ NSN0STFD P-
MQ(9G81E#4(JH4E..)B*VLU/@"ITF$"WO3T RHB"BR%](<<D,*J[& S7F-2UW
MP1!)1@;G5O 3-=WE24O)F<IN%-Q"N(9^C7)1:,Z4,B"S>3$>66C,$&6BP6D*
M98'OC<54:0^FQB,WN, #8(%I->H@<6P71_75N.,.($8K%AF+,]2-^G(S<D%0
MK( +#0G%R!C<F]/D!L6C,=;2B@D51 9^QT(6F.[:N2UI2B7EL:$@AYT*L-R,
MU^_,"NPLYVX@;A!^%Q$^!F9N)Q$M$/=8'Y@*7,M <Y%1E)$(\1,SS4F%I$8/
M276UL$'WM5DW0PV,@JR& >9ZA'1C[HQR1/CY+7]-L'.TH"0SNCIYL!,CY_7#
M\/_.;+\0[L^-@=T+7/C>M/^F6-J!07 C0B*LF*5^6.2A<>N#?QU4W^Z/#/N7
MRMX_4$L#!!0    ( (4X2U(TKRF_9@X  &EN   6    =FYD865X,3 T,#$R
M,S$R,#(P+FAT;>U=67/;.!)^WU^!<6HS3I5NR?&5394B*VNG'-EK:\8[3UL0
M"4H8DX0& *UH?OUV-T@=MN0CB2PJSE2-RKS 1J.[O[[ O/OEZ*S5_>.\S08V
M"MGY;Q].3UILJU@N7]5;Y?)1]X@==S^?LD:I4F5=S6,CK50Q#\OE=F>+;0VL
M'1Z4RZ/1J#2JEY3NE[L791RJ40Z5,J+D6W_K_3L\ [^"^^__\>Z78I$=*2^)
M1&R9IP6WPF>)D7&?7?G"7+-B,;VKI89C+?L#RVJ56I5=*7TM;[B[;J4-Q?ML
MG'=E=_RN3"]YUU/^^/T[7]XPZ?]K2_KU'4]4=NK!?CUH[/;V]_E.H_YVMQ8T
M]AJ]W;?[_]O9!2K+<+][R-AQ*/ZU%<FX.!!(P,%N;6@/1]*W@X-JI?+/K;G[
MK/ABBSR4_?B R(6K@8HMD*%A5/?GG<&7/)1=]E2H],&K"OUWB%>* 8]D.#[X
MM2LC85A'C-B%BGC\:\' NA2-T#)P-QKYMSBH(L5T.$JG ..$,A;9E*HUG$?[
MO\<G'TZZK%HI-2KSQ.:3Y$.BPA>>TAQE\2")?:'Q+IQ,N_5;]^2LPUIGYW\\
ME?6/7B\/)$[HW,V^^;G=.8+_NZQS5F([K'O&3MO-R_9CIO1G8JP,QD_E1/J8
MHTH"*;$]J+\=KEXR&@N%N7M\<LF6L8%MOWZU5ZM5#K.)K4/=FF"M?+)\'07$
M/0\IBYE%W*@>OF'2L(C[@G'#5,#L0+!JU0Z8S\=XW!QJ&1;  E?W<\'!=A (
MS\H;P8X .?+ P +KC1F/?=83=B1$S"[_\UOSHLUV&NSLX\>35IN=777:%^ST
MM%5@G!V)D(^X%BR4D43L"R7OR5#:,?-4-.3Q.!=\/H49P9O\?' 8V?M[LW/4
M9.?'S8O/S58;['RK>7K)3CJMTAQ;P30.4^N8"T9V1<S10UD_&TO?P:1O.DA>
MG70[[<O+=O=XG3+Q^M7.WN'+P>6KX_8%0# 9RE/!C0!P0<OG$.=3$HY9;8<P
MILJV$8!RH+8G,80Z/'3TYD%["\@NCOX#< X8:0?<LGE_HLJL6L#@SUQ[ U;=
M(PXW<F$4;]&=$_X"R"S@:FTQ5S\EL0"&$E/?YI"IM5PSM7Z?J-:<J.[ED*OU
M7'.U<2]7]W/+U48>N.J@9\[N%VX;V-LG:K=/U&EI;LVN $YI&+JP)1P76$X@
M+D?0ED4;&(R&0!9F T&4G>\,_)+:CHMVH(6  Y489'* 0>  ?#LM_.R60"6:
M;=?KA9UZXPTS?R48$01"6%0##0O">R%$NEKPW#@:YUI$T@B3AX5@H?+(;LB8
MA+3-C65=-1(Z2PWT$AGZN#K9G6"#@(,5=B[BV(S#&QY+SIHW(DY >SJE*PC.
MKK@9P"-6Q05V5&J5<L/Z#^ED\L#Z AL-)%AI&7MAX@L#QQ)%W;H\ 04R:#GF
M5,".U$0#C "F3U6@4-M]2 .R)51NL0T$3##F]FH<A]W2WB/X<3A4KL1PH"&>
M1WMY:-7PH-@H(3=OA+;2XV$:Y?3 ?+FH+EYKFN(-"T*E-(L4L'K(D<8DY!JB
M&E\$<#?!<$Y$_C9:M;\,L:H#(G YY%X>T !BX_VGQ,;?G*G(:[ \P<2^!A $
M*9J@H;CC=#3#4(UX[ E$S1[H]W 82H3%"8;RT J7#C'@C1AK,AO_@$30<J!3
M\W-)9I8$C6_*6+#54A/?*3@GGCH7'$X!_=FY(;Q;^<Q/-,*G,_;I$!$?@VG^
M*Y'.]CVPPF3X%5@;'UC$/+")')92P4.:P1I'DS2^HP*N<<\#HNEA!!4:P22]
M/\$CQ9'P7O<@7D 0D$Y.#*!&H#0\T1/P]F?-'^9,!#IG5P7613GX>';1+B!7
M@5%&^JE293R/$IM ]."I&UI:Q])AZN+A([A8H)BP6 )7!JZZE>LKY<3JAH<)
M8?3<^"YHT,(3<FC3!0P"Z4D1>U2G<0*%8(]#8T7"NX[5*!1^7_B+)3>[L4\^
MQ5WY!=0*%(J=>6'YRFKI]:OJV\KAW=_UX>-]2>VCU,WHHA*O$\)+#.T4\_@0
M/-80'O13PY*8>9F/E75R/Y*8JTCI3V\P PZ##/B-<'XIR"6+! 06<=^@4 ZU
MNI&8!07;!&H 8N]>D@(:">]+ME6U#1/?-H*D28THOI,6=BD KEO ;]$ES<20
M3I/SO@B%I20&(O] HSE-O7]$8)34D0A!P+>KM3< Y;$=@&@'%B$<X^Z)#]92
M$8SJ"7HA5KQ3+SD3=A>T%:TJAABK(\7(Q4M,-L'C;[?]-]M2RC>D=3(V&$$M
M) NYKP'G PQB*+==I]QVK3+S1@F 9JS@_DM6K_J&J=<%G %/@<ZO67?:7SR!
M[HN9,?[B"[A'QD"T3!ZMS*I;8M:9!26[U3I3F'%4'&" DX6.<!)[ Q[WA9]Y
MLR#P";G!00)W@7RG/K2@3I(4LI;*X6P#X-WDQ+*6P)ZR5D4'E>DCO&=4F-CE
MCT1<]V5<Q'0'R/;A\Y?2E_A"W\7MF_T=Z&R$(>^+8D\+?ETDVW? PQ$?FZTG
M=6%^0[/E4D(?,\OG7@C2AL*MR&(F6)L+^M"_6J!8F0<VC1)@@$#J*-463:8B
M.W#ZM$QQJ A%1>D@T13"9/CGABY0 &.E!:''H$:Z47M@P!&!5 ]XRB>D+XI/
M1$SO= E+"F'3LL#4..![A0I>,APU-@R./FAU+?2:@6BAN'&()+1 I4&4P2LC
MKC6EW)S,I3D6K+O&0M*!T[H(HA7#1#0,U1@3ZAH<0![:+-LR9CV:-&A+'X>&
MZP$*CJ8T KQC3!KA/+I8])65J68XH,FD_BX*+IF* T1\111CD@@O#53HS\QB
MP'44@GE@@581W<#[H.[&$KU>R&6$=-(?AAQR-P>8 9YW@WC@G4ICB%1NT+ET
MZ'W?E$7<YWUWVX1TN)I2#G\1TT8#H&K!=>2SXZW+P,2IHTL/+>304I4><A\-
M2C$4@5/@PZ],9#QAH.<6]9T-,P[-Q Z4EG:\9OOP<G)=R^1CF[]9=FD^?3BQ
MF&;69!KJ1,GTETQF^ABH*&<^]OPIW><Q)8G(J_@B#9FZV09>BEHILT/Y46.Y
M\QY(9,B:A7PT\7TN+03(>#!I!N9I0O,(QM;2HR)H"_SPJ"=YP9&%EA*L")A"
MKL>3EZ/'012@P>EA5[?EU_BK&'GC0-(2DSSMS4FS_@9&,;#R+NY>\ !<[PFP
MV 'E/Z9VCEY+G.).+?YV%1U?,:.>XO+\J"+:6RJB$\E[6$@G5358L=DVE/N%
M='GS_AI$-GWQ>@1VRNIG%]D< ^_;#0/>15[D1:8TJ3-*G6W3JA(*Q'JK#3]-
MX'TH[6*6GC!VBBN8RZWN'AHV6<7"O *#^H.O3_D ,#+P'*9\9V/UJ1ES=1;&
MGOXB,"F8H  3Z8N )^#,WQIU9B\:]K$R%^479H53(BG.8L*=%+-DN1"*6Z3V
MD@B-+Q:]L39:8+V$RMG.S$&X0J$,O 4K#A2RA?)&:*JF GG2 Y(Q[(%0I\!&
M*@G]V8P&CQDU7.'=V2QF0YH%?)HB>ZR8EVA-.Z IP"K@&"+&&C'6M(0MJB P
MV<RNI2OY.\+'41I0I6M%4[S+^/L7K:.P"M&_6Y%VH6,/BW(B<L9[Q+'3$@DQ
MP%(P[\(%C1ER3AT]8AC>F'$$#AV7TB5(P[3OP?]9KJ>4/$J*7G*NZ"L\J5O:
MG:WT(OV>$?!O-R./>-$WF9%98Y1'0[)8I&?S/2LS)'=8OWI3,HT4,X?\05/R
MLV*SK/S_LV*3CQA@16"WS,7X=KC;<'3;W;"8Z[/K%>Q,$_YYK8I,BH6SM4?J
M&S0N<T!W48*$A)HZM+*.GH4IA$FRX$\E8QNZM(EKGH2#K :29EUF<@E !>K(
M(E(+:8\+:< $4@E"I!F2&FE).XMP5T5ZZ4%*%[=.TGQ])2:]/U-@2TLG04JU
M&<CAI+0R+;_@-H'Q,]0F\JNM>QNFK?\6L="@KN>9Q*R[TW*17*:]O%DR;V%7
M]S*5=.X:#PWM(+C5'TY-F!-EP<)DG[MZ/'40H#!)3GE0W*5.G^'(O,&TX2UK
M2:OME&J5#*CF=EN6EOMT+T ?]C=,'SZDC1SN@SQKUH7N<H'&$!'D64R^&S3;
MA9+$5 /'4PE(<$BM+F,FO@@OR= G==4<^)#A3X67MGJE$&!5VDB67IM"Y501
M")H6(8S;\P?TN- 2*<[J"U85*(2>CC?7YP/*-M?<@VTWD[!K,LEA5DF+$[=3
MQ07:L0BD73P9ZJZ3&M3<#%.VX3&$ER$H?CBMIU!091ST0A@)1"/5)O&P.@'H
MY_#;8#G!K-(5777$12,>4%>[]ZA$RW[U\((:J'S7)8*1$]9@T%#B%Q1!RGHA
MCZ\?Q92<S>X2:.(VH=V.?9%M$@'[M5]?_<Z]EQ[>UW^&]WF ZY,.2[\EQ6A[
MX-G')9NL<!O+!$\6.EZ3;W;<"N!QE+'@V#FEL2^K!QC 1AI-;/S(T*%:V5OH
M*WV=ZBT;^CE7XZD?_#IM=HY.SRZ.UKNS^;[M<_-<W:U^IT:T:J.1IX+X/1]%
MW,CY/.9#CL^^Y'N5A[6]N$:C^6%,JK LT/EP_OI58_?PJ,7.+\[.VQ?=D_9E
MP7WA\=L8L#89^<SU.'3Q]Z2IK>"V4:D0=S5&/6R<Q]P7CP%\]7.+3*WZO1I?
MG7YFIPC5\;L=.T_"GV=<H=W&PP*Y)M  TNZ#-%(20[_LDQK$[%.)75J-KUPV
MD>_U^Q0UW#!1Z/!(;* PK$@ ?LR%=A_DQ7\J((\K_8 G^[OT!#O7PE"VM4 Q
M [!]-2M;J]0>LXS%>A5O^PK<6?'X3PU\\A.P=-N=9J>;WZ\3/XK-F[Q@BZW&
M/5\?_S$FN/@3ZGD1@Q7[HS_=SZ]S/S_+ 1<A.RZQ<Q6.(Z'54"6A,BMR-S8Q
MQ-A0O_+GROZPCN3$AZ3$0ZM]MO*@85GMY.O*>ZMXZJ57E1J/X>>3JDIE]X^P
MT3\']_[_4$L#!!0    ( (4X2U)'>@44F X  ,QO   6    =FYD865X,3 T
M,3$R,S$R,#(P+FAT;>U=67/;.!)^WU^!<6HS294DZ_*=394B*VNG;-EK:\8[
M3UL0"4H8@P0' *UH?OUV Z0N4S[BV*+B3-6HS MH-+J_/LE\^.7PK-W[X[Q#
MAB84Y/RW3R?';;)1WMR\:K0W-P][A^2H=WI"FI5JC?04C30W7$94;&YVNAMD
M8VA,O+^Y.1J-*J-&1:K!9N]B$X=J;@HI-:OXQM_X^ '/P"^C_L=_?/BE7":'
MTDM"%AGB*48-\TFB>30@5S[3UZ1<3N]JRWBL^&!H2+U:KY$KJ:[Y#777#3>"
M?<S&^;#ICC]LVDD^]*4__OC!YS>$^__:X+[7\+>JU4:3>GO-;5:GC7IMFWE;
MC=V]';_/V/^V=H#*3;C?/:3-6+!_;80\*@\9$K"_4X_-P8C[9KA?JU;_N3%W
MGV%?39D*/HCV+;EP-9"1 3(4C.K^O#7XDH>RRYX44NV_J=K_#O!*.: A%^/]
M7WL\9)ITV8A<R)!&OY8T[$M9,\4#=Z/F?[/]&E)L#T?I$F <P2.6+:E6QW5T
M_GMT_.FX1VK52K,V3VPQ23ZP5/C,DXJB+.XGD<\4WH6+Z;1_ZQV?=4G[[/R/
MQ[+^P?OE@<0Q5;C5MTX[W4/XOT>Z9Q6R37IGY*33NNP\9$E_)MKP8/Q83J2/
M.:HXD!*9_<9V_/R2T<P5YM[1\259Q@;R[NV;W7J]>I M;!7JU@*T\BWR=240
M]S*DY#/+<J-V\)YP34+J,T(UD0$Q0T9VS)#X=(R'IW1<0OBM%H)]G2!@GN$W
MC!R"V2@"]TJD/R8T\DF?F1%C$;G\SV^MBP[9:I*SSY^/VQUR=M7M7)"3DW:)
M4'+(!!U1Q8C@(4?#)SCM<\'-F'@RC&DT+@2?3V!%,)-?# XC>W]O=0];Y/RH
M=7'::G< Y-NMDTMRW&U7YM@*N!BGT%@(1O981-$]63T;*]\!S]?=0EX=][J=
MR\M.[VB5,O'VS=;NP>LQRE='G0NPOQ8H3QC5#$P+(I\S-U\2,2;U+;0QM1IY
MA]:G &I['$&<0X6CMPC:6T)V470>@'/ 2#.DALP[$S5B9 Z#3ZGRAJ2V:SG<
M+ 0H+M!=$/Z"D<GA:CV?JU^2B %#+5.W"\C4>J&9VKA+5.M.5'<+R-5&H;G:
MO).K>X7E:K/07-W*YVHK5ER06LUR=:^ 7-TJ E>=09^SIJ5%L[5XHKYXHK%X
MHFGW:F&Y)?#]A7#1H8"8M2">1($\B"RHPX!? %F8<079=B$*\(LK,RZ;H6(,
M#F2BD<D!QMI#<*$5\[-; IDH\J[1*&TUFN^)_BO!P"M@S*!>*-@0VA>,P$E:
M&'_N7+&0:Z:+L!%$2,\""8^LD':H-J0G1TQEZ9=^PH6/NY/=": $'*R2<Q9%
M>BQN:,0I:=VP* %UZE:N( :^HGH(CQ@9E<AAI5TI#.L_I8LI NM+9#3D8 QY
MY(G$9QJ..8JZ<>D8&R\B<LRI@!G)B09H!DR?JD"IOG.?!F1;*-UF:XA+8<QW
MS^.?[51V'\"/@UBZ,LZ^8H(B7AX8&>^7FQ7DY@U3AGM4I,%D'^#+!<_12K-!
M[TD@I%0DE,#JF"*-B: *@D>?!7"WM<L%$?E%9[?S-<;*&8C 94R](EB#MV^V
M]AZ3@GAR0JBH.8F)31PH,((@11-KR&[%+"TAY(A&'D.KV0?]CF/!T2Q.;"@5
MAKFLDP9O1!N=8?P]$F&W@_S<CQ*)$Z43NP$2L=+F<;??^>_?<<[?6[][T36<
MSXO<<@J1^S$0)7WB)PJ-JC,!Z8Z%= R _5?"'2+>L^\CF P8YF8#"FT6H%%U
M!1*WB6@Q?F[DC&(A0U)F@\7ERFJ/W3'+;!=9P:D@47"L4OY^WWU;V*I:&NQ)
ML"8^,(]X8/,HJ*JT%( .AY-2F*,/KE'/@^4X,0"GP8Z@D_Z?(*0X$M[K'L0+
M:.2YPP$-7D$@86T &4#/BZ;A"R8<W;.K$NFAA'P^N^B4D*O *,W]%#0SGH>)
M22!<].2-W6S'TCAUX?$1W"S00-@LACL#5]W.#:1T G=#16)]L+GQ'1HHYC$>
MFW0#@X![G$6>+78Z$4-G#H?&PIYW'<F18/Z ^?DRG=TXL#[C;<D&Q @D"J)^
M96G_6N7MF]IV]>#V[^K\G[MJ0X>I&]E#)5ZEBU8AB%S$HS%$) (>]%-@2?2\
MS$?2.+D?<4Q.I?2G-^@AA4&&](:YN /DDH0, L=HH%$H8R5O.)HQP"90 Q![
M-TGJL%CA?7ZLFNVNNAV5+.NWZDMC9+A?G3Y"^UJ*Q"Q_)*1JP*,RQCE V\'+
MERJ7*$E>QY7[':J,F)@.6+D/P>1UF09 ZSX5(SK6&T_M5;L79_*W??704E\S
M:.F@2Z-3 X=S6J5;ZJZL&'QZH/X"<U(:-0/]':#Z\I&^> F3C*EM])E@:;Z+
M@S&'^\$+-*YK1K%80 #D.Y\*D<=92X I:R])%L^WHC&)P8V:<1/N\/<PC3\$
M:A B^]B5,^,K.DH6W3DWM6(#B;XF3J+@23PS[SJFP-I'P&4A$DX!JIQ+ '<'
M#+MZ*FF8_9HC@<::*>D%G %?T)Y?L09VOGH,'50]8][95W" M19C%[/PK V
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M\YR9^W7_SIW]%_<^_A]02P$"% ,4    " "%.$M2=/'C3\6W P#J@B4 $0
M            @ $     =FYD82TR,#(P,3(S,2YH=&U02P$"% ,4    " "%
M.$M2XYA(PW87   (!@$ $0              @ 'TMP, =FYD82TR,#(P,3(S
M,2YX<V102P$"% ,4    " "%.$M2GVO,RA,L  "\WP$ %0
M@ &9SP, =FYD82TR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @ A3A+4JQ
M4EZ87@  22H$ !4              ( !W_L# '9N9&$M,C R,#$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( (4X2U*';^.'Y1$  "P2   4              "
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M82TR,#(P,3(S,5]P<F4N>&UL4$L! A0#%     @ A3A+4O^HV^-G P  11@
M !4              ( !<.L* '9N9&$Q,C,Q,C R,&5X,C$Q+FAT;5!+ 0(4
M Q0    ( (4X2U*\>@S+.P,  - (   5              "  0KO"@!V;F1A
M,3(S,3(P,C!E>#(S,2YH=&U02P$"% ,4    " "%.$M24'U6N4L(  !<*0
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M              "  :88"P!V;F1A97@Q,#0Q,3(S,3(P,C N:'1M4$L%!@
0   2 !( JP0  '(G"P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
